

Final

Pancreatic cancer in adults:

diagnosis and management

NICE Guideline NG85

Methods, evidence and recommendations

February 2018

Final

*Developed by the National Guideline Alliance, hosted
by the Royal College of Obstetricians and
Gynaecologists*

Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the Welsh Government, Scottish Government, and Northern Ireland Executive. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE 2018. All rights reserved. Subject to [Notice of rights](#).
ISBN 978-1-4731-2794-4

Contents

1	Introduction	12
2	Guideline summary	13
2.1	Guideline Committee membership, NGA staff and acknowledgements	13
2.2	Other versions of the guideline	14
2.3	Schedule for updating the guideline.....	14
3	Development of this guideline	15
3.1	What is a NICE Guideline?	15
3.2	Remit.....	15
3.3	Who developed this guideline?	16
3.4	What this guideline covers.....	16
3.4.1	Groups that will be covered.....	16
3.4.2	Key clinical areas that will be covered	16
3.5	What this guideline does not cover	17
3.5.1	Clinical areas that will not be covered	17
3.6	Relationship between the guideline and other NICE guidance.....	17
3.6.1	Related NICE guidance.....	17
4	Guideline development methodology	18
4.1	Developing the review questions and outcomes	18
4.2	Searching for evidence.....	22
4.2.1	Health economic literature search.....	23
4.3	Reviewing and synthesising research evidence	23
4.3.1	Systematic review process.....	23
4.3.2	Inclusion/exclusion criteria	25
4.3.3	Type of studies.....	25
4.3.4	Appraising the quality of the evidence by outcomes	31
4.3.5	Evidence statements.....	41
4.3.6	Evidence of cost effectiveness	41
4.4	Developing recommendations	42
4.4.1	Guideline recommendations.....	42
4.4.2	Research recommendations	43
4.5	Validation process	43
4.6	Updating the guideline.....	43
4.7	Disclaimer	43
4.8	Funding	43
4.9	References.....	43
5	Diagnosis	45
5.1	People with jaundice	45
5.1.1	Introduction	45

5.1.2	Description of Clinical Evidence	46
5.1.3	Summary of included studies	47
5.1.4	Clinical evidence profile	50
5.1.5	Economic evidence	55
5.1.6	Evidence Statements	55
5.1.7	Recommendations	57
5.1.8	Evidence to recommendations	57
5.1.9	References	59
5.2	People without jaundice but with a pancreatic abnormality	60
5.2.1	Introduction	60
5.2.2	Description of clinical evidence	61
5.2.3	Summary of included studies	63
5.2.4	Clinical evidence profile	66
5.2.5	Economic evidence	73
5.2.6	Evidence statements	73
5.2.7	Recommendations	75
5.2.8	Evidence to recommendations	76
5.2.9	References	77
5.3	Pancreatic Cysts	79
5.3.1	Introduction	79
5.3.2	Description of Clinical Evidence	80
5.3.3	Summary of included studies	84
5.3.4	Clinical evidence profile	95
5.3.5	Economic evidence	112
5.3.6	Evidence statements	112
5.3.7	Recommendations	119
5.3.8	Evidence to recommendations	119
5.3.9	References	122
5.4	People with inherited high risk of pancreatic cancer	125
5.4.1	Introduction	125
5.4.2	Description of clinical evidence	126
5.4.3	Summary of included studies	128
5.4.4	Clinical evidence profile	132
5.4.5	Economic evidence	136
5.4.6	Evidence Statements	136
5.4.7	Recommendations	137
5.4.8	Evidence to recommendations	138
5.4.9	Research recommendations	140
5.4.10	References	140
6	Referral to specialist multidisciplinary teams	142

6.1	Introduction	142
6.1.1	Review protocol summary	142
6.2	Description of the clinical evidence	143
6.3	Summary of included studies	143
6.4	Clinical evidence profile	143
6.5	Economic evidence	143
6.6	Evidence statements	143
6.7	Recommendations	143
6.8	Evidence to recommendations	143
6.8.1	Relative value placed on the outcomes considered	143
6.8.2	Quality of evidence	143
6.8.3	Consideration of clinical benefits and harms	143
6.8.4	Consideration of economic benefits and harms	144
6.9	References	144
7	Staging	145
7.1	Introduction	145
7.1.1	Review protocol summary	145
7.2	Description of clinical evidence	146
7.3	Summary of included studies	148
7.4	Clinical evidence profile	151
7.4.1	Tests for overall TNM Staging	151
7.4.2	Tests for resectability	153
7.4.3	Tests for T Staging	157
7.4.4	Tests for N Staging	159
7.4.5	Tests for M Staging	163
7.4.6	Tests for vascular invasion	165
7.4.7	Tests for indicating laparoscopic resectability	168
7.5	Economic evidence	170
7.5.1	Systematic literature review	170
7.6	Evidence statements	171
7.6.1	Tests for overall TMN Staging	171
7.6.2	Tests for resectability	172
7.6.3	Tests for T-Staging	174
7.6.4	Tests for N-Staging	174
7.6.5	Tests for M Staging	176
7.6.6	Tests for vascular invasion	177
7.6.7	Tests for indicating laparoscopic resectability	178
7.7	Recommendations	179
7.8	Evidence to recommendations	179
7.8.1	Relative value placed on the outcomes considered	179

7.8.2	Quality of evidence	180
7.8.3	Consideration of clinical benefits and harms	180
7.8.4	Consideration of economic benefits and harms.....	181
7.9	References.....	182
8	Support needs	185
8.1	Psychological support needs	185
8.1.1	Introduction	185
8.1.2	Description of Clinical Evidence	186
8.1.3	Summary of included studies	188
8.1.4	Clinical evidence profile	190
8.1.5	Economic evidence	193
8.1.6	Evidence Statements	193
8.1.7	Recommendations	197
8.1.8	Evidence to recommendations	198
8.1.9	Research recommendations	199
8.1.10	References	199
8.2	Pain.....	200
8.2.1	Introduction	200
8.2.2	Description of Clinical Evidence	201
8.2.3	Summary of included studies	203
8.2.4	Clinical evidence profile	207
8.2.5	Economic evidence	222
8.2.6	Evidence Statements	222
8.2.7	Recommendations	229
8.2.8	Evidence to recommendations	229
8.2.9	Research recommendations	231
8.2.10	References	231
8.3	Nutritional Interventions.....	232
8.3.1	Introduction	232
8.3.2	Description of Clinical Evidence	234
8.3.3	Summary of included studies	235
8.3.4	Clinical evidence profile	239
8.3.5	Economic evidence	258
8.3.6	Evidence Statements	258
8.3.7	Recommendations	266
8.3.8	Evidence to recommendations	266
8.3.9	Research recommendations	268
8.3.10	References	269
9	Interventions to relieve biliary and duodenal obstruction.....	270
9.1	Biliary obstruction	270

9.1.1	Introduction	270
9.1.2	Description of clinical evidence	271
9.1.3	Summary of included studies	274
9.1.4	Clinical evidence profiles.....	278
9.1.5	Economic Evidence	304
9.1.6	Evidence statements.....	307
9.1.7	Recommendations	323
9.1.8	Evidence to recommendations	324
9.1.9	References	328
9.2	Duodenal obstruction	329
9.2.1	Introduction	329
9.2.2	Description of Clinical Evidence	330
9.2.3	Summary of included studies	332
9.2.4	Clinical evidence profile	334
9.2.5	Economic evidence.....	344
9.2.6	Evidence Statements	344
9.2.7	Recommendations	350
9.2.8	Evidence to recommendations	350
9.2.9	References	352
10	Management of resectable and borderline resectable pancreatic cancer	353
10.1	Neoadjuvant treatment	353
10.1.1	Introduction	353
10.1.2	Description of Clinical Evidence	354
10.1.3	Summary of included studies	356
10.1.4	Clinical evidence profile	359
10.1.5	Economic evidence.....	368
10.1.6	Evidence statements.....	369
10.1.7	Recommendations	376
10.1.8	Evidence to recommendations	376
10.1.9	Research recommendation	378
10.1.10	References	378
10.2	Resectable and borderline resectable pancreatic cancer.....	380
10.2.1	Introduction	380
10.2.2	Description of Clinical Evidence	381
10.2.3	Summary of included studies	383
10.2.4	Clinical Evidence Profile.....	386
10.2.5	Economic evidence.....	397
10.2.6	Evidence Statements	397
10.2.7	Recommendations	409
10.2.8	Evidence to recommendations	409

10.2.9	Research Recommendations	412
10.2.10	References	412
10.3	Adjuvant treatment	422
10.3.1	Introduction	422
10.3.2	Description of clinical evidence	423
10.3.3	Summary of included studies	425
10.3.4	Clinical evidence profile	428
10.3.5	Economic evidence	462
10.3.6	Evidence statements.....	463
10.3.7	Recommendations	478
10.3.8	Evidence to recommendations	478
10.3.9	References	480
10.4	Follow-up for people with resected pancreatic cancer	482
10.4.1	Introduction	482
10.4.2	Description of clinical evidence	483
10.4.3	Summary of included studies	484
10.4.4	Clinical evidence profile	485
10.4.5	Economic evidence	487
10.4.6	Evidence statements.....	488
10.4.7	Recommendations	490
10.4.8	Evidence to recommendations	491
10.4.9	References	492
11	Management of unresectable pancreatic cancer	493
11.1	Management of locally advanced pancreatic cancer	493
11.1.1	Introduction	493
11.1.2	Description of Clinical Evidence	494
11.1.3	Summary of included studies	496
11.1.4	Clinical evidence profile	500
11.1.5	Economic evidence	516
11.1.6	Evidence Statements for pair-wise comparisons	520
11.1.7	Recommendations	531
11.1.8	Evidence to recommendations	531
11.1.9	References	533
11.2	Management of metastatic pancreatic cancer	535
11.2.1	Introduction	535
11.2.2	Description of Clinical Evidence	536
11.2.3	Summary of included studies	539
11.2.4	Clinical evidence profile	550
11.2.5	Economic evidence	611
11.2.6	Evidence statements.....	612

11.2.7	Recommendations	642
11.2.8	Evidence to recommendations	643
11.2.9	Research recommendation	646
11.2.10	References	646
12	Economic modelling: cost effectiveness of different types of stent for the management of biliary obstruction in people with unresectable pancreatic cancer.....	652
12.1	Introduction	652
12.2	Methods	652
12.2.1	Interventions considered	652
12.2.2	Model structure	653
12.2.3	Population.....	654
12.2.4	Model parameters	654
12.3	Results	660
12.3.1	Deterministic base case results.....	660
12.3.2	Stochastic base case results.....	660
12.3.3	Deterministic one way sensitivity analysis	660
12.3.4	Secondary Analysis including VAS Quality of Life Values	662
12.3.5	Probabilistic sensitivity analyses	662
12.4	Discussion.....	665
12.5	References.....	666
13	Network Meta-Analysis (Mixed Treatment Comparison) and Economic Model on treatment of unresectable locally advanced non-metastatic pancreatic cancer.....	667
13.1	Methods	667
13.1.1	Clinical data considered in the network meta-analyses	667
13.1.2	Review Strategy and Evidence Synthesis	667
13.1.3	Network meta-analysis Model structure	670
13.2	Network Meta-analysis Results	676
13.2.1	Estimated Hazard Ratios and Odds Ratios	676
13.2.2	Model Fit.....	680
13.3	Economic Model.....	680
13.3.1	Interventions Considered	680
13.3.2	Model Structure.....	681
13.3.3	Model Parameters.....	682
13.3.4	Costs	684
13.3.5	Quality of Life.....	686
13.3.6	Discounting	687
13.3.7	Probabilistic sensitivity analysis	687
13.3.8	Net Monetary Benefit	687
13.4	Results Economic Model	689

13.4.1 Overall and Progression Free Survival	689
13.4.2 Deterministic Base Case Results	690
13.4.3 Deterministic one way sensitivity analysis	691
13.4.4 Secondary analysis of treatment for patients with stable or responding disease	692
13.4.5 Probabilistic Sensitivity Analysis	693
13.4.6 Secondary Analysis Including FOLFIRINOX	694
13.4.7 Threshold Sensitivity Analysis around FOLFIRINOX.....	695
13.4.8 Probabilistic Sensitivity Analysis	695
13.4.9 Discussion	696
13.5 References.....	697

1 Introduction

Pancreatic cancer is the fifth leading cause of cancer death in the UK. On average, 23 people die each day from the disease. The UK has one of the worst survival rates in Europe, with average life expectancy on diagnosis just 4–6 months and a relative survival to 1 year of approximately 20%.

Only 3% of people survive for 5 years or longer. This figure has not improved much in over 40 years, and the more recent effects of increased surgery and use of adjuvant chemotherapy on survival outcomes is not yet established.

Because of late diagnosis only 8% of people with pancreatic cancer have potentially curative surgery. However, people have up to a 30% chance of surviving 5 years if their tumour can be surgically removed and they have adjuvant chemotherapy.

The symptoms of pancreatic cancer are non-specific. One survey found that 40% of people diagnosed with pancreatic cancer in England had visited their GP 3 or more times before the diagnosis was made. Fifty per cent of people are diagnosed as an emergency in the A&E system. Even after diagnosis of pancreatic cancer there is evidence from the National Cancer Intelligence Network of wide variation in practice throughout England. There are often delays in access to diagnosis and treatment (as highlighted in the [NHS England Five Year Forward View](#)), and this guideline will help to improve this.

The evidence reviewed for this guideline has highlighted the lack of useful national data on pancreatic cancer in the UK. In many cancers, national datasets have contributed significantly to improving outcomes of patient management. For pancreatic cancer, there has been no comprehensive national database and therefore comparing outcomes between pancreatic centres and pancreatic specialists has not been possible. This lack of continuous audit may result in inappropriate variation in the standard of treatments between centres. The Committee is of the unanimous opinion that a national database of pancreatic cancer patients needs to be established to provide a continuous comparative audit of patient management.

2 Guideline summary

2.1 Guideline Committee membership, NGA staff and acknowledgements

Table 1: Guideline Committee Members

Name	Role
Mark Callaway	Consultant Radiologist, Department of Molecular and Clinical Cancer Medicine, Bristol Royal Infirmary, University Hospitals Bristol NHS Foundation Trust
Fiona Campbell	Consultant Gastrointestinal Pathologist, Royal Liverpool University Hospital
Margred Capel	Consultant in Palliative Medicine, George Thomas Hospice
Richard Charnley	Consultant Hepatobiliary and Pancreatic Surgeon, Freeman Hospital, Newcastle upon Tyne
Pippa Corrie	Consultant and Associate Lecturer in Medical Oncology, Cambridge University Hospitals NHS Foundation Trust and University of Cambridge
Dawn Elliot	UGI Clinical Nurse Specialist, Northumbria Healthcare Foundation Trust
Lesley Goodburn	Lay member
Anna Jewell	Lay member
Suzanne Joharchi	Lay member
Laura McGeeney	Specialist Pancreatic Dietitian, Department of Nutrition and Dietetics, Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust
Somnath Mukherjee	Associate Professor & Consultant Clinical Oncologist, CRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford & Churchill Hospital
John Neoptolemos (Clinical Lead)	The Owen and Ellen Evans Chair of Surgery, University of Liverpool and The Royal Liverpool & Broadgreen University Hospital NHS Trust (until August 2017)
Kofi Oppong	Consultant Gastroenterologist, Newcastle upon Tyne University Hospitals NHS Trust
Derek O'Reilly	Consultant Hepatobiliary and Pancreatic Surgeon, Manchester Royal Infirmary, Central Manchester NHS Foundation Trust
John Primrose (Chair)	Professor of Surgery, University of Southampton, C Level South Academic Block, Southampton General Hospital

Table 2: NGA Staff

Name	Role
Angela Bennett	Guideline Lead (until August 2017)
Katharina Dworzynski	Guideline Lead (from August 2017)
Michaela Dijmarescu	Project Manager (from September 2017)
Linyun Fou	Systematic Reviewer (from October 2016)
John Graham	Clinical Advisor
Elise Hasler	Information Scientist
James Hawkins	Health Economist
Fionnuala O'Brien	Project Manager (from September 2016)
Ferruccio Pelone	Systematic Reviewer

Name	Role
Kelly Williams	Assistant Systematic Reviewer (from October 2016 until February 2017)

1 **Acknowledgements**

2 Additional support was received from Alex Bates (Senior Health Economist), Nathan
3 Bromham (Senior Systematic Reviewer), Matthew Prettyjohns (Senior Health Economist)
4 and Katie Webster (External Contractor).

5 **2.2 Other versions of the guideline**

6 NICE produces a number of versions of this guideline:

- 7 • The 'short guideline' lists the recommendations, context and recommendations for
8 research.
- 9 • NICE Pathways brings together all connected NICE guidance.

10 **2.3 Schedule for updating the guideline**

11 For the most up-to-date information about guideline reviews, please see the latest version of
12 the NICE guidelines manual available from the NICE website.

3 Development of this guideline

3.1 What is a NICE Guideline?

NICE guidelines are recommendations for the care of individuals in specific clinical conditions or circumstances within the NHS – from prevention and self-care through primary and secondary care to more specialised services. We base our NICE guidelines on the best available research evidence, with the aim of improving the quality of healthcare. We use predetermined and systematic methods to identify and evaluate the evidence relating to specific review questions.

NICE guidelines can:

- Provide recommendations for the treatment and care of people by healthcare professionals.
- Be used to develop standards to assess the clinical practice of individual healthcare professionals.
- Be used in the education and training of healthcare professionals.
- Help patients to make informed decisions.
- Improve communication between patients and healthcare professionals.

While guidelines assist the practice of healthcare professionals, they do not replace their knowledge and skills.

We produce our guidelines using the following steps:

- The guideline topic is referred to NICE from the Department of Health.
- Stakeholders register an interest in the guideline and are consulted throughout the development process.
- The scope is prepared by the NGA.
- The NGA establishes a committee.
- A draft guideline is produced after the committee members assess the available evidence and makes recommendations.
- There is a consultation on the draft guideline.
- The final guideline is produced.

The NGA and NICE produce a number of versions of this guideline.

- The 'full guideline' contains all the recommendations, together with details of the methods used and the underpinning evidence.
- The 'short guideline' lists the recommendations, context and recommendations for research.
- NICE Pathways brings together all connected NICE guidance.

3.2 Remit

NICE received the remit for this guideline from the Department of Health. It commissioned the NGA to produce the guideline and has supported the development of this guideline.

The remit for this guideline is to develop a NICE guideline on the diagnosis and management of pancreatic cancer in adults.

1 **3.3 Who developed this guideline?**

2 A multidisciplinary committee comprising healthcare professionals and researchers as well
3 as lay members developed this guideline (see the list of group members and
4 acknowledgements).

5 The committee was convened by the NGA and chaired by Professor John Primrose.

6 The group met approximately every 6 weeks during the development of the guideline. At the
7 start of the guideline development process all group members declared interests including
8 consultancies, fee-paid work, shareholdings, fellowships and support from the healthcare
9 industry. At all subsequent group meetings, members declared arising conflicts of interest.

10 Members were either required to withdraw completely or for part of the discussion if their
11 declared interest presented a conflict and it was considered appropriate to do so. The details
12 of declared interests and the actions taken are shown in the Committee Member List in
13 accordance with the NICE conflict of interest policy.

14 Staff from the NGA provided methodological support and guidance for the development
15 process. The team working on the guideline included a guideline lead, a project manager,
16 systematic reviewers, health economists, and information scientists. They undertook
17 systematic searches of the literature, appraised the evidence, conducted meta-analysis and
18 cost-effectiveness analysis where appropriate and drafted the guideline in collaboration with
19 the group.

20 **3.4 What this guideline covers**

21 **3.4.1 Groups that will be covered**

22 The guideline covers the following groups.

- 23
- 24 • Adults (18 and over) referred to secondary care with suspected pancreatic cancer
 - 25 • Adults (18 and over) with newly diagnosed or recurrent pancreatic ductal adenocarcinoma.

26 **3.4.2 Key clinical areas that will be covered**

27 The following clinical areas will be covered in this guideline:

- 28
- 29 • Information and support needs for people with pancreatic cancer and their families and carers
 - 30 • Referring people to specialist teams
 - 31 • Diagnosing suspected pancreatic cancer
 - 32 • Staging pancreatic cancer
 - 33 • Managing pancreatic cancer
 - 34 • Follow-up of people with pancreatic cancer.

35 Note that guideline recommendations will normally fall within licensed indications.
36 Exceptionally, and only if clearly supported by evidence, the use outside a licensed indication
37 may be recommended. This guideline will assume that prescribers will use a drug's summary
38 of product characteristics to inform decisions made with individual patients.

39 For further details please refer to the scope in Appendix A and review questions in Appendix
40 C.

1 **3.5 What this guideline does not cover**

2 **3.5.1 Clinical areas that will not be covered**

3 This guideline does not cover:

- 4 • Identifying people in primary care with suspected pancreatic cancer and referring them to
5 secondary care.

6 **3.6 Relationship between the guideline and other NICE**
7 **guidance**

8 **3.6.1 Related NICE guidance**

- 9 • [Care of dying adults in the last days of life](#) NICE Guideline NG31.
10 • [Improving supportive and palliative care in adults](#) (update) NICE guideline. Publication
11 expected January 2018.
12 • [Pancreatic cancer \(metastatic, untreated\) – liposomal cisplatin \(with gemcitabine\)](#) NICE
13 technology appraisal. Publication date to be confirmed
14 • [Pancreatic cancer \(metastatic\) - nimotuzumab \(1st line\)](#) NICE technology appraisal.
15 Publication date to be confirmed

4 Guideline development methodology

This chapter describes the methods used to review the evidence and generate the recommendations presented in subsequent chapters. This guidance was developed in accordance with the methods outlined in the [NICE guidelines manual 2014](#) (PMG 20).

Declarations of interest were recorded according to the 2014 NICE conflicts of interest policy.

4.1 Developing the review questions and outcomes

The review questions were drafted by the NGA, and refined and validated by the committee. The questions were based on the key areas identified in the guideline scope (See Appendix A).

A total of 17 questions were identified (See Table 3).

The review questions were based on the following frameworks:

- intervention reviews – using population, intervention, comparator and outcome (PICO framework)
- reviews of diagnostic test accuracy – using population, diagnostic test (index tests), reference standard and target condition
- qualitative reviews – using population, area of interest and themes of interest

These frameworks guided the literature searching process, critical appraisal and synthesis of evidence and facilitated the development of recommendations by the committee.

Full literature searches, critical appraisals and evidence reviews were completed for all review questions.

Table 3: Description of review questions

Chapter or section number	Type of review	Review questions	Outcomes
8.1	<ul style="list-style-type: none"> • Qualitative Evidence • Mixed Methods (including quantitative and qualitative analysis) • Audits (patient experience survey) 	What are the specific psychological support needs (including information) of adults with newly diagnosed or recurrent pancreatic cancer and their families or carers (as appropriate) throughout the care pathway?	<ul style="list-style-type: none"> • Health Related Quality of Life • Patient satisfaction • Patient/family/carer understanding of disease impact • Patient reported outcomes • Patient experience
6	Interventional	Does referral of all people with suspected pancreatic cancer to a specialist MDT for review improve patient management and outcomes?	<ul style="list-style-type: none"> • Survival Outcomes • Proportion receiving chemotherapy • Entry into clinical trials • Resection rates • Post-operative mortality • Patient Satisfaction • Quality of Life

Chapter or section number	Type of review	Review questions	Outcomes
5.1	Diagnostic	What is the most effective diagnostic pathway (imaging +/-CA 19–9, biopsy (cytology or histology)) for adults with suspected pancreatic cancer in secondary care who have jaundice?	Diagnostic Accuracy including: <ul style="list-style-type: none"> ○ Sensitivity ○ Specificity ○ Positive Predictive Value ○ Negative Predictive Value ○ Adverse events
5.2	Diagnostic	What is the most effective diagnostic pathway (imaging +/- CA 19–9, biopsy (cytology or histology)) for adults with suspected pancreatic cancer in secondary care who do not have jaundice but have a pancreatic abnormality on imaging?	Diagnostic Accuracy including: <ul style="list-style-type: none"> ○ Sensitivity ○ Specificity ○ Positive Predictive Value ○ Negative Predictive Value ○ Adverse events
5.3	Diagnostic	In adults with a pancreatic cyst, what is the diagnostic pathway to identify the cyst(s) at high risk of pancreatic malignancy?	Diagnostic Accuracy including: <ul style="list-style-type: none"> ○ Sensitivity ○ Specificity ○ Positive Predictive Value ○ Negative Predictive Value ○ Adverse events
5.4	Diagnostic	What is the most effective monitoring protocol for adults with an inherited high risk of pancreatic cancer in secondary care to ensure early diagnosis?	<ul style="list-style-type: none"> ● Early diagnosis ● Survival ● Diagnostic Accuracy including: <ul style="list-style-type: none"> ○ Sensitivity ○ Specificity ○ Positive Predictive Value ○ Negative Predictive Value ● Adverse events of interventions ● HRQoL
7	Diagnostic	What is the most effective investigative pathway for staging adults with newly diagnosed pancreatic cancer or a non-definitive diagnostic result as resectable, borderline resectable, locally advanced and metastatic disease?	<ul style="list-style-type: none"> ● Diagnostic test accuracy data (diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value) for the following outcomes: <ul style="list-style-type: none"> ● Precise Staging ● N Staging ● M Staging ● Resectability ● Vascular invasion ● Adverse events
10.2	Interventional	What is the most effective surgery (type and extent) for adults with resectable and borderline resectable pancreatic cancer?	<ul style="list-style-type: none"> ● Local Recurrence ● Distant Recurrence ● Overall Survival ● Post-operative death (30 day/90 day) ● Treatment related morbidity ● Treatment related mortality ● Lymph node harvest

Chapter or section number	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Health Related Quality of Life • Patient experience • PROMS
10.1	Interventional	Is neoadjuvant therapy for adults with resectable and borderline resectable pancreatic adenocarcinoma an effective treatment?	<ul style="list-style-type: none"> • Response to neoadjuvant treatment pre-surgery • Disease-free interval • Relapse-free survival • Overall Survival • Resection rate • Time from initiating treatment to Surgery • Adverse Events • Health Related Quality of Life • Patient experience • PROMS
10.3	Interventional	What is the most effective adjuvant therapy (chemotherapy, chemoradiotherapy, biological therapy, immunotherapy, combinations of therapies) for adults who have undergone surgical resection of pancreatic adenocarcinoma?	<ul style="list-style-type: none"> • Disease-free interval • Relapse-free survival • Overall Survival • Adverse Events • Health Related Quality of Life • Patient experience • PROMS
11.2	Interventional	What is the most effective treatment (chemotherapy, chemoradiotherapy, radiotherapy, combinations of chemotherapy and chemoradiotherapy, biological therapies, immunotherapy or other local therapies) for adults with newly diagnosed or recurrent unresectable locally advanced non-metastatic pancreatic cancer?	<ul style="list-style-type: none"> • Objective Response (CR/PR/PD/SD/) • Resection rate • Progression Free Survival (local, distant) • Overall Survival • Adverse Events • Health Related Quality of Life • pain control • Patient experience • PROMS
8.2	Interventional	What is the role of interventional techniques (including sympathectomy or neurolytic techniques) in the management of pain in adults with newly diagnosed or recurrent pancreatic ductal adenocarcinoma?	<ul style="list-style-type: none"> • Reduction in opioid medication • Pain Relief/ improved analgesia (pain scores) • Duration of effect/ duration of relief • Adverse Events (Diarrhoea, reduction in Opioid induced side effects) • Health Related Quality of Life (functional domains) • Patient experience • PROMS • Overall survival
11.1	Interventional	What are the most effective interventions (excluding	<ul style="list-style-type: none"> • Response rate • Progression Free Survival

Chapter or section number	Type of review	Review questions	Outcomes
		relevant NICE TAs) for adults with newly diagnosed or recurrent metastatic pancreatic cancer (chemotherapy, surgery, radiotherapy)?	<ul style="list-style-type: none"> • Overall Survival • Adverse Events • Health Related Quality of Life • Patient experience and PROMs • Symptom control
9.2	Interventional	What is the optimal treatment of adults with newly diagnosed or recurrent resectable pancreatic cancer, borderline resectable pancreatic cancer and unresectable/metastatic pancreatic cancer who have duodenal obstruction?	<ul style="list-style-type: none"> • Relief of obstruction • Change in symptoms • Nutritional status • Adverse events • Overall Survival • Health Related Quality of Life • Patient experience • PROMS
9.1	Interventional	What is the optimal treatment of biliary obstruction in adults with newly diagnosed or recurrent pancreatic cancer?	<ul style="list-style-type: none"> • Relief of obstruction • Relief of symptoms • Treatment-related mortality • Treatment related morbidity • Treatment-related complications • Overall Survival • Time to definitive treatment • Health Related Quality of Life • Patient experience • PROMS
8.3	Interventional	What nutritional interventions (e.g. pancreatic enzyme replacement therapy, oral nutritional supplements, dietary manipulation, omega 3 fatty acids) are effective for patients with newly diagnosed or recurrent pancreatic cancer?	<ul style="list-style-type: none"> • Overall Survival • Treatment related morbidity • Health Related Quality of Life • Symptom control • Nutritional status (weight, BMI, lean body mass, strength test/ muscle function, sarcopenia, percentage weight change) • Adverse events • Patient experience • recurrence • tolerance to treatment (as in chemo/ surgery) • Ability to carry out normal activities
10.4	Interventional	What is the optimal follow-up protocol for people with resected pancreatic adenocarcinoma?	<ul style="list-style-type: none"> • Survival • Time to detection of recurrence • Proportion of asymptomatic recurrence (imaging) • Fitness for further intervention • HRQL • Adverse events • Risk of increased radiation (following repeated imaging) • PROMS

Chapter or section number	Type of review	Review questions	Outcomes
			<ul style="list-style-type: none"> • Patient acceptability / patient choice

1 4.2 Searching for evidence

2 Systematic literature searches were undertaken to identify all published clinical evidence
3 relevant to the review questions.

4 Databases were searched using relevant medical subject headings, free-text terms and
5 study type filters where appropriate. Studies published in languages other than English were
6 not reviewed. Where possible, searches were restricted to retrieve only articles published in
7 English. All searches were conducted in MEDLINE, Embase and The Cochrane Library, with
8 some additional database searching in AMED, PsycINFO and Web of Science Core
9 Collection for certain topic areas. The following searches were updated in April 2017.

- 10
- Diagnosing suspected pancreatic cancer
 - 11 • Staging pancreatic cancer
 - 12 • Managing pancreatic cancer
 - 13 • Follow-up of people with pancreatic cancer.

14 The following searches were run in June 2016 and October 2016 respectively

- 15
- Information and support needs of pancreatic cancer patients
 - 16 • Referral of pancreatic cancer patients to a specialist MDT

17 The decision not to re-run these two topics was based on the limited evidence identified for
18 these two topics and the likelihood that there wouldn't be evidence identified in a re-run. The
19 committee were asked to keep abreast of the literature in these areas.

20 We prioritised the list below for re-runs based on the following criteria:

- 21
- Topics with significant evidence movement where it is likely that new evidence will have
22 been published
 - 23 • Topics where HE modelling work had been conducted

24 Any studies added to the databases after the search dates (even those published prior to the
25 search dates) were not included unless specifically stated in the text.

26 Search strategies were quality assured by cross-checking reference lists of highly relevant
27 papers, analysing search strategies in other systematic reviews and asking the group
28 members to highlight any additional studies. The questions, the study types applied, the
29 databases searched and the years covered can be found in Appendix D.

30 The titles and abstracts of records retrieved by the searches were inspected for relevance,
31 with potentially significant publications obtained in full text. These were assessed against the
32 inclusion criteria.

33 During the scoping stage, a search was conducted for guidelines and reports on websites of
34 organisations relevant to the topic. Searching for grey literature or unpublished literature was
35 not undertaken. Searches for electronic, ahead-of-print publications were not routinely
36 undertaken unless indicated by the committee. All references suggested by stakeholders at
37 the scoping consultation were initially considered.

1 4.2.1 Health economic literature search

2 A global search of economic evidence relating to pancreatic cancer was undertaken in
3 August 2015 and re-ran in April 2017. The following databases were searched:

- 4 • MEDLINE (Ovid);
- 5 • EMBASE (Ovid);
- 6 • HTA database (HTA);
- 7 • NHS Economic Evaluations Database (NHS EED).

8 Further to the database searches, the committee was contacted with a request for details of
9 relevant published and unpublished studies of which they may have knowledge; reference
10 lists of key identified studies were also reviewed for any potentially relevant studies. Finally,
11 the NICE website was searched for any recently published guidance relating to pancreatic
12 cancer that had not been already identified via the database searches.

13 The search strategy for existing economic evaluations combined terms capturing the target
14 condition (pancreatic cancer) and, for searches undertaken in MEDLINE and EMBASE,
15 terms to capture economic evaluations. No restrictions on language or setting were applied
16 to any of the searches, but a standard exclusions filter was applied (letters, animals, etc.).
17 Conference abstracts were considered for inclusion from 1st January 2014, as high-quality
18 studies reported in abstract form before 2014 were expected to have been published in a
19 peer-reviewed journal. Full details of the search strategies are presented in Appendix D.

20 The titles and abstracts of papers identified through the searches were independently
21 assessed for inclusion using pre-defined eligibility criteria defined in Table 4.

22 **Table 4: Inclusion and exclusion criteria for the systematic reviews of economic**
23 **evaluations**

Inclusion criteria
Economic evaluations that compare costs and health consequences of interventions (i.e. true cost-effectiveness analyses)
Population, interventions, comparators and outcomes match those specified in the PICO
Quality of life based outcomes were used as the measure of effectiveness in at least 1 of the analyses presented
Incremental results reported or enough information for incremental results to be derived
Conducted from the perspective of a healthcare system in an OECD country
Exclusion criteria
abstracts with insufficient methodological details for quality assessment
Non-English language papers

24 Once the screening of titles and abstracts was complete, full versions of the selected papers
25 were acquired for assessment.

26 The quality of evidence was assessed using the economic evaluations checklist as specified
27 in the [NICE guidelines manual](#). Quality assessments of included studies and data extraction
28 tables are provided in Appendix J.

29 4.3 Reviewing and synthesising research evidence

30 4.3.1 Systematic review process

31 The evidence was reviewed following these steps (See Figure 1):


- 32 • Potentially relevant studies were identified for each review question from the relevant
33 search results by reviewing titles and abstracts. Full papers were then obtained.

- 1 • Full papers were reviewed against pre-specified inclusion and exclusion criteria in the
2 review protocols (in Appendix C).
- 3 • Key information was extracted on the study's methods, according to the factors specified
4 in the protocols and results. These were presented in summary tables (in each review
5 chapter) and evidence tables (in Appendix G)
- 6 • Relevant studies were critically appraised using the appropriate checklist as specified in
7 the [NICE guidelines manual](#) (NICE 2014).
- 8 • Summaries of evidence were generated by outcome or study where appropriate (included
9 in the relevant review chapters) and were presented in committee meetings (details of
10 how the evidence was appraised is described in Section 4.3.5 below):
- 11 ○ Randomised studies: meta-analysis was carried out where appropriate and results
12 were reported in GRADE profiles (for intervention reviews).
- 13 ○ Observational studies: data were presented individually by study in GRADE profiles.
- 14 ○ Diagnostic studies: data were presented individually by study as measures of
15 diagnostic test accuracy (sensitivity and specificity, positive and negative likelihood
16 ratios) and were presented in modified GRADE profiles.
- 17 ○ Qualitative studies: each study was summarised by theme and meta-synthesis was
18 carried out where appropriate to identify an overarching framework of themes and
19 subthemes. An adapted Critical Appraisal Skills Programme Qualitative checklist
20 (Public Health Resource Unit England 2006) was used to present quality evaluations of
21 each study

22 For quality assurance of study identification, either whole study selections or a sample of the
23 study selection results were double checked by a second reviewer. Searches related to the
24 NMA were also double sifted.

25 A sample of all evidence tables, including a sample of evidence tables related to the NMA
26 were checked by a second reviewer. All drafts of reviews were checked by a second
27 reviewer. Any discrepancies were resolved by discussion between the 2 reviewers.

Figure 1: Step-by-step review of evidence in the guideline



1 **4.3.2 Inclusion/exclusion criteria**

2 The inclusion and exclusion of studies was based on the review protocols, which can be
3 found in Appendix C. Excluded studies by review question (with the reasons for their
4 exclusion) are listed in Appendix G. In addition, the committee was consulted about any
5 uncertainty regarding inclusion or exclusion.

6 **4.3.3 Type of studies**

7 Systematic reviews (SRs) with meta-analyses were considered the highest quality evidence
8 to be selected for inclusion.

9 For most intervention reviews in this guideline, parallel randomised controlled trials (RCTs)
10 were prioritised because they are considered the most robust type of study design that could
11 produce an unbiased estimate of the intervention effects. Crossover RCTs were appropriate
12 for some of the interventional questions. If there was limited evidence from RCTs,
13 observational studies were included.

14 For diagnostic reviews, cross-sectional, retrospective or prospective observational studies
15 were considered for inclusion. Where evidence was limited, case-control studies were also
16 considered for inclusion.

17 For qualitative reviews, studies using focus groups, or structured or semi-structured
18 interviews were considered for inclusion. Survey data or other types of questionnaires were
19 only included if they provided analysis from open-ended questions, but not if they reported
20 descriptive quantitative data only.

1 Literature reviews, posters, letters, editorials, comment articles, unpublished studies and
2 studies not in English were excluded. Conference abstracts were only considered for
3 inclusion in the absence of full published studies.

4 **4.3.3.1 Data synthesis for intervention studies**

5 **Pairwise meta-analysis**

6 Meta-analysis was conducted whenever it could be robustly performed, to combine the
7 results of studies for each review question using Cochrane Review Manager (RevMan5)
8 software.

9 The generic inverse variance option in RevMan5 was used where any studies reporting
10 solely the summary treatment effect and 95% confidence interval (95% CI) or standard error
11 could be included.

12 Fixed-effect (Mantel–Haenszel) techniques were used in the first instance to calculate risk
13 ratios (relative risk) for binary outcomes, such as rate of adverse events or rate of people
14 with symptom improvements (Mantel & Haenszel 1959).

15 For continuous outcomes, measures of central tendency (mean) and variation (standard
16 deviation) are required for meta-analysis. However, in cases where standard deviations were
17 not reported per intervention group, the standard error (SE) for the mean difference was
18 calculated from other reported statistics (p-values or 95% CIs): meta-analysis was then
19 undertaken for the mean difference and SE using the generic inverse variance method in
20 RevMan5

21 When the only evidence was based on studies summarising results by presenting medians
22 (and interquartile ranges) or only p values were given, this information was assessed in
23 terms of the study's sample size and was included in the GRADE tables without calculating
24 the relative or absolute effects. Consequently, aspects of quality assessment, such as
25 imprecision of effect, could not be assessed for evidence of this type. However, the limited
26 reporting of this outcome was classified as a risk of bias in study limitations.

27 Stratified analyses were predefined for some review questions at the protocol stage when the
28 committee identified that these strata are different in terms of biological and clinical
29 characteristics and the interventions were expected to have a different effect.

30 Statistical heterogeneity was assessed by visually examining the forest plots (please see
31 Appendix H) and by considering the chi-squared test for significance at $p < 0.1$ or an I-squared
32 inconsistency statistic (with an I-squared value of more than 50% indicating considerable
33 heterogeneity). Where considerable heterogeneity was present, predefined subgroup
34 analyses were performed.

35 Assessments of potential differences in effect between subgroups were based on the chi-
36 squared tests for heterogeneity statistics between subgroups. If no sensitivity analysis was
37 found to completely resolve statistical heterogeneity, then a random-effects (DerSimonian
38 and Laird) model was employed to provide a more conservative estimate of the effect –
39 (DerSimonian & Laird 1986).

40 Where data from observational studies were included, the committee decided that the results
41 for each outcome should be presented separately for each study and meta-analysis was not
42 conducted.

1 **Network Meta-Analysis (NMA)**

2 In some circumstances, the results of conventional pairwise meta-analyses of direct
3 evidence does not help assess which intervention is most effective. The challenge of
4 interpretation may arise for two main reasons:

- 5 • Relative treatment efficacies based on separate individual pairwise comparisons across
6 multiple treatments are difficult to assess.
- 7 • Direct RCT comparison between treatments of clinical interest are not available in
8 published literature.

9 To overcome these issues, NMA can be performed. The advantages of performing this type
10 of analysis are:

- 11 • It allows the synthesis of data from direct and indirect comparisons without breaking
12 randomisation, to produce measures of treatment effect and ranking of different
13 interventions. If treatment A has never been compared against treatment B head to head,
14 but these 2 interventions have been compared to a common comparator, then an indirect
15 treatment comparison can use the relative effects of the two treatments versus the
16 common comparator. This is also the case whenever there is a path linking two
17 treatments through a set of common comparators. All the randomised evidence is
18 considered within the same model.
- 19 • For every intervention in a connected network, a relative effect estimate (with its 95%
20 credible intervals (95% CrI) can be estimated versus any other intervention. These
21 estimates provide a useful clinical summary of the results and facilitate the formation of
22 recommendations based on all of the best available evidence, whilst appropriately
23 accounting for uncertainty. Furthermore, these estimates will be used to parameterise
24 treatment effectiveness in the de novo cost-effectiveness modelling.

25 There are 3 key assumptions behind an NMA: similarity, transitivity and consistency.

26 Consistency is the assumption that the direct estimates are equal to the indirect estimates
27 (i.e. that the relative effect of A versus C is equal to the relative effect of A versus B
28 versus C).

29 Similarity across trials is the critical rationale for the consistency assumption to be valid as,
30 by ensuring the clinical characteristics of the trials are similar, we ensure consistency in the
31 data analysis.

32 More specifically, randomisation holds only within individual trials, not across the trials.
33 Therefore, if the trials differ in terms of patient characteristics, measurement and/or definition
34 of outcome, length of follow-up across the direct comparisons, the similarity assumption is
35 violated and this can bias the analysis.

36 Transitivity is the assumption that an intervention (A) will have the same efficacy in a study
37 comparing A versus B as it will in a study comparing A versus C. Another way of looking at it,
38 in terms of the study participants, is that we assume that it is equally likely that any patient in
39 the network could have been given any of the treatments in the network and would have
40 responded to the treatments in the same way (depending on how efficacious the treatments
41 are). This assumption is closely related to similarity in that if participants in a study
42 comparing A versus B are not the same as those in a study comparing A versus C.

43 As it is the case for ordinary pairwise meta-analysis, NMA may be conducted using either
44 fixed or random effects models. A fixed effects model typically assumes that there is no
45 variation in relative effects across trials for a particular pairwise comparison and any
46 observed differences are solely due to chance. For a random effects model, it is assumed
47 that the relative effects are different in each trial but that they are from a single common
48 distribution. The variance reflecting heterogeneity is often assumed to be constant across
49 trials.

1 In a Bayesian analysis, for each parameter the evidence distribution is weighted by a
2 distribution of prior beliefs. Markov Chain Monte Carlo (MCMC) algorithm was used to
3 generate a sequence of samples from a joint posterior distribution of 2 or more random
4 variables and is particularly well adapted to sampling the treatment effects (known as
5 posterior distribution) of a Bayesian network. A non-informative prior distribution was used to
6 maximise the weighting given to the data and to generate the posterior distribution for each
7 log odds ratio (OR), log rate ratio or mean difference (MD) of interest in the networks. We
8 used the median of the distribution as our point estimate and the centiles provided the 95%
9 Credible Intervals (CrI). Non-informative priors were used which were normally distributed
10 with a mean of 0 and standard deviation of 100.

11 For the analyses, a series of 50,000 burn-in simulations were run to allow the posterior
12 distributions to convergence and then a further 100,000 simulations were run to produce the
13 outputs. Convergence was assessed by examining the history, autocorrelation and Brooks-
14 Gelman-Rubin plots.

15 Goodness-of-fit of the model was also estimated by using the posterior mean of the sum of
16 the deviance contributions for each item by calculating the residual deviance and deviance
17 information criteria (DIC). If the residual deviance was close to the number of unconstrained
18 data points (the number of trial arms in the analysis) then the model was explaining the data
19 at a satisfactory level. The choice of a fixed or random effects model can be made by
20 comparing their goodness-of-fit to the data.

21 Incoherence in NMA between direct and indirect evidence can be assessed in closed
22 treatment loops within the network. These closed treatment loops are regions within a
23 network where direct evidence is available on at least 3 different treatments that form a
24 closed "circuit" of treatment comparisons (for example A versus B, B versus C, C versus A).
25 If closed treatment loops existed then discrepancies between direct and indirect evidence
26 was assessed for each loop using node-splitting (van Valkenhoef, 2016).

27 The outputs of the NMA were:

- 28 • Treatment specific log HRs, log odd ratios, and MDs with their 95% CrI were generated
29 for every possible pairs of comparisons by combining direct and indirect evidence in each
30 network.
- 31 • The ranking of treatments (presented as median rank and its 95% CrI).

32 One of the main advantages of the Bayesian approach is that the method leads to a decision
33 framework that supports decision making. The Bayesian approach also allows the probability
34 that each intervention is best for achieving a particular outcome, as well as its ranking, to be
35 calculated.

36 We adapted a model templates for continuous and dichotomous data available from NICE
37 Decision Support UNIT (DSU) technical support document number 2. This model accounts
38 for the within-study correlation between treatment effects induced by multi-arm trials.

39 NMA was considered particularly important for the review question where it was used
40 because it allows use of indirect evidence to make comparisons between treatments that
41 have not been compared in head-to-head RCTs. NMA allows us to estimate relative effects
42 between all active treatments regardless of whether they had been compared directly in
43 RCTs or not. NMA also allows all treatments to be compared to a single comparator, which is
44 useful for health economic analysis that takes a fully incremental approach to determine the
45 most cost-effective treatment out of all treatments under consideration. The primary
46 motivation behind NMA for the chosen review question was that health economic analysis
47 was prioritised for this review question.

1 4.3.3.2 Data synthesis for diagnostic test accuracy and staging reviews

24.3.3.2.1 Data and outcomes

3 There are a number of diagnostic test accuracy measures. Sensitivity, specificity, positive
4 and negative predictive values were used as outcomes for diagnostic reviews in this
5 guideline. These diagnostic accuracy parameters (with 95% CI) were obtained from the
6 studies or calculated by the technical team using data from the studies.

7 Sensitivity and specificity are measures of the ability of a test to correctly classify a person as
8 having a condition or not having a condition. When Sensitivity is high, a negative test result
9 rules out the target condition; when Specificity is high, a positive test result rules in the target
10 condition. An ideal test would be both highly sensitive and highly specific, but this is
11 frequently not possible and typically there is a trade-off in accuracy between the two.

12 The following definitions were used when summarising the levels of sensitivity or specificity
13 for the committee:

- 14 • High: 90% and above
- 15 • Moderate: 75% to 89%
- 16 • Low: 74% or below

17 Predictive values are measures of the proportion of true cases relative to the total number of
18 diagnosed cases: a positive predictive value is the probability that the target condition is
19 present given a positive test result, whilst a negative predictive value is the probability that
20 the target condition is not present given a negative test result.

21 Since predictive values are dependent on the prevalence of the target condition in the
22 sample used, likelihood ratios were calculated from the sensitivity and specificity of the
23 relevant studies (or the pooled sensitivity and specificity if a meta-analysis was possible) and
24 used when presenting the evidence to the committee. Positive and negative likelihood ratios
25 are measures of the association between a test result and the target condition. A positive
26 likelihood ratio greater than 1 indicates how much more likely a person with the target
27 condition is to have a positive test compared to a person without the target condition; a
28 negative likelihood ratio less than 1 indicates how much less likely a person with the target
29 condition is to have a negative test compared to a person without the target condition.

30 The following definitions were used when summarising the likelihood ratios for the
31 committee:

- 32 • Very useful test: LR+ higher than 10; LR- lower than 0.1
- 33 • Moderately useful test: LR+ 5 to 10; LR- 0.1 to 0.2
- 34 • Not a useful test: LR+ lower than 5; LR- higher than 0.2

35 **Table 5: '2 x 2' table for calculation of diagnostic accuracy parameters**

	Reference standard positive	Reference standard negative	Total
Index test result positive	True positive (TP)	False positive (FP)	TP+FP (Total number of subjects with positive result in screening tool)
Index test result negative	False negative (FN)	True negative (TN)	FN+TN (Total number of subjects with negative results in screening tool)

	Reference standard positive	Reference standard negative	Total
Total	TP+FN (Total number of subjects with diagnosis)	FP+TN (Total number of subjects without diagnosis)	TP+FP+FN+Tn=N (Total number of subjects in study)
<p>Note: $Sensitivity = TP / (TP + FN)$ $Specificity = TN / (TN + FP)$ $Positive\ predictive\ value = TP / (TP + FP)$ $Negative\ predictive\ value = TN / (FN + TN)$ $Positive\ likelihood\ ratio = sensitivity / (1 - specificity)$ $Negative\ likelihood\ ratio = (1 - sensitivity) / specificity$</p>			

14.3.3.2.2 Diagnostic meta-analysis

2 When data from 4 or more studies were available, a diagnostic meta-analysis was carried
3 out. To show the differences between study results, pairs of sensitivity and specificity were
4 plotted for each study on a receiver operating characteristics (ROC) curve in RevMan5 (for
5 plots please see Appendix H. Study results were pooled using the bivariate method for the
6 direct estimation of summary sensitivity and specificity using a random effects approach (in
7 STATA® or R® software). Using the output from Stata® or R®, we constructed and plotted
8 confidence and prediction regions and, where appropriate ROC curves. The advantage of
9 this approach is that it produces summary estimates of sensitivity and specificity that account
10 for the correlation between the 2 measures (sensitivity and specificity). Other advantages of
11 this method have been described elsewhere (Reitsma et al. 2005; Van Houwelingen et al.
12 1993; Van Houwelingen et al. 2002). In cases where many cell counts were 0, 1 was added
13 to that cell and 1 subtracted from the cell with the highest count to ensure the model was
14 able to run whilst not significantly distorting the results. Likelihood ratios were calculated from
15 either the sensitivity and specificity estimates or the raw diagnostic test accuracy data. The
16 related 95% CIs were calculated using the log method (Altman et al. 2013); when there were
17 zero true positives or false positives, 0.5 was added to all cells to enable calculation of the
18 positive likelihood ratio and related 95% confidence intervals.

19 This model also assesses the variability by incorporating the precision by which sensitivity
20 and specificity have been measured in each study. A 95% confidence and prediction ellipse
21 is shown in the graph that indicates the confidence and prediction region around the pooled
22 sensitivity or specificity point estimate a summary ROC curve is also presented. From the
23 STATA® or R® output we report the summary estimate of sensitivity and specificity (plus
24 their 95% confidence intervals) as well as between study variation measured as logit
25 sensitivity and specificity as well as correlations between the 2 measures of variation.

26 4.3.3.3 Data synthesis for qualitative reviews

27 Where possible, a meta-synthesis was conducted to combine qualitative study results. The
28 main aim of the synthesis of qualitative data was to produce a description of the topics that
29 may influence the experience of person with pancreatic cancer, those people important to
30 them and healthcare professionals involved in their care, rather than build new theories or
31 reconceptualise the topic under review. Whenever studies identified a qualitative theme, this
32 was extracted and the main characteristics were summarised. The methodologies in the
33 majority of studies employed some form of questionnaire or interview to assess patient
34 opinion and experience. In most cases, these were pre-existing, validated tools designed for
35 the purpose of the study. Limitations of each study were assessed using a modified CASP
36 Qualitative checklist

1 4.3.4 Appraising the quality of the evidence by outcomes

2 4.3.4.1 GRADE methodology

3 For intervention reviews, the evidence for outcomes from the included RCTs and
4 observational studies were evaluated and presented using GRADE, which was developed by
5 the international GRADE working group (Schünemann et al. 2013). Modified GRADE
6 assessments were also carried out for accuracy measures in diagnostic reviews. For the
7 appraisal of the quality of the evidence from qualitative reviews an adapted Critical Appraisal
8 Skills Programme (CASP) Qualitative checklist was used (NICE 2015; Public Health
9 Resource Unit England 2006).

10 The software developed by the GRADE working group (GRADEpro) was used to assess the
11 quality of each outcome, taking into account individual study quality factors and the meta-
12 analysis results. The clinical/economic evidence profile tables include details of the quality
13 assessment and pooled outcome data, where appropriate, an absolute measure of
14 intervention effect and the summary of quality of evidence for that outcome. In this table, the
15 columns for intervention and control indicate summary measures of effect and measures of
16 dispersion (such as mean and standard deviation or median and interquartile range) for
17 continuous outcomes and frequency of events (n/N: the sum across studies of the number of
18 patients with events divided by sum of the number of completers) for binary outcomes.
19 Reporting or publication bias was only taken into consideration in the quality assessment and
20 included in the clinical evidence profile tables if it was apparent.

21 The selection of outcomes for each review question was decided when each review protocol
22 was discussed with the committee. However, given the nature of most of the review
23 questions included in this guideline (driven by short- or long-term outcomes), the
24 categorisation of outcomes as critical and important did not follow the standard GRADE
25 approach. The outcomes selected for a review question were critical for decision-making in a
26 specific context.

27 The evidence for each outcome in interventional reviews was examined separately for the
28 quality elements listed and defined in Table 6.

29 **Table 6: Description of quality elements in GRADE for intervention studies**

Quality element	Description
Risk of bias (study limitations)	Limitations in the study design and implementation may bias the estimates of the treatment effect. High risk of bias for the majority of the evidence decreases confidence in the estimate of the effect.
Inconsistency	Inconsistency refers to an unexplained heterogeneity of results or findings.
Indirectness	Indirectness refers to differences in study population, intervention, comparator and outcomes between the available evidence and the review question, or recommendation made, such that the effect estimate is changed. This is also related to applicability or generalisability of findings.
Imprecision	Results are imprecise when studies include relatively few patients and few events and thus have wide confidence intervals around the estimate of the effect. Imprecision results if the confidence interval includes the clinically important threshold. For qualitative research this can relate to the sufficiency of data within each theme.
Publication bias	Publication bias is a systematic underestimate or an overestimate of the underlying beneficial or harmful effect due to the selective publication of studies.

30 The GRADE toolbox is designed only for RCTs and observational studies. For diagnostic test
31 accuracy and staging reviews, the QUADAS-2 checklist risk of bias and applicability items

1 were used for evaluating the risk of bias and indirectness, respectively, of the studies. The
2 quality assessment of inconsistency and imprecision were adapted as detailed below in
3 Sections 4.3.4.4 and 4.3.4.6.

4 **Table 7: Description of the elements in GRADE and how they are used to assess the**
5 **quality for diagnostic accuracy reviews**

Quality element	Description
Risk of bias (‘Study limitations’)	Limitations in the study design and implementation may bias the estimates of the diagnostic accuracy. High risk of bias for the majority of the evidence decreases confidence in the estimate of the effect. Diagnostic accuracy studies are not usually randomised and therefore would not be downgraded for study design from the outset and start as high level evidence. Evaluated using QUADAS-2 risk of bias items.
Inconsistency	Inconsistency refers to unexplained heterogeneity of test accuracy measures such as sensitivity and specificity between studies.
Indirectness	Indirectness refers to differences in study population, differences in index tests across studies, reference standards and outcomes between the available evidence and the review question. Evaluated using QUADAS-2 applicability items.
Imprecision	Results are considered not imprecise, seriously imprecise, or very seriously imprecise according to how wide the confidence intervals of the primary measure of sensitivity were.

6 The main criteria considered in the rating of these elements are discussed below (see
7 section 4.3.4.1). Footnotes were used to describe reasons for grading a quality element as
8 having serious or very serious problems. The ratings for each component were summed to
9 obtain an overall assessment for each outcome.

10 The main criteria considered in the rating of these elements are discussed below. Footnotes
11 beneath GRADE tables were used to describe reasons for grading a quality element as
12 having serious or very serious limitations. The ratings for each component were summed to
13 obtain an overall assessment for each outcome (See Table 10).

14 4.3.4.2 Grading the quality of clinical evidence

15 After results were pooled using data synthesis methods, the overall quality of evidence for
16 each outcome was considered. The following procedure was adopted when using the
17 GRADE approach:

- 18 • An initial quality rating was assigned, based on the study design. RCTs start as ‘High’ in
19 intervention reviews and observational studies as ‘Low’. In diagnostic and qualitative
20 reviews, evidence from non-randomised studies start as ‘High’.
- 21 • The rating was then downgraded for the specified criteria: risk of bias (study limitations);
22 inconsistency; indirectness; imprecision; and publication bias. These criteria are detailed
23 below. Evidence from observational studies (which had not previously been downgraded)
24 was upgraded if there was a large magnitude of effect or a dose-response gradient, and if
25 all plausible confounding would reduce a demonstrated effect, or suggest a spurious
26 effect when results showed no effect.

27 Each quality element considered to have ‘serious’ or ‘very serious’ issues was rated down by
28 1 or 2 points respectively. Value based judgements for relevant interpretation of the levels of
29 quality elements were informed by discussion with the committee for each review to balance
30 consistency of approach across the guideline and clinical relevance within each review (see
31 Table 8). The downgraded/upgraded ratings were then summed and the overall quality rating
32 was revised, taking into account the relative contributions from the individual studies within a
33 meta-analyses, where performed. For example, RCTs start as high and the overall quality

1 becomes moderate, low or very low if 1, 2 or 3 points are deducted respectively. The reasons
2 or criteria used for downgrading were specified in the footnotes.

3 For qualitative reviews, each quality element considered to have ‘minor or ‘serious’
4 limitations was rated down by 1 or 2 points respectively. A quality assessment of ‘Unclear’
5 was added to the list of possible GRADE-CERQual levels. Together with the committee, it
6 was decided that in qualitative reviews 1 ‘Unclear’ rating did not mean an automatic
7 downgrade of the evidence for this theme. However, 2 ‘Unclear’ ratings were downgraded by
8 1. Footnotes were not used for the CERQual tables (See Table 9).

9 **Table 8: Levels of quality elements in GRADE for intervention and diagnostic reviews**

Level	Description
None	There are no serious issues with the evidence.
Serious	The issues are serious enough to downgrade the outcome evidence by 1 level.
Very serious	The issues are serious enough to downgrade the outcome evidence by 2 levels.

10 **Table 9: Levels of quality elements in GRADE for qualitative reviews**

Level	Description
No limitations	There are no serious issues with the evidence.
Minor limitations	The issues are serious enough to downgrade the outcome evidence by 1 level.
Serious limitations	The issues are serious enough to downgrade the outcome evidence by 2 levels.
Unclear	There is no enough information available to assess the domain.

11 **Table 10: Overall quality of outcome evidence in GRADE**

Level	Description
High	Further research is very unlikely to change our confidence in the estimate of effect.
Moderate	Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low	Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low	Any estimate of effect is very uncertain.

12 The details of the criteria used for each of the main quality elements are discussed further in
13 Sections 4.3.5.2.1 to 4.3.5.3.4 below.

14 **4.3.4.3 Risk of bias / methodological limitations**

15 **Intervention studies**

16 For intervention studies, the Cochrane Risk of Bias tool was used for randomised control
17 trials (Higgins & Green 2011; NICE 2015).

18 Bias can be defined as anything that causes a consistent deviation from the truth. Bias can
19 be perceived as a systematic error. The risk of bias for a given study and outcome is
20 associated with the risk of over or underestimation of the true effect. Sources of bias in
21 randomised controlled trials are listed in Table 11).

22 A study with a poor methodological design does not automatically imply high risk of bias; the
23 bias is considered individually for each outcome and it is assessed whether this poor design
24 will impact on the estimation of the intervention effect.

1 **Table 11: Summary of Cochrane risk of bias tool**

Risk of bias	Explanation
Allocation concealment	Those enrolling patients are aware of the group to which the next enrolled patient will be allocated (this is a major problem in 'pseudo' or 'quasi' randomised trials with allocation by, for example, day of week, birth date, chart number).
Lack of blinding	Patient, caregivers, those recording outcomes, those adjudicating outcomes or data analysts are aware of the arm to which patients are allocated.
Incomplete accounting of patients and outcome events	Missing data not accounted for and failure of the investigators to adhere to the intention to treat principle when indicated.
Selective outcome reporting	Reporting of some outcomes and not others on the basis of the results.
Other risks of bias	For example: <ul style="list-style-type: none"> • stopping early for benefit observed in randomised trials, in particular in the absence of adequate stopping rules • use of unvalidated patient-reported outcomes • recruitment bias in cluster randomised trials.

2 For observational studies, quality was assessed using the Newcastle-Ottawa Scale (Wells et
3 al. 2008; NICE 2015).

4 The risk of bias was derived by assessing the risk of bias across 3 domains – selection,
5 comparability and outcome. Studies are given a rating depending on how they perform on
6 each of the domains. More details about the quality assessment items for observational
7 studies are shown in Table 12.

8 **Table 12: Summary of Newcastle and Ottawa scale**

Risk of bias category	Quality assessment item
Selection	Representativeness of the cohort
	Selection of the non-exposed cohort
	Ascertainment of exposure
	Demonstration that the outcome of interest was not present at the start of the study
Comparability	Comparability of cohorts on the basis of the design or analysis
Outcome	Assessment of outcome
	Was follow-up long enough for outcomes to occur
	Adequacy of follow-up of cohorts

9 **Diagnostic studies**

10 For diagnostic accuracy studies, the Quality Assessment of Diagnostic Accuracy Studies
11 version 2 (QUADAS- 2) checklist was used (Whiting et al. 2011).

12 Evaluating risk of bias in primary diagnostic accuracy and staging studies in QUADAS- 2
13 consists of assessing patient selection, the index test, the reference standard, and patient
14 flow and timing of the tests. More details about the quality assessment of diagnostic studies
15 are shown in Table 13.

1

Table 13: Summary of QUADAS-2 risk of bias items

Domain	Patient Selection	Index text	Reference standard	Flow and timing
Description	Describe methods of patient selection: Describe included patients (prior testing, presentation, intended use of index test and setting):	Describe the index test and how it was conducted and interpreted:	Describe the reference standard and how it was conducted and interpreted:	Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded from the 2x2 table: Describe the time interval and any interventions between index test(s) and reference standard:
Signalling questions (yes/no/unclear)	Was a consecutive or random sample of patients enrolled?	Were the index test results interpreted without knowledge of the results of the reference standard?	Is the reference standard likely to correctly classify the target condition?	Was there an appropriate interval between index test(s) and reference standard?
	Was a case-control design avoided?	If a threshold was used, was it pre-specified?	Were the reference standard results interpreted without knowledge of the results of the index test?	Did all patients receive a reference standard?
	Did the study avoid inappropriate exclusions?			Did all patients receive the same reference standard? Were all patients included in the analysis?
Risk of bias: (high/low/unclear)	Could the selection of patients have introduced bias?	Could the conduct or interpretation of the index test have introduced bias?	Could the reference standard, its conduct, or its interpretation have introduced bias?	Could the patient flow have introduced bias?
Concerns regarding applicability: (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	

1 **Qualitative studies**

2 For qualitative studies, quality was assessed using a checklist for qualitative studies (NICE
3 2015). This was based on the Critical Appraisal Skills Programme (CASP) checklist for
4 qualitative studies (Public Health Resource Unit England 2006). The quality rating for risk of
5 bias (low, high and unclear) was derived by assessing the risk of bias across 6 domains.

6 The evidence was then assessed by theme using a modified CASP approach for each study
7 as described above (see Table 14).

8 **Table 14: Summary of CASP tool for qualitative studies**

Risk of bias	Explanation
Aim and appropriateness of qualitative evidence.	This refers to an assessment of whether the aims and relevance of the study were clearly described and whether qualitative research methods were appropriate for investigating the research question.
Rigour in study design or validity of theoretical approach	This domain assesses whether the study approach has been clearly described and is based on a theoretical framework (for example ethnography or grounded theory). This does not necessarily mean that the framework has to be explicitly stated, but that at least a detailed description is provided which makes it transparent and reproducible.
Sample selection	The background, the procedure and reasons for the chosen method of selecting participants should be stated. It should also be assessed whether there was a relationship between the researcher and the informant and if so, how this may have influenced the findings that were described.
Data collection	Consideration was given to how well the method of data collection (in-depth interviews, semi-structured interviews, focus groups or observations) was described, whether details were provided and how the data were collected (who conducted the interviews, how long did they last and where did they take place).
Data analysis	For this criterion it is assessed whether sufficient detail is provided about the analytical process and whether it is in accordance with the theoretical approach. For instance, if a thematic analysis was used, it is assessed whether there was a clear description of how the theme was arrived at. Data saturation is also part of this section. This refers to whether a theoretical point of theme saturation was achieved at which point no further citations or observations would provide more insight or suggest a different interpretation of this theme. This could be explicitly stated, or it may be clear from the citations presented that it may have been possible to find more themes.
Results	In relation to this section the reasoning about the results are important, for instance whether a theoretical proposal or framework is provided rather than being restricted to citations / presentation of data.

9 **4.3.4.4 Inconsistency / coherence of findings**

10 Inconsistency refers to unexplained heterogeneity of results. When estimates of treatment
11 effect measures vary widely across studies (that is, there is heterogeneity or variability in
12 results between studies), this suggests that there are true differences in underlying effects.

13 Heterogeneity in meta-analyses was evaluated. If present, sensitivity and subgroup analyses
14 were performed as pre-specified in the protocols (Appendix C).

15 If there was heterogeneity (chi-squared probability less than 0.1, I-squared inconsistency
16 statistic of greater than 50%, or from visually examining forest plots), but no plausible
17 explanation (for example duration of intervention or different follow-up periods) could be
18 found, the quality of the evidence was downgraded in GRADE by 1 or 2 levels, depending on
19 the extent of inconsistency in the results. When outcomes were derived from a single trial,
20 inconsistency is not applicable. However, 'no inconsistency' is nevertheless used to describe

1 this quality assessment in the GRADE profiles as this is the default option in the GRADEpro
2 software used.

3 For diagnostic test accuracy and staging reviews, inconsistency in the studies was assessed
4 by visual inspection of the sensitivity and specificity forest plots.

5 For qualitative research, a similar concept to inconsistency is coherence, which refers to the
6 way findings within themes are described and whether they make sense. This concept was
7 used in the quality assessment across studies for individual themes. This does not mean that
8 contradictory data was downgraded automatically, but that it was highlighted and presented,
9 and that reasoning was provided. As long as the themes, or components of themes, from
10 individual studies fit into a theoretical framework, they do not necessarily have to have the
11 same perspective. It should, however, be possible to explain these by differences in context
12 (for example, the views of healthcare professionals might not be the same as those of family
13 members, but they could contribute to the same overarching theme). Coherence was graded
14 across studies with the following labels: coherent, incoherent or unclear.

15 **4.3.4.5 Indirectness / applicability or relevance of findings**

16 For quantitative reviews, directness refers to the extent to which the populations,
17 intervention, comparisons and outcome measures are similar to those defined in the
18 inclusion criteria for the reviews. Indirectness is important when these differences are
19 expected to contribute to a difference in effect size, or may affect the balance of harms and
20 benefits considered for an intervention.

21 For the reviews on diagnostic test accuracy and staging, the applicability items of the
22 QUADAS-2 checklist (Whiting et al. 2011) covering patient selection, the index test and the
23 reference standard were used. More details about the quality assessment of diagnostic
24 studies are shown in Table 15.

25 **Table 15: Summary of QUADAS-2 applicability items**

Domain	Patient Selection	Index text	Reference standard	Flow and timing
Concerns regarding applicability: (high/low/unclear)	Are there concerns that the included patients do not match the review question?	Are there concerns that the index test, its conduct, or interpretation differ from the review question?	Are there concerns that the target condition as defined by the reference standard does not match the review question?	Not applicable

26 Relevance of findings in qualitative research is the equivalent of indirectness for quantitative
27 outcomes and refers to how closely the aims and context of the studies contributing to a
28 theme reflect the objectives outlined in the review protocol of the guideline question.

29 **4.3.4.6 Imprecision / theme saturation or sufficiency**


30 For quantitative reviews, imprecision in guidelines concerns whether the uncertainty
31 (confidence interval) around the effect estimate means that it is not clear whether there is a
32 clinically important difference between interventions or not (that is, whether the evidence
33 would clearly support 1 recommendation or appear to be consistent with several different
34 types of recommendations). Therefore, imprecision differs from the other aspects of evidence
35 quality because it is not really concerned with whether the point estimate is accurate or
36 correct (has internal or external validity). Instead, it is concerned with the uncertainty about

1 what the point estimate actually is. This uncertainty is reflected in the width of the confidence
2 interval.

3 The 95% confidence interval (95% CI) is defined as the range of values within which the
4 population value will fall on 95% of repeated samples, were this procedure to be repeated.
5 The larger the trial, the smaller the 95% CI and the more certain the effect estimate.

6 Imprecision in the evidence reviews was assessed by considering whether the width of the
7 95% CI of the effect estimate was relevant to decision-making, taking each outcome in
8 isolation. This is explained in Figure 2, which considers a positive outcome for the
9 comparison of treatment A versus treatment B. Three decision-making zones can be
10 identified, bounded by the thresholds for clinical importance (minimal important difference,
11 MID) for benefit and for harm. The MID for harm for a positive outcome means the threshold
12 at which drug A is less effective than drug B by an amount that is clinically important to
13 patients (favours B).

Figure 2: Illustration of precise, imprecise and very imprecise evidence based on the confidence interval of outcomes in forest plots



14 When the confidence interval of the effect estimate is wholly contained in 1 of the 3 zones
15 (for example clinically important benefit), we are not uncertain about the size and direction of
16 effect (whether there is a clinically important benefit, or the effect is not clinically important, or
17 there is a clinically important harm), so there is no imprecision.

18 When a wide confidence interval lies partly in each of 2 zones, it is uncertain in which zone
19 the true value of effect estimate lies and therefore there is uncertainty over which decision to
20 make (based on this outcome alone). The confidence interval is consistent with 2 possible
21 decisions and so this is considered to be imprecise in the GRADE analysis and the evidence
22 is downgraded by 1 level ('serious imprecision').

23 If the confidence interval of the effect estimate crosses into 3 zones, this is considered to be
24 very imprecise evidence because the confidence interval is consistent with 3 possible clinical
25 decisions and there is therefore a considerable lack of confidence in the results. The
26 evidence is therefore downgraded by 2 levels in the GRADE analysis ('very serious
27 imprecision').

28 Implicitly, assessing whether the confidence interval is in, or partially in, a clinically important
29 zone, requires the committee to estimate an MID or to say whether they would make different
30 decisions for the 2 confidence limits.

31 **Minimally Important Differences**

32 The literature was searched for established minimally important differences (MIDs) for the
33 selected outcomes in the evidence reviews, such as symptom measurement tools. The
34 following MIDs were used consistently throughout the guideline:

- 1 • For survival outcomes (e.g. overall survival, disease-free survival), any statistically
- 2 significant change was considered by the committee to be clinically important.
- 3 • For adverse events, the default MIDs of 0.8 and 1.25 were used.
- 4 • For EORTC QLQ-C30, a published MID of 5 points was used (Osoba et al. 1998).
- 5 • For all other quality of life measures, the default MIDs were assumed.

6 Finally, if no published or acceptable MIDs were identified, the committee considered
7 whether it was clinically acceptable to use the GRADE default MID to assess imprecision.
8 For binary outcomes clinically important thresholds for a risk ratio of 0.8 and 1.25
9 respectively were used (due to the statistical distribution of this measure this means that this
10 is not a symmetrical interval). This default MID was used for all the binary outcomes in the
11 interventions' evidence reviews as a starting point and decisions on clinical importance were
12 then considered based on the absolute risk difference. For continuous outcomes, the
13 GRADE default MIDs were assumed to be half of the standard deviation of the control group
14 at baseline.

15 In evaluating diagnostic accuracy and staging measures, imprecision was assessed using
16 the 95% CI of sensitivity as the primary measure of interest as the harmful consequences of
17 false negatives (e.g. death caused by malignant tumours not identified as such) were
18 considered to be worse than the harmful consequences of false positives (e.g. unnecessary
19 surgery or treatment on benign tumour).

- 20 • Sensitivity and specificity
 - 21 ○ Not serious: both upper and lower 95% CI >0.9
 - 22 ○ Serious: 95% CI crosses 0.75 or 0.9
 - 23 ○ Very serious: 95% CI crosses both 0.75 and 1.0 or difference between upper and lower
 - 24 95% CI ≥ 0.25
- 25 • Positive likelihood ratio:
 - 26 ○ Very useful test: >10
 - 27 ○ Moderately useful test: 5-10
 - 28 ○ Not a useful test: <5
- 29 • Negative likelihood ratio:
 - 30 ○ Very useful test: <0.1
 - 31 ○ Moderately useful test: 0.1 to 0.2
 - 32 ○ Not a useful test: >0.2

33 Theme saturation or sufficiency refers to a similar concept in qualitative research. This refers
34 to whether a theoretical point of theme saturation was achieved, at which point no further
35 citations or observations would provide more insight or suggest a different interpretation of
36 this theme. As already highlighted in a previous section on qualitative reviewing methods, it
37 is not equivalent to the number of studies contributing to a theme, but rather to the depth of
38 data and whether sufficient quotes or observations were provided that could underpin these
39 findings.

40 4.3.4.7 NMA quality appraisal

41 The use of GRADE to assess the quality of studies addressing a particular review question
42 for pairwise comparisons of interventions is relatively established. However, the use of
43 GRADE to assess the quality of evidence across a NMA is still a developing methodology.
44 Therefore the ISPOR checklist was used to appraise the risk of bias of NMAs (Jansen et al.
45 2014).

1 **Table 16: Rationale for downgrading quality of evidence in NMAs**

GRADE criteria	Example reasons for downgrading quality
Risk of bias	Risk of bias was assessed in accordance with the 26-item checklist developed by the ISPOR Good Research Practices. This includes (22 items of the checklist) limitations in the design or execution of the study, including 1) the used evidence base, 2) analysis methods, 3) reporting quality and transparency, 4) interpretation of findings, and 5) conflicts of interest.
Inconsistency	Evidence of any inconsistency between the direct and indirect estimates of effect was assessed using the residual deviance, deviance information criterion and the statistic tau; outcome was downgraded if $\tau > 0.5$
Indirectness	The extent to which the available evidence fails to address the specific review question (this can reduce the quality rating). This may be in relation to the setting, population, outcomes, interventions or study designs used in the evidence base. Indirectness was assessed in accordance with the 26-item checklist developed by the ISPOR Good Research Practices. This includes (4 items of the checklist) assessments about the applicability of network meta-analysis results to the setting of interest.
Imprecision	This is considered to be present when there is uncertainty around the estimate of effect, and reflects the confidence in, or 'credibility' of, the estimate of effect. It is assessed based on the overall distribution of the rankings, such that evidence was downgraded if no interventions had rank credible intervals $\leq 33\%$ of total distribution of comparators.

2 **4.3.4.8 Assessing clinical significance**

3 **Intervention reviews**

4 The committee assessed the evidence by outcome. To facilitate this, where possible, binary
5 outcomes were converted into absolute risk differences (ARDs) using GRADEpro software:
6 the median control group risk across studies was used to calculate the ARD and its 95% CI
7 from the pooled risk ratio. For continuous outcomes, the mean difference between the
8 intervention and control arm of the trial was calculated. This was then assessed in relation to
9 a published MID (if available) or the default MID (0.5 times the median control group
10 standard deviation at baseline or if not available, follow up).

11 The clinical significance of a treatment effect was evaluated as a combination of the
12 minimally / clinically important difference (MID) thresholds and statistical significance / the
13 null hypothesis value (zero for continuous outcomes and 1 for RRs, ORs and HRs):

- 14 • If the point estimate for a treatment effect exceeded the MID and the 95% CI did not
15 include the null hypothesis value then the result was considered to be “clinically
16 significant”
- 17 • If the point estimate for a treatment effect did not exceed the MID then the result was not
18 considered to be “clinically significant”

19 **Diagnostic reviews**

20 The clinical usefulness of a test for diagnosis was determined based on either sensitivity,
21 specificity, positive likelihood ratio or negative likelihood ratio, depending on what the
22 committee believed was the most important – correctly identifying if a patient had the target
23 condition (ruling in) or correctly identifying if a patient did not have the target condition (ruling
24 out).

25 The value of the point estimate within the different MID thresholds for sensitivity, specificity,
26 positive likelihood ratio or negative likelihood ratio were used to determine clinical
27 usefulness.

1 **Qualitative reviews**

2 For themes stemming from qualitative findings, clinical significance was decided upon by the
3 committee taking into account the generalisability of the context from which the theme was
4 derived and whether it was convincing enough to support or warrant a change in current
5 practice, as well as the evidence quality.

6 **4.3.5 Evidence statements**

7 Evidence statements are summary statements that are presented after the GRADE profiles,
8 summarising the key features of the clinical evidence presented. The wording of the
9 evidence statements reflects the certainty or uncertainty in the estimate of effect. The
10 evidence statements are presented by outcome or theme and encompass the following key
11 features of the evidence:

- 12 • the quality of the evidence (GRADE rating)
- 13 • the number of studies and the number of participants for a particular outcome
- 14 • a brief description of the participants
- 15 • the clinical significance of the effect and an indication of its direction (for example, if a
16 treatment is clinically important [beneficial or harmful] compared with another, or whether
17 there is no clinically important difference between the tested treatments).

18 **4.3.6 Evidence of cost effectiveness**

19 The aims of the health economic input to the guideline were to inform the committee of
20 potential economic issues related to the diagnosis and management of pancreatic cancer to
21 ensure that recommendations represented a cost-effective use of healthcare resources.
22 Health economic evaluations aim to integrate data on healthcare benefits (ideally in terms of
23 quality-adjusted life-years (QALYs) with the costs of different care options. In addition, the
24 health economic input aimed to identify areas of high resource impact; recommendations
25 which – while nevertheless cost-effect – might have a large impact on CCG or Trust finances
26 and so need special attention.

27 **4.3.6.1 Undertaking new health economic analysis**

28 As well as reviewing the published economic literature, as described above, new economic
29 analysis was undertaken by the Health Economist in selected areas. The following priority
30 areas for de novo economic analysis were agreed by the committee after formation of the
31 review questions and consideration of the available health economic evidence:

- 32 • management of biliary obstruction
- 33 • management of locally advanced non-metastatic pancreatic cancer

34 A costing tool was also developed for the review question relating to models of care, where
35 little clinical evidence was uncovered. It was thought that the committee may wish to make
36 recommendations that would lead to a high resource impact, although current practice was
37 recommended.

38 The methods and results of de novo economic analyses are reported in Chapters 12 and 13.
39 When new economic analysis was not prioritised, the committee made a qualitative
40 judgement regarding cost effectiveness by considering expected differences in resource and
41 cost use between options, alongside clinical effectiveness evidence identified from the
42 clinical evidence review.

1 4.3.6.2 Cost effectiveness criteria

2 NICE's report Social value judgements: principles for the development of NICE guidance
3 sets out the principles that committees should consider when judging whether an intervention
4 offers good value for money. In general, an intervention was considered to be cost effective if
5 either of the following criteria applied (given that the estimate was considered plausible):

- 6 • the intervention dominated other relevant strategies (that is, it was both less costly in
7 terms of resource use and more clinically effective compared with all the other relevant
8 alternative strategies), or;
- 9 • the intervention cost less than £20,000 per QALY gained compared with the next best
10 strategy, or;
- 11 • the intervention provided clinically significant benefits at an acceptable additional cost
12 when compared with the next best strategy.

13 The committee's considerations of cost-effectiveness are discussed explicitly in the
14 'Consideration of economic benefits and harms' section of the relevant chapters.

15 4.4 Developing recommendations

16 4.4.1 Guideline recommendations

17 Over the course of the guideline development process, the committee was presented with:

- 18 • evidence tables of the clinical and economic evidence reviewed from the literature: all
19 evidence tables are in Appendix F and economic evidence tables are in Appendix J
- 20 • summary of clinical and economic evidence and quality assessment (as presented in
21 Chapters 5 to 11)
- 22 • forest plots (Appendix H)
- 23 • a description of the methods and results of the cost-effectiveness analysis undertaken for
24 the guideline (Chapters 12 & 13).

25 Recommendations were drafted on the basis of the group's interpretation of the available
26 evidence, taking into account the balance of benefits, harms and costs between different
27 courses of action. This was either done formally, in an economic model, or informally. Firstly,
28 the net benefit over harm (clinical effectiveness) was considered, focusing on the critical
29 outcomes, although most of the reviews in the guideline were outcome driven. When this
30 was done informally, the group took into account the clinical benefits and harms when 1
31 intervention was compared with another. The assessment of net benefit was moderated by
32 the importance placed on the outcomes (the group's values and preferences) and the
33 confidence the group had in the evidence (evidence quality). Secondly, the group assessed
34 whether the net benefit justified any differences in costs.

35 When clinical and economic evidence was of poor quality, conflicting or absent, the group
36 drafted recommendations based on their expert opinion. The considerations for making
37 consensus-based recommendations include the balance between potential harms and
38 benefits, the economic costs or implications compared with the economic benefits, current
39 practices, recommendations made in other relevant guidelines, patient preferences and
40 equality issues. The group also considered whether the uncertainty was sufficient to justify
41 delaying making a recommendation to await further research, taking into account the
42 potential harm of failing to make a clear recommendation.

43 The wording of recommendations was agreed by the group and focused on the following
44 factors:

- 45 • the actions healthcare professionals need to take,
- 46 • the information readers of the guideline need to know,

- 1 • the strength of the recommendation (for example the word ‘offer’ was used for strong
2 recommendations and ‘consider’ for weak recommendations),
3 • the involvement of patients (and their carers if needed) in decisions about treatment and
4 care,
5 • consistency with NICE’s standard advice on recommendations about drugs, waiting times
6 and ineffective intervention.

7 The main considerations specific to each recommendation are outlined in the
8 ‘Recommendations and link to evidence’ sections within each chapter.

9 **4.4.2 Research recommendations**

10 When areas were identified for which good evidence was lacking, the committee considered
11 making recommendations for future research. Decisions about inclusion were based on
12 factors such as:

- 13 • the importance to patients or the population,
14 • national priorities,
15 • potential impact on the NHS and future NICE guidance,
16 • ethical and technical feasibility.

17 **4.5 Validation process**

18 This guidance is subject to a 6-week public consultation and feedback as part of the quality
19 assurance and peer review of the document. All comments received from registered
20 stakeholders are responded to in turn and posted on the NICE website at publication.

21 **4.6 Updating the guideline**

22 Following publication, and in accordance with the [NICE guidelines manual](#), NICE will
23 undertake a review of whether the evidence base has progressed significantly to alter the
24 guideline recommendations and warrant an update.

25 **4.7 Disclaimer**

26 Healthcare providers need to use clinical judgement, knowledge and expertise when
27 deciding whether it is appropriate to apply guidelines. The recommendations cited here are a
28 guide and may not be appropriate for use in all situations. The decision to adopt any of the
29 recommendations cited here must be made by practitioners in light of individual patient
30 circumstances, the wishes of the patient, clinical expertise and resources.

31 The NGA disclaims any responsibility for damages arising out of the use or non-use of these
32 guidelines and the literature used in support of these guidelines.

33 **4.8 Funding**

34 The NGA was commissioned by the National Institute for Health and Care Excellence (NICE)
35 to undertake the work on this guideline.

36 **4.9 References**

37 Altman D, Machin D, Bryant T et al. (Eds.) (2013) Statistics with confidence: confidence
38 intervals and statistical guideline. Second edition. John Wiley & Sons

- 1 DerSimonian R and Laird N (1986) Meta-analysis in clinical trials. *Controlled Clinical Trials*
2 7(3): 177-188
- 3 Dixon-Woods M, Agarwal S, Jones D et al. (2005) Synthesising qualitative and quantitative
4 evidence: a review of possible methods. *Journal of Health Services Research & Policy* 10(1):
5 45-53
- 6 Hayden JA., van der Windt DA., Cartwright JL et al. (2013) Assessing bias in studies of
7 prognostic factors. *Annals of Internal Medicine* 158: 280-6
- 8 Higgins JPT and Green S (2011) *Cochrane Handbook for Systematic Reviews of*
9 *Interventions* [version 5.1.0, updated March 2011]. The Cochrane Collaboration [Available at:
10 [http: www.handbook.cochrane.org](http://www.handbook.cochrane.org) (accessed 27 April 2017)]
- 11 Jansen JP, Trikalinos T, Cappelleri JC et al. (2014) Indirect treatment comparison/network
12 meta-analysis study questionnaire to assess relevance and credibility to inform health care
13 decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. *Value in Health*
14 17(2): 157-73
- 15 Mantel N and Haenszel W (1959) Statistical aspects of the analysis of data from
16 retrospective studies of disease. *Journal of the National Cancer Institute* 22: 719-748
- 17 NICE (2015) *Developing NICE guidelines: the manual appendix H*. London, UK: National
18 Institute for Health and Care Excellence
- 19 Osoba D, Rodrigues G, Myles J et al. (1998) Interpreting the significance of changes in
20 health-related quality-of-life scores. *Journal of Clinical Oncology* 16(1): 139-144
- 21 Public Health Resource Unit England (2006) *Critical Appraisal Skills Programme (CASP) –*
22 *Qualitative Checklist – 10 questions to help you make sense of qualitative research*. [online].
23 [Available at: <http://www.casp-uk.net/checklists> (Accessed May 31 2017)]
- 24 Reitsma JB, Glas AS, Rutjes AW et al. (2005) Bivariate analysis of sensitivity and specificity
25 produces informative summary measures in diagnostic reviews. *Journal of Clinical*
26 *Epidemiology* 58(10): 982-90
- 27 Schünemann H, Brozek J, Guyatt G et al. (Eds) (2013) *GRADE Handbook: Handbook for*
28 *grading quality of evidence and strength of recommendation using the GRADE approach*
29 (updated 2013). The GRADE Working Group
- 30 Tierney JF, Stewart LA, Ghersi D et al. (2007) Practical methods for incorporating summary
31 time-to-event data into meta-analysis. *Trials* 8(1): 16
- 32 Van Houwelingen HC, Zwinderman KH, Stijnen T (1993) A bivariate approach to meta-
33 analysis. *Statistics in medicine* 12(24): 2273-84
- 34 Van Houwelingen HC, Arends LR, Stijnen T. (2002) Advanced methods in meta- analysis:
35 multivariate approach and meta- regression. *Statistics in medicine* 21(4): 589-624
- 36 van Valkenhoef G, Dias S, Ades AE et al. (2016) Automated generation of node-splitting
37 models for assessment of inconsistency in network meta-analysis. *Research Synthesis*
38 *Methods* 7(1): 80-93
- 39 Wells GA, Shea B, O'Connell D et al. (2008) The Newcastle-Ottawa Scale (NOS) for
40 assessing the quality of nonrandomised studies in meta-analyses. [Available at:
41 http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed 27 April 2017)]
- 42 Whiting, PF, Rutjes, AW, Westwood, ME et al. (2011) QUADAS-2: a revised tool for the
43 quality assessment of diagnostic accuracy studies. *Annals of internal medicine* 155(8): 529-
44 536

5 Diagnosis

5.1 People with jaundice

Review question: What is the most effective diagnostic pathway (imaging +/-CA 19–9, biopsy (cytology or histology)) for adults with suspected pancreatic cancer in secondary care who have jaundice?

5.1.1 Introduction

Obstructive jaundice is the most common presenting symptom in people with pancreatic cancer, although it is to be noted that most people presenting with jaundice do not actually have pancreatic cancer.

There is currently uncertainty about the most accurate technique for diagnosing the disease in people with obstructive jaundice. CT scans are commonly used to diagnose pancreatic cancer in this group of people, however it is not always possible for the CT scan to visualise the cancer that is causing the obstruction. Ultrasound is another technique which can identify pancreatic cancer. MRI and fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) are both increasingly being used but their diagnostic accuracy in this group of people is not clearly understood. Whether histology and cytology are needed to make the diagnosis of pancreatic cancer in someone with obstructive jaundice is uncertain, with some centres operating on imaging alone. There is also variation in practice as to how the histology and cytology are obtained. The role of cancer antigen 10-9 (CA 19-9) in combination with imaging is not defined.

In the group of people thought not suitable for resection based on imaging, brushing the duct (for cytology) at the time of ERCP and stenting is common. Where this does not confirm a diagnosis, endoscopic ultrasound (EUS) and fine needle aspiration (FNA) is usually done. However there are still a small group of people in whom the imaging is highly suggestive of malignancy but the cytology/histology does not confirm, leaving the question of what to do next.

Guidance is needed on the most effective diagnostic pathway to identify pancreatic cancer in people who have jaundice.

5.1.1.1 Review protocol summary

The review protocol summary used for this question can be found in Table 17. Full details of the review protocol can be found in Appendix C.

Table 17: Clinical review protocol summary for the review of most effective diagnostic pathway for people with suspected pancreatic cancer who have jaundice

Population	Adults suspected of having pancreatic cancer who have jaundice
Index Test	Imaging +/- CA 19–9 (Ultrasound , CT, MRI, FDG-PET/CT) Biopsy (cytology or histology) <ul style="list-style-type: none"> • endoscopic ultrasound +/- FNA • ERCP+/- biliary brushings, • EUS +/- core biopsy • Percutaneous liver biopsy • laparoscopy + biopsy • percutaneous pancreatic biopsy

Reference standard	<ul style="list-style-type: none"> • Definitive diagnosis (preferably Pathological diagnosis) • Each other
Outcome	<ul style="list-style-type: none"> • Diagnostic Accuracy including: <ul style="list-style-type: none"> • Sensitivity • Specificity • Positive Predictive Value • Negative Predictive Value • Adverse events

1 5.1.2 Description of Clinical Evidence

2 Six observational studies (n=806) - 1 multicentre prospective cohort study (n=159) and five
3 single-centre retrospective cohort studies (n=647) - were included in the review. A summary
4 of the included studies is presented in Table 18.

5 One study (n=47) reported on the diagnostic accuracy of spiral CT. This study was carried
6 out in the USA and included patients with obstructive jaundice with a suspicion of pancreatic
7 cancer (Agarwal et al. 2004).

8 One study (n=47) reported on the diagnostic accuracy of EUS. This study was carried out in
9 the USA and included patients with obstructive jaundice with a suspicion of pancreatic
10 cancer (Agarwal et al. 2004).

11 Five studies (n=691) reported on the diagnostic accuracy of EUS-FNA based cytology
12 (Agarwal et al. 2004; Kim et al. 2015; Oppong et al. 2010; Ross et al. 2008; Tummala et al.
13 2013). All studies included patients with obstructive jaundice with a suspicion of pancreatic
14 cancer. One study was conducted in the UK (Oppong et al. 2010), whilst the remaining 4
15 studies were conducted in the USA.

16 One prospective multicentre UK study (n=393) – known as PET-PANC - reported on the
17 diagnostic accuracy of MDCT and FDG-PET/CT (Ghaneh et al. 2018) in patients with
18 obstructive jaundice and a suspicion of pancreatic cancer. The main aim of the latter study
19 was to assess - in a multicentre setting and using a standardised protocol - whether the
20 addition of FDG-PET/CT to MDCT, which is standard practice in the UK, provides tangible
21 diagnostic and staging benefits. Two studies (n=89) reported on the diagnostic accuracy of
22 ERCP + brushings of biliary strictures (Oppong et al. 2010; Ross et al. 2008). Both studies
23 included patients with obstructive jaundice with a suspicion of pancreatic. One study was
24 conducted in the UK (Oppong et al. 2010), with the other study conducted in the USA (Ross
25 et al. 2008).

26 All included studies reported on diagnostic accuracy outcome measures, whilst only 2
27 studies reported adverse effects or complications. Positive and likelihood ratios were
28 calculated, where appropriate, from the raw diagnostic test accuracy data or the estimated
29 sensitivity and specificity of the studies to enable evaluation of the relevant tests. The
30 QUADAS-2 checklist was used to evaluate the risk of bias and indirectness (applicability) of
31 the studies.

32 Further information about the search strategy can be found in Appendix D. See study
33 selection flow chart in Appendix E, single and multiple test ROC curves and forest plots in
34 Appendix H, summary of Risk of Bias in Appendix J, study evidence tables in Appendix F
35 and list of excluded studies in Appendix G.

36

37

5.1.3 Summary of included studies

A summary of the studies that were included in this review is presented in Table 18.

Table 18: Summary of included studies

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes	Overall risk of bias
Agarwal et al., 2004	Sample size N= 47 Characteristics M/F (n): not reported Median age (range): not reported Final diagnosis: malignant(n): 45 benign(n): 2	Retrospective single-centre study USA	Index test 1 (n=47): EUS Index test 2 (n=47): EUS-FNA cytology Index test 3 (n=47): Spiral CT	The final diagnosis was based on: definitive cytology, surgical pathology or the development of metastatic disease. Number of patients by reference standard test are not reported	Diagnostic accuracy Sensitivity Specificity NPV PPV	Serious risk of bias Potential risk of verification bias: as the reference standard used for is different across the study sample Unclear review bias (lack of blinding) * Patients were finally considered not to have cancer if they did not have any evidence of cancer after 1 yr. of clinical follow-up with partial or complete resolution of suspicious lesion on follow-up CT scans.
Ghaneh et al. 2018	Sample size N=159 people with jaundice (Total sample was 619 people with suspected PC) Characteristics M/F (n): 353/266 Mean age (IQR, range): 66 (15, 21-87) years	Prospective multicentre study UK	Index test 1 (n=159 [ITT]): MDCT Index test 2 (n=159 [ITT]): FDG-PET/CT	The final diagnosis was based on: Histology (resection or biopsy) or 12-mo clinical FU	Diagnostic accuracy Sensitivity Specificity	No serious risk of bias. Incomplete outcome data (13% dropout rate)

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes	Overall risk of bias
	Final diagnosis (ITT): malignant(n): 384 benign(n): 166					
Kim et al., 2015	Sample size N= 180 Characteristics M/F (n): 108 / 72 Mean age (SD): 65 (12) years Final diagnosis: malignant (n): 172 benign (n): 8	Retrospective single-centre study USA	Index test (n=180): EUS-FNA cytology	The final diagnosis was based on: histologic diagnosis of malignancy on EUS-FNA CYTOLOGY (n=166) surgically resected specimen (number not reported) and/or other tissue acquisition from endoscopic or percutaneous modalities (n=6)	Diagnostic accuracy Sensitivity Specificity NPV PPV	Very serious risk of bias Potential risk of verification bias: as the reference standard used for is different across the study sample Unclear of review bias (lack of blinding) High Incorporation bias: as the test that is being evaluated is included in the reference standard, there can be an overestimation of test accuracy
Oppong et al., 2010	Sample size N= 37 (39 procedures) Characteristics M/F (n): 21 / 17 Mean age (range): 62.4 (26- 87) years Final diagnosis: malignant (n): 32 benign (n): 5	Retrospective single-centre study UK	Index test 1 (n=39): EUS-FNA cytology Index test 2 (n=39): ERCP + Brushings of biliary strictures A cytopathologist was not present in the endoscopy suite for any of the procedures.	The final diagnosis was based on surgical histology or other biopsy methods (n=30) any + cytology result combined with clinical follow-up that provided further evidence of malignancy (n=3) clinical, biochemical and radiological follow-up until death or for at least two years if there	Diagnostic accuracy Sensitivity Specificity NPV PPV	Serious risk of bias Potential risk of verification bias: as the reference standard used for is different across the study sample Unclear of review bias (lack of blinding)

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes	Overall risk of bias
				was no pathological or radiological evidence of malignancy (n=4).		
Ross et al., 2008	Sample size N= 114 Characteristics M/F (n): 66 / 48 Mean age (SD): 62.6 (11.8) years Final diagnosis: malignant (n): 80 benign (n): 34	Retrospective single-centre study USA	Index test 1 (n=83): EUS-FNA cytology Index test 2 (n=50): ERCP + Brushings of biliary strictures	The final diagnosis was based on: tissue acquisition (n=78) or clinical course (n=2)	Diagnostic accuracy Sensitivity Specificity NPV PPV	Very serious risk of bias Potential risk of verification bias: as the reference standard used for is different across the study sample Unclear of review bias (lack of blinding) High risk of bias due to bias due to inappropriate exclusions (4 cases of suspicious aspirates are excluded from analysis and not considered as either diagnostic or false negative)
Tummala et al., 2013	Sample size N= 348 Characteristics M/F (n): 176 / 166 Mean age (range): 68 (12.5) years Final diagnosis: malignant (n): 248 benign (n): 9	Retrospective single-centre study USA	Index test (n=342): EUS-FNA cytology	The final diagnosis was based on: surgical pathology or definitive cytology and clinical follow-up of >=12 months	Diagnostic accuracy Sensitivity Specificity NPV PPV Adverse events/complications	Serious risk of bias Potential risk of verification bias: as the reference standard used for is different across the study sample Unclear of review bias (lack of blinding)

Abbreviations: CT-computed tomography; EUS-endoscopic ultrasonography; EUS-FNA- Endoscopic ultrasound-guided fine-needle aspiration; ERCP-Endoscopic retrograde cholangiopancreatography; PC-pancreatic cancer; MRI-magnetic resonance imaging; FDG-PET/CT-fluorodeoxyglucose-positron emission tomography/CT- computed tomography; NPV- Negative Predictive Value; PPV- Positive Predictive Value.

5.1.4 Clinical evidence profile

The clinical evidence profiles for this review question are presented in Table 19 to Table 22.

Table 19: Summary of clinical evidence for CT to detect malignancy in people with jaundice

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Agarwal et al. 2004	47	Serious ⁶	Not applicable	Not serious	Serious ⁷	0.67 (0.51-0.8)	1.0 (0.16-1.0)	3.98 (0.31-50.4) ⁸	0.33 (0.22-0.5)	LOW
Ghaneh et al. 2018	148	Not serious	Not applicable	Not serious	Serious ⁷	0.90 (0.82-0.95)	0.58 (0.44-0.71)	2.14 (1.57-2.92)	0.17 (0.09-0.33)	MODERATE
Overall	195	Not serious	Serious ⁹	Not serious	Very serious ¹⁰					VERY LOW

¹, Risk of bias was assessed using the QUADAS-2 checklist

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable

³, Indirectness was assessed using the QUADAS-2 checklist items referring to applicability

⁴, The judgement of precision was based on the confidence interval of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. If the 95% CI crosses either 75% or 90%, the result was judged to be seriously imprecise (90% was considered to be the cut-off for the test to be highly sensitive and if the sensitivity was less than 75% the test was considered to be of low sensitivity). If the 95% CI crosses both 75% and 90%, the results was judged to be very seriously imprecise

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), unclear risk of verification bias (not all patients received the same reference test)

⁷ 95% CI of sensitivity crosses 0.75 or 0.9.

⁸, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs;

⁹, sensitivity ranges from 0.67 to 0.9, specificity from 0.58 to 1.0;

¹⁰, 95% CI of sensitivity estimates crosses both 0.75 and 0.9.

Table 20: Summary of clinical evidence for EUS to detect malignancy in people with jaundice

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Agarwal et al. 2004	47	Serious risk of bias ⁶	Not applicable	Not serious	Not serious	1.0 (0.92-1.0)	0.5 (0.1-0.99)	2.0 (0.5-8.0)	0	MODERATE

¹ Risk of bias was assessed using the QUADAS-2 checklist

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable

³, Indirectness was assessed using the QUADAS-2 checklist items referring to applicability

⁴, The judgement of precision was based on the confidence interval of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. If the 95% CI crosses either 75% or 90%, the result was judged to be seriously imprecise (90% was considered to be the cut-off for the test to be highly sensitive and if the sensitivity was less than 75% the test was considered to be of low sensitivity). If the 95% CI crosses both 75% and 90%, the results was judged to be very seriously imprecise

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶ Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), unclear risk of verification bias (not all patients received the same reference test).

Table 21: Summary of clinical evidence for EUS-FNA cytology to detect malignancy in people with jaundice

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Diagnostic test accuracy										
5 retrospective cohort studies (Agarwal et al. 2004; Kim et al. 2015; Oppong et al. 2010; Ross et al. 2008; Tummala et al. 2013)	691	Serious ⁶	Serious ⁷	Not serious	Not serious	0.85 (0.79-0.90)	0.96 (0.86-0.99)	22.0 (5.81-84.75)	0.15 (0.11-0.22)	LOW
Procedure-related complications						Details of complications				
Tummala et al. 2013	342	Very serious ⁸	Not serious	Not serious	Not serious	1 case of acute pancreatitis requiring hospitalization for 3 days; 1 case aspiration pneumonia requiring oral antibiotics			LOW	

¹ Risk of bias was assessed using the QUADAS-2 checklist;

² Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable

³ Indirectness was assessed using the QUADAS-2 checklist items referring to applicability;

⁴ The judgement of precision was based on the confidence interval of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. If the 95% CI crosses either 75% or 90%, the result was judged to be seriously imprecise (90% was considered to be the cut-off for the test to be highly sensitive and if the sensitivity was less than 75% the test was considered to be of low sensitivity). If the 95% CI crosses both 75% and 90%, the results was judged to be very seriously imprecise;

⁵ positive and negative likelihood ratios from meta-analysis.

⁶ There were 4 suspicious exclusions in one study (Ross et al., 2008). Furthermore there was potential risk review bias (lack of blinding in the interpretation both of the index test and reference standard) and unclear risk of verification bias in all studies;

⁷ 95% prediction region was very wide and ranged from 0 to 1.0 along the sensitivity axis and from 0.2 to 1.0 along the specificity axis (i.e. if the model is correct, there is probability of 0.95 that a future study will have sensitivity and specificity within these regions);

⁸, Very high risk of selection and performance bias.

Table 22: Summary of clinical evidence for ERCP + brushings of biliary strictures to detect malignancy in people with jaundice

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Oppong et al. 2010	39	Serious ⁶	Not applicable	Not serious	Serious ⁷	0.65 (0.46-0.80)	1.0 (0.48- 1.0)	7.71 (0.54-110.87) ⁸	0.35 (0.22-0.56)	LOW
Ross et al. 2008	50	Very serious ⁹	Not applicable	Not serious	Not serious	0.13 (0.04-0.31)	1.0 (0.83- 1.0)	6.1 (0.35-107.4)	0.87 (0.75-1.0)	LOW
Overall	89	Very serious ¹⁰	Serious ¹¹	Not serious	Serious					VERY LOW

¹ Risk of bias was assessed using the QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, Indirectness was assessed using the QUADAS-2 checklist items referring to applicability;

⁴, The judgement of precision was based on the confidence interval of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. If the 95% CI crosses either 75% or 90%, the result was judged to be seriously imprecise (90% was considered to be the cut-off for the test to be highly sensitive and if the sensitivity was less than 75% the test was considered to be of low sensitivity). If the 95% CI crosses both 75% and 90%, the results was judged to be very seriously imprecise;

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), unclear risk of verification bias (not all patients received the same reference test); g, 95% CI of sensitivity crosses 0.75;

⁷, 95% CI of sensitivity crosses 0.75

⁸, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

⁹, There were 4 suspicious aspirates that were excluded from analysis and not considered as either diagnostic or false negative. Furthermore there was potential risk review bias (lack of blinding in the interpretation both of the index test and reference standard), and unclear risk of verification bias (not all patients received the same reference test);

¹⁰, Ross et al. 2008 contributes more than 50% of the sample;

¹¹, sensitivity estimates range from 0.13 to 0.65.

Table 23: Summary of clinical evidence for FDG-PET/CT to detect malignancy in people with jaundice

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Ghaneh et al. 2007	148	Not serious	Not applicable	Not serious	Serious ⁶	0.96 (0.89-0.99)	0.53 (0.39-0.66)	2.02 (1.53-2.66)	0.08 (0.03-0.22)	MODERATE

¹ Risk of bias was assessed using the QUADAS-2 checklist

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable

³, Indirectness was assessed using the QUADAS-2 checklist items referring to applicability

⁴, The judgement of precision was based on the confidence interval of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. If the 95% CI crosses either 75% or 90%, the result was judged to be seriously imprecise (90% was considered to be the cut-off for the test to be highly sensitive and if the sensitivity was less than 75% the test was considered to be of low sensitivity). If the 95% CI crosses both 75% and 90%, the results was judged to be very seriously imprecise

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, 95% CI of sensitivity crosses 0.9.

1
2

3 **5.1.5 Economic evidence**

4 A literature review of published cost effectiveness analyses did not identify any relevant
5 studies for this topic. Although there were potential implications for resource use associated
6 with making recommendations in this area, other topics in the guideline were agreed as a
7 higher economic priority. Consequently, bespoke economic modelling was not done for this
8 topic.

9 **5.1.6 Evidence Statements**

10 **5.1.6.1 Computed tomography (CT)**

11 **Diagnostic accuracy**

12 Low quality evidence from 1 retrospective cohort study (n=47) found that spiral CT (n=47)
13 had a low sensitivity of 0.67 (95% CI, 0.51-0.8) and a high specificity of 1.0 (95% CI, 0.16-
14 1.0) in detecting malignancy in pancreatic cancer patients with obstructive jaundice. The
15 positive likelihood ratio of 3.98 (95% CI, 0.31-50.34) suggests that a positive result for
16 malignancy is not particularly useful for ruling it in, though there is uncertainty in the estimate.
17 The negative likelihood ratio of 0.33 (95% CI, 0.22-0.50) suggests that a negative result for
18 malignancy is not particularly useful for ruling it out.

19
20 Moderate quality evidence from 1 prospective cohort study (n=148) found that multidetector
21 computed tomography had a high sensitivity of 0.9 (95% CI, 0.82-0.95) and a low specificity
22 of 0.58 (95% CI, 0.44-0.71) in detecting malignancy in pancreatic cancer patients with
23 obstructive jaundice. The positive likelihood ratio of 2.14 (95% CI, 1.57-2.92) suggests that a
24 positive result for malignancy is not particularly useful for ruling it in. The negative likelihood
25 ratio of 0.17 (95% CI, 0.09-0.33) suggests that a negative result for malignancy is moderately
26 useful for ruling it out, though there is substantial uncertainty in the estimate.

27 **Adverse events**

28 In 1 multicentre prospective cohort study (n=583) that examined the diagnostic test accuracy
29 of CT, no adverse events related to the tests were reported.

30 **5.1.6.2 Endoscopic ultrasonography (EUS)**

31 **5.1.6.2.1 EUS**

32 **Diagnostic accuracy**

33 Moderate quality evidence from 1 retrospective observational study (n=47) people found that
34 EUS had high sensitivity of 1.0 (95% CI, 0.92-1.0) and low specificity of 0.5 (95%CI, 0.01-
35 0.99) in detecting malignancy in pancreatic cancer patients with obstructive jaundice. The
36 positive likelihood ratio of 2.0 (95% CI, 0.5-8.0) suggests that a positive result for malignancy
37 is not particularly useful for ruling it in, though there is uncertainty in the estimate. The
38 negative likelihood ratio of 0 suggests that a negative result for malignancy is very useful for
39 ruling it out.

40 **Adverse events**

41 No evidence was identified to inform this outcome.

15.1.6.2.2 **EUS-FNA cytology**

2 **Diagnostic accuracy**

3 Low quality evidence from a meta-analysis of 5 retrospective observational studies (n=691)
4 found that EUS-FNA-based cytology had a moderate sensitivity of 0.85 (95% CI, 0.79-0.9)
5 and a high specificity of 0.96 (95% CI, 0.86-0.99) in detecting malignancy in pancreatic
6 cancer patients with obstructive jaundice. The positive likelihood ratio of 22.2 (95% CI, 5.81-
7 84.75) suggests that a positive result for malignancy is very useful for ruling it in, though
8 there is uncertainty in the estimate. The negative likelihood ratio of 0.15 (95% CI, 0.11-0.22)
9 suggests that a negative result for malignancy is moderately useful for ruling it out, though
10 there is uncertainty in the estimate.

11 **Adverse events**

12 Low quality evidence from 1 retrospective observational study (n=342 with resectable
13 pancreatic cancer) found that there were 2 overall complications related to the EUS-FNA
14 procedure: 1 patient had acute pancreatitis requiring hospitalization for 3 days and another
15 patient had aspiration pneumonia requiring oral antibiotics.

16 **5.1.6.3 Endoscopic retrograde cholangiopancreatography (ERCP)**

175.1.6.3.1 **ERCP + Brushings of biliary strictures**

18 **Diagnostic accuracy**

19 Very low quality evidence from 2 retrospective observational studies with (n=39; n=50) found
20 that ERCP plus brushings of biliary strictures had a low sensitivity, ranging from 0.13 to 0.65
21 and a high specificity of 1.0 (in both studies) in detecting malignancy in pancreatic cancer
22 patients with obstructive jaundice. The positive likelihood ratios ranged from 7.71 (95% CI,
23 0.54-110.87) to 6.1 (95% CI, 0.35-107.4) suggesting that a positive result for malignancy is
24 moderately useful for ruling it in, though there is uncertainty in the estimates. The negative
25 likelihood ratios ranged from 0.35 (95% CI, 0.22-0.56) to 0.87 (95% CI, 0.75-1.0) suggesting
26 that a negative result for malignancy is not particularly useful for ruling it out.

27 **Adverse events**

28 No evidence was identified to inform this outcome.

29 **5.1.6.4 Positron emission tomography/-CT (PET/-CT)**

30 **Diagnostic accuracy**

31 Moderate quality evidence from 1 prospective cohort study (n=148) found that FDG-PET/CT
32 had a high sensitivity of 0.96 (95% CI, 0.89-0.99) and a low specificity of 0.53 (95% CI, 0.39-
33 0.66) in detecting malignancy in pancreatic cancer patients with obstructive jaundice. The
34 positive likelihood ratio of 2.02 (95% CI, 1.53-2.66) suggests that a positive result for
35 malignancy is not particularly useful for ruling it in. The negative likelihood ratio of 0.08 (95%
36 CI, 0.03-0.22) suggests that a negative result for malignancy is very useful for ruling it out,
37 though there is substantial uncertainty in the estimate.

38

39 **Adverse events**

40 In 1 multicentre prospective cohort study (n=583) that examined the diagnostic test accuracy
41 of CT, no adverse events related to the tests were reported.

1

2 **5.1.7 Recommendations**

- 3 1. **For people with obstructive jaundice and suspected pancreatic cancer, offer a**
4 **pancreatic protocol CT scan before draining the bile duct.**
- 5 2. **If the diagnosis is still unclear, offer fluorodeoxyglucose-positron emission**
6 **tomography/CT (FDG-PET/CT) and/or endoscopic ultrasound (EUS) with EUS-**
7 **guided tissue sampling.**
- 8 3. **Take a biliary brushing for cytology if:**
- 9 • endoscopic retrograde cholangiopancreatography (ERCP) is being used
10 to relieve the biliary obstruction and
 - 11 • there is no tissue diagnosis.

12 **5.1.8 Evidence to recommendations**

13 **5.1.8.1 Relative value placed on the outcomes considered**

14 Diagnostic accuracy (sensitivity, specificity, positive predictive value and negative predictive
15 value) and adverse events were considered the critical outcomes for this question.
16 Diagnostic accuracy was reported for all comparisons of interest. Adverse events were only
17 reported for EUS-FNA, MDCT and FDG-PET/CT.

18 **5.1.8.2 Quality of evidence**

19 Evidence was identified on the diagnostic accuracy of spiral and MDCT, EUS, EUS-FNA
20 cytology, FDG-PET/CT and ERCP plus brushings of biliary strictures. The quality of the
21 evidence for FDG-PET/CT was moderate, for ERCP plus brushings of biliary strictures it
22 ranged from very low to low, for CT was low (for spiral CT) to moderate (for MDCT), EUS-
23 FNA cytology was low and for EUS was moderate.

24 The committee noted that all studies, except for FDG-PET/CT, had either a serious or a very
25 serious risk of bias due to different reference standards being used across the study sample;
26 a lack of blinding; the test being evaluated being included in the reference standard
27 (potentially leading to an overestimation of test accuracy); people inappropriately excluded
28 from the analysis. The committee had more confidence in the quality of evidence from the
29 report related to FDG-PET/CT by Ghaneh et al. (2018) because it was the largest multicentre
30 study, it was conducted in a UK NHS setting (and therefore directly applicable) and the study
31 design was judged by the committee to be more robust than that of the other included
32 studies. Therefore in their discussion the committee placed relatively more weight on the
33 evidence from this study than in the rest of the evidence base.

34 The committee also noted that all patients had either imaging or ERCP in order to get into
35 these studies –the quality of this imaging could have had an effect on the accuracy results. In
36 addition the data for spiral CT were very old as the paper was from 2004. The committee
37 considered that the accuracy of CT was likely to be better than reported by these data as the
38 technology has advanced significantly since that time, as suggested by the data for MDCT.
39 They also agreed that CT was able to image the entire body which would be beneficial in
40 these patients and this contributed to the committee’s decision to make a strong
41 recommendation..

42 The committee noted that adverse event data were only found for EUS-FNA, CT and FDG-
43 PET/CT. Based on their clinical knowledge and experience, that there is a relatively low

1 occurrence of adverse events with these procedures, the committee did not apply much
2 weight to this data when making recommendations.

3 No evidence was found on the diagnostic accuracy of CA19-9 or CT-guided biopsy in
4 diagnosing pancreatic cancer in people with jaundice. Therefore no recommendations were
5 made about these investigations. No further research was recommended since these were
6 not considered high priorities for research funding.

7 **5.1.8.3 Consideration of clinical benefits and harms**

8 The evidence showed that there was heterogeneity in results for CT with one study reporting
9 high specificity for detecting pancreatic cancer but low sensitivity whereas the other study
10 reported the opposite findings (high sensitivity and lower specificity). The study with higher
11 sensitivity and lower specificity provided higher quality evidence and the committee gave
12 more weight to this in their discussion. EUS had low specificity but high sensitivity. Based on
13 their clinical experience and knowledge the committee noted that a CT scan was a less
14 invasive technique and was able to identify metastases, which EUS could not do. Given that
15 CT is less invasive and would capture most positive cases (according to the higher quality
16 evidence) the committee therefore recommended CT as the first investigation to diagnose
17 pancreatic cancer as a rule-out test in someone with obstructive jaundice. Based on their
18 clinical knowledge and experience, the committee noted that if a CT scan is used, a
19 pancreatic protocol CT scan should be used to ensure good visualisation of any pathology in
20 the pancreas. The committee noted that this is current practice and that their
21 recommendation reinforces this message. They also agreed, based on their knowledge and
22 experience, that if biliary drainage was performed to relieve the jaundice before the CT scan
23 was conducted, this would detrimentally affect the interpretation of the CT scan. They
24 therefore agreed that the CT scan should be conducted before biliary drainage.

25 For people with uncertain findings after CT scanning had been conducted, the committee
26 believed that FDG-PET/CT added significant additional information. Based on the evidence
27 and their knowledge committee members noted that this was particularly the case in in the
28 detection of metastatic disease. In addition, due to its non-invasive nature and the low false
29 negative rates FDG-PET/CT was considered to be an appropriate additional diagnostic test
30 to rule out malignancy in people with suspected pancreatic cancer. The committee
31 recommended FDG-PET/CT and / or EUS with tissue sampling. If EUS is used in
32 combination with FDG-PET/CT or on its own, taking a tissue sample at the same time as
33 EUS is recommended because it would be needed to confirm the diagnosis and taking it at
34 the same time as EUS would reduce the need for repeated tests which would be more
35 acceptable to patients. The committee noted that EUS with tissue sampling had both high
36 sensitivity and specificity whereas FDG-PET/CT had high sensitivity but lower specificity. The
37 committee decided that the non-invasive nature of FDG-PET/CT, the low false negative rate
38 and the additional information related to metastatic disease that it can provide, would put FDG-
39 PET/CT alongside EUS with tissue sampling as the next step if further diagnostic information
40 is required after the CT scan. The committee therefore decided that a FDG-PET/CT scan
41 should be conducted and / or EUS (with tissue sampling) if the diagnosis is still unclear after
42 CT.

43 The committee noted that the evidence for ERCP plus brushings of biliary strictures showed
44 high specificity but relatively low sensitivity and was of very low or low quality. They therefore
45 agreed not to make any recommendation about whether ERCP should be performed or not.
46 However, the committee noted, based on their knowledge and experience, that some people
47 who are deeply jaundiced or who are unfit for surgery will have an ERCP to relieve the
48 obstruction that is causing the jaundice before they have a tissue diagnosis. Brushings of
49 biliary strictures taken during the ERCP will give further diagnostic information which will
50 inform treatment. They therefore agreed to recommend biliary brushing to obtain cytology if
51 an ERCP is being performed and there is no tissue diagnosis. The committee agreed that
52 despite the low quality of the evidence, this should be a strong recommendation because

1 having the diagnostic information provided by the brushings was essential, and in this group
2 it could only be obtained by biliary brushings.

3 The potential benefits of the recommendations made were considered to be a more efficient
4 pathway to diagnosis for people with obstructive jaundice which optimises non-invasive
5 investigations and a reduction in the need for multiple diagnostic investigations. The potential
6 harms were complications associated with the use of EUS and ERCP. However, as these
7 complication rates are low the potential benefits were considered to outweigh the potential
8 harms.

9 **5.1.8.4 Consideration of economic benefits and harms**

10 The committee noted that whilst no relevant published economic evaluations had been
11 identified, diagnosis (including patients with jaundice) formed part of the diagnosis and
12 staging pathway for the cost utility analysis in a health technology assessment (HTA) by
13 Ghaneh et al. (2018) discussed in detail in section 7.5.1.

14 The HTA highlighted that including FDG-PET/CT as part of the diagnostic and staging work
15 up of patients with suspected pancreatic cancer was very likely cost saving and health
16 improving. It was acknowledged that the HTA did not look at the cost effectiveness of the
17 addition of FDG-PET/CT in a sub-group of patients with obstructive jaundice although this
18 group was part of the larger study cohort considered. However, the committee could not see
19 any clinical reason why the conclusions would not remain the same if such a sub group was
20 considered.

21 The committee also acknowledged that the majority of the cost savings and health
22 improvements identified in the HTA would be as a result of better staging and a reduction in
23 unnecessary resections (which is why the study was discussed in detail for the staging topic).
24 The recommendations for that topic, for diagnosis of people with obstructive jaundice and
25 suspected pancreatic cancer, and staging of those with confirmed pancreatic cancer almost
26 identically match the diagnosis and staging pathway used as the intervention in the HTA's
27 cost utility study. The committee therefore considered the reasons discussed in section 7.8.4.
28 applied to the diagnostic recommendation for FDG-PET/CT as well (see recommendation 2).
29 The committee were therefore confident this recommendation was cost effective and very
30 likely cost saving and health improving.

31 The recommendation would lead to an initial increase in patients with obstructive jaundice
32 receiving FDG-PET/CT as only a minority of this patient group currently receive these. Given
33 the relatively large patient group this could be significant. The HTA strongly suggests that
34 this initial increase in resource use would be recouped within a year.

35 **5.1.9 References**

36 Agarwal B, Abu-Hamda E, Molke KL et al. (2004) Endoscopic ultrasound-guided fine needle
37 aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. *American*
38 *Journal of Gastroenterology* 99(5): 844-50

39 Ghaneh P, Hanson R, Titman A et al. (2018) PET-PANC: multicentre prospective diagnostic
40 accuracy and health economic analysis study of the impact of combined modality ¹⁸fluorine-
41 2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography
42 scanning in the diagnosis and management of pancreatic cancer. *Health Technology*
43 *Assessment* 22(7)

44 Kim JJ, Walia S, Lee SH et al. (2015) Lower yield of endoscopic ultrasound-guided fine-
45 needle aspiration in patients with pancreatic head mass with a biliary stent. *Digestive*
46 *diseases and sciences* 60(2): 543-549

1 Oppong K, Raine D, Nayar M et al. (2010) EUS-FNA versus biliary brushings and
 2 assessment of simultaneous performance in jaundiced patients with suspected malignant
 3 obstruction. *Journal of the Pancreas* 11(6): 560-567

4 Ross WA, Wasan SM, Evans DB et al. (2008) Combined EUS with FNA and ERCP for the
 5 evaluation of patients with obstructive jaundice from presumed pancreatic malignancy.
 6 *Gastrointestinal endoscopy* 68(3): 461-466

7 Tummala P, Munigala S, Eloubeidi MA et al. (2013) Patients with obstructive jaundice and
 8 biliary stricture±mass lesion on imaging: prevalence of malignancy and potential role of EUS-
 9 FNA. *Journal of clinical gastroenterology* 47(6): 532-537

10 5.2 People without jaundice but with a pancreatic abnormality

11 **Review question: What is the most effective diagnostic pathway (imaging +/-CA 19–9,
 12 biopsy (cytology or histology)) for adults with suspected pancreatic cancer in
 13 secondary care who do not have jaundice but have a pancreatic abnormality on
 14 imaging?**

15 5.2.1 Introduction

16 The availability and use of imaging, both ultrasound and CT, continues to increase in clinical
 17 practice and, as a consequence, incidental lesions are detected with increasing frequency.
 18 Incidental lesions in the pancreas, both solid and cystic, in asymptomatic people are a
 19 common finding. There is no consensus as to the most appropriate pathway to establish an
 20 accurate diagnosis in this patient group.

21 Pancreatic CT scanning is regarded as the mainstay of the imaging pathway, but the role of
 22 pancreatic MRI and FDG-PET/CT, although not well defined, is increasing.

23 In addition, the role of both cytology and histology and the best method of obtaining tissue to
 24 confirm the diagnosis has not been established. Imaging may also reveal metastatic disease,
 25 which could be sampled to help establish the diagnosis.

26 Guidance is needed on the most effective diagnostic pathway to identify pancreatic cancer in
 27 people who have a pancreatic abnormality on imaging.

28 5.2.1.1 Review protocol summary

29 The review protocol summary used for this question can be found in Table 24. Full details of
 30 the review protocol can be found in Appendix C.

31 **Table 24: Clinical review protocol summary for the review of the most effective
 32 diagnostic pathway for people with suspected pancreatic cancer who do not
 33 have jaundice but have a pancreatic abnormality on imaging**

Population	Adults suspected of having pancreatic cancer who do not have jaundice but have a pancreatic abnormality on imaging
Index Test	<ul style="list-style-type: none"> • Imaging +/- CA 19–9 • Ultrasound • CT • MRI • FDG-PET/CT • Biopsy (cytology or histology) • EUS +/- FNA • EUS +/- Core biopsy

Population	Adults suspected of having pancreatic cancer who do not have jaundice but have a pancreatic abnormality on imaging
	<ul style="list-style-type: none"> • Percutaneous liver biopsy • Laparoscopy + biopsy • Percutaneous pancreatic biopsy
Reference Standard	<ul style="list-style-type: none"> • Definitive diagnosis (preferably Pathological diagnosis) • Each other
Outcomes	<ul style="list-style-type: none"> • Diagnostic Accuracy including: <ul style="list-style-type: none"> • Sensitivity • Specificity • Positive Predictive Value • Negative Predictive Value • Adverse events

1 5.2.2 Description of clinical evidence

2 Twenty-one articles reporting a total of 32 datasets were identified: 3 of these were RCTs
3 (Bang et al. 2012; Lee et al. 2014; Ramesh et al. 2015), 13 were prospective cohort studies
4 (Bournet et al. 2015; Bournet et al. 2009; Fabbri et al. 2011; Harewood & Wiersema 2002;
5 Iglesias-Garcia et al. 2007; Kliment et al. 2010; Krishna et al. 2009; Mishra et al. 2006;
6 Seicean et al. 2016; Strand et al. 2014; Touchefeu et al. 2009; Wakatsuki et al. 2005;
7 Wittman et al. 2006) and 5 were retrospective cohort studies (Fritscher-Ravens et al. 2002;
8 Hikichi et al. 2009; Tamm et al. 2007; Yang et al. 2015; Yusuf et al. 2009). A summary of the
9 included studies is presented in Table 25.

10 The majority of the studies examined the diagnostic test accuracy of EUS-FNA for detecting
11 malignancy in patients with suspected pancreatic cancer due to a solid lesion identified
12 through previous imaging (e.g. EUS, CT, MRI, ERCP). The majority of the studies reported
13 sensitivity and specificity, as well as positive/negative predictive value. Three articles (Hikichi
14 et al. 2009; Ramesh et al. 2015; Yusuf et al. 2009) contributed two sets of data to the review
15 on EUS-FNA. The majority of the studies also used a composite 'gold standard' reference
16 test generally comprised of histo-/cyto-pathology from surgery, and subsequent clinical and
17 imaging follow-up results. The majority of the studies also reported that there were no
18 procedure-related adverse events, serious or otherwise. No studies were found that
19 examined percutaneous liver biopsy, laparoscopy + biopsy.

20 One single centre retrospective cohort study (n=117) examined the diagnostic accuracy of
21 multidetector CT (Tamm et al. 2007) in detecting malignancy in solid lesions initially identified
22 through imaging.

23 Two single centre cohort studies (n=330) – 1 prospective (n=213; Krishna et al. 2009) and 1
24 retrospective (n=117; Tamm et al. 2007) - examined the diagnostic accuracy of EUS in
25 detecting malignancy in solid lesions initially identified through imaging. The sample in
26 Krishna et al. (2009) had a low prevalence of malignant lesions (0.52) and included 15%
27 patients whose lesions were revealed to be cystic by EUS-FNA.

28 Twenty-two datasets (n=2869) from 19 studies - 3 RCTs (Bang et al. 2012; Lee et al. 2014;
29 Ramesh et al. 2015) and 16 (11 prospective and 5 retrospective) cohort studies - examined
30 the diagnostic accuracy of EUS-FNA in detecting malignancy in solid lesions initially
31 identified through imaging (Bournet et al. 2009, 2015; Fabbri et al. 2011; Fritscher-Ravens et
32 al. 2002; Harewood & Wiersema 2002; Hikichi et al. 2009; Iglesias-Garcia et al. 2007;
33 Kliment et al. 2010; Krishna et al. 2009; Mishra et al. 2006; Seicean et al. 2016; Tamm et al.
34 2007; Touchefeu et al. 2009; Wakatsuki et al. 2005; Wittman et al. 2006; Yusuf et al. 2009).
35 The majority of these studies used a 22-gauge needle to extract a cytological specimen. The
36 number of included studies (≥ 4) allowed a meta-analysis of the diagnostic test accuracy data

1 to be performed, which produces a summary point estimate of the sensitivity and specificity
2 of EUS-FNA. Although there was not sufficient data to examine heterogeneity for covariates
3 such as needle type and type of reference test, a subgroup analysis by type of study
4 (RCT/prospective cohort vs retrospective cohort) was conducted.

5 Four studies (n=158) - 2 RCTs (Bang et al. 2012; Lee et al. 2014) and 2 prospective cohort
6 studies (Strand et al. 2014; Wittman et al. 2006) - examined the diagnostic accuracy of EUS-
7 core biopsy in detecting malignancy in solid lesions initially identified through imaging. The
8 number of included studies (≥ 4) allowed a meta-analysis of the diagnostic test accuracy data
9 to be performed, which produces a summary point estimate of the sensitivity and specificity
10 of EUS-core biopsy. The two RCTs, which randomised participants to receive either EUS-
11 FNA or EUS-core, both used fine biopsy (ProCore) needles (EUS-FNB), whilst the cohort
12 studies used either FNB (Strand et al. 2014) or trucut (Wittman et al. 2006) biopsy needles
13 (EUS-TNB).

14 One prospective cohort study (n=36) examined the diagnostic accuracy of combining EUS-
15 FNA with EUS-Core (Wittman et al. 2006).

16 One multicentre retrospective cohort study (n=60) examined the diagnostic accuracy of
17 percutaneous US-guided core in detecting malignancy in solid lesions initially identified
18 through imaging (Yang et al. 2015).

19 One multicentre retrospective cohort study (n=15) examined the diagnostic accuracy of
20 percutaneous US-guided FNA + core in detecting malignancy in solid lesions initially
21 identified through imaging (Yang et al. 2015).

22 Positive and likelihood ratios were calculated, where appropriate, from the raw diagnostic
23 test accuracy data or the estimated sensitivity and specificity of the studies to enable
24 evaluation of the relevant tests. The QUADAS-2 checklist was used to evaluate the risk of
25 bias and indirectness (applicability) of the studies.

26

1 **5.2.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 25.

3 **Table 25: Summary of included studies**

Study ID	Population	Study design Country	Index test	Reference standard	Outcomes	Overall risk of bias (ROB)/ Indirectness (ROA) (High/Low/Unclear)
Bang et al. 2012	56 consecutive patients with solid lesion	RCT USA	EUS-FNA EUS-Core (FNB)	Histology	Sensitivity Specificity	ROB: LOW ROA: LOW
Bournet, Selves et al. 2015	186 consecutive patients with suspected solid lesion	Prospective cohort France	EUS-FNA	Clinical follow up (including subsequent imaging and surgery)	Sensitivity Specificity	ROB: LOW ROA: LOW
Bournet, Souque et al. 2009	178 consecutive patients with suspected solid lesion	Prospective cohort France	EUS-FNA	Clinical follow up (including subsequent imaging and cytopathology)	Sensitivity Specificity	ROB: LOW ROA: LOW
Fabbri et al. 2011	50 consecutive patients with solid lesion	Prospective cohort Italy	EUS-FNA	Surgery, death from disease or clinical/imaging follow up	Sensitivity Specificity	ROB: HIGH ROA: LOW
Fritscher-Ravens et al. 2002	207 consecutive patients with solid lesion	Retrospective cohort Germany	EUS-FNA	Histology, bacteriology, or clinical follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Harewood et al. 2002	185 consecutive patients with suspected or known solid lesion	Prospective cohort USA	EUS-FNA	Surgical pathology, cytology, and clinical course + sequential radiological imaging	Sensitivity Specificity	ROB: LOW ROA: LOW
Hikichi et al. 2009	73 consecutive patients with solid lesion	Retrospective cohort Japan	EUS-FNA	Surgery, autopsy, or >12 months clinical follow up	Sensitivity Specificity	ROB: LOW ROA: LOW

Study ID	Population	Study design Country	Index test	Reference standard	Outcomes	Overall risk of bias (ROB)/ Indirectness (ROA) (High/Low/Unclear)
Iglesias-Garcia et al. 2007	62 consecutive patients with solid lesion	Prospective cohort Spain	EUS-FNA	Surgery or clinical follow up (including subsequent imaging and biochemical evaluation)	Sensitivity Specificity	ROB: LOW ROA: LOW
Kliment et al. 2010	207 consecutive patients with solid lesion	Prospective cohort Czech Republic	EUS-FNA	Histology from resection, or clinical/imaging follow up >6 months	Sensitivity Specificity	ROB: LOW ROA: LOW
Krishna et al. 2009	213 consecutive patients with solid lesion	Prospective cohort USA	EUS EUS-FNA	Definitive cytology, surgical pathology, and >12 months follow up.	Sensitivity Specificity	ROB: LOW ROA: LOW
Lee et al. 2014	118 consecutive patients with solid lesion	RCT South Korea	EUS-FNA EUS-Core (FNB)	Surgery or clinical/imaging follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Mishra et al. 2006	52 consecutive patients with solid lesion	Prospective cohort USA	EUS-FNA	Cytology on EUS-FNA or CT-guided biopsy and clinical follow up, or surgical exploration with intraoperative biopsy	Sensitivity Specificity	ROB: LOW ROA: LOW
Ramesh et al. 2015	100 consecutive patients with suspected solid lesion	Multicentre RCT USA	EUS-FNA with 19-gauge needle EUS-FNA with 22-gauge needle	Histology	Sensitivity Specificity	ROB: LOW ROA: LOW
Seicean et al. 2016	118 consecutive patients with solid lesion	Prospective cohort Romania	EUS-FNA	EUS-FNA core biopsy (follow up EUS-FNA if inconclusive), hepatic biopsy, or >6 months clinical follow up (including repeated CT-EUS if needed)	Sensitivity Specificity	ROB: LOW ROA: LOW

Study ID	Population	Study design Country	Index test	Reference standard	Outcomes	Overall risk of bias (ROB)/ Indirectness (ROA) (High/Low/Unclear)
Strand et al. 2014	32 consecutive patients with suspected solid lesion	Prospective cohort USA	EUS-FNB	EUS-FNA cytology	Sensitivity Specificity	ROB: UNCLEAR ROA: HIGH
Tamm et al. 2007	117 consecutive patients with solid lesion	Retrospective cohort USA	MDCT EUS EUS-FNA	Histopathology on biopsy or surgery samples, or >9 months clinical follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Touchefeu et al. 2009	90 consecutive patients with solid lesion	Prospective cohort France	EUS-FNA	Histology on surgery samples or clinical/imaging follow up	Sensitivity Specificity	ROB: HIGH ROA: LOW
Wakatsuki et al. 2005	83 consecutive patients with solid lesion	Retrospective cohort Japan	EUS-FNA	Surgery, autopsy or >6 months follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Wittman et al. 2006	83 consecutive patients with solid lesion	Prospective cohort UK	EUS-FNA EUS-Core (Trucut needle) EUS-FNA+Core	Cytology, histology, surgery, or clinical follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Yang et al. 2015	88 consecutive patients with solid lesion	Retrospective cohort Canada	Percutaneous US-guided Core Percutaneous US-guided FNA Percutaneous US-guided Core + FNA	Surgical pathology or clinical follow up	Sensitivity Specificity	ROB: LOW ROA: LOW
Yusuf et al. 2009	N=540 consecutive patients with suspected PC due to	Retrospective cohort USA	EUS-FNA with 22-gauge needle	Surgical histopathology or long-term follow up	Sensitivity Specificity	ROB: LOW ROA: LOW

Study ID	Population	Study design Country	Index test	Reference standard	Outcomes	Overall risk of bias (ROB)/ Indirectness (ROA) (High/Low/Unclear)
	solid mass (22-gauge needle) N=302 consecutive patients with suspected PC due to solid mass (25-gauge needle)		EUS-FNA with 25-gauge needle			

1 **5.2.4 Clinical evidence profile**

2 The clinical evidence profiles for this review question are presented in Table 26 to Table 33.

3 **5.2.4.1 Computed tomography**

4 **Table 26: Summary of clinical evidence for computed tomography to detect malignancy in people without jaundice but who have a**
5 **pancreatic abnormality on imaging**

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Tamm et al. 2007	117	Not serious	Not applicable	Not serious	Not serious	0.97 (0.91-0.99)	0.72 (0.46-0.89)	3.49 (1.66-7.36)	0.04 (0.01-0.13)	HIGH

6 ¹ risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

7 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
8 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

9 ³, indirectness was evaluated using the applicability items of QUADAS-2;

10 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
11 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
12 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
13 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
14 and 0.9.

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

5.2.4.2 Endoscopic ultrasonography (EUS)

45.2.4.2.1 EUS

Table 27: Summary of clinical evidence for EUS to detect malignancy in people without jaundice but who have a pancreatic abnormality on imaging

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Krishna et al. 2009	213	Not serious	Not serious	Serious ⁶	Not serious	1.0 (0.97-1.0)	0.66 (0.57-0.75)	2.94 (2.25-3.85)	0	MODERATE
Tamm et al. 2007	117	Not serious	Not serious	Not serious	Not serious	0.99 (0.94-0.99)	0.5 (0.27-0.73)	1.98 (1.25-3.14)	0.02 (0-0.15)	HIGH
Overall	330	Not serious	Not serious	Serious ⁷	Not serious					MODERATE

¹ risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, although Krishna et al. 2009 excluded patients whose lesions appeared to be cystic on CT or MRI, the sample included 33 participants (15% of analysed sample) whose focal lesions were found to be cystic by EUS-FNA;

⁷, Krishna et al. 2009 contributes more than 50% of the total sample.

15.2.4.2.2 **EUS-FNA**

2 **Table 28: Summary of clinical evidence for EUS-FNA to detect malignancy in people without jaundice but who have a pancreatic**
3 **abnormality on imaging**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
22 datasets (3 RCTs and 16 observational cohort) ⁶	2869	Not serious ⁷	Serious ⁸	Not serious	Not serious	0.89 (0.85-0.92)	0.99 (0.96-1.0)	121.03 (20.64-709.55)	0.11 (0.08-0.15)	MODERATE

4 ¹, risk of bias evaluated using QUADAS-2 checklist;

5 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
6 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

7 ³, indirectness was evaluated using the applicability items of QUADAS-2;

8 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
9 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
10 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
11 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
12 and 0.9;

13 ⁵, positive and negative likelihood ratios calculated from meta-analysis;

14 ⁶, 11 prospective, and 7 retrospective, cohort studies;

15 ⁷, note that risk of bias for patient selection, index test, and flow and timing was low in all studies except for Fabbri et al. (2011) and Touchefeu et al. (2009), which both had
16 high risk of bias for flow and timing; also, in all the studies it was unclear how long the period was between initial index and subsequent reference test, whilst in the
17 majority of included studies, the same reference standard was not used;

18 ⁸, the 95% prediction region was very wide and ranged from approximately 0.58 to 0.97 along the sensitivity axis and approximately 0.2 to 1.0 along the specificity axis (i.e. if
19 the model is correct, there is probability of 0.95 that a future study will have sensitivity and specificity within these regions).

1

2

Table 29: Pooled sensitivity and specificity of EUS-FNA by type of study

Parameter	Type of study		Significant difference between subgroups (t-value, p-value) ¹
	RCTs/prospective cohort (15 studies, n=1612)	Retrospective cohort (7 studies, n=1285)	
Pooled sensitivity (95% CI)	0.89 (0.84-0.93)	0.88 (0.84-0.91)	t=0.02, p=0.99
Pooled specificity (95% CI)	0.99 (0.91-1.0)	0.99 (0.97-1.0)	t=0, p=1.0
Positive likelihood ratio (95% CI) ²	92.82 (9.29-927.71)	109.95 (25.14-480.83)	
Negative likelihood ratio (95% CI) ²	0.11 (0.07-0.17)	0.12 (0.09-0.16)	

3

¹, Unpaired t-test to compare pooled estimates of RCTs and prospective cohort studies with retrospective cohort studies. Standard errors for each subgroup used to conduct t-test calculated from 95% confidence intervals;

4

5

², positive and negative likelihood ratios calculated from meta-analysis.

65.2.4.2.3 EUS-Core (FNB or TNB)

7

Table 30: Summary of clinical evidence for EUS-guided core biopsy (FNB or trucut) to detect malignancy in people without jaundice but who have a pancreatic abnormality on imaging

8

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled Sensitivity (95% CI)	Pooled Specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 studies (2 RCTs and 2 prospective cohort)	154	Not serious	Very serious ⁶	Not serious	Very serious ⁷	0.70 (0.3-0.93)	1.0 (0.03-1.0)	176.61 (0.02-1867693) ⁸	0.3 (0.09-1.02)	VERY LOW

9

¹ risk of bias evaluated using QUADAS-2 checklist;

10

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

11

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from meta-analysis

⁶, the 95% prediction region was extremely wide and ranged from 0 to 1.0 along both the sensitivity and specificity axes. Note that the 2 RCTs have a much higher sensitivity and specificity than the 2 prospective cohort studies;

⁷, 95% CI of sensitivity crosses both 0.75 and 1.0;

⁸, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

125.2.4.2.4 EUS-FNA + Core

Table 31: Summary of clinical evidence for EUS-FNA + Core to detect malignancy in people without jaundice but who have a pancreatic abnormality on imaging

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI) ⁶	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Wittmann et al. 2006	36	Not serious	Not applicable	Not serious	Very serious ⁶	0.76 (0.55-0.91)	1.0 (0.72-1.0)	18 (1.18-273.95) ⁷	0.24 (0.12-0.48)	LOW

¹ risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, 95% CI of specificity crosses both 0.75 and 0.9 thresholds;

⁷, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

Percutaneous ultrasonography

35.2.4.2.5 Percutaneous US-guided Core

Table 32: Summary of clinical evidence for percutaneous US-guided core to detect malignancy in people without jaundice but who have a pancreatic abnormality on imaging

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Yang et al. 2015	60	Not serious	Not applicable	Not serious	Serious ⁶	0.93 (0.82-0.98)	1.0 (0.54-1.0)	12.85 (0.89-186.03) ⁷	0.07 (0.03-0.19)	LOW

¹ risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, 95% CIs of sensitivity crosses 0.9 threshold

⁷, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

15.2.4.2.6 Percutaneous US-guided FNA + Core

Table 33: Summary of clinical evidence for percutaneous US-guided FNA + core to detect malignancy in people without jaundice but who have a pancreatic abnormality on imaging

Study	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Yang et al. 2015	15	Not serious	Not applicable	Not serious	Very serious ⁶	0.92 (0.64-1.0)	1.0 (0.16-1.0)	5.36 (0.42-67.71) ⁷	0.08 (0.01-0.51)	LOW

¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details).

⁶, 95% CIs of sensitivity crosses both 0.75 and 0.9 thresholds

⁷, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

1 **5.2.5 Economic evidence**

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 **5.2.6 Evidence statements**

8 **5.2.6.1 Computed tomography (CT)**

9 **Diagnostic accuracy**

10 Moderate quality evidence from 1 single centre retrospective cohort study (n=117) found that
11 multidetector CT had a high sensitivity of 0.97 (95% CI, 0.91-0.99) and a low specificity of
12 0.72 (95% CI, 0.46-0.89) in detecting malignant incidental solid pancreatic lesions in adults
13 with suspected pancreatic cancer. The positive likelihood ratio of 3.49 (1.66-7.36) suggests
14 that a positive result for malignancy is not particularly useful for ruling it in, though there is
15 uncertainty in the estimate. The negative likelihood ratio of 0.04 (95% CI, 0.01-0.13)
16 suggests that a negative result for malignancy is very useful for ruling it out, though there is
17 uncertainty in the estimate.

18 **Adverse events**

19 No evidence was identified to inform this outcome.

20 **5.2.6.2 Endoscopic ultrasonography (EUS)**

21 **5.2.6.2.1 EUS**

22 **Diagnostic accuracy**

23 Moderate quality evidence from 2 single centre cohort studies - 1 prospective (n=213) and 1
24 retrospective (n=117) - found that EUS had a high sensitivity ranging from 0.99 to 1.0 and
25 low specificity ranging from 0.5 to 0.66 in detecting malignant incidental solid pancreatic
26 lesions in adults with suspected pancreatic cancer. The positive likelihood ratios were 1.98
27 (95% CI, 1.25-3.14) and 2.94 (95% CI, 2.25-3.85) suggesting that a positive result for
28 malignancy is not useful for ruling it in. The negative likelihood ratios were 0 and 0.02 (95%
29 CI, 0-0.15) suggesting that a negative result for malignancy is very useful for ruling it out,
30 though there is uncertainty in the latter estimate.

31 **Adverse events**

32 No evidence was identified to inform this outcome.

33 **5.2.6.2.2 EUS-FNA**

34 **Diagnostic accuracy**

35 Moderate quality evidence from a meta-analysis of 22 studies (n=2869) found that
36 endoscopic ultrasound fine needle aspiration had a moderate pooled sensitivity of 0.89 (95%
37 CI, 0.85-0.92) and a high pooled specificity of 0.99 (95% CI, 0.96-1.0) in detecting malignant
38 incidental solid pancreatic lesions in adults with suspected pancreatic cancer. The positive
39 likelihood ratio of 121.03 (95%, 20.64-709.55) suggests that a positive result for malignancy

1 is very useful for ruling it in. The negative likelihood ratio of 0.11 (0.08-0.15) suggests that a
2 negative result for malignancy is moderately useful for ruling it out, though there is
3 uncertainty in the estimate.

4 A subgroup analysis by study type (RCTs and prospective cohort studies vs retrospective
5 cohort studies) showed that there was no significant difference between the two groups in
6 the estimated pooled sensitivity (0.89 [95% CI, 0.84-0.93] vs 0.88 [95% CI, 0.84-0.91],
7 respectively) and pooled specificity (0.99 [95% CI, 0.91-1.0] vs 0.99 [95% CI, 0.97-1.0],
8 respectively), although there was more uncertainty in the pooled estimates from the
9 RCT/prospective cohort study group. The similar positive likelihood ratios of 92.82 (95% CI,
10 9.29-927.71) and 109.95 (95% CI, 25.14-480.83) in the two subgroups support the
11 conclusion above that a positive result for malignancy is very useful for ruling it in. Similarly,
12 the negative likelihood ratios for the subgroups of 0.11 (95% CI, 0.07-0.17) and 0.12 (95%
13 CI, 0.09-0.16) also support the conclusion above that a negative result for malignancy is
14 moderately useful for ruling it out, though there is uncertainty in the estimates.

15 **Adverse events**

16 Fourteen studies (N=2123) reported data on adverse events with complication rates ranging
17 from 0% to 4%. Nine studies reported that there were no adverse events, whilst the most
18 common adverse event reported in the remaining 8 studies was mild pancreatitis (13
19 reported cases). Other reported adverse events included post-procedural pain (2 cases),
20 bleeding and fever (1 case each).

215.2.6.2.3 ***EUS-Core (FNB or trucut)***

22 **Diagnostic accuracy**

23 Very low quality evidence from a meta-analysis of 4 studies (n=154) found that endoscopic
24 ultrasound core biopsy had a low pooled sensitivity of 0.7 (95% CI, 0.3-0.93) and a high
25 pooled specificity of 0.99 (95% CI, 0.03-1.0) in detecting malignant incidental solid pancreatic
26 lesions in adults with suspected pancreatic cancer. The positive likelihood ratio of 176.61
27 (95% CI, 0.02-1867693) suggests that a positive result for malignancy is very useful for ruling
28 it in, though there is substantial uncertainty in the estimate. The negative likelihood ratio of
29 0.3 (95% CI, 0.09-1.02) suggests that a negative result for malignancy is not particularly
30 useful for ruling, though there is substantial uncertainty in the estimate.

31 **Adverse events**

32 The studies reported no serious procedure-related adverse events. The complication rate
33 ranged from 0% to 5.2%. One study reported a case of mild acute pancreatitis that required
34 hospitalisation for 2 days, and 1 study reported 2 cases of gastric haematoma and 1 case of
35 mild bleeding.

365.2.6.2.4 ***EUS-FNA + Core***

37 **Diagnostic accuracy**

38 Low quality evidence from 1 single-centre prospective cohort study (N=36) found that
39 combining EUS-FNA with EUS-Core biopsy had a moderate sensitivity of 0.76 (95% CI,
40 0.55-0.91) and a high specificity of 1.0 (95% CI, 0.72-1.0) in detecting malignant incidental
41 solid pancreatic lesions in adults with suspected pancreatic cancer. The positive likelihood
42 ratio of 18 (95% CI, 1.18-273.95) suggests that a positive result for malignancy is very useful
43 for ruling it in, though there is substantial uncertainty in the estimate. The negative likelihood
44 ratio of 0.24 (95% CI, 0.12-0.48) suggests that a negative result for malignancy is not
45 particularly useful for ruling it out, though there is uncertainty in the estimate.

1 **Adverse events**

2 The study did not report any serious adverse events. There was a 3% complication rate with
3 1 case of moderate self-limiting abdominal pain (not requiring analgesia) after biopsy of a
4 pancreatic tail lesion.

5 **5.2.6.3 Percutaneous ultrasonography (percutaneous US)**

65.2.6.3.1 ***Percutaneous US-guided Core***

7 **Diagnostic accuracy**

8 Low quality evidence from 1 multicentre retrospective cohort study (n=60) found that
9 percutaneous US-guided core biopsy had a high sensitivity of 0.93 (95% CI, 0.82-0.98) and a
10 high specificity of 1.0 (95% CI, 0.54-1.0) in detecting malignant incidental solid lesions in
11 adults with suspected pancreatic cancer. The positive likelihood ratio of 12.85 (95% CI, 0.89-
12 186.03) suggests that a positive result for malignancy is very useful for ruling it in, though
13 there is substantial uncertainty in the estimates. The negative likelihood ratio of 0.07 (95%
14 CI, 0.03-0.19) suggests that a negative result for malignancy is very useful for ruling it out,
15 though there is uncertainty in the estimates.

16 **Adverse events**

17 The study did not report any serious adverse events. There was a 3% complication rate with
18 1 case of haematoma and 1 case of pain, both reported immediately after the biopsy was
19 taken.

205.2.6.3.2 ***Percutaneous US-guided FNA + Core***

21 **Diagnostic accuracy**

22 Low quality evidence from 1 multicentre retrospective cohort study (n=15) found that
23 percutaneous US-guided core biopsy combined with PUS-FNA had high sensitivity of 0.92
24 (95% CI, 0.64-1.0) and a high specificity of 1.0 (95% CI, 0.16-1.0) in detecting malignant
25 incidental solid lesions in adults with suspected pancreatic cancer. The positive likelihood
26 ratio of 5.36 (95% CI, 0.42-67.71) suggests that a positive result for malignancy is
27 moderately useful for ruling it in, though there is substantial uncertainty in the estimates. The
28 negative likelihood ratio of 0.08 (95% CI, 0.01-0.51) suggests that a negative result for
29 malignancy is very useful for ruling it out, though there is substantial uncertainty in the
30 estimates.

31 **Adverse events**

32 The study did not report any serious adverse events. There was a complication rate of 7%
33 with 1 case of pain reported immediately after the biopsy was taken.

34 **5.2.7 Recommendations**

- 35 **4. Offer a pancreatic protocol CT scan to people with pancreatic abnormalities but**
36 **no jaundice.**
- 37 **5. If the diagnosis is still unclear, offer fluorodeoxyglucose-positron emission**
38 **tomography/CT (FDG-PET/CT) and/or EUS with EUS-guided tissue sampling.**
- 39 **6. If cytological or histological samples are needed, offer EUS with EUS-guided**
40 **tissue sampling.**

1 **5.2.8 Evidence to recommendations**

2 **5.2.8.1 Relative value placed on the outcomes considered**

3 Diagnostic accuracy (sensitivity, specificity, positive predictive value and negative predictive
4 value) and adverse events were considered the critical outcomes for this question.
5 Diagnostic accuracy was reported for all interventions of interest. Adverse events were
6 reported for all interventions except CT and EUS.

7 **5.2.8.2 Quality of evidence**

8 Evidence was identified on the diagnostic accuracy of CT, EUS, EUS-FNA, EUS-core, EUS-
9 FNA + core, percutaneous US-guided core and percutaneous US-guided FNA + core. The
10 quality of the evidence for CT and EUS-FNA was moderate, for EUS was high, for all other
11 investigations was either very low or low.

12 Given the low quality of the data for EUS-core, EUS-FNA + core, percutaneous US-guided
13 core and percutaneous US-guided FNA + core, the committee were less certain of the
14 balance between diagnostic accuracy and potential adverse events for these investigations.
15 They, therefore, agreed to apply more weight to the investigations with moderate and high
16 quality data. They did not make any recommendations about core biopsy by percutaneous
17 routes.

18 No evidence was identified on percutaneous liver or pancreatic biopsy or laparoscopy +
19 biopsy. Therefore, no recommendations were made about these investigations. No further
20 research was recommended since these were not considered high priorities for research
21 funding.

22 **5.2.8.3 Consideration of clinical benefits and harms**

23 The committee noted that of the investigations with moderate or high quality evidence, EUS
24 had shown the highest sensitivity but the lowest specificity for diagnosing malignancy in a
25 solid lesion suspected to be pancreatic cancer. Given that other investigations had similar
26 sensitivities but better specificities, they agreed not to make a recommendation about EUS
27 alone.

28 The committee noted, based on the evidence, that whilst the positive likelihood ratio for CT
29 was not as good as that for EUS-FNA/FNB, CT had a better negative likelihood ratio. They
30 also agreed, based on their knowledge and experience, that CT was more widely available
31 than EUS-FNA and was non-invasive so the risk of adverse events was lower. Therefore,
32 they agreed to recommend a CT scan as the first option in people with a solid lesion
33 suspected to be pancreatic cancer as a ruling out test. Based on their clinical knowledge and
34 experience, the committee noted that if a CT scan is used a pancreatic protocol CT scan
35 should be used to ensure good visualisation of any pathology in the pancreas.

36 Although there was no direct evidence on FDG-PET/CT as a diagnostic test for pancreatic
37 solid lesions, the committee believed that the evidence regarding its use in the diagnosis of
38 pancreatic cancer in people with jaundice (see section 5.1) and of people without jaundice
39 but with pancreatic abnormalities such as cysts (as described in Ghaneh et al. 2018 – see
40 section 5.3) merited its wider use in the diagnosis of people with solid lesions. As such, the
41 committee believed that FDG-PET/CT will add significant additional information, particularly
42 with respect to detecting metastatic disease if the diagnosis is unclear after the initial CT
43 scan. The committee noted that EUS with tissue sampling had both high sensitivity and
44 specificity whereas FDG-PET/CT had high sensitivity but lower specificity. The committee
45 decided that the non-invasive nature of FDG-PET/CT, the low false negative rate and the
46 additional information related to metastatic disease that it can provide, would put FDG-PET/CT
47 alongside EUS with tissue sampling as the next step if further diagnostic information is

1 required after the CT scan. For these reasons even though there was a lack of direct
2 evidence the committee decided, based on consensus, to make a strong recommendation
3 that a FDG-PET/CT scan should be conducted and / or EUS (with tissue sampling) if the
4 diagnosis is still unclear after CT.

5 The committee noted that EUS-guided tissue sampling can provide cytology or histology,
6 which a CT scan is unable to do. Based on their knowledge and experience, the committee
7 agreed that having cytology or histology would help to resolve diagnostic uncertainty,
8 facilitate oncological management and is needed to enrol people in clinical trials. Therefore,
9 based on the evidence and their knowledge, the committee agreed to recommend EUS-
10 guided tissue sampling for those people whose CT scan was inconclusive. They were unable
11 to specify whether FNA or FNB should be used for the tissue sampling as the evidence did
12 not support recommending 1 method over another. The committee considered that the
13 potential benefits of the recommendations made would be more accurate diagnosis of
14 pancreatic cancer in people with a solid lesion. The potential harms of the recommendations
15 were the potential for complications associated with EUS-guided tissue sampling. However,
16 the committee agreed that the benefits outweighed the harms as tissue sampling was only
17 recommended for a sub-set of the people being investigated.

18 **5.2.8.4 Consideration of economic benefits and harms**

19 The committee noted that whilst no relevant published economic evaluations were identified
20 for this topic, diagnosis (including patients with jaundice) formed part of the diagnosis and
21 staging pathway for the cost utility analysis in a health technology assessment (HTA) by
22 Ghaneh et al. (2018) identified for staging and discussed in detail in section 7.5.1.

23 The HTA highlighted that including FDG-PET/CT as part of the diagnostic and staging work
24 up of patients with suspected pancreatic cancer was very likely cost saving and health
25 improving. It was acknowledged that the HTA did not look at the cost effectiveness of the
26 addition of FDG-PET/CT in a sub-group of patients without jaundice but with pancreatic
27 abnormalities although this group would be a large component of study cohort considered. It
28 was noted that the definition of pancreatic abnormality for the inclusion criteria in the HTA
29 study (focal lesion in the pancreas/bulky pancreas/dilated pancreatic duct) was more
30 restrictive than the definition used for this question although it would account for the majority
31 of such abnormalities and the committee were confident that the evidence from this study
32 could be extrapolated since it also included people with pancreatic cysts.

33 The recommendations related to the topic in this section, as well as those for diagnosis of
34 people with suspected pancreatic cancer with jaundice and for staging almost identically
35 match the diagnosis and staging pathway used as the intervention in the HTA's cost utility
36 study. The committee therefore considered the reasons discussed in section 7.8.4. applied to
37 the two diagnostic recommendations as well. The committee were therefore confident this
38 recommendation was cost effective and very likely cost saving and health improving.

39 As for diagnosis for patients with jaundice (see section 5.1.7) this recommendation in favour
40 of FDG-PET/CT impacts upon a large proportion of the population considered for this
41 guideline. There will be an initial increase in resource use through increased imaging with
42 more expensive FDG-PET/CT, but this is likely to be recouped within one year.

43 **5.2.9 References**

44 Bang JY, Hebert-Magee S, Trevino J et al. (2012) Randomized trial comparing the 22-gauge
45 aspiration and 22-gauge biopsy needles for EUS-guided sampling of solid pancreatic mass
46 lesions. *Gastrointestinal Endoscopy* 76(2): 321-327

47 Bournet B, Selves J, Grand D et al. (2015) Endoscopic Ultrasound-guided Fine-Needle
48 Aspiration Biopsy Coupled with a KRAS Mutation Assay Using Allelic Discrimination

- 1 Improves the Diagnosis of Pancreatic Cancer. *Journal of Clinical Gastroenterology* 49(1): 50-
2 56
- 3 Bournet B, Souque A, Senesse P et al. (2009) Endoscopic ultrasound-guided fine-needle
4 aspiration biopsy coupled with KRAS mutation assay to distinguish pancreatic cancer from
5 pseudotumoral chronic pancreatitis. *Endoscopy* 41(06): 552-557
- 6 Fabbri C, Polifemo AM, Luigiano C et al. (2011) Endoscopic ultrasound-guided fine needle
7 aspiration with 22-and 25-gauge needles in solid pancreatic masses: a prospective
8 comparative study with randomisation of needle sequence. *Digestive and Liver Disease*
9 43(8): 647-652
- 10 Fritscher-Ravens A, Brand L, Knöfel WT et al. (2002) Comparison of endoscopic ultrasound-
11 guided fine needle aspiration for focal pancreatic lesions in patients with normal parenchyma
12 and chronic pancreatitis. *The American Journal of Gastroenterology*, 97(11): 2768-2775
- 13 Ghaneh P, Hanson R, Titman A et al. (2018) PET-PANC: multicentre prospective diagnostic
14 accuracy and health economic analysis study of the impact of combined modality ¹⁸fluorine-
15 2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography
16 scanning in the diagnosis and management of pancreatic cancer. *Health Technology*
17 *Assessment* 22(7)
- 18 Harewood GC and Wiersema MJ (2002) Endosonography-guided fine needle aspiration
19 biopsy in the evaluation of pancreatic masses. *The American Journal of Gastroenterology*
20 97(6): 1386-1391
- 21 Hikichi T, Irisawa A, Bhutani MS et al. (2009) Endoscopic ultrasound-guided fine-needle
22 aspiration of solid pancreatic masses with rapid on-site cytological evaluation by
23 endosonographers without attendance of cytopathologists. *Journal of Gastroenterology*
24 44(4): 322-328
- 25 Iglesias-Garcia J, Dominguez-Munoz E, Lozano-Leon A et al. (2007) Impact of endoscopic
26 ultrasound-guided fine needle biopsy for diagnosis of pancreatic masses. *World Journal of*
27 *Gastroenterology* 13(2): 289
- 28 Kliment M, Urban O, Cegan M et al. (2010) Endoscopic ultrasound-guided fine needle
29 aspiration of pancreatic masses: the utility and impact on management of patients.
30 *Scandinavian Journal of Gastroenterology* 45(11): 1372-1379
- 31 Krishna NB, LaBundy JL, Saripalli S et al. (2009) Diagnostic value of EUS-FNA in patients
32 suspected of having pancreatic cancer with a focal lesion on CT scan/MRI but without
33 obstructive jaundice. *Pancreas* 38(6): 625-630
- 34 Lee YN, Moon JH, Kim HK et al. (2014) Core biopsy needle versus standard aspiration
35 needle for endoscopic ultrasound-guided sampling of solid pancreatic masses: a randomized
36 parallel-group study. *Endoscopy* 46(12): 1056-1062
- 37 Mishra G, Zhao Y, Sweeney J et al. (2006) Determination of qualitative telomerase activity as
38 an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle
39 aspiration. *Gastrointestinal Endoscopy* 63(4): 648-654
- 40 Ramesh J, Bang JY, Hebert-Magee S et al. (2015) Randomized trial comparing the flexible
41 19G and 25G needles for endoscopic ultrasound-guided fine needle aspiration of solid
42 pancreatic mass lesions. *Pancreas* 44(1): 128-133
- 43 Seicean A, Gheorghiu M, Zaharia T et al. (2016) Performance of the Standard 22G Needle
44 for Endoscopic Ultrasound-guided Tissue Core Biopsy in Pancreatic Cancer. *Journal of*
45 *Gastrointestinal Liver Disease* 25(2): 213-218

- 1 Strand DS, Jeffus SK, Sauer BG et al. (2014) EUS-guided 22-gauge fine-needle aspiration
2 versus core biopsy needle in the evaluation of solid pancreatic neoplasms. *Diagnostic*
3 *Cytopathology* 42(9): 751-758
- 4 Tamm EP, Loyer EM, Faria SC et al. (2007) Retrospective analysis of dual-phase MDCT and
5 follow-up EUS/EUS-FNA in the diagnosis of pancreatic cancer. *Abdominal Imaging* 32(5):
6 660-667
- 7 Touchefeu Y, Le Rhun M, Coron E et al. (2009) Endoscopic ultrasound-guided fine-needle
8 aspiration for the diagnosis of solid pancreatic masses: the impact on patient-management
9 strategy. *Alimentary Pharmacology & Therapeutics* 30(10): 1070-1077
- 10 Wakatsuki T, Irisawa A, Bhutani MS et al. (2005) Comparative study of diagnostic value of
11 cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and that by
12 endoscopic retrograde pancreatography for the management of pancreatic mass without
13 biliary stricture. *Journal of Gastroenterology and Hepatology* 20(11): 1707-1711
- 14 Wittmann J, Kocjan G, Sgouros SN et al. (2006) Endoscopic ultrasound-guided tissue
15 sampling by combined fine needle aspiration and trucut needle biopsy: a prospective study.
16 *Cytopathology* 17(1): 27-33
- 17 Yang RY, Ng D, Jaskolka JD et al. (2015) Evaluation of percutaneous ultrasound-guided
18 biopsies of solid mass lesions of the pancreas: a center's 10-year experience. *Clinical*
19 *Imaging* 39(1): 62-65
- 20 Yusuf TE, Ho S, Pavey DA et al. (2009) Retrospective analysis of the utility of endoscopic
21 ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic masses, using a 22-gauge
22 or 25-gauge needle system: a multicenter experience. *Endoscopy* 41(05): 445-448

23 **5.3 Pancreatic Cysts**

24 **Review question: In adults with a pancreatic cyst, what is the diagnostic pathway to**
25 **identify the cyst(s) at high risk of pancreatic malignancy?**

26 **5.3.1 Introduction**

27 The diagnosis of pancreatic cysts continues to increase in frequency as more people
28 undergo cross sectional imaging.

29 The morphological identification of a cyst is straightforward on both MRI and CT but the
30 identification of the exact nature of the cystic lesion continues to present diagnostic difficulty.

31 Three broad groups of cystic lesions can be identified; definitely malignant, definitely benign
32 and indeterminate. There are features on imaging that suggest a cyst is suspicious in nature,
33 but often these are not definitive.

34 The presence of mucin within the cyst and the measurement of markers such as
35 Carcinoembryonic antigen (CEA) and amylase can help determine whether a lesion is benign
36 or pre-malignant, and the role of cytology and histology is important.

37 Several diagnostic pathways have been suggested within the literature but there remains
38 inconsistency within the UK as to the most effective method for diagnosis.

39 Guidance is needed on the most effective diagnostic pathway to identify cysts at high risk of
40 malignancy in people with pancreatic cysts.

1 5.3.1.1 Review protocol summary

2 The review protocol summary used for this question can be found in Table 34. Full details of
3 the review protocol can be found in Appendix C.

4 **Table 34: Clinical review protocol summary for the review of most effective diagnostic**
5 **pathway to identify the cyst(s) at high risk of pancreatic malignancy**

Population	Adults with pancreatic cysts
Index test	<ul style="list-style-type: none"> • CA 19–9, CEA – in serum and cyst fluid • Histology • Cytology • Imaging (MRI/MRCP, FDG-PET/CT, CT, Ultrasound, needle Confocal Laser Endomicroscopy, EUS+/-FNA)
Reference standard	<ul style="list-style-type: none"> • Definitive diagnosis (preferably pathological diagnosis) • Each Other
Outcomes	Diagnostic Accuracy including: <ul style="list-style-type: none"> • Sensitivity • Specificity • Positive Predictive Value • Negative Predictive Value • Adverse events

6

7 5.3.2 Description of Clinical Evidence

8 Thirty-five publications were included in this review: 2 of these were systematic reviews (Cao
9 et al. 2016; Zhu et al. 2017), 6 were prospective cohort studies (Brugge et al. 2004; Cizginer
10 et al. 2011; Frossard et al. 2003; Ghaneh et al. 2007; Pitman et al. 2013; Sperti et al. 2005),
11 and 27 of them were retrospective cohort studies (Ardengh et al. 2007; Gaddam et al. 2015;
12 Gerke et al. 2006; Hirono et al. 2012; Jang et al. 2014; Jin et al. 2015; Kamata et al. 2016;
13 Kim et al. 2012; Kim et al. 2015; Lee et al. 2001; Linder et al. 2006; Moris et al. 2016;
14 Nagashio et al. 2014; Nara et al. 2009; Oh et al. 2014; Oppong et al. 2015; Othman et al.
15 2012; Pais et al. 2007; Park et al. 2011; Pitman et al. 2010; Smith et al. 2016; Song et al.
16 2007; Sperti et al. 2001; Takanami et al. 2011; Talar-Wojnarowska et al. 2013; Wu et al.
17 2007; Zhang et al. 2010). A summary of the included studies is presented in Table 36.

18 Fourteen studies examined the diagnostic accuracy of cyst fluid analysis, cytology or imaging
19 for distinguishing between mucinous cystic neoplasms (MCNs; including IPMNs) and non-
20 mucinous cystic neoplasms (NMCNs) of the pancreas (Brugge et al. 2004; Cizginer et al.
21 2011; Frossard et al. 2003; Gaddam et al. 2015; Jin et al. 2015; Linder et al. 2006; Moris et
22 al. 2016; Nagashio et al. 2014; Oh et al. 2014; Oppong et al. 2015; Park et al. 2011; Pitman
23 et al. 2010; Song et al. 2007; Zhang et al. 2010).

24 Twenty studies examined the diagnostic accuracy of cyst fluid analysis, cytology or imaging
25 for distinguishing between benign and potentially malignant or malignant pancreatic cystic
26 lesions (PCLs) (Ardengh et al. 2007; Cao et al. 2016; Gerke et al. 2006; Ghaneh et al. 2018;
27 Hirono et al. 2012; Jang et al. 2014; Kamata et al. 2016; Kim et al. 2012; Kim et al. 2015; Lee
28 et al. 2011; Nara et al. 2009; Othman et al. 2012; Pais et al. 2007; Pitman et al. 2013; Smith
29 et al. 2016; Sperti et al. 2001, Sperti et al. 2005; Takanami et al. 2011; Talar-Wojnarowska et
30 al. 2013; Wu et al. 2007).

1 One study (Park et al. 2011) examined the diagnostic accuracy of cyst fluid analysis,
2 cytology or imaging for distinguishing between both (i) MCNs and NMCNs and (ii) benign and
3 potentially malignant PCLs.

4 One of the systematic reviews (Cao et al. 2016) aimed to evaluate the diagnostic value of
5 serum CA 19-9 in identifying malignant PCLs and included 13 studies (n=1437). The other
6 systematic review (Zhu et al. 2017) evaluated the morbidity and mortality associated with
7 EUS-FNA for the diagnosis of PCLs, and included 40 studies (n=5147). Both systematic
8 reviews were assessed as being of high methodological quality, but included very low to
9 moderate quality evidence. See Table 36 for more details of the included studies.

10 Positive and likelihood ratios were calculated, where appropriate, from the raw diagnostic
11 test accuracy data or the estimated sensitivity and specificity of the studies to enable
12 evaluation of the relevant tests. The QUADAS-2 tool was used for assessing risk of bias and
13 indirectness of included studies.

14 Further information about the search strategy can be found in Appendix D. See study
15 selection flow chart in Appendix E, single and multiple test ROC curves and forest plots in
16 Appendix H, summary of QUADAS-2 study quality evaluations in Appendix J, study evidence
17 tables in Appendix F and list of excluded studies in Appendix G.

18 5.3.2.1 CEA

19 5.3.2.1.1 Cystic fluid CEA

20 Thirteen studies (n=1542) examined the diagnostic accuracy of cyst fluid CEA: 2 of these
21 were prospective cohort studies (Brugge et al. 2004; Cizginer et al. 2011), whilst the
22 remaining 11 were retrospective cohort studies. The median number of patients was 112
23 (range 52-226).

24 Nine studies focused on distinguishing between MCNs and NMCNs (Brugge et al. 2004;
25 Cizginer et al. 2011; Gaddam et al. 2015; Jin et al. 2015; Linder et al. 2006; Moris et al.
26 2016; Nagashio et al. 2014; Oppong et al. 2015; Oh et al. 2014). One study examined the
27 diagnostic accuracy of CEA for distinguishing between both types of cystic lesions (Park et
28 al. 2011). The cut-off value of cystic fluid CEA used to differentiate pancreatic MCNs and
29 NMCNs ranged from 5 to 6000 ng/ml, and were categorised as detailed in Table 35:

30 **Table 35: Studies on cystic fluid CEA by cut-off level**

Cystic fluid CEA cut-off level	Studies
<10	Gaddam et al. 2015; Oppong et al. 2015
<30-701	Jin et al. 2015; Oh et al. 2014; Oppong et al. 2015; Park et al. 2011; Nagashio et al. 2014
<30	Hirono et al. 2012
<45	Talar-Wojnarowska et al. 2013
<105	Gaddam et al. 2015
<110	Cizginer et al. 2011; Oppong et al. 2015
<129	Moris et al. 2016
<192a	Brugge et al. 2004; Gaddam et al. 2015; Jin et al. 2015; Oppong et al. 2015
<200	Park et al. 2011
<300	Jin et al. 2015
<800	Gaddam et al. 2015; Jin et al. 2015; Park et al. 2011
<6000	Linder et al. 2006

31 ¹ sufficient studies to permit meta-analysis of diagnostic test accuracy data.

1 Three studies evaluated the diagnostic accuracy of cyst fluid CEA for distinguishing between
2 benign from potentially malignant and malignant PCLs (Hirono et al. 2012; Othman et al.
3 2012; Talar-Wojnarowska et al. 2013). The cut-off value of cystic fluid CEA used to
4 differentiate benign from malign cysts ranged from 30 to 6000 ng/ml, and were categorised
5 as follow:

- 6 • 30-70 ng/ml: Hirono et al. 2012; Talar-Wojnarowska et al. 2013
- 7 • 6000 ng/ml: Othman et al. 2012

85.3.2.1.2 **Serum CEA**

9 One retrospective study (n= 85) conducted in Taiwan evaluated serum levels of CEA for the
10 differential diagnosis of pancreatic cystadenoma (benign PLC) or cystadenocarcinoma
11 (malign PLC) (Wu et al. 2007).

12 **5.3.2.2 CA 19-9**

135.3.2.2.1 **Cystic fluid CA 19-9**

14 One meta-analysis (n=1437; Cao et al. 2016) of 13 observational studies (Fritz et al. 2011;
15 Goh et al. 2008; Grobmyer et al. 2009; Hirono et al. 2012; Hwang et al. 2011; Ingkakul et al.
16 2010; Jones et al. 2009; Kitagawa et al. 2003; Ohtsuka et al. 2012; Sadakari et al. 2010;
17 Shin et al. 2010; Sperti et al. 2007; and Xu et al. 2011) and 1 additional retrospective study
18 (n=52; Talar-Wojnarowska et al. 2013) examined the diagnostic accuracy of CA 19-9 for
19 distinguishing between benign and potentially malignant and malignant PCLs. The cut-off
20 levels ranged from 35 to 45 ng/ml.

215.3.2.2.2 **Serum CA 19-9**

22 One study (n=85) conducted in Taiwan evaluated serum levels of CA 19-9 (Wu et al. 2007)
23 for the differential diagnosis of pancreatic cystadenoma (benign PLC) or
24 cystadenocarcinoma (malign PLC) (Wu, Yan et al. 2007).

25 **5.3.2.3 Cytology: EUS-FNA**

26 Ten studies (n=1164), 4 prospective and 6 retrospective cohort, examined the diagnostic
27 accuracy of EUS-FNA cytology (Ardengh et al. 2007; Brugge et al. 2004; Cizginer et al.
28 2011; Frossard et al. 2003; Oppong et al. 2015; Pais et al. 2007; Pitman et al. 2010; Pitman
29 et al. 2013; Smith et al. 2016; Zhang et al. 2010). Six of the studies evaluated the diagnostic
30 accuracy of EUS-FNA based cytology for distinguishing between pancreatic MCNs and
31 NMCNs (Brugge et al. 2004; Cizginer et al. 2011; Frossard et al. 2003; Oppong et al. 2015;
32 Pitman et al. 2010; Zhang et al. 2010), whilst the remaining studies focused on distinguishing
33 benign from potentially malignant or malignant PCLs (Ardengh et al. 2007; Pais et al. 2007;
34 Pitman et al. 2013; Smith et al. 2016).

35 **5.3.2.4 Imaging: CT**

36 Seven studies (n=936), 2 prospective and 5 retrospective cohort, examined the diagnostic
37 accuracy of CT (Gerke et al. 2006; Ghaneh et al. 2018; Lee et al. 2011; Nara et al. 2009;
38 Song et al. 2007; Sperti et al. 2001; Sperti et al. 2005). Six of the studies focused on
39 distinguishing between benign from potentially malignant and malignant PCLs (Gerke et al.
40 2006; Ghaneh et al. 2018; Lee et al. 2011; Nara et al. 2009; Sperti et al. 2001; Sperti et al.
41 2005).

42 **5.3.2.5 Imaging: EUS**

43 Seven studies (n=670), 3 prospective and 4 retrospective cohort, examined the diagnostic
44 accuracy of EUS for the morphological evaluation of suspected pancreatic cystic neoplasms

1 (Brugge et al. 2004; Cizginer et al. 2011; Frossard et al. 2003; Gerke et al. 2006; Kamata et
2 al. 2016; Kim et al. 2012; Oppong et al. 2015). Three of the studies evaluated the accuracy
3 of EUS for distinguishing between pancreatic MCNs and NMCNs (Gerke et al. 2006; Kamata
4 et al. 2016; Kim et al. 2012); 4 studies focused on distinguishing between benign from
5 potentially malignant and malignant PCLs (Brugge et al. 2004; Cizginer et al. 2011; Frossard
6 et al. 2003; Oppong et al. 2015); and 3 studies evaluated the accuracy of EUS.

7 **5.3.2.6 Imaging: EUS-FNA**

8 One retrospective cohort study (n=119) examined the diagnostic accuracy of EUS-FNA for
9 distinguishing between pancreatic MCNs and NMCNs (Oppong et al. 2015).

10 **5.3.2.7 Imaging: FDG-PET/CT**

11 Four studies (n=715), 2 prospective and 2 retrospective, examined the diagnostic accuracy
12 of 18-fluorodeoxyglucose PET in distinguishing benign from malignant cystic lesions of the
13 pancreas (Ghaneh et al. 2018; Sperti et al. 2001; Sperti et al. 2005; Takanami et al. 2011).
14 The most recent study (Ghaneh et al. 2018), known as PET-PANC, was a multicentre UK
15 study and used a standardised protocol to examine whether the addition of FDG-PET/CT to
16 MDCT provides tangible diagnostic and staging benefits.

17 **5.3.2.8 Imaging: MRI**

18 Five retrospective cohort studies (n=324) examined the diagnostic accuracy of MRI: 4 of
19 these (n=271) examined the diagnostic accuracy of MRI for distinguishing benign from
20 malignant PCLs (Jang et al. 2014; Kim et al. 2012; Kim et al. 2015; and Lee et al. 2011),
21 whilst 1 of these examined the accuracy of MRI in the differentiation of IPMNs from other
22 pancreatic cystic masses (n=53; Song et al. 2007).

23

24

1 **5.3.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 36

3 **Table 36: Summary of included studies**

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Ardengh et al. 2007	Sample size n=197 Characteristics M/F (n): n.r./n.r. Median age (range): n.r.	Retrospective observational study Brazil	Index test 1 (n= 196): EUS-FNA cytology Final diagnosis: Benign (n): 44 Malign (n): 152	The final diagnosis was based on surgical findings or by a mean clinical follow-up of 11.8 months (356 and 255 respectively, numbers refer to the overall cohort of patients - n==611)	Diagnostic accuracy	Serious risk of bias
Brugge et al. 2004	Sample size n=112 Characteristics M/F (n): 41/71 Mean age (yr): 60.1	Prospective observational study (multicentre) USA	Index test 1 (n=111): Cyst fluid CEA -192 ng/ml Final diagnosis: Mucinous(n): 56 Non-mucinous(n):55 Index test 2 (n=111): EUS Final diagnosis: Mucinous(n): 56 Non-mucinous(n): 55 Index test 3 (n=110): EUS-FNA cytology Final diagnosis: Mucinous(n): 56 Non-mucinous(n): 54	The final diagnosis was based on surgical histopathology (n=111)	Diagnostic accuracy	Serious risk of bias
Cao et al. 2016 Time frame: The literature search	Sample size 13 studies with 1437 patients	1 MA of 13 studies (1 prospective-12 retrospectives)	Index test 1 (n=1437): Cyst fluid CA 19-9 [35 ng/ml (n=1 studies); 37	The final diagnosis was based on surgical	Diagnostic accuracy	Fritz et al. 2011

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
was up to March 2016. The included paper ranged from 2007 to 2011	<p>Fritz et al. 2011 (n=142)</p> <p>Goh et al. 2008 (n=176)</p> <p>Grobmyer et al. 2009 (n=78)</p> <p>Hirono et al. 2012 (n=134)</p> <p>Hwang et al. 2011 (n=237)</p> <p>Ingkakul et al. 2010 (n=200)</p> <p>Jones et al. 2009 (n=114)</p> <p>Kitagawa et al. 2003 (n=63)</p> <p>Ohtsuka et al. 2012 (n=138)</p> <p>Sadakari et al. 2010 (n=73)</p> <p>Shin et al. 2010 (n=204)</p> <p>Sperti et al. 2007 (n=64)</p> <p>Xu et al. 2011 (n=86)</p>		<p>ng/ml (n=9); 45 ng/ml (n=1); n.r. (n=2)]</p> <p>Final diagnosis: Benign (n): 948 Malign (n): 489</p>	<p>histopathology (n=11 studies – 1227 patients), histopathology results and clinical follow-up (n=2 - 310)</p>		<p>Serious risk of bias</p> <p>Goh et al. 2008</p> <p>Serious risk of bias</p> <p>Grobmyer et al. 2009</p> <p>No serious risk of bias</p> <p>Hirono et al. 2012</p> <p>No serious risk of bias</p> <p>Hwang et al. 2011</p> <p>No serious risk of bias</p> <p>Ingkakul et al. 2010</p> <p>Very serious</p>

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
						risk of bias Jones et al. 2009 Serious risk of bias Kitagawa et al. 2003 No serious risk of bias Ohtsuka et al. 2012 Serious risk of bias Sadakari et al. 2010 No serious risk of bias Shin et al. 2010 No serious risk of bias Sperti et al. 2007

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
						Very serious risk of bias Xu et al. 2011 No serious risk of bias
Cizginer et al. 2011	Sample size n=198 Characteristics M/F (n): 77/121 Mean age (yr): 60.6	Prospective observational study USA	Index test 1 (n=154): Cyst fluid CEA - 109,9 ng/ml Final diagnosis: Mucinous(n):110 Non-mucinous(n):44 Index test 2 (n=194): EUS Final diagnosis: Mucinous(n):141 Non-mucinous(n):53 Index test 3 (n=194): EUS -FNA cytology Final diagnosis: Mucinous(n):141 Non-mucinous(n):53	The final diagnosis was based on histology (n=194) or malignant cytology (n=4) -number provided for the total study cohort, n=198	Diagnostic accuracy	Serious risk of bias
Frossard et al. 2003	Sample size n=127 Characteristics M/F (n): 49/78 Median age (range): 59.3 (15)	Prospective observational study France	Index test 1 (n=67): EUS Index test 2 (n=67): EUS -FNA cytology Final diagnosis: Mucinous(n):40 Non-mucinous(n): 27	The final diagnosis was based on surgery (n=59) or post-mortem (n=8)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Gaddam et al. 2015	Sample size n=226 Characteristics M/F (n): 88/138 Mean age (SD): 60.9 (13.1)	Retrospective observational study USA	Index test 1 (n=226): Cyst fluid CEA -5, 105, 192, 800 ng/ml Final diagnosis: Mucinous(n): 150 Non-mucinous(n): 76	The final diagnosis was based on surgical histopathology (n=226)	Diagnostic accuracy	Serious risk of bias
Gerke et al. 2006	Sample size n=66 Characteristics M/F (n): 28/38 Median age (range): 59 (27- 82)	Retrospective observational study USA	Index test 1 (n=41): CT Final diagnosis: Benign (n): 20 Malign (n): 21 Index test 2 (n=66): EUS Final diagnosis: Benign (n): 35 Malign (n): 31	The final diagnosis was based on surgical pathology (n = 43), diagnostic fine needle aspiration (n = 13) or follow-up imaging (n = 10)	Diagnostic accuracy	Serious risk of bias
Ghaneh et al. 2018	Sample size N=619 Characteristics M/F (n): 353/266 Mean age (IQR, range): 66 (15, 21-87) years Final diagnosis (ITT): (n): 384 benign(n): 166	Prospective multicentre study UK	Index test 1 (n=583 [ITT]): MDCT Index test 2 (n=583 [ITT]): FDG-PET/CT	The final diagnosis was based on: Histology (resection [n=242] or biopsy [n=249]) or 12-mo clinical FU (n=92)	Diagnostic accuracy	No serious risk of bias
Hirono et al. 2012	Sample size n=134 Characteristics M/F (n): 74/60 Mean age (SD): 68.9 (9.7)	Retrospective observational study Japan	Index test 1 (n=134): Cyst fluid CEA 30 ng/ml Final diagnosis: Benign (n): 78 Malign (n): 56	The final diagnosis was based on histopathology (n=134)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Jang et al. 2014	Sample size n=65 Characteristics M/F (n): 38/23 Mean age (SD): n.r.	Retrospective observational study Korea	Index test 1 (n=61): MRI Final diagnosis: Benign (n): 42 Malign (n): 19	The final diagnosis was based on surgical histopathology (n=61)	Diagnostic accuracy	Very serious risk of bias
Jin et al. 2015	Sample size n=86 Characteristics M/F (n): 32/54 Mean age (SD): 65.0 (13.0)	Retrospective observational study USA	Index test 1 (n=86): Cyst fluid CEA – 30.7, 192, 300, 800 ng/ml Final diagnosis: Mucinous(n): 77 Non-mucinous(n): 9	The final diagnosis was based on surgical histology (n=86)	Diagnostic accuracy	Serious risk of bias
Kamata et al. 2016	Sample size n=70 Characteristics M/F (n): 31/29 Mean age (SD): 62.0 (n.r)	Retrospective observational study Japan	Index test 1 (n=70): EUS Final diagnosis: Benign (n): 40 Malign (n): 30	The final diagnosis was based on surgical histopathology (n=70)	Diagnostic accuracy	Very serious risk of bias
Kim et al. 2012	Sample size n=51 Characteristics M/F (n): 23/28 Mean age (years): 43	Retrospective observational study Korea	Index test 1 (n=51): EUS Index test 2 (n=51): MRI Final diagnosis: Benign (n): 15 Malign (n): 36	The final diagnosis was based on surgical histopathology (n=51)	Diagnostic accuracy	No serious risk of bias
Kim et al. 2015	Sample size N= 123 Characteristics M/F (n): n.r. Mean age (SD): n.r.	Retrospective observational study Korea	Index test 1 (n=96): MRI Final diagnosis: Benign (n): 51 Malign (n): 45	The final diagnosis was based on surgical histopathology (n=96)	Diagnostic accuracy	Very serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Lee et al. 2001	Sample size n=63 Characteristics M/F (n): 25/38 Mean age (range): 55.7 (12-79)	Retrospective observational study Korea	Index test 1 (n=63): CT Index test 2 (n=63): MRI Final diagnosis: Benign (n): 37 Malign (n): 26	The final diagnosis was based on surgical histopathology (n=63)	Diagnostic accuracy	Serious risk of bias
Linder et al. 2006	Sample size n=102 Characteristics M/F (n): 60/42 Mean age (range): 51 (23- 76)	Retrospective observational study USA	Index test 1 (n=71): Cyst fluid CEA – 6000 ng/ml Final diagnosis: Mucinous(n): 35 Non-mucinous(n): 36	The final diagnosis was based on surgical histopathology (n=71)	Diagnostic accuracy	Serious risk of bias
Moris et al. 2016	Sample size n=180 Characteristics M/F (n): 58/83 Mean age (SD): 68 (9.2)	Retrospective observational study USA	Index test 1 (n=180): Cyst fluid CEA – 129 ng/ml Final diagnosis: Mucinous(n): 145 Non-mucinous(n): 35	The final diagnosis was based on surgical histopathology (n=180)	Diagnostic accuracy	Serious risk of bias
Nagashio et al. 2014	Sample size n=78 Characteristics M/F (n): 26/42 Mean age (range): n.r.	Retrospective observational study Japan	Index test 1 (n=68): Cyst fluid CEA –67.3 ng/ml Final diagnosis: Mucinous(n): 39 Non-mucinous(n): 29	The final diagnosis was based on surgical histopathology (n=58) or cytology, imaging or clinical follow-up (n=20)	Diagnostic accuracy	Serious risk of bias
Nara et al. 2014	Sample size n=123 Characteristics M/F (n): 70/53	Retrospective observational study Japan	Index test 1 (n=123): CT Benign (n): 92 Malign (n): 31	The final diagnosis was based on surgical histopathology (n=123)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
	Median age (range): 66 -(40-84)					
Oh et al. 2014	Sample size n=69 Characteristics M/F (n): 32/46 Median age (range): 62 (24-84)	Retrospective observational study USA	Index test 1 (n=78): Cyst fluid CEA – 50 ng/ml Final diagnosis: Mucinous(n):62 Non-mucinous [pseudocysts] (n): 16	The final diagnosis was based on surgical histology (n=78)	Diagnostic accuracy	Serious risk of bias
Oppong et al. 2015	Sample size n=119 Characteristics M/F (n): 37/82 Mean age (range): 61.4 (19-84)	Retrospective observational study UK	Index test 1 (n=78): Cyst fluid CEA – 7, 30, 110, 192 ng/ml Final diagnosis: Mucinous(n): 50 Non-mucinous(n): 28 Index test 2 (n=111): EUS Final diagnosis: Mucinous(n):81 Non-mucinous(n): 30 Index test 3 (n=102): EUS-FNA cytology Final diagnosis: Mucinous(n): 72 Non-mucinous(n): 30 Index test 4 (n=119): EUS-FNA imaging Final diagnosis: Mucinous(n): 79 Non-mucinous(n): 40	The final diagnosis was based on definitive tissue sampling (n=119 - diagnostic malignant cytology, resection histology or biopsy histology)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Othman et al. 2012	Sample size n=63 Characteristics M/F (n): 19/44 Mean age (SD): 68.9 (0.8)	Retrospective observational study USA	Index test 1 (n=63): Cyst fluid CEA – 6000 ng/ml Final diagnosis: Benign (n): 47 Malign (n): 16	The final diagnosis was based on surgical histopathology (n=63)	Diagnostic accuracy	Serious risk of bias
Pais et al. 2007	Sample size n=74 Characteristics M/F (n): 38/36 Mean age (range): 65 (41- 84)	Retrospective observational study USA	Index test 1 (n=65): EUS- FNA cytology Final diagnosis: Benign (n): 45 Malign (n): 20	The final diagnosis was based on histopathology (n=65)	Diagnostic accuracy	Serious risk of bias
Park et al. 2011	Sample size n=124 Characteristics M/F (n): n.r./n.r. Median age (range): n.r.	Retrospective observational study USA	Index test 1 (n=124): Cyst fluid CEA – n.r. Final diagnosis: Benign (n): 104 Malign (n): 20 Index test 2 (n=124): Cyst fluid CEA – n.r. Final diagnosis: Mucinous(n): 81 Non-mucinous(n): 43	The final diagnosis was based on surgical histopathology (n=104), true-cut histology or cytology (22)	Diagnostic accuracy	Serious risk of bias
Pitman et al. 2010	Sample size n=112 Characteristics M/F (n): 39/73 Mean age (years): 68	Retrospective observational study USA	Index test 1 (n=112): EUS-FNA cytology Final diagnosis: Mucinous(n): 39 Non-mucinous(n): 73	The final diagnosis was based on confirmed histology (n=112)	Diagnostic accuracy	Serious risk of bias
Pitman et al. 2013	Sample size n=70	Prospective observational study USA	Index test 1 (n=66): EUS- FNA cytology Final diagnosis:	The final diagnosis was based on	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
	Characteristics M/F (n): 24/46 Mean age (range): 57 (19-60)		Benign (n): 24 Malign (n): 42	confirmed histology (n=66)		
Smith et al. 2016	Sample size n=127 Characteristics M/F (n): 38/89 Median age (range):	Retrospective observational study USA	Index test 1 (n=127): EUS-FNA cytology Final diagnosis: Benign (n): 29 Malign (n): 98	The final diagnosis was based on confirmed histology (n=127)	Diagnostic accuracy	Serious risk of bias
Song et al. 2007	Sample size n=53 Characteristics M/F (n): 29/24 Median age (range): 67 (44-87)	Retrospective observational study South Korea	Index test 1 (n=53): CT Index test 2 (n=53): MRI Final diagnosis: Mucinous(n): 31 Non-mucinous(n): 22	The final diagnosis was based on histopathology findings (n=53)	Diagnostic accuracy	No serious risk of bias
Sperti et al. 2001	Sample size n=56 Characteristics M/F (n): 21/35 Mean age (range): 60.1 (31-86)	Retrospective observational study Italy	Index test 1 (n=56): CT Index test 2 (n=56): F-18- PET Final diagnosis: Benign (n): 39 Malign (n): 17	The final diagnosis was based on definitive pathology: resection (n=36) biopsy (n=19); and follow-up (n=1)	Diagnostic accuracy	Serious risk of bias
Sperti et al. 2005	Sample size n=50 Characteristics M/F (n): 17/33 Mean age (range): 58.1 (14-87)	Prospective observational study Italy	Index test 1 (n=50): CT Index test 2 (n=50): F-18- PET Final diagnosis: Benign (n): 33 Malign (n): 17	The final diagnosis was based on pathologic findings of resected specimen, biopsy, or follow-up (numbers are not provided)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Takanami et al. 2011	Sample size n=59 Characteristics M/F (n): 56/3 Mean age (SD): 66 (n.r.)	Retrospective observational study Japan	Index test 1 (n=16): F-18- PET Final diagnosis: Benign (n): 7 Malign (n): 9	The final diagnosis was based on surgical histopathology	Diagnostic accuracy	Very serious risk of bias
Talar- Wojnarowska et al. 2013	Sample size n=52 Characteristics M/F (n): 28/24 Mean age (SD): 55 (3.2)	Retrospective observational study Poland	Index test 1 (n=52): Cyst fluid CEA – 45 ng/ml Index test 2 (n=52): Cyst fluid CA 19-9 – 37 ng/ml Final diagnosis: Benign (n): 36 Malign (n): 16	The final diagnosis was based on surgical histopathology, cytology results and/or imaging follow-up (>18 months)	Diagnostic accuracy	Serious risk of bias
Wu et al. 2007	Sample size n=85 Characteristics M/F (n): 26/69 Median age (range): n.r.	Retrospective observational study Taiwan	Index test 1 (n=85): Cyst fluid CEA – n.r. Index test 2 (n=85): Cyst fluid CA 19-9 – n.r. Index test 3 (n=85): Serum fluid CEA – n.r. Index test 4 (n=85): Serum fluid CA 19-9 – n.r. Final diagnosis: Benign (n): 37 Malign (n): 48	The final diagnosis was based on surgical histopathology (n=85)	Diagnostic accuracy	Serious risk of bias
Zhang et al. 2010	Sample size n=140 Characteristics M/F (n): n.r./n.r. Median age (range): n.r.	Retrospective observational study USA	Index test 1 (n=54): EUS- FNA cytology Final diagnosis: Mucinous(n): 25 Non-mucinous(n): 29	The final diagnosis was based on surgical histopathology (n=54)	Diagnostic accuracy	Serious risk of bias

Study	Population	Study design Country	Index test (s)	Reference standard*	Outcomes and results	Overall risk of bias [^]
Zhu et al. 2017 Time frame: The literature search was up to September 2015. The included paper ranged from 1997 to 2015	Sample size 40 studies with 5124 patients	1 MA of 40 studies (19 prospective-21 retrospectives)	Aims and intervention To systematically evaluate morbidity and mortality associated with EUS-FNA for the diagnosis of PCLs	Exclusion criteria conference abstracts and letters reviews and guidelines case reports insufficient data therapeutic EUS-FNA	Adverse events/complications	No serious risk of bias ^{^^}

1 **Notes:** [^], QUADAS 2 checklist; ^{^^} the Assessment of Multiple Systematic Reviews (AMSTAR) appraisal tool to evaluate methodological quality;. **Abbreviations:** CA, Carbohydrate antigen; CEA, Carcinoembryonic antigen; CT, Computed tomography; EUS, Endoscopic ultrasound; FNA, Fine-needle aspiration; IPMN, intraductal papillary mucinous neoplasm; MCN, Mucinous cystic neoplasm; MRI, Magnetic resonance imaging; NMCN, Non-mucinous cystic neoplasms; NPV, Negative predictive value; PCL, Pancreatic cystic lesion; FDG-PET/CT, Positron emission tomography/computed tomography; PPV, Positive predictive value; SCA, Serous cystadenoma.

5 5.3.4 Clinical evidence profile

6 The clinical evidence profiles for this review are presented in Table 39 to Table 54

7 5.3.4.1 Cystic fluid or serum CEA

8 5.3.4.1.1 Cystic fluid CEA

9 **Table 37: Summary of clinical evidence for meta-analyses of cystic fluid CEA to distinguish between mucinous cystic and non-**
10 **mucinous cystic neoplasms of the pancreas**

Study	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
5 retrospective cohort studies	434	<30-70	Serious ⁶	Not serious	Not serious	Serious ⁷	0.88 (0.82-0.92)	0.82 (0.72-0.89)	4.83 (3.08-7.58)	0.15 (0.1-0.23)	LOW

Study	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 studies (1 prospective and 3 retrospective cohort)	401	<192	Serious ⁸	Not serious	Not serious	Not serious	0.58 (0.49-0.67)	0.87 (0.74-0.94)	4.33 (2.27-8.26)	0.48 (0.39-0.59)	MODE RATE

- 1 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 2 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
3 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 4 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 5 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
6 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
7 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
8 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
9 and 0.9;
- 10 ⁵, positive and negative likelihood ratios calculated from meta-analysis;
- 11 ⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text) for all studies. Flow and timing
12 of patient unclear for all studies;
- 13 ⁷, 95% CI for sensitivity crosses 0.9;
- 14 ⁸, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text) for 3 studies (Jin et al. 2015,
15 Opong et al. 2015; Gaddam et al. 2015). High risk of verification bias in Gaddam et al. 2015 (Not all patients received the same reference test).

1
2

Table 38: Summary of clinical evidence for other studies on cystic fluid CEA at various cut-offs to distinguish between mucinous cystic and non-mucinous cystic neoplasms of the pancreas

Studies	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Gaddam et al. 2015	226	<5	Very serious ⁶	Not applicable	Not serious	Not serious	0.94 (0.89-0.97)	0.42 (0.31-0.54)	1.62 (1.33-1.98)	0.14 (0.07-0.28)	LOW
Oppong et al. 2015	78	<7	Serious ⁷	Not applicable	Not serious	Serious ⁸	0.94 (0.83-0.99)	0.75 (0.55-0.89)	3.76 (1.97-7.17)	0.08 (0.03-0.24)	LOW
Gaddam et al. 2015	226	<105	Very serious ⁹	Not applicable	Not serious	Serious ¹⁰	0.7 (0.62-0.77)	0.63 (0.51-0.74)	1.9 (1.39-2.6)	0.48 (0.35-0.64)	VERY LOW
Cizginer et al. 2011	154	<110	Serious ¹¹	Not serious	Not serious	Serious ¹⁰	0.81 (0.72-0.88)	0.98 (0.88-1.0)	35.6 (5.12-247.66)	0.2 (0.13-0.29)	LOW
Oppong et al. 2015	78	<110	Serious ⁷	Not serious	Not serious	Not serious	0.62 (0.47-0.75)	0.93 (0.77-0.99)	8.68 (2.24-33.58)	0.41 (0.28-0.59)	MODE RATE
Overall	232	<110	Serious	Not serious	Serious ¹²	Serious ¹⁰					VERY LOW
Moris et al. 2016	180	<129	Serious ⁷	Not applicable	Not serious	Serious ¹⁰	0.77 (0.70-0.84)	0.83 (0.66-0.93)	4.51 (2.16-9.38)	0.27 (0.2-0.38)	LOW
Park et al. 2011	124	<200	Serious ⁷	Not applicable	Not serious	Not serious	0.6 (0.49-0.71)	0.93 (0.81-0.99)	8.67 (2.87-26.19)	0.42 (0.32-0.56)	MODE RATE
Jin et al. 2015	86	<300	Serious ⁷	Not applicable	Not serious	Not serious	0.41 (0.30-0.53)	0.89 (0.52-1.0)	3.86 (0.6-24.92)	0.64 (0.48-0.87)	MODE RATE

Studies	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Gaddam et al. 2015	226	<800	Very serious ⁶	Not applicable	Not serious	Not serious	0.33 (0.26-0.42)	0.86 (0.76-0.93)	2.3 (1.27-4.16)	0.78 (0.67-0.9)	LOW
Jin et al. 2015	86	<800	Serious ⁷	Not applicable	Not serious	Not serious	0.27 (0.18-0.39)	0.89 (0.52-1.0)	2.45 (0.37-16.14)	0.82 (0.63-1.07)	MODE RATE
Park et al. 2011	124	<800	Serious ⁷	Not applicable	Not serious	Not serious	0.38 (0.28-0.50)	0.95 (0.84-0.99)	8.23 (2.07-32.75)	0.65 (0.54-0.78)	MODE RATE
Overall	436	<800	Very serious ¹³	Not serious	Not serious	Not serious					LOW
Linder et al. 2006	71	<6000	Serious ¹⁴	Not applicable	Not serious	Very serious ¹⁵	0.86 (0.7-0.95)	1.0 (0.9-1.0)	62.69 (3.98-987.16) ¹⁶	0.14 (0.06-0.32)	VERY LOW

- 1 All studies were retrospective cohort except for Cizginer et al., 2011, which was a prospective cohort study;
- 2 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 3 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
- 4 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 5 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 6 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
- 7 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
- 8 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
- 9 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
- 10 and 0.9;
- 11 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
- 12 for details);

- 1 ⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), high risk of verification bias
2 (not all patients received the same reference test);
- 3 ⁷, unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text);
- 4 ⁸, 95%CI of sensitivity crosses 0.9;
- 5 ⁹, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), high risk of verification bias
6 (not all patients received the same reference test);
- 7 ¹⁰, 95% CI of sensitivity crosses 0.75;
- 8 ¹¹, Unclear risk of review bias for all studies (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text);
- 9 ¹², sensitivity estimates range from 0.62 to 0.81;
- 10 ¹³, Gaddam et al. (2015) 226 contributes more than 50% of total sample;
- 11 ¹⁴, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text). Flow and timing of patient
12 unclear;
- 13 ¹⁵, 95% CI of sensitivity crosses both 0.75 and 0.9
- 14 ¹⁶, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

Table 39: Summary of clinical evidence for studies on cystic fluid CEA to distinguish between (potentially) malignant and benign pancreatic cystic lesions

Studies	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Hirono et al. 2012	134	<30	Very serious ⁶	Not applicable	Not serious	Serious ⁷	0.95 (0.85-0.99)	0.85 (0.75-0.92)	6.15 (3.64-10.39)	0.06 (0.02-0.19)	VERY LOW
Talar-Wojnarowska et al. 2013	52	<45	Serious ⁸	Not applicable	Not serious	Very serious ⁹	0.94 (0.7-1.0)	0.64 (0.46-0.79)	2.6 (1.65-4.08)	0.1 (0.01-0.66)	VERY LOW
Othman et al. 2012	63	<6000	Serious ¹⁰	Not applicable	Not serious	Not serious	0.31 (0.11-0.59)	0.85 (0.72-0.94)	2.1 (0.77-5.69)	0.81 (0.57-1.15)	MODERATE

All studies were retrospective cohort;

- 1 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 2 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
3 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 4 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 5 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
6 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
7 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
8 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
9 and 0.9;
- 10 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
11 for details);
- 12 ⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text), high risk of verification bias
13 (not all patients received the same reference test);
- 14 ⁷, 95% CI for sensitivity crosses 0.9;
- 15 ⁸, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text);
- 16 ⁹, 95% CI of sensitivity crosses both 0.75 and 0.9;
- 17 ¹⁰, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text). Flow and timing of patient
18 unclear.

195.3.4.1.2 Serum CEA

20 **Table 40: Summary of clinical evidence for studies on serum CEA to distinguish between benign and (potentially) malignant**
21 **pancreatic cystic lesions**

Studies	N	CEA level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Wu et al. 2007	85	Not specified	Very serious ⁶	Not applicable	Not serious	Not serious	0.35 (0.22-0.51)	0.84 (0.68-0.94)	2.18 (0.96-4.99)	0.77 (0.6-0.99)	LOW

- 22 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 23 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
24 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 25 ³, indirectness was evaluated using the applicability items of QUADAS-2;

- 1 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
 2 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
 3 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
 4 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
 5 and 0.9;
- 6 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
 7 for details);
- 8 ⁶, potential risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text); flow and timing of patient
 9 unclear; and cut-off value not reported.

10 **5.3.4.2 Cystic fluid or serum CA 19-9**

11 **5.3.4.2.1 Cystic fluid CA 19-9**

12 **Table 41: Summary of clinical evidence for meta-analysis of cystic fluid CA 19-9 to distinguish between mucinous cystic and non-**
 13 **mucinous cystic neoplasms of the pancreas**

Studies	N	CA 19-9 level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
14 studies (Cao et al. 2016 + Talar-Wojnarowska et al. 2013)	1489	<35-45	Serious ⁶	Not serious	Not serious	Not serious	0.5 (0.37-0.63)	0.87 (0.84-0.9)	3.92 (3.16-4.87)	0.58 (0.46-0.73)	MODERATE

14 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

15 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
 16 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

17 ³, indirectness was evaluated using the applicability items of QUADAS-2;

18 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
 19 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
 20 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
 21 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
 22 and 0.9;

23 ⁵, positive and negative likelihood ratios calculated from meta-analysis;

1 ⁶, Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text) for most part of studies.

25.3.4.2.2 **Serum CA 19-9**

3 **Table 42: Summary of clinical evidence for studies on serum CA 19-9 to distinguish between malignant and benign pancreatic cystic**
4 **lesions**

Studies	N	CA 19-9 level (ng/ml)	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Wu et al. 2007	85	Not specified	Very serious ⁶	Not applicable	Not serious	Not serious	0.58 (0.43-0.72)	0.86 (0.71-0.95)	4.32 (1.85-10.09)	0.48 (0.34-0.69)	LOW

- 5 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 6 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
7 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 8 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 9 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
10 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
11 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
12 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
13 and 0.9;
- 14 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
15 for details);
- 16 ⁶, Potential risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text). Flow and timing of patient
17 unclear. Cut-off value not reported.

1 **5.3.4.3 Cytology: EUS-FNA**

2 **Table 43: Summary of clinical evidence for meta-analysis of EUS-FNA cytology to distinguish between mucinous cystic and non-**
3 **mucinous cystic neoplasms of the pancreas**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
6 studies (3 prospective and 3 retrospective cohort)	639	Serious ⁶	Very serious ⁷	Not serious	Serious ⁸	0.55 (0.27-0.8)	0.94 (0.86-0.97)	8.52 (3.41-21.31)	0.48 (0.25-0.91)	VERY LOW

4 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

5 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
6 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

7 ³, indirectness was evaluated using the applicability items of QUADAS-2;

8 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
9 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
10 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
11 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
12 and 0.9;

13 ⁵, positive and negative likelihood ratios calculated from meta-analysis;

14 ⁶, Reference test varied depending on index test in Frossard et al. 2003. Four patients were excluded from the analysis for unclear reasons (Cizginer et al. 2011). One study
15 was likely to be subject to unclear risk of review bias (Frossard et al. 2003);

16 ⁷, 95% prediction region was very wide, with sensitivity ranging from approximately 0 to 1.0, and specificity ranging from approximately 0.3 to 1.0;

17 ⁸, 95% CI of sensitivity crosses 0.75.

Table 44: Summary of clinical evidence for meta-analysis of EUS-FNA cytology to distinguish between malignant and benign pancreatic cystic lesions

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 studies (1 prospective and 3 retrospective cohort)	454	Not serious	Very serious ⁶	Not serious	Serious ⁷	0.7 (0.54-0.81)	0.93 (0.88-0.96)	9.67 (6.14-15.24)	0.33 (0.21-0.5)	VERY LOW

¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

⁵, positive and negative likelihood ratios calculated from meta-analysis;

⁶, 95% prediction region was very wide, with sensitivity ranging from approximately 0 to 1.0, and specificity ranging from approximately 0.4 to 1.0;

⁷, 95% CI of sensitivity crosses 0.75.

5.3.4.4 Imaging: CT

Table 45: Summary of clinical evidence for studies on computed tomography to distinguish between mucinous cystic and non-mucinous cystic neoplasms of the pancreas

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Song et al. 2007	53	Not serious	Not applicable	Not serious	Very serious ⁶	0.81 (0.63-0.93)	0.86 (0.78-0.93)	5.96 (3.49-10.16)	0.22 (0.11-0.46)	LOW

Study was retrospective cohort;

- 1 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 2 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
3 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 4 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 5 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
6 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
7 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
8 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
9 and 0.9;
- 10 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
11 for details);
- 12 ⁶, 95% CI of sensitivity crosses both 0.75 and 0.9.

13 **Table 46: Summary of clinical evidence for meta-analysis of computed tomography to distinguish between malignant and benign**
14 **pancreatic cystic lesions**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
6 studies (2 prospective and 4 retrospective cohort)	883	Serious ⁶	Very serious ⁷	Not serious	Serious ⁸	0.69 (0.60-0.78)	0.91 (0.89-0.93)	8.00 (6.17-10.37)	0.34 (0.26-0.44)	VERY LOW

- 15 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 16 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
17 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 18 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 19 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
20 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
21 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
22 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
23 and 0.9;
- 24 ⁵, positive and negative likelihood ratios calculated from meta-analysis;
- 25 ⁶, Unclear flow and timing of patient for 5 of the 6 studies;

⁷, 95% prediction region was very wide with sensitivity ranging from approximately 0.33 to 0.9 and specificity ranging from approximately 0 to 1.0.

⁸, 95% CI of sensitivity crosses 0.75.

3 5.3.4.5 Imaging: EUS

4 **Table 47: Summary of clinical evidence for meta-analysis of EUS to distinguish between mucinous cystic and non-mucinous cystic**
5 **neoplasms of the pancreas**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 studies (1 prospective and 3 retrospective cohort)	210	Not serious	Very serious ⁶	Not serious	Serious ⁷	0.67 (0.43-0.84)	0.65 (0.48-0.78)	1.88 (1.18-3.0)	0.52 (0.28-0.96)	VERY LOW

6 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

7 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
8 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

9 ³, indirectness was evaluated using the applicability items of QUADAS-2;

10 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
11 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
12 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
13 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
14 and 0.9;

15 ⁵, positive and negative likelihood ratios calculated from meta-analysis;

16 ⁶, 95% prediction region was very wide with both sensitivity and specificity ranging from approximately 0 to 1.0;

17 ⁷, 95% CI of sensitivity crosses 0.75.

1

Table 48: Summary of clinical evidence for studies on EUS to distinguish between malignant and benign pancreatic cystic lesions

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Gerke et al. 2006	66	Serious ⁶	Not applicable	Not serious	Serious ⁷	0.71 (0.52-0.86)	0.63 (0.45-0.79)	1.91 (1.17-3.11)	0.46 (0.25-0.85)	LOW
Kamata et al. 2016	70	Very Serious ⁸	Not applicable	Not serious	Serious ⁷	0.97 (0.83-1.0)	0.4 (0.25-0.57)	1.61 (1.24-2.09)	0.08 (0.01-0.59)	VERY LOW
Kim et al. 2012	51	Serious ⁶	Not applicable	Not serious	Serious ⁷	0.97 (0.85-1.0)	0.73 (0.45-0.92)	3.65 (1.57-8.45)	0.04 (0.01-0.27)	LOW
Overall	187	Serious ⁹	Serious ¹⁰	Not serious	Very serious ¹¹					VERY LOW

2

All studies were retrospective cohort;

3

¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

4

², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

5

6

³, indirectness was evaluated using the applicability items of QUADAS-2;

7

⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

8

9

10

11

⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);

12

13

14

⁶, High risk of verification bias: all patients did not receive the same reference test;

15

⁷, 95% CI of sensitivity crosses 0.75 or 0.9;

16

⁸, 419 (85.7%) patients were excluded from the analysis for unclear reasons, and the study was likely to be subject to risk of review bias;

17

⁹, Gerke et al. 2006 and Kim et al. 2012 comprise over 50% of the total sample;

18

¹⁰, sensitivity estimates range from 0.71 to 0.97. Specificity estimates range from 0.4 to 0.73;

19

¹¹, 95% CIs of sensitivity point estimates cross both 0.75 and 0.9.

1 **5.3.4.6 Imaging: EUS-FNA**

2 **Table 49: Summary of clinical evidence for studies on EUS-FNA to distinguish between mucinous cystic and non-mucinous cystic**
3 **neoplasms of the pancreas**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Oppong et al. 2015	119	Serious ⁶	Not applicable	Not serious	Serious ⁷	0.76 (0.65-0.85)	0.73 (0.56--0.85)	2.76 (1.64-4.64)	0.33 (0.21-0.51)	LOW

4 *Study was retrospective cohort;*

5 ¹, *risk of bias evaluated using risk of bias items of QUADAS-2 checklist;*

6 ², *Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;*

8 ³, *indirectness was evaluated using the applicability items of QUADAS-2;*

9 ⁴, *judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;*

14 ⁵, *positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);*

16 ⁶, *Unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text);*

17 ⁷, *95% CI of sensitivity crosses 0.75.*

1 **5.3.4.7 Imaging: FDG-PET/CT**

2 **Table 50: Summary of clinical evidence for studies on FDG-PET/CT to distinguish between (potentially) malignant and benign**
3 **pancreatic cystic lesions**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 studies (2 prospective and 2 retrospective studies)	672	Serious ⁶	Serious ⁷	Not serious	Very serious ⁸	0.86 (0.71-0.94)	0.96 (0.94-0.97)	20.80 (13.6-30.0)	0.16 (0.06-0.29)	VERY LOW

4 ¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

5 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

7 ³, indirectness was evaluated using the applicability items of QUADAS-2;

8 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative - missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75 and 0.9;

13 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);

15 ⁶, 2 studies (Sperti et al. 2001, 2005) had unclear risk of review bias (lack of blinding in the interpretation both of the index test and reference standard – no details are given in the text); Ghaneh et al. 2018 had missing data (69 patients not included in per protocol analysis); 1 study (Takanami et al. 2011) also was at high risk of review bias with high dropout rate with 73% of enrolled patients excluded for unclear reasons

18 ⁷, it was not possible to represent the 95% prediction region on the summary ROC curve. However, the sensitivity estimates ranged from 0.75 to 0.94;

19 ⁸, 95% CI of sensitivity crosses both 0.75 and 0.9.

1 **5.3.4.8 Imaging: MRI**

2 **Table 51: Summary of clinical evidence for meta-analysis of MRI to distinguish between mucinous cystic and non-mucinous cystic**
3 **neoplasms of the pancreas**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
Song et al. 2007	53	Not serious	Not applicable	Not serious	Serious ⁶	0.97 (0.83-1.0)	0.91 (0.71--0.99)	10.65 (2.84-39.97)	0.04 (0.01-0.25)	MODERATE

4 ¹, risk of bias evaluated using QUADAS-2 checklist;

5 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
6 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

7 ³, indirectness was evaluated using the applicability items of QUADAS-2;

8 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
9 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
10 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
11 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
12 and 0.9;

13 ⁵, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
14 for details);

15 ⁶, 95% CI of sensitivity crosses 0.9.

16 **Table 52: Summary of clinical evidence for studies on MRI to distinguish between (potentially) malignant and benign pancreatic**
17 **cystic lesions**

Studies	N	Risk of bias ¹	Inconsistency ²	Indirectness ³	Imprecision ⁴	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Positive likelihood ratio (95% CI) ⁵	Negative likelihood ratio (95% CI) ⁵	Quality
4 retrospective cohort studies	271	Serious ⁶	Not serious	Not serious	Serious ⁷	0.79 (0.64-0.89)	0.84 (0.69-0.92)	4.81 (2.54-9.08)	0.25 (0.15-0.43)	LOW

18 ¹, risk of bias evaluated using QUADAS-2 checklist;

- 1 ², Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
2 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 3 ³, indirectness was evaluated using the applicability items of QUADAS-2;
- 4 ⁴, judgement of imprecision was based on consideration of the 95% CIs of test sensitivity as this was considered to be the primary measure of interest as a false negative -
5 missing malignancy - risks a potentially avoidable death, whilst a false positive - indicating malignancy when there is none - risks potentially avoidable surgery or other
6 treatment such as chemotherapy. Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below
7 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if it crossed both 0.75
8 and 0.9;
- 9 ⁵, positive and negative likelihood ratios calculated from meta-analysis;
- 10 ⁶, Risk of inappropriate exclusions and flow and timing of patient unclear in two studies (Jang et al. 2014, and Kim et al. 2015). Unclear risk of review bias in all included studies;
- 11 ⁷, 95% CI of sensitivity crosses 0.75.
- 12
- 13

1 5.3.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 5.3.6 Evidence statements

8 5.3.6.1 Carcinoembryonic antigen (CEA) tests

9 5.3.6.1.1 Cystic fluid CEA

10 Mucinous cystic neoplasms versus non-mucinous cystic neoplasms of the pancreas

11 Diagnostic accuracy

12 Moderate quality evidence from a meta-analysis of 4 cohort studies (1 prospective and 3
13 retrospective) (n=401) found that cystic fluid CEA with a cut-off level of 192 ng/ml had a low
14 sensitivity of 0.58 (95% CI, 0.49-0.67) and a moderate specificity of 0.87 (95% CI, 0.74-0.94)
15 for distinguishing between mucinous and non-mucinous cystic neoplasms of the pancreas in
16 adults with pancreatic cysts. The positive likelihood ratio of 4.33 (95% CI, 2.27-8.26)
17 suggests that a positive result for a mucinous cystic neoplasm is not particularly useful for
18 ruling it in, though there is uncertainty in the estimate. The negative likelihood ratio of 0.48
19 (95% CI, 0.39-0.59) suggests that a negative result for a mucinous cystic neoplasm is not
20 particularly useful for ruling it in or ruling it out.

21 Low quality evidence from a meta-analysis of 5 retrospective cohort studies (n=434) found
22 that cystic fluid CEA with a cut-off level of between 30 and 70 ng/ml had a moderate
23 sensitivity of 0.88 (95% CI, 0.82-0.92) and moderate specificity of 0.82 (95% CI, 0.72-0.89)
24 for distinguishing between mucinous and non-mucinous cystic neoplasms of the pancreas in
25 adults with pancreatic cysts. The positive likelihood ratio of 4.83 (95% CI, 3.08-7.58)
26 suggests that a positive result for a mucinous cystic neoplasm is not particularly useful in
27 ruling it in, though there is uncertainty in the estimates. The negative likelihood ratio of 0.15
28 (0.1-0.23) suggests that a negative result for a mucinous cystic neoplasm is moderately
29 useful for ruling it out, though there is uncertainty in the estimates.

30 Low quality evidence from 1 retrospective cohort study (n=226) found that cystic fluid CEA
31 with a cut-off level of 5 ng/ml had a high sensitivity of 0.94 (95% CI, 0.89-0.97) and a low
32 specificity of 0.42 (95% CI, 0.31-0.54) for distinguishing between mucinous and non-
33 mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
34 likelihood ratio of 1.62 (95% CI, 1.33-1.98) suggests that a positive result for a mucinous
35 cystic neoplasm is not particularly useful for ruling it in. The negative likelihood ratio of 0.4
36 (95% CI, 0.07-0.28) suggests that neither a negative result for a mucinous cystic neoplasm is
37 not particularly useful for ruling it out, though there is substantial uncertainty in the estimate.

38 Very low quality evidence from 1 retrospective cohort study (n=78) found that cystic fluid
39 CEA with a cut-off level of 7 ng/ml had a high sensitivity of 0.94 (95% CI, 0.83-0.99) and a
40 moderate specificity of 0.75 (95% CI, 0.55-0.89) for distinguishing between mucinous and
41 non-mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
42 likelihood ratio of 3.76 (95% CI, 1.97-7.17) suggests that a positive result for a mucinous
43 cystic neoplasm is not particularly useful in ruling it in, though there is uncertainty in the
44 estimate. The negative likelihood ratio of 0.08 (95% CI, 0.03-0.24) suggests that a negative
45 result for a mucinous cystic neoplasm is very useful for ruling it out, though there is
46 substantial uncertainty in the estimate.

1 Very low quality evidence from 1 retrospective cohort study (n=226) found that cystic fluid
2 CEA with a cut-off level of 105 ng/ml had a moderate sensitivity of 0.7 (95% CI, 0.62-0.77)
3 and a low specificity of 0.63 (95% CI, 0.51-0.74) for distinguishing between mucinous and
4 non-mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
5 likelihood ratio of 1.9 (95% CI, 1.39-2.6) and negative likelihood ratio of 0.48 (95% CI, 0.35-
6 0.64) suggests that neither a positive or negative result for a mucinous cystic neoplasm is
7 particularly useful for ruling it in or ruling it out.

8 Very low quality evidence from 2 cohort studies (1 prospective and 1 retrospective) (n=436)
9 found that cystic fluid CEA with a cut-off level of 110 ng/ml had a low to moderate sensitivity
10 ranging from 0.62 to 0.81 and a high specificity ranging from 0.93 to 0.98 for distinguishing
11 between mucinous and non-mucinous cystic neoplasms of the pancreas in adults with
12 pancreatic cysts. The positive likelihood ratios were 8.68 (95% CI, 2.24-33.58) to 35.6 (5.12-
13 247.66) suggesting that a positive result for a mucinous cystic neoplasm is either moderately
14 useful or very useful for ruling it in, though there is substantial uncertainty in the estimates.
15 The negative likelihood ratios were 0.2 (95% CI, 0.13-0.29) and 0.41 (95% CI, 0.28-0.59)
16 suggesting that a negative result for a mucinous cystic neoplasm is not particularly useful for
17 ruling it out, though there is uncertainty in the estimates.

18 Low quality evidence from 1 retrospective cohort study (n=180) found that cystic fluid CEA
19 with a cut-off level of 129 ng/ml had a moderate sensitivity of 0.77 (95% CI, 0.7-0.84) and a
20 moderate specificity of 0.83 (95% CI, 0.66-0.93) for distinguishing between mucinous and
21 non-mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
22 likelihood ratio of 4.51 (95% CI, 2.16-9.38) suggests that a positive result for a mucinous
23 cystic neoplasm is not particularly useful for ruling it out, though there is uncertainty in the
24 estimate. The negative likelihood ratio of 0.27 (95% CI, 0.2-0.38) suggests that a negative
25 result for a mucinous cystic neoplasm is not particularly useful for ruling it out.

26 Moderate quality evidence from 1 retrospective cohort study (n=124) found that cystic fluid
27 CEA with a cut-off level of 200 ng/ml had a low sensitivity of 0.6 (95% CI, 0.49-0.71) and a
28 high specificity of 0.93 (95% CI, 0.81-0.99) for distinguishing between mucinous and non-
29 mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
30 likelihood ratio of 8.67 (95% CI, 2.87-26.19) suggests that a positive result for a mucinous
31 cystic neoplasm is moderately useful for ruling it in, though there is substantial uncertainty in
32 the estimate. The negative likelihood ratio of 0.42 (95% CI, 0.32-0.56) suggests that a
33 negative result for a mucinous cystic neoplasm is not particularly useful for ruling it out.

34 Very low quality evidence from 1 retrospective cohort study (n=71) found that cystic fluid
35 CEA with a cut-off level of 300 ng/ml had a low sensitivity of 0.41 (95% CI, 0.3-0.53) and a
36 moderate specificity of 0.89 (95% CI, 0.52-1.0) for distinguishing between mucinous and
37 non-mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
38 likelihood ratio of 3.86 (95% CI, 0.6-24.92) suggests that a positive result for a mucinous
39 cystic neoplasm is not particularly useful for ruling it in, though there is substantial
40 uncertainty in the estimate. The negative likelihood ratio of 0.64 (95% CI, 0.48-0.87)
41 suggests that a negative result for a mucinous cystic neoplasm is not particularly useful for
42 ruling it out.

43 Low quality evidence from 3 retrospective cohort studies (n=436) found that cystic fluid CEA
44 with a cut-off level of 800 ng/ml had a low sensitivity ranging from 0.27 to 0.38 and a
45 moderate to high specificity ranging from 0.86 to 0.95 for distinguishing between mucinous
46 and non-mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The
47 positive likelihood ratios were 2.3 (95% CI, 1.27-4.16), 2.45 (95% CI, 0.37-16.14) to 8.23
48 (95% CI, 2.07-32.75) suggesting that a positive result for a mucinous cystic neoplasm is
49 either not particularly useful or moderately useful, though there is uncertainty in the estimates
50 the negative likelihood ratios were 0.65 (95% CI, 0.57-0.78), 0.78 (95% CI, 0.67-0.9) to 0.82
51 (95% CI, 0.63-1.07) suggesting that a negative result for a mucinous cystic neoplasm is not
52 particularly useful for ruling it out.

1 Moderate quality evidence from 1 retrospective cohort study (n=71) found that cystic fluid
2 CEA with a cut-off level of 6000 ng/ml had a moderate sensitivity of 0.86 (95% CI, 0.7-0.95)
3 and a high specificity of 1.0 (0.9-1.0) for distinguishing between mucinous and non-mucinous
4 cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive likelihood ratio
5 of 62.69 (95% CI, 3.98-987.16) suggests that a positive result for a mucinous cystic
6 neoplasm is very useful for ruling it in, though there is substantial uncertainty in the estimate.
7 The negative likelihood ratio of 0.14 (95% CI, 0.06-0.32) suggests that a negative result for a
8 mucinous cystic neoplasm is moderately useful for ruling it out, though there is substantial
9 uncertainty in the estimate.

10 **Adverse events**

11 No evidence was identified to inform this outcome.

12 **Malignant versus benign pancreatic cystic lesions**

13 **Diagnostic accuracy**

14 Very low quality evidence from 1 retrospective cohort study (n=134) found that cystic fluid
15 CEA with a cut-off level of 30 ng/ml had a high sensitivity of 0.95 (95% CI, 0.85-0.99) and a
16 moderate specificity of 0.85 (95% CI, 0.75-0.92) for detecting malignancy or potential
17 malignancy of pancreatic cystic lesions in adults. The positive likelihood ratio of 6.15 (95%
18 CI, 3.64-10.39) suggests that a positive result for malignancy is moderately useful for ruling it
19 in, though there is substantial uncertainty in the estimate. The negative likelihood ratio of
20 0.06 (95% CI, 0.02-0.19) suggests that a negative result for malignancy is very useful for
21 ruling it out, though there is uncertainty in the estimate.

22 Low quality evidence from 1 retrospective cohort study (n=52) found that cystic fluid CEA
23 with a cut-off level of 45 ng/ml had a high sensitivity of 0.94 (95% CI, 0.7-1.0) and a low
24 specificity of 0.64 (95% CI, 0.46-0.79) for detecting malignancy or potential malignancy of
25 pancreatic cystic lesions in adults. The positive likelihood ratio of 2.6 (95% CI, 1.65-4.08)
26 suggests that positive result for malignancy is not particularly useful for ruling it in, whilst the
27 negative likelihood ratio of 0.1 (95% CI, 0.01-0.66) suggests that a negative result for
28 malignancy is moderately useful in ruling it out, though there is substantial uncertainty in the
29 estimate.

30 Low quality evidence from 1 retrospective cohort study (n=63) found that cystic fluid CEA
31 with a cut-off level of 6000 ng/ml had a low sensitivity of 0.31 (95% CI, 0.11-0.59) and
32 moderate specificity of 0.85 (95% CI, 0.72-0.94) for detecting malignancy or potential
33 malignancy of pancreatic cystic lesions in adults. The positive likelihood ratio of 2.1 (95% CI,
34 0.77-5.69) suggests that a positive result for malignancy is not particularly useful for ruling it
35 in, though there is uncertainty in the estimate. The negative likelihood ratio of 0.81 (95% CI,
36 0.57-1.15) suggests that a negative result for malignancy is not particularly useful for ruling it
37 out.

38 **Adverse events**

39 No evidence was identified to inform this outcome.

405.3.6.1.2 **Serum CEA**

41 **Diagnostic accuracy**

42 Low quality evidence from 1 retrospective study (n= 85), which did not specify the cut-off
43 level, found that serum CEA had a low sensitivity of 0.35 (95% CI, 0.22-0.51) and moderate
44 specificity of 0.84 (95% CI, 0.68-0.94) for detecting malignancy or potential malignancy of
45 pancreatic cystic lesions in adults. The positive likelihood ratio of 2.18 (95% CI, 0.96-4.99)

1 and negative likelihood ratio of 0.77 (95% CI, 0.6-0.99) suggest that neither a positive or
2 negative result for malignancy is particularly useful for ruling it in and ruling it out.

3 **Adverse events**

4 No evidence was identified to inform this outcome.

5 **5.3.6.2 Cancer antigen 19-9 (CA 19-9) test**

65.3.6.2.1 **Cystic fluid CA 19-9**

7 **Diagnostic accuracy**

8 Moderate quality evidence from a meta-analysis of 14 studies (n=1489) found that cystic fluid
9 CA 19-9 at a cut-off of between 35 and 45 ng/ml had a low sensitivity of 0.5 (95% CI, 0.37-
10 0.63) and moderate specificity of 0.87 (95% CI, 0.84-0.9) for distinguishing between
11 mucinous and non-mucinous cystic neoplasms of the pancreas in adults with pancreatic
12 cysts. The positive likelihood ratio of 3.92 (95% CI, 3.16-4.87) and negative likelihood ratio of
13 0.58 (95% CI, 0.46-0.73) suggest that neither a positive or negative result for a mucinous
14 cystic neoplasm is particularly useful for ruling it in and ruling it out.

15 **Adverse events**

16 No evidence was identified to inform this outcome.

175.3.6.2.2 **Serum CA 19-9**

18 **Diagnostic accuracy**

19 Low quality evidence from 1 retrospective study (n= 85), which did not specify the cut-off
20 level, found that serum CA 19-9 had a low sensitivity of 0.58 (95% CI, 0.43-0.72) and
21 moderate specificity of 0.86 (95% CI, 0.71-0.95) for detecting malignancy or potential
22 malignancy of pancreatic cystic lesions in adults. The positive likelihood ratio of 4.32 (95%
23 CI, 1.85-10.09) suggest that a positive result for malignancy is not particularly useful for
24 ruling it in, though there is substantial uncertainty in the estimate. The negative likelihood
25 ratio of 0.48 (95% CI, 0.34-0.69) suggest that a negative result for malignancy is not
26 particularly useful for ruling it out.

27 **Adverse events**

28 No evidence was identified to inform this outcome.

29 **5.3.6.3 Cytology: EUS-FNA**

30 **Mucinous cystic neoplasms versus non-mucinous cystic neoplasms of the pancreas**

31 **Diagnostic accuracy**

32 Very low quality evidence from a meta-analysis of 6 cohort studies (3 prospective and 3
33 retrospective) (n=639) found EUS-FNA-based cytology had a low sensitivity of 0.55 (95% CI,
34 0.27-0.8) and high specificity of 0.94 (95% CI, 0.86-0.97) for distinguishing between
35 mucinous and non-mucinous cystic neoplasms of the pancreas in adults with pancreatic
36 cysts. The positive likelihood ratio of 8.52 (95% CI, 3.41-21.31) suggests that a positive
37 result for a mucinous cystic neoplasm is moderately useful for ruling it in, though there is
38 substantial uncertainty in the estimate, the negative likelihood ratio of 0.48 (95% CI, 0.25-
39 0.91) suggests that a negative result for a mucinous cystic neoplasm is not particularly useful
40 for ruling it out.

41 **Adverse events**

1 No evidence was identified to inform this outcome.

2 **Malignant versus benign pancreatic cystic lesions**

3 **Diagnostic accuracy**

4 Low quality evidence from a meta-analysis of 4 cohort studies (1 prospective and 3
5 retrospective) (n=454) found that EUS-FNA-based cytology had a low sensitivity of 0.7 (95%
6 CI, 0.54-0.81) and a high specificity of 0.93 (95% CI, 0.88-0.96) for detecting malignancy or
7 potential malignancy of pancreatic cystic lesions in adults. The positive likelihood ratio of
8 9.67 (95% CI, 6.14-15.24) suggests that a positive result for a mucinous cystic neoplasm is
9 moderately useful for ruling it in, though there is uncertainty in the estimate. The negative
10 likelihood ratio of 0.33 (95% CI, 0.21-0.5) suggests that a negative result for malignancy is
11 not particularly useful for ruling it out.

12 **Adverse effects**

13 High quality evidence from a meta-analysis of 40 studies (n=5124) found that EUS-FNA
14 cytology is a safe procedure for diagnosis of pancreatic cystic lesions and is associated with
15 a relatively low incidence of adverse events.

16 **5.3.6.4 Imaging: CT**

17 **Mucinous cystic neoplasms versus non-mucinous cystic neoplasms of the pancreas**

18 **Diagnostic accuracy**

19 Low quality evidence from 1 retrospective cohort study (n=53) found that CT had a moderate
20 sensitivity of 0.81 (95% CI, 0.63-0.93) and a moderate specificity of 0.86 (95% CI, 0.78-0.93)
21 for distinguishing between mucinous and non-mucinous cystic neoplasms of the pancreas in
22 adults with pancreatic cysts. The positive likelihood ratio of 5.96 (95% CI, 3.49-10.16)
23 suggests that a positive result for a mucinous cystic neoplasm is moderately useful for ruling
24 it in, though there is substantial uncertainty in the estimate. The negative likelihood ratio of
25 0.22 (95% CI, 0.11-0.46) suggests that a negative result for a mucinous cystic neoplasm is
26 not particularly useful for ruling it out, though there is uncertainty in the estimate.

27 **Adverse events**

28 No evidence was identified to inform this outcome.

29 **Malignant versus benign pancreatic cystic lesions**

30 **Diagnostic accuracy**

31 Very low quality evidence from a meta-analysis of 6 cohort studies (2 prospective and 4
32 retrospective) (n=883) found that CT had a low sensitivity of 0.69 (95% CI, 0.60-0.78) and a
33 high specificity of 0.91 (95% CI, 0.89-0.93) for detecting malignancy or potential malignancy
34 of pancreatic cystic lesions in adults. The positive likelihood ratio of 8.00 (95% CI, 6.17-
35 10.37) suggests that a positive result for malignancy is moderately useful for ruling it in,
36 though there is uncertainty in the estimate. The negative likelihood ratio of 0.34 (95% CI,
37 0.26-0.44) suggests that a negative result for malignancy is not particularly useful for ruling it
38 out.

39 **Adverse events**

40 In 1 multicentre prospective cohort study (n=583) that examined the diagnostic test accuracy
41 of CT, no adverse events related to the tests were reported.

1 **5.3.6.5 Imaging: EUS**

2 **Diagnostic accuracy**

3 Very low quality evidence from a meta-analysis of 4 cohort studies (1 prospective and 3
4 retrospective) (n=210) found that EUS had a low sensitivity of 0.67 (95% CI, 0.43-0.84) and
5 low specificity of 0.65 (95% CI, 0.48-0.78) for distinguishing between mucinous and non-
6 mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
7 likelihood ratio of 1.88 (95% CI, 1.18-3.0) and negative likelihood ratio of 0.52 (95% CI, 0.28-
8 0.96) suggests that neither a positive or negative result for a mucinous cystic neoplasm is
9 particularly useful for ruling it in or ruling it out.

10 **Adverse events**

11 No evidence was identified to inform this outcome.

12 **Mucinous cystic neoplasms versus non-mucinous cystic neoplasms of the pancreas**

13 **Diagnostic accuracy**

14 Very low quality evidence from a meta-analysis of 4 cohort studies (1 prospective and 3
15 retrospective) (n=210) found that EUS had a low sensitivity of 0.67 (95% CI, 0.43-0.84) and
16 low specificity of 0.65 (95% CI, 0.48-0.78) for distinguishing between mucinous and non-
17 mucinous cystic neoplasms of the pancreas in adults with pancreatic cysts. The positive
18 likelihood ratio of 1.88 (95% CI, 1.18-3.0) and negative likelihood ratio of 0.52 (95% CI, 0.28-
19 0.96) suggests that neither a positive or negative result for a mucinous cystic neoplasm is
20 particularly useful for ruling it in or ruling it out.

21 **Adverse events**

22 No evidence was identified to inform this outcome.

23

24 **Malignant versus benign pancreatic cystic lesions**

25 **Diagnostic accuracy**

26 Very low quality evidence from 3 retrospective cohort studies (n=187) found that EUS had a
27 low to high sensitivity ranging from 0.71 to 0.97 and a low specificity ranging from 0.4 to 0.73
28 for detecting malignancy or potential malignancy of pancreatic cystic lesions in adults. The
29 positive likelihood ratios were 1.61 (95% CI, 1.24-2.09), 1.91 (95% CI, 1.17-3.11) and 3.65
30 (95% CI, 1.57-8.45) suggesting that a positive result for malignancy is not particularly useful
31 for ruling it in. The negative likelihood ratios were 0.04 (95% CI, 0.01-0.27), 0.08 (95% CI,
32 0.01-0.59) and 0.46 (95% CI, 0.25-0.85) suggesting that a negative result for malignancy is
33 either very useful or not particularly useful in ruling it out, though there is substantial
34 uncertainty in the estimates.

35 **Adverse events**

36 No evidence was identified to inform this outcome.

37 **5.3.6.6 Imaging: EUS-FNA**

38 **Diagnostic accuracy**

39 Low quality evidence from 1 retrospective study (n=119) found that EUS-FNA had a
40 moderate sensitivity of 0.76 (95% CI, 0.65-0.85) and a low specificity of 0.73 (95% CI, 0.56--
41 0.85) for distinguishing between mucinous and non-mucinous cystic neoplasms of the
42 pancreas in adults with pancreatic cysts. The positive likelihood ratio of 2.76 (95% CI, 1.64-

1 4.64) and negative likelihood ratio of 0.33 (95% CI, 0.21-0.51) suggests that neither a
2 positive or negative result for a mucinous cystic neoplasm is particularly useful for ruling it in
3 or ruling it out.

4 **Adverse events**

5 No evidence was identified to inform this outcome.

6 **Malignant versus benign pancreatic cystic lesions**

7 **Diagnostic accuracy**

8 Low quality evidence from 1 retrospective study (n=119) found that EUS-FNA had a
9 moderate sensitivity of 0.76 (95% CI, 0.65-0.85) and a low specificity of 0.73 (95% CI, 0.56--
10 0.85) for distinguishing between mucinous and non-mucinous cystic neoplasms of the
11 pancreas in adults with pancreatic cysts. The positive likelihood ratio of 2.76 (95% CI, 1.64-
12 4.64) and negative likelihood ratio of 0.33 (95% CI, 0.21-0.51) suggests that neither a
13 positive or negative result for a mucinous cystic neoplasm is particularly useful for ruling it in
14 or ruling it out.

15 **Adverse events**

16 No evidence was identified to inform this outcome.

17 **5.3.6.7 Imaging: FDG-PET/CT**

18 **Malignant versus benign pancreatic cystic lesions**

19 **Diagnostic accuracy**

20 Very low quality evidence from 4 cohort studies (2 prospective and 2 retrospective) (n=672)
21 found that 18-FDG FDG-PET/CT had a moderate sensitivity of 0.86 (95% CI, 0.71-0.94) and
22 a high specificity of 0.96 (95% CI, 0.94-0.97) for detecting malignancy or potential
23 malignancy of pancreatic cystic lesions in adults. The positive likelihood ratio of 20.8 (95%
24 CI, 13.6-30.0) suggests that a positive result for malignancy is very useful for ruling it in. The
25 negative likelihood ratio of 0.16 (95% CI, 0.06-0.29) suggests that a negative result for
26 malignancy is moderately useful for ruling it out, though there is substantial uncertainty in the
27 estimates.

28 **Adverse events**

29 In 1 multicentre prospective cohort study (n=583) that examined the diagnostic test accuracy
30 of CT, no adverse events related to the tests were reported.

31

32 **5.3.6.8 Imaging: MRI**

33 **Mucinous cystic neoplasms versus non-mucinous cystic neoplasms of the pancreas**

34 **Diagnostic accuracy**

35 Moderate quality evidence from 1 retrospective study (n=53) found that MRI had a high
36 sensitivity of 0.97 (95% CI, 0.83-1.0) and a high specificity of 0.91 (95% CI, 0.71-0.99) for
37 distinguishing between non-mucinous and mucinous neoplasms. The positive likelihood ratio
38 of 10.65 (95% CI, 2.84-39.97) and negative likelihood ratio of 0.04 (95% CI 0.01-0.25,
39 suggest that both a positive and negative result for a mucinous cystic neoplasm are very
40 useful for ruling it in and ruling it out, though there is substantial uncertainty in the estimates.

1 **Adverse events**

2 No evidence was identified to inform this outcome.

3 **Malignant versus benign pancreatic cystic lesions**

4 **Diagnostic accuracy**

5 Low quality evidence from a meta-analysis of 4 retrospective cohort studies (n=271) found
6 that MRI had a moderate sensitivity of 0.79 (95% CI, 0.64-0.89) and a moderate sensitivity of
7 0.84 (95% CI, 0.69-0.92) for detecting malignancy or potential malignancy of pancreatic
8 cystic lesions in adults. The positive likelihood ratio of 4.81 (95% CI, 2.54-9.08) and negative
9 likelihood ratio of 0.25 (95% CI, 0.15-0.43) suggest that neither a positive or negative result
10 for malignancy is particularly useful for ruling it and ruling it out, though there is uncertainty in
11 the estimates.

12 **Adverse events**

13 No evidence was identified to inform this outcome.

14 **5.3.7 Recommendations**

15 **7. Offer a pancreatic protocol CT scan or magnetic resonance**
16 **cholangiopancreatography (MRI-MRCP) to people with pancreatic cysts. If more**
17 **information is needed after one of these tests, offer the other one.**

18 **8. Refer people with any of these high-risk features for resection:**
19 • obstructive jaundice with cystic lesions in the head of the pancreas
20 • enhancing solid component in the cyst
21 • a main pancreatic duct that is 10 mm diameter or larger.

22 **9. Offer EUS after CT and MRI-MRCP if more information on the likelihood of**
23 **malignancy is needed, or if it is not clear whether surgery is needed.**

24 **10. Consider fine-needle aspiration during EUS if more information on the likelihood**
25 **of malignancy is needed.**

26 **11. When using fine-needle aspiration, perform carcinoembryonic antigen (CEA)**
27 **assay in addition to cytology if there is sufficient sample.**

28 **12. For people with cysts that are thought to be malignant, follow the**
29 **recommendations on [staging](#).**

30 **5.3.8 Evidence to recommendations**

31 **5.3.8.1 Relative value placed on the outcomes considered**

32 Diagnostic accuracy (sensitivity, specificity, positive predictive value and negative predictive
33 value) and adverse events were considered the critical outcomes for this question.
34 Diagnostic accuracy was reported for all comparisons of interest. Adverse events were only
35 reported for EUS-FNA, MDCT and FDG-PET/CT.

1 5.3.8.2 Quality of evidence

2 Evidence was identified on the diagnostic accuracy of CEA, CA 19-9, EUS-FNA, CT, EUS,
3 PET, FDG-PET/CT and MRI. The evidence for CEA ranged from very low to moderate
4 quality, for CA 19-9 was very low, for EUS-FNA ranged from very low to low, for CT was low
5 quality, for EUS ranged from low to moderate quality, for FDG-PET/CT was very low, and for
6 MRI was moderate quality.

7 The committee noted several limitations with the evidence base. First, a good proportion of
8 the included studies are old and imaging quality is known to have improved since. Second,
9 many of these older studies do not differentiate between IPMN and mucinous cystic
10 neoplasms. Information which is now considered important in identifying which cysts are at
11 higher risk of becoming cancer. Third, there is no validated assay for CEA that is consistently
12 used across all laboratories. This makes it difficult to assess the true diagnostic accuracy of
13 the test. Fourth, the evidence was very fragmented due to different descriptions for
14 malignancy, gold standard of diagnosis, study design and type of cysts.

15 The committee noted, whilst there was a good amount of data on the diagnostic accuracy of
16 investigations to differentiate mucinous cysts from non-mucinous cysts, there was very little
17 data about what investigations can accurately identify those mucinous cysts which are at
18 high risk of becoming pancreatic cancer. The committee focused on making
19 recommendations about the most effective diagnostic pathway to identify cysts at high risk of
20 becoming malignant as this was the focus of the question.

21 The committee had more confidence in the quality of evidence from one of the studies
22 related to FDG-PET/CT (Ghaneh et al. 2018) because it was the largest, conducted in a UK
23 NHS setting (and therefore directly applicable) and the study design was judged by the
24 committee to be more robust than that of the other included studies. Therefore in their
25 discussion the committee placed relatively more weight on the evidence from this study than
26 on the rest of the evidence base. Even though the committee believed that the results from
27 this study looked promising (with high specificity and lower yet still relatively good sensitivity),
28 the difficulty is that pancreatic cysts are common and that only those thought to be malignant
29 require further review. The committee also noted that even though the study population was
30 large it only contained a small group of people with pancreatic cysts. Therefore the
31 committee agreed that the evidence from this study was not as applicable for people with
32 pancreatic cysts as for people with jaundice and people without jaundice who have
33 pancreatic abnormalities on imaging.

34 5.3.8.3 Consideration of clinical benefits and harms

35 Based on the evidence, the committee noted that MRI had moderate sensitivity and
36 specificity for detecting pancreatic cancer in people with pancreatic cysts. They also noted
37 that whilst CT had low sensitivity, it had high specificity for detecting pancreatic cancer in this
38 population. The committee agreed, based on their knowledge, that both of these
39 investigations are widely available, non-invasive and can provide information on high-risk
40 features of cysts. However they also noted that MRI is more expensive than CT, waiting lists
41 are longer for this investigation and the use of MRI can be contraindicated for some people.
42 Therefore, despite the evidence showing that the sensitivity of CT was not equivalent to that
43 of MRI, the committee recommended either CT or MRI as the initial diagnostic investigation
44 for people with pancreatic cysts in light of the practical constraints around the use of MRI.

45 Based on their clinical knowledge and experience, the committee noted that if a CT scan is
46 used a pancreatic protocol CT scan should be used to ensure good visualisation of any
47 pathology in the pancreas. They agreed that if MRI is used MRI-MRCP should be used as
48 this will enable the pancreatic duct anatomy to be visualised.

49 The committee agreed, based on their knowledge, that if the initial CT/MRI identified any
50 high-risk features then the cyst was likely to become malignant so resection would be

1 indicated. They noted that the evidence did not help to identify what the ‘high-risk’ features
2 are. However, they agreed that their recommendation would need to specify them in order to
3 be implementable. The committee agreed the high-risk features that should prompt resection
4 based on their experience and informed by their knowledge of currently accepted definitions.

5 The committee considered that after an initial CT/MRI there may be some instances where
6 there is uncertainty over whether or not to operate. In these equivocal cases the committee
7 agreed, based on the evidence, that EUS and FNA could help to provide additional
8 information. However, because both EUS and FNA are more invasive, and carry the risk of
9 potential complications, the committee recommended these investigations be reserved for
10 when more information must be obtained in order to determine whether to operate or not.

11 Although the evidence suggested that FDG-PET/CT may also be helpful in both ruling in and
12 ruling out malignancy of pancreatic cysts, the committee agreed not to recommend its use as
13 it would lead to a very significant increase in costs given the wide variety of cystic lesions
14 and the fact that cysts are relatively commonplace.

15 The committee also agreed, based on the evidence and their experience, whilst CEA was not
16 helpful in distinguishing between benign and malignant pancreatic cysts, it can provide
17 additional useful diagnostic information. They, therefore, recommended that if an FNA was
18 being done, CEA should be requested at the same time to avoid unnecessary repeat
19 procedures.

20 The committee agreed that the potential benefits of the recommendations made would be
21 improved and streamlined diagnosis of pancreatic cancer in people with cysts. They
22 considered that EUS/FNA are more invasive investigations and, therefore, are associated
23 with potential complications. They balanced these harms by only recommending the more
24 invasive investigations for a sub-set of people where additional diagnostic information is
25 necessary.

26 **5.3.8.4 Consideration of economic benefits and harms**

27 The committee noted that no relevant published economic evaluations had been identified
28 and no additional economic analysis had been undertaken in this area.

29 The committee agreed that current practice is to use EUS to investigate most cysts. There
30 should, therefore, be some decrease in costs associated with the recommendations as EUS
31 will now only be used in a sub-set of the population. However, there may also be a
32 corresponding increase in costs associated with the use of the other investigations
33 recommended. The committee agreed that overall the recommendations were likely to be
34 cost neutral.

35 The committee also noted that although FDG-PET/CT appeared to be very useful in ruling in
36 malignancy and moderately useful in ruling it out. recommending it would have a very
37 significant resource impact. Whilst evidence from the cost utility analysis in Ghaneh et al.
38 (2018; discussed in detail in section 7.5.1) suggested that FDG-PET/CT could be cost
39 effective and cost saving in a patient cohort which included this population the committee
40 acknowledged that malignant cysts only made up 1.5% of the study cohort. The committee
41 also noted, based on their knowledge, that non-malignant pancreatic cysts are otherwise
42 common. The potential number of people that would be eligible for FDG-PET/CT could be
43 large. It would therefore not be appropriate to attach the conclusions of the cost utility study
44 to this subgroup alone. The committee agreed that without stronger evidence of cost
45 effectiveness it could not recommend the use of FDG-PET/CT in the diagnostic pathway of
46 people with pancreatic cysts.

1 **5.3.9 References**

- 2 Ardengh JC, Lopes CV, de Lima LF et al. (2007) Diagnosis of pancreatic tumors by
3 endoscopic ultrasound-guided fine-needle aspiration. *World Journal of Gastroenterology*
4 13(22): 3112-6
- 5 Brugge WR, Lewandrowski K, Lee-Lewandrowski E et al. (2004) Diagnosis of pancreatic
6 cystic neoplasms: a report of the cooperative pancreatic cyst study. *Gastroenterology* 126(5):
7 1330-6
- 8 Cao S, Hu Y, Gao X et al. (2016) Serum Carbohydrate Antigen 19-9 in Differential Diagnosis
9 of Benign and Malignant Pancreatic Cystic Neoplasms: A Meta-Analysis. *PLoS One* 11(11):
10 e0166406
- 11 Cizginer S, Turner BG, Bilge AR et al. (2011) Cyst fluid carcinoembryonic antigen is an
12 accurate diagnostic marker of pancreatic mucinous cysts. *Pancreas* 40(7): 1024-8
- 13 Frossard JL, Amouyal P, Amouyal G et al. (2003) Performance of endosonography-guided
14 fine needle aspiration and biopsy in the diagnosis of pancreatic cystic lesions. *American*
15 *Journal of Gastroenterology* 98(7): 1516-24
- 16 Gaddam S, Ge PS, Keach JW et al. (2015) Suboptimal accuracy of carcinoembryonic
17 antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large
18 multicenter study. *Gastrointestinal Endoscopy* 82(6): 1060-9
- 19 Gerke H, Jaffe TA, Mitchell RM et al. (2006) Endoscopic ultrasound and computer
20 tomography are inaccurate methods of classifying cystic pancreatic lesions. *Digestive and*
21 *Liver Disease* 38(1): 39-44
- 22 Ghaneh P, Hanson R, Titman A et al. (2018) PET-PANC: multicentre prospective diagnostic
23 accuracy and health economic analysis study of the impact of combined modality ¹⁸fluorine-
24 2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography
25 scanning in the diagnosis and management of pancreatic cancer. *Health Technology*
26 *Assessment* 22(7)
- 27 Hirono S, Tani M, Kawai M et al. (2012) The carcinoembryonic antigen level in pancreatic
28 juice and mural nodule size are predictors of malignancy for branch duct type intraductal
29 papillary mucinous neoplasms of the pancreas. *Annals of Surgery* 255(3): 517-22
- 30 Jang KM, Kim SH, Min JH et al. (2014) Value of diffusion-weighted MRI for differentiating
31 malignant from benign intraductal papillary mucinous neoplasms of the pancreas. *American*
32 *Journal of Roentgenology* 203(5): 992-1000
- 33 Jin DX, Small AJ, Vollmer CM et al. (2015) A lower cyst fluid CEA cut-off increases
34 diagnostic accuracy in identifying mucinous pancreatic cystic lesions. *Journal of Pancreas*
35 16(3): 271-7
- 36 Kamata K, Kitano M, Omoto S et al. (2016) Contrast-enhanced harmonic endoscopic
37 ultrasonography for differential diagnosis of pancreatic cysts. *Endoscopy* 48(1): 35-41
- 38 Kim JH, Eun HW, Park HJ et al. (2012) Diagnostic performance of MRI and EUS in the
39 differentiation of benign from malignant pancreatic cyst and cyst communication with the
40 main duct. *European Journal of Radiology* 81(11): 2927-35
- 41 Kim SH, Lee JM, Lee ES et al. (2015) Intraductal papillary mucinous neoplasms of the
42 pancreas: Evaluation of malignant potential and surgical resectability by using MR imaging
43 with MR cholangiography. *Radiology* 274(3): 723-33
- 44 Lee HJ, Kim MJ, Choi JY et al. (2011) Relative accuracy of CT and MRI in the differentiation
45 of benign from malignant pancreatic cystic lesions. *Clinical Radiology* 66: 315-21, 2011

- 1 Linder JD, Geenen JE, Catalano MF (2006) Cyst fluid analysis obtained by EUS-guided FNA
2 in the evaluation of discrete cystic neoplasms of the pancreas: A prospective single-center
3 experience. *Gastrointestinal Endoscopy* 64(5): 697-702
- 4 Moris M, Raimondo M, Woodward TA et al. (2016) Diagnostic Accuracy of Endoscopic
5 Ultrasound-Guided Fine-Needle Aspiration Cytology, Carcinoembryonic Antigen, and
6 Amylase in Intraductal Papillary Mucinous Neoplasm. *Pancreas* 45(6): 870-5
- 7 Nagashio Y, Hijioka S, Mizuno N et al. (2014) Combination of cyst fluid CEA and CA 125 is
8 an accurate diagnostic tool for differentiating mucinous cystic neoplasms from intraductal
9 papillary mucinous neoplasms. *Pancreatology* 14(6): 503-9
- 10 Nara S, Onaya H, Hiraoka N et al. (2009) Preoperative evaluation of invasive and
11 noninvasive intraductal papillary-mucinous neoplasms of the pancreas: clinical, radiological,
12 and pathological analysis of 123 cases. *Pancreas* 38(1): 8-16
- 13 Oh HC, Kang H, Brugge WR (2014) Cyst fluid amylase and CEA levels in the differential
14 diagnosis of pancreatic cysts: a single-center experience with histologically proven cysts.
15 *Digestive Diseases and Sciences* 59(12): 3111-6
- 16 Opong KW, Dawwas MF, Charnley RM et al. (2015) EUS and EUS-FNA diagnosis of
17 suspected pancreatic cystic neoplasms: Is the sum of the parts greater than the CEA?
18 *Pancreatology* 15(5): 531-7
- 19 Othman MO, Patel M, Dabizzi E, et al. (2012) Carcino embryonic antigen and long-term
20 follow-up of mucinous pancreatic cysts including intraductal papillary mucinous neoplasm.
21 *Digestive and Liver Disease* 44: 844–8
- 22 Pais SA, Attasaranya S, Leblanc JK et al. (2007) Role of endoscopic ultrasound in the
23 diagnosis of intraductal papillary mucinous neoplasms: correlation with surgical
24 histopathology. *Clinical Gastroenterology and Hepatology* 5(4): 489-95
- 25 Park WG, Mascarenhas R, Palaez-Luna M et al. (2011) Diagnostic performance of cyst fluid
26 carcinoembryonic antigen and amylase in histologically confirmed pancreatic cysts.
27 *Pancreas* 40(1): 42-5
- 28 Pitman MB, Genevay M, Yaeger K et al. (2010) High-grade atypical epithelial cells in
29 pancreatic mucinous cysts are a more accurate predictor of malignancy than "positive"
30 cytology. *Cancer Cytopathology* 118(6): 434-40
- 31 Pitman MB, Yaeger KA, Brugge WR et al. (2013) Prospective analysis of atypical epithelial
32 cells as a high-risk cytologic feature for malignancy in pancreatic cysts. *Cancer*
33 *Cytopathology* 121(1): 29-36
- 34 Smith AL, Abdul-Karim FW, Goyal A (2016) Cytologic categorization of pancreatic neoplastic
35 mucinous cysts with an assessment of the risk of malignancy: A retrospective study based
36 on the Papanicolaou Society of Cytopathology guidelines. *Cancer Cytopathology* 124(4):
37 285-93
- 38 Song SJ, Lee JM, Kim YJ et al. (2007) Differentiation of intraductal papillary mucinous
39 neoplasms from other pancreatic cystic masses: comparison of multirow-detector CT and
40 MR imaging using ROC analysis. *Journal of Magnetic Resonance Imaging* 26(1): 86-93
- 41 Sperti C, Pasquali C, Chierichetti F et al. (2001) Value of 18-fluorodeoxyglucose positron
42 emission tomography in the management of patients with cystic tumors of the pancreas.
43 *Annals of Surgery* 234(5): 675-80
- 44 Sperti C, Pasquali C, Decet G et al. (2005) F-18-fluorodeoxyglucose positron emission
45 tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
46 *Journal of Gastrointestinal Surgery* 9(1): 22-8

- 1 Takanami K, Hiraide T, Tsuda M et al. (2011) Additional value of FDG FDG-PET/CT to
2 contrast-enhanced CT in the differentiation between benign and malignant intraductal
3 papillary mucinous neoplasms of the pancreas with mural nodules. *Annals of Nuclear*
4 *Medicine* 25(7): 501–10
- 5 Talar-Wojnarowska R, Pazurek M, Durko L et al. (2013) Pancreatic cyst fluid analysis for
6 differential diagnosis between benign and malignant lesions. *Oncology Letters* 5(2): 613-616
- 7 Wu H, Yan LN, Cheng NS et al. (2007) Role of cystic fluid in diagnosis of the pancreatic
8 cystadenoma and cystadenocarcinoma. *Hepatogastroenterology* 54(79): 1915-8
- 9 Zhang S, Defrias DV, Alasadi R et al. (2010) Endoscopic ultrasound-guided fine needle
10 aspiration (EUS-FNA): experience of an academic centre in the USA. *Cytopathology* 21(1):
11 35-43
- 12 Zhu H, Jiang F, Zhu J et al. (2017) Assessment of morbidity and mortality associated with
13 EUS-guided FNA for pancreatic cystic lesions: A System Review and Meta-Analysis.
14 *Digestive Endoscopy* Feb 20
- 15 **5.3.9.1 Studies included in Cao et al., 2016 (n=13)**
- 16 Fritz S, Hackert T, Hinz U et al. (2011) Role of serum carbohydrate antigen 19–9 and
17 carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary
18 mucinous neoplasm of the pancreas. *British Journal of Surgery* 98(1): 104–10
- 19 Goh BKP, Tan Y, Thng C et al. (2008) How Useful Are Clinical, Biochemical, and Cross-
20 Sectional Imaging Features in Predicting Potentially Malignant or Malignant Cystic Lesions of
21 the Pancreas? Results from a Single Institution Experience with 220 Surgically Treated
22 Patients. *Journal of the American College of Surgeons* 206(1): 17–27
- 23 Grobmyer SR, Cance WG, Copeland EM et al. (2009) Is there an indication for initial
24 conservative management of pancreatic cystic lesions? *Journal of Surgical Oncology* 100(5):
25 372–74
- 26 Hirono S, Tani M, Kawai M et al. (2012) The Carcinoembryonic Antigen Level in Pancreatic
27 Juice and Mural Nodule Size Are Predictors of Malignancy for Branch Duct Type Intraductal
28 Papillary Mucinous Neoplasms of the Pancreas. *Annals of Surgery* 255(3): 517–22
- 29 Hwang DW, Jang J, Lim C et al. (2011) Determination of Malignant and Invasive Predictors
30 in Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas: A
31 Suggested Scoring Formula. *Journal of Korean Medical Science* 26(6): 740
- 32 Ingkakul T, Sadakari Y, Ienaga J et al. (2010) Predictors of the Presence of Concomitant
33 Invasive Ductal Carcinoma in Intraductal Papillary Mucinous Neoplasm of the Pancreas.
34 *Annals of Surgery* 2010; 251(1): 70–75
- 35 Jones NB, Hatzaras I, George N et al. (2009) Clinical factors predictive of malignant and
36 premalignant cystic neoplasms of the pancreas: a single institution experience. *HPB* 11(8):
37 664–70
- 38 Kitagawa Y, Unger TA, Taylor S et al. (2003) Mucus is a predictor of better prognosis and
39 survival in patients with intraductal papillary mucinous tumor of the pancreas. *Journal of*
40 *Gastrointestinal Surgery* 7(1):12–18
- 41 Ohtsuka T, Kono H, Nagayoshi Y et al.(2012) An increase in the number of predictive factors
42 augments the likelihood of malignancy in branch duct intraductal papillary mucinous
43 neoplasm of the pancreas. *Surgery* 151(1): 76–83.

1 Sadakari Y, Ienaga J, Kobayashi K et al. (2010) Cyst size indicates malignant transformation
2 in branch duct intraductal papillary mucinous neoplasm of the pancreas without mural
3 nodules. *Pancreas* 39(2): 232–36

4 Shin SH, Han DJ, Park KT et al. (2010) Validating a Simple Scoring System to Predict
5 Malignancy and Invasiveness of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
6 *World Journal of Surgery* 34(4): 776–83

7 Sperti C, Bissoli S, Pasquali C et al. (2007) 18-fluorodeoxyglucose positron emission
8 tomography enhances computed tomography diagnosis of malignant intraductal papillary
9 mucinous neoplasms of the pancreas. *Annals of Surgery* 246(6): 932–37

10 Xu B, Zheng W, Jin D et al. (2011) Predictive Value of Serum Carbohydrate Antigen 19-9 in
11 Malignant Intraductal Papillary Mucinous Neoplasms. *World Journal of Surgery* 35(5): 1103–
12 09

13 **5.4 People with inherited high risk of pancreatic cancer**

14 **Review question: What is the most effective monitoring protocol for adults with an**
15 **inherited high risk of pancreatic cancer in secondary care to ensure early diagnosis?**

16 **5.4.1 Introduction**

17 There are three main groups of people who are at a high risk of developing pancreatic
18 cancer:

- 19 1. those with familial pancreatic cancer
- 20 2. those with hereditary pancreatitis
- 21 3. those with hereditary tumour predisposition syndromes

22 People with hereditary pancreatitis have a 70 fold increased risk of pancreatic cancer. The
23 life time risk is 35-40% and rises with age. People with familial pancreatic cancer have a life
24 time risk of 30-50% which rises with age.

25 Guidance is needed on the most effective monitoring protocol to ensure early diagnosis in
26 people with an inherited high risk of pancreatic cancer.

27 **5.4.1.1 Review protocol summary**

28 The review protocol summary used for this question can be found in Table 58. Full details of
29 the review protocol can be found in Appendix C.

30 **Table 53: Clinical review protocol summary for the review of most effective monitoring**
31 **protocol for adults with an inherited high risk of pancreatic cancer**

Population	<p>Adults who have a history of:</p> <ul style="list-style-type: none"> • familial pancreatic cancer (FPC) • associated with chronic inflammation of the pancreas, namely cystic fibrosis and hereditary chronic pancreatitis • hereditary tumour predisposition syndromes, namely <ul style="list-style-type: none"> ○ ataxia-telangiectasia ○ familial atypical multiple mole melanoma (FAMMM) ○ familial adenomatous polyposis (FAP)
-------------------	--

	<ul style="list-style-type: none"> ○ hereditary breast and ovarian cancer syndrome (HBOC) ○ Li-Fraumeni syndrome ○ Lynch syndrome (HNPCC) ○ Peutz-Jeghers syndrome
Index test	<ul style="list-style-type: none"> ● Biomarkers in blood, serum or pancreatic juice ● CA19-9 ● CEA ● Kras ● GNAS ● p53 ● p16) ● Imaging ● Ultrasound ● CT ● MRI/MRCP ● FDG-PET/CT ● Biopsy (cytology or histology) <ul style="list-style-type: none"> ○ endoscopic ultrasound +/- FNA ○ EUS +/- core biopsy ○ ERCP ○ laparoscopy + biopsy ○ percutaneous pancreatic biopsy
Reference standard	<ul style="list-style-type: none"> ● Definitive diagnosis ● Preferably pathological diagnosis ● Each Other ● Alone and in combination
Outcomes	<ul style="list-style-type: none"> ● Early diagnosis ● Survival ● Diagnostic Accuracy including: <ul style="list-style-type: none"> ● Sensitivity ● Specificity ● Positive Predictive Value ● Negative Predictive Value ● Adverse events of interventions ● HRQoL

1 5.4.2 Description of clinical evidence

2 Eighteen articles were identified: 17 of these concerned screening/surveillance programs,
3 whilst 1 was a secondary study that reported on the psychological burden/quality of life of
4 participating in 1 of these screening programs. All 17 of the primary studies reported
5 diagnostic yield (early diagnosis). A summary of the included studies is presented in Table
6 54.

7 Seventeen studies (n=2661) were identified that evaluated the diagnostic performance of
8 screening and/or surveillance programs for adults with an inherited 'high' risk of pancreatic
9 cancer: 5 prospective cohort studies (Canto et al. 2006; Chang et al. 2017; Potjer et al. 2013;
10 Vasen et al. 2016; Verna et al. 2010), 1 retrospective review of a prospective cohort study
11 (Nocholson et al. 2015), and 11 case series (Al-Sukhni et al. 2012; Bartsch et al. 2016;
12 Canto et al. 2004; Canto et al. 2012; Del Chiaro et al. 2015; Harinck et al. 2016; Kimmey et
13 al. 2002; Ludwig et al. 2011; Poley et al. 2009; Sud et al. 2014; Zubarik et al. 2011). The

1 majority of the studies included familial pancreatic cancer (FPC), which was typically defined
2 as an individual that has two or more relatives with pancreatic cancer. In addition, all of the
3 studies (with the exception of Canto et al. 2012 and Harinck et al. 2016) consisted of an
4 initial test(s) and, given an abnormal result, subsequent imaging or other tests. The most
5 common initial test (11 studies) was MRI/MRCP, or MRI combined with EUS±FNA, whilst the
6 most common subsequent test was EUS±FNA. Only two studies (Canto et al. 2006; Canto et
7 al. 2012) used CT as part of the initial screening test and in both cases this was in
8 combination with other tests (EUS and/or MRI). One multicentre prospective study (n=546;
9 Zubarik et al. 2011) used serum CA 19-9 as the initial test and EUS-FNA given an abnormal
10 result (values >37 U/ml). Data on the diagnostic yield and adverse events of
11 screening/surveillance programs is not amenable to a meta-analysis or depiction using forest
12 plots (however see Nicholson et al. 2015 below). Therefore a narrative summary and table
13 listing the relevant results have been presented.

14 One retrospective review of a prospective cohort study (n=60; Nicholson et al. 2015)
15 examined the incidence of post-ERCP pancreatitis with and without prophylaxis in people
16 with familial pancreatic cancer or hereditary pancreatitis.

17 One interrupted time series study (n=152; Konings et al. 2016) examined participants
18 enrolled in the annual surveillance program reported in Harinck et al. 2016 (see above).
19 Although this secondary study did not report health-related quality of life, it reported change
20 on the Cancer Worry scale and the HADS-Anxiety and HADS–Depression scales and so was
21 included.

22 The QUADAS-2 checklist was used to evaluate the risk of bias and applicability
23 (indirectness) of the screening/surveillance studies. Due to the type of data (diagnostic yield)
24 reported, the criteria of inconsistency and imprecision were not evaluated for these studies,
25 and the quality of each study was therefore rated individually. A narrative summary of the
26 evidence is presented. The GRADE risk of bias tool was used to evaluate 1 study that
27 reported post-ERCP pancreatitis with and without prophylaxis.

28 Further information about the search strategy can be found in Appendix D. See study
29 selection flow chart in Appendix E, forest plots in Appendix H, summary of QUADAS-2 study
30 quality evaluations in Appendix J, study evidence tables in Appendix F and list of excluded
31 studies in Appendix G.

32

1 **5.4.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 54.

3 **Table 54: Summary of included studies**

Study	Country	N	Groups at risk of pancreatic cancer	Initial baseline test(s)	Test(s) conducted if abnormal initial baseline test(s) result	Frequency of follow up if normal result	Frequency of follow up if abnormal result	Outcomes
Al-Sukhni et al. 2012	Canada	262	BRCA1, BRCA2, FDR with multiple primary cancers, FPC, HP, p16, PJS,	MRI	MRI-CT +/-or ERCP +/-or EUS	Annually	-	Diagnostic yield
Bartsch et al. 2016	Germany (FaPaCa ^b)	253	BRCA1, BRCA2, FPC, PALB2	MRI/MRCP + EUS	MRI/MRCP + EUS±FNA	Annually	Every 3 months if no surgery	Diagnostic yield Adverse events
	Spain (PanGen-Fam)			MRI + EUS	MRI + EUS			
	Netherlands (Leiden ^b)			MRI/MRCP, EUS*	EUS + CT			
Canto et al. 2006	USA	78	FPC, PJS	EUS + CT	EUS-FNA + CT; ERCP*	Annually	Within 3-6 months of initial test	Diagnostic yield Adverse events
Canto et al. 2004	USA	38	FPC, PJS	EUS	EUS-FNA If high-risk: CT; ERCP*	Annually	Within 3-6 months of initial test	Diagnostic yield Adverse events
Canto et al. 2012	USA	216	BRCA2, FPC, PJS	MRI + CT + linear/radial EUS±FNA	-	Within 1-3 years	<3 months if no surgery; 6-12 months if small cyst or	Diagnostic yield Adverse events

Study	Country	N	Groups at risk of pancreatic cancer	Initial baseline test(s)	Test(s) conducted if abnormal initial baseline test(s) result	Frequency of follow up if normal result	Frequency of follow up if abnormal result	Outcomes
							worrisome lesion	
Chang et al. 2017c	Taiwan	303	FPC, BRCA2, HP	MRI/MRCP	EUS±FNA*	Every 2-3 years	Annually	Diagnostic yield Adverse events
Del Chiaro et al. 2015	Sweden	40	BRCA1, BRCA2, FPC, p16	MRI/MRCP	CT, EUS±FNA	Annually	6 months if unspecific or IPMN without indication for surgery	Diagnostic yield
Harinck et al. 2016/ Konings et al. 2016	Netherlands	166/140	CDKN2A, BRCA1, BRCA2, FPC, p53, PJS	EUS + MRI	-	Annually if normal or cystic lesion>10mm	3 months if unclear; 6 months if cyst or side-branch IPMN >10 mm and <30 mm without malignant features	Diagnostic yield Adverse events/ Quality of life
Kimmey et al. 2002	USA	46	FPC	EUS	ERCP	Not reported	-	Diagnostic yield Adverse events
Ludwig et al. 2011	USA	109	FPC, PJS	MRI/MRCP	EUS±FNA	Annually	-	Diagnostic yield Adverse events
Nicholson et al. 2015	UK	60	FPC, HP	ERCP with and without prophylaxisd	-	Not reported	-	Diagnostic yield Adverse events

Study	Country	N	Groups at risk of pancreatic cancer	Initial baseline test(s)	Test(s) conducted if abnormal initial baseline test(s) result	Frequency of follow up if normal result	Frequency of follow up if abnormal result	Outcomes
Poley et al. 2009	Netherlands	44	BRCA1, BRCA2, FPC, HP, p16, p53	EUS	CT, MRI	Not reported	EUS+MRI every 6 months for cystic lesions	Diagnostic yield Adverse events
Potjer et al. 2013	Germany (FaPaCa ^b)	125	FPC	MRI/MRCP + EUS	MRI/MRCP, EUS	Annually	After 3 months	Diagnostic yield
	Netherlands (Leiden ^b)	116	p16	MRI/MRCP, EUS*				
Sud et al. 2014	USA	30	FPC, HP, Lynch Syndrome, p16, PJS	EUS	EUS-FNA	Annually	-	Diagnostic yield Adverse events
Vasen et al. 2016	Netherlands (Leiden ^{b,e})	178	CDKNA2, p16	MRI/MRCP	EUS, CT	Annually	MRI/MRCP within 3-6 months if small lesion	Diagnostic yield Overall survival Adverse events
Verna et al. 2010c	USA	51	BRCA1, BRCA2, FPC, HP, p16, PJS, Other	Moderate risk: EUS±FNA or MRI; ERCP* High-risk: EUS±FNA + MRI; ERCP*	EUS±FNA and/or ERCP**	Annually if low or moderate risk; every 6 months if high risk	-	Diagnostic yield Adverse events
Zubarik et al. 2011	USA	546	BRCA2, FPC, PJS	CA 19-9	EUS-FNA	Annually if normal CA 19-9; After 3 months if normal EUS-FNA	-	Diagnostic yield

Notes: *, test was optional for participant; **, EUS±FNA and/or ERCP if it was not performed at baseline; \$, includes detection at baseline and follow up; ^, Results include only pancreatic neoplasms that were pathologically proven via histology or cytology; a, 'Diagnostic yield' defined as detection of any pathologically-proven malignant or premalignant lesion (PanIN≥2, IPMN and pancreatic adenocarcinoma), or lesions that are morphologically suspicious for BD-IPMNs; b, Multisite study. In FaPaCa

1
2
3

1 *program, from 2002-2010, participants received annual screening with MRI/MRCP and EUS; from 2011 onwards, participants received annual MRI/MRCP with EUS*
2 *every 3 years. In Leiden program, participants from 2011 onwards were given option of having EUS. See evidence table (Appendix 4) for further details; c, study*
3 *included individuals at low risk (i.e. <5% compared to normal population/1 relative of any degree with PC more than 55 years-old). Data presented only for high- and*
4 *moderate-risk individuals; diagnostic yield including low-risk groups was 15/303 in Chang et al. 2017 and 6/46 in Verna et al 2010; d, participants in this study were*
5 *part of EUROPAC registry and received CT or MRI (and EUS for FPC group. ERCP was optional; e, Data presented only for Leiden CDKN2A/p16 cohort. Updated*
6 *results for FPC and BRCA cohorts reported in Bartsch et al. 2017.*

7 *Abbreviations: BRCA, breast cancer susceptibility gene; CDKN2A, cyclin dependent kinase inhibitor 2A; CT, computed tomography; EUS-endoscopic ultrasonography; EUS-*
8 *FNA, endoscopic ultrasound-guided fine-needle aspiration; ERCP, endoscopic retrograde cholangiopancreatography; FPC, familial pancreatic cancer; HP, hereditary*
9 *pancreatitis; p16, hereditary multiple mole melanoma syndrome; p53, Li-Fraumeni Syndrome; PALB2, partner and localiser of BRCA2; PC, pancreatic cancer; MRI,*
10 *magnetic resonance imaging; MRI-CT, MRI with contrast, multiphase contrast-enhanced CT; MRCP, magnetic resonance cholangiopancreatography; FDG-PET/CT,*
11 *positron emission tomography-computed tomography; PJS, Peutz-Jeghers Syndrome (LKB1).*

12
13
14

1 5.4.4 Clinical evidence profile

2 5.4.4.1 Screening/surveillance studies

35.4.4.1.1 Narrative summary of evidence

4 The majority of the 17 studies were in adults with familial pancreatic cancer, the majority of
5 which also included relatively small numbers of individuals with identified germline mutations
6 such as BRCA, p16 or p53. The majority of the participants were female, ranging from 55%
7 to 75% of the samples (approximately 60% female across 15 studies). One study did not
8 report patient characteristics, and in 1 study this information was unclear. Nine studies were
9 conducted in the USA/Canada, 6 in Europe (2 of which were international multicentre
10 studies), and 1 in Taiwan. Only 1 study was conducted in the UK (Nicholson et al. 2015).

11 The most common initial screening test in the 17 published studies was MRI/MRCP with or
12 without additional EUS (8 studies), whilst the most common test given an abnormal initial
13 result was EUS±FNA (10 studies). Three screening programs did not use a subsequent test
14 given an abnormal result. Fifteen of the articles included only individuals with at least a 5% or
15 more increased risk of pancreatic cancer compared to those in the normal population, whilst
16 two of the studies included individuals at 'average' risk of pancreatic cancer.

17 The diagnostic yield reported in the identified screening/surveillance studies varied widely,
18 ranging from 0.9% to 39%, depending on the type of malignant or premalignant lesion
19 identified, the population and reference test (e.g. surgical pathology only) employed, whether
20 additional tests were conducted given initial abnormal results, and whether results included
21 baseline results only or included follow up.

22 Of the 2661 individuals at risk, 2418 were screened: 41 (1.7%) of these were diagnosed with
23 pancreatic cancer, resulting in an overall screening efficiency of 59 screened individuals to
24 detect 1 case of pancreatic cancer. If individuals with premalignant lesions are included (i.e.
25 those with IPMN and/or PanIN \geq 2), 145 individuals (including those with pancreatic cancer)
26 were identified, resulting in a screening efficiency of 6.0% (1 malignant or premalignant
27 lesions for every 17 individuals at risk screened). This suggests that screening high- and
28 moderate- individuals at risk for malignant lesions only will be both costly and time
29 consuming and that screening programs should include premalignant lesions.

30 Only 1 study (Vasen et al. 2016), which evaluated the diagnostic yield of MRI/MRCP,
31 reported overall survival (a 5-year overall survival of 24% for the CDKN2A/p16 cohort with
32 pancreatic ductal adenocarcinoma). Very few adverse events as a result of participating in
33 the screening/surveillance programs were reported in the 13 studies that reported procedure-
34 related complications. The majority of these were reported in 1 study (Canto et al. 2006) or
35 were related to post-ERCP pancreatitis. Although no studies were found that reported health-
36 related quality of life, there was 1 secondary study (Konings et al. 2016) related to
37 participation in the screening/surveillance program reported in Harinck et al. 2016
38 (comprising EUS and MRI), that reported significant decreases in worry associated with
39 having cancer (approximately 0.5 point decrease on the Cancer Worry Scale) for every year
40 enrolled in the program. However, participants in this study reported no significant change in
41 depression and anxiety.

42 The risk of bias and indirectness for each study was generally low for both quality measures
43 with the exception of 2 studies (Canto et al. 2012; Ludwig et al. 2011) both of which had an
44 unclear risk of bias. Overall, the majority of the studies were of 'high' quality (rated as ++),
45 with the aforementioned 2 studies rated as 'low' (+) quality. Generally it was not clear
46 whether the reference test(s) was interpreted without knowledge of the index test(s) results.

47 A summary of the evidence for this review question is presented in Table 55.

1 Table 55: Summary of evidence and quality evaluation

Study	Risk of bias	Indirectness	Overall study quality ^a	Diagnostic yield ^b	Other outcomes
Al-Sukhni et al. 2012	LOW	LOW	++	19/262 (1.1%)\$	Not reported
Bartsch et al. 2016	LOW	LOW	++	15/253 (5.9%) [^] , \$	No MRI- nor EUS-related complications
Canto et al. 2006	LOW	LOW	++	8/78 (10.3%) [^] , \$	No severe EUS/EUS-FNA complications Mild post-EUS/EUS-FNA abdominal pain=22/78 Other mild adverse events=2 Post-ERCP pancreatitis=5/67 No significant post-operative complications
Canto et al. 2004	LOW	LOW	++	2/38 (5.3%) [^]	No post-EUS-FNA complications. Mild post-ERCP pancreatitis=2/24
Canto et al. 2012	UNCLEAR	LOW	+c	5/216 (2.3%) [^] 85/216 (39.4%)\$	No surgery-related complications
Chang et al. 2017	LOW	LOW	++	6/131c (4.6%) [^] , \$	No procedure-related complications
Del Chiaro et al. 2015	LOW	LOW	++	5/40 (12.5%) [^] , \$	Not reported
Harinck et al. 2016/ Konings et al. 2016	LOW	LOW	++	9/139 (6.4%)	No procedure-related complications Significant improvement on Cancer Worry Scale (decrease of 0.5 point every year); mean score=13 (sd 3.6) No significant change on depression scores (HADS-D) over time; mean score=2.8 (sd 3.2); 5% of participants had clinically significant scores (HADS-D>10)

Study	Risk of bias	Indirectness	Overall study quality ^a	Diagnostic yield ^b	Other outcomes
					No significant change on anxiety scores (HADS-A) over time; mean score=4.5 (sd 3.7); 7% of participants had clinically significant scores (HADS-A>10)
Kimme et al. 2002	LOW	LOW	++	12/46 (26.0%) [^] , \$	No post-ERCP complications (0/28)
Ludwig et al. 2011	UNCLEAR	LOW	+d	9/109 (8.3%)\$	No procedure-related complications
Nicholson et al. 2015	LOW	LOW	++	2/60 (3.3%) [^]	Post-ERCP pancreatitis=13 cases in 56 procedures (No prophylaxis group=7 cases in 16 procedures; Prophylaxis group=6 in 40 procedures) Post-ERCP duodenal perforation=1
Poley et al. 2009	LOW	LOW	++	10/44 (23.0%)	No EUS-related complications
Potjer et al. 2013	LOW	LOW	++	FPC: 7/125 (5.6%) [^] , \$	Not reported
			++	p16: 7/116 (6.0%) [^] , \$	
Sud et al. 2014	LOW	LOW	++	3/16 (18.8%) [^] , \$	No EUS-related complications
Vasen et al. 2016	LOW	LOW	++	15/178 ^e (8.4%) [^] , \$	No procedure-related complications Resection rate of 75% and 5-year survival rate of 24% for p16 cohort with PDAC
Verna et al. 2010	LOW	LOW	++	6/46c (13.0%) [^]	No procedure-related complications
Zubarik et al. 2011	LOW	LOW	++	5/546 (0.9%) [^] , \$	Not reported

1 Notes: Data on diagnostic yield is not amenable to evaluation of imprecision and inconsistency and so are not applicable. \$, includes detection at baseline and follow up; ^, Results include only pancreatic neoplasms that were pathologically proven via histology or cytology; a, Since a meta-analysis was not possible, overall study quality

1 was assessed using the following method: ‘++’ indicates that all or most of the QUADAS-2 checklist criteria were fulfilled, and where they were not fulfilled the
2 conclusions are unlikely to alter; ‘+’ indicates that some of the QUADAS-2 checklist criteria were fulfilled, and whether they were not fulfilled or not adequately
3 described, the conclusions are unlikely to alter; ‘-’ indicates that few or none of the checklist criteria were fulfilled and the conclusions are likely to alter; b, ‘Diagnostic
4 yield’, in line with the definition suggested by the CAPS Consortium summit (Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J. W., Kamel, I., & Levy,
5 M. J. (2013). International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic
6 cancer. *Gut*, 62(3), 339-347.), is defined as detection of any pathologically-proven malignant or premalignant lesion (PanIN \geq 2, IPMN and pancreatic adenocarcinoma),
7 or lesion that is morphologically suspicious for BD-IPMNs; c, study included individuals at low risk (i.e. <5% compared to normal population/1 relative of any degree
8 with PC more than 55 years-old). Data presented only for high- and moderate-risk individuals; diagnostic yield including low-risk groups was 15/303 (5.0%) in Chang et
9 al. 2017 and 6/51 (11.8%) in Verna et al 2010; d, there was 4% dropout rate. Participants were included in the data for diagnostic yield if they had an abnormal result
10 on any one of the index texts (MRI, CT or EUS \pm FNA). Ten percent of the sample received initial CT rather than MRI/MRCP; e, Data presented only for Leiden
11 CDKNA2/p16 cohort. Updated results for FPC and BRCA cohorts reported in Bartsch et al. 2017.

12

13

1 **5.4.4.2 ERCP with prophylaxis versus ERCP only**

2 **Table 56: Summary clinical evidence profile for ERCP with prophylaxis versus ERCP**
 3 **only on reducing post-ERCP pancreatitis in people at high risk of pancreatic**
 4 **cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	ERCP only	ERCP with prophylaxis				
# ERCP procedures resulting in pancreatitis - Familial Pancreatic Cancer group	438 per 1000 ¹	149 per 1000 (61 to 376) ¹	RR 0.34 (0.14 to 0.86)	48 (1 study)	⊕⊖⊖⊖ very low ^{2,3}	There were no cases of pancreatitis in hereditary pancreatitis subgroup in either prophylaxis or no prophylaxis group.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Data/relative effect is given in terms of number of cases of post-ERCP pancreatitis relative to number of ERCP procedures (n=56) (rather than number of patients [n=48]).
 2 Nicholson et al. (2015): Unclear risk of selection bias (study period of 13 years, groups not matched, confounders not controlled for); unclear selective reporting (adverse events reported by number of ERCP procedures rather than number of events per patient). [Risk of bias assessed using Newcastle-Ottawa Scale for assessing quality of nonrandomised studies].
 3 95% CI crosses 1 default MID (0.8 or 1.25).

5 **5.4.5 Economic evidence**

6 A literature review of published cost effectiveness analyses did not identify any relevant
 7 studies for this topic. Although there were potential implications for resource use associated
 8 with making recommendations in this area, other topics in the guideline were agreed as a
 9 higher economic priority. Consequently, bespoke economic modelling was not done for this
 10 topic.

11 **5.4.6 Evidence Statements**

12 **5.4.6.1 Screening/surveillance studies**

13 **Diagnostic yield**

14 There was inconsistent evidence from 17 prospective cohort studies (n=2661) on the
 15 diagnostic yield – i.e. early diagnosis or identification of malignant and premalignant
 16 pancreatic lesions - of pancreatic cancer screening/surveillance programs in high- and
 17 moderate- risk adults. Although the majority of the studies reporting the results of these
 18 programs were of high (++) quality and used pathological diagnosis, the diagnostic yield was
 19 highly variable, ranging from 0.9% to 39%. This variability is likely dependent on the initial
 20 index tests on the subgroups (e.g. breast cancer susceptibility gene, p16, p53) and types of

1 lesion included in the samples recruited by the programs. The overall screening efficiency of
2 the programs, which were mainly conducted in the USA, in detecting pancreatic cancer was
3 1.7% (1 detected case of pancreatic cancer for every 59 individuals at risk screened or
4 monitored) and 6.0% if premalignant lesions (IPMN and PanIN \geq 2) are included (1 detected
5 case for every 16 individuals at risk screened or monitored).

6 **Overall survival**

7 No evidence was identified to inform this outcome.

8 **Adverse events**

9 Eleven high (++) quality and 2 low (+) quality prospective cohort studies (n=1329) indicated
10 that the incidence of adverse events related to the tests used in the screening/surveillance
11 programs of high- and moderate-risk individuals was very low (<1% excluding post-ERCP
12 pancreatitis). The majority of the reported adverse events – 22 cases of post-test abdominal
13 pain (of 78 participants), and 5 cases of post-ERCP pancreatitis (of 65 participants) - were
14 from 1 'high' (++) quality study (Canto 2006) that combined EUS with CT as either the initial
15 index test or subsequent test given an initial abnormal finding. In the 3 studies (excluding
16 Nicholson 2015; see below) that utilised ERCP, there were 7 cases of post-ERCP
17 pancreatitis (5.9%) out of the 119 participants that received it.

18 **5.4.6.2 ERCP with prophylaxis vs ERCP only**

19 **Adverse events**

20 Very low quality evidence from 1 single centre prospective cohort study (n=48, 56 ERCP
21 procedures) showed that there is a clinically important difference favouring ERCP with
22 prophylaxis on reducing post-ERCP pancreatitis in people with familial pancreatic cancer
23 compared to ERCP without prophylaxis: RR 0.34 (95%CI, 0.14-0.86).

24 Very low quality evidence from 1 single centre prospective cohort study (n=12, 24 ERCP
25 procedures) showed no clinically important difference between ERCP with prophylaxis and
26 ERCP without prophylaxis in people with hereditary pancreatitis (there were no cases in
27 either group).

28 **5.4.7 Recommendations**

29

30 **13. Ask people with pancreatic cancer if any of their first-degree relatives has had it.**
31 **Address any concerns the person has about inherited risk.**

32 **14. Offer surveillance for pancreatic cancer to people with:**

- 33
- 34 • hereditary pancreatitis and a PRSS1 mutation
 - 35 • BRCA1, BRCA2, PALB2, or CDKN2A (p16) mutations, and one or more
36 first-degree relatives with pancreatic cancer
 - 37 • Peutz–Jeghers syndrome.

38 **15. Consider surveillance for pancreatic cancer for people with:**

- 39
- 40 • 2 or more first-degree relatives with pancreatic cancer, across 2 or more
41 generations
 - 42 • Lynch syndrome (mismatch repair gene [MLH1, MSH2, MSH6, or PMS2]
43 mutations) and any first-degree relatives with pancreatic cancer.

1 **16. Consider an MRI-MRCP or EUS for pancreatic cancer surveillance in people**
2 **without hereditary pancreatitis.**

3 **17. Consider a pancreatic protocol CT scan for pancreatic cancer surveillance in**
4 **people with hereditary pancreatitis and a PRSS1 mutation.**

5 **18. Do not offer EUS to detect pancreatic cancer in people with hereditary**
6 **pancreatitis.**

7 **5.4.8 Evidence to recommendations**

8 **5.4.8.1 Relative value placed on the outcomes considered**

9 Early diagnosis, survival, diagnostic accuracy (including sensitivity, specificity, positive
10 predictive value and negative predictive value), adverse events of interventions and health
11 related quality of life were considered to be the critical outcomes for this question.

12 Diagnostic yield was reported for all studies and adverse events were reported for the
13 majority of studies. Overall survival was only reported by one study and early diagnosis and
14 health-related quality of life were not reported.

15 **5.4.8.2 Quality of evidence**

16 The QUADAS-2 checklist was used to evaluate the risk of bias and applicability of the
17 screening or surveillance studies. Due to the type of data reported (diagnostic yield), the
18 criteria of inconsistency and imprecision were not evaluated for the screening or surveillance
19 studies. The GRADE risk of bias tool was used to evaluate the study that reported post-
20 ERCP pancreatitis with and without prophylaxis.

21 For screening or surveillance, there were high quality studies for diagnostic yield and overall
22 survival. The studies reporting adverse events were mostly high quality but with two low
23 quality studies. For ERCP with prophylaxis versus ERCP only, there was only low quality
24 evidence on adverse events.

25 **5.4.8.3 Consideration of clinical benefits and harms**

26 Based on their clinical knowledge, the committee noted that 5-10% of cases of pancreatic
27 cancer are caused by hereditary factors. Consequently they agreed that it was very important
28 to discuss family history with everyone who has pancreatic cancer so that people who have
29 any hereditary factors can be identified earlier.

30 The committee noted, based on the evidence, that there are certain groups of hereditary
31 factors that carry a higher risk of developing pancreatic cancer (an affected individual with
32 hereditary pancreatitis with a PRSS1 mutation; people who are BRCA1, BRCA2, PALB2 or
33 CDKN2A (p16) mutation carriers with one or more affected first-degree relatives with
34 pancreatic cancer; people with Peutz–Jeghers syndrome, regardless of family history). The
35 committee acknowledged that the data on survival were too limited to prove there is a
36 survival benefit of surveillance in these people. However, they noted the data from Vasen et
37 al (2016), who had surveilled individuals at high risk of pancreatic cancer, reported an overall
38 resection rate of 75% and overall survival at 5 years of 24% compared to a resection rate of
39 15% and 5-year survival rate of 4-7% for patients with sporadic symptomatic pancreatic
40 ductal adenocarcinoma. Since these figures are higher than what would normally be
41 expected for people with pancreatic cancer, the committee agreed these data were
42 suggestive that surveillance could confer benefits to survival outcomes.

43 The committee also noted that these hereditary factors are usually associated with very poor
44 prognosis which can cause a lot of anxiety to the people who have them. The committee

1 considered that offering surveillance to those people with hereditary factors that carry a
2 higher risk of developing pancreatic cancer, would help to resolve this anxiety. They also
3 agreed, based on their experience, that surveillance of these people should lead to earlier
4 diagnosis of pancreatic cancer and earlier treatment, which will help to improve the
5 experience of patients. They therefore agreed to recommend that people with these
6 hereditary factors should be offered surveillance for pancreatic cancer.

7 The committee also noted there are other groups of hereditary factors that carry an
8 increased risk of developing pancreatic cancer, but which are not classified as 'high risk'. The
9 committee agreed that there were likely to be benefits of surveillance for these people for
10 pancreatic cancer but the balance was less clear. They therefore agreed a weaker
11 recommendation for surveillance in people with first-degree relatives (FDRs) with pancreatic
12 cancer from a familial pancreatic cancer kindred with at least 2 FDRs in 2 or more
13 generations; people with mismatch repair gene (MLH1, MSH2, MSH6, PMS2) mutations
14 (Lynch syndrome) and one affected FDR with pancreatic cancer. This would be consistent
15 with the current [EUROPAC](#) registry entry requirements (unpublished) and the International
16 Cancer of the Pancreas Screening (CAPS) Consortium consensus statement on inherited
17 risk (Canto et al. 2013).

18 The committee agreed that the evidence on the diagnostic yield of CT, MRI and EUS in
19 surveillance had shown they were all accurate at identifying early tumours. However, from
20 the available evidence the committee could not identify which of these investigations was the
21 most effective. Given this uncertainty, the committee recommended further research to
22 evaluate the surveillance tests and frequency of surveillance that produce the greatest
23 diagnostic yield and overall surveillance efficiency. The Committee also noted that repeated
24 CT scanning would expose people to harms associated with radiation and therefore did not
25 want to recommend this as an option for people without hereditary pancreatitis in whom a
26 larger percentage of people would have a relatively smaller risk. However, they agreed that a
27 pancreatic protocol CT scan, for pancreatic cancer surveillance should be considered for
28 people with hereditary pancreatitis and a PRSS1 mutation who would be at higher risk of
29 developing pancreatic cancer.

30 Based on their clinical knowledge and experience, the committee noted that if a CT scan is
31 used (in people with hereditary pancreatitis) a pancreatic protocol CT scan would be needed
32 to ensure good visualisation of any pathology in the pancreas. They also agreed that if MRI
33 is used MRI-MRCP should be used as this will enable the pancreatic duct anatomy to be
34 visualised.

35 The committee noted, based on their knowledge and experience, that the fibrosis, distortion
36 and calcium deposits caused by hereditary pancreatitis prevent the detection of small
37 pancreatic tumours by EUS. They therefore agreed that EUS should not be used to detect
38 pancreatic cancer if the person has hereditary pancreatitis.

39 The committee noted that the data had shown ERCP with prophylaxis was better at reducing
40 post-ERCP pancreatitis in people with familial pancreatic cancer, compared to ERCP without
41 prophylaxis. However, given that the evidence was from a single, very low quality study the
42 committee agreed not to make a recommendation about this intervention.

43 The committee agreed that the potential benefits of the recommendations made would be
44 more directed and integrated management of people with hereditary factors, improved
45 detection of pre-malignant lesions and potential improvements in survival. They noted that
46 the recommendations for surveillance had the potential to both increase and decrease
47 anxiety of the person; knowing you are at high risk of developing pancreatic cancer may
48 increase anxiety which would hopefully be offset by being offered surveillance. However,
49 anxiety may also increase around the time that the surveillance occurs as you wait to find out
50 if you have developed pancreatic cancer or not. On balance, the committee agreed that the
51 potential benefits outweighed the harms.

1 **5.4.8.4 Consideration of economic benefits and harms**

2 The committee noted that no relevant published economic evaluations had been identified
3 and no additional economic analysis had been undertaken in this area.

4 Extending surveillance to individuals with two blood relatives affected by pancreatic cancer
5 would lead to an increase in resource use through increased imaging and health care
6 practitioners time. However, as for other recommendations in this area, only a small
7 proportion of people have an inherited elevated risk of developing pancreatic cancer and
8 consequently the overall resource impact would be small. It was also noted that surveillance
9 of these high risk individuals could lead to earlier intervention improving quality of life and
10 avoiding costs of adverse events and complications.

11 The committee agreed that the recommendations made were unlikely to have a significant
12 resource impact due to the small number of people who have an inherited risk of developing
13 pancreatic cancer.

14 **5.4.9 Research recommendations**

15 **1. Research should be undertaken to evaluate the most clinically effective and cost** 16 **effective initial surveillance tests, additional tests and frequency of surveillance** 17 **that produce the greatest diagnostic yield and overall surveillance efficiency.**

18 At the present time we do not know what the best initial surveillance and subsequent tests
19 are, nor the frequency of the surveillance that will produce the best diagnostic yield for
20 people with an inherited high risk of pancreatic cancer, whilst maintaining quality of life.
21 These will depend upon the accuracy of the tests available, the level of risk and the rate at
22 which the risk materialises.

23 Individuals with an inherited risk of pancreatic cancer have a highly variable risk dependent
24 on their particular genotype, each with a widely differing levels of risk, or the particular
25 phenotype each also with a variable level of risk. In each case there is a threshold of risk and
26 frequency of testing that would need to be determined to make surveillance effective.

27 **5.4.10 References**

28 Al-Sukhni W, Borgida A, Rothenmund H et al. (2012) Screening for pancreatic cancer in a
29 high-risk cohort: an eight-year experience. *Journal of Gastrointestinal Surgery* 16(4): 771-783

30 Bartsch DK, Slater EP, Carrato A et al. (2016) Refinement of screening for familial pancreatic
31 cancer. *Gut* 65(8): 1314-1321

32 Canto MI, Goggins M, Hruban RH et al. (2006) Screening for early pancreatic neoplasia in
33 high-risk individuals: a prospective controlled study. *Clinical Gastroenterology and*
34 *Hepatology* 4(6): 766-781

35 Canto MI, Goggins M, Yeo CJ et al. (2004). Screening for pancreatic neoplasia in high-risk
36 individuals: an EUS-based approach. *Clinical Gastroenterology and Hepatology* 2(7): 606-
37 621

38 Canto, MI, Harink, F, Hruban, RH et al. (2013). International Cancer of the Pancreas
39 Screening (CAPS) Consortium summit on the management of patients with increased risk for
40 familial pancreatic cancer. *Gut* 62(3): 339-347

41 Canto MI, Hruban RH, Fishman EK et al. (2012) Frequent detection of pancreatic lesions in
42 asymptomatic high-risk individuals. *Gastroenterology* 142(4): 796-804.

- 1 Chang MC, Wu CH, Yang SH et al. (2017) Pancreatic cancer screening in different risk
2 individuals with family history of pancreatic cancer-a prospective cohort study in Taiwan.
3 American Journal of Cancer Research 7(2): 357
- 4 Del Chiaro M, Verbeke CS, Kartalis N et al. (2015) Short-term Results of a Magnetic
5 Resonance Imaging–Based Swedish Screening Program for Individuals at Risk for
6 Pancreatic Cancer. JAMA Surgery 150(6): 512-518
- 7 Harinck F, Konings IC, Kluijt I et al. (2016) A multicentre comparative prospective blinded
8 analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals. Gut
9 65(9): 1505-1513
- 10 Kimmey MB, Bronner MP, Byrd DR et al. (2002) Screening and surveillance for hereditary
11 pancreatic cancer. Gastrointestinal Endoscopy 56(4): S82-S86
- 12 Konings IC, Sidharta GN, Harinck, F et al. (2015) Repeated participation in pancreatic cancer
13 surveillance by high-risk individuals imposes low psychological burden. Psycho-Oncology
14 25(8): 971-978
- 15 Ludwig E, Olson SH, Bayuga S et al. (2011) Feasibility and yield of screening in relatives
16 from familial pancreatic cancer families. The American Journal of Gastroenterology 106(5):
17 946-954
- 18 Nicholson JA, Greenhalf W, Jackson R et al. (2015) Incidence of post-ERCP pancreatitis
19 from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer
20 before and after the introduction of prophylactic pancreatic stents and rectal diclofenac.
21 Pancreas 44(2): 260-265
- 22 Poley JW, Kluijt I, Gouma DJ et al. (2009) The yield of first-time endoscopic ultrasonography
23 in screening individuals at a high risk of developing pancreatic cancer. The American Journal
24 of Gastroenterology 104(9): 2175-2181
- 25 Potjer TP, Schot I, Langer P et al. (2013) Variation in precursor lesions of pancreatic cancer
26 among high-risk groups. Clinical Cancer Research 19(2): 442-449.
- 27 Sud A, Wham D, Catalano M et al. (2014) Promising outcomes of screening for pancreatic
28 cancer by genetic testing and endoscopic ultrasound. Pancreas 43(3): 458-461
- 29 Vasen H, Ibrahim I, Ponce CG et al. (2016) Benefit of surveillance for pancreatic cancer in
30 high-risk individuals: outcome of long-term prospective follow-up studies from three
31 European expert centers. Journal of Clinical Oncology 34(17): 2010-2019
- 32 Verna EC, Hwang C, Stevens PD et al. (2010) Pancreatic cancer screening in a prospective
33 cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clinical
34 Cancer Research 16(20): 5028-5037
- 35 Zubarik R, Gordon SR, Lidofsky, SD et al. (2011) Screening for pancreatic cancer in a high-
36 risk population with serum CA 19-9 and targeted EUS: a feasibility study. Gastrointestinal
37 Endoscopy 74(1): 87-95

6 Referral to specialist multidisciplinary teams

Review question: Does referral of all adults with suspected pancreatic cancer to a specialist MDT for review improve patient management and outcomes?

6.1 Introduction

Central to the UK's cancer services are multidisciplinary teams (MDTs). Before the introduction of multidisciplinary team working, a cancer patient's care was often determined solely by one clinician. Care at this time was characterised by unequal access to specialist care, disjointed referrals, and missed opportunities for adjuvant treatment. Variation in treatment uptake, caseload for each clinician and ultimately in outcomes for patients was widespread.

An MDT approach was enshrined in England's Cancer Plan in 2000 and was rapidly adopted across the UK. MDT working was officially included in national guidance in 2004. This stated that all patients newly diagnosed with cancer in England should be discussed at an MDT meeting. The 2015 cancer strategy for England described MDTs as the 'gold standard' for cancer patient management. However, recognising the significant challenges faced by MDTs today, the strategy also made several recommendations to streamline MDT working.

Given the widespread use of MDTs and the complex nature of healthcare systems, it is extremely difficult to robustly assess the impact of introducing MDT working. There is some limited evidence to link decision-making through MDT working to improved survival for some cancer types.

Guidance is needed on whether review by a specialist MDT, for people with suspected pancreatic cancer, improves patient management and outcomes.

6.1.1 Review protocol summary

The review protocol summary used for this question can be found in Table 57. Full details of the review protocol can be found in Appendix C.

Table 57: Clinical review protocol summary for the review of specialist versus local MDTs

Population	Adults with suspected pancreatic cancer Stage <ul style="list-style-type: none"> • I • II • III • IV
Intervention	Referral by region to <ul style="list-style-type: none"> • Specialist pancreatic MDT • Local MDT
Comparison	Each Other
Outcomes	<ul style="list-style-type: none"> • Survival Outcomes • Proportion receiving chemotherapy • Entry into clinical trials • Resection rates • Post-operative mortality

- Patient Satisfaction
- Quality of Life

1 **6.2 Description of the clinical evidence**

2 No relevant studies were identified for this review question.

3 Further information about the search strategy can be found in Appendix D. See study
4 selection flow chart in Appendix E, and list of excluded studies in Appendix G.

5 **6.3 Summary of included studies**

6 No relevant studies were identified for this review question.

7 **6.4 Clinical evidence profile**

8 No relevant studies were identified for this review question.

9 **6.5 Economic evidence**

10 A literature review of published cost effectiveness analyses did not identify any relevant
11 studies for this topic. Although there were potential implications for resource use associated
12 with making recommendations in this area, other topics in the guideline were agreed as a
13 higher economic priority. Consequently, bespoke economic modelling was not done for this
14 topic.

15 **6.6 Evidence statements**

16 No relevant studies were identified for this review question.

17 **6.7 Recommendations**

18 **19. A specialist pancreatic cancer multidisciplinary team should decide what care is**
19 **needed, and involve the person with suspected or confirmed pancreatic cancer in**
20 **the decision. Care should be delivered in partnership with local cancer units.**

21 **6.8 Evidence to recommendations**

22 **6.8.1 Relative value placed on the outcomes considered**

23 Survival outcomes, proportion of people receiving chemotherapy, entry into clinical trials,
24 resection rates, post-operative mortality, patient satisfaction and quality of life were the
25 critical outcomes for this question. None of these outcomes were reported.

26 **6.8.2 Quality of evidence**

27 No evidence was identified that met the inclusion criteria for this question. Therefore the
28 committee made recommendations based on their knowledge and experience.

29 **6.8.3 Consideration of clinical benefits and harms**

30 Based on their knowledge and experience, the committee agreed that people with pancreatic
31 cancer have multiple, complex needs which would be optimally managed by early referral to

1 a specialist multidisciplinary approach that ensures a range of opinions by specialists are
2 considered and that surgery is centralised . The pancreatic-cancer specific expertise
3 available at a specialist MDT, compared with a local MDT, means that there would be more
4 access to novel treatments and a greater knowledge of relevant ongoing clinical trials that
5 patients can be recruited to. It would also provide an opportunity for people to access
6 specialist pancreatic cancer nutritional assessment and intervention. In addition, people often
7 report that they would prefer their case to be discussed by a specialist MDT as this provides
8 reassurance that they are receiving specialist input on potential relevant treatments, this is
9 something that is particularly important given the poor prognosis of this cancer.

10 The committee were also aware that there are likely to be some people for whom it would be
11 advantageous for their management to be undertaken by a local MDT, for example those
12 who have very advanced disease and are very poorly. They discussed whether it would be
13 possible for the specialist MDT to issue a protocol for the management of these people.
14 However, it was noted that doing so could lead to the local MDT simply following the protocol
15 and not involving the specialist MDT at all which would not be appropriate. They agreed that
16 for these people, the specialist MDT should determine the management protocol, but that
17 this management could be delivered locally.

18 Given these factors and that referral to, and management by, specialist MDTs has already
19 been recommended by the Improving Outcomes in Upper Gastro-intestinal Cancers
20 guidance, and is part of peer review measures, the committee agreed to make a strong
21 recommendation that all people with a suspected or confirmed diagnosis of pancreatic
22 cancer should have their management determined by a specialist pancreatic cancer MDT.

23 The committee agreed that making this recommendation would help to standardise the
24 quality of care and the involvement of specialists should help to improve patient outcomes.
25 No potential harms of these recommendations were identified.

26 **6.8.4 Consideration of economic benefits and harms**

27 Specialist pancreatic cancer MDTs already exist so there should not be any additional costs
28 to set them up. The recommendations will increase the number of people who are discussed
29 by the specialist MDT. These specialist MDTs can develop pathways to make the discussion
30 in the MDT more efficient so the time needed to discuss patients is unlikely to significantly
31 increase. However, should there be an increase in discussion time, the committee agreed
32 that the discussion by specialists within the MDTs would lead to better management
33 decisions resulting in downstream cost savings that would offset any additional costs from
34 increased discussion time.

35 **6.9 References**

36 No relevant studies were identified for this review question.

37

38

7 Staging

Review question: What is the most effective investigative pathway for staging adults with newly diagnosed pancreatic cancer or a non-definitive diagnostic result as resectable, borderline resectable, locally advanced or metastatic disease?

7.1 Introduction

Pancreatic cancer is one of the most difficult cancers to stage accurately but given that surgical resection is the only potential cure it is vital that an accurate staging of the disease at the time of diagnosis can be obtained. Accurate staging is very important to avoid unsuccessful surgical intervention and a failure to resect the pancreatic tumour. Staging of pancreatic cancer can be undertaken by multiple imaging modalities including pancreatic CT, MRI, CT-PET and endoscopic ultrasound, both in isolation and using various combinations.

Guidance is needed the best investigative pathway to accurately stage people with pancreatic cancer.

7.1.1 Review protocol summary

The review protocol summary used for this question can be found in Table 58. Full details of the review protocol can be found in Appendix C.

Table 58: Clinical review protocol summary for the review of most effective investigative pathway for staging adults with pancreatic cancer

Population	Adults with newly diagnosed pancreatic cancer or a non-definitive diagnostic result
Index Test	Investigative pathways including combinations of: <ul style="list-style-type: none"> • Imaging (MRI/MRCP, FDG-PET/CT, CT, Ultrasound, EUS) • Laparoscopy (with or without ultrasound) • CA 19–9 • Histology • cytology
Reference Standard	<ul style="list-style-type: none"> • Each Other • Histological TNM classification • Surgery
Outcomes	Diagnostic test accuracy data (diagnostic accuracy, sensitivity, specificity, positive predictive value, negative predictive value) for the following outcomes: <ul style="list-style-type: none"> • Precise Staging • N Staging • M Staging • Resectability • Vascular invasion • Adverse events
Study design	<ul style="list-style-type: none"> • Prospective diagnostic test accuracy studies (including retrospective reviews of prospective studies)

- Systematic reviews of diagnostic test accuracy studies
- Sample size ≥ 50 patients

1 7.2 Description of clinical evidence

2 Thirty-two datasets in 30 observational studies (including 23 prospective cohort studies and 7
3 retrospective reviews of prospective databases) were identified. The majority of studies
4 reported data on the ability of the relevant imaging test (mainly CT) to determine resectability
5 and were in adults with suspected pancreatic cancer who had had prior imaging tests (also
6 predominantly CT). The majority of studies also used a histopathological reference standard
7 but did not report TNM classification. A summary of the included studies is presented in
8 Table 59.

9 Three studies (n=660) were identified that reported diagnostic accuracy data of imaging tests
10 on overall TNM staging of pancreatic tumours (Shami et al. 2011; Soriano et al. 2004). One
11 study (Shami et al. 2011) compared EUS-FNA and MRI, 1 study (Soriano et al. 2004)
12 compared CT, EUS and MRI, whilst 1 study compared MDCT and FDG-PET/CT (Ghaneh et
13 al. 2018). The main aim of the latter study, known as PET-PANC, was to assess - in a
14 multicentre setting and using a standardised protocol - whether the addition of FDG-PET/CT
15 to MDCT, which is standard practice in the UK, provides tangible diagnostic and staging
16 benefits.

17 Sixteen studies were identified that reported diagnostic accuracy data on imaging tests on
18 resectability (DeWitt et al. 2004; Doucas et al. 2007; Fang et al. 2012; Frstrup et al. 2006;
19 Furukawa et al. 2008; Imbriaco et al. 2005; Klauss et al. 2008; Koelblinger et al. (2011);
20 Kwon et al. 2002; Mansfield et al. 2008; Minniti et al. 2003; Phoa et al. 2005; Schacter et al.
21 2000; Shah et al. 2008; Soriano et al. 2004; Taylor et al. 2001). Twelve studies (n=768)
22 evaluated CT (DeWitt et al. 2004; Doucas et al. 2007; Fang et al. 2012; Furukawa et al.
23 2008; Imbriaco et al. 2005; Klauss et al. 2008; Koelblinger et al. (2011); Mansfield et al.
24 2008; Minniti et al. 2003; Phoa et al. 2005; Soriano et al. 2004; Taylor et al. 2001). There
25 were a sufficient number of studies on the ability of CT to determine resectability to enable a
26 meta-analysis, as well as a subgroup analysis comparing the studies whose participants had
27 prior imaging with those who did not. One study (n=64) evaluated abdominal ultrasound
28 (Minniti et al. 2003), 1 study (n=57) evaluated CT-3D (Fang et al. 2012), 3 studies (n=191)
29 evaluated EUS (DeWitt et al. 2004; Mansfield et al. 2008; Soriano et al. 2004), and 3 studies
30 (n=) evaluated MRI (Fischer et al. 2002; Koelblinger et al. 2011; Soriano et al. 2004). One
31 study (n=52 to 59; Soriano et al. 2004) also evaluated three combinations of CT and EUS:
32 CT and EUS, CT and EUS only if deemed resectable on CT, and EUS and CT only if
33 deemed resectable on EUS. Six studies (n=278) evaluated the accuracy of laparoscopy with
34 laparoscopic ultrasound (Doucas et al. 2007; Frstrup et al. 2006; Kwon et al. 2002; Schacter
35 et al. 2000; Shah et al. 2008; Taylor et al. 2001). A meta-analysis was also conducted on
36 laparoscopy with laparoscopic ultrasound.

37 Three studies (n=138) were identified that reported diagnostic accuracy data of imaging tests
38 on tumour or T staging (DeWitt et al. 2004; Maluf-Filho et al. 2004; Soriano et al. 2004). Two
39 studies compared CT and EUS (DeWitt et al. 2004; Maluf-Filho et al. 2004), whilst 1 study
40 compared CT, EUS and MRI (Soriano et al. 2004).

41 Eight studies were identified that reported diagnostic accuracy data of imaging tests on
42 lymph node or N staging (DeWitt et al. 2004; Furukawa et al. 2008; Klek et al. 2004; Lemke,
43 et al. 2004; Mansfield et al. 2008; Roche et al. 2003; Soriano et al. 2004; Yoneyama et al.
44 2014). Seven studies (n=329) evaluated the accuracy of CT (DeWitt et al. 2004; Furukawa et
45 al. 2008; Klek et al. 2004; Lemke et al. 2004; Mansfield et al. 2008; Roche et al. 2003;
46 Soriano et al. 2004). There was a sufficient number of studies to conduct a meta-analysis of
47 the ability of CT to detect nodal involvement. One study (n=126) evaluated abdominal
48 ultrasound (Klek et al. 2004), 3 studies (n=187) evaluated EUS (DeWitt et al. 2004; Mansfield

1 et al. 2008; Soriano et al. 2004), 1 study (n=53) evaluated MRI (Soriano et al. 2004), and 2
2 studies (n=195) evaluated FDG-PET/CT (Lemke et al. 2004; Yoneyama et al. 2014). One
3 study calculated the diagnostic test accuracy of CT using the number of lymph nodes
4 deemed to have nodal involvement (Roche et al. 2003), with the remaining 7 studies using
5 the number of participants deemed to have such involvement

6 Five studies were identified that reported diagnostic accuracy data on imaging tests on
7 metastatic or M staging. Two studies (n=141) evaluated the accuracy of CT (Farma et al.
8 2008; Soriano et al. 2004), 1 study (n=52) evaluated EUS (Soriano et al. 2004), 1 study
9 (n=53) evaluated MRI (Soriano et al. 2004), 2 studies (n=177) evaluated FDG-PET/CT
10 (Farma et al. 2008; Yoneyama et al. 2014), and 1 study (n=82) evaluated CT combined with
11 FDG-PET/CT (Farma et al. 2008). Two studies (n=164) evaluated staging information
12 provided by diagnostic laparoscopy conducted on participants with no evidence of metastasis
13 on CT (Liu & Traverso 2005; White et al. 2001).

14 Five studies were identified that reported diagnostic accuracy data on imaging tests on the
15 extent of vascular invasion (Klauss et al. 2007; Klek et al. 2004; Lemke, et al. 2004; Soriano
16 et al. 2004; Tellez-Avila et al. 2012). All five of these studies (n=409) evaluated the accuracy
17 of CT, thus enabling a meta-analysis of these studies. Two studies (n=102) also evaluated
18 EUS (Soriano et al. 2004; Tellez-Avila et al. 2012), 1 study (n=126) evaluated abdominal US
19 (Klek et al. 2004), 1 study (n=53) evaluated MRI (Soriano et al. 2004) and 1 study (n=47)
20 evaluated FDG-PET/CT (Lemke et al. 2004).

21 Two studies were identified that reported diagnostic accuracy data on the tumour marker CA
22 19-9 with a threshold of 130 kU/ml as an indication for laparoscopic resectability in
23 participants who had prior imaging (Connor et al. 2005; Maithel et al. 2008). One of these
24 studies also examined the accuracy of CA 19-9 in those with and without jaundice (Connor et
25 al. 2005).

26 Positive and likelihood ratios were calculated, where appropriate, from the raw diagnostic
27 test accuracy data or the estimated sensitivity and specificity of the studies to enable
28 evaluation of the relevant tests. The QUADAS-2 checklist was used to evaluate the risk of
29 bias and indirectness (applicability) of the studies.

30 Further information about the search strategy can be found in Appendix D. See study
31 selection flow chart in Appendix E, single and multiple test ROC curves and forest plots in
32 Appendix H, summary of QUADAS-2 study quality evaluations in Appendix J, study evidence
33 tables in Appendix F and list of excluded studies in Appendix G.

34

35

1 7.3 Summary of included studies

2 A summary of the studies that were included in this review is presented in Table 59.

3 **Table 59: Summary of included studies**

Study	Sample N	Prior imaging test(s)	Index test N	Index test(s)	Reference standard	Outcome
Connor et al. 2005a	159 potentially resectable PC	CE CT	159	CA 19-9	Laparoscopy + LUS	Resectability
DeWitt et al. 2004	120 suspected or recently diagnosed PC	-	104	MDCT EUS	Surgical histopathology or EUS-FNA/previous cytology and clinical FU	T Staging N Staging Resectability
Doucas et al. 2006	100 suspected PC	-	94	CT	Laparoscopy + LUS, surgical histopathology + clinical FU	Resectability
		CT	65 potentially resectable	Laparoscopy + LUS	Surgical histopathology + clinical FU	
Fang et al. 2012	80 confirmed pancreatic or periampullary tumours	-	57 confirmed PAC	MDCT MDCT-3D	Surgical histopathology	Resectability
Farma et al. 2008a	83 suspected PC	-	82	CT FDG-PET/CT CT + FDG-PET/CT	Histopathology (Percutaneous or EUS-Core, or EUS-FNA)	M Staging
Fischer et al. 2002	99 suspected PC	CT and/or US	29 pancreatic head tumours	MRI	Surgical histopathology	Resectability
			36 solid tumours	MRI		
Fristrup et al. 2006	146 potentially resectable PC	CT or US	52 (after EUS screening)	Laparoscopy with LUS	Surgery	Resectability

Study	Sample N	Prior imaging test(s)	Index test N	Index test(s)	Reference standard	Outcome
Furukawa et al. 2008	213 confirmed PDAC	-	213	MDCT	Surgical histopathology	N Staging Resectability
Ghaneh et al. 2018	619 suspected PC	MDCT	393	FDG-PET/CT	Surgical histopathology or clinical FU	Overall TNM Stage
Imbriaco et al. 2005	71 suspected PC	ERCP or US	71	MDCT	Surgical histopathology or percutaneous FNA and clinical FU	Resectability
Klauss et al. 2007	80 suspected PC	CT or US	80	CE-MDCT + invasion score	Surgery, surgical histopathology or biopsy	Resectability Vascular invasion
Klęk et al. 2004	140 suspected PC	-	126 confirmed PC	CT US (Routine, Power, Colour, 3D)	Post-operative histopathology	N Staging Vascular invasion
Koelblinger et al. 2011	89 suspected PC	CT or US	23 potentially resectable	MDCT MRI	Surgery, surgical histopathology, CT-/US-guided biopsy, imaging or clinical FU	Resectability
Kwon et al. 2002	118 suspected PC	Angiography, CT, ERCP, MRI, and/or US	52 potentially resectable	Laparoscopy with LUS	Surgery, surgical histopathology or LUS	Resectability
Lemke et al. 2004	104 suspected PC	-	100	MSCT FDG-PET/CT	Histopathology or clinical FU	N Staging Vascular invasion
Liu & Traverso 2005a	74 locally advanced, unresectable PAC	-	74	CT	Laparoscopy	M Staging
Maithel et al. 2008a	491 potentially resectable PC	CT or MRI	262	CA 19-9	Laparoscopy/surgery	Resectability
Maluf-Filho et al. 2004	61 suspected pancreatic or ampullary tumours	US or CT	27 confirmed PC	Spiral CT EUS	Surgical histopathology or biopsy from	T Staging

Study	Sample N	Prior imaging test(s)	Index test N	Index test(s)	Reference standard	Outcome
					laparotomy or EUS-FNA	
Mansfield et al. 2008	84 suspected pancreatic tumours ^b	-	35 potentially resectable	EUS MSCT	Surgical histopathology	Resectability
					Histology	N Staging
Minniti et al. 2003	108 suspected PC	CT or MRI	64	Abdominal US Helical CT	Surgical or post-operative histopathology	Resectability Vascular + arterial invasion
Phoa et al. 2005	72 suspected PC	-	71	MSCT	Surgical histopathology	Resectability
Roche et al. 2003	62 suspected PC	-	9 PDAC	CT	Histopathology	N Staging
Schacter et al. 2000	67 suspected PC	TUS, CE-CT and/or ERCP	67	Laparoscopy with LUS	Laparotomy	Resectability
Shah et al. 2008a,c	88 confirmed PAC	-	88	MDCT	Laparotomy or surgical histopathology	Resectability
		MDCT	19	Laparoscopy with LUS	Surgical histopathology	
Shami et al. 2011	127 confirmed PC	-	127	EUS-FNA MRI	Surgical histopathology or cytology	Overall TNM Stage
Soriano et al. 2004	127 suspected PC	US	59	Helical CT	Surgical histopathology	Overall TNM Stage T-Staging N Staging M Staging Resectability Vascular Invasion
			52	EUS EUS + Helical CT if EUS-resectable Helical CT + EUS Helical CT + EUS if CT-resectable		
			53	MRI		

Study	Sample N	Prior imaging test(s)	Index test N	Index test(s)	Reference standard	Outcome
Taylor et al. 2001	51 potentially resectable pancreatic tumours ^b	US, ERCP	51	CE-CT	Surgery or histopathology	Resectability
		CE-CT	26	Laparoscopy with LUS	Surgery or histopathology	
Tellez-Avila et al. 2012	50 suspected PC	CT or US	50 potentially resectable	EUS±FNA MDCT	Surgical histopathology	Vascular Invasion
White 2001a	98 confirmed PDAC	-	98	CE-CT	Laparoscopy	M Staging
Yoneyama et al. 2014a,d	95 pathologically confirmed PC	MRI and FDG-PET/CT	43	CE FDG-PET/CT	Surgical histopathology, post-operative histopathology (EUS-FNA) or dynamic CT	N Staging
			52	Non-CE FDG-PET/CT		M Staging

Notes: a, retrospective review of prospective database. All other studies were prospective cohort studies; b, sample includes some participants with suspected periampullary cancer; c, criteria for staging laparoscopy were: (i) increased CA 19-9>1000 U/mL, (ii) tumour>4cm, (iii) weight loss>20% body weight, (iv) ascites or (v) liver lesions too small for either CT imaging or percutaneous biopsy; d, inclusion criteria were undetected lesions on MRI and FDG-PET/CT. Patients were assigned to undergo CE FDG-PET/CT or non-CE FDG-PET/CT. Abbreviations: CE CT, contrast enhanced computed tomography; CE MDCT, contrast-enhanced multidetector computed tomography; CE FDG-PET/CT; contrast-enhanced positron emission tomography-computed tomography; EUS-endoscopic ultrasonography; EUS-FNA- Endoscopic ultrasound-guided fine-needle aspiration; ERCP-Endoscopic retrograde cholangiopancreatography; PC-pancreatic cancer; MDCT, multidetector computed tomography; MRI-magnetic resonance imaging; FDG- PET/CT-positron emission tomography- computed tomography; PAC, pancreatic adenocarcinoma; PDAC, pancreatic ductal adenocarcinoma; TUS, transabdominal ultrasonography.

1
2
3
4
5
6
7
8

9 7.4 Clinical evidence profile

10 The clinical evidence profiles for this review question are presented in Table 60 to Table 75.

11 7.4.1 Tests for overall TNM Staging

12
13

1

Table 60: Summary of imaging studies on overall TNM staging in patients with suspected pancreatic cancer

Study	N	Index Test	Reference test	Accuracy (%)	Overstaged (%)	Understaged (%)	Risk of bias ¹	Indirectness ²	Overall quality
Ghaneh et al. 2018	393	CT	Surgical histopathology or 12-mo clinical FU	60	7	34	Serious ³	Not serious	MODERATE
		FDG-PET/CT		70	8	22			
Shami et al. 2011	48	EUS-FNA	Surgical histopathology or cytology	71	2	27	Very serious ⁴	Not serious	LOW
		MRI		75	0	25			
Soriano et al. 2004	62	CT	Surgical histopathology	46	8	46	Not serious	Not serious	HIGH
		EUS		40	5	56			
		MRI		36	7	57			

2

Due to the type of data, inconsistency and imprecision are not applicable here;

3

¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

4

², indirectness was evaluated using the applicability items of QUADAS-2;

5

³, concerns about flow and timing (69 patients dropped out and not included in per protocol analysis);

6

⁴, unclear reference and index test conduct (blinding), concerns about reference test (not all patients received same reference standard) and flow and timing (not all patients included in analysis).

8

Table 61: Change in TNM staging category after FDG-PET/CT

Change in staging category ²	TNM staging category at final diagnosis ¹				
	Stage 0/IA/IB/IIA, n=196 (%)	Stage IIB, n=107 (%)	Stage III, n=27 (%)	Stage IV, n=63 (%)	Overall, n=393 (%)
Remained correct	171 (87)	19 (18)	10 (37)	21 (33)	221 (56)

Change in staging category ²	TNM staging category at final diagnosis ¹				
	Stage 0/IA/IB/IIA, n=196 (%)	Stage IIB, n=107 (%)	Stage III, n=27 (%)	Stage IV, n=63 (%)	Overall, n=393 (%)
Remained incorrect	6 (3)	22 (21)	1 (4)	27 (43)	94 (24)
Changed to correct	10 (5)	55 (51)	15 (56)	14 (22)	56 (14)
Changed from correct to incorrect	8 (4)	5 (5)	0 (0)	1 (2)	14 (4)
Changed between incorrect groups	1 (<1)	6 (6)	1 (4)	0 (0)	8 (2)

¹, data is from Ghaneh et al. 2018;

², Change in TNM staging category is relative to the category assigned using MDCT prior to FDG-PET/CT.

7.4.2 Tests for resectability

Table 62: Summary of diagnostic accuracy of computed tomography on resectability¹

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Summary positive likelihood ratio (95% CI) ⁶	Summary negative likelihood ratio (95% CI) ⁶	Overall quality
CT for resectability (12 studies)	766	Not serious	Very serious ⁷	Not serious	Serious ⁸	0.89 (0.76-0.95)	0.74 (0.44-0.91)	3.4 (1.29-8.96)	0.15 (0.06-0.36)	VERY LOW

¹, positive test result corresponds to CT-resectability;

², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

⁴, indirectness was evaluated using the applicability items of QUADAS-2;

⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative – missing a resectable tumour – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating a tumour is resectable when it is not - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high specificity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

⁶, summary positive and likelihood ratio calculated from the meta-analysis;

⁷, 95% prediction range very wide with sensitivity ranging from approximately 0.1 to 1.0 and specificity ranging from 0 to 1.0;

⁸, 95% CI of sensitivity crosses 0.9.

Table 63: Subgroup analysis of computed tomography on resectability according to prior imaging

Parameter	Prior tests (7 studies, n=349)	No prior tests (5 studies, n=417)	Significant difference between subgroups (t-value, p-value) ¹
Pooled sensitivity (95% CI)	0.86 (0.71-0.94)	0.91 (0.64-0.98)	t=0.44, p=0.66
Pooled specificity (95% CI)	0.76 (0.30-0.96)	0.65 (0.29-0.89)	t=0.49, p=0.63
Positive likelihood ratio (95% CI) ²	3.61 (0.86-15.14)	2.58 (0.89-7.5)	
Negative likelihood ratio (95% CI) ²	0.18 (0.1-0.35)	0.13 (0.02-1.0)	

¹, Unpaired t-test to compare pooled estimates of subgroup that had prior imaging compared to subgroup that did not have prior imaging. Standard errors for each subgroup used to conduct t-test calculated from 95% confidence intervals;

², Likelihood ratios calculated from meta-analysis.

Table 64: Summary of other imaging studies on resectability

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Abdominal US										
Minniti et al. 2003	64	Not serious	n/a	Not serious	Very serious ⁷	0.89 (0.65-0.99)	0.76 (0.55-0.91)	3.7 (1.81-7.58)	0.15 (0.04-0.55)	LOW
CT-3D										
Fang et al. 2012	57	Not serious	n/a	Not serious	Not serious	1.0 (0.91-1.0)	1.0 (0.82-1.0)	39.49 (2.56-609.84) ⁸	0	HIGH
CT + EUS										
Soriano et al. 2004	52	Not serious	n/a	Not serious	Serious ⁹	0.73 (0.5-0.89)	0.97 (0.83-1.0)	21.82	0.28	MODERATE

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
CT + EUS only if CT-resectable										
Soriano et al. 2004	59	Not serious	n/a	Not serious	Serious ⁹	0.98 (0.89-1.0)	0.8 (0.28-0.99)	4.89 (0.85-28.26)	0.03 (0.0-0.19)	MODERATE
EUS										
DeWitt et al. 2004	104	Serious ¹⁰	n/a	Not serious	Very serious ⁷	0.88 (0.69-0.97)	0.68 (0.48-0.84)	2.74 (1.57-4.78)	0.18 (0.06-0.53)	VERY LOW
Mansfield et al. 2008	35	Serious ¹¹	n/a	Not serious	Very serious ⁷	0.82 (0.63-0.94)	0.43 (0.1-0.82)	1.44 (0.74-2.79)	0.42 (0.13-1.34)	VERY LOW
Soriano et al. 2004	52	Not serious	n/a	Not serious	Not serious	0.23 (0.08-0.45)	1.0 (0.88-1.0)	14.83 (0.86-254.88) ⁸	0.77 (0.62-0.97)	HIGH
Overall	191	Serious ¹²	Very serious ¹³	Not serious	Very serious ¹⁰					VERY LOW
EUS + CT only if EUS-resectable										
Soriano et al. 2004	52	Not serious	n/a	Not serious	Serious ⁹	0.63 (0.38-0.84)	0.97 (0.84-1.0)	20.84 (2.93-148.02)	0.38 (0.21-0.69)	MODERATE
MRI										
Fischer et al. 2002	26	Serious ¹⁰	n/a	Not serious	Serious ⁹	0.71 (0.44-0.90)	0.78 (0.40-0.97)	3.18 (0.9-11.2)	0.38 (0.17-0.85)	LOW
Koelblinger et al. 2011	23	Serious ¹⁰	n/a	Not serious	Very serious ⁷	0.83 (0.36-1.00)	0.82 (0.57-0.96)	4.72 (1.59-14.01)	0.20 (0.03-1.23)	LOW

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Soriano et al. 2004	53	Not serious	n/a	Not serious	Serious ⁹	0.57 (0.34- 0.77)	0.90 (0.73-0.98)	5.65 (1.82-17.53)	0.48 (0.3-0.78)	MODERATE
Overall	102	Not serious	Not serious	Not serious	Very serious ⁷					LOW

1 ¹, positive test result corresponds to resectability according to the relevant index test;

2 ², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

3 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
4 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

5 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;

6 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because
7 a false negative – missing a resectable tumour – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating a tumour is resectable
8 when it is not - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high
9 sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95%
10 CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

11 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
12 for details);

13 ⁷, 95% CI of sensitivity crosses both 0.75 and 0.9;

14 ⁸, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs.

15 ⁹, 95% CI of sensitivity crosses either 0.75 or 0.9;

16 ¹⁰, concerns over conduct of reference standard and flow and timing of tests;

17 ¹¹, concerns over conduct of reference standard

18 ¹², Soriano 2004 comprises more than 50% of sample;¹³, 95% CI of sensitivity has wide range

1

Table 65: Summary of laparoscopy with laparoscopic ultrasonography in patients with potentially resectable pancreatic cancer

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Summary positive likelihood ratio (95% CI) ⁶	Summary negative likelihood ratio (95% CI) ⁶	Overall quality
Laparoscopy with LUS for resectability ¹ (6 studies)	278	Not serious	Serious ⁷	Not serious	Not serious	0.98 (0.93-0.99)	0.67 (0.44-0.83)	3.1 (1.74-5.59)	0.04 (0.01-0.11)	MODERATE

2

¹, positive test result corresponds to resectability according to the relevant index test;

3

², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

4

³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

6

⁴, indirectness was evaluated using the applicability items of QUADAS-2;

7

⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative – missing a resectable tumour – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating a tumour is resectable when it is not - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

8

9

10

11

12

⁶, summary positive and negative likelihood ratios calculated from meta-analysis;

13

⁷, 95% prediction region very wide with specificity ranging from approximately 0 to 1.0.

14 7.4.3 Tests for T Staging

15

Table 66: Summary of imaging studies on T Staging in patients with suspected pancreatic cancer

Study	N	Index Test	Reference test	Accuracy (%)	Overstaged (%)	Understaged (%)	Risk of bias ¹	Indirectness ²	Overall quality
Dewitt et al. 2004	49	CT	Surgical histopathology or EUS-FNA/previous cytology and clinical FU	41	14	45	Serious ⁴	Not serious	MODERATE
		EUS		67	18	14			

Study	N	Index Test	Reference test	Accuracy (%)	Overstaged (%)	Understaged (%)	Risk of bias ¹	Indirectness ²	Overall quality
Maluf-Filho et al. 2004 ³	27	CT	Surgical histopathology or intraoperative biopsy from laparotomy or EUS-FNA	59	7	33	Not serious	Not serious	HIGH
		EUS		89	7	4			
Soriano et al. 2004	62	CT (n=59)	Surgical histopathology	73	2	25	Not serious	Not serious	HIGH
		EUS (n=52)		63	0	37			
		MRI (n=53)		62	6	32			

1

Due to the type of data, inconsistency and imprecision are not applicable here;

2

¹, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

3

², indirectness was evaluated using the applicability items of QUADAS-2;

4

³, study enrolled 61 people with suspected pancreatic or ampullary tumours. Data shown only for people with confirmed pancreatic cancer;

5

⁴, concerns with conduct of reference standard (reference standard not blinded, not all patients received same reference standard nor included in analysis).

6

1 **7.4.4 Tests for N Staging**

2 **Table 67: Summary of computed tomography studies on N Staging in patients with suspected or confirmed pancreatic cancer (by**
3 **number of participants)**

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Summary positive likelihood ratio (95% CI) ⁶	Summary negative likelihood ratio (95% CI) ⁶	Overall quality
CT for N Staging ¹ (6 studies)	329	Serious ⁷	Very serious ⁸	Not serious	Not serious	0.38 (0.26-0.52)	0.87 (0.7-0.95)	2.86 (0.91-8.97)	0.71 (0.52-0.98)	VERY LOW

4 ¹, positive test result corresponds to detection of regional lymph node metastasis;

5 ², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

6 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
7 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

8 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;

9 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because
10 a false negative - missing cancer that has spread to the regional lymph nodes - risks understaging (and hence potentially avoidable death), whilst a false positive -
11 indicating cancer has spread to the regional lymph nodes when it has not - risks overstaging (and hence potentially avoidable surgery or other treatment such as
12 chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies
13 were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and
14 0.9;

15 ⁶, summary positive and likelihood ratio calculated from meta-analysis;

16 ⁷, there were concerns in 3 of the studies about the conduct of the index test, the reference standard used, and/or the patient flow and timing of the tests;

17 ⁸, 95% prediction region was very wide ranging approximately from 0 to 0.9 for sensitivity and from 0 to 1.0 for specificity.

1 **Table 68: Subgroup analysis of computed tomography studies on N Staging according to prior imaging (by number of participants)**

Parameter	Prior tests (1 study, n=58)	No prior tests (5 studies, n=271)	Significant difference between subgroups (t-value, p-value) ¹
Pooled sensitivity (95% CI)	0.38 (0.19-0.59)	0.39 (0.25-0.56)	t=0.05, p=0.96
Pooled specificity (95% CI)	0.79 (0.62-0.91)	0.88 (0.67-0.96)	t=0.55, p=0.58
Positive likelihood ratio (95% CI) ²	1.82 (0.79-4.21)	3.3 (0.78-13.93)	
Negative likelihood ratio (95% CI) ²	0.79 (0.55-1.12)	0.69 (0.47-1.01)	

2 ¹, Unpaired t-test to compare pooled estimates of subgroup that had prior imaging compared to subgroup that did not have prior imaging. Standard errors for each subgroup
3 used to conduct t-test calculated from 95% confidence intervals;

4 ², Likelihood ratios calculated from meta-analysis.

5 **Table 69: Summary of computed tomography studies on N Staging in patients with suspected pancreatic cancer (by number of lymph
6 nodes)¹**

Study	# of participants (# of nodes)	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
CT										
Roche et al. 2003	9 (40)	Not serious	n/a	Not serious	Not serious	0.14 (0-0.58)	0.85 (0.68-0.95)	0.94 (0.13-6.87)	1.01 (0.72-1.41)	HIGH

7 ¹, positive test result corresponds to detection of regional lymph node metastasis. Sensitivity and specificity for this study calculated from number of lymph nodes correctly and
8 incorrectly identified as involved (where short-axis diameter > 10 mm indicates nodal involvement);

9 ², risk of bias evaluated using relevant items of QUADAS-2 checklist;

10 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
11 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

12 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;

13 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because
14 a false negative - missing cancer that has spread to the regional lymph nodes - risks understaging (and hence potentially avoidable death), whilst a false positive -
15 indicating cancer has spread to the regional lymph nodes when it has not - risks overstaging (and hence potentially avoidable surgery or other treatment such as
16 chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies

1 were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and
2 0.9;

3 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
4 for details).

5 **Table 70: Summary of other imaging studies on N Staging with suspected or confirmed pancreatic cancer (by number of**
6 **participants)¹**

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Abdominal US										
Klek et al. 2004	126	Not serious	n/a	Not serious	Very serious ⁷	0.75 (0.53-0.9)	0.91 (0.79-0.98)	8.62 (3.29-22.63)	0.27 (0.14-0.55)	LOW
EUS										
DeWitt et al. 2004	100	Serious ⁸	n/a	Not serious	Not serious	0.25 (0.11-0.43)	0.92 (0.64-1.0)	3.25 (0.45-23.45)	0.81 (0.63-1.05)	MODERATE
Mansfield et al. 2008	35	Not serious	n/a	Not serious	Not serious	0.31 (0.11-0.59)	0.93 (0.68-1.0)	4.69 (0.62-35.63)	0.74 (0.52-1.05)	HIGH
Soriano et al. 2004	52	Not serious	n/a	Not serious	Not serious	0.36 (0.17-0.59)	0.87 (0.69-0.96)	2.73 (0.94-7.93)	0.73 (0.52-1.04)	HIGH
Overall	187	Serious ⁹	Not serious	Not serious	Not serious					MODERATE
MRI										
Soriano et al. 2004	53	Not serious	n/a	Not serious	Not serious	0.15 (0.03-0.38)	0.93 (0.78-0.99)	2.25 (0.41-12.28)	0.91 (0.74-1.12)	HIGH
FDG-PET/CT										
Lemke et al. 2004	100	Serious	n/a	Not serious	Not serious	0.32 (0.17-0.51)	0.75 (0.48-0.93)	1.29	0.9	MODERATE

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
								(0.48-3.47)	(0.62-1.31)	
Yoneyama et al. 2014 non-CE group	52	Not serious	n/a	Not serious	Very serious ⁷	0.73 (0.39-0.94)	0.9 (0.77-0.97)	7.45 (2.75-20.24)	0.3 (0.11-0.8)	LOW
Yoneyama et al. 2014 CE group	43	Not serious	n/a	Not serious	Very serious ⁷	0.83 (0.52-0.98)	0.9 (0.74-0.98)	8.61 (2.85-25.99)	0.18 (0.05-0.66)	LOW
Overall	195	Serious ¹⁰	Serious	Not serious	Very serious ¹¹					VERY LOW

1 ¹, positive test result corresponds to detection of regional lymph node metastasis;

2 ², risk of bias evaluated using relevant items of QUADAS-2 checklist;

3 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

4 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;

5 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative - missing cancer that has spread to the regional lymph nodes - risks understaging (and hence potentially avoidable death), whilst a false positive - indicating cancer has spread to the regional lymph nodes when it has not - risks overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

6 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);

7 ⁷, 95% CI crosses both 0.75 and 0.9;

8 ⁸, there were concerns over the reference standard, and the patient flow and timing of tests;

9 ⁹, Overall serious risk of bias since DeWitt et al. (2005) contributed over 50% of the overall sample;

10 ¹⁰, overall serious risk of bias since Lemke et al., (2004) contributed over 50% of the overall sample;

11 ¹¹, 95% CI of sensitivity ranges from 0.17 to 0.98.

1 **7.4.5 Tests for M Staging**

2 **Table 71: Summary of imaging studies on M Staging in patients with suspected pancreatic cancer**

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
CT										
Farma et al. 2008	82	Serious ⁷	n/a	Not serious	Serious ⁸	0.57 (0.34-0.77)	0.92 (0.81-0.97)	6.67 (2.68-16.6)	0.48 (0.3-0.76)	LOW
Soriano et al. 2004	59	Not serious	n/a	Not serious	Serious ⁸	0.55 (0.23-0.83)	0.96 (0.86-0.99)	13.09 (3.04-56.37)	0.47 (0.25-0.91)	MODERATE
Overall	141	Serious ⁹	Not serious	Not serious	Serious ⁸					LOW
EUS										
Soriano et al. 2004	52	Not serious	n/a	Not serious	Not serious	0	1.0 (0.92-1.0)	5.0 (0.11-235.93) ¹⁰	1.0	HIGH
MRI										
Soriano et al. 2004	53	Not serious	n/a	Not serious	Not serious	0.3 (0.07-0.65)	0.95 (0.84-0.99)	6.45 (1.24-33.64)	0.73 (0.49-1.11)	HIGH
FDG-PET/CT										
Farma et al. 2008	82	Serious ⁷	n/a	Not serious	Serious ⁸	0.61 (0.39-0.8)	1.0 (0.94-1.0)	72.5 (4.5-1167.71) ¹⁰	0.39 (0.24-0.65)	LOW
Yoneyama et al. 2014 non-CE group	52	Not serious	n/a	Not serious	Very serious ¹¹	0.76 (0.53-0.92)	0.84 (0.66-0.95)	4.72 (2.04-10.92)	0.28 (0.13-0.62)	LOW

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Yoneyama et al. 2014 CE group	43	Not serious	n/a	Not serious	Very serious ¹¹	0.9 (0.7-0.98)	0.91 (0.71-0.99)	9.95 (2.64-37.58)	0.1 (0.03-0.39)	LOW
Overall	134	Not serious	Not serious	Not serious	Very serious ¹¹					LOW
CT + FDG-PET/CT										
Farma et al. 2008	82	Serious ⁷	n/a	Not serious	Very serious ¹²	0.87 (0.66-0.97)	0.92 (0.81-0.97)	10.26 (4.37-24.09)	0.14 (0.05-0.41)	VERY LOW

- 1 ¹, positive test result corresponds to detection of distant metastasis;
- 2 ², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 3 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 4
- 5 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;
- 6 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative - missing cancer that has spread to the distant regions of the body such as the liver and lungs - risks understaging (and hence potentially avoidable death), whilst a false positive - indicating cancer has spread to the distant regions of the body when it has not - risks overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low sensitivity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;
- 7
- 8
- 9
- 10 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);
- 11
- 12
- 13
- 14 ⁷, insufficient information regarding index test, reference standard and patient flow and timing of test;
- 15 ⁸, 95% CI crosses 0.75 or range of 95% CI crosses 0.75;
- 16 ⁹, sensitivity is undefined since there are no true positives nor false positives;
- 17 ¹⁰, since the specificity was 1, a continuity correction of 0.5 was added to all cells to enable calculation of the positive likelihood ratio and related 95% CIs;
- 18 ¹¹, 95% CI crosses both 0.75 and 0.9.

Table 72: Summary of diagnostic laparoscopy studies on M Staging in patients with pancreatic cancer and prior computed tomography

Study ¹	N	Risk of bias ²	Indirectness ³	Groups	# patients detected with metastatic disease ⁴	Diagnostic yield ⁴	NPV	Overall quality
Liu & Traverso 2005	74 CT-unresectable and locally advanced	Not serious	Not serious	n/a	25	34%	0.66	HIGH
White et al. 2001	90 CT-potentially resectable or CT-locally advanced tumours	Not serious	Not serious	Overall	21	23%	0.77	HIGH
				45 CT-potentially resectable	8	18%	0.82	
				55 CT-locally advanced	13	24%	0.76	

¹, CT is the index test and diagnostic laparoscopy is the reference test. Due to the type of data, inconsistency and imprecision are not applicable here;

², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

³, indirectness was evaluated using the applicability items of QUADAS-2;

⁴, the number/percentage of patients (as appropriate) who had CT for whom diagnostic laparoscopy identified distant metastasis and changed management plan.

7.4.6 Tests for vascular invasion

Table 73: Summary of computed tomography studies on vascular invasion

Study	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Pooled sensitivity (95% CI)	Pooled specificity (95% CI)	Summary positive likelihood ratio (95% CI) ⁶	Summary negative likelihood ratio (95% CI) ⁶	Overall quality
CT for vascular invasion (5 studies) ¹	419	Not serious	Serious ⁷	Not serious	Serious ⁷	0.7 (0.49-0.85) ⁸	0.92 (0.86-0.96)	9.5 (4.47-17.8)	0.33 (0.17-0.55)	LOW

1, positive test result corresponds to detection of vascular invasion by CT;

2, risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

3, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

4, indirectness was evaluated using the applicability items of QUADAS-2;

5, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative – missing vascular invasion – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating vascular invasion where there is none - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

6, summary positive and negative likelihood ratios calculated from meta-analysis;

7, it was not possible to represent the 95% prediction region on the summary ROC curve. However, the sensitivity estimates ranged from 0.48 to 0.91;

8, 95% CI of sensitivity crosses 0.75.

Table 74: Summary of other imaging studies on vascular invasion

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Abdominal US										
Klek et al. 2004	126	Not serious	n/a	Not serious	Serious ⁷	0.91 (0.8-0.97)	0.96 (0.88-0.99)	21.52 (7.09-65.32)	0.09 (0.04-0.22)	MODERATE
EUS										
Soriano et al. 2004	52	Not serious	n/a	Not serious	Not serious	0.42 (0.2-0.67)	0.97 (0.84-1.0)	13.89 (1.88-102.75)	0.6 (0.4-0.88)	HIGH
Tellez-Avila et al. 2012	50	Not serious	n/a	Not serious	Serious ⁷	0.61 (0.36-0.83)	0.9 (0.73-0.98)	6.11 (1.96-19.01)	0.43 (0.24-0.78)	MODERATE
Overall	102	Not serious	Serious ⁸	Not serious	Serious ⁹					LOW
MRI										

Study ¹	N	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Soriano et al. 2004	53	Not serious	n/a	Not serious	Not serious	0.59 (0.46-0.72)	0.84 (0.74-0.94)	3.66 (1.53-8.79)	0.49 (0.29-0.82)	HIGH
FDG-PET/CT										
Lemke et al. 2004	104	Serious ¹⁰	n/a	Not serious	Serious ⁷	0.68 (0.52-0.81)	0.67 (0.09-0.99)	2.0 (0.41-10.26)	0.48 (0.19-1.19)	LOW

- 1 ¹, positive test result corresponds to vascular invasion according to the relevant index test;
- 2 ², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;
- 3 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies, inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;
- 4 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;
- 5 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because a false negative – missing vascular invasion – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating vascular invasion where there is none - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy). Studies were considered to be of high sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95% CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;
- 6 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2 for details);
- 7 ⁷, 95% CI crosses 0.9;
- 8 ⁸, estimated sensitivity ranged from 0.42 to 0.61;
- 9 ⁹, range of 95% CI is from 0.2 to 0.83;
- 10 ¹⁰, unclear risk of bias due to insufficient information about index test and reference standard.

1 **7.4.7 Tests for indicating laparoscopic resectability**

2 **Table 75: Summary of CA19-9 studies to improve staging laparoscopy in patients with potentially resectable pancreatic cancer and**
3 **who had had prior imaging¹**

Study	N	Thresho ld (kU/ml)	Risk of bias ²	Inconsistency ³	Indirectness ⁴	Imprecision ⁵	Point estimates of sensitivity (95% CI)	Point estimates of specificity (95% CI)	Positive likelihood ratio (95% CI) ⁶	Negative likelihood ratio (95% CI) ⁶	Overall quality
Connor et al. 2005 ⁷	159	≤150	Not serious	n/a	Not serious	Not serious	0.44 (0.36-0.53)	0.88 (0.68-0.97)	3.56 (1.21- 10.42)	0.63 (0.51-0.79)	HIGH
		≤150 (or ≤300 If bilirubin level >35µmol /l) ⁸				Not serious	0.61 (0.52-0.69)	0.8 (0.56-0.94)	3.04 (1.25-7.39)	0.49 (0.36-0.67)	
		≤300 If bilirubin level >35µmol /l) ⁹				Not serious	0.3 (0.18-0.44)	0.94 (0.73-1.0)	5.43 (0.77- 38.13)	0.74 (0.6-0.91)	
Maithel et al. 2008 ⁷	262	≤130	Not serious	n/a	Not serious	Not serious	0.5 (0.43-57)	0.75 (0.6-0.86)	1.95 (1.2-3.18)	0.67 (0.55-0.83)	HIGH

4 ¹, positive test result corresponds to resectability according to the relevant CA 19-9 threshold where lower than the threshold indicates resectability;

5 ², risk of bias evaluated using risk of bias items of QUADAS-2 checklist;

6 ³, Inconsistency was assessed by inspection of the 95% prediction region in a summary ROC plot if a diagnostic meta-analysis was conducted. If between 2 and 3 studies,
7 inconsistency was assessed by visual inspection of the point estimates of sensitivity and specificity. If only 1 study, then inconsistency is not applicable;

8 ⁴, indirectness was evaluated using the applicability items of QUADAS-2;

9 ⁵, judgement of imprecision was based on consideration of the 95% confidence intervals of test sensitivity as this was considered to be the primary measure of interest because
10 a false negative – missing a resectable tumour – risks understaging (and hence a potentially avoidable death), whilst a false positive – indicating a tumour is resectable
11 when it is not - leads to overstaging (and hence potentially avoidable surgery or other treatment such as chemotherapy. Studies were considered to be of high
12 sensitivity (and not imprecise) if the 95% CI was above 0.9 or of low specificity if it was below 0.75. Studies were assessed as subject to serious imprecision if the 95%
13 CI crossed either 0.75 or 0.9, or subject to very serious imprecision if the 95%CI crossed both 0.75 and 0.9;

- 1 ⁶, positive and negative likelihood ratios calculated from raw diagnostic test accuracy data if not already reported; 95% CIs calculated using log method (see Chapter 4.3.3.2.2
- 2 for details);
- 3 ⁷, Connor et al. 2005 had prior CT, whilst Maithel et al. 2008 had prior CT or MRI;
- 4 ⁸, n=145 because bilirubin levels were not available for 14 patients);
- 5 ⁹, n=71 jaundiced patients only.

1 **7.5 Economic evidence**

2 **7.5.1 Systematic literature review**

3 The literature search of previous economic evidence identified 2 economic evaluation
4 relevant to this topic (Morris et al. 2015 and Ghaneh et al. 2018). Morris et al. (2015)
5 compared diagnostic laparoscopy, to assess the resectability of a tumour, performed at an
6 appointment prior to laparotomy to direct laparotomy with no diagnostic work-up in people
7 with pancreatic or periampullary cancer which has been identified as resectable through CT
8 scanning.

9 The study took a UK NHS and PSS perspective and was deemed to only have minor
10 methodological issues. The effectiveness side of the model was based almost entirely on 1
11 Cochrane review (16 studies, n=1146) which matched the decision problem considered by
12 the model. All costs were obtained from NHS reference costs. The utilities for the model were
13 taken from patient responses to the EQ-5D questionnaire scored using the UK population
14 weightings they were drawn from a different patient group (hepatic colorectal metastases).
15 The model considered both pancreatic and periampullary cancer although the model was
16 rerun separately for each disease and reported similar results for the combined and
17 pancreatic cancer models, although this analysis was not presented in detail.

18 The model concluded that a diagnostic laparoscopy would be both cost saving and health
19 improving if held at an appointment prior to surgery and thus wasted operating theatre time
20 could be averted in patients subsequently identified as having unresectable tumours.
21 However, the cost savings (£10) and health improvements (0.009 QALYS) per patient were
22 small.

23 Both deterministic and probabilistic sensitivity analysis were undertaken. The results were
24 sensitive to alternate assumptions around key variables especially around the proportion of
25 patients with unresectable disease sent to surgery and the post-test probability of
26 unresectable disease. The preferred option changed to no further diagnostic work-up prior to
27 laparotomy for values less than 36% and greater than 22% for these two variables
28 respectively. Both of these values were plausible and within the 95% confidence intervals
29 estimated in the Cochrane review. The uncertainty around the preferred option was further
30 supported by the probabilistic sensitivity analysis which showed diagnostic laparoscopy cost
31 effective a £20,000 willingness to pay per QALY only having a 63.2% probability of being the
32 preferred option.

33 The study by Ghaneh et al. (2018) was a health technology assessment (HTA) with an
34 economic evaluation conducted alongside a UK prospective diagnostic accuracy study to
35 assess whether the addition of FDG-PET/CT to standard diagnostic and staging work-up was
36 cost effective in patients with suspected pancreatic ductal adenocarcinoma (PDAC).

37 The study took a UK NHS and PSS perspective and was deemed to only have minor
38 methodological issues. Effectiveness evidence, quality of life and resource use were all
39 collected prospectively during the diagnostic accuracy study (n=550). Quality of life was
40 collected using the EQ-5D-3L questionnaire given to participants in the study at 3 monthly
41 intervals and were scored using UK population weightings. Resource use was calculated
42 from complete primary and secondary care NHS contact for 279 patients in the trial and
43 costed using NHS reference costs, Unit Costs of Health and Social Care or other publicly
44 available tariffs.

45 The base case suggested that the addition of FDG-PET/CT to standard diagnostic and
46 staging work-up would be both cost saving and health improving mostly driven through a
47 20% reduction in costly unnecessary surgical resections. This conclusion was sensitive to

1 structural assumptions around whether all patients would receive resection and the cost of
2 FDG-PET/CT.

3 Probabilistic sensitivity analysis suggested that the conclusion of cost effectiveness was
4 robust in the base case analysis with an 82% probability of being cost effective at a
5 willingness to pay of £20,000 per QALY, assuming the higher cost estimate of FDG-
6 PET/CT. There was a greater than 80% probability of the addition of FDG-PET/CT being cost
7 saving under all FDG-PET/CT cost assumptions. The probability of cost effectiveness
8 dropped considerably when alternate estimates of FDG-PET/CT costs were used and there
9 was a less than 20% probability of being cost effective under the alternate structural
10 assumption around resection.

11 Both studies looked at the restaging of patients prior to surgical resection to identify those
12 who were not suitable. The patient group which matched that used in Morris et al. (2015) was
13 the 'Patients diagnosed with pancreatic cancer and indicated for surgical resection' subgroup
14 in Ghaneh et al. (2018). Adding FDG-PET/CT to the diagnostic and staging work-up of this
15 subgroup led to cost savings of £1,275 and increase in QALYs of 0.0175 indicating both
16 greater cost savings and health improvements of FDG-PET/CT compared to diagnostic
17 laparoscopy prior to surgical resection (£10/0.009 QALYs). References to all included studies
18 and evidence tables for all economic evaluations included in the systematic literature review
19 of the economic evidence are presented in Appendix L. Economic evidence profiles of these
20 studies are presented in Appendix K.

21 **7.6 Evidence statements**

22 **7.6.1 Tests for overall TMN Staging**

23 **Staging accuracy**

24 High quality evidence from 1 prospective cohort study (n=62) found that CT had the best
25 accuracy of 46% in people with suspected pancreatic cancer who had had prior ultrasound,
26 compared to an accuracy of 40% for EUS and 36% for MRI. Computed tomography also
27 understaged the least number of people (46%), followed by EUS and MRI (56% and 57%
28 respectively). However, CT overstaged the most number of people (8%), followed by MRI
29 (7%) and EUS (5%).

30 Low quality evidence from 1 prospective cohort study (n=48) found that MRI had an accuracy
31 of 75% in people with confirmed pancreatic cancer, compared to 71% for EUS-FNA. MRI
32 also both understaged and overstaged the least number of people (25% and 0%
33 respectively) closely followed by EUS-FNA (27% and 2%).

34 Moderate quality evidence from 1 prospective cohort study (n=393) found that FDG-PET/CT
35 had a higher accuracy of 70% compared to only 60% for MDCT in people with suspected
36 pancreatic cancer. Although FDG-PET/CT overstaged slightly more people compared to
37 MDCT (8% vs 7%), it understaged only 22%, compared to 34%, of the sample. Overall,
38 FDG-PET/CT changed patients' staging classification (as determined by a reference
39 standard) from incorrect to correct more often than it changed their classification from correct
40 to incorrect (p<0.001). Although FDG-PET/CT incorrectly changed the staging classification
41 of more Stage IA/IB and IIA patients than MDCT (8 patients vs 6 patients, p=0.79) and had
42 no significant effect on classifying Stage III patients (1 patient vs no patients), there was a
43 significant difference in the number of Stage IIB (22 patients vs 5 patients, p=0.002) and
44 Stage IV (27 patients vs 1 patient, p<0.001) patients whose staging classification was
45 correctly changed compared to those incorrectly changed.

1 **7.6.2 Tests for resectability**

2 **Staging accuracy of CT**

3 Very low quality evidence from a meta-analysis of 12 observational studies (n=766) found
4 that CT had a moderate pooled sensitivity of 0.89 (95% CI, 0.76-0.95) and a low pooled
5 specificity of 0.74 (95% CI, 0.44-0.91) in determining pancreatic tumour resectability in
6 adults. The positive likelihood ratio of 3.4 (95% CI, 1.29-9.86) suggests that a positive result
7 for resectability is not particularly useful for ruling it in, though there is uncertainty in the
8 estimate. The negative likelihood ratio of 0.15 (0.06-0.36) suggests that a negative result for
9 resectability is moderately useful for ruling it out, though there is substantial uncertainty in the
10 estimate.

11 A subgroup analysis by whether the participants had had prior imaging (prior imaging versus
12 no prior imaging) showed that there was no significant difference between the two groups in
13 the estimated pooled sensitivity (0.86 [95% CI, 0.71-0.94] vs 0.91 [95% CI, 0.64-0.98]
14 respectively) and estimated pooled specificity (0.76 [95% CI, 0.3-0.96] vs 0.62 [95% CI, 0.29-
15 0.89]). Similarly, the positive likelihood ratios of 3.61 (95% CI, 0.86-15.14) and 2.58 (95% CI,
16 0.89-7.5) suggest that a positive result for resectability is not particularly useful for ruling it in,
17 though there is substantial uncertainty in the estimates. The negative likelihood ratios of 0.18
18 (95% CI, 0.1-0.35) and 0.13 (95% CI, 0.02-1.0), suggest– in line with the main meta-analysis
19 – that a negative result for resectability is moderately useful for ruling it out, though there is
20 substantial uncertainty in the estimates.

21 High quality evidence from 1 prospective cohort study (n=57) found that three-dimensional
22 computed tomography (CT-3D) had a high sensitivity of 1.0 (95% CI, 0.91-1.0) and a high
23 specificity of 1.0 (95% CI, 0.82-1.0) in determining pancreatic tumour resectability in adults
24 with confirmed pancreatic cancer. However, the positive likelihood ratio of 39.49 (95% CI,
25 2.56-609.84) suggests that a positive result for resectability is very useful for ruling it in,
26 though there is substantial uncertainty in the estimate. The negative likelihood ratio of 0
27 suggests that a negative result for resectability is very useful for ruling it out.

28 **Staging accuracy of abdominal ultrasound**

29 Low quality evidence from 1 prospective cohort study (n=64) found that abdominal
30 ultrasound had a moderate sensitivity of 0.89 (95% CI, 0.65-0.99) and moderate specificity of
31 0.76 (95% CI, 0.55-0.91) in determining pancreatic tumour resectability in adults with
32 suspected pancreatic cancer. The positive likelihood ratio of 3.7 (95% CI, 1.81-7.58)
33 suggests that a positive result for resectability is not particularly useful for ruling it in, though
34 there is uncertainty in the estimate. The negative likelihood ratio of 0.15 (95% CI, 0.04-0.55)
35 suggests that a negative result for resectability is moderately useful for ruling it out, though
36 there is substantial uncertainty in the estimate.

37 **Staging accuracy of combined computed tomography and EUS**

38 Moderate quality evidence from 1 prospective cohort study (n=52) found that combined
39 computed tomography and EUS had a low sensitivity of 0.73 (95% CI, 0.5-0.89) and a high
40 specificity of 0.97 (95% CI, 0.83-1.0) in determining pancreatic tumour resectability in adults.
41 The positive likelihood ratio of 21.82 (95% CI, 3.12-152.43) suggests that a positive result for
42 resectability is very useful for ruling it in, though there is substantial uncertainty in the
43 estimate. The negative likelihood ratio of 0.28 (95% CI, 0.14-0.56) suggests that a negative
44 result for resectability is not particularly useful for ruling it out, though there is uncertainty in
45 the estimate.

46 Moderate quality evidence from 1 prospective cohort study (n=59) found that combined CT
47 and EUS only if resectable on CT had a high sensitivity of 0.98 (95% CI, 0.89-1.0) and
48 moderate specificity of 0.8 (95% CI, 0.28-0.99) in determining pancreatic tumour resectability

1 in adults. The positive likelihood ratio of 4.89 (95% CI, 0.85-28.26) suggests that a positive
2 result for resectability is not particularly useful for ruling it in, though there is substantial
3 uncertainty in the estimate. The negative likelihood ratio of 0.03 (95% CI, 0-0.19) suggests
4 that a negative result for resectability is very useful for ruling it out, though there is
5 uncertainty in the estimate.

6 **Staging accuracy of EUS**

7 Very low quality evidence from 2 prospective cohort studies (n=139) in adults with suspected
8 or confirmed pancreatic cancer though no prior imaging found that EUS had a moderate
9 sensitivity ranging from 0.82 to 0.88 and low specificity ranging from 0.43 to 0.68 in
10 determining pancreatic tumour resectability. The positive likelihood ratios of 1.44 (95% CI,
11 0.74-2.79) and 2.74 (95% CI, 1.57-4.78) suggest that a positive result for resectability is not
12 particularly useful for ruling it in. The negative likelihood ratios of 0.18 (95% CI, 0.06-0.53)
13 and 0.42 (95% CI, 0.13-1.34) suggest that a negative result for resectability is either
14 moderately useful or not particularly useful for ruling it out, though there is substantial
15 uncertainty in the estimates. By contrast, high quality evidence from 1 prospective cohort
16 study (n=52) in adults with suspected pancreatic cancer who had had prior ultrasound found
17 that EUS had a low sensitivity of 0.23 (95% CI, 0.08-0.45) and high specificity of 1.0 (95% CI,
18 0.88-1.0). The positive likelihood ratio of 14.83 (0.86-254.88) suggests that a positive result
19 for resectability is very useful after prior ultrasound for ruling it in, though there is substantial
20 uncertainty in the estimate. The negative likelihood ratio of 0.77 (95% CI, 0.62-0.97)
21 suggests that a negative result for resectability is not particularly useful for ruling it out.

22 Moderate quality evidence from 1 prospective cohort study (n=52) in adults with suspected
23 pancreatic cancer found that combined EUS and CT only if resectable on EUS had a low
24 sensitivity of 0.63 (95% CI, 0.38-0.84) and high specificity of 0.97 (95% CI, 0.84-1.0) in
25 determining pancreatic tumour resectability in adults. The positive likelihood ratio of 20.84
26 (95% CI, 2.93-148.02) suggests that a positive result for resectability is very useful for ruling
27 it in, though there is substantial uncertainty in the estimate. The negative likelihood ratio of
28 0.38 (95% CI, 0.21-0.69) suggests that a negative result for resectability is not particularly
29 useful for ruling it out.

30 **Staging accuracy of laparoscopy with laparoscopic ultrasound**

31 Moderate quality evidence from a meta-analysis of 6 observational studies (n=278) found
32 that laparoscopy with laparoscopic ultrasound had a high sensitivity of 0.98 (95% CI, 0.93-
33 0.99) and a low specificity of 0.67 (95% CI, 0.44-0.83) in determining pancreatic tumour
34 resectability. The positive likelihood ratio of 3.0 (95% CI, 1.74-5.59) suggests that a positive
35 result for resectability is not particularly useful for ruling it in, though there is uncertainty in
36 the estimate. The negative likelihood ratio of 0.04 (95% CI, 0.01-0.11) suggests that a
37 negative result for resectability is very useful for ruling it out, though there is uncertainty in
38 the estimate.

39 **Staging accuracy of magnetic resonance imaging**

40 Low quality evidence from 3 studies (n=102) in adults with suspected pancreatic cancer who
41 had had prior imaging found that MRI had a low to moderate sensitivity ranging from 0.57 to
42 0.83 and a moderate specificity ranging from 0.78 to 0.9 in determining pancreatic tumour
43 resectability. The positive likelihood ratios were 3.18 (95% CI, 0.9-11.2), 4.72 (95% CI, 1.59-
44 14.01) and 5.65 (95% CI, 1.82-17.53) suggesting that a positive result for resectability is
45 either moderately useful or not particularly useful for ruling it in, though there is substantial
46 uncertainty in the estimates. The negative likelihood ratios were 0.2 (95% CI, 0.03-1.23),
47 0.38 (95% CI, 0.17-0.85) and 0.48 (95% CI, 0.3-0.78) suggesting that a negative result for
48 resectability is not particularly useful for ruling it out, though there is substantial uncertainty in
49 the estimates.

1 7.6.3 Tests for T-Staging

2 T-Staging accuracy

3 Moderate quality evidence from 1 prospective cohort study (n=49) compared the ability of CT
4 and EUS to determine the size and extent of a primary tumour in adults with suspected or
5 recently diagnosed pancreatic cancer and found that EUS was more accurate than CT (67%
6 vs 41% respectively). EUS overstaged 18% and understaged 14% of the sample, compared
7 with 14% and 45%, respectively, for CT.

8 High quality evidence from 1 prospective cohort study (n=27) compared the ability of CT and
9 EUS to determine the size and extent of a primary tumour in adults with confirmed pancreatic
10 cancer who had previous CT or ultrasound and found that EUS was more accurate than CT
11 (89% vs 59%, respectively). Both EUS and CT overstaged 7% of the sample, whilst EUS
12 only understaged 4% compared to 33% of the sample for CT.

13 High quality evidence from 1 prospective cohort study (n=53 to 59) compared the ability of
14 CT, EUS and MRI to determine the size and extent of a primary tumour in adults with
15 suspected pancreatic cancer who had had prior ultrasound and found that CT was more
16 accurate than either EUS or MRI (73%, 63% and 62%, respectively). CT also understaged
17 the least amount of the sample followed by MRI and EUS (25%, 32% and 37%, respectively).
18 By contrast EUS did not overstage any of the sample, whilst CT and MRI overstaged 2% and
19 6%, respectively, of the sample.

20 7.6.4 Tests for N-Staging

21 N-Staging accuracy of CT

22 Very low quality evidence from a meta-analysis of 6 prospective cohort studies (n=329) found
23 that computed tomography has a low sensitivity of 0.38 (95% CI, 0.26-0.52) and a moderate
24 specificity of 0.87 (95% CI, 0.7-0.95) in detecting whether a pancreatic tumour has spread to
25 the lymph nodes in adults. The positive likelihood ratio of 2.86 (95% CI, 0.91-8.97) suggests
26 that a positive result for nodal involvement is not particularly useful for ruling it in, though
27 there is uncertainty in the estimate. The negative likelihood ratio of 0.71 (95% CI, 0.52-0.98)
28 suggests that a negative result for nodal involvement is not particularly useful for ruling it in
29 and ruling it out.

30 A subgroup analysis by whether the participants had had prior imaging (prior imaging [1
31 study, n=58] vs no prior imaging [5 studies, n=271]) showed that there was no significant
32 difference (t=0.05, p=0.96) between the two groups in the estimated pooled sensitivity (0.38
33 [95% CI, 0.19-0.59] vs 0.39 [95% CI, 0.25-0.56] respectively). Similarly, there was no
34 significant difference (t=0.55, p=0.58) in the estimated pooled specificity between the two
35 groups (0.79 [95% CI, 0.62-0.91] vs 0.88 [95% CI, 0.67-0.96]). The positive likelihood ratios
36 of 1.82 (95% CI, 0.79-4.21) and 3.3 (95% CI, 0.78-13.93) suggests that a positive result for
37 nodal involvement, regardless of whether prior imaging has been conducted, is not
38 particularly useful for ruling it in, though there is substantial uncertainty in the latter estimate.
39 The negative likelihood ratios of 0.79 (95% CI, 0.55-1.12) for the single study in the prior
40 imaging group and 0.69 (95% CI, 0.47-1.01) in the no prior imaging group suggests that a
41 negative result for nodal involvement is not particularly useful for ruling it out regardless of
42 whether prior imaging has occurred

43 High quality evidence from 1 prospective cohort study (n=9, 40 lymph nodes) that calculated
44 accuracy of CT for detecting nodal involvement according to the number of detected lymph
45 nodes (rather than number of patients) found that it had low sensitivity of 0.14 (95% CI, 0-
46 0.58) and a moderate specificity of 0.85 (95% CI, 0.68-0.95) in adults with confirmed
47 pancreatic cancer. The positive likelihood ratio of 0.94 (95% CI, 0.13-6.87) suggests that a
48 positive result for nodal involvement is not particularly useful for ruling it in, though there is

1 uncertainty in the estimate. The negative likelihood ratio of 1.01 (95% CI, 0.72-1.41)
2 suggests that a negative result for nodal involvement is not particularly useful for ruling it out.

3 **N-Staging accuracy of abdominal ultrasound**

4 Low quality evidence from 1 prospective cohort study (n=126) found that abdominal
5 ultrasound had a moderate sensitivity of 0.75 (95% CI, 0.53-0.9) and a high specificity of
6 0.91 (95% CI, 0.79-0.98) in detecting whether a pancreatic tumour has spread to the lymph
7 nodes in adults with suspected pancreatic cancer. The positive likelihood ratio of 8.62 (95%
8 CI, 3.29-22.63) suggests that a positive result for nodal involvement is moderately useful for
9 ruling it in, though there is substantial uncertainty in the estimate. The negative likelihood
10 ratio of 0.27 (95% CI, 0.14-0.55) suggests that a negative result for nodal involvement is not
11 particularly useful for ruling it out, though there is uncertainty in the estimate.

12 **N-Staging accuracy of EUS**

13 Moderate quality evidence from 3 prospective cohort studies (n=187) found that EUS had a
14 low sensitivity ranging from 0.25 to 0.36 and a moderate to high specificity ranging from 0.87
15 to 0.93 in detecting whether a pancreatic tumour has spread to the lymph nodes in adults
16 with suspected pancreatic cancer who had had prior ultrasound. The positive likelihood ratios
17 were 2.73 (95% CI, 0.94-7.93), 3.25 (95% CI, 0.45-23.45) and 4.69 (95% CI, 0.62-35.63)
18 suggesting that a positive result for nodal involvement is not particularly useful for ruling it in,
19 though there is substantial uncertainty in the estimates. The negative likelihood ratios were
20 0.73 (95% CI, 0.52-1.04), 0.74 (95% CI, 0.52-1.05) and 0.81 (95% CI, 0.63-1.05) suggesting
21 that a negative result for nodal involvement is not particularly useful for ruling it out.

22 **N-Staging accuracy of MRI**

23 High quality evidence from 1 prospective cohort study (n=53) found that MRI had a low
24 sensitivity of 0.15 (95% CI, 0.03-0.38) and a high specificity of 0.93 (95% CI, 0.78-0.99) in
25 detecting whether a pancreatic tumour has spread to the lymph nodes in adults with
26 suspected pancreatic cancer who had had prior ultrasound. The positive likelihood ratio of
27 2.25 (95% CI, 0.41-12.28) suggests that a positive result for nodal involvement is not
28 particularly useful for ruling it in, though there is substantial uncertainty in the estimate. The
29 negative likelihood ratio of 0.91 (95% CI, 0.74-1.12) suggests that a negative result for nodal
30 involvement is not particularly useful for ruling it out.

31 **N-Staging accuracy of FDG-PET/CT**

32 Moderate quality evidence from 1 prospective cohort study (n=100) found that standard
33 FDG-PET/CT had a low sensitivity of 0.32 (95% CI, 0.17-0.51) and a moderate specificity of
34 0.75 (95% CI, 0.48-0.93) in detecting whether a pancreatic tumour has spread to the lymph
35 nodes in adults with suspected pancreatic cancer. The positive likelihood ratio of 1.29 (95%
36 CI, 0.48-3.47) and negative likelihood ratio of 0.9 (95% CI, 0.62-1.31) suggest that neither a
37 positive nor negative result for nodal involvement is particularly useful for ruling it in and
38 ruling it out.

39 Low quality evidence from 1 retrospective review of a prospective database compared
40 standard FDG-PET/CT (n=52) with contrast-enhanced FDG-PET/CT (n=43) and found that
41 both had a moderate sensitivity (ranging from 0.73 to 0.83) and a high specificity of 0.9 in
42 detecting whether a pancreatic tumour has spread to the lymph nodes in adults with
43 confirmed pancreatic cancer. The positive likelihood ratio was 7.45 (95% CI, 2.75-20.24) for
44 standard FDG-PET/CT and 8.61 (95% CI, 2.85-25.99) for contrast-enhanced FDG-PET/CT
45 suggesting that a positive result on either test for nodal involvement is moderately useful for
46 ruling it in, though there is substantial uncertainty in the estimates. The negative likelihood
47 ratio ranged from 0.18 (95% CI, 0.05-0.66) for contrast-enhanced FDG-PET/CT and 0.3
48 (95% CI, 0.11-0.8) for standard FDG-PET/CT suggesting that a negative result for nodal

1 involvement in the former test is moderately useful for ruling it out but that a negative result in
2 the latter test is not particularly useful for ruling it out, though there is uncertainty in both
3 estimates.

4 **7.6.5 Tests for M Staging**

5 **M-Staging accuracy of CT**

6 Low quality evidence from 2 observational studies (n=141; 1 prospective cohort and 1
7 retrospective review of a prospective database) found that CT had a low sensitivity ranging
8 from 0.55 to 0.57 and a high specificity ranging from 0.92-0.96 in detecting whether a
9 pancreatic tumour has metastasised in adults with suspected pancreatic cancer. The positive
10 likelihood ratios were 6.67 (95% CI, 2.68-16.6) and 13.09 (95% CI, 3.04-56.37) suggesting
11 that a positive result for metastases is either moderately or very useful for ruling it in, though
12 there is substantial uncertainty in the estimates. By contrast, the negative likelihood ratios
13 were 0.47 (95% CI, 0.25-0.91) and 0.48 (95% CI, 0.3-0.76) suggesting that a negative result
14 for metastases is not particularly useful for ruling it out.

15 **M-Staging accuracy of EUS**

16 High quality evidence from 1 prospective cohort study (n=52) found that EUS had a high
17 specificity of 1.0 (95% CI, 0.92-1.0) in detecting whether a pancreatic tumour has
18 metastasised in adults with suspected pancreatic cancer who had had prior ultrasound. The
19 positive likelihood ratio of 5.0 (95% CI, 0.11-235.93) suggest that a positive result for
20 metastases is moderately useful for ruling it in, though there is substantial uncertainty in the
21 estimate. The negative likelihood ratio of 1.0 (95% CI, 1.0-1.0) suggests that a negative
22 result for metastases is not particularly useful ruling it out.

23 **M-Staging accuracy of MRI**

24 High quality evidence from 1 prospective cohort study (n=53) found that MRI had a low
25 sensitivity of 0.3 (95% CI, 0.07-0.65) and a high specificity of 0.95 (95% CI, 0.84-0.99) in
26 detecting whether a pancreatic tumour has metastasised in adults with suspected pancreatic
27 cancer who had had prior ultrasound. The positive likelihood ratio of 6.45 (95% CI, 1.24-
28 33.64) suggests that a positive result for metastases is moderately useful for ruling it in,
29 though there is substantial uncertainty in the estimate. The negative likelihood ratio of 0.73
30 (95% CI, 0.49-1.11) suggests that a negative result for metastases is not particularly useful
31 for ruling it out.

32 **M-Staging accuracy of FDG-PET/CT**

33 Low quality evidence from 1 retrospective review of a prospective database (n=82) found that
34 standard FDG-PET/CT had a low sensitivity of 0.61 (95% CI, 0.39-0.8) and a high specificity
35 of 1.0 (95% CI, 0.94-1.0) in detecting whether a pancreatic tumour has metastasised in
36 adults with suspected pancreatic cancer. The positive likelihood ratio of 72.5 (95% CI, 4.5-
37 1167.71) suggest that a positive result for metastases is very useful for ruling it in, though
38 there is substantial uncertainty in the estimate. The negative likelihood ratio of 0.39 (95% CI,
39 0.24-0.65) suggests that a negative result for metastases is not particularly useful for ruling it
40 out.

41 Low quality evidence from 1 retrospective review of a prospective database compared
42 standard FDG-PET/CT (n=52) with contrast-enhanced FDG-PET/CT (n=43) and found the
43 former had a moderate sensitivity of 0.76 (95% CI, 0.53-0.92) and moderate specificity of
44 0.84 (95% CI, 0.66-0.95), whilst the latter had a high sensitivity of 0.9 (95% CI, 0.7-0.98) and
45 a high specificity of 0.91 (95% CI, 0.71-0.99), in detecting whether a pancreatic tumour has
46 metastasised in adults with confirmed pancreatic cancer. The positive likelihood ratios of

1 4.72 (95% CI, 2.04-10.92) for standard FDG-PET/CT and 9.95 (95% CI, 2.64-37.58) for
2 contrast-enhanced FDG-PET/CT suggest that a positive result for metastases using the
3 former is not particularly useful for ruling it in, whilst a positive result using the latter is
4 moderately useful for ruling it in, though there is substantial uncertainty in both estimates.
5 The negative likelihood ratios of 0.28 (95% CI, 0.13-0.62) for standard FDG-PET/CT and 0.1
6 (95% CI, 0.03-0.39) for contrast-enhanced FDG-PET/CT suggest that a negative result for
7 metastases using the former is not particularly useful for ruling it in, whilst a negative result
8 using the latter is moderately useful for ruling it out, though there is uncertainty in both
9 estimates.

10 **M-Staging accuracy of combined CT and FDG-PET/CT**

11 Very low quality evidence from 1 retrospective review of a prospective database (n=82)
12 found that combined CT and FDG-PET/CT had a moderate sensitivity of 0.87 (95% CI, 0.66-
13 0.97) and a high specificity of 0.92 (95% CI, 0.81-0.97) in detecting whether a pancreatic
14 tumour has metastasised in adults with suspected pancreatic cancer. The positive likelihood
15 ratio of 10.26 (95% CI, 4.37-24.09) suggests that a positive result for metastases is very
16 useful for ruling it in, whilst the negative likelihood ratio of 0.14 (95% CI, 0.05-0.41) suggests
17 that a negative result for metastases is moderately useful for ruling it out, though there is
18 substantial uncertainty in both estimates.

19 **M-Staging accuracy of diagnostic laparoscopy**

20 High quality evidence from 1 retrospective review of a prospective database (n=74 CT-
21 unresectable or locally advanced pancreatic cancer participants) found that 34% of the
22 sample had pancreatic tumours that had metastasised and that the negative predictive value
23 was 0.66.

24 High quality evidence from 1 retrospective review of a prospective database (n=90 CT-
25 resectable or locally advanced pancreatic cancer participants) found that 23% of the sample
26 had pancreatic tumours that had metastasised and that the negative predictive value was
27 0.77. The diagnostic yield was 18% (NPV=0.82) for CT-resectable participants (n=45), whilst
28 it was 24% (NPV=0.76) for CT-locally advanced participants (n=55).

29 **7.6.6 Tests for vascular invasion**

30 **Vascular invasion accuracy of CT**

31 Low quality evidence from a meta-analysis of 5 prospective cohort studies (n=419) found that
32 CT had a low pooled sensitivity of 0.70 (95% CI, 0.49-0.85) and high specificity of 0.92 (95%
33 CI, 0.86-0.96) in detecting whether a pancreatic tumour has spread to the arteries and/or
34 veins in adults with suspected or confirmed pancreatic cancer. The positive likelihood ratio of
35 9.5 (95% CI, 4.47-17.8) suggests that a positive result for vascular invasion is moderately
36 useful for ruling it in, though there is substantial uncertainty in the estimate. The negative
37 likelihood ratio of 0.33 (95% CI, 0.17-0.55) suggests that a negative result for vascular
38 invasion is not particularly useful for ruling it out, though there is uncertainty in the estimate.

39 **Vascular invasion accuracy of abdominal ultrasound**

40 Moderate quality evidence from 1 prospective cohort study (n=126) found that abdominal
41 ultrasound had a high sensitivity of 0.91 (95% CI, 0.8-0.97) and a high specificity of 0.96
42 (95% CIU, 0.88-0.99) in detecting whether a pancreatic tumour has spread to the arteries
43 and/or veins in adults with suspected pancreatic cancer. The positive likelihood ratio of 21.52
44 (95% CI, 7.09-65.32) suggests that a positive result for vascular invasion is very useful for
45 ruling it in, though there is uncertainty in the estimate. The negative likelihood ratio of 0.09

1 (95% CI, 0.04-0.22) suggests that a negative result for vascular invasion is very useful for
2 ruling it out, though there is substantial uncertainty in the estimate.

3 **Vascular invasion accuracy of EUS**

4 Low quality evidence from 2 prospective cohort studies (n=102) found that EUS had a low
5 sensitivity ranging from 0.42 to 0.61 and a high specificity ranging from 0.9 to 0.97 in
6 detecting whether a pancreatic tumour has spread to the arteries and/or veins in adults with
7 suspected pancreatic cancer who had had prior imaging tests. The positive likelihood ratios
8 were 6.11 (95% CI, 1.96-19.01) and 13.89 (95% CI, 1.88-102.75) suggesting that a positive
9 result for vascular invasion is either very useful or moderately useful for ruling it in, though
10 there is substantial uncertainty in both estimates. The negative likelihood ratios were 0.43
11 (95% CI, 0.24-0.78) to 0.6 (95% CI, 0.4-0.88) suggesting that a negative result for vascular
12 invasion is not particularly useful for ruling it out.

13 **Vascular invasion accuracy of MRI**

14 High quality evidence from 1 prospective cohort study (n=53) found that MRI had a low
15 sensitivity of 0.59 (95% CI, 0.46-0.72) and moderate specificity of 0.84 (95% CI, 0.74-0.94) in
16 detecting whether a pancreatic tumour has spread to the arteries and/or veins in adults with
17 suspected pancreatic cancer who had had prior ultrasound. The positive likelihood ratio of
18 3.66 (95% CI, 1.53-8.79) suggests that a positive result for vascular invasion is not
19 particularly useful for ruling it in, though there is uncertainty in the estimate. The negative
20 likelihood ratio of 0.49 (95% CI, 0.29-0.82) suggests that a negative result for vascular
21 invasion is not particularly useful for ruling it out.

22 **Vascular invasion accuracy of FDG-PET/CT**

23 Low quality evidence from 1 prospective cohort study (n=104) found that standard FDG-
24 PET/CT had a low sensitivity of 0.68 (95% CI, 0.52-0.81) and a low specificity of 0.67 (95%
25 CI, 0.09-0.99) in detecting whether a pancreatic tumour has spread to the arteries and/or
26 veins in adults with suspected pancreatic cancer. The positive likelihood ratio of 2.05 (95%
27 CI, 0.41-10.26) suggests that a positive result for vascular invasion is not particularly useful
28 for ruling it in, though there is substantial uncertainty in the estimate. The negative likelihood
29 ratio of 0.48 (95% CI, 0.19-1.19) suggests that a negative result for vascular invasion is not
30 particularly useful for ruling it out, though there is uncertainty in the estimate.

31 **7.6.7 Tests for indicating laparoscopic resectability**

32 **Laparoscopic resectability accuracy of CA 19-9 \leq 150 kU/ml or \leq 300 kU/ml**

33 High quality evidence from 1 retrospective review of a prospective database (n=159) found
34 that a CA 19-9 level of 150 kU/ml or less for indicating laparoscopic resectability had a low
35 sensitivity of 0.44 (95% CI, 0.36-0.53) and a moderate specificity of 0.88 (95% CI, 0.68-0.97)
36 in adults with suspected pancreatic cancer. The positive likelihood ratio of 3.56 (95% CI,
37 1.21-10.42) suggests that a positive result for indicating laparoscopic resectability according
38 to this threshold is not particularly useful for ruling it in, though there is substantial uncertainty
39 in the estimate. The negative likelihood ratio of 0.63 (95% CI, 0.51-0.79) suggest that a
40 negative result for indicating laparoscopic resectability according to this threshold is not
41 particularly useful for ruling it out.

42 High quality evidence from the same study (n=145) found that a CA 19-9 level of 150 kU/ml
43 in people with a bilirubin level of less than 35 μ mol/l and a CA 19-9 level of 300 kU/ml or less
44 in people with a bilirubin level greater than 35 μ mol/l for indicating laparoscopic resectability
45 had a low sensitivity of 0.61 (95% CI, 0.52-0.69) and a moderate specificity of 0.8 (95% CI,
46 0.56-0.94) in adults with suspected pancreatic cancer with or without obstructive jaundice.

1 The positive likelihood ratio of 3.04 (95% CI, 1.25-7.39) suggests that a positive result for
2 indicating laparoscopic resectability according to these thresholds is not particularly useful for
3 ruling it in, though there is uncertainty in the estimate. The negative likelihood ratio of 0.49
4 (95% CI, 0.36-0.67) suggests that a negative result for indicating laparoscopic resectability
5 according to these thresholds is not particularly useful for ruling it out.

6 High quality evidence from the same study (n=71) found that a CA 19-9 level of 300 kU/ml or
7 less in people with a bilirubin level greater than 35 µmol/l for indicating laparoscopic
8 resectability had a low sensitivity of 0.29 (95% CI, 0.18-0.43) and a high specificity of 0.94
9 (95% CI, 0.7-1.0) in adults with suspected pancreatic cancer and obstructive jaundice. The
10 positive likelihood ratio of 5.43 (95% CI, 0.77-38.13) suggests that a positive result for
11 indicating laparoscopic resectability according to these thresholds is moderately useful for
12 ruling it in, though there is substantial uncertainty in the estimate. The negative likelihood
13 ratio of 0.74 (95% CI, 0.6-0.91) suggests that a negative result for indicating laparoscopic
14 resectability according to these thresholds is not particularly useful for ruling it out.

15 **Laparoscopic resectability accuracy of CA 19-9 ≤ 130 kU/ml**

16 High quality evidence from 1 retrospective review of a prospective database (n=262) found
17 that a CA 19-9 level of 130 kU/ml or less for indicating laparoscopic resectability had a low
18 sensitivity of 0.5 (95% CI, 0.43-0.57) and a moderate specificity of 0.75 (95% CI, 0.6-0.86) in
19 adults with potentially resectable pancreatic cancer. The positive likelihood ratio of 1.95 (95%
20 CI, 1.2-3.18) and negative likelihood ratio of 0.67 (95% CI, 0.55-0.83) suggest that neither a
21 positive nor negative result for indicating laparoscopic resectability according to this
22 threshold is particularly useful for ruling it in and ruling it out.

23 **7.7 Recommendations**

24 **20. For people with newly diagnosed pancreatic cancer who have not had a**
25 **pancreatic protocol CT scan, offer a pancreatic protocol CT scan that includes the**
26 **chest, abdomen and pelvis.**

27 **21. Offer fluorodeoxyglucose-positron emission tomography/CT (FDG-PET/CT) to**
28 **people with localised disease on CT who will be having cancer treatment (surgery,**
29 **radiotherapy or systemic therapy).**

30 **22. If more information is needed to decide the person's clinical management,**
31 **consider one or more of the following:**

- 32 • MRI, for suspected liver metastases
- 33 • endoscopic ultrasound, if more information is needed for tumour and
34 node staging
- 35 • laparoscopy with laparoscopic ultrasound, for suspected small-volume
36 peritoneal and/or liver metastases if resectional surgery is a possibility.

37 **See recommendation 19 on how care should be agreed and delivered.**

38 **7.8 Evidence to recommendations**

39 **7.8.1 Relative value placed on the outcomes considered**

40 Diagnostic accuracy (sensitivity, specificity, positive predictive value and negative predictive
41 value) for T staging, N staging, M staging, resectability and vascular invasion, and adverse
42 events were considered the critical outcomes for this question.

1 Resectability was reported for most studies. Staging information and vascular invasion were
2 reported for about half the studies. No studies reported adverse events.

3 **7.8.2 Quality of evidence**

4 Evidence was identified on CT, CT-3D, abdominal ultrasound, EUS, CT + EUS, laparoscopy
5 with laparoscopic ultrasound, MRI, FDG-PET/CT, EUS-FNA, CA 19-9 and diagnostic
6 laparoscopy + CT.

7 The quality of the evidence for the critical outcomes was as follows:

- 8 • resectability ranged from very low for CT and EUS, to low for abdominal US and moderate
9 for laparoscopy with LUS and combination CT and EUS
- 10 • overall TNM staging was low (for EUS-FNA and MRI), moderate (for CT and FDG-
11 PET/CT) or high (for CT, EUS and MRI)
- 12 • T staging ranged from moderate to high quality studies
- 13 • N staging ranged from very low for CT, low for abdominal US, low or moderate for FDG-
14 PET/CT and moderate or high for EUS and MRI
- 15 • M staging ranged from low for PER/CT, low or moderate for CT, and high for EUS, MRI
16 and diagnostic laparoscopy
- 17 • Vascular invasion ranged from low for CT and FDG-PET/CT, moderate for abdominal US,
18 moderate or high for EUS, and high for MRI.

19 The committee noted that in the Klek et al. (2014) study, most of the participants had a prior
20 ultrasound to stage the cancer. The committee considered that the use of abdominal
21 ultrasound for staging is inadequate in that it does not have the ability to detect metastases
22 outside of the abdomen and is operator dependent. Therefore, they did not use the data from
23 this study when making their recommendations.

24 The committee noted that many of the studies in this review included people with
25 periampullary cancers as well as pancreatic cancer. Where possible, the data for these 2
26 groups had been reported separately. However, in instances where they had been reported
27 together, the committee agreed that it was still appropriate to use this data to make
28 recommendations because it is not always possible to determine the primary origin of cancer
29 in the head of the pancreas.

30 The committee had more confidence in the quality of evidence from one of the studies
31 related to FDG-PET/CT (Ghaneh et al. 2018) because it was the largest (and multicentre)
32 study, was conducted in a UK NHS setting (and therefore directly applicable) and the study
33 design was judged by the committee to be more robust than that of the other included
34 studies. Therefore in their discussion the committee placed relatively more weight on the
35 findings from this study than on the rest of the evidence base.

36 **7.8.3 Consideration of clinical benefits and harms**

37 The committee noted, based on the evidence, that CT had good sensitivity and specificity for
38 T staging and identifying vascular invasion. They noted, based on their experience, that CT
39 is widely available, non-invasive and allows both local and distant sites to be imaged. The
40 committee agreed that the diagnostic accuracy of CT for N staging and M staging was not as
41 good as for some other investigations and, therefore, CT was not as good at picking up
42 smaller deposits and low volume disease in the liver, lymph nodes and peritoneum.
43 However, the committee agreed that the advantages of using CT, in terms of accessibility,
44 non-invasiveness and ability to image local and distant sites, made it the best choice for the
45 initial staging investigation.

46 Based on the evidence, the committee felt that FDG-PET/CT added significant additional
47 information, particularly with respect to detecting metastatic disease, and would reduce the

1 number of patients having unnecessary surgery or radical local treatment. Therefore, the
2 committee recommended that it should be offered to people with localised disease on CT in
3 whom cancer treatment is planned. They acknowledged the findings from the Health
4 Technology Assessment by Ghaneh et al. (2018) which showed that FDG-PET/CT corrected
5 the staging of pancreatic cancer in a significant proportion of patients. The committee also
6 noted that this study suggested that FDG-PET/CT influenced management in 45 percent of
7 patients, and prevented resection in 20 percent of patients scheduled for surgery. The
8 committee recognised that although recommending using FDG-PET/CT represents a
9 significant change in current practice, the evidence showed that FDG-PET/CT is clinically
10 important and cost effective. They noted that this recommendation on FDG-PET/CT does not
11 apply to people in whom best supportive care is the preferred option because the reason for
12 the staging is to guide further treatment (pharmacological or surgical).

13 Based on the evidence the committee noted that the role of MRI should be limited to those
14 people who have indeterminate liver lesions on CT and FDG-PET/CT and where
15 confirmation of liver metastases will change the treatment plan. The committee noted that
16 EUS had good sensitivity for T and N staging and it is possible to obtain histology and
17 cytology so agreed it was a useful supplementary investigation to perform. The committee
18 agreed that FDG-PET/CT and MRI do not have good enough resolution to pick up small
19 volume metastases in the peritoneum and liver. If such metastases are suspected, the
20 committee agreed that the better resolution at this scale provided by laparoscopy with
21 laparoscopic ultrasound, which had high sensitivity but low specificity, would be a useful test
22 if resectional surgery were being contemplated.

23 The committee agreed, based on the evidence available, that CA 19-9 did not appear to be a
24 useful staging investigation for pancreatic cancer. However, they noted that this evidence
25 was low quality and came from a limited number of studies. Therefore, they did not make any
26 recommendations about CA 19-9.

27 The committee agreed that the potential benefits of the recommendations made would be a
28 more effective and streamlined sequence of staging investigations for pancreatic cancer.
29 This would lead to improved staging and people getting the correct treatment. The committee
30 considered that the potential harms would be the risks associated with invasive investigative
31 procedures. However, they considered these risks were likely to be minimal compared with
32 the potential for benefit.

33 **7.8.4 Consideration of economic benefits and harms**

34 The literature search of previous economic evidence identified two economic evaluation
35 relevant to this topic. Morris et al. (2015) and Ghaneh et al. (2018) considered differing
36 interventions and therefore could not be compared directly.

37 The study by Morris et al. (2015) compared diagnostic laparoscopy (to assess the
38 resectability of a tumour) performed at an appointment prior to laparotomy to direct
39 laparotomy with no diagnostic work-up in people with pancreatic or periampullary cancer
40 which had been identified as resectable through CT scanning. The study took a UK NHS and
41 PSS perspective and was deemed to have only minor methodological issues. The model
42 concluded that a diagnostic laparoscopy would be both cost saving and health improving if
43 held at an appointment prior to surgery. Wasted operating theatre time could be averted in
44 patients identified as having unresectable tumours. The committee noted that both the cost
45 savings (£10) and health improvements (0.009 QALYS) per patient were small and did not
46 strongly indicate a preferred option. The results were sensitive to alternate assumptions
47 around key variables, especially around the proportion of patients with unresectable disease
48 sent to surgery and post-test probability of unresectable disease. During sensitivity analysis
49 no further diagnostic work-up prior to laparotomy became cost effective when the proportion
50 of unresectable patients going to surgery was less than 36% or the post test probability of
51 unresectable disease was greater than 22%. Given the clinical evidence for this topic both

1 these values were plausible. The uncertainty around the preferred option was further
2 highlighted by the probabilistic sensitivity analysis which showed that diagnostic laparoscopy
3 only had a 63.2% probability of being cost effective at a £20,000 willingness to pay per QALY
4 threshold. Whilst the committee acknowledged the study's high applicability and minor
5 methodological issues, given the uncertainties described above the committee did not base
6 any recommendations on this evidence.

7 The health technology assessment (HTA) by Ghaneh et al. (2018) was an economic
8 evaluation conducted alongside a UK prospective diagnostic accuracy study to assess
9 whether the addition of FDG-PET/CT to standard diagnostic and staging work-up was cost
10 effective in patients with suspected pancreatic ductal adenocarcinoma. The study strongly
11 suggested that the addition of FDG-PET/CT to the diagnostic work up of these patients
12 would lead to both cost savings and health improvements, mostly driven by the reduction in
13 unnecessary resections. The results were robust to alternative assumptions with a greater
14 than 80% probability of being cost effective at a £20,000 per QALY threshold even under the
15 less favourable assumptions around the costing of FDG-PET/CT. The conclusions were only
16 sensitive to structural assumptions. The committee did not consider the results of the
17 alternate structural assumptions as it seemed less plausible than the base case
18 assumptions.

19 As the HTA was a large UK study, with costs and outcomes collected prospectively and EQ-
20 5D quality of life data using UK population weightings (NICE's preferred measure) with only
21 minor methodological issues the committee agreed to make strong recommendations based
22 upon it. It was noted that the one year time horizon was too short but a longer time horizon is
23 likely to favour the more effective FDG-PET/CT, strengthening the conclusions of the study.

24 The committee acknowledged that there would be an initial significant resource impact from
25 a greater number of FDG-PET/CT scans but based on the conclusions of the HTA this would
26 be regained within the first year. It should be noted that the recommendations for this topic
27 differ slightly to those recommended by the HTA study as only those going on to receive
28 treatment (resection, radiotherapy or systemic treatment) would receive a FDG-PET/CT and
29 not all patients. This group make up a large proportion of patients and whilst the total number
30 of FDG-PET/CT scans would be slightly less it was unlikely to change the conclusions of the
31 HTA's analysis. Given the strong clinical and economic evidence for FDG-PET/CT the
32 committee agreed very strongly that this would be an efficient use of NHS resources.

33 **7.9 References**

34 Connor S, Bosonnet L, Alexakis, N et al. (2005) Serum CA19-9 measurement increases the
35 effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
36 *Digestive Surgery* 22(1-2): 80-85

37 DeWitt J, Devereaux B, Chriswell M et al. (2004) Comparison of endoscopic ultrasonography
38 and multidetector computed tomography for detecting and staging pancreatic cancer. *Annals*
39 *of Internal Medicine* 141(10): 753-763

40 Doucas H, Sutton CD, Zimmerman A et al. (2007) Assessment of pancreatic malignancy with
41 laparoscopy and intraoperative ultrasound. *Surgical Endoscopy* 21(7): 1147-1152

42 Fang CH, Zhu W, Wang H et al. (2012). A new approach for evaluating the resectability of
43 pancreatic and periampullary neoplasms. *Pancreatology* 12(4): 364-371

44 Farma JM, Santillan AA, Melis M et al. (2008) FDG-PET/CT fusion scan enhances CT
45 staging in patients with pancreatic neoplasms. *Annals of Surgical Oncology* 15(9): 2465-2471

46 Fischer U, Vosshenrich R, Horstmann O et al. (2002) Preoperative local MRI-staging of
47 patients with a suspected pancreatic mass. *European Radiology* 12(2): 296

- 1 Frstrup CW, Mortensen MB, Pless T et al. (2006) Combined endoscopic and laparoscopic
2 ultrasound as preoperative assessment of patients with pancreatic cancer. *HPB* 8(1): 57-60
- 3 Furukawa H, Uesaka K, Boku N (2008) Treatment decision making in pancreatic
4 adenocarcinoma: multidisciplinary team discussion with multidetector-row computed
5 tomography. *Archives of Surgery* 143(3): 275-280
- 6 Ghaneh P, Hanson R, Titman A et al. (2018) PET-PANC: multicentre prospective diagnostic
7 accuracy and health economic analysis study of the impact of combined modality ¹⁸fluorine-
8 2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography
9 scanning in the diagnosis and management of pancreatic cancer. *Health Technology
10 Assessment* 22(7)
- 11 Imbriaco M, Megibow AJ, Ragazzino A et al. (2005) Value of the single-phase technique in
12 MDCT assessment of pancreatic tumors. *American Journal of Roentgenology* 184(4): 1111-
13 1117
- 14 Klaus M, Mohr A, von Tengg-Koblighk H et al. (2008) A new invasion score for determining
15 the resectability of pancreatic carcinomas with contrast-enhanced multidetector computed
16 tomography. *Pancreatology* 8(2): 204-210
- 17 Klek S, Kulig J, Popiela T et al. (2004) The value of modern ultrasonographic techniques
18 and computed tomography in detecting and staging of pancreatic carcinoma. *Acta Chirurgica
19 Belgica* 104(6): 659-667
- 20 Koelblinger C, Ba-Ssalamah A, Goetzinger P et al. (2011) Gadobenate dimeglumine–
21 enhanced 3.0-T MR imaging versus multiphasic 64–detector row CT: prospective evaluation
22 in patients suspected of having pancreatic cancer. *Radiology* 259(3): 757-766
- 23 Kwon AH, Inui H, Kamiyama Y (2002) Preoperative laparoscopic examination using surgical
24 manipulation and ultrasonography for pancreatic lesions. *Endoscopy* 34(06): 464-468
- 25 Lemke AJ, Niehues SM, Hosten N et al. (2004) Retrospective digital image fusion of
26 multidetector CT and 18F-FDG PET: clinical value in pancreatic lesions—a prospective study
27 with 104 patients. *Journal of Nuclear Medicine* 45(8): 1279-1286
- 28 Liu RC & Traverso LW (2005) Diagnostic laparoscopy improves staging of pancreatic cancer
29 deemed locally unresectable by computed tomography. *Surgical Endoscopy and Other
30 Interventional Techniques* 19(5): 638-642
- 31 Maithel SK, Maloney S, Winston C et al. (2008) Preoperative CA 19-9 and the yield of
32 staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma.
33 *Annals of Surgical Oncology* 15(12): 3512-3520
- 34 Maluf-Filho F, Sakai P, Cunha JE et al. (2004) Radial endoscopic ultrasound and spiral
35 computed tomography in the diagnosis and staging of periampullary tumors. *Pancreatology*
36 4(2): 122-8
- 37 Mansfield SD, Scott J, Oppong K et al. (2008) Comparison of multislice computed
38 tomography and endoscopic ultrasonography with operative and histological findings in
39 suspected pancreatic and periampullary malignancy. *British Journal of Surgery* 95(12):1512-
40 20
- 41 Minniti S, Bruno C, Biasiutti C et al. (2003) Sonography versus helical CT in identification and
42 staging of pancreatic ductal adenocarcinoma. *Journal of Clinical Ultrasound* 31(4): 175-182
- 43 Morris S, Gurusamy KS, Sheringham J et al. (2015) Cost-effectiveness of diagnostic
44 laparoscopy for assessing resectability in pancreatic andperiampullary cancer. *BMC
45 Gastroenterology* 15(1): 44

- 1 Phoa SS, Tilleman EH, Delden OMV et al. (2005) Value of CT criteria in predicting survival in
2 patients with potentially resectable pancreatic head carcinoma. *Journal of Surgical Oncology*
3 91(1): 33-40
- 4 Roche CJ, Hughes ML, Garvey CJ et al. (2003) CT and pathologic assessment of
5 prospective nodal staging in patients with ductal adenocarcinoma of the head of the
6 pancreas. *American Journal of Roentgenology* 180(2): 475-80
- 7 Schachter PP, Avni Y, Shimonov M et al. (2000) The impact of laparoscopy and laparoscopic
8 ultrasonography on the management of pancreatic cancer. *Archives of Surgery* 135(11):
9 1303-1307
- 10 Shah D, Fisher WE, Hodges SE et al. (2008) Preoperative prediction of complete resection in
11 pancreatic cancer. *Journal of Surgical Research* 147(2): 216-220
- 12 Shami VM, Mahajan A, Loch MM et al. (2011) Comparison between endoscopic ultrasound
13 and magnetic resonance imaging for the staging of pancreatic cancer. *Pancreas* 40(4): 567-
14 570
- 15 Soriano A, Castells A, Ayuso C et al. (2004) Preoperative staging and tumor resectability
16 assessment of pancreatic cancer: prospective study comparing endoscopic ultrasonography,
17 helical computed tomography, magnetic resonance imaging, and angiography. *The American*
18 *Journal of Gastroenterology* 99(3): 492-501
- 19 Taylor AM, Roberts SA, Manson JM (2001) Experience with laparoscopic ultrasonography
20 for defining tumour resectability in carcinoma of the pancreatic head and periampullary
21 region. *British Journal of Surgery* 88(8): 1077-1083
- 22 Tellez-Avila FI, Chavez-Tapia NC, López-Arce G et al. (2012) Vascular invasion in
23 pancreatic cancer: predictive values for endoscopic ultrasound and computed tomography
24 imaging. *Pancreas* 41(4): 636-638
- 25 White RR, Paulson EK, Freed KS et al. (2001) Staging of pancreatic cancer before and after
26 neoadjuvant chemoradiation. *Journal of Gastrointestinal Surgery* 5(6): 626-633
- 27 Yoneyama T, Tateishi U, Endo I et al. (2014) Staging accuracy of pancreatic cancer:
28 comparison between non-contrast-enhanced and contrast-enhanced FDG-PET/CT.
29 *European Journal of Radiology* 83(10): 1734-1739

8 Support needs

8.1 Psychological support needs

Review question: What are the specific psychological support needs (including information) of adults who are diagnosed with pancreatic cancer and their families or carers (as appropriate) throughout the care pathway?

8.1.1 Introduction

People and their families or carers are often left devastated by a diagnosis of pancreatic cancer particularly when they learn that there are limited treatment options for the disease and often a poor prognosis. This means they can have significant psychological information and support needs to help them cope with the diagnosis of a life limiting disease and the impact this has on them and their families.

The disease and treatment for the disease can also leave people feeling very unwell and they may experience a range of symptoms that can impact on their quality of life and ability to take part in normal daily activities. These symptoms can include pain, anxiety, depression, fatigue, bowel or digestive problems, loss of appetite, itchiness and nausea. People and their families and carers need timely access to psychological, physical, practical and spiritual information and support to help them cope with these symptoms and side effects and maintain as good a quality of life as possible for as long as possible.

The NICE guideline 'Supportive and palliative care for adults with cancer' contains a recommendation that 'Assessment and discussion of peoples' needs for physical, psychological, social, spiritual and financial support should be undertaken at key points (such as at diagnosis; at commencement, during, and at the end of treatment; at relapse; and when death is approaching). NHS England in their guidance document implementing the cancer taskforce recommendations for commissioning person centred care for people affected by cancer (2016) stated that everyone with cancer should be offered a holistic needs assessment and care plan. However, feedback to national charities and from the National Cancer Patient Experience Survey suggests that this may not always be happening for pancreatic cancer patients and it is important that these assessments cover the specific needs of people with pancreatic cancer.

People and families and carers also need access to information and support to help them understand their diagnosis, the treatment and care options available and to fully participate in shared decision making.

Unfortunately, pancreatic cancer patients currently do not always get access to the support and information they need. National Patient Experience Surveys have shown that pancreatic cancer patients experience a worse experience of treatment and care than those with other cancer types. In particular, there are problems with how people receive their diagnosis and a lack of communication about diagnosis, type of cancer, treatment options and what to expect following discharge from hospital.

Access to a clinical nurse specialist has also been shown to improve patient experience through National Patient Experience Surveys and feedback to patient organisations. The NICE guidance 'Supportive and palliative care for adults with cancer' recommends that 'Teams may wish to consider nominating (with the agreement of each patient) a person to act as 'key worker'; this person might be, for instance, a community nurse, allied health professional, nurse specialist or social worker, and the role might involve orchestrating assessments to ensure patients' needs are elicited, ensuring care plans have been agreed with patients, ensuring findings from assessments and care plans are communicated to

1 others involved in a patient's care and ensuring patients know who to contact when help or
2 advice is needed'.

3 Research has identified that pancreatic cancer patients can have significant unmet needs in
4 the areas of psychological wellbeing, anxiety and depression, as well as the psychological
5 impact of pain, decreased energy or tiredness, fatigue and coping with bowel or digestive
6 problems caused by pancreatic cancer on daily living and quality of life. The diagnosis of
7 pancreatic cancer and the impact of the disease can also have a psychological impact on
8 carers or family members.

9 Guidance is needed on the specific psychological support needs of people with pancreatic
10 cancer and their families or carers.

11 8.1.1.1 Review protocol summary

12 The review protocol summary used for this question can be found in Table 76. Full details of
13 the review protocol can be found in Appendix C.

14 **Table 76: Clinical review protocol summary for the review of specific psychological**
15 **support needs**

Population	Adults with pancreatic cancer and their carers or family members
Context	<ul style="list-style-type: none"> • Psychological support needs/information: • Pain • Bowel/digestive problems • Nutritional concerns • Anxiety • Depression • Fatigue • Timing
Outcomes	<ul style="list-style-type: none"> • Health Related Quality of Life • Patient satisfaction • Patient/family/carer understanding of disease impact • Patient reported outcomes • Patient experience

16 8.1.2 Description of Clinical Evidence

17 The evidence for this topic was drawn from a total of fourteen studies employing primarily
18 qualitative methodologies to investigate the information and support needs of patients with
19 pancreatic cancer or the family and/or care-givers of people with pancreatic cancer. A
20 summary of the included studies is presented in Table 77.

21 Two studies (Arthur et al. 2016; Sun et al. 2016) assessed the effectiveness of specific
22 interventions designed to help meet the needs of pancreatic cancer patients. Arthur et al.
23 (2016) collected data to inform the development of a specific exercise and diet intervention
24 while Sun et al. (2016) conducted a pilot study to assess the feasibility of an interdisciplinary
25 supportive care planning intervention which included the development of tailored care plans
26 for patients and specific focus groups for information delivery.

27 Five studies (Chapple et al. 2012; Coleman et al. 2005; D'Angelica et al. 1998; Grant et al.
28 2015; Petrin et al. 2009) reported information and patient feedback around the source of
29 information and support and mode of delivery of information.

30 Three studies (Beesley et al. 2016a; Beesley et al. 2016b; Uitdehaag et al. 2015) reported on
31 the unmet needs of pancreatic cancer patients.

1 Two studies (Akizuki et al. 2016; Boyd et al. 2012) reported on depression and pancreatic
2 cancer.

3 The remaining two studies (Andersson et al. 2012; Schildmann et al. 2013) reported patients'
4 perceptions and opinions about their experiences following a pancreatic cancer diagnosis.

5 Given the qualitative nature of the evidence, a modified CASP checklist was used (see
6 methodology chapter).

7 Further information about the search strategy can be found in Appendix D. See study
8 selection flow chart in Appendix E, study evidence tables in Appendix F and list of excluded
9 studies in Appendix G.

10

11

1 **8.1.3 Summary of included studies**

2 A summary of the studies that were included in this review are presented in Table 77.

3 **Table 77: Summary of included studies**

Study	Sample Country	Type of psychological support	Measures	Outcomes
Akizuki 2016	110 pancreatic cancer patients Japan	n/a	Structured interviews (SCID-III-R)/questionnaires	Presence of depression and anxiety, time of onset
Andersson 2012	13 pancreatic or periampullary resected patients Sweden	n/a	Interviews	Qualitative analysis of lived experience post-recovery
Arthur 2016	51 survivors of resectable pancreatic cancer USA	Healthy lifestyle program to aid patients to manage their diet and exercise	Telephone survey	Interest in, preference for, perceived barriers and facilitators to participating in intervention program Acceptability and comfort of technology-based intervention using face-to-face applications (e.g. Skype)
Beesley, Janda et al. 2016	136 patients with suspected or confirmed pancreatic cancer Australia	Support services	Self-report questionnaire	Patient need and use of support services
Beesley, Wockner 2016	116 patients with pancreatic cancer Australia	Support services	Self-report questionnaire	Current and future patient need and use of support services
Boyd 2012	22 patients with confirmed pancreatic cancer USA	n/a	Questionnaires (PHQ9/PSWQ, UMSAQ)	Screening for depressive symptoms, general anxiety, sleep disturbance
Chapple 2012	40 patients, or relatives of people,	Internet	Interview	Use of internet

Study	Sample Country	Type of psychological support	Measures	Outcomes
	with pancreatic cancer UK			
Coleman 2005	600 postings on pancreatic cancer patient/family internet chatroom USA	FAQ module on PC website	Qualitative and quantitative analysis of chat room conversations	Pre- and post- qualitative and quantitative changes in chat room conversations
D'Angelica 1998	48 pancreatic resected patients USA	Information and emotional support	Questionnaire	Short- and long-term surgeon-patient communication, surgeon's role in providing emotional support
Grant 2015	Convenience sample of users of pancreatic cancer website USA	Palliative care nurse practitioner	Questionnaire	Use of PC website
Petrin 2009	First-degree relatives of people with pancreatic cancer USA	n/a	Interview	Relatives' experience of communicating about and adjusting to relative with PC
Schildmann 2013	12 confirmed pancreatic cancer with ≥1 CT regimen Germany	n/a	Interview	Qualitative analysis of perception/views of information and treatment decision making
Sun 2016	11 confirmed pancreatic cancer USA	Supportive care + education	Questionnaires (FACT-Hep, service use, financial burden)	Quality of life, service use, financial burden, satisfaction with intervention
Uitdehaag 2015	57 oesophageal or pancreaticobiliary cancer Netherlands	n/a	Questionnaires (PNPCQ, EORTC QLQ-PAN26)	Problems, needs, quality of life

1

Abbreviations: CT, chemotherapy; EORTC QLQ-PAN26, The European Organization for Research and Treatment of Cancer PAN26 ; FACT Hep, Functional Assessment of

Cancer Therapy-Hepatobiliary questionnaire; n/a, not applicable; PHQ9, Personal Health Questionnaire 9; PSWQ, Penn State Worry Questionnaire; PNPCQ, Problems and Needs for Palliative Care Questionnaire; QoL, quality of life; SCID III R, structured clinical interview for DSM III-R; University of Michigan Sleep Assessment Questionnaire

8.1.4 Clinical evidence profile

The methodologies in the majority of studies employed some form of questionnaire or interview to assess patient opinion and experience. In most cases, these were pre-existing, validated tools designed for the purpose of the study. Limitations of each study were assessed using a modified CASP Qualitative checklist and are detailed below in Table 78.

Table 78: Summary of clinical evidence for psychological support needs/information

Study	Population and methods	Risk of Bias	Study Quality
Akizuki et al. (2016)	Results of the study are based on a survey conducted >10 years ago	Unclear: new chemotherapy agents have been introduced which may give longer survival times however pancreatic cancer still has one of the poorest prognoses.	-
	Duration between baseline the follow-up assessment may have been too short.	Unclear: may not have been long enough to assess the predictive factors however given the poor prognosis for pancreatic cancer information regarding depression and anxiety in the 1-2 months post diagnosis is important.	-
Andersson et al. (2012)	Participants were recruited from the same hospital so the results are not generalisable to a wider pancreatic population	Unclear: the participants varied with regard to age, gender and follow-up time and the type of surgery is generally only carried out in specialist centres and likely to be only in a highly selected group of patients, so not clear what impact including patients from other centres would have on the results.	-
	Credibility of results	Low: to prevent retrospective distortion or misinterpretation, participants statements were followed up by additional questions	-
Arthur et al. (2016)	93% of participants were diagnosed with stage 1 or 2 pancreatic cancer	High: Bias towards more healthy survivors with longer survival times	-
	Small sample size	Low: pancreatic cancer is a rare cancer type	
	Methodology was not mixed methods	Unclear: Pilot study and there appeared to be consistency in the results	
Beesley et al. (2016a)	Analysis was cross-sectional and included patients with a wide variation in the time from diagnosis to questionnaire completion	Unclear: Not possible to determine temporal associations between access to services and supportive care needs	-

Study	Population and methods	Risk of Bias	Study Quality
	Higher proportion of people with resectable disease than would be found in the overall population	Unclear: likely to have underestimated the level of unmet need	
	Measure of supportive care needs was validated for patients with a mixture of prognoses	Unclear: possible there are other needs specific to palliation that have not been identified.	
Beesley et al. (2016b)	Small sample size	Low: appropriate analysis used to detect significant effects	-
	Participants in this study had better overall prognosis compared with the general overall population	Unclear: possible underestimation of supportive care needs particularly with increasing as the population in this study was indicative of increasing needs over time in patients with advanced cancer	
	Considerable intermittent missing data and attrition due to death/incapacity	Possible underestimation of the level of unmet needs as those who withdrew due to sickness were significantly less likely to have had a resection and non-curative disease was associated with higher odds of future needs	
Boyd et al. (2012)	Study carried out in a referral centre so patients likely to have had an initial diagnosis prior to clinic visit	Unclear: possible impact on the baseline depression measures, participants may have had depression prior to malignant diagnosis	-
	Protocol may have created opportunity for participant exclusion	Unclear: treating clinicians assessed suitability for inclusion and immediate referrals were made for severely depressed or anxious patients.	
	No data collected on the use of psychotropic drugs	Unclear	
Chapple et al. (2012)	No specific limitations	n/a	+
Coleman et al. (2005)	Convenience sample of patients, families and friends dealing with advanced cancer	Unclear: results cannot be generalised to all patients, family or friends dealing with non-life threatening forms of cancer	-
	No way to track the number of individual people who posted the 600 messages	High: possible unequal representation of the type of posters in this sample as some posters may post more than once	
	Assumption that posts are truthful and representative of people dealing with pancreatic cancer	Unclear: no way to know if people are misrepresenting themselves/experiences	
D'Angeli et al. (1998)	Survey conducted by medical personnel from the treating institution	Unclear: possible response bias as patients may be more likely to respond positively fear of insulting/upsetting the source of their life prolonging medical care	-

Study	Population and methods	Risk of Bias	Study Quality
	Patients are a select sample of elderly, white, middle to upper class patients being treated in a specialist centre	Unclear: possible selection bias meaning the results are not generalisable	
	Of the original cohort, 43% of patients had died and 16% of patients refused to take part	Unclear: possible only satisfied patients were surveyed although this is unlikely as dissatisfied often find surveys the ideal opportunity to express their feeling.	
Grant et al. (2015)	Small sample size of patients who had not read the webpage before responding and sample drawn from one site	Unclear: difficult to generalise the results as patients accessing other websites may have had different questions	-
	The modified CMSNS questions on the online survey were not validated for this population	Unclear	
Petrin et al. (2009)	Limitations not reported	Unclear risks of bias	-
Schildmann et al. (2013)	Selective memory and socially desirable answers may have influenced the narratives	Unclear risk of recall bias	
	Patients not receiving chemotherapy were excluded Small sample of patients selected from a single institution	Unclear risk of selection bias. Results cannot be generalised to the wider pancreatic population	-
Sun et al. (2016)	Small sample size and heterogeneous population regarding stage of disease and type of treatments	Unclear risk of selection bias. Results may not be generalised to the wider pancreatic population	-
Ultdehag et al. (2015)	Cross-sectional design measuring results at a single time point	Unclear: possible patients responses may change over time	
	Patients were excluded if they were too ill to participate	Possible underestimation of certain problems and needs in pancreatic cancer patients	-
	Small sample size	Unclear risk of selection bias	
	Symptoms analysed individually	Unclear: possible that symptom clusters should be analysed as some symptoms are related to each other	

1
2
3

1 8.1.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 8.1.6 Evidence Statements

8 8.1.6.1 Common information and support needs of pancreatic cancer patients and their 9 families and friends

10 In 1 low quality (-) study, the most commonly reported symptom in a chat room was pain and
11 this was the case both before and after the addition of a frequently asked questions (FAQ)
12 section. By comparison, questions relating to fatigue decline 3-fold after the introduction of
13 the FAQ section. Postings made describing end of life symptoms indicated a lack of
14 awareness that death was near. (Coleman et al. 2005).

15 In 1 low quality (-) study, messages sent via a website to a Palliative Care Nurse Practitioner
16 included questions relating to pain, gastrointestinal symptoms, post-operative complications
17 and nutrition (Grant et al. 2015).

18 In 1 low quality (-) study, fatigue was the primary problem of 88% of pancreatic patients,
19 followed by fear of physical suffering (79%), metastases (73%), inability to continue usual
20 activities (76%) and difficulties coping with the unpredictability of the future (73%) (Uitdehaag
21 et al. 2015).

22 In 1 low quality (-) study, pain, fatigue and overall treatment side effects were the most
23 commonly discussed physical themes at interdisciplinary meetings while the most common
24 psychological concerns included anxiety, changes in appearance, feeling sad and the
25 inability to work or undertake normal activities (Sun et al. 2016).

26 Reasons for seeking information and support varied across the studies however the common
27 themes emerging included seeking information on their diagnosis in relation to treatment,
28 survival or symptoms and seeking information on how to tell family or friends.

29 In 1 low quality (-) study, seeking information was one of the most commonly reported coping
30 strategies (Petrin et al. 2009).

31 *"I needed to get more information I think was the big thing. I needed to find out...so exactly
32 what does this mean? How big is the tumour? What's going on? You know, how did he know
33 he was even sick? I mean, what was he feeling? You know, I just needed to know
34 everything."*

35 In 1 low quality (-) study, patients reported a strong desire to return to normal daily routine
36 but had an awareness of the need for a recovery period (Andersson et al. 2012). In relation
37 to recapturing everyday life, food and drink were associated with negative experiences due
38 to symptoms such as altered taste. Eating was no longer pleasant and considered merely
39 necessary for the recovery process. And as a result of difficulties with food intake, weight did
40 not stabilise for a while and bodily changes resulted in various emotional problems
41 (Andersson et al. 2012):

42 *"The most difficult part was coming home and finding that food was not tasty and that I was
43 not hungry. I think it is fair to say that it was like being tired of food"*

1 *"I do not want to have close contact with other people. I realise that I do not like my own body*
2 *at present. It was a shock that I should think I was so repulsive"*

3 Prior to discharge participants in the same study had access to healthcare professionals
4 continuously providing them with attention and care. It was a shock to some participants that
5 they no longer had someone to rely on post discharge or to discuss their self-care
6 experiences with (Andersson et al. 2012):

7 *"It may be that that's it. Now that I have been discharged they do not care about me as much*
8 *as before. So now I'm discharged, written off somehow."*

9 Participants highlighted the importance of support from healthcare staff after discharge as
10 they felt it gave them a chance to discuss symptom management and self-care needs
11 (Andersson et al. 2012):

12 *"As soon as a problem arose, I phoned her. She always took the time and talked. If she*
13 *wasn't in, she would phone back. It was nice to know that I could contact her."*

14 In another low quality (-) study, patients expected professional care to help deal with pain,
15 the fear of physical suffering, fatigue and lack of appetite but did not feel they needed
16 professional care for issues relating to employment/study, inability to continue usual
17 activities, the frustration that they can do less or their dependency on others (Uitdehaag et al.
18 2015).

19 For the participants of 1 low quality (-) study, being healthy did not equate to being symptom
20 free with participants who experienced debilitating symptoms coping by using successful
21 symptom management (Andersson et al. 2012):

22 *"Good health may not necessarily mean that I am in top form but that I feel well, can manage*
23 *my everyday life and think that living is great fun"*

24 In another low quality (-) study, patients reported feeling as though they had no choice and
25 having limited interest in the details of treatment related information but that trust in the
26 physician was paramount (Schildmann et al. 2013):

27 *"I was told that this would be the only way to treat me, in this way. It does not work differently*
28 *for me. [...]Yes, and he said, 'You must do this' otherwise you won't live to see the next half*
29 *year."*

30 *"Did you want to know something specific about the operation?"*

31 *"No, I placed my life and my illness in the hands of the specialist and said you will do this*
32 *right[...]."*

33 *"One also needs a bit of trust in the doctor or total trust in such a thing. I think if I trust a*
34 *doctor then I would do what the doctor tells me. One must really have trust."*

35 **8.1.6.2 Interventions to meet specific needs of pancreatic cancer patients**

36 In 1 low quality (-) qualitative study (Arthur et al. 2016), a telephone survey was conducted
37 and data from 12 patients previously treated for resectable pancreatic cancer to inform the
38 development of an exercise and diet intervention was collected. The study reported that 69%
39 of participants indicated an interest in participating in a non-research exercise and diet
40 intervention and 32% of participants perceived there to be no barriers to program
41 participation. In relation to intervention preferences, 50% of participants indicated a
42 preference to exercise alone and 30% indicated a preference for supervised exercise. In
43 terms of information provision, 34% of participants indicated a preference to have exercise
44 information provided personally while 48% indicated a preference to have diet/nutrition
45 advice delivered personally.

1 One low quality (-) pilot study (Sun et al. 2016) assessed a nurse-led intervention to
2 determine the feasibility of an interdisciplinary supportive care planning intervention in 10
3 patients with pancreatic cancer. The intervention included a care plan completed by the
4 nurse and discussed at interdisciplinary meetings where care coordination recommendations
5 were made by the team which were tailored to individual patient need. Participants were also
6 invited to attend education sessions designed to educate patients on quality of life concerns.
7 There was a high level of satisfaction with 70% of patients rating the intervention as
8 'excellent' and 30% rating the intervention as 'very good'. 80% of participants considered the
9 time spent in the education sessions to be the right amount however 70% of participants
10 considered there to be too much information in the written manuals provided.

11 **8.1.6.3 Depression in pancreatic cancer**

12 Two low quality (-) studies (Akizuki et al. 2016; Boyd et al. 2012) reported on depression and
13 anxiety in patients diagnosed with pancreatic cancer. Boyd et al. (2012) assessed 22
14 patients with pancreatic cancer to investigate the association between symptoms of
15 depression and anxiety and sleep disturbances. The study reported a total of 60% of
16 participants reported mild (32%), moderate (23%) or moderately severe depressive
17 symptoms (5%). 40% of participants reported no symptoms of depression and no
18 participants reported severe depressive symptoms. In relation to general anxiety, 55% of
19 participants screened reported subclinical levels of anxiety (score of 0-40), 36% of
20 participants reported a moderate level of anxiety of possible clinical significance (score of 40-
21 60) and 5% (n=1) participant reported an anxiety score indicative of a likely anxiety disorder
22 (score >60).

23 In relation to sleep disturbances, 45% of participants reported no sleep disturbances, 41% of
24 participants recorded scores indicative of a potential sleep problem and 10% (n=2) recorded
25 scores indicative of a sleep problem. No correlation was observed between the scores for
26 depression or anxiety and sleep disturbances. There is a possible link between depressive
27 symptoms and sleep disturbances though this correlation was not significant (p=0.009). It
28 was estimated that 16% of the depressive score is explained by the SQ scores. Similarly,
29 there was a possible correlation between SAQ and cancer stage (p=0.08) and between PHQ
30 and stage (p=0.11), though again this was not significant.

31 Akizuki et al. (2016) reported 15 (13.6%) patients were diagnosed with depression and
32 anxiety at baseline; 12 of these patients experienced their first psychiatric symptoms
33 concomitant with or after onset of somatic symptoms (median=1 month after onset). Twelve
34 of these patients were assessed at follow-up and 4 of them continued to have psychiatric
35 disorders.

36 **8.1.6.4 Unmet needs**

37 Two low quality (-) studies (Beesley et al. 2016a; Beesley et al. 2016b) explored the unmet
38 needs of 136 patients with pancreatic cancer and how those needs changed over time.
39 Beesley et al. (2016a) reported that 32% of respondents described moderated to high unmet
40 needs relating to help with health system/information, 21% reported moderated to high
41 unmet patient care needs with no significant difference between patients following a palliative
42 care pathway or a surgical resection pathway. The most commonly reported 'moderate to
43 high' unmet need was 'participants not being able to do what they used to' (41%) and
44 'concerns about the worries of those close to them' (37%). Beesley et al. (2016b) reported no
45 significant change in the proportion of patients reporting moderate to high unmet needs over
46 time (70% at baseline versus 75% at four months: OR=0.9, 95% CI, 0.3-2.1). There was an
47 indication of a reduction in needs over time for patients who had complete surgical resection
48 (71%-63%) and an increase in needs for patients with locally advanced disease (73%-85%)
49 and metastatic disease (66%-88%).

1 Pancreatic cancer patients (n=33) in 1 low quality (-) study completed questionnaires
2 exploring problems and needs for palliative care and reported inadequate professional care
3 for their fear of physical suffering (34%), lack of written information (28%) and fatigue (22%)
4 (Uitdehaag et al. 2015).

5 One low quality (-) study (D'Angelica et al. 1998) investigated the experiences of 48 patients
6 regarding the face-to-face patient-surgeon communication relating to preparation for surgery
7 and information about the surgery. 94% of respondents did not require more time with their
8 surgeon and 92% were satisfied with the information provided and had no more questions
9 following their initial meeting. A total of 88% of respondents remembered their surgeon
10 discussing the necessity and explaining the surgical procedure and mean understanding
11 reported by patients was 4.7 (5 being complete understanding).

12 **8.1.6.5 The internet as a source of information and support**

13 Three studies (Chapple et al. 2012; Coleman et al. 2005; Grant et al. 2015) explored the role
14 of the internet as a source of information for pancreatic cancer patients and the families and
15 friends of pancreatic cancer patients. One high quality (+) study (Chapple et al. 2012)
16 reported that 80% of participants interviewed had used the internet at least once to find out
17 something in relation to their pancreatic cancer or had children, partners or friends who had
18 done so on their behalf. One low quality (-) study (Grant et al. 2015) reported an average of
19 62 visits per week to a specific pancreatic cancer website where patients could interact with
20 a palliative care nurse and ask questions.

21 One low quality (-) study (Coleman et al. 2005) explored the effect off adding an FAQ section
22 to a pancreatic cancer website and found that a greater proportion of chat room users were
23 seeking information after the addition of the FAQ section and the chat room was most likely
24 to be accessed by family members with only 7% of postings coming from pancreatic cancer
25 patients.

26 Reasons reported for using the internet included finding information about signs and
27 symptoms, treatments, medical terms, clinical trials and side effects of treatment; finding
28 information about how to prepare children for a parent's life threatening or terminal illness or
29 to raise awareness of pancreatic cancer (Chapple et al. 2012). Some participants appear to
30 find both support and information by going online:

31 *"And looking at the internet, was that useful or not?"*

32 *"Oh, very useful. I don't think I could have through it as well as I did without the information*
33 *that I got off the internet and the people that I spoke to on the internet as well, people that I*
34 *spoke to on the internet as well, people who had been through it. There was one lady in*
35 *particular; her sister had just had the Whipple's [operation] while I was waiting to have mine.*
36 *And her sister was absolutely wonderful, gave me in great detail...what her sister had gone*
37 *through with her operation, so I knew what to expect which was what I wanted..."*

38 *"How did you find those people on the Internet to ask questions?"*

39 *"I just did, I just kept searching in the search engines really under pancreatic cancer*
40 *headings, usually, or Whipple's, which was the operation. And that would bring up a wealth*
41 *of sites to look at. And it was just a case of going through the sites one by one, trawling*
42 *through them and seeing what they were and how they worked, and just negotiating my way*
43 *through them really."*

44 Some participants used the internet to confirm the information they were being given by
45 doctors (Chapple et al. 2012):

46 *"Have you looked at the internet considerably for information or not?"*

1 *“A fair amount. In general I found that the information which I got from the hospital has been*
2 *sufficient really for most of my needs. [Um], and I suppose I’ve used the internet a little bit, to*
3 *just confirm what I’ve been told is true. I think that obviously in the early stages, there was a*
4 *little bit of just generally trying to understand more about what pancreatic cancer means, and*
5 *the treatments available and so on.”*

6 One respondent noted that he was surprised to have had to search the internet to find his
7 own solution to symptoms he was suffering as a result of chemotherapy (Chapple et al.
8 2012):

9 *“And do you have to take any other medication? Or medicines like Creon because of the*
10 *pancreatic cancer?”*

11 *“I have to take Creon. It was me, I looked up Creon on the internet, you know because I was*
12 *getting, feeling so sick with everything I ate (...) and I spoke to the oncologist, I said, ‘Is there*
13 *an enzyme I can take?’ And he said ‘Yes there is’ and I thought ‘Oh it’s funny that I have to*
14 *ask for it, why didn’t they say there is an enzyme you can take.’ I looked it up on the internet*
15 *and it said you know, you often will be prescribed an enzyme, to help with the digestion of*
16 *these foods etcetera. Because you won’t be able to digest it. So I actually asked for that.”*

17 **8.1.6.6 Use of technology**

18 Three low-quality (-) studies reported on the use of technology. Beesley et al. (2016b)
19 reported that only 10% of the patients used a tablet to enter their own data into the system
20 with 90% of participants filling out the paper forms and the data were entered by research
21 staff.

22 Arthur et al. (2016) investigated the level of comfort of participants with using technology to
23 aid the delivery of an exercise and nutrition intervention. 54% of participants reported using a
24 smartphone or tablet and 58% reported they would be happy to use a loaned tablet. 62% of
25 participants reported using Wi-Fi at home and of these, 81% reported they were comfortable
26 using Wi-Fi. 44% of participants reported feeling comfortable using visual communication
27 technology such as Skype™ and FaceTime®.

28 From 1 study in which 39 participants completed an online survey, responses to the modified
29 computer mediated social network scale (CMSNS) showed that use of social networks
30 varied; 35.9% did not use them for gaining information on pancreatic cancer while 25.7%
31 used them daily. 76.9% of participants did not contact people through online social media to
32 ask for help or use internet chatrooms or discussion boards to get information on pancreatic
33 cancer (Grant et al. 2015).

34 **8.1.7 Recommendations**

35 **23. Throughout the person’s pancreatic cancer care pathway, specifically assess the**
36 **psychological impact of:**

- 37 • fatigue
38 • pain
39 • gastrointestinal symptoms (including changes to appetite)
40 • nutrition
41 • anxiety
42 • depression.

43 **24. Provide people and their family members or carers (as appropriate) with**
44 **information and support to help them manage the psychological impact of**
45 **pancreatic cancer on their lives and daily activities. This should be:**

- 1 • available on an ongoing basis
- 2 • relevant to the stage of the person's condition
- 3 • tailored to the person's needs.

4 **25. For more guidance on providing information and support, see the NICE guideline**
5 **on [patient experience in adult NHS services](#).**

6 **8.1.8 Evidence to recommendations**

7 **8.1.8.1 Relative value placed on the outcomes considered**

8 Health related quality of life, patient satisfaction, patient, family or carer understanding of
9 disease impact, patient reported outcomes and patient experience were the critical outcomes
10 for this question. All of these outcomes were reported qualitatively.

11 **8.1.8.2 Quality of evidence**

12 The committee noted that the majority of studies included in the evidence employed some
13 form of questionnaire or interview to assess patient opinion and experience. In most cases,
14 these were pre-existing, validated tools designed for the purpose of the study. There is,
15 therefore, the possibility that the study populations were highly selected and, in some
16 studies, were convenience samples. The committee noted that most studies had small
17 sample sizes.

18 The committee noted that there was very little evidence about the effective information and
19 support interventions to address the psychological needs of people with pancreatic cancer.
20 They, therefore, agreed to recommend further research in this area.

21 **8.1.8.3 Consideration of clinical benefits and harms**

22 The committee noted, based on the evidence, that people with pancreatic cancer have a
23 variety of psychological support needs. Common support needs reported by the evidence
24 included dealing with pain, fatigue and gastrointestinal symptoms and also issues around
25 food and nutrition. Based on the evidence, people with pancreatic cancer also often report
26 anxiety and depression.

27 The committee were aware, based on both the evidence and their knowledge of information
28 from national charities and National Patient Experience Surveys, that these psychological
29 support needs are often not met. They, therefore, made recommendations that information
30 should be provided in the areas that had been highlighted by the evidence. This will ensure
31 that the impact of these issues on people with pancreatic cancer is properly addressed.
32 Based on their experience, the committee noted that provision of support has traditionally
33 been associated with having advanced disease, but that all people with pancreatic cancer
34 were likely to have some psychological support needs. They, therefore, agreed to
35 recommend provision of information and support throughout the patient pathway.

36 However, the committee were aware, based on the evidence and their experience, that
37 people have individualised requirements for information and support. What information may
38 be enough for one person, may be too much or too little for someone else. They, therefore,
39 recommended that peoples' needs in these specific support areas, and those of their families
40 and carers, should be assessed in order to determine what level of information and support
41 they require.

1 **8.1.8.4 Consideration of economic benefits and harms**

2 The committee noted that no relevant published economic evaluations had been identified
3 and no additional economic analysis had been undertaken in this area.

4 They agreed that assessing peoples' need for support would require formalised time with a
5 healthcare professional and there were likely to be costs associated with doing this.
6 However, this would not all be additional costs as assessments are currently carried out, just
7 not necessarily this early in the pathway. Overall, the committee agreed these
8 recommendations were unlikely to have a significant resource impact as most of the costs
9 are already being incurred. The assessments will happen at a different time point to what
10 happens currently. This will mean earlier identification of issues and a reduction in the need
11 for later support requirements and healthcare professional time.

12 **8.1.8.5 Other considerations**

13 The committee noted that the NICE guidance on Patient experience in NHS adult services
14 makes recommendations on improving care in some areas such as good communication,
15 provision of information, treating the person as an individual and shared decision making
16 which are applicable to the care of people with pancreatic cancer. They, therefore, agreed it
17 was important to cross reference this guidance.

18 **8.1.9 Research recommendations**

19 **2. A qualitative study should be undertaken to evaluate information and support** 20 **interventions to address psychological needs at different points in the care** 21 **pathway for people with pancreatic cancer.**

22 People with pancreatic cancer often have unmet psychological support needs that impact on
23 their quality of life. These can be related to anxiety and depression, and to the psychological
24 impact of fatigue, pain, gastrointestinal symptoms (particularly changes to appetite) and
25 nutritional status. There has been very little research into the information and support
26 interventions that would meet these needs. Research would help identify effective
27 information and support interventions that would improve quality of life for people with
28 pancreatic cancer and their family members or carers. Outcomes of interest are:

- 29 • quality of life
- 30 • psychological wellbeing
- 31 • ability to carry out normal activities
- 32 • patient experience and patient-reported outcome measures.

33 **8.1.10 References**

34 Akizuki N, Shimizu K, Asai M et al. (2016) Prevalence and predictive factors of depression
35 and anxiety in patients with pancreatic cancer: a longitudinal study. Japanese journal of
36 clinical oncology 46(1): 71-7

37 Andersson T, Falk K, Bjerså K et al. (2012) Health Is Belonging: Lived Experiences during
38 Recovery after Pancreaticoduodenectomy. ISRN Nursing 5(Dec 2)

39 Arthur AE, Delk A, Demark-Wahnefried W et al. (2016) Pancreatic cancer survivors'
40 preferences, barriers, and facilitators related to physical activity and diet interventions.
41 Journal of Cancer Survivorship 10(6): 981-9

42 Beesley VL, Janda M, Goldstein D et al. (2016a) A tsunami of unmet needs: pancreatic and
43 ampullary cancer patients' supportive care needs and use of community and allied health
44 services. Psycho-Oncology 25(2): 150-7

- 1 Beesley VL, Wockner LF, O'Rourke P et al. (2016b) Risk factors for current and future unmet
2 supportive care needs of people with pancreatic cancer. A longitudinal study. Supportive
3 Care in Cancer 24(8): 3589-3599
- 4 Boyd AD, Brown D, Henrickson C et al. (2012) Screening for depression, sleep-related
5 disturbances, and anxiety in patients with adenocarcinoma of the pancreas: a preliminary
6 study. The Scientific World Journal May 22
- 7 Chapple A, Evans J, Ziebland S (2012) An alarming prognosis: how people affected by
8 pancreatic cancer use (and avoid) internet information. Policy & Internet 4(2): 1-20
- 9 Coleman J, Olsen SJ, Sauter PK et al. (2005) The effect of a Frequently Asked Questions
10 module on a pancreatic cancer Web site patient/family chat room. Cancer Nursing 28(6):
11 460-8
- 12 D'Angelica M, Hirsch K, Ross H et al. (1998) Surgeon-patient communication in the
13 treatment of pancreatic cancer. Archives of Surgery 133(9), 962-6
- 14 Grant MS, Wiegand DL, Dy SM (2015) Asking questions of a palliative care nurse
15 practitioner on a pancreatic cancer website. Palliative and Supportive Care 13(03): 787-93
- 16 Petrin K, Bowen DJ, Alfano CM et al. (2009) Adjusting to pancreatic cancer: perspectives
17 from first-degree relatives. Palliative and Supportive Care 7(03): 281-8
- 18 Schildmann J, Ritter P, Salloch S et al. (2013) 'One also needs a bit of trust in the doctor...':
19 a qualitative interview study with pancreatic cancer patients about their perceptions and
20 views on information and treatment decision-making. Annals of oncology 24(9): 2444-9
- 21 Sun V, Ruel N, Chung V et al. (2016) Pilot study of an interdisciplinary supportive care
22 planning intervention in pancreatic cancer. Supportive Care in Cancer 24(8): 3417-24
- 23 Uitdehaag MJ, Verschuur EM, van Eijck CH et al. (2015) Problems and Needs in Patients
24 With Incurable Esophageal and Pancreaticobiliary Cancer. Gastroenterology Nursing 38(1):
25 42-54

26 **8.2 Pain**

27 **Review question: What is the role of interventional techniques in the management of**
28 **pain from pancreatic cancer?**

29 **8.2.1 Introduction**

30 Pain is the commonest symptom reported by people with pancreatic cancer. Standard pain
31 management involves individualised titration of medication according to the World Health
32 Organisation (WHO) analgesic ladder. It is often necessary to combine different classes of
33 pharmacotherapy, including opioid and adjuvant analgesics, to successfully manage the pain
34 and reduce side effects.

35 Occasionally, various interventional techniques are employed to palliate the pain
36 experienced by some individuals. These procedures are targeted at the nerve supply to the
37 pancreas.

38 Methods involve injection with a drug and/or ethanol with the intention of nerve block or
39 neurolysis. Neurolysis can also be achieved by direct destruction of the nerve with surgical
40 techniques.

41 These interventional techniques can be performed by differing approaches. Percutaneous
42 radiological guidance (plain film, CT, MRI), endoscopic ultrasound and laparoscopic,
43 thorascopic or open surgery have all been utilised.

1 Uncertainty remains over which of these procedures and techniques is the most effective and
2 appropriate to palliate the pain in people with pancreatic cancer. Currently the methods used
3 can depend upon local expertise.

4 The appropriate timing in the administration of these techniques is also unclear. Current
5 variation in practice includes applying these techniques during the diagnostic process or later
6 during the illness trajectory.

7 Interventional techniques are often considered if adequate pain control is elusive for the
8 individual, or in an attempt to reduce the pharmacotherapy used and relieve unacceptable
9 side effects the individual is experiencing.

10 Guidance is needed on the role of interventional techniques to manage pain in people with
11 pancreatic cancer.

12 8.2.1.1 Review protocol summary

13 The review protocol summary used for this question can be found in Table 79. Full details of
14 the review protocol can be found in Appendix C.

15 **Table 79: Clinical review protocol summary for the review of interventional**
16 **techniques for the management of pain**

Population	Patients with pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Sympathectomy (splanchnicectomy) • Neurolytic Techniques (nerve block/ablation, coeliac plexus block/ablation, coeliac ganglion block/ablation, superior hypogastric block/ablation)
Comparison	<ul style="list-style-type: none"> • Each Other • Other methods of pain management
Outcomes	<ul style="list-style-type: none"> • Reduction in opioid medication • Pain Relief/ improved analgesia (pain scores) • Duration of effect/ duration of relief • Adverse Events (Diarrhoea, reduction in Opioid induced side effects) • HRQoL (functional domains) • Patient experience • PROMS • Overall survival

17 8.2.2 Description of Clinical Evidence

18 Six RCTs (Amr et al. 2013; Gao et al. 2014; Johnson et al. 2009; LeBlanc et al. 2011;
19 Özyalçin et al. 2004; Wyse et al. 2011) and 1 systematic review (Arcidiacono et al. 2011)
20 involving 6 RCTs (Kawamata et al. 1996; Lillemoe et al. 1993; Mercadante 1993; Polati et al.
21 1998; Wong et al. 2004; Zhang et al. 2008) were included in the review. A summary of the
22 included studies is presented in Table 80.

23 Three RCTs (Gao et al. 2014; Johnson et al. 2009; Wyse et al. 2011) and 1 systematic
24 review (Arcidiacono et al. 2011) compared the efficacy and safety of conventional analgesic
25 pain medication with or without neurolytic coeliac plexus blockade (NCPB) in patients with
26 pancreatic cancer (n=619).

27 One RCT (Amr et al. 2013) compared the efficacy and safety of controlling severe pain with
28 medication followed by performing a coeliac block with performing the coeliac block first
29 followed by medication for controlling severe pain in patients with pancreatic cancer (n=60).

1 One RCT (Johnson et al. 2009) compared the efficacy of NCPB plus medical management
2 versus thoracic splanchnicectomy plus medical management in adults with pancreatic cancer
3 (n=65). The same study compared the efficacy of thoracic splanchnicectomy plus medical
4 management with medical management alone in adults with pancreatic cancer.

5 One RCT (LeBlanc et al. 2011) compared pain relief given as 1 versus 2 injections during
6 EUS-guided NCPB in patients with pancreatic cancer (n=50).

7 One RCT (Özyalçın et al. 2004) compared the efficacy of NCPB and splanchnic neurolytic
8 blockade on pain caused by pancreatic cancer in the body and tail of the pancreas (n=39).

9 Where possible data were extracted from the included systematic review (Arcidiacono et al.
10 2011). Where there was not enough detail included in the review, the full copy of the original
11 studies (included in the review) were checked for accuracy and completeness.

12 AMSTAR (A Measurement Tool to Assess Systematic Reviews) was used for assessing the
13 methodological quality of systematic reviews; the Cochrane Collaboration's 'Risk of bias' tool
14 was used for assessing risk of bias of RCTs. Where possible, the risk of bias information was
15 taken from the systematic review (Arcidiacono et al. 2011) though in some cases, where
16 there was not enough detail included in the review, the original studies were used to
17 determine risk of bias.

18 Further information about the search strategy can be found in Appendix D. See study
19 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
20 study evidence tables in Appendix F and list of excluded studies in Appendix G.

21

22

1 **8.2.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 80.

3 **Table 80: Summary of included studies**

Study	Study Type	Population	Intervention	Comparison	Outcomes
Amr et al. (2013)	Unblinded RCT Duration: One year	N=60 patients randomised	Early NCPB (NCPB was performed early after the first meeting and then analgesic requirements were managed according to the severity of the pain WHO analgesic ladder).	Late NCPB (Medical management (analgesic therapy) was given first according to the WHO analgesic ladder and the NCPB was performed later when they reported a VAS score <40).	Reduction in opioid medication Pain Relief/ improved analgesia (pain scores) Adverse Events (Diarrhoea, reduction in Opioid induced side effects)
Arcidiacono et al. (2011)	Cochrane review (CR) Searches up to December 2010.	This CR includes 6 RCTs: Lillemoe et al. 1993: N=137; Mercadante et al. 1993: N=20; Polati et al. 1998: N=24; Kawamata et al. 1996: N=21; Wong et al. 2004: N=100; Zhang et al. 2008: N=56;	SR: CPB, the surgical approach, and EUS-guided neurolysis Included studies: Lillemoe et al. 1993: NCPB (chemical splanchnicectomy - Intraoperative bilateral 20 mL 50% ethanol) Mercadante et al. 1993: NCPB (X-ray posterior bilateral 25 ml 75% alcohol) Polati et al. 1998: Fluoroscopy posterior bilateral 7 mL 100% ethanol) Kawamata et al. 1996: NCPB (X-ray posterior bilateral 15 to 20 ml 80% ethanol) Wong et al. 2004: NCPB (Fluoroscopy posterior bilateral 10 mL 100% ethanol)	SR: NSAIDs and morphine Included studies: Lillemoe et al. 1993: analgesic therapy (NSAID, morphine). Mercadante et al. 1993: analgesic therapy (NSAID, morphine - saline). Polati et al. 1998: analgesic therapy (NSAID, morphine). Kawamata et al. 1996: analgesic therapy (NSAID, morphine) Wong et al. 2004: analgesic therapy (NSAID, morphine). Zhang et al. 2008: analgesic therapy (MS Contin - oral controlled-release morphine)	SR: Reduction in pain intensity using a visual analogue scale (VAS) or other pain relief scales (during the procedure the patients are usually sedated, so no discomfort will be reported). Consumption of analgesics. Included studies: Where possible data was extracted from the Cochrane SR. The full copy of the study was checked for accuracy and completeness. additional outcomes extracted from primary studies Lillemoe et al. 1993

Study	Study Type	Population	Intervention	Comparison	Outcomes
			Zhang et al. 2008: NCPB (CT-guided posterior bilateral block with 20 ml 100% ethanol)		Pain Relief (VAS pain scores) Adverse effect Overall survival Mercadante et al. 1993 Reduction in opioid medication Pain Relief (VAS pain scores) Adverse effect Polati et al. 1998 Reduction in opioid medication Adverse effect Kawamata et al. 1996 Pain Relief (VAS pain scores) Reduction in opioid medication Adverse effect Health Related Quality of Life (functional domains) PROS Wong et al. 2004 Pain Relief (VAS pain scores) Reduction in opioid medication Adverse effect Overall survival Zhang et al. 2008 Reduction in opioid medication

Study	Study Type	Population	Intervention	Comparison	Outcomes
					Pain Relief (VAS pain scores) Adverse effect HRQoL (functional domains)
Özyalçın et al. (2004)	Outcomes' assessor blinded RCT Duration: 18 weeks	N=39 patients randomised	NCPB (performed by transaortic techniques by injecting 40 mL of ethanol approx. 75% -30 ml of ethanol 96%+10 ml of lidocaine 10 mg/ml)	SNB (Splanchnic nerves neurolytic blockade – 6 ml of ethanol approx. 75% solution -4.5 ml ethanol 96% + 1.5 ml of lidocaine 10 mg/ml -was administered bilaterally -a total of 12 ml)	Reduction in opioid medication Pain Relief/ improved analgesia (pain scores)
LeBlanc et al. (2011)	Single (patients) blinded RCT Duration: not clear	N=50 patients randomised	EUS-NCPB (1 injections) All patients received the same amount of medication (20 mL 0.75% bupivacaine and 10 mL 98% alcohol). In the G1, the medication was injected into the base of the coeliac trunk at its origin from the aorta.	EUS-NCPB (2 injections) In the G2, half of the medication was injected into both sides of the coeliac trunk	Reduction in pain medication Pain Relief
Wyse et al. (2011)	Double blinded RCT Duration: 3 months	N=96 patients randomised	EUS-NCPB In patients assigned to G2, the technique was performed immediately using a 19-gauge needle (Echotip 19, Cook Medical, Winston-Salem, NC) with bilateral injection around the coeliac axis with a total of 10 mL of 0.5% bupivacaine and 20 mL of 100% alcohol.	Conventional pain management	Reduction in opioid medication Pain Relief/ improved analgesia (pain scores)

Study	Study Type	Population	Intervention	Comparison	Outcomes
Johnson et al. (2009)	Open RCT Duration: 2 months	N=65 patients (58 with PC) were randomised (18 withdrew)	MM + NCPB (injection of a neurolytic agent -usually alcohol- in two sites adjacent to the coeliac trunk, aorta and vertebral bodies to achieve bilateral destruction of the coeliac plexus and/or splanchnic nerves) MM + thoracoscopic splanchnicectomy-TS (patient positioned prone under general anaesthesia with a single lumen endotracheal tube, and partial lung collapse induced by pneumothorax)	MM – medical management (oral morphine-or other opioid- was prescribed according to standard practice at each centre)	Pain Relief/ improved analgesia (pain scores)
Gao et al. (2014)	Blinded RCT Duration: 2 months	N=100 patients randomised	G1: NCPB + pain medication (EUS-NCPB was carried out using a 19-gauge needle injecting 10 mL 100% alcohol + 5 mL 0.5% bupivacaine on each side of the coeliac take-off)	G2: Sham procedure (pain medication alone: same medication [analgesic therapy] injected into gastric lumen)	Reduction in opioid medication Pain Relief/ improved analgesia (pain scores) HRQoL (functional domains) PROS

1 CPB: Coeliac plexus block; SR: Cochrane review; EUS: Endoscopic ultrasound; MM: Medical management; NCPB: Neurolytic coeliac plexus block; NSAID: Non-steroidal anti-
2 inflammatory drugs; PC: Pancreatic cancer; RCT: Randomised controlled trial; SNB: Splanchnic nerves neurolytic blockade; TS: Thoracic splanchnicectomy; VAS:
3 Visual Analogue Scale; WHO: World Health Organization.

1
2
3
4

1 **8.2.4 Clinical evidence profile**

2 The clinical evidence profiles for this review question are presented in Table 81 to Table 86.

3 **Table 81: Summary clinical evidence profile for neurolytic coeliac plexus blockade**
4 **versus medical management alone in adults with pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
Overall Survival Follow-up: 6 months	Median time: 6.1 (n.r.) months	Median time: 5.5 (n.r.) months	HR 0.80 (0.50 to 1.28)	100 (1 study ⁶)	⊕⊕⊕⊖ moderate ²⁴	
Reduction in opioid medication: Opioid use at 2 weeks Follow-up: 2 weeks		The mean reduction in opioid medication: opioid use at 2 weeks in the intervention groups was 64.52 lower (99.45 to 29.59 lower)		76 (2 studies ¹)	⊕⊕⊕⊖ low ^{2,3}	
Reduction in opioid medication: Opioid use at 4 weeks		The mean reduction in opioid medication: opioid use at 4 weeks in the intervention groups was 51.07 lower (82.71 to 19.43 lower)		120 (4 studies ⁴)	⊕⊕⊕⊖ low ³	
Reduction in opioid medication: Opioid use the day before to death		The mean reduction in opioid medication: opioid use the day before to death in the intervention groups was 48.52 lower (68.82 to 28.22 lower)		111 (4 studies ⁴)	⊕⊕⊕⊖ low ⁵	
Reduction in opioid medication: Percentage change in		The mean reduction in opioid medication: percentage		100 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
analgesic medications use and 3 months - NSAIDs		change in analgesic medications use and 3 months - nsaid in the intervention groups was 54.6 lower (54.82 to 54.38 lower)				
Reduction in opioid medication: Percentage change in analgesic medications use and 3 months - Morphine		The mean reduction in opioid medication: percentage change in analgesic medications use and 3 months - morphine in the intervention groups was 76.6 lower (76.8 to 76.4 lower)		100 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
Reduction in opioid medication: Percentage change in analgesic medications use and 3 months - Oxycodone		The mean reduction in opioid medication: percentage change in analgesic medications use and 3 months - oxycodone in the intervention groups was 68.4 lower (68.7 to 68.1 lower)		100 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
Reduction in opioid medication: Absolute change in morphine use at 1 month		The mean reduction in opioid medication: absolute change in morphine use		98 (1 study ⁶)	⊕⊖⊖⊖ very low ^{8,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
		at 1 month in the intervention groups was 1 lower (48.5 lower to 46.5 higher)				
Reduction in opioid medication: Absolute change in morphine use at 3 months		The mean reduction in opioid medication: absolute change in morphine use at 3 months in the intervention groups was 50 lower (118.52 lower to 18.52 higher)		98 (1 study ¹⁰)	⊕⊕⊕⊕ very low ^{8,9}	
Pain Relief/ improved analgesia: Pain scores at 2 weeks		The mean pain relief/ improved analgesia: pain scores at 2 weeks in the intervention groups was 0.34 standard deviations lower (1.09 lower to 0.4 higher)		109 (3 studies ¹¹)	⊕⊕⊕⊕ low ^{2,12}	SMD - 0.34 (-1.09 to 0.4)
Pain Relief/ improved analgesia: Pain scores at 4 weeks		The mean pain relief/ improved analgesia: pain scores at 4 weeks in the intervention groups was 0.43 lower (0.73 to 0.14 lower)		173 (4 studies ¹³)	⊕⊕⊕⊕ moderate ¹⁴	
Pain Relief/ improved analgesia: Pain scores at 8 weeks		The mean pain relief/ improved analgesia: pain scores at 8 weeks in the		279 (6 studies ^{10,13,15})	⊕⊕⊕⊕ low ^{9,14}	SMD - 1.09 (-2.33 to 0.15)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
		intervention groups was 1.09 standard deviations lower (2.33 lower to 0.15 higher)				
Patients reporting effective pain management - 2 weeks	316 per 1000	357 per 1000 (114 to 704)	RR 1.13 (0.43 to 2.97)	33 (1 study ¹⁵)	⊕⊕⊕⊕ very low ^{16,17,18}	
Patients reporting effective pain management - 8 weeks	417 per 1000	554 per 1000 (183 to 875)	RR 1.33 (0.55 to 3.24)	21 (1 study ¹⁵)	⊕⊕⊕⊕ very low ^{16,17,18}	
Absolute Change in Pain score at 1 and 3 months - 1 Month		The mean absolute change in pain score at 1 and 3 months - 1 month in the intervention groups was 1 lower (1.73 to 0.27 lower)		98 (1 study ¹⁰)	⊕⊕⊕⊕ moderate ¹⁹	
Absolute Change in Pain score at 1 and 3 months - 3 months		The mean absolute change in pain score at 1 and 3 months - 3 months in the intervention groups was 2.3 lower (3.09 to 1.51 lower)		98 (1 study ¹⁰)	⊕⊕⊕⊕ moderate ¹⁹	
Adverse effects: constipation	525 per 1000	199 per 1000 (131 to 310)	RR 0.38 (0.25 to 0.59)	161 (6 studies ²⁰)	⊕⊕⊕⊕ moderate ²¹	
Adverse effects: diarrhoea	33 per 1000	108 per 1000 (32 to 371)	RR 3.25 (0.95 to 11.13)	121 (4 studies ²²)	⊕⊕⊕⊕ low ^{23,24}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
QOL scores at 1 month - Appetite		The mean QOL scores at 1 month - appetite in the intervention groups was 0.3 higher (0.57 lower to 1.17 higher)		56 (1 study ²⁵)	⊕⊕⊕⊕ very low ^{18,26}	
QOL scores at 1 month - Sleep		The mean QOL scores at 1 month - sleep in the intervention groups was 0.5 higher (0.55 lower to 1.55 higher)		56 (1 study ²⁵)	⊕⊕⊕⊕ very low ^{18,26}	
QOL scores at 1 month - communication		The mean QOL scores at 1 month - communication in the intervention groups was 1.1 lower (2.27 lower to 0.07 higher)		56 (1 study ²⁵)	⊕⊕⊕⊕ low ^{24,26}	
QOL scores at 3 months - Appetite		The mean QOL scores at 3 months - appetite in the intervention groups was 0.3 lower (1.48 lower to 0.88 higher)		56 (1 study ²⁵)	⊕⊕⊕⊕ very low ^{18,25}	
QOL scores at 3 months - Sleep		The mean QOL scores at 3 months - sleep in the intervention groups was 0.2 higher (1 lower to 1.4 higher)		56 (1 study ²⁵)	⊕⊕⊕⊕ very low ^{18,26}	
QOL scores at 3 months - Communication		The mean QOL scores at 3 months - communication in the		56 (1 study ²⁵)	⊕⊕⊕⊕ very low ^{18,26}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
		intervention groups was 0.4 higher (0.65 lower to 1.45 higher)				
QOL scores at 3 months - Physical function		The mean QOL scores at 3 months - physical function in the intervention groups was 11.6 higher (8.26 to 14.94 higher)		100 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
QOL scores at 3 months - Role function		The mean QOL scores at 3 months - role function in the intervention groups was 1.6 higher (1.77 lower to 4.97 higher)		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	
QOL scores at 3 months - Emotional function		The mean QOL scores at 3 months - emotional function in the intervention groups was 18 higher (14.53 to 21.47 higher)		100 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
QOL scores at 3 months - Cognitive function		The mean QOL scores at 3 months - cognitive function in the intervention groups was 2.9 higher (3.76 lower to 9.56 higher)		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	
QOL scores at 3 months - Social function		The mean QOL scores at 3 months - social function in the intervention groups was		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
		1 higher (3.57 lower to 5.57 higher)				
QOL scores - Digestive Disease questionnaire-15: 1 month		The mean QOL scores - digestive disease questionnaire-15: 1 month in the intervention groups was 8 higher (0.07 to 15.93 higher) ²⁷		98 (1 study ¹⁰)	⊕⊕⊖⊖ low ^{8,24}	
QOL scores - Digestive Disease questionnaire-15: 3 months		The mean QOL scores - digestive disease questionnaire-15: 3 months in the intervention groups was 1 higher (9.73 lower to 11.73 higher) ²⁷		98 (1 study ¹⁰)	⊕⊕⊖⊖ low ^{8,24}	
QOL scores – Global quality at 3 months		The mean QOL scores – global quality at 3 months in the intervention groups was 14.3 higher (14.1 to 14.5 higher) ²⁸		100 (1 study ⁶)	⊕⊕⊖⊖ low ⁷	
QOL scores – Symptom at 3 months - Fatigue		The mean QOL scores – symptom at 3 months - fatigue in the intervention groups was 16.7 higher (11.97 to 21.43 higher) ²⁸		100 (1 study ⁶)	⊕⊕⊖⊖ low ⁷	
QOL scores – Symptom at 3 months -		The mean QOL scores – symptom at 3		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
Nausea/vomiting		months - nausea/vomiting in the intervention groups was 1.6 higher (2.59 lower to 5.79 higher) ²⁸				
QOL scores – Symptom at 3 months - Pain		The mean QOL scores – symptom at 3 months - pain in the intervention groups was 33.9 lower (38.64 to 29.16 lower) ²⁸		100 (1 study ⁶)	⊕⊕⊕⊖ low ⁷	
QOL scores – Symptom at 3 months - Dyspnea		The mean QOL scores – symptom at 3 months - dyspnea in the intervention groups was 0.3 higher (7.15 lower to 7.75 higher) ²⁸		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	
QOL scores – Symptom at 3 months - Insomnia		The mean QOL scores – symptom at 3 months - insomnia in the intervention groups was 40.9 lower (46.6 to 35.2 lower) ²⁸		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	
QOL scores – Symptom at 3 months - Appetite loss		The mean QOL scores – symptom at 3 months - appetite loss in the intervention groups was 28.8 lower (35.28 to 22.32 lower) ²⁸		100 (1 study ⁶)	⊕⊕⊕⊖ low ⁷	
QOL scores – Symptom at 3		The mean QOL scores –		100 (1 study ⁶)	⊕⊖⊖⊖ very low ^{7,18}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
months - Constipation		symptom at 3 months - constipation in the intervention groups was 1.2 higher (7.12 lower to 9.52 higher) ²⁸				
QOL scores – Symptom at 3 months - Financial difficulties		The mean QOL scores – symptom at 3 months - financial difficulties in the intervention groups was 1.1 lower (3.03 lower to 0.83 higher) ²⁸		100 (1 study ⁶)	⊕⊕⊕⊕ very low ^{7,18}	
QOL scores – Symptom 3 months - Diarrhoea		The mean QOL scores – symptom 3 months - diarrhoea in the intervention groups was 0.7 lower (2.12 lower to 0.72 higher) ²⁸		100 (1 study ⁶)	⊕⊕⊕⊕ very low ^{7,18}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Mercadante et al. 1993 and Zhang et al. 2010

2 Evidence was downgraded by 1 due to unclear selection bias in all studies and potential risk of performance bias (no blinding of outcome assessors) in Mercadante et al. 1993

3 Serious inconsistency: I²=80%

4 Mercadante et al,1993; Kawamata et al,1996; Polati et al. 1998; Zhang et al. 2008

5 Evidence was downgraded by 1 due to potential risk of performance bias (no blinding of outcome assessors) in 2 studies (Mercadante et al,1993; Kawamata et al,1996) and potential selection bias in all studies

6 Gao et al. 2014

7 The quality of the evidence was downgraded because of the uncertain risk of selection and potential risk of performance bias (no blinding of outcome assessors)

8 The quality of the evidence was downgraded due to potential risk of contamination bias: 2 patients from the control group received open-label CPN at 43 and 52 days

9 The quality of the evidence was further downgraded from moderate to low due to imprecision in the effect size estimates (95%CI crossed two default MIDs)

10 Wyse et al. 2011

11 Jonshon 2009; Mercadante et al. 1993; Zhang et al. 2008.

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Medical management (MM)	NCPB				
<p>12 Serious inconsistency: I²=71%</p> <p>13 Kamawata et al. 1996, Wong 1994; Mercadante et al. 1993; Zhang et al. 2008.</p> <p>14 The quality of the evidence was downgraded from high to moderate because of the unclear risk of selection bias in two studies (Mercadante et al. 1993; and Zhang et al. 2008) and potential risk of performance bias (Kamawata et al. 1996; Mercadante et al. 1993)</p> <p>15 Johnson et al. 2009</p> <p>16 The quality of the evidence was downgraded from high to moderate because of the potential risk of performance bias (no blinding of outcome assessors) and unclear risk of attrition bias</p> <p>17 The quality of the evidence was further downgraded from moderate to low due to indirectness in Johnson et al. 2009 (the cohort included 65 patients (only 58 with PC)</p> <p>18 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID</p> <p>19 The quality of the evidence was downgraded due to potential risk of contamination bias: 2 patients from the control group received open-label CPN at 43 and 52 days</p> <p>20 Kawamata et al. 1996; Lillimoe 1993; Mercadante et al. 1993; Polati et al. 1998; Wong et al. 2004; Zhang et al. 2008</p> <p>21 Evidence was downgraded by 1 due to performance bias: no blinding of outcome assessors in 2 studies (Mercadante et al. 1993; Kawamata et al. 1996) and unclear selection bias in 5 studies (Lillemoie et al. 1993; Mercadante et al. 1993; Polati et al. 1998; Kawamata et al. 1996; Zhang et al. 2008)</p> <p>22 Kawamata et al. 1996; Mercadante et al. 1993; Polati et al. 1998; Zhang et al. 2008</p> <p>23 Evidence was downgraded by 1 due to performance bias: no blinding of outcome assessors in 2 studies (Mercadante et al. 1993; Kawamata et al. 1996) and unclear selection bias in all studies (Mercadante et al. 1993; Polati et al. 1998; Kawamata et al. 1996; Zhang et al. 2008)</p> <p>24 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MID. This outcome was therefore downgraded for imprecision by one level as it was not statistically significant.</p> <p>25 Zhang et al. 2008</p> <p>26 The quality of the evidence was downgraded from high to moderate because of the potential risk of attrition bias and unclear risk of selection bias</p> <p>27 The QOL scores were collected by means of the Digestive Disease questionnaire-15</p> <p>28 The QOL scores were collected by means of the questionnaire "Changes in function and symptom scores on European Organization for Research and Treatment of Cancer QLQ-C30"</p>						

1
2

Table 82: Summary clinical evidence profile for early NCPB versus late NCPB in adults with pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Late NCPB	Early NCPB				
Reduction in opioid medication: Oral morphine use at 16 weeks		The mean reduction in opioid medication: oral morphine use at 16 weeks in the intervention groups was 55.82 higher (40.91 to 70.73 higher)		23 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Reduction in opioid medication: Oral morphine use at 24 weeks		The mean reduction in opioid medication: oral morphine use at 24 weeks in the intervention groups		22 (1 study ¹)	⊕⊕⊕⊖ moderate ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Late NCPB	Early NCPB				
		was 62.41 higher (46.07 to 78.75 higher)				
Reduction in opioid medication: Oral Tramadol Hydrochloride use at 16 weeks		The mean reduction in opioid medication: oral tramadol hydrochloride use at 16 weeks in the intervention groups was 209.68 higher (143.2 to 276.16 higher)		21 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Reduction in opioid medication: Oral Tramadol Hydrochloride use at 24 weeks		The mean reduction in opioid medication: oral tramadol hydrochloride use at 24 weeks in the intervention groups was 160 higher (1.9 to 318.1 higher)		12 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Pain Relief/ improved analgesia: Pain scores at 16 weeks		The mean pain relief/ improved analgesia: pain scores at 16 weeks in the intervention groups was 21.3 higher (18.88 to 23.72 higher) ⁵		60 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Pain Relief/ improved analgesia: Pain scores at 24 weeks		The mean pain relief/ improved analgesia: pain scores at 24 weeks in the intervention groups was 26 higher (22.34 to 29.66 higher) ⁵		60 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Adverse effects: nausea	33 per 1000	333 per 1000 (45 to 1000)	RR 10 (1.36 to 73.33)	60 (1 study ¹)	⊕⊕⊖⊖ low ^{2,6}	
Adverse effects: constipation	267 per 1000	533 per 1000 (269 to 1000)	RR 2 (1.01 to 3.95)	60 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Adverse effects: pliritus	33 per 1000	100 per 1000 (11 to 908)	RR 3 (0.33 to 3.33)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Late NCPB	Early NCPB				
			to 27.23)			
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio;</p> <p>1 Amr et al. 2013 2 The quality of the evidence was downgraded from high to moderate due to potential indirectness (as the randomised trial was conducted in Egypt and the outcomes may not be transferrable to the UK settings) 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed 1 default MID 5 Pain relief was assessed using the visual analogue scale (VAS) pain score 6 The low sample size doesn't allow for precision in the effect estimates</p>						

1
2
3

Table 83: Summary clinical evidence profile for NCPB plus medical management versus thoracic splanchnicectomy plus medical management in adults with pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Thoracic splanchnicectomy + MM	NCPB + MM				
Pain Relief/ improved analgesia: Pain scores at 2 weeks		The mean pain relief/ improved analgesia: pain scores at 2 weeks in the intervention groups was 0.16 higher (1.31 lower to 1.63 higher) ¹		28 (1 study ²)	⊕⊖⊖ ⊖ very low ^{3,4,5}	
Pain Relief/ improved analgesia: Pain scores at 8 weeks		The mean pain relief/ improved analgesia: pain scores at 8 weeks in the intervention groups was 1.02 lower (2.95 lower to 0.91 higher) ¹		18 (1 study ²)	⊕⊖⊖ ⊖ very low ^{3,4,5}	
Patients reporting effective pain management at 2 weeks	286 per 1000	357 per 1000 (100 to 731)	RR 1.25 (0.35 to 2.56) ⁶	28 (1 study ²)	⊕⊖⊖ ⊖ very low ^{3,4,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Thoracic splanchnicectomy + MM	NCPB + MM				
Patients reporting effective pain management at 2 months	364 per 1000	556 per 1000 (171 to 884)	RR 1.53 (0.47 to 2.43) ⁶	20 (1 study ²)	⊕⊕⊕⊖ ⊖ very low ^{3,4,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Pain scores were assessed using a 4-point Likert scale

2 Jonshon et al. 2009

3 The quality of the evidence was downgraded from high to moderate because of the potential risk of performance bias (no blinding of outcome assessors) and unclear risk of attrition bias

4 The quality of the evidence was further downgraded from moderate to low due to indirectness in the study population (the cohort included 65 patients (only 58 with PC)

5 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

6 Patients reporting effective pain relief was assessed as one or more of the following: (i) a Brief Pain Inventory (BPI) 'worst' pain rated over the last week as 0-4 (none or mild), (ii) a reduction of >50% between the mean of the three BPI items ('worst', 'least' and 'average') obtained at the baseline assessment and that obtained at the 2-month assessment, (iii) a decrease from baseline to 2 months of at least 2 points in the response to the question 'During the past week, have you had pain?'

1
2
3

Table 84: Summary clinical evidence profile for thoracic splanchnicectomy plus medical management versus medical management alone in adults with pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	MM	Thoracic splanchnicectomy + MM				
Pain Relief/ improved analgesia: Pain scores at 2 and 8 weeks - Pain scores at 2 weeks		The mean pain relief/ improved analgesia: pain scores at 2 and 8 weeks - pain scores at 2 weeks in the intervention groups was 0.3 lower (1.81 lower to 1.21 higher)		33 (1 study ¹)	⊕⊕⊕⊖ very low ^{2,3,4}	
Pain Relief/ improved analgesia: Pain scores at 2 and 8 weeks - Pain		The mean pain relief/ improved analgesia: pain scores at 2 and 8 weeks - pain scores at 8 weeks in the		22 (1 study ¹)	⊕⊕⊕⊖ very low ^{2,3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	MM	Thoracic splanchnicectomy + MM				
scores at 8 weeks		intervention groups was 0.52 lower (2.11 lower to 1.07 higher)				
Patients reporting effective pain management at 2 and 8 weeks - At 2 months	316 per 1000	287 per 1000 (82 to 644)	RR 0.91 (0.26 to 2.04) ⁵	33 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Patients reporting effective pain management at 2 and 8 weeks - At 8 months	417 per 1000	362 per 1000 (96 to 754)	RR 0.87 (0.23 to 1.81) ⁵	23 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Johnson et al. 2009

2 The quality of the evidence was downgraded from high to moderate because of the potential risk of performance bias (no blinding of outcome assessors) and unclear risk of attrition bias

3 The quality of the evidence was further downgraded from moderate to low due to indirectness in study population (the cohort included 65 patients (only 58 with PC)

4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

5 Patients reporting effective pain relief was assessed as one or more of the following: (i) a Brief Pain Inventory (BPI) 'worst' pain rated over the last week as 0-4 (none or mild), (ii) a reduction of >50% between the mean of the three BPI items ('worst', 'least' and 'average') obtained at the baseline assessment and that obtained at the 2-month assessment, (iii) a decrease from baseline to 2 months of at least 2 points in the response to the question 'During the past week, have you had pain?'.

1
2

Table 85: Summary clinical evidence profile for EUS-guided NCPB - 1 injection versus 2 injections in adults with pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	EUS-guided NCPB: 2 injections	EUS-guided NCPB: 1 injection				
Reduction in pain medication	333 per 1000	310 per 1000 (120 to 600)	RR 0.93 (0.36 to 1.8)	50 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Patients with pain relief	810 per 1000	688 per 1000 (372 to 890)	RR 0.85	50 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	EUS-guided NCPB: 2 injections	EUS-guided NCPB: 1 injection				
			(0.46 to 1.1)			
Patients reporting a block effective (subjective)	619 per 1000	687 per 1000 (409 to 879)	RR 1.11 (0.66 to 1.42)	50 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Patient with a complete pain relief	95 per 1000	69 per 1000 (10 to 365)	RR 0.72 (0.1 to 3.83)	50 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 LeBlanc et al. 2013

2 The quality of the evidence was downgraded from high to moderate because of the unclear risk of attrition bias (insufficient reporting of attritions/exclusions), the unclear risk of performance bias (no details given on blinding of outcome assessors) and the high risk of selective reporting bias (All outcomes of interest [Pain score and analgesic use overtime] are reported completely, but no details about the time frame of the outcome measurement)

3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

1
2

Table 86: Summary clinical evidence profile for NCPB versus splanchnic neurolytic blockade in adults with pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Splanchnic nerve blocks	NCPB				
Reduction in opioid medication: total daily codeine consumption	See comment	See comment	Not estimable ¹	39 (1 study ²)	⊕⊕⊕⊕ very low ^{3,4,5}	
Pain Relief/ improved analgesia: Pain scores (VAS)	See comment	See comment	Not estimable ⁶	39 (1 study ²)	⊕⊕⊕⊕ very low ^{3,4,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Data are reported as medians (mg - COD consumption) and p values overtime: "There are significant

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Splanchnic nerve blocks	NCPB				
<p>differences between two groups at 2nd (4 weeks), 4th (8 weeks), and 5th (10 weeks) controls (respectively; p=0.041, p=0.021, p=0.028). **There are highly significant differences between two groups at 1st (2 weeks), 3rd (6 weeks), controls (respectively; p=0.003, p=0.005)"</p> <p>2 Özyalçin et al. 2004</p> <p>3 The quality of the evidence was downgraded from high to moderate because of the unclear risk of attrition bias (insufficient reporting of attritions/exclusions) and the high risk of selective reporting bias (all outcomes of interest [Pain score, analgesic use overtime and survival rates] are reported incompletely)</p> <p>4 The quality of the evidence was downgraded from moderate to low due to potential indirectness (as the randomised trial was conducted in Turkey and the outcomes may not be transferrable to the UK settings)</p> <p>5 The quality of evidence was further downgraded from low to very low due to imprecision in the effect estimates (not possible to estimate how precise the effect estimates: no information regarding uncertainty of the estimates reported)</p> <p>6 Data reported as medians (VAS scores) and p values overtime: ""There are significant differences between two groups at 2nd (4 weeks), 4th (8 weeks), and 5th (10 weeks) controls (respectively; p=0.041, p=0.021, p=0.028). **There are highly significant differences between two groups at 1st (2 weeks), 3rd (6 weeks), controls (respectively; p=0.003, p=0.005)"</p>						

1 8.2.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 8.2.6 Evidence Statements

8 8.2.6.1 NCPB versus medical management alone

9 Reduction in medication use

10 Low quality evidence from a meta-analysis of 2 RCTs (n=76) showed a clinically important
11 difference favouring NCPB on opioid usage (in mg/day oral morphine) compared to medical
12 management (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and
13 morphine) at 2 weeks follow-up in adults with pancreatic cancer: MD -64.52 (95% CI 99.45 to
14 -29.59).

15 Low quality evidence from a meta-analysis of 4 RCTs (n=120) showed a clinically important
16 difference favouring NCPB on opioid usage (in mg/day oral morphine) compared to medical
17 management (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and
18 morphine) at 4 weeks follow-up in adults with pancreatic cancer: MD -51.07 (95% CI -82.71
19 to -19.43).

20 Moderate quality evidence from a meta-analysis of 4 RCTs (n=111) showed a clinically
21 important difference favouring NCPB on opioid usage (in mg/day oral morphine) compared to
22 medical management (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and
23 morphine) until the day before death in adults with pancreatic cancer: MD -48.52 (95% CI -
24 68.82 to -28.22).

25 Moderate quality evidence from 1 RCT (n=100) showed a clinically important difference
26 favouring NCPB on change [percentage] in analgesic medications usage (NSAIDs,
27 morphine, and oxycodone) compared to medical management (analgesic therapy: non-
28 steroid anti-inflammatory drugs [NSAIDs] and morphine) at 3 months follow-up in adults with

1 pancreatic cancer: NSAIDs: MD -54.60 (95% CI -54.82 to -54.38); morphine: MD -76.60
2 (95% CI -76.80 to -76.40); and oxycodone: MD -68.40 (95% CI -68.70 to -68.10).

3 Very low quality evidence from 1 RCT (n=98) showed no clinically important difference
4 between NCPB and medical management (analgesic therapy: non-steroid anti-inflammatory
5 drugs [NSAIDs] and morphine) on morphine consumption at 1 month (MD -1.00 [95% CI -
6 48.50 to 46.50]) and 3 months (MD -50.00 [95% CI -118.52 to 18.52]) follow-up in adults with
7 pancreatic cancer, where MD less than 0 favours the NCPB arm.

8 **Pain relief/improved analgesia**

9 Low quality evidence from a meta-analysis of 3 RCTs (n=109) showed no clinically important
10 difference between NCPB and medical management (analgesic therapy: non-steroid anti-
11 inflammatory drugs [NSAIDs] and morphine) on pain scores at 2 weeks follow-up in adults
12 with pancreatic cancer: SMD -0.34 (95% CI -1.09 to 0.40), where SMD less than 0 favours
13 the NCPB arm.

14 Moderate quality evidence from a meta-analysis of 4 RCTs (n=174) showed a clinically
15 important difference favouring NCPB on VAS pain scores compared to medical management
16 (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and morphine) at 4 weeks
17 follow-up in adults with pancreatic cancer: MD -0.43 (95% CI -0.73 to -0.14).

18 Low quality evidence from a meta-analysis of 6 RCTs (n=279) showed no clinically important
19 difference between NCPB and medical management (analgesic therapy: non-steroid anti-
20 inflammatory drugs [NSAIDs] and morphine) on pain scores at 8 weeks follow-up in adults
21 with pancreatic cancer: SMD -1.09 (95% CI -2.33 to 0.15), where SMD less than 0 favours
22 the NCPB arm.

23 Very low quality evidence from 1 RCT (n=33) showed no clinically important difference
24 between NCPB and medical management (analgesic therapy: non-steroid anti-inflammatory
25 drugs [NSAIDs] and morphine) in the number of people reporting “effective pain relief” at 2
26 weeks (RR 1.13 [95% CI 0.43 to 2.97]) and 2 months (RR 1.33 [95% CI 0.55 to 3.24]) follow-
27 up in adults with pancreatic cancer, where RR less than 1 favours the NCPB arm.

28 Moderate quality evidence from 1 RCT (n=98) showed a clinically important difference
29 favouring NCPB on VAS pain scores (absolute change) compared to medical management
30 (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and morphine) at 1 month
31 (MD -1.00 [95% CI -1.73 to -0.27]) and 3 months (MD -2.30 [95% CI -3.09 to -1.51]) follow-up
32 in adults with pancreatic cancer.

33 **Duration of effect/ duration of relief**

34 No evidence was identified to inform this outcome.

35 **Adverse events**

36 Moderate quality evidence from a meta-analysis of 6 RCTs (n=161) showed a clinically
37 important difference favouring NCPB on constipation-related adverse effects compared to
38 medical management (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and
39 morphine) in adults with pancreatic cancer: RR 0.38 (95% CI 0.25-0.59)

40 Low quality evidence from a meta-analysis of 4 RCTs (n=121) showed no clinically important
41 difference between NCPB and medical management (analgesic therapy: non-steroid anti-
42 inflammatory drugs [NSAIDs] and morphine) on diarrhoea-related adverse effects in adults
43 with pancreatic cancer: RR 3.25 (95% CI 0.95 to 11.13), where RR less than 1 favours the
44 NCPB arm.

45 **Health related quality of life (functional domains)**

- 1 Low and very low quality evidence from 1 RCT (n=56) showed no clinically important
2 difference between NCPB and medical management (analgesic therapy: non-steroid anti-
3 inflammatory drugs [NSAIDs] and morphine) in QOL scores (as interference with appetite,
4 sleep, and communication) at 1 month and 3 months follow-up in adults with pancreatic
5 cancer.
- 6 Moderate quality evidence from 1 RCT (n=100) showed a clinically important difference
7 favouring NCPB on QOL scores (including physical and emotional functions) compared to
8 medical management (analgesic therapy: non-steroid anti-inflammatory drugs [NSAIDs] and
9 morphine) at 3 months follow-up in adults with pancreatic cancer: physical function: MD
10 11.60 (95% CI 8.26 to 14.94); emotional function: RR = 18.00 (95% CI 14.53 to 21.47). The
11 same trial showed no clinically important difference between NCPB and medical
12 management on QOL scores, regarding role (MD 1.60 [95% CI 1.77 to 4.97]), cognitive (MD
13 2.90 [95% CI -3.76 to 9.56]) and social functions (MD 1.00 [95% CI -3.57 to 5.57]) in adults
14 with pancreatic cancer, where MD higher than 0 favours the NCPB arm.
- 15 Moderate quality evidence from 1 RCT (n=98) showed no clinically important difference
16 between NCPB and medical management (analgesic therapy: non-steroid anti-inflammatory
17 drugs [NSAIDs] and morphine) in QOL scores (percentage change measured using the
18 Digestive Disease questionnaire-15) between patients treated with NCPB and those treated
19 with standard analgesic care at 1 month (MD 8.00 [95% CI 0.07 to 15.93]) or 3 months (MD
20 1.00 [95% CI -9.73 to 11.73]) follow-up in adults with pancreatic cancer, where MD higher
21 than 0 favours the NCPB arm.
- 22 Low quality evidence from 1 RCT (n=100) showed a clinically important difference favouring
23 NCPB on global QOL scores compared to medical management (analgesic therapy: non-
24 steroid anti-inflammatory drugs [NSAIDs] and morphine) at 3 month follow-up in adults with
25 pancreatic cancer: MD 14.30 (95% CI 14.10 to 14.50).
- 26 Very low quality evidence from 1 RCT (n=100) showed:
- 27 • a clinically important difference favouring NCPB on QOL scores (including self-assessed
28 scores for pain (MD -33.90 [95% CI -38.64 to -29.16]), insomnia (MD -40.90 [95% CI -
29 46.60 to -35.20]) and appetite loss symptoms (MD -28.80 [95% CI -35.28 to -22.32])
30 compared to medical management (analgesic therapy: non-steroid anti-inflammatory
31 drugs [NSAIDs] and morphine) at 3 month follow-up in adults with pancreatic cancer.
 - 32 • a clinically important difference favouring medical management (analgesic therapy: non-
33 steroid anti-inflammatory drugs [NSAIDs] and morphine) on QOL scores (including fatigue
34 symptoms) compared to NCPB at 3 month follow-up in adults with pancreatic cancer: MD
35 16.70 (95% CI 11.97 to 21.43)
 - 36 • no clinically important difference between NCPB and medical management in QOL
37 scores, regarding the following symptoms nausea/vomiting: MD 1.6 (95% CI -2.59 to
38 5.79); dyspnoea MD 0.3 (95% CI -7.15 to 7.75); constipation MD 1.2 (95% CI -7.12 to
39 9.52); financial difficulties -1.1 (95% CI -3.03 to 0.83) and diarrhoea MD -0.70 (95% CI -
40 2.12 to 0.72), where MD less than 0 favours the NCPB arm.

41 **Patient experience**

42 No evidence was identified to inform this outcome.

43 **PROMS**

44 No evidence was identified to inform this outcome.

45 **Overall survival**

46 Moderate quality evidence from 1 RCT (n=100) showed no clinically important difference
47 between neurolytic coeliac plexus blockade (NCPB) and medical management (analgesic
48 therapy: non-steroid anti-inflammatory drugs [NSAIDs] and morphine) on overall survival in

1 adults with pancreatic cancer: HR=0.80 (95% CI 0.50 to 1.28), where HR less than 1 favours
2 the NCPB arm.

3 **8.2.6.2 Early NCPB versus late NCPB**

4 **Reduction in opioid medication**

5 Moderate quality evidence from 1 RCT (n=23) showed a clinically important difference
6 favouring late NCPB [analgesics were given first to control pain and the NCPB was
7 performed only when the patients reported a VAS score <40] on oral morphine sulphate
8 consumption compared to early NCPB [the NCPB was performed first and then the analgesic
9 therapy] in adults with pancreatic cancer at 16 weeks (MD 55.82 [95% CI 40.91 to 70.73])
10 and 24 weeks (MD 62.41 [95% CI 46.07 to 78.75]) follow-up.

11 Moderate to low quality evidence from 1 RCT (n=21) showed a clinically important difference
12 favouring late NCPB [analgesics were given first to control pain and the NCPB was
13 performed only when the patients reported a VAS score <40] on oral tramadol consumption
14 compared to early NCPB [the NCPB was performed first and then the analgesic therapy] in
15 adults with pancreatic cancer at 16 weeks follow-up: MD 209.68 (95% CI 143.20 to 276.16).
16 The same trial showed no clinically important difference between late and early NCPB on
17 oral tramadol consumption at 24 weeks follow-up: MD 160.00 (95% CI 1.90 to 318.10),
18 where MD less than 0 favours the early NCPB arm.

19 **Pain relief/ improved analgesia**

20 Moderate quality evidence from 1 RCT (n=60) showed a clinically important difference
21 favouring late NCPB [analgesics were given first to control pain and the NCPB was
22 performed only when the patients reported a VAS score <40] in pain scores compared to
23 early NCPB [the NCPB was performed first and then the analgesic therapy] in adults with
24 pancreatic cancer both at 16 weeks (MD 21.30 [95% CI 18.88 to 23.72]) and 24 weeks (MD
25 26.00 [95% CI 22.34 to 29.36]) follow-up.

26 **Duration of effect/ duration of relief**

27 No evidence was identified to inform this outcome.

28 **Adverse Events**

29 Moderate quality evidence from 1 RCT (n=60) showed a clinically important difference
30 favouring late NCPB [analgesics were given first to control pain and the NCPB was
31 performed only when the patients reported a VAS score <40] on opioid adverse effects
32 (nausea) compared to early NCPB [the NCPB was performed first and then the analgesic
33 therapy] in adults with pancreatic cancer: RR 10.00 (95% CI 1.36 to 73.33).

34 The same RCT showed no clinically important difference between late and early NCPB on
35 opioid adverse effects (including constipation (RR 2.00 [95% CI 1.01 to 3.95]) and pruritus
36 (RR 3.00 [95% CI 0.33 to 27.3]) in adults with pancreatic cancer, where RR less than 1
37 favours the early NCPB arm.

38 **Health related quality of life (functional domains)**

39 No evidence was identified to inform this outcome.

40 **Patient experience**

41 No evidence was identified to inform this outcome.

42 **PROMS**

43 No evidence was identified to inform this outcome.

1 **Overall survival**

2 No evidence was identified to inform this outcome.

3 **8.2.6.3 NCPB plus medical management versus thoracic splanchnicectomy plus medical**
4 **management**

5 **Reduction in opioid medication**

6 No evidence was identified to inform this outcome.

7 **Pain Relief/ improved analgesia**

8 Very low quality evidence from a multicentre RCT (n=28) showed no clinically important
9 difference between NCPB + medical management and thoracoscopic splanchnicectomy +
10 medical management on pain scores at 2 weeks (MD 0.16 [95% CI -1.31 to 1.63]) and 2
11 months (MD -1.02 [95% CI -2.95 to 0.91]) follow-up in adults with pancreatic cancer, where
12 MD less than 0 favours the NCPB + medical management arm.

13 Very low quality evidence from a multicentre RCT (n=28) showed no clinically important
14 difference between NCPB + medical management and thoracoscopic splanchnicectomy +
15 medical management on the number of people reporting “effective pain relief” at 2 weeks
16 (RR 1.25 [95% CI 0.42 to 3.70]) and 2 months (RR 1.53 [95% CI 0.58 to 4.05]) follow-up in
17 adults with pancreatic cancer, where RR less than 1 favours the NCPB + medical
18 management arm.

19 **Duration of effect/ duration of relief**

20 No evidence was identified to inform this outcome.

21 **Adverse events**

22 No evidence was identified to inform this outcome.

23 **Health related quality of life (functional domains)**

24 No evidence was identified to inform this outcome.

25 **Patient experience**

26 No evidence was identified to inform this outcome.

27 **PROMS**

28 No evidence was identified to inform this outcome.

29 **Overall survival**

30 No evidence was identified to inform this outcome.

31 **8.2.6.4 Thoracic splanchnicectomy plus medical management versus medical management**
32 **alone**

33 **Reduction in opioid medication**

34 No evidence was identified to inform this outcome.

35 **Pain Relief/ improved analgesia**

36 Low quality evidence from 1 RCT (n=33) showed no clinically important difference between
37 thoracic splanchnicectomy + medical management and medical management alone on pain
38 scores at 2 weeks (n=33) (MD -0.30 [95% CI -1.81 to 1.21]) and 2 months (n=22) (MD -0.52

1 [95% CI -2.11 to 1.07]) follow-up in adults with pancreatic cancer, where MD less than 0
2 favours the thoracic splanchnicectomy + medical management arm.

3 Very low quality evidence from 1 RCT (n=33) showed no clinically important difference
4 between thoracic splanchnicectomy + medical management and medical management alone
5 on the number of people reporting “effective pain relief” at 2 weeks (RR 0.90 [95% CI 0.31 to
6 2.61]) and 2 months (RR 0.87 [95% CI 0.31 to 2.44]) follow-up in adults with pancreatic
7 cancer, where RR less than 1 favours the thoracic splanchnicectomy + medical management
8 arm.

9 **Duration of effect/ duration of relief**

10 No evidence was identified to inform this outcome.

11 **Adverse Events**

12 No evidence was identified to inform this outcome.

13 **Health related quality of life (functional domains)**

14 No evidence was identified to inform this outcome.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **PROMS**

18 No evidence was identified to inform this outcome.

19 **Overall survival**

20 No evidence was identified to inform this outcome.

21 **8.2.6.5 EUS- guided NCPB: 1 injection versus EUS- guided NCPB: 2 injections**

22 **Reduction in opioid medication**

23 Very low quality evidence from 1 RCT (n=50) showed no clinically important difference
24 between EUS-guided NCPB performed with 1 or 2 injections on the usage of pain medication
25 in adults with pancreatic cancer: RR 0.93 (95% CI 0.41-2.10), where RR less 1 favours the 1
26 injection arm.

27 **Pain Relief/ improved analgesia**

28 Very low quality evidence from 1 RCT (n=50) showed no clinically important difference
29 between EUS-guided NCPB performed with 1 or 2 injections on pain relief in adults with
30 pancreatic cancer: RR 0.85 (95% CI 0.62-1.17), where RR less 1 favours the 1 injection arm.

31 Very low quality evidence from 1 RCT (n=50) showed no clinically important difference
32 between EUS-guided NCPB performed with 1 or 2 injections on the number of people
33 reporting complete pain relief in adults with pancreatic cancer: RR 0.72 (95% CI 0.11-4.74),
34 where RR less 1 favours the 1 injection arm.

35 Very low quality evidence from 1 RCT (n=50) showed no clinically important difference
36 between EUS-guided NCPB performed with 1 or 2 injections on the number of people
37 reporting an effective block in adults with pancreatic cancer: RR 1.11 (95% CI 0.74-1.69),
38 where RR less 1 favours the 1 injection arm.

39 **Duration of effect/ duration of relief**

40 No evidence was identified to inform this outcome.

- 1 **Adverse Events**
- 2 No evidence was identified to inform this outcome.
- 3 **Health related quality of life (functional domains)**
- 4 No evidence was identified to inform this outcome.
- 5 **Patient experience**
- 6 No evidence was identified to inform this outcome.
- 7 **PROMS**
- 8 No evidence was identified to inform this outcome.
- 9 **Overall survival**
- 10 No evidence was identified to inform this outcome.
- 11 **8.2.6.6 NCPB versus splanchnic nerve blocks**
- 12 **Reduction in opioid medication**
- 13 Very low quality evidence from 1 RCT (n=39) suggests clinically important differences
14 favouring splanchnic nerve blocks on total daily codeine consumption compared to NPCB at
15 2, 4, 6, 8, and 10 weeks follow-up in adults with pancreatic cancer [Relative effect not
16 estimable].
- 17 **Pain Relief/ improved analgesia**
- 18 Very low quality evidence from 1 RCT (n=39) showed a clinically important difference
19 favouring splanchnic nerve blocks on VAS pain scores when compared to those treated with
20 NPCB at 2, 4, 6, 8, 10 and 12 weeks follow-up in adults with pancreatic cancer [Relative
21 effect not estimable].
- 22 **Duration of effect/ duration of relief**
- 23 No evidence was identified to inform this outcome.
- 24 **Adverse Events**
- 25 No evidence was identified to inform this outcome.
- 26 **Health related quality of life (functional domains)**
- 27 No evidence was identified to inform this outcome.
- 28 **Patient experience**
- 29 No evidence was identified to inform this outcome.
- 30 **PROMS**
- 31 No evidence was identified to inform this outcome.
- 32 **Overall survival**
- 33 No evidence was identified to inform this outcome.
- 34
- 35

1 **8.2.7 Recommendations**

2 **26. Consider EUS-guided or image-guided percutaneous neurolytic coeliac plexus**
3 **block to manage pain for people with pancreatic cancer who:**

- 4 • have uncontrolled pancreatic pain **or**
5 • are experiencing unacceptable opioid adverse effects **or**
6 • are receiving escalating doses of analgesics.

7 **27. Do not offer thoracic splanchnicectomy to people with pancreatic cancer.**

8 **8.2.8 Evidence to recommendations**

9 **8.2.8.1 Relative value placed on the outcomes considered**

10 Reduction in opioid medication, pain relief or improved analgesia, duration of effect, adverse
11 events, overall survival, health-related quality of life, patient experience and PROMS were
12 considered the critical outcomes for this question.

13 Patient experience was not reported for any comparisons of interest. Health related quality of
14 life and PROMs were only reported for the comparison of neurolytic coeliac plexus blockade
15 (NCPB) against medical management alone. Duration of effect or duration of relief was
16 reported for the comparison of endoscopic ultrasound (EUS)-guided NCPB with one injection
17 against EUS-guided NCPB with 2 injections. Adverse events were only reported for the
18 comparison of neurolytic coeliac plexus blockade (NCPB) against medical management
19 alone and for early versus late NCPB. Reduction in opioid medication, pain relief and overall
20 survival were reported for the majority of the included comparisons.

21 The committee noted that as most patients were in the palliative setting, overall survival was
22 not a useful outcome on which to base recommendations.

23 **8.2.8.2 Quality of evidence**

24 The quality of the evidence was assessed by GRADE, the Cochrane risk of bias checklist for
25 individual studies and the AMSTAR (A Measurement Tool to Assess Systematic Reviews)
26 checklist was used to assess the methodological quality of systematic reviews.

27 No evidence was found comparing either EUS-guided NCPB with percutaneous NCPB or
28 late EUS-guided NCPB with early EUS-guided NCPB.

29 The quality of the evidence for NCPB versus medical management ranged from moderate to
30 very low. The committee noted that the evidence base included non-UK studies. It was not
31 possible to determine whether the RCT evidence was adequately randomised or blinded and
32 for the outcome of overall survival, the studies were not exclusively on people with pancreatic
33 cancer. The committee acknowledged that there were some limitations with the evidence, but
34 agreed that it was possible to make recommendations for clinical practice as there was
35 moderate quality evidence for some outcomes.

36 The committee noted that NCPB can be done by either percutaneous or by EUS guidance,
37 but the evidence did not demonstrate superiority for any particular route. The committee
38 considered making a research recommendation to compare the effectiveness of
39 percutaneous NCPB with EUS-guided NCBP. However, they agreed that this would be
40 unlikely to be picked up because EUS-guidance is becoming the preferred technique in most
41 UK centres.

42 The quality of the evidence for the comparison of early versus late NCPB was moderate for
43 all reported outcomes. The committee noted, based on the evidence, that opioid medication

1 usage, pain relief and opioid adverse effects (nausea and constipation) improved with late
2 NCPB, for example for people in whom the NCPB was performed after the analgesic
3 therapy. However, the committee noted that the evidence for this comparison consisted of
4 only 1 study and that this study was not transferrable to the UK setting. They, therefore,
5 agreed not to make any recommendations for clinical practice in this area. Instead, they
6 recommended further research comparing early NCPB with late NCPB in order to establish
7 the most effective time point for this intervention.

8 The quality of evidence for thoracic splanchnicectomy ranged from low to very low for the
9 outcomes of interest. The committee noted that only 1 study had been found and that this
10 study was not exclusively in people with pancreatic cancer. Also, very few of the outcomes of
11 interest had been reported. However, the committee noted that for pain relief, the evidence
12 did not show any meaningful clinical benefit. They, therefore, agreed it was important to
13 make recommendations about this intervention.

14 The quality of the evidence for the comparison of one EUS-guided NCPB injection versus
15 two injections was very low quality for all outcomes. The committee noted that, based on the
16 evidence, opioid medication usage, pain relief, duration of effect and overall survival
17 improved in people who received EUS-guided NCPB injections. However, there was no
18 meaningful difference in these outcomes relative to the number of injections used. They
19 were, therefore, unable to make any recommendations about the number of injections that
20 was most effective.

21 The quality of evidence for the comparison of NCPB versus splanchnic nerve blocks was
22 very low for all outcomes. The committee noted that, based on the evidence, opioid
23 medication usage reduced and survival improved in people who underwent splanchnic nerve
24 blocks. However, due to the limitations in the evidence, the committee agreed not to make
25 any recommendations for clinical practice on the use of splanchnic nerve blocks.

26 **8.2.8.3 Consideration of clinical benefits and harms**

27 The committee did not make clinical practice recommendations for several of the
28 comparisons of interest as they considered the quality of the evidence to be insufficient to
29 allow them to adequately evaluate the benefits and harms for people.

30 The committee noted that current practice for pain management in people with pancreatic
31 cancer is medical management with analgesics. If these analgesics do not adequately
32 control the pain or the person has difficulties with the side effects of the analgesia then
33 NCPB may be considered. It was also noted that people with pancreatic cancer often have
34 issues with poorly-controlled pain and would like to be aware of other options if the medical
35 management does not work. However, NCPB is often under-used due to a lack of expertise
36 and/or awareness of it.

37 The committee noted, based on the evidence, that medication or opioid usage, pain relief,
38 constipation and quality of life appeared to improve for people treated with NCPB. They
39 agreed that NCPB should be considered for pain management for those people who have
40 uncontrolled pancreatic pain, are receiving escalating doses of analgesia or are experiencing
41 unacceptable opioid adverse effects as these were the groups from the evidence who
42 showed a benefit from this intervention.

43 The committee considered that the potential benefit of the recommendation to use NCPB
44 was that people with pancreatic cancer would be made aware of this intervention, which is
45 effective in managing pain. As a result of its use, the use of opioids, and their resulting side
46 effects, would likely be reduced. However, the committee noted that the evidence for the side
47 effects or complications of NCPB was limited. Thus, they only recommended NCPB in those
48 people in whom conventional analgesia is suboptimal.

1 Based on their clinical experience, the committee noted that thoracic splanchnicectomy is an
2 invasive technique that needs to be done under general anaesthetic. This procedure is not
3 currently in widespread use in UK centres and, consequently, is only being done in small
4 numbers. Given the lack of evidence showing any effectiveness of thoracic
5 splanchnicectomy, particularly for pain relief, the committee agreed to recommend that this
6 procedure should not be performed. The committee considered that the benefits of the
7 recommendation on thoracic splanchnicectomy would be to stop a practice that was shown
8 to be ineffective.

9 **8.2.8.4 Consideration of economic benefits and harms**

10 The committee noted that no relevant published economic evaluations had been identified
11 and no additional economic analysis had been undertaken in this area.

12 The committee agreed that the recommendations made were unlikely to result in a
13 substantial increase in costs. This was because the number of people involved would not be
14 large. Moreover, EUS facilities and the expertise to perform EUS-guided procedures would
15 already be available at all pancreatic resectional centres. Peripheral hospitals would also be
16 able to send people to the centres for this procedure. With more widespread use of NCPB,
17 the requirement for analgesia would be reduced, which would contribute to cost saving.

18 **8.2.9 Research recommendations**

19 **3. A randomised trial should be undertaken comparing early endoscopic ultrasound-** 20 **guided neurolytic coeliac plexus (EUS-guided NCP) interventions with on-demand** 21 **EUS-guided NCP interventions in people with unresectable pancreatic cancer.**

22 There is a limited number of randomised trials in this area, and the methods used to perform
23 NCP intervention are heterogeneous. It is not clear if early NCP intervention is superior to
24 on-demand NCP intervention in terms of the important outcomes for the patient and duration
25 of effect of the procedure. On-demand NCP intervention may benefit people with
26 uncontrolled pain, people receiving escalating doses of analgesia, people experiencing
27 unacceptable analgesic side effects, and others. However, people who receive early NCP
28 intervention may not need on-demand NCP intervention later on. Further research should
29 clarify if the timing of the intervention confers any advantage. The outcomes of interest are:

- 30 • reduction in pain
- 31 • patient experience (including nutritional status)
- 32 • health-related quality of life
- 33 • adverse events
- 34 • analgesic use
- 35 • survival.

36 **8.2.10 References**

37 Amr YM and Makharita MY (2013) Comparative study between 2 protocols for management
38 of severe pain in patients with unresectable pancreatic cancer: one-year follow-up. *Clinical*
39 *Journal of Pain* 29(9): 807-13

40 Arcidiacono PG, Calori G, Carrara S et al. (2011) Celiac plexus block for pancreatic
41 cancerpain in adults. *Cochrane Database Systematic Reviews* (3): CD007519

42 Gao L, Yang YJ, Xu HY et al. (2014) A randomised clinical trial of nerve block to manage
43 end-stage pancreatic cancerous pain. *Tumor Biology* 35(3): 2297-301

- 1 Johnson CD, Berry DP, Harris S et al. (2009) An open randomised comparison of clinical
2 effectiveness of protocol-driven opioid analgesia, celiac plexus block or thoracoscopic
3 splanchnicectomy for pain management in patients with pancreatic and other abdominal
4 malignancies. *Pancreatology* 9(6): 755-63
- 5 LeBlanc JK, Al-Haddad M, McHenry L et al. (2011) A prospective, randomised study of EUS-
6 guided celiac plexus neurolysis for pancreatic cancer: one injection or two? *Gastrointestinal*
7 *Endoscopy* 74(6): 1300-7
- 8 Özyalçın NS, Talu GK, Çamlıca H et al. (2004) Efficacy of coeliac plexus and splanchnic
9 nerve blockades in body and tail located pancreatic cancer pain. *European Journal of Pain*
10 8(6): 539-45
- 11 Wyse JM, Carone M, Paquin SC et al. (2011) Randomised, double-blind, controlled trial of
12 early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in
13 patients with newly diagnosed, painful, inoperable pancreatic cancer. *Journal of Clinical*
14 *Oncology* 29(26): 3541-6
- 15 **8.2.10.1 Studies included in Arcidiacono et al., 2011 (n=6)**
- 16 Kawamata M, Ishitani K, Ishikawa K et al. (1996) Comparison between celiac plexus block
17 and morphine treatment on quality of life in patients with pancreatic cancer pain. *Pain* 64(3):
18 597-602.
- 19 Lillemoe KD, Cameron JL, Kaufman HS et al. (1993) Chemical splanchnicectomy in patients
20 with unresectable pancreatic cancer. A prospective randomised trial. *Annals of Surgery*
21 217(5): 447-55.
- 22 Mercadante S (1993) Celiac plexus block versus analgesics in pancreatic cancer pain. *Pain*
23 52(2): 187-92
- 24 Polati E, Finco G, Gottin L et al. (1998) Prospective randomised double-blind trial of
25 neurolytic coeliac plexus block in patients with pancreatic cancer. *British Journal of Surgery*
26 85(2): 199-201
- 27 Wong GY, Schroeder DR, Carns PE et al. (2004) Effect of neurolytic celiac plexus block on
28 pain relief, quality of life, and survival in patients with unresectable pancreatic cancer: a
29 randomised controlled trial. *JAMA* 291(9): 1092-9.
- 30 Zhang CL, Zhang TJ, Guo YN et al. (2008) Effect of neurolytic celiac plexus block guided by
31 computerized tomography on pancreatic cancer pain. *Digestive Diseases Sciences* 53(3):
32 856-60

33 **8.3 Nutritional Interventions**

34 **Review question: What nutritional interventions are effective for patients with newly**
35 **diagnosed or recurrent pancreatic cancer?**

36 **8.3.1 Introduction**

37 Weight loss is common in patients with pancreatic cancer, both in resectable and non-
38 resectable disease. This is multifactorial but may be due to one or a combination of reduced
39 dietary intake, malabsorption, post-surgical complications affecting nutritional status, cancer
40 associated muscle wasting (cachexia) and hyperglycaemia due to impaired glucose
41 tolerance or undiagnosed diabetes. Weight loss can be severe and debilitating for the
42 patient, and contribute towards the development of sarcopenia (low muscle mass) and
43 reduced muscle function affecting quality of life.

1 There is considerable variation in the nutritional input received by people with pancreatic
2 cancer in different parts of the country (and in some cases between local hospitals or GPs
3 and tertiary centres). This has been reported to be an area of confusion for people with
4 pancreatic cancer, their families and some professionals, meaning that some people
5 continue to experience symptoms that have a negative impact on their quality of life. Good
6 nutritional input can improve quality of life for people with pancreatic cancer and, potentially
7 improve their ability to undergo oncological treatment and survival.

8 There is a high incidence of pancreatic exocrine insufficiency (not producing or secreting
9 enough digestive enzymes from the pancreas for adequate digestion) in those with
10 pancreatic cancer, this is treated with pancreatic enzyme replacement therapy (PERT).
11 However, there is variation in the amount of specialist information people receive on how to
12 take PERT effectively, which means they may continue to experience the symptoms and
13 consequences of poor digestion and not get the full benefit of this intervention.

14 Many people with pancreatic cancer benefit from dietary counselling to increase their
15 nutritional intake. Most can consume adequate nutrition with advice on modifying food
16 choices and preparation methods and some require additional measures such as oral
17 nutritional supplements. However, there is variation in the level and type of information given
18 and the route nutrition is provided. There is uncertainty over what are the most effective
19 interventions and route for providing nutrition.

20 Guidance is needed on the nutritional interventions that are effective for people with
21 pancreatic cancer.

22 8.3.1.1 Review protocol summary

23 The review protocol summary used for this question can be found in Table 87. Full details of
24 the review protocol can be found in Appendix C.

25 Table 87: Clinical review protocol summary for the review of nutritional interventions

Population	Patients with: <ul style="list-style-type: none"> • Resectable pancreatic cancer (pre and post-operative) • Unresectable or metastatic pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Pancreatic Enzyme replacement therapy +/- Proton Pump Inhibitors • Oral nutritional supplements • Fish oils (Omega 3 fatty acids, DHA, EPA) • Glycaemic control • Enteral/ parenteral/oral nutrition
Comparison	<ul style="list-style-type: none"> • No intervention • Each other
Outcome	<ul style="list-style-type: none"> • Overall Survival • Treatment related morbidity • Health Related Quality of Life • Symptom control • Nutritional status (weight, BMI, lean body mass, strength test/ muscle function, sarcopenia, percentage weight change) • Adverse events • Patient experience

1 **8.3.2 Description of Clinical Evidence**

2 Eleven randomised trials involving nine comparisons were included in the review. A summary
3 of the included studies is presented in Table 88.

4 2 RCTs (Hamza et al., 2015; Gianotti et al. 2000) compared enteral immunonutrition with
5 standard enteral nutrition on nutritional outcomes in patients with pancreatic cancer (n=181).
6 One RCT focused on patients before and after surgery for pancreatic cancer (Hamza et al.
7 2015). In the other RCT (Gianotti et al. 2000) the intervention was implemented and
8 evaluated after surgery.

9 One RCT (Gade et al. 2016) compared the effect of supplementary enteral immunonutrition
10 seven days before surgery for pancreatic cancer against standard nutrition on postoperative
11 complications and body weight (n=35).

12 2 RCTs (Gianotti et al. 2000; Liu et al. 2011) compared the effectiveness of parenteral
13 nutrition with standard enteral nutrition on nutritional outcomes in patients who underwent
14 surgery for pancreatic cancer (n=126).

15 One RCT (Gianotti et al. 2000) compared the effectiveness of parenteral nutrition against
16 enteral immunonutrition to evaluate whether the route of administration and the composition
17 of the post-operative nutritional support could affect the immunometabolic response and
18 outcome in patients with pancreatic cancer (n=139).

19 One RCT (Brennan et al. 1994) assessed the impact of adjuvant parenteral nutrition after
20 surgery for patients with pancreatic cancer (n=117).

21 Two RCTs (Fearon et al. 2003; Moses et al. 2013) compared a protein and energy dense
22 supplement enriched with n-3 fatty acids with an isocaloric-isonitrogenous supplement
23 (without n-3 fatty acids) for their effects on nutritional outcomes and physical capability in
24 patients with unresectable pancreatic cancer (n=224).

25 One RCT (Kraft et al. 2012) examined the role of oral L-Carnitine supplementation on cancer
26 cachexia in pancreatic cancer (n=72).

27 Two RCTs (Bruno et al. 1998; Woo et al. 2016) compared pancreatic enzyme replacement
28 therapy (PERT) with placebo in reducing or preventing weight loss in patients with
29 unresectable pancreatic cancer (n=101).

30 One RCT (Satoi et al. 2016) compared the effectiveness of pancrelipase replacement
31 therapy against conventional PERT on protecting against non-alcoholic fatty liver disease
32 (NAFLD) development after surgery in patients with pancreatic cancer (n=39).

33 The Cochrane Collaboration's 'Risk of bias' tool was used for assessing risk of bias of
34 randomised trials. Further information about the search strategy can be found in Appendix D.
35 See study selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in
36 Appendix I, study evidence tables in Appendix F and list of excluded studies in Appendix G.

37

38

8.3.31 Summary of included studies

2 A summary of the studies that were included in this review is presented in Table 88.

3 Table 88: Summary of included studies

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Brennan et al. 1994	Design: Un-blinded RCT Randomization method: not stated Duration: not stated	N=117 patients with PC after surgery	To analyse the impact of adjuvant PN after major resection for PC.	PN (n=60)	No intervention (n=57)	Overall Survival at median follow up of 18 months Treatment related morbidity Major complications Minor complications Overall complications
Bruno et al. 1998	Design: Double blinded RCT Randomization method: not stated Duration: 8 weeks	N=24 patients with unresectable PC	To assess the role of pancreatic PERT in combination with dietary counselling in reducing/preventing weight loss in patients with unresectable PC with occlusion of the pancreatic duct.	PERT (n=11)	Placebo (n=10)	Nutritional status at 8 weeks follow-up Change in body weight (%) Change in body weight (Kg) Daily dietary intake of total calories (MJ)
Fearon et al. 2003	Design: Double blind RCT Randomization method: computer generated random assignments and sealed envelopments Duration: 8 weeks	N=200 losing weight patients with unresectable PC	To compare the effect of the n-3 fatty acid and antioxidant enriched supplement with an isocaloric-isonitrogenous supplement on weight, body composition, dietary intake, and quality of life in weight losing pancreatic cancer patients.	EPA enriched oral supplement (n=95)	Identical supplement without EPA (n=105)	Health Related Quality of Life at 8 weeks Nutritional status at 4/8 weeks Change in Lean body mass Change Weight

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
Gade et al. 2016	Design: Personnel-blind RCT Randomization method: unclear Duration: 1 month	N=35 patients with PC after surgery	To examine the effect of supplementary per oral EIN seven days before surgery for PC on postoperative complications, length of hospital stay, functional capability and body weight.	E IN (n=19)	No intervention –habitual diet (n=16)	Nutritional status (weight loss) Treatment related morbidity Patients with infectious complications Patients with non-infectious complications Total patients with complications (infectious+ non-infectious) Postoperative mortality PROMS: Satisfaction
Gianotti et al. 2000	Design: Assessors-blind RCT Randomization method: randomization was performed using sealed envelopes Duration: 8 days post-surgery	N=220 patients with PC after surgery	To evaluate whether early SEN may be a suitable alternative to PN for patients with PC undergoing surgery, and whether EIN could improve outcome in these patients.	PN (n = 68) SNT(n = 73)	G3: EIN (n=71)	Treatment related morbidity Patients with infectious complications Patients with non-infectious complications Total patients with complications Postoperative mortality SEN versus EIN side effects
Hamza et al. 2015	Design: Un-blind RCT Randomization method: randomization was performed using sequential series of 4 per block of 10 patients Duration: 3 weeks (2 weeks before and 1 week after surgery)	N=37 patients with resectable PC	To compare the effects of perioperative EIN versus SEN on systemic and mucosal immunity in patients undergoing surgery for periampullary cancer.	EIN (n=17)	SEN (n=20)	Treatment related morbidity Complication rate at 1 week after surgery Health Related Quality of Life at 1 week after surgery Karnofsky score Nutritional status at 1 week after surgery

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
						BMI strength test/ muscle function: midarm circumference, corrected arm muscle area
Kraft et al. 2012	Design: Double-blind RCT Randomization method: randomization was performed using sequential series of 4 per block, sealed envelopes, and computer generated randomization code Duration: 12 weeks	N=72 patients with unresectable PC	To investigate the role of oral L-Carnitine supplementation on cancer cachexia in pancreatic cancer.	Oral nutritional supplement: L-Carnitine (n = 38)	Placebo (n = 34)	Overall Survival at follow up of 1500 days Health Related Quality of Life EORTC-QLQ- C30/PAN26* Nutritional status % change of BMI at 6/12 weeks body composition (% change of body fat and BCM at 6/12 weeks)
Liu et al. 2011	Design: Un-blind RCT Randomization method: randomization was performed according to the smallest imbalance index scheme Duration: 14 days post- surgery	N=58 patients with PC after surgery	To determine the effects of PN and SEN on clinical outcomes in pancreatic cancer patients who underwent surgery.	PN (n=30)	SEN (n=28)	Treatment related morbidity Total patients with postoperative complications Postoperative mortality
Moses et al. 2004	Design: Double-blind RCT Randomization method: randomization was performed using a sequential series of numbered, sealed, opaque envelopes containing computer-	N=24 patients with advanced PC	To determine whether the decreased TEE and PAL is observed in patients with pancreatic cancer and to test the influence of an energy and protein dense oral supplement either enriched with or without the EPA.	GJJ – n=18 (GJJ was open-n = 16, or laparoscopic-n = 2, and either antecolic-n = 12, or retrocolic-n = 6)	Duodenal stent placement (Enteral Wallstent) – n=21	Nutritional status Change in weight (kg) at 8 weeks Change in lean body mass at 8 weeks TEE and PAL Change in TEE at 8 weeks Change in REE at 8 weeks

Study	Study Type	Population	Aim	Intervention	Comparison	Outcomes
	generated random assignments Duration: 8 weeks					Change in PAL at 8 weeks
Satoi et al. 2016	Design: Un-blind RCT Randomization method: no stated Duration: 12 months	N=39 patients randomised	To evaluate the role of pancrelipase replacement therapy on NAFLD after surgery in patients with pancreatic cancer in comparison with conventional PERT.	Pancrelipase replacement therapy (n = 29)	Conventional PERT (n = 28)	Treatment related morbidity NAFLD at 1 year follow-up Nutritional status BMI at 6 and 12 months follow-up
Woo et al. 2016	Design: Double-blind phase II randomised trial Randomization method: patients were randomly allocated between groups first stratifying for the extent of disease (i.e. locally advanced or metastatic), and then by using unique patients number Duration: 8 weeks	N=77 patients with unresectable PC	To assessed whether pancreatic PERT could reduce or prevent weight loss in patients with unresectable PC.	PERT (n=34)	Placebo (n=33)	Nutritional status at 8 weeks follow-up Change in body weight (%) Change in body weight (Kg) Health Related Quality of Life EORTC-QLQ-C30 Overall Survival

TEE: Total energy expenditure; PAL: Physical activity level; EPA: N-3 fatty acid eicosapentaenoic acid; NAFLD: Non-alcoholic fatty liver disease; EIN: Enteral immunonutrition; SEN: Standard enteral nutrition; PN: Parenteral nutrition; BMI: Body mass index; PERT: Pancreatic enzyme replacement therapy; REE: Resting energy expenditure.

1
2
3

1 **8.3.4 Clinical evidence profile**

2 The clinical evidence profiles for this review question are presented in Table 89 to Table 98.

3 **Table 89: Summary clinical evidence profile for standard enteral nutrition versus**
4 **enteral immunonutrition before and after surgery**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus Standard Enteral nutrition (SEN) before and after surgery				
Treatment related morbidity - postoperative complications - Patients with infectious complications	400 per 1000	332 per 1000 (128 to 860)	RR 0.83 (0.32 to 2.15)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{3,4}	
Treatment related morbidity - postoperative complications - Patients with non-infectious complications	400 per 1000	400 per 1000 (168 to 960)	RR 1 (0.42 to 2.4)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Health Related Quality of Life - Karnofsky score at 2 weeks after surgery, change from baseline		The mean health related quality of life - Karnofsky score at 2 weeks after surgery, change from baseline in the intervention groups was 2 lower (7.33 lower to 3.33 higher)		37 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Nutritional status at 2 weeks after surgery - BMI (kg/m ²), change from baseline		The mean nutritional status at 2 weeks after surgery - BMI (kg/m ²), change from baseline in the intervention groups was 1.5 standard deviations lower (3.93 lower to 0.93 higher)		37 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Nutritional status at 2 weeks after surgery - mid-arm		The mean nutritional status at 2 weeks after surgery - mid-		37 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus Standard Enteral nutrition (SEN) before and after surgery				
circumference (cm), change from baseline		arm circumference (cm), change from baseline in the intervention groups was 0.6 lower (2.92 lower to 1.72 higher)				
Nutritional status at 2 weeks after surgery - corrected arm muscle area (cm ²), change from baseline		The mean nutritional status at 2 weeks after surgery - corrected arm muscle area (cm ²), change from baseline in the intervention groups was 1.6 lower (7.09 lower to 3.89 higher)		37 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3,4}	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;*

*1 Hamza et al. 2015
2 Evidence was downgraded by 1 due to attrition bias (Data were missing for 5 of the 42 randomised patients: G1 n=3 DG n=2 were missed because inadequate intake and metastatic disease, respectively. For these reasons, missing data were judged to affect the true outcome of the trial) and unclear risk of performance bias
3 Evidence was downgraded by 1 due to indirectness of the study population (only 26 of 47 participants had PC)
4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID*

1
2

Table 90: Summary clinical evidence profile for standard enteral nutrition versus enteral immunonutrition after surgery

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus Standard Enteral nutrition (SEN) after surgery				
Treatment related morbidity - postoperative	151 per 1000	84 per 1000 (33 to 217)	RR 0.56 (0.22)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus Standard Enteral nutrition (SEN) after surgery				
complications - Patients with infectious complications			to 1.44)			
Treatment related morbidity - postoperative complications - Patients with non-infectious complications	288 per 1000	253 per 1000 (147 to 434)	RR 0.88 (0.51 to 1.51)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - postoperative mortality	14 per 1000	28 per 1000 (3 to 304)	RR 2.06 (0.19 to 22.18)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Tube clogging/kinking	68 per 1000	42 per 1000 (10 to 171)	RR 0.62 (0.15 to 2.49)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Tube dislodgment	14 per 1000	28 per 1000 (3 to 304)	RR 2.06 (0.19 to 22.18)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Tube breakage	14 per 1000	5 per 1000 (0 to 113)	RR 0.34 (0.01 to 8.27)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Local skin infection	14 per 1000	5 per 1000 (0 to 113)	RR 0.34 (0.01 to 8.27)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus Standard Enteral nutrition (SEN) after surgery				
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Abdominal cramps	151 per 1000	140 per 1000 (63 to 310)	RR 0.93 (0.42 to 2.06)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Abdominal distention	123 per 1000	141 per 1000 (60 to 325)	RR 1.14 (0.49 to 2.64)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Vomiting	27 per 1000	6 per 1000 (0 to 115)	RR 0.21 (0.01 to 4.21)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - Jejunostomy and enteral nutritional related complications - Diarrhoea	123 per 1000	99 per 1000 (38 to 250)	RR 0.8 (0.31 to 2.03)	144 (1 study ¹)	⊕⊕⊖⊖ low ²	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>¹ Gianotti et al. 2000 ² Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2

Table 91: Summary clinical evidence profile for enteral immunonutrition versus standard nutrition after surgery

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Enteral immunonutrition (EIN) versus no intervention (standard nutrition) after surgery				
Treatment related morbidity - postoperative complications	See comment	See comment	Not estimable	35 (1 study ¹)	⊕⊕⊖ ⊖ low ²	“There was no difference between the two groups for postoperative complications graded with respect to severity”
Nutritional status at 30 days after surgery - Absolute change in weight (kg) from baseline		The mean nutritional status at 30 days after surgery - absolute change in weight (kg) from baseline in the intervention groups was 0.97 higher (1.37 lower to 3.32 higher)		31 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{3,4}	
PROMS - Satisfaction with nutritional treatment at 1 month after surgery		The mean proms - satisfaction with nutritional treatment at 1 month after surgery in the intervention groups was 0.04 higher (0.34 lower to 0.41 higher)		30 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{3,4}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Gade et al. 2016

2 Evidence was downgraded by 2 due to selective outcome reporting bias (data were unclearly reported on the postoperative complications, so that it was not possible to judge the certainty of the evidence) and unclear risk of performance and selection bias

3 Evidence was downgraded by 1 due to unclear risk of performance and selection bias

4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

1
2

Table 92: Summary clinical evidence profile for parenteral nutrition versus standard enteral nutrition after surgery

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Parenteral nutrition (PN) versus SEN after surgery				
Treatment related morbidity - postoperative complications - Patients with infectious complications	151 per 1000	220 per 1000 (108 to 446)	RR 1.46 (0.72 to 2.96)	141 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - postoperative complications - Patients with non-infectious complications	288 per 1000	368 per 1000 (227 to 593)	RR 1.28 (0.79 to 2.06)	141 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - postoperative complications - Total patients with complications (infectious+ non-infectious)	438 per 1000	587 per 1000 (425 to 815)	RR 1.34 (0.97 to 1.86)	141 (1 study ¹)	⊕⊕⊖⊖ low ²	
Treatment related morbidity - postoperative mortality	14 per 1000	59 per 1000 (7 to 513)	RR 4.29 (0.49 to 37.47)	199 (2 studies ³)	⊕⊕⊖⊖ low ²	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 Gianotti et al. 2000 2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 3 Gianotti et al. 2000; Liu et al. 2011</p>						

1
2

Table 93: Summary clinical evidence profile for parenteral nutrition versus enteral immunonutrition after surgery

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Enteral immunonutrition (EIN) after surgery	Parenteral nutrition (PN)				
Treatment related morbidity - postoperative complications - Patients with infectious complications	85 per 1000	221 per 1000 (91 to 535)	RR 2.61 (1.08 to 6.33)	139 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Treatment related morbidity - postoperative complications - Patients with non-infectious complications	254 per 1000	368 per 1000 (221 to 611)	RR 1.45 (0.87 to 2.41)	139 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Treatment related morbidity - postoperative complications - Total patients with complications (infectious+ non-infectious)	338 per 1000	588 per 1000 (402 to 862)	RR 1.74 (1.19 to 2.55)	139 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Treatment related morbidity - Postoperative mortality	28 per 1000	59 per 1000 (11 to 311)	RR 2.09 (0.4 to 11.03)	139 (1 study ¹)	⊕⊕⊖⊖ low ³	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 Gianotti et al. 2000 2 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed two default MID 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2

Table 94: Summary clinical evidence profile for parenteral nutrition versus no intervention after surgery

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No Intervention	Parenteral nutrition (PN) after surgery				
Treatment related morbidity - major complications - Deep infection	70 per 1000	67 per 1000 (18 to 254)	RR 0.95 (0.25 to 3.62)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Fistula	88 per 1000	133 per 1000 (46 to 383)	RR 1.52 (0.53 to 4.37)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Abscess	35 per 1000	200 per 1000 (47 to 855)	RR 5.7 (1.33 to 24.36)	117 (1 study ¹)	⊕⊕⊕ ⊖ low ²	
Treatment related morbidity - major complications - Peritonitis	35 per 1000	117 per 1000 (25 to 538)	RR 3.33 (0.72 to 15.34)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Haemorrhage	35 per 1000	17 per 1000 (1 to 179)	RR 0.48 (0.04 to 5.1)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Intestinal obstruction	0 per 1000	0 per 1000 (0 to 0)	RR 8.56 (0.47 to 155.45)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Anastomotic breakdown	53 per 1000	117 per 1000 (32 to 429)	RR 2.22 (0.6 to 8.16)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity -	18 per 1000	6 per 1000 (0 to 134)	RR 0.32 (0.01 to 7.62)	117 (1 study ¹)	⊕⊕⊕ ⊖	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No Intervention	Parenteral nutrition (PN) after surgery				
major complications - Aspiration					very low ^{2,4}	
Treatment related morbidity - major complications - Pneumonia	105 per 1000	83 per 1000 (27 to 258)	RR 0.79 (0.26 to 2.45)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Pulmonary embolus	18 per 1000	6 per 1000 (0 to 134)	RR 0.32 (0.01 to 7.62)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Myocardial infarction	18 per 1000	33 per 1000 (3 to 358)	RR 1.9 (0.18 to 20.38)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Reoperation	53 per 1000	100 per 1000 (26 to 381)	RR 1.9 (0.5 to 7.24)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - major complications - Total major complications (excluding death)	211 per 1000	383 per 1000 (211 to 697)	RR 1.82 (1 to 3.31)	117 (1 study ¹)	⊕⊕⊕ ⊖ low ²	
Treatment related morbidity - minor complications - Superficial wound infection	18 per 1000	83 per 1000 (10 to 692)	RR 4.75 (0.57 to 39.42)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor	0 per 1000	0 per 1000 (0 to 0)	RR 2.85 (0.12 to 68.62)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No Intervention	Parenteral nutrition (PN) after surgery				
complications - Cellulitis						
Treatment related morbidity - minor complications - Prolonged ileus	88 per 1000	217 per 1000 (82 to 569)	RR 2.47 (0.94 to 6.49)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Treatment related morbidity - minor complications - Gastric atony	18 per 1000	33 per 1000 (3 to 358)	RR 1.9 (0.18 to 20.38)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor complications - Atelectasis	211 per 1000	251 per 1000 (128 to 486)	RR 1.19 (0.61 to 2.31)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor complications - Pleural effusion	228 per 1000	201 per 1000 (100 to 401)	RR 0.88 (0.44 to 1.76)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor complications - Catheter sepsis	18 per 1000	83 per 1000 (10 to 692)	RR 4.75 (0.57 to 39.42)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor complications - Urinary tract infection	105 per 1000	66 per 1000 (20 to 224)	RR 0.63 (0.19 to 2.13)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - minor complications - PN related complication	0 per 1000	0 per 1000 (0 to 0)	RR 4.75 (0.23 to 96.93)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity -	See comment	See comment	Not estimable	117 (1 study ¹)	⊕⊕⊕ ⊖	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No Intervention	Parenteral nutrition (PN) after surgery				
minor complications - Liver function abnormality					very low ^{2,4}	
Treatment related morbidity - minor complications - Total minor complications	421 per 1000	535 per 1000 (362 to 783)	RR 1.27 (0.86 to 1.86)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Treatment related morbidity - Postoperative mortality	18 per 1000	67 per 1000 (8 to 579)	RR 3.8 (0.44 to 32.99)	117 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Overall Survival at median follow up of 18 months	See comment	See comment	Not estimable	117 (1 study ¹)	⊕⊕⊕ ⊖ low ²	“The actuarial median survival is 24 months. (No difference between the two groups has been identified P=0.25)”
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i> ¹ Brennan et al. 1994 ² The quality of the evidence was downgraded from high to low because of the unclear risk of detection, performance bias and of attrition bias (No details were given in the text) ³ Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID ⁴ Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2

Table 95: Summary clinical evidence profile for oral nutritional supplements (n-3 fatty acids) versus isocaloric-isonitrogenous supplement (without n-3 fatty acids)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Isocaloric-isonitrogenous supplement (No n-3 fatty acids)	Oral nutritional supplements (n-3 fatty acids)				
Nutritional status - Change in		The mean nutritional status - change in		110 (1 study ¹)	⊕⊕⊕⊕ low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Isocaloric-isonitrogenous supplement (No n-3 fatty acids)	Oral nutritional supplements (n-3 fatty acids)				
weight (kg/month) at 8 weeks		weight (kg/month) at 8 weeks in the intervention groups was 0.12 higher (0.09 lower to 0.33 higher)				
Nutritional status - Change in lean body mass (kg) at 8 weeks		The mean nutritional status - change in lean body mass (kg) at 4 and 8 weeks in the intervention groups was 0.15 higher (0.02 to 0.28 higher)		97 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
Change in resting energy expenditure at 8 weeks		The mean change in resting energy expenditure at 8 weeks in the intervention groups was 14 higher (81.8 lower to 109.8 higher)		19 (1 study ⁴)	⊕⊕⊕⊖ low ⁵	
Change in total energy expenditure at 8 weeks		The mean change in total energy expenditure at 8 weeks in the intervention groups was 187 higher (114.38 lower to 488.38 higher)		19 (1 study ⁴)	⊕⊕⊕⊖ moderate ³	
Change in physical activity level at 8 weeks		The mean change in physical activity level at 8 weeks in the intervention groups was 0.17 higher (0.05 lower to 0.39 higher)		19 (1 study ⁴)	⊕⊕⊕⊖ moderate ³	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Isocaloric-isonitrogenous supplement (No n-3 fatty acids)	Oral nutritional supplements (n-3 fatty acids)				
Health Related Quality of Life at 8 weeks	See comment	See comment	Not estimable	110 (1 study ¹)	⊕⊕⊖⊖ low ⁶	"there were no significant differences in quality of life measures between the two groups" (data not shown)
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval;</p> <p>1 Fearon et al. 2003 2 The quality of the evidence was downgraded from high to moderate because of the potential risk of attrition bias (more than 55% of patients were not available for analysis at the last follow-up, and there was not reported enough information to judge whether the true outcome of the trial would have been affected) 3 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 4 Moses et al. 2004 5 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 6 The quality of the evidence was downgraded from high to moderate because of the potential risk of attrition bias (see comment 2) and selective reporting for this outcome</p>						

1
2

Table 96: Summary clinical evidence profile for oral nutritional supplements (oral L-Carnitine therapy) versus placebo

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Oral nutritional supplements (oral L-Carnitine therapy)				
Nutritional status - % change of BMI at 12 weeks		The mean nutritional status - % change of BMI at 12 weeks in the intervention groups was 4.9 higher (2.71 to 7.09 higher)		72 (1 study ¹)	⊕⊕⊖⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Oral nutritional supplements (oral L-Carnitine therapy)				
Nutritional status - % change of BCM at 12 weeks		The mean nutritional status - % change of BCM at 12 weeks in the intervention groups was 8.8 higher (7.20 to 10.40 higher)		72 (1 study ¹)	⊕⊕⊖ ⊖ low ²	
Health Related Quality of Life - EORTC-QLQ-C30/PAN26 - cognitive function at 6 weeks follow-up	See comment	See comment	Not estimable	72 (1 study ¹)	⊕⊕⊖ ⊖ low ²	There was a significant improvement in favour of the L-Carnitine group, p = 0.034
Health Related Quality of Life - EORTC-QLQ-C30/PAN26 - global health status at 12 weeks follow-up	See comment	See comment	Not estimable	72 (1 study ¹)	⊕⊕⊖ ⊖ low ²	There was a significant improvement in favour of the L-Carnitine group, p = 0.041
Overall Survival at follow up of 1500 days	See comment	See comment		72 (1 study ¹)	⊕⊕⊖ ⊖ low ²	No difference between intervention and control group (p value not reported, median 519 ± 50 days in the intervention group versus 399 ± 43 days with placebo)
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval;</i> ¹ Kraft et al. 2012 ² The quality of the evidence was downgraded from high to low because of the potential risk of attrition bias (Even though in the report was stated that "Dropout rates and reasons were not different between both treatment arms", the high dropout rate (data missing on 43 of the 72 randomised patients [59%] is still significant) and the selective reporting of findings.</p>						

1
2

Table 97: Summary clinical evidence profile for pancreatic enzyme replacement therapy versus placebo

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Pancreatic enzyme replacement therapy (PERT)				
Nutritional status - Percentage change in body weight (%) at 8 weeks follow-up		The mean nutritional status - percentage change in body weight (%) at 8 weeks follow-up in the intervention groups was 2.89 higher (0.51 to 5.27 higher)		88 (2 studies ¹)	⊕⊕⊕⊖ moderate ²	
Nutritional status - Absolute change in body weight (Kg) at 8 weeks follow-up		The mean nutritional status - absolute change in body weight (kg) at 8 weeks follow-up in the intervention groups was 1.64 higher (0.7 lower to 3.98 higher)		88 (2 studies ¹)	⊕⊕⊕⊖ moderate ²	
Nutritional status - Daily dietary intake of total calories at 8 weeks follow-up		The mean nutritional status - daily dietary intake of total calories at 8 weeks follow-up in the intervention groups was 1.76 higher (0.19 to 3.33 higher)		21 (1 study ³)	⊕⊕⊖⊖ low ^{2,4}	
Health related quality of life - Global Health status EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - global health status in the intervention groups was 8.76 higher (2.63 lower to 20.15 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Functional scale EORTC-QLQ-C30 -		The mean health related quality of life - functional scale in the intervention groups was		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Pancreatic enzyme replacement therapy (PERT)				
Korean version Follow-up: 8 weeks		6.93 higher (5.36 lower to 19.22 higher)				
Health related quality of life - Physical EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - physical in the intervention groups was 7.15 higher (5.89 lower to 20.19 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Role EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - role in the intervention groups was 9.7 higher (6.58 lower to 25.98 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Emotional EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - emotional in the intervention groups was 1.24 higher (12.78 lower to 15.26 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Cognitive EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - cognitive in the intervention groups was 7.18 higher (7.53 lower to 21.89 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Social EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - social in the intervention groups was 9.36 higher (1.21 lower to 19.93 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Pancreatic enzyme replacement therapy (PERT)				
Health related quality of life - Symptom scale EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - symptom scale in the intervention groups was 4.67 lower (17.73 lower to 8.39 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Fatigue EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - fatigue in the intervention groups was 4.87 lower (19.51 lower to 9.77 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Nausea and vomiting EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - nausea and vomiting in the intervention groups was 7.44 lower (22.43 lower to 7.55 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Pain EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - pain in the intervention groups was 4.57 lower (20.73 lower to 11.59 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Dyspnea EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - dyspnea in the intervention groups was 3.25 higher (13.96 lower to 20.46 higher)		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	
Health related quality of life - Insomnia EORTC-		The mean health related quality of life - insomnia in the intervention		62 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Pancreatic enzyme replacement therapy (PERT)				
QLQ-C30 - Korean version Follow-up: 8 weeks		groups was 2.99 lower (20.14 lower to 14.16 higher)				
Health related quality of life - Appetite loss EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - appetite loss in the intervention groups was 18.8 lower (36.51 to 1.09 lower)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Constipation EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - constipation in the intervention groups was 1.2 higher (15.26 lower to 17.66 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Diarrhoea EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - diarrhoea in the intervention groups was 3.25 lower (19.52 lower to 13.02 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Health related quality of life - Financial difficulties EORTC-QLQ-C30 - Korean version Follow-up: 8 weeks		The mean health related quality of life - financial difficulties in the intervention groups was 4.53 lower (17.45 lower to 8.39 higher)		62 (1 study ⁵)	⊕⊕⊕⊖ low ^{2,7}	
Overall survival	See comment	See comment	Not estimable	62 (1 study ⁵)	⊕⊕⊕⊖ low ^{6,7}	Overall survival did not differ significantly between intervention groups (PERT group: 5.84 month;

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Placebo	Pancreatic enzyme replacement therapy (PERT)				
						placebo: 8.13 months [p=0.774].
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval;</p> <p>1 Bruno et al. 1998; Woo et al. 2016 2 Evidence for this outcome was downgraded by 1 due to imprecision as 95%CI crossed one default MID 3 Bruno et al. 1998 4 Evidence was downgraded by 1 due to indirectness (2 of the 24 participants did not have PC 5 Woo et al. 2016 6 Evidence for this outcome was downgraded by 1 due to potential selective reporting of findings. 7 The quality of the evidence was downgraded from moderate to low due to potential indirectness (as the randomised trial was conducted in Korea and the outcomes may not be transferrable to the UK settings).</p>						

1
2

Table 98: Summary clinical evidence profile for pancreatic enzyme replacement therapy versus pancrelipase replacement therapy

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Pancreatic enzyme replacement therapy (PERT) versus pancrelipase replacement therapy				
Nutritional status - BMI (kg/m ²) at 6 and 12 months follow-up - at 6 months follow-up		The mean nutritional status - BMI (kg/m ²) at 6 and 12 months follow-up - at 6 months follow-up in the intervention groups was 0.95 higher (0.68 lower to 2.58 higher)		57 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Nutritional status - BMI (kg/m ²) at 6 and 12 months follow-up - at 12 months follow-up		The mean nutritional status - BMI (kg/m ²) at 6 and 12 months follow-up - at 12 months follow-up in the intervention groups was 0.51 higher (1.11 lower to 2.13 higher)		57 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Treatment related morbidity -	393 per 1000	208 per 1000 (90 to 483)	RR 0.53 (0.23)	57 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	Pancreatic enzyme replacement therapy (PERT) versus pancrelipase replacement therapy				
NAFLD at 1 year follow-up			to 1.23)			
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 Satoi et al. 2016 2 The quality of the evidence was downgraded from high to moderate because of the unclear risk of performance bias (no information blinding of outcome assessors) and unclear risk of selection bias 3 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID 4 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</p>						

1 **8.3.5 Economic evidence**

2 A literature review of published cost effectiveness analyses did not identify any relevant
 3 studies for this topic. Although there were potential implications for resource use associated
 4 with making recommendations in this area, other topics in the guideline were agreed as a
 5 higher economic priority. Consequently, bespoke economic modelling was not done for this
 6 topic.

7 **8.3.6 Evidence Statements**

8 **8.3.6.1 Enteral immunonutrition versus Standard Enteral nutrition**

9 **98.3.6.1.1 Before and after surgery (perioperative)**

10 **Overall Survival**

11 No evidence was identified to inform this outcome.

12 **Treatment related morbidity**

13 Very low quality evidence from 1 RCT (n=30) showed no clinically important difference
 14 between enteral immunonutrition and standard enteral nutrition on either post-operative
 15 infectious complications (RR 0.83 [95% CI 0.32-2.15]) or post-operative non-infectious
 16 complications (RR 1.00 [95% CI 0.42-2.40]) in adults with resectable pancreatic cancer.

17 **Health Related Quality of Life**

18 Very low quality evidence from 1 RCT (n=37) showed no clinically important difference
 19 between enteral immunonutrition and standard enteral nutrition on mean Karnofsky score 2
 20 weeks after surgery in adults with resectable pancreatic cancer: MD -2.00 (95% CI -7.33 to
 21 3.33).

22 **Symptom control**

23 No evidence was identified to inform this outcome.

24 **Nutritional status**

1 Very low quality evidence from 1 RCT (n=37) showed no clinically important difference
2 between enteral immunonutrition and standard enteral nutrition on mean change on BMI
3 from baseline (MD -1.50 kg/m² [95% CI -3.93 to 0.93]), mid-arm circumference (MD -0.60 cm
4 [95% CI -2.92 to 1.72]), and corrected arm muscle area (MD -1.60 cm² [95% CI -7.09 to
5 3.89]) 2 weeks after surgery in adults with resectable pancreatic cancer.

6 **Adverse events**

7 No evidence was identified to inform this outcome.

8 **Patient experience**

9 No evidence was identified to inform this outcome.

10 **108.3.6.1.2 After surgery (postoperative)**

11 **Overall Survival**

12 No evidence was identified to inform this outcome.

13 **Treatment related morbidity**

14 Low quality evidence from 1 RCT (n=144) showed no clinically important difference between
15 enteral immunonutrition and standard enteral nutrition on either post-operative infectious
16 complications (RR 0.56 [95% CI 0.22-1.44]) or post-operative non-infectious complications
17 (RR 0.88 [95% CI 0.51-1.51]) in adults with pancreatic cancer after surgery.

18 Low quality evidence from 1 RCT (n=144) showed no clinically important difference between
19 enteral immunonutrition and standard enteral nutrition on post-operative mortality in adults
20 with pancreatic cancer after surgery: RR 2.06 (95% CI, 0.19-22.18).

21 Low quality evidence from 1 RCT (n=144) showed no clinically important difference between
22 enteral immunonutrition and standard enteral nutrition on tube clogging/kinking (RR 0.62
23 [95% CI, 0.15-2.49]), tube dislodgment (RR 2.06 [95% CI, 0.19-22.18]), tube breakage (RR
24 0.34 [95% CI, 0.01-8.27]), local skin infection (RR 0.34 [95% CI, 0.01-8.27]), abdominal
25 cramps (RR 0.93 [95% CI, 0.42-2.06]), abdominal distension (RR 1.14 [95% CI, 0.49-2.64]),
26 diarrhoea (RR 0.8 [95% CI, 0.31-2.03]), and vomiting (RR 0.21 [95% CI, 0.01-4.21]) in adults
27 with pancreatic cancer after surgery.

28 **Health Related Quality of Life**

29 No evidence was identified to inform this outcome.

30 **Symptom control**

31 No evidence was identified to inform this outcome.

32 **Nutritional status**

33 No evidence was identified to inform this outcome.

34 **Adverse events**

35 No evidence was identified to inform this outcome.

36 **Patient experience**

37 No evidence was identified to inform this outcome.

38 **8.3.6.2 Enteral immunonutrition versus Standard nutrition (no intervention)**

39 **Overall Survival**

1 No evidence was identified to inform this outcome.

2 **Treatment related morbidity**

3 Low quality evidence from 1 RCT (n=35) showed no statistically significant difference
4 between enteral immunonutrition and standard nutrition (no intervention) on total post-
5 operative infectious or non-infectious complications in adults with pancreatic cancer after
6 surgery (the data was not reported).

7 **Health Related Quality of Life**

8 No evidence was identified to inform this outcome.

9 **Symptom control**

10 No evidence was identified to inform this outcome.

11 **Nutritional status**

12 Very low quality evidence from 1 RCT (n=35) showed no clinically important difference
13 between enteral immunonutrition and standard nutrition (no intervention) on absolute change
14 30 days after surgery in weight from baseline in adults with pancreatic cancer: MD 0.97 kg
15 (95% CI -1.37 to 3.32).

16 **Adverse events**

17 No evidence was identified to inform this outcome.

18 **Patient experience**

19 Very low quality evidence from 1 RCT (n=35) showed no clinically important difference
20 between enteral immunonutrition and standard nutrition (no intervention) on PROMS
21 satisfaction with nutritional treatment 30 days after surgery in adults with pancreatic cancer:
22 MD 0.04 (95% CI -0.34 to 0.41)

23 **8.3.6.3 Parenteral nutrition versus standard enteral nutrition after surgery**

24 **Overall Survival**

25 No evidence was identified to inform this outcome.

26 **Treatment related morbidity**

27 Moderate quality evidence from 1 RCT (n=141) showed no clinically important difference
28 between parenteral nutrition and standard enteral nutrition on the relative risk of
29 postoperative adverse effects (including infectious complications, non-infectious
30 complications, and total complications) in adults with pancreatic cancer after surgery: RR
31 1.46 (95% CI 0.72-2.96), RR 1.28 (95% CI 0.79-2.76), and RR 1.34 (95% CI 0.97-1.86),
32 where RR higher than 1 favours SEN group

33 Low quality evidence from 2 RCTs (n=141) showed no clinically important difference
34 between parenteral nutrition and standard enteral nutrition about the relative risk of
35 postoperative mortality in adults with pancreatic cancer after surgery: RR 4.29 (95% CI 0.49-
36 37.47), where RR higher than 1 favours SEN group

37 **Health Related Quality of Life**

38 No evidence was identified to inform this outcome.

39 **Symptom control**

40 No evidence was identified to inform this outcome.

1 **Nutritional status**

2 No evidence was identified to inform this outcome.

3 **Adverse events**

4 No evidence was identified to inform this outcome.

5 **Patient experience**

6 No evidence was identified to inform this outcome.

7 **8.3.6.4 Parenteral nutrition versus enteral immunonutrition after surgery**

8 **Overall Survival**

9 No evidence was identified to inform this outcome.

10 **Treatment related morbidity**

11 Moderate quality evidence from 1 RCT (n=139) showed that there is a clinically important
12 difference favouring enteral immunonutrition on post-operative infectious and non-infectious
13 complications compared to parenteral nutrition in adults with pancreatic cancer after surgery:
14 RR 1.74 (95% CI 1.19-2.55).

- 15 • Moderate quality evidence from 1 RCT showed there is a clinically important difference
16 favouring enteral immunonutrition on post-operative infectious complications compared to
17 parenteral nutrition in adults with pancreatic cancer after surgery: RR 2.61 (95% CI 1.08-
18 6.33).
- 19 • Moderate quality evidence from 1 RCT (n=139) showed no clinically important difference
20 between parenteral nutrition and enteral immunonutrition on post-operative non-infectious
21 complications in adults with pancreatic cancer after surgery: RR 1.45 (95% CI 0.87-2.41).

22 Low quality evidence from 1 RCT (n=139) showed no clinically important difference between
23 parenteral nutrition and enteral immunonutrition on post-operative mortality in adults with
24 pancreatic cancer after surgery: RR 2.09 (95% CI 0.40-11.3).

25 **Health Related Quality of Life**

26 No evidence was identified to inform this outcome.

27 **Symptom control**

28 No evidence was identified to inform this outcome.

29 **Nutritional status**

30 No evidence was identified to inform this outcome.

31 **Adverse events**

32 No evidence was identified to inform this outcome.

33 **Patient experience**

34 No evidence was identified to inform this outcome.

35 **8.3.6.5 Parenteral nutrition versus no intervention after surgery**

36 **Overall Survival**

1 Low quality evidence from 1 RCT (n=117) showed no clinically important difference between
2 parenteral nutrition and no intervention on overall survival (actuarial median survival=24
3 months) at 18 months in adults with pancreatic cancer after surgery (data not reported).

4 **Treatment related morbidity**

5 Very low quality evidence from 1 RCT (n=117) showed there is a clinically important
6 difference favouring no intervention on major treatment-related complications (excluding
7 death) compared to parenteral nutrition in adults with pancreatic cancer after surgery: RR
8 1.82 (95% CI 1.0-3.31).

- 9 • Very low quality evidence from 1 RCT (n=117) showed no clinically important difference
10 between parenteral nutrition and no intervention on the majority of treatment-related major
11 complications including deep infection (RR 0.95 [95% CI 0.25-3.62]), fistula (RR 1.52
12 [95% CI 0.53-4.37]), peritonitis (RR 3.33 [95% CI 0.72-15.34]), haemorrhage (RR 0.47
13 [95% CI, 0.04-5.1]), intestinal obstruction (RR 8.56 [95% CI 0.47-155.45]), anastomotic
14 breakdown (RR 2.22 [95% CI 0.6-8.16]), aspiration (RR 0.32 [95% CI 0.01-7.62]),
15 pneumonia (RR 0.79 [95% CI 0.26-2.45]), pulmonary embolus (RR 0.32 [95% CI 0.01-
16 7.62]), myocardial infarction (RR 1.9 [95% CI 0.18-20.38]), and reoperation rate (RR 1.9
17 [95% CI 0.5-7.24]) in adults with pancreatic cancer after surgery.
- 18 • Low quality evidence from 1 RCT (n=117) showed that there is a clinically important
19 difference favouring no intervention on treatment-related abscesses compared to
20 parenteral nutrition in adults with pancreatic cancer after surgery: RR 5.7 (95% CI 1.33-
21 24.36).

22 Very low quality evidence from 1 RCT (n=117) showed no clinically important difference
23 between parenteral nutrition and no intervention on minor treatment-related complications in
24 adults with pancreatic cancer after surgery: RR 1.27 (95% CI 0.86-1.86).

- 25 • Very low quality evidence from 1 RCT (n=117) showed no clinically important difference
26 between parenteral nutrition and no intervention on the majority of treatment-related minor
27 complications including superficial wound infection (RR 4.75 [95% CI 0.57-39.42]),
28 cellulitis (RR 2.85 [95% CI 0.12-68.62]), gastric atony (RR 1.9 [95% CI 0.18-20.38]),
29 atelectasis (RR 1.19 [95% CI 0.61-2.31]), pleural effusion (RR 0.88 [95% CI 0.44-1.76]),
30 catheter sepsis (RR 4.75 [95% CI 0.57-39.42]), urinary tract infection (RR 0.63 [95% CI
31 0.19-2.13]), complications related to parenteral nutrition (RR 4.75 [95% CI 0.23-96.93]),
32 and liver function abnormality (RR 1.0), in adults with pancreatic cancer after surgery.
- 33 • Very low quality evidence from 1 RCT (n=117) showed there may be a clinically important
34 difference favouring no intervention on prolonged ileus compared to parenteral nutrition in
35 adults with pancreatic cancer after surgery, although there is some uncertainty: RR 2.47
36 (95% CI 0.94-6.49).

37 Very low quality evidence from 1 RCT (n=117) showed no clinically important difference
38 between parenteral nutrition and no intervention on post-operative mortality in adults with
39 pancreatic cancer after surgery: RR 3.8 (95% CI 0.44-32.99).

40 **Health Related Quality of Life**

41 No evidence was identified to inform this outcome.

42 **Symptom control**

43 No evidence was identified to inform this outcome.

44 **Nutritional status**

45 No evidence was identified to inform this outcome.

46 **Adverse events**

1 No evidence was identified to inform this outcome.

2 **Patient experience**

3 No evidence was identified to inform this outcome.

4 **8.3.6.6 Oral nutritional supplements (n-3 fatty acids) versus isocaloric-isonitrogenous**
5 **supplement (without n-3 fatty acids)**

6 **Overall Survival**

7 No evidence was identified to inform this outcome.

8 **Treatment related morbidity**

9 No evidence was identified to inform this outcome.

10 **Health Related Quality of Life**

11 No evidence was identified to inform this outcome.

12 **Symptom control**

13 No evidence was identified to inform this outcome.

14 **Nutritional status**

15 Low quality evidence from 1 RCT (n=110) showed no clinically important difference between
16 n-3 fatty acids oral nutritional supplements and isocaloric-isonitrogenous supplements on
17 absolute monthly change in weight (kg) at 8 weeks in weight-losing adults with unresectable
18 pancreatic cancer: MD 0.12 (95% CI -0.09 to 1.72).

19 Low quality evidence from 1 RCT (n=97) showed that there is a clinically important difference
20 favouring isocaloric-isonitrogenous supplements on change in lean body mass (kg) at 4 and
21 8 weeks compared to n-3 fatty acids oral nutritional supplements in weight-losing adults with
22 unresectable pancreatic cancer: MD 0.15 (95% CI 0.02 to 0.28).

23 Low to moderate quality evidence from 1 RCT (n=24) showed no clinically important
24 difference between n-3 fatty acids oral nutritional supplements and isocaloric-isonitrogenous
25 supplements on change at 8 weeks in resting energy expenditure (MD 14.0 [95% CI, -81.8 to
26 109.8]), total energy expenditure (MD 187.0 [95% CI -114.4 to 488.4]) and physical activity
27 level (MD 0.17 [95% CI -0.05 to 0.39]) in adults with advanced pancreatic cancer.

28 **Adverse events**

29 No evidence was identified to inform this outcome.

30 **Patient experience**

31 No evidence was identified to inform this outcome.

32 **8.3.6.7 Oral nutritional supplements (oral L-Carnitine therapy) versus placebo**

33 **Overall Survival**

34 Low quality evidence from 1 RCT (n=72) showed no clinically important difference between
35 oral L-Carnitine-enriched nutritional supplements (median survival=519 days [SD=50]) and
36 placebo (median survival=399 days [SD=43]) on overall survival at 1500 days in adults with
37 unresectable pancreatic cancer.

38 **Treatment related morbidity**

1 No evidence was identified to inform this outcome.

2 **Health Related Quality of Life**

3 Low quality evidence from 1 RCT (n=72) showed that there is a clinically important difference
4 favouring oral L-Carnitine-enriched nutritional supplements on the EORTC QLQ C30-Pan26
5 cognitive function subscale at 6 weeks (p=0.034) and global health status subscale at 12
6 weeks (p=0.041) compared to placebo in adults with unresectable pancreatic cancer.

7 **Symptom control**

8 No evidence was identified to inform this outcome.

9 **Nutritional status**

10 Low quality evidence 1 RCT (n=72) showed that there is a clinically important difference at
11 12 weeks favouring oral L-Carnitine-enriched nutritional supplements on percentage change
12 in BMI (MD 4.9 [95% CI 2.71-7.09]) and percentage change of body fat and body cell mass
13 (MD 8.8 [95% CI 7.2 to 10.4]) compared to placebo in adults with unresectable pancreatic
14 cancer.

15 **Adverse events**

16 No evidence was identified to inform this outcome.

17 **Patient experience**

18 No evidence was identified to inform this outcome.

19 **8.3.6.8 Pancreatic enzyme replacement therapy (PERT) versus placebo**

20 **Overall Survival**

21 Low quality evidence from 1 RCT (n=67) showed no clinically important difference between
22 pancreatic enzyme replacement therapy and placebo on overall survival (5.84 vs 8.13
23 months, p=0.77) in adults with unresectable cancer.

24 **Treatment related morbidity**

25 No evidence was identified to inform this outcome.

26 **Health Related Quality of Life**

27 Low quality evidence from 1 RCT (n=62) showed no clinically important difference between
28 pancreatic enzyme replacement therapy and placebo at 8 weeks on the EORTC QLQ-C30
29 global health status scale (MD 8.76 (95% CI, -2.63 to 20.15]), functional scale (MD 6.93
30 [95% CI, -5.36 to 19.22]) and symptom scale (MD -4.67 [95% CI -17.73 to 8.39]), and the
31 majority of their subscales, in adults with unresectable cancer.

- 32 • Low quality evidence from 1 RCT (n=62) showed that there may be a clinically important
33 difference at 8 weeks favouring pancreatic enzyme replacement therapy on the EORTC
34 QLQ-C30 social functioning subscale compared to placebo in adults with unresectable
35 cancer, although there is some uncertainty: MD 9.36 (95% CI -1.21 to 19.93).
- 36 • Low quality evidence from 1 RCT (n=62) showed that there is a clinically important
37 difference at 8 weeks favouring pancreatic enzyme replacement therapy on the EORTC
38 QLQ-C30 appetite loss subscale compared to placebo in adults with unresectable cancer:
39 MD -8.8 (95% CI -36.51 to -1.09).

40 **Symptom control**

41 No evidence was identified to inform this outcome.

1 **Nutritional status**

2 Moderate quality evidence from 2 RCTs (n=88) showed that there is a clinically important
3 difference at 8 weeks favouring pancreatic enzyme replacement therapy on percentage
4 change in body weight compared to placebo in adults with unresectable pancreatic cancer:
5 MD 2.89 (95% CI 0.51 to 5.27).

6 Moderate quality evidence from 2 RCTs (n=88) showed no clinically important difference
7 between pancreatic enzyme replacement therapy and placebo on absolute change in body
8 weight (kg) in adults with unresectable pancreatic cancer: MD 1.64 (95% CI -0.7 to 3.98).

9 Low quality evidence from 1 RCT (n=21) that there is a clinically important difference at 8
10 weeks favouring pancreatic enzyme replacement therapy on daily dietary intake of total
11 calories compared to placebo in adults with unresectable pancreatic cancer: MD 1.76 (95%
12 CI 0.19 to 3.33).

13 **Adverse events**

14 No evidence was identified to inform this outcome.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **8.3.6.9 Pancrelipase replacement therapy versus PERT**

18 **Overall Survival**

19 No evidence was identified to inform this outcome.

20 **Treatment related morbidity**

21 Low quality evidence from 1 RCT (n=57) showed no clinically important difference between
22 pancreatic enzyme replacement therapy and pancrelipase replacement therapy on non-
23 alcoholic fatty liver disease in adults with pancreatic cancer 12 months after surgery: RR 0.53
24 (95% CI 0.23-1.23).

25 **Health Related Quality of Life**

26 No evidence was identified to inform this outcome.

27 **Symptom control**

28 No evidence was identified to inform this outcome.

29 **Nutritional status**

30 Low quality evidence 1 RCT (n=57) showed no clinically important difference between
31 pancreatic enzyme replacement therapy and pancrelipase replacement therapy on BMI in
32 adults with pancreatic cancer 6 months (MD 0.95 [95% CI -0.68 to 2.58]) and 12 months (MD
33 0.51 [95% CI -1.11 to 2.13]) after surgery.

34 **Adverse events**

35 No evidence was identified to inform this outcome.

36 **Patient experience**

37 No evidence was identified to inform this outcome.

1 **8.3.7 Recommendations**

2 **28. Offer enteric-coated pancreatin for people with unresectable pancreatic cancer.**

3 **29. Consider enteric-coated pancreatin before and after pancreatic cancer resection.**

4 **30. Do not use fish oils as a nutritional intervention to manage weight loss in people**
5 **with unresectable pancreatic cancer.**

6 **31. For people who have had pancreatoduodenectomy and who have a functioning**
7 **gut, offer early enteral nutrition (including oral and tube feeding) rather than**
8 **parenteral nutrition.**

9 **32. For more guidance on nutrition support, see the NICE guideline on [nutrition](#)**
10 **[support in adults](#).**

11 **8.3.8 Evidence to recommendations**

12 **8.3.8.1 Relative value placed on the outcomes considered**

13 Overall survival, treatment related morbidity, health-related quality of life, symptom control,
14 nutritional status, adverse events and patient experience were considered to be the critical
15 outcomes for this question.

16 Nutritional status was reported for the majority of studies. Overall survival, treatment related
17 morbidity and health-related quality of life were reported for approximately half of the studies.
18 Patient experience was only reported by 1 study. The outcomes of symptom control and
19 adverse events were not reported by any studies.

20 **8.3.8.2 Quality of evidence**

21 The quality of the outcomes for the comparisons identified by this review were as follows:

- 22 • Enteral immunonutrition versus standard enteral nutrition – ranged from very low to low
- 23 • Enteral immunonutrition versus standard nutrition (no intervention) – ranged from very low
24 to low
- 25 • Parenteral nutrition versus no intervention after surgery – ranged from very low to low
- 26 • Pancreolipase replacement therapy versus pancreatic enzyme replacement therapy
27 (PERT) - low
- 28 • Parenteral nutrition versus standard enteral nutrition after surgery - low
- 29 • Oral nutritional supplements versus placebo – low
- 30 • Parenteral nutrition versus enteral immunonutrition after surgery – ranged from low to
31 moderate
- 32 • Oral nutritional supplements (n-3 fatty acids) versus isocaloric-isonitrogenous supplement
33 (without n-3 fatty acids) – ranged from low to moderate
- 34 • PERT versus placebo – ranged from low to moderate.

35 No evidence was found on the effectiveness of glycaemic control or the addition of proton
36 pump inhibitors to pancreatic replacement enzyme therapy (PERT), so the committee did not
37 make any recommendations for clinical practice. They agreed not to recommend further
38 research in these areas as they considered other areas were a higher priority for research
39 funding.

1 The committee noted that the post hoc analysis of an RCT by Davidson et al (2004) only
2 found an association in a post hoc analysis between weight stabilisation and survival. No
3 causal relationship was demonstrated They therefore agreed not to use the data from this
4 study when making recommendations.

5 The committee noted that there were several studies investigating the effectiveness of
6 enteral immunonutrition. However, this evidence was mostly of low quality and the studies
7 had used different immunonutrition, which confounded interpretation of the results. The
8 committee agreed that there was not enough evidence of benefit for immunonutrition
9 compared to standard enteral nutrition and so did not make a recommendation for clinical
10 practice. They also agreed that other topics were a higher priority for research funding and
11 so did not recommend any further research in this area.

12 The committee noted that whilst the data on oral L-Carnitine therapy showed an
13 improvement in nutritional status, the study had used bioelectrical impedance to measure
14 nutritional status, which is not an accurate measure in this patient group. They also noted
15 that the authors of the study had said this data was preliminary and needs further
16 investigation. Given this, the committee agreed not to make any recommendations for clinical
17 practice about L-Cartinine. They also agreed that the data on other nutritional supplements
18 was not strong enough to support a recommendation for clinical practice.

19 The committee agreed that overall, the evidence base for nutritional interventions was quite
20 poor, most of the evidence was either very low or low quality and the comparators used often
21 made it difficult to determine if the intervention was better or worse than standard care. They
22 therefore agreed to recommend further research comparing nutritional interventions against
23 standard care. The committee also agreed to recommend further research to compare
24 cachexia assessment methods and anti-cachexia interventions with standard care as no
25 effective treatments for cachexia had been identified by the evidence.

26 The committee noted that of the two studies comparing pancreatic enzyme replacement
27 therapy with placebo, 1 was conducted in Korea which decreased its relevance to the UK
28 population (as different pancreatic enzymes were used to those used in the UK). They
29 therefore applied less weight to the results of this study when making recommendations
30 about pancreatic enzyme replacement therapy.

31 **8.3.8.3 Consideration of clinical benefits and harms**

32 The committee noted that the evidence on PERT came from people with unresectable
33 pancreatic cancer and showed that nutritional status was improved with the use of PERT.
34 They therefore agreed to recommend the use of PERT in this patient group - they
35 recommended enteric coated pancreatin treatment as this was the type of PERT that was
36 used in the trials.

37 Based on their clinical experience and knowledge, the committee also agreed that people
38 with resectable pancreatic cancer were unlikely to produce sufficient pancreatic enzymes
39 and would probably also benefit from taking PERT. They therefore also recommended PERT
40 for people with resectable disease (both before and after resection), but this was a weaker
41 recommendation due to the lack of evidence.

42 The committee noted that, based on the evidence, fish oils had not been shown to reduce
43 weight loss in people with unresectable pancreatic cancer. Given that the evidence was
44 moderate quality, they agreed to recommend that this intervention should not be used for
45 managing weight loss for people with unresectable pancreatic cancer.

46 Based on the evidence, the committee noted that there were less post-operative
47 complications with enteral nutrition compared with parenteral nutrition following
48 pancreatoduodenectomy and no clinically important difference in overall survival. They

1 therefore agreed to recommend enteral feeding as the preferred method for providing
2 nutrition but were not able to specify a particular route (oral or tube feeding).

3 **8.3.8.4 Consideration of economic benefits and harms**

4 The committee noted that no relevant published economic evaluations had been identified
5 and no additional economic analysis had been undertaken in this area.

6 The committee considered that the recommendations made were unlikely to result in a
7 substantial increase in resource use. Pancreatic enzymes do not have a high unit cost. Any
8 additional costs compared with current usage would likely to be offset by a reduction in the
9 costs associated with dealing with malnutrition.

10 **8.3.8.5 Other considerations**

11 Given that a high proportion of people with pancreatic cancer have less than optimal
12 nutrition, the committee considered that the recommendations in the NICE guideline on
13 Nutrition support in adults would also apply to this patient group. They therefore agreed to
14 cross-reference these recommendations.

15 **8.3.9 Research recommendations**

16 **4. A randomised trial should be undertaken comparing nutritional interventions** 17 **(including pancreatic enzyme replacement, types of feed, route of administration,** 18 **timing) against standard of care or against each other for people with resected or** 19 **unresectable pancreatic cancer**

20 The nutritional status of patients with resectable and unresectable pancreatic cancer can be
21 significantly impacted by their disease, which can impact on morbidity and quality of life (it is
22 a key issue frequently raised by patients in helping them manage the disease). There is no
23 good quality research into the use of pancreatic enzyme replacement therapy in people with
24 resected or resectable pancreatic cancer, the use of proton pump inhibitors, the preferred
25 composition of nutritional supplements or enteral feeds, glycaemic control or the preferred
26 route of nutritional delivery following pancreatic resection. Further research into nutritional
27 interventions should help to improve nutritional support to people with pancreatic cancer. It
28 should also enable resources to be focused on effective interventions which would
29 streamline service delivery and be cost saving to the NHS. Outcomes of interest are survival,
30 nutritional status, quality of life and patient experience.

31 **5. A cohort study followed by phase II and III studies should be undertaken in people** 32 **with pancreatic cancer and cachexia or pre-cachexia, to compare cachexia** 33 **assessment methods and anti-cachexia interventions with standard care.**

34 Most people with advanced and metastatic pancreatic cancer also have cachexia. This
35 causes severe reductions in their quality of life and is associated with reduced overall
36 survival. Cachexia has 3 phases: pre-cachexia, cachexia, and refractory cachexia. The
37 condition cannot be stopped by conventional nutritional support and leads to progressive
38 functional impairment. Complete or partial reversal of cachexia would cause major
39 improvements in quality of life, and potentially improve survival if people recover enough to
40 have more effective cancer treatments. The outcomes of interest are:

- 41 • prevention or reversal of cachexia
- 42 • overall survival
- 43 • quality of life
- 44 • pain relief
- 45 • lean tissue mass

- 1 • tolerance to treatment.

2 **8.3.10 References**

- 3 Brennan MF, Pisters PW, Posner M et al. (1994) A prospective randomized trial of total
4 parenteral nutrition after major pancreatic resection for malignancy. *Annals of Surgery*
5 220(4): 436-41
- 6 Bruno MJ, Haverkort EB, Tijssen GP et al. (1998) Placebo controlled trial of enteric coated
7 pancreatin microsphere treatment in patients with unresectable cancer of the pancreatic
8 head region. *Gut* 42(1): 92-6
- 9 Davidson W, Ash S, Capra S et al. & Cancer Cachexia Study Group (2004). Weight
10 stabilisation is associated with improved survival duration and quality of life in unresectable
11 pancreatic cancer. *Clinical nutrition* 23(2): 239-247.
- 12 Fearon KC, Von Meyenfeldt MF, Moses AG et al. (2003) Effect of a protein and energy
13 dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer
14 cachexia: a randomised double blind trial. *Gut* 52(10): 1479-86
- 15 Fearon KC, Strasser F, Anker SD et al. (2011). Definition and classification of cancer
16 cachexia: an international consensus. *Lancet Oncology* 12(5): 489-95.
- 17 Gade J, Levring T, Hillingso J et al. (2016) The Effect of Preoperative Oral Immunonutrition
18 on Complications and Length of Hospital Stay After Elective Surgery for Pancreatic Cancer-A
19 Randomized Controlled Trial. *Nutrition & Cancer* 68(2): 225-33
- 20 Gianotti L, Braga M, Gentilini O et al. (2000) Artificial nutrition after
21 pancreaticoduodenectomy. *Pancreas* 21(4): 344-51
- 22 Hamza N, Darwish A, O'Reilly DA et al. (2015) Perioperative Enteral Immunonutrition
23 Modulates Systemic and Mucosal Immunity and the Inflammatory Response in Patients With
24 Periampullary Cancer Scheduled for Pancreaticoduodenectomy: A Randomized Clinical
25 Trial. *Pancreas* 44(1): 41-52
- 26 Kraft M, Kraft K, Gartner S et al. (2012) L-Carnitine-supplementation in advanced pancreatic
27 cancer (CARPAN)--a randomized multicentre trial. *Nutrition Journal* 11(1): 52
- 28 Liu C, Du Z, Lou C et al. (2011) Enteral nutrition is superior to total parenteral nutrition for
29 pancreatic cancer patients who underwent pancreaticoduodenectomy. *Asia Pacific Journal of*
30 *Clinical Nutrition* 20(2): 154-60
- 31 Moses AW, Slater C, Preston T et al. (2004) Reduced total energy expenditure and physical
32 activity in cachectic patients with pancreatic cancer can be modulated by an energy and
33 protein dense oral supplement enriched with n-3 fatty acids. *British Journal of Cancer* 90(5):
34 996-1002
- 35 Satoi S, Sho M, Yanagimoto H et al. (2016) Do pancrelipase delayed-release capsules have
36 a protective role against non-alcoholic fatty liver disease after pancreatoduodenectomy in
37 patients with pancreatic cancer? A randomized controlled trial. *Journal of Hepatobiliary*
38 *Pancreatic Sciences* 23(3): 167-73
- 39 Woo SM, Joo J, Kim SY et al. (2016) Efficacy of pancreatic exocrine replacement therapy for
40 patients with unresectable pancreatic cancer in a randomized trial. *Pancreatology* 16(6):
41 1099-1105

9 Interventions to relieve biliary and duodenal obstruction

9.1 Biliary obstruction

Review question: What is the optimal treatment of biliary obstruction in adults with newly diagnosed or recurrent pancreatic cancer?

9.1.1 Introduction

Biliary obstruction causing obstructive jaundice is the most visible manifestation of pancreatic cancer in the head of pancreas. Although it is not present in all patients, the main symptom associated with obstructive jaundice is itching, which can be severe and debilitating. Other symptoms that may be caused or exacerbated by biliary obstruction include early satiety and nausea. The visible signs of biliary obstruction, which may most concern the individual, include yellow sclera and skin. Biliary obstruction leads to malabsorption of the fat soluble vitamins, resulting in a vitamin K deficiency if obstruction is prolonged, and consequent derangement of blood clotting.

In patients with resectable tumours, standard practice has been to relieve the obstruction via insertion of a stent, and normalise blood tests as far as possible prior to surgery; due to concern that operating on patients with significant biliary obstruction would increase operative morbidity and possibly mortality. As the jaundice worsens quickly, the delay between presentation and the date for surgery (which at best is only a few weeks but usually longer), can be associated with a significant worsening of jaundice.

In addition to whether or not jaundice needs to be relieved prior to surgery, another important issue is the timing of any drainage, relative to imaging for staging. This is because the process of placing a biliary stent (usually when endoscopic retrograde cholangiopancreatography [ERCP] is performed) has been associated with pancreatitis, which may make staging of the tumour more difficult. In addition, whilst plastic stents (which have a small diameter lumen) are cheap and have been used for drainage in the last few years, considerably more expensive self-expanding mesh metal stents (SEMS) (which have a larger diameter and therefore considerably better flow and longevity) have become widely available. Moreover, it is thought that SEMS cause less morbidity than plastic stents. Thus, in individuals with resectable tumours, it remains to be established whether or not drainage is required before surgery, whether SEMS are better than plastic stents, and - if it is indicated - when is the optimal time for drainage.

With regards to treatment of biliary obstruction in individuals with borderline resectable tumours, the issues are similar to those for individuals with resectable tumours (although they are perhaps clearer because the patient will not be considered for immediate surgery). The case for pre-operative drainage is stronger based on a patient's symptoms and any jaundice will need to be relieved prior to neoadjuvant chemotherapy. However, which stent should be used for drainage and when drainage should occur are still open questions.

With regards to biliary obstruction in individuals with unresectable tumours, it is still unclear whether a plastic or metal stent should be used. One important issue is endoscopic management (ERCP and stenting), which is the most commonly-performed intervention, as it is perceived to be less invasive than alternative methods.

Guidance is needed on the optimal treatment of biliary obstruction in people with pancreatic cancer.

1 9.1.1.1 Review protocol summary

2 The review protocol summary used for this question can be found in Table 99. Full details of
3 the review protocol can be found in Appendix C.

4 **Table 99: Clinical review protocol summary for the review of optimal treatment of**
5 **biliary obstruction**

Population	Patients with biliary obstruction: <ul style="list-style-type: none"> • Resectable pancreatic cancer • Borderline resectable pancreatic cancer • Unresectable or metastatic pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Biliary stent placement • Plastic stents • Self-expandable metallic/metal stents (fully covered, partially covered, uncovered) • Preoperative biliary drainage followed by resection • Biliary bypass Surgery • Surgical resection without stenting
Comparison	Best supportive care Each Other
Outcomes	<ul style="list-style-type: none"> • Relief of obstruction • Relief of symptoms • Treatment-related mortality • Treatment related morbidity • Treatment-related complications • Overall Survival • Time to definitive treatment • Health Related Quality of Life • Patient experience • PROMS

6 9.1.2 Description of clinical evidence

7 Twenty-two RCTs were included in the review. Several of the studies included individuals
8 that did not have pancreatic cancer. Generally, the Committee decided to only include
9 studies that had at least 66% pancreatic cancer patients, though the quality of evidence for
10 relevant outcomes was downgraded one level for indirectness.

11 Further information about the search strategy can be found in Appendix D. See study
12 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
13 study evidence tables in Appendix F and list of excluded studies in Appendix G.

14 9.1.2.1 Plastic stent versus self-expanding metal stents (SEMS) in adults with pancreatic 15 cancer and biliary obstruction

16 Eight studies (n=815) compared the use of plastic stents with SEMS (Gardner et al., 2016;
17 Isayama et al., 2011; Kaassis et al., 2003; Moses et al., 2013; Schmidt et al., 2015;
18 Söderlund & Linder, 2006; Travis & Nicholson, 1997; Walter et al., 2015). Seven of these
19 studies used ERCP to aid insertion of a stent, whilst only 1 used percutaneous transhepatic
20 cholangiography (PTC) (Travis & Nicholson, 1997). Seven of the studies were in adults with
21 either unresectable pancreatic cancer or unresectable malignant biliary obstruction (Isayama
22 et al., 2011; Kaassis et al., 2003; Moses et al., 2013; Schmidt et al., 2015; Söderlund &
23 Linder, 2006; Travis & Nicholson, 1997; Walter et al., 2015). One study included resectable

- 1 and borderline resectable adult pancreatic cancer patients in addition to those whose
2 tumours were unresectable (Gardner et al., 2016). A variety of plastic stents (e.g.
3 polyethylene or polyurethane) and SEMS (e.g. covered, partially covered, or uncovered)
4 were used.
- 5 **9.1.2.2 Covered self-expanding metal stent versus uncovered self-expanding metal stent in**
6 **adults with pancreatic cancer and biliary obstruction**
- 7 Five studies (n=708) compared a covered SEMS with an uncovered SEMS (Gardner et al.,
8 2016; Kitano et al., 2013; Krokidis et al., 2011; Kullman et al., 2010; Ung et al., 2013). The
9 majority of the studies were in adults with unresectable pancreatic cancer.
- 10 **9.1.2.3 Partially-covered self-expanding metal stent versus uncovered self-expanding metal**
11 **stent in adults with pancreatic cancer and biliary obstruction**
- 12 Two studies (n=243) compared a partially-covered SEMS with an uncovered SEMS (Telford
13 et al., 2010; Walter et al., 2015) in adults with unresectable tumours.
- 14 **9.1.2.4 Paclitaxel-eluting self-expanding metal stent versus covered self-expanding metal**
15 **stent in adults with an unresectable distal malignant biliary obstruction**
- 16 One study (n=52) compared a paclitaxel-eluting SEMS with a covered SEMS in adults with
17 unresectable distal malignant biliary obstruction (Song et al., 2011). Although this study only
18 included 51% pancreatic cancer patients, it was decided to include it and downgrade the
19 quality of evidence two levels for indirectness for the relevant outcomes.
- 20 **9.1.2.5 Preoperative endoscopic biliary drainage (PEBD) then surgery versus surgery in**
21 **adults with suspected pancreatic cancer**
- 22 One study (n=196) compared endoscopic preoperative biliary drainage using a plastic stent
23 followed by surgery with surgery only in adults with obstructive jaundice due to suspected
24 pancreatic head cancer (Eshuis et al., 2010). The study included resectable and
25 unresectable tumour patients.
- 26 **9.1.2.6 Endoscopic sphincterotomy then stent versus stent in adults with unresectable**
27 **pancreatic cancer**
- 28 Three studies (n=446) compared endoscopic sphincterotomy (ES) followed by the insertion
29 of a stent with a stent only (Artifon et al. 2008; Giorgio & Luca, 2004; Hayashi et al., 2015) in
30 adults with unresectable tumours. The majority of these studies used a partially-covered or
31 covered SEMS.
- 32 **9.1.2.7 Endoscopic sphincterotomy then stent versus surgical bypass in adults with**
33 **unresectable pancreatic cancer**
- 34 One study (n=30) compared endoscopic sphincterotomy (ES) followed by the insertion of a
35 covered SEMS with surgical bypass only (Artifon et al., 2006) in adults with unresectable
36 pancreatic cancer.
- 37 **9.1.2.8 Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) and stent versus**
38 **percutaneous transhepatic biliary drainage (PTBD) in adults with an unresectable**
39 **malignant biliary obstruction where either ERCP or EUS-guided transpapillary**
40 **rendezvous has failed**
- 41 One study (n=25) compared endoscopic ultrasound-guided choledochoduodenostomy (EUS-
42 CD) and insertion of a partially-covered SEMS with percutaneous transhepatic biliary
43 drainage (PTBD) (Artifon et al., 2012) in adults with an unresectable tumour where either

1 ERCP or EUS-guided transpapillary rendezvous has failed. Although data regarding the
2 number of individuals with pancreatic cancer in this study was not available, it was decided to
3 include it but downgrade the relevant outcomes by two levels for indirectness.

4 **9.1.2.9 Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) and stent versus**
5 **surgical bypass in adults with an unresectable malignant biliary obstruction where**
6 **ERCP has failed**

7 One study (n=32) compared endoscopic ultrasound-guided choledochoduodenostomy (EUS-
8 CD) and insertion of a partially-covered SEMS with surgical bypass/drainage only (Artifon et
9 al., 2015) in adults with unresectable tumour where ERCP has failed. Although data
10 regarding the number of individuals with pancreatic cancer in this study was not available, it
11 was decided to include it but downgrade the relevant outcomes by two levels for
12 indirectness.

13

14

9.1.31 Summary of included studies

2 A summary of the studies that were included in this review are presented in Table 100.

3 **Table 100: Summary of included studies**

Study	Population	Intervention	Comparison	Outcomes
Artifon, Aparicio et al. 2012	Unresectable malignant biliary obstruction in which ERCP or EUS-guided transpapillary rendezvous has failed (n=25) [Number of PC patients unclear]	EUS-CD	PTBD	Relief of symptoms Treatment-related complications Quality of life
Artifon, Loureiro et al. 2015	Unresectable malignant biliary obstruction in which ERCP has failed (n=32) [Number of PC patients unclear]	EUS-CD	Surgical Bypass (HJT)	Relief of symptoms # >50% reduction in bilirubin Overall survival Treatment-related complications Quality of life
Artifon, Sakai et al. 2006	Unresectable metastatic PC with biliary obstruction	Endoscopic Sphincterotomy + Stent	Surgery	Relief of obstruction Relief of symptoms Treatment related-mortality Treatment-related morbidity Treatment-related complications Quality of life
Artifon, Sakai et al. 2008	Unresectable malignant distal bile duct obstruction (n=74) [81% PC patients]	Endoscopic Sphincterotomy + Stent	Stent	Treatment-related complications
Eshuis et al. 2010/van der Gaag et al. 2010	Obstructive jaundice with suspected PC of head (n=196) [92% PC patients; includes 45% resectable or borderline resectable patients]	Preoperative Biliary Drainage then Surgery	Surgery	Mortality/Overall Survival Time to surgery Time to complications Stent Dysfunction Treatment-related complications Treatment-related hospitalisation

Study	Population	Intervention	Comparison	Outcomes
Gardner et al. 2016	PC with malignant biliary obstruction receiving neoadjuvant CRT (n=63) [3-arm trial including covered (n=17) and uncovered (n=20) SEMS; includes resectable and unresectable patients]	Plastic Stent Covered SEMS	Uncovered SEMS	Stent Dysfunction Treatment-related complications
Giorgio et al. 2004	Unresectable malignant bile duct obstruction (n=172) [76% PC patients]	Endoscopic Sphincterotomy + Stent	Stent	Stent Dysfunction Treatment-related complications
Hayashi et al. 2015	Unresectable PC with malignant distal biliary stricture(n=200)	Endoscopic Sphincterotomy + Stent	Stent	Stent Dysfunction Treatment-related complications Deaths due to PC progression Serum amylase
Isayama et al. 2011	Unresectable PC of head with distal biliary obstruction (n=120)	Plastic Stent	SEMS	Overall Survival Stent Dysfunction Stent-related complications
Kaassis et al. 2003	Unresectable malignant common bile duct stricture (n=118) [75% PC patients]	Plastic Stent	SEMS	Stent Dysfunction Stent-related complications Hospitalisation
Kitano et al. 2013	Unresectable PC with malignant distal biliary obstruction (n=120)	Covered SEMS	Uncovered SEMS	Survival Stent patency Time to stent dysfunction Adverse events
Krokidis et al 2013	Unresectable PC with jaundice caused by occlusion of biliary tree (n=80)	Covered SEMS	Uncovered SEMS	Survival Stent patency Stent dysfunction Adverse events
Kullman et al 2010	Unresectable malignant bile duct obstruction (n=400)	Covered SEMS	Uncovered SEMS	Survival Stent dysfunction

Study	Population	Intervention	Comparison	Outcomes
	[77% PC patients]			Adverse events
Moses et al. 2013	Unresectable malignant biliary obstruction (n=85) [68% PC patients]	Plastic Stent	SEMS	Reduction in bilirubin Stent Dysfunction Stent-related complications
Schmidt et al. 2014	Unresectable malignant distal biliary obstruction (n=37) [67% PC patients]	Plastic Stent	SEMS	Overall Survival Stent Dysfunction Stent-related complications
Söderlund et al. 2006	Non-referred patients with unresectable malignant common bile duct stricture (n=100) [78% PC patients]	Plastic Stent	SEMS	Treatment-related mortality Overall Survival Stent-related complications Aspartate aminotransferase Serum bilirubin
Song et al. 2011	Unresectable malignant biliary obstruction (n=52) [51% PC patients]	Paclitaxel-eluting SEMS	Covered SEMS	Treatment-related mortality Overall Survival Stent Dysfunction Treatment-related complications
Telford 2010	Unresectable malignant distal biliary obstruction (n=129) [82% PC patients]	Partially covered SEMS	Uncovered SEMS	Survival Time to obstruction Adverse events
Travis et al. 1997	PC with unresectable malignant biliary obstruction (n=52) [All participants had PTC]	Plastic Stent	SEMS	Stent Dysfunction
Ung et al. 2013	Incurable malignant distal biliary obstruction (n=71) [84% PC patients]	Covered SEMS	Uncovered SEMS	Survival Stent patency Adverse events
Walter et al. 2015	Unresectable extrahepatic malignant bile duct obstruction (n=240) [75% PC patients; 3-arm trial including partially covered and uncovered SEMS; also	Plastic Stent Partially covered SEMS	SEMS Uncovered SEMS	Stent Dysfunction Treatment-related complications

Study	Population	Intervention	Comparison	Outcomes
	primary and secondary stent subgroups]			

1

2

1 **9.1.4 Clinical evidence profiles**

2 The clinical evidence profiles for this review question are presented in Table 101 to Table
3 109.

4 **Table 101: Summary clinical evidence profile for plastic stent versus self-expanding**
5 **metal stent in adults with pancreatic cancer and biliary obstruction**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
Treatment-related mortality	0 per 1000	0 per 1000 (0 to 0)	RR 2.88 (0.12 to 69.16)	100 (1 study)	⊕⊕⊕⊕ very low ^{1,2}	
Overall Survival	Study population		HR 1 (0.75 to 1.31)	247 (3 studies)	⊕⊕⊕⊕ very low ^{1,4,5,9,13,21,22}	
	See comment ³	See comment ³				
	Moderate					
	0 per 1000 ³	- 2147483648 per 1000 (- 2147483648 to - 2147483648) ³				
Time to stent dysfunction for unresectable PC - primary and/or secondary stent	Study population		HR 2.59 (1.67 to 4)	229 (3 studies)	⊕⊕⊕⊕ very low ^{3,4,5,8,9,13,17,18}	
	See comment ³	See comment ³				
	Moderate					
	0 per 1000 ³	- 2147483648 per 1000 (- 2147483648 to - 2147483648) ³				
Time to stent dysfunction for unresectable PC - Covered or Partially Covered SEMS	257 per 1000	489 per 1000 (350 to 649)	HR 2.26 (1.45 to 3.53)	224 (2 studies)	⊕⊕⊕⊕ very low ^{4,5,6,7,8}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
(Primary Stent only)						
Time to stent dysfunction for unresectable PC - Uncovered SEMS (Primary Stent only)	167 per 1000	421 per 1000 (232 to 677)	HR 3 (1.45 to 6.2)	117 (1 study)	⊕⊕⊕⊕ very low ^{4,6,7,8}	
Time to stent dysfunction for unresectable PC - Partially Covered SEMS (Secondary Stent only)	118 per 1000	567 per 1000 (160 to 982)	HR 6.69 (1.39 to 32.07)	33 (1 study)	⊕⊕⊕⊕ very low ^{4,6,7,8}	
Time to stent dysfunction for unresectable PC - Uncovered SEMS (Secondary Stent only)	67 per 1000	497 per 1000 (212 to 862)	HR 9.97 (3.46 to 28.74)	31 (1 study)	⊕⊕⊕⊕ very low ^{4,6,7,8}	
Stent Dysfunction - Stent Occlusion	191 per 1000	430 per 1000 (319 to 577)	RR 2.25 (1.67 to 3.02)	471 (6 studies)	⊕⊕⊕⊕ low ^{1,4,5,9,10,11,12,13,14,15}	
Stent Dysfunction - Stent Migration	91 per 1000	17 per 1000 (2 to 143)	RR 0.19 (0.02 to 1.57)	113 (1 study)	⊕⊕⊕⊕ very low ^{2,4,5}	
Stent Dysfunction - Stent Occlusion or Migration	167 per 1000	403 per 1000 (240 to 677)	RR 2.42 (1.44 to 4.06)	171 (1 study)	⊕⊕⊕⊕ very low ^{4,6,7,8}	
Stent Occlusion -	176 per 1000	387 per 1000	RR 2.2 (1.45	258 (4 studies)	⊕⊕⊕⊕ very low ^{4,8,9,10,11,12,13,14,15}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
any type of SEMS		(255 to 590)	to 3.35)			
Stent Occlusion - Covered SEMS	212 per 1000	487 per 1000 (319 to 738)	RR 2.3 (1.51 to 3.49)	213 (2 studies)	⊕⊕⊕⊕ very low ^{1,4,5,8}	
Stent Occlusion - unresectable patients	174 per 1000	410 per 1000 (295 to 570)	RR 2.36 (1.7 to 3.28)	417 (5 studies)	⊕⊕⊕⊕ low ^{1,4,5,9,11,12,13,14}	
Stent Occlusion - resectable, borderline resectable or locally advanced	303 per 1000	524 per 1000 (270 to 1000)	RR 1.73 (0.89 to 3.34)	54 (1 study)	⊕⊕⊕⊕ low ^{4,10,15,16}	
Pancreatitis	22 per 1000	18 per 1000 (7 to 46)	RR 0.81 (0.32 to 2.04)	720 (7 studies)	⊕⊕⊕⊕ very low ^{1,2,4,5,6,9,10,11,13,14,15,17}	
Pancreatitis - any SEMS	25 per 1000	26 per 1000 (9 to 73)	RR 1.02 (0.36 to 2.92)	473 (4 studies)	⊕⊕⊕⊕ very low ^{2,4,6,7,10,11,14,15,17,18}	
Pancreatitis - covered SEMS	19 per 1000	6 per 1000 (1 to 58)	RR 0.32 (0.03 to 3.01)	213 (2 studies)	⊕⊕⊕⊕ very low ^{1,2,4,5}	
Pancreatitis - unresectable patients	1 per 100	1 per 100 (0 to 4)	RR 1.52 (0.51 to 4.59)	632 (5 studies)	⊕⊕⊕⊕ very low ^{1,2,4,5,6,7,9,11,14,17,18}	
Pancreatitis - resectable, borderline resectable or locally advanced patients	182 per 1000	22 per 1000 (2 to 365)	RR 0.12 (0.01 to 2.01)	54 (1 study)	⊕⊕⊕⊕ very low ^{2,4,10,15}	
Cholangitis - unresectable patients	30 per 1000	93 per 1000 (38 to 224)	RR 3.1 (1.28 to 7.48)	334 (4 studies)	⊕⊕⊕⊕ low ^{1,4,9,11,13,17,18}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
			to 7.48)			
Cholangitis - any SEMS	39 per 1000	67 per 1000 (19 to 229)	RR 1.71 (0.5 to 5.89)	152 (2 studies)	⊕⊕⊕⊕ very low ^{2,4,9,11,13,14}	
Cholangitis - covered SEMS	0 per 1000	0 per 1000 (0 to 0)	RR 4.81 (0.24 to 97.68)	100 (1 study)	⊕⊕⊕⊕ very low ^{1,2}	
Cholangitis - partially-covered SEMS	49 per 1000	244 per 1000 (57 to 1000)	RR 5 (1.17 to 21.43)	82 (1 study)	⊕⊕⊕⊕ very low ^{4,16,17,18}	
Cholecystitis - unresectable patients	27 per 1000	13 per 1000 (4 to 41)	RR 0.47 (0.15 to 1.53)	448 (4 studies)	⊕⊕⊕⊕ very low ^{2,4,5,6,7,9,13,17,18}	
Cholecystitis - any SEMS	6 per 1000	16 per 1000 (2 to 123)	RR 2.56 (0.33 to 20.1)	253 (2 studies)	⊕⊕⊕⊕ very low ^{2,4,6,7,9,13}	
Cholecystitis - partially-covered SEMS	49 per 1000	10 per 1000 (0 to 197)	RR 0.2 (0.01 to 4.04)	82 (1 study)	⊕⊕⊕⊕ very low ^{2,4,17,18}	
Cholecystitis - Covered SEMS	73 per 1000	8 per 1000 (1 to 139)	RR 0.11 (0.01 to 1.91)	113 (1 study)	⊕⊕⊕⊕ very low ^{2,4,5}	
# patients with cholestatic symptoms to 2-year FU Follow-up: 2 years	250 per 1000	360 per 1000 (183 to 710)	RR 1.44 (0.73 to 2.84)	79 (1 study)	⊕⊕⊕⊕ very low ^{2,4,17,18}	
Post-ES Haemorrhage	Study population		RR 3 (0.12 to	118 (1 study)	⊕⊕⊕⊕ very low ^{2,4,11,14}	
	0 per 1000	0 per 1000 (0 to 0)				
	Moderate					

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
	0 per 1000	0 per 1000 (0 to 0)	72.18)			
Hospitalisation Days		The mean hospitalisation in the intervention groups was 0.49 standard deviations higher (0.21 to 0.77 higher)		197 (2 studies)	⊕⊕⊕⊕ very low ^{4,11,14,16,17,18}	
# ≥30% decrease in serum bilirubin	1000 per 1000	940 per 1000 (790 to 1000)	RR 0.94 (0.79 to 1.1)	34 (1 study)	⊕⊕⊕⊕ low ^{9,16}	
% Reduction in total serum bilirubin levels	The mean % reduction in total serum bilirubin levels in the control groups was 74 percentage	The mean % reduction in total serum bilirubin levels in the intervention groups was 10.3 lower (32.51 lower to 11.91 higher)		79 (1 study)	⊕⊕⊕⊕ very low ^{4,17,18,19,20}	
Total Serum Bilirubin - rate of change		The mean total serum bilirubin - rate of change in the intervention groups was 0.23 standard deviations lower (0.62 lower to 0.17 higher)		98 (1 study)	⊕⊕⊕⊕ low ^{1,16}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	SEMS	Plastic				
<p>1 Soderlund et al. 2006 sample included 78% pancreatic cancer patients. 2 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25). 3 Not all included studies provided data regarding number of patients who were still alive or experienced stent dysfunction. 4 Majority of studies are high/unclear risk of bias due to insufficient reporting regarding blinding and incomplete reporting of outcomes. 5 Isayama et al. 2001 (all patients received endoscopic sphincterotomy). 6 Walter et al. 2015 (unclear whether blinding would affect outcome; selective reporting of outcomes). 7 Walter et al. 2015 included 75% pancreatic cancer patients. 8 Small sample size for dichotomous outcomes (<300 events). 9 Schmidt et al. 2015 (selective reporting of outcomes; study terminated early due to high rate of stent failure in plastic [winged] stent group). 10 Gardner et al. 2016 (unclear allocation concealment and blinding of outcome assessment; selective reporting of outcomes; participants were receiving 1 of 3 neoadjuvant chemoradiotherapy regimens). 11 Kaassis et al. 2003 (unclear randomisation method and allocation concealment; selective reporting of outcomes; significant difference in % weight loss at baseline; some patients also received sphincterotomy). 12 Travis et al. 1997 (unclear randomisation method, allocation concealment, blinding of personnel/participants/outcome assessment; imbalance in group numbers and selective reporting of outcomes). 13 Schmidt et al 2015 sample included 67% pancreatic cancer patients. 14 Kaassis et al. 2003 sample included 75% pancreatic cancer patients. 15 Gardner et al. 2016 includes both resectable (19%), borderline resectable (26%), and unresectable (55%) pancreatic cancer patients. 16 Crosses 1 default MID for dichotomous (0.8 or 1.25) or continuous outcomes (0.5 or -0.5). 17 Moses et al. 2013 (unclear randomisation method; selective reporting of outcomes). 18 Moses et al. 2013 sample included 68% pancreatic cancer patients. 19 MID for this outcome assumed to be 21.81/-21.81 (0.5 SD of control group at follow up; data from Moses et al. 2013). 20 Crosses 1 MID for this outcome. 21 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant. 22 Not statistically significant.</p>						

1
2

Table 102: Summary clinical evidence profile for covered SEMS versus uncovered SEMS in adults with pancreatic cancer and biliary obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Covered				
Relief of obstruction cumulative - stent patency, time to obstruction ^a	Mean time=74 (R: 45-90) days	Mean time=220 (R: 21-341) days	Not estimable	63 (1 study)	⊕⊕⊕⊖ low ¹⁹	Log-rank p-value=n.r.
	Median time=314 (n.r.) days	Median time=583 (n.r.) days	Not estimable	120 (1 study)	⊕⊕⊕⊖ low ¹⁹	Log-rank p-value=0.02
	Median time=166 (SE: 13.1; SD: 82.8) days	Median time=234 (SE: 20.8; SD: 132) days	Not estimable	80 (1 study)	⊕⊕⊕⊖ low ¹⁹	Log-rank p-value=0.01

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Covered				
	Median time[1st quartile]=199 (n.r) days	Median time[1st quartile]=154 (n.r.) days	Not estimable	400 (1 study)	⊕⊕⊕⊖ low ¹⁹	Log-rank p-value=0.33 for pancreatic cancer patients only, log-rank p-value=0.349
	Median time=127 (IQR: 70-196; R: 18-486) days	Median time=153 (IQR: 65-217; R: 20-609) days	Not estimable	71 (1 study)	⊕⊕⊕⊖ low ¹⁹	Log-rank p-value=n.s.
Stent Dysfunction	259 per 1000	210 per 1000 (158 to 272)	RR 0.81 (0.61 to 1.05)	701 (5 studies)	⊕⊖⊖⊖ very low ^{1,2,3}	
Stent Dysfunction by cause - Sludge formation	33 per 1000	81 per 1000 (41 to 162)	RR 2.43 (1.22 to 4.85)	600 (3 studies)	⊕⊖⊖⊖ very low ^{4,5,6}	
Stent Dysfunction by cause - Stent migration	0 per 1000	0 per 1000 (0 to 0)	RR 13 (0.74 to 229.23)	520 (2 studies)	⊕⊖⊖⊖ very low ^{7,8,9}	
Stent Dysfunction by cause - Tumour ingrowth	133 per 1000	48 per 1000 (27 to 85)	RR 0.36 (0.2 to 0.64)	600 (3 studies)	⊕⊖⊖⊖ very low ^{3,8,10}	
Stent Dysfunction by cause - Tumour overgrowth	40 per 1000	75 per 1000 (39 to 146)	RR 1.88 (0.97 to 3.66)	600 (3 studies)	⊕⊖⊖⊖ very low ^{6,8,11}	
Adverse Events	78 per 1000	69 per 1000 (40 to 118)	RR 0.89 (0.52 to 1.51)	668 (4 studies)	⊕⊖⊖⊖ very low ^{2,9,12}	
Adverse Events by type - Cholangitis	60 per 1000	40 per 1000 (17 to 96)	RR 0.67 (0.28 to 1.6)	400 (1 study)	⊕⊖⊖⊖ very low ^{8,9,13}	
Adverse Events by type - Cholecystitis	15 per 1000	12 per 1000 (3 to 51)	RR 0.75 (0.17 to 3.31)	520 (2 studies)	⊕⊖⊖⊖ very low ^{9,14}	
Adverse Events by type - Haemorrhage	12 per 1000	9 per 1000 (2 to 44)	RR 0.71 (0.14 to 3.52)	480 (2 studies)	⊕⊖⊖⊖ very low ^{8,9,15}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Covered				
Adverse Events by type - Pancreatitis	14 per 1000	16 per 1000 (5 to 53)	RR 1.2 (0.37 to 3.89)	588 (3 studies)	⊕⊕⊕⊕ very low ^{2,9,11}	
Adverse Events by type - Peritoneal irritation	50 per 1000	0 per 1000 (13 to 425)	RR 0 (0.26 to 8.5)	80 (1 study)	⊕⊕⊕⊕ very low ^{9,16}	
Adverse Events by type - Retroperitoneal perforation	5 per 1000	5 per 1000 (0 to 79)	RR 1 (0.06 to 15.88)	400 (1 study)	⊕⊕⊕⊕ very low ^{8,9,13}	
Adverse Events by type - Sepsis	0 per 1000	0 per 1000 (0 to 0)	RR 3 (0.13 to 71.15)	68 (1 study)	⊕⊕⊕⊕ very low ^{9,17,18}	
Overall survival - time to death ^a	Median time=242(R: 122-453) days	Median time=71(R: 7-196) days	Not estimable	63 (1 study)	⊕⊕⊕⊕ low ¹⁹	Log-rank p-value=n.r.
	Median time=222 (n.r.) days	Median time=285(n.r.) days	Not estimable	120 (1 study)	⊕⊕⊕⊕ low ¹⁹	Log-rank p-value=0.68
	Median time=203.2(SE : 11.8; SD: 74.8) days	Median time=247(SE: 20; SD: 126.7) days	Not estimable	80 (1 study)	⊕⊕⊕⊕ low ¹⁹	Log-rank p-value=0.06
	Median time=174(IQR: 284) days	Median time=116(IQR : 242) days	Not estimable	400 (1 study)	⊕⊕⊕⊕ low ¹⁹	Log-rank p-value=0.32
	Median time=157(IQR: 70-273; R: 20-690) days	Median time=154 (IQR: 65-217; R: 21-609) days	Not estimable	71 (1 study)	⊕⊕⊕⊕ low ¹⁹	Log-rank p-value=n.s.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; IQR: interquartile range; R: range; n.s.: not significant; n.r.: not reported; SEMS: self-expanding metal stent.

a The five included RCTs did not report data for cumulative stent patency (time to obstruction) and overall survival in a way that allowed a meta-analysis (Gardner et al. 2016; Kitano et al. 2013; Krokidis et al. 2011; Kullman et al. 2010; and Ung et al. 2013).

1 Overall high risk of bias due to selective reporting and other source of bias. Kullman et al. 2010 contributed almost 50% to this outcome and had risk of bias due to significant difference in mean age of groups, number with hepatic or metastasis (at baseline) and number with unknown causes of stent failure.

2 Two of the studies (Kullman et al. 2010; Ung et al. 2013) used samples that had less than 85% pancreatic cancer patients.

3 Small sample size for dichotomous outcomes (<300 events).

4 Overall all 3 studies had high/unclear risk of bias mainly due to selective reporting. Two of these, which contributed approximately 57% and 38% to outcome, were at high risk due to other sources of bias: in Kitano et al. 2013, there was significant difference in the length of stents used in each group, whilst majority of sample had had prior biliary drainage; in Kullman et al 2010 there were significant differences in mean age of groups

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Covered				
<p>and number with hepatic or metastasis (at baseline) and number with unknown causes of stent failure). 5 Sample in Kullman et al. 2010, which contributed 38% to the outcome, had 77% pancreatic cancer patients. 6 Crosses 1 default MID for dichotomous outcomes (0.8 or 1.25). 7 Both studies had high risk of bias due to selective reporting and other sources of bias. Kullman et al. 2010 contributed 100% to this outcome and there were significant differences between the groups in mean age and hepatic or other metastasis at baseline and in number of patients with unknown causes of stent failure. 8 Sample in Kullman et al. 2010 had 77% pancreatic cancer patients. 9 Crosses 2 default MID for dichotomous outcomes (0.8 and 1.25). 10 Overall high risk of bias due to selective reporting and other source of bias. Kullman et al. 2010 contributed almost 52% to this outcome and had risk of bias due to significant difference in mean age of groups, number with hepatic or metastasis (at baseline) and number with unknown causes of stent failure. Kitano et al. 2013 contributed approximately 38% to this outcome and similar risk of bias due to significant differences in the length of stent used in each group and fact that majority of sample had had prior biliary drainage. 11 Overall high risk of bias due to selective reporting and other source of bias. Kullman et al. 2010 contributed 80% to this outcome and had risk of bias due to significant difference in mean age of groups, number with hepatic or metastasis (at baseline) and number with unknown causes of stent failure. 12 Overall high risk of bias due to selective reporting and other source of bias. Kullman et al. 2010 contributed almost 80% to this outcome and had risk of bias due to significant difference in mean age of groups, number with hepatic or metastasis (at baseline) and number with unknown causes of stent failure. 13 Kullman et al. 2010 is at high risk of bias due to selective reporting and other sources of bias. There were significant differences between the groups in mean age and hepatic or other metastasis at baseline and in number of patients with unknown causes of stent failure. 14 Both studies, each of which contributed 50% to this outcome, had high risk of bias due to selective reporting and other sources of bias (in Kullman et al. 2010, there were significant differences between the groups in mean age and hepatic or other metastasis at baseline and in number of patients with unknown causes of stent failure; in Kitano et al. 2013, there was significant difference in length of stents used in each group, and majority of sample had received prior biliary drainage). 15 Overall high or unclear risk of bias. Krokidis et al. 2011, which contributed approximately 57% to this outcome, at risk due to selective reporting, and unclear randomisation method/allocation concealment. 16 Krokidis et al. 2011 had overall high or unclear risk of bias due to selective reporting, and unclear randomisation method/allocation concealment. 17 Ung et al. 2013 had high risk of bias due to unclear randomisation method, selective reporting, and fact that more than 80% of the sample died with patent stents. 18 Sample in Ung et al. 2013 had 84% pancreatic cancer patients. 19 Overall the studies were at high risk of bias due to selective (e.g. incomplete) reporting of outcomes, other sources of bias (such as significant differences at baseline), and insufficient information about the randomisation method or allocation concealment (Gardner et al. 2016; Kitano et al. 2013; Krokidis et al. 2011; Kullman et al. 2010; and Ung et al. 2013).</p>						

1
2

Table 103: Summary clinical evidence profile for partially covered SEMS versus uncovered SEMS in adults with pancreatic cancer and biliary obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Partially covered				
Relief of obstruction cumulative - stent patency,	Median time= 711 (IQR: 264-1302) days	Median time= 357 (IQR: 283-n.r.) days	Not estimable	129 (1 study)	⊕⊕⊖⊖ low ⁹	Log-rank p-value=0.53

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Partially covered				
time to obstruction ^a	Median time= 268 (219-317) days	Median time= 286 (240-332) days	Not estimable	240 (1 study)	⊕⊕⊖⊖ low ⁹	Log-rank p-value=n.r.
Stent Dysfunction - Any cause	174 per 1000	234 per 1000 (141 to 387)	RR 1.35 (0.81 to 2.23)	243 (2 studies)	⊕⊖⊖⊖ very low ^{1,2,3}	
Stent Dysfunction - Stent migration	0 per 1000	0 per 1000 (0 to 0)	RR 15.28 (0.9 to 259.23)	129 (1 study)	⊕⊖⊖⊖ very low ^{3,4,5}	
Adverse events - Any cause	443 per 1000	620 per 1000 (443 to 868)	RR 1.4 (1 to 1.96)	129 (1 study)	⊕⊖⊖⊖ very low ^{3,4,5}	
Adverse events - Pancreatitis	7 per 1000	7 per 1000 (1 to 48)	RR 0.97 (0.14 to 6.58)	275 (2 studies)	⊕⊖⊖⊖ very low ^{2,6,7}	
Adverse events - Cholecystitis	25 per 1000	25 per 1000 (5 to 115)	RR 0.98 (0.21 to 4.59)	237 (2 studies)	⊕⊖⊖⊖ very low ^{4,5,7}	
Adverse events - Other	140 per 1000	159 per 1000 (92 to 278)	RR 1.14 (0.66 to 1.99)	275 (2 studies)	⊕⊖⊖⊖ very low ^{2,7,8}	
Overall survival ^a	Median time=239 (IQR: 84-401) days	Median time=227 (IQR: 99-365) days	Not estimable	129 (1 study)	⊕⊕⊖⊖ low ⁹	Log-rank p-value=1.0
	Median time= n.r.	Median time= n.r.	Not estimable	240 (1 study)	⊕⊕⊖⊖ low ⁹	Log-rank p-value=n.r.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; IQR: interquartile range; R: range; n.s.: not significant; n.r.: not reported; SEMS: self-expanding metal stent.

a The two included RCTs did not report data for cumulative stent patency (time to obstruction) and overall survival in a way that allowed a meta-analysis (Telford et al. 2010; and Walter et al. 2015a).

1 Telford et al. 2010, which contributed 55% to this outcome, had high/unclear risk of bias due to insufficient information about allocation concealment, imbalance in numbers due to failure to attain adequately powered groups, and selective reporting.

2 Both studies used samples comprised of less than 85% pancreatic cancer patients.

3 Crosses 1 default MID for dichotomous outcomes (0.8 or 1.25).

4 Telford et al. 2010 had high/unclear risk of bias due to insufficient information about allocation concealment, imbalance in numbers due to failure to attain adequately powered groups, and selective reporting.

5 Telford et al. 2010 had 82% pancreatic cancer patients.

6 Telford et al. 2010, which contributed approximately 77% to this outcome, had high/unclear risk of bias due to insufficient information about allocation concealment, imbalance in numbers due to failure to attain adequately powered groups, and selective reporting.

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Uncovered	SEMS: Partially covered				

7 Crosses 2 default MID for dichotomous outcomes (0.8 and 1.25).

8 Telford et al. 2010, which contributed 65% to this outcome, had high/unclear risk of bias due to insufficient information about allocation concealment, imbalance in numbers due to failure to attain adequately powered groups, and selective reporting.

9 Overall the studies were at high risk of bias due to selective (e.g. incomplete) reporting of outcomes, other sources of bias (such as significant differences at baseline), and insufficient information about the randomisation method or allocation concealment (Telford et al. 2010; and Walter et al. 2015a).

1
2
3

Table 104: Summary clinical evidence profile for paclitaxel-eluting SEMS versus covered SEMS in adults with an unresectable distal malignant biliary obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Covered SEMS for unresectable PC	Paclitaxel-eluting SEMS				
Time to stent dysfunction- All patients	Study population		HR 0.53 (0.16 to 1.78)	52 (1 study)	⊕⊕⊕⊕ very low ^{2,3,4}	
	See comment ¹	See comment ¹				
	Moderate					
	0 per 1000 ¹	-2147483648 per 1000 (-2147483648 to -2147483648) ¹				
Time to stent dysfunction - Pancreatic cancer patients	Study population		HR 0.52 (0.1 to 3.09)	25 (1 study)	⊕⊕⊕⊕ very low ^{2,3,4}	
	See comment ¹	See comment ¹				
	Moderate					
	0 per 1000 ¹	-2147483648 per 1000 (-2147483648 to -2147483648) ¹				
Overall Survival - All patients	Study population		HR 1.19 (0.65 to 2.18)	52 (1 study)	⊕⊕⊕⊕ very low ^{2,3,5,6}	
	See comment ¹	See comment ¹				
	Moderate					
	0 per 1000 ¹	-2147483648 per 1000 (-2147483648 to -2147483648) ¹				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Covered SEMS for unresectable PC	Paclitaxel-eluting SEMS				
Overall Survival - Pancreatic cancer patients	Study population		HR 0.85 (0.35 to 2.06)	25 (1 study)	⊕⊕⊖⊖ low ^{2,5,6}	
	See comment ¹	See comment ¹				
	Moderate 0 per 1000 ¹	-2147483648 per 1000 (-2147483648 to -2147483648) ¹				
Stent Dysfunction - Stent Occlusion	320 per 1000	208 per 1000 (80 to 547)	RR 0.65 (0.25 to 1.71)	49 (1 study)	⊕⊖⊖⊖ very low ^{2,3,4}	
Cholangitis symptoms <30 days after surgery	0 per 1000	0 per 1000 (0 to 0)	RR 7.28 (0.4 to 133.89)	49 (1 study)	⊕⊖⊖⊖ very low ^{2,3,4}	
Pancreatitis <30 days after surgery	40 per 1000	42 per 1000 (3 to 629)	RR 1.04 (0.07 to 15.73)	49 (1 study)	⊕⊖⊖⊖ very low ^{2,3,4}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Study did not report number of deaths nor number of stent failures.

2 Song et al. 2011: overall high risk of bias (unclear allocation concealment, blinding of outcome assessment and selective reporting; no power calculation; randomised participants were patients with unresectable distal malignant biliary obstruction who did not wish to undergo chemotherapy nor radiotherapy).

3 There were only 51% pancreatic cancer patients in this study. Since this was the only study that compared paclitaxel-eluting SEMS with another type of SEMS, it was decided to include this study though downgrade one level for indirectness.

4 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).

5 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

6 Not statistically significant.

1
2
3

Table 105: Summary clinical evidence profile for preoperative endoscopic biliary drainage then surgery versus surgery in adults with suspected pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgery	Preoperative Endoscopic Biliary Drainage>Surgery				
Mortality at 120 days	128 per 1000	147 per 1000 (73 to 297)	RR 1.15 (0.57 to 2.33)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Mortality at 2 years	844 per 1000	811 per 1000 (709 to 920)	RR 0.96 (0.84 to 1.09)	185 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
Treatment-related mortality	43 per 1000	88 per 1000 (28 to 277)	RR 2.07 (0.66 to 6.51)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Overall Survival at 2 years	844 per 1000	839 per 1000 (738 to 917)	HR 0.98 (0.72 to 1.34)	185 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,6}	
Overall Survival at 2 years - resectable patients after resection	783 per 1000	701 per 1000 (562 to 835)	HR 0.79 (0.54 to 1.18)	113 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,6,7}	
Overall Survival at 2 years - unresectable patients after palliative surgery	966 per 1000	968 per 1000 (880 to 996)	HR 1.02 (0.63 to 1.67)	67 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,6,7}	
Time to surgery Weeks	The mean time to surgery in the control groups was 1.2 Weeks	The mean time to surgery in the intervention groups was 4 higher (3.58 to 4.42 higher)		196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4,8}	
Hospitalisation due to protocol-specific complication	117 per 1000	334 per 1000 (179 to 619)	RR 2.85 (1.53)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgery	Preoperative Endoscopic Biliary Drainage>Surgery				
			to 5.29)			
Rate of serious complications (<120 days after randomisation)	394 per 1000	606 per 1000 (506 to 706)	HR 1.86 (1.41 to 2.45)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
Total protocol-specified complications	394 per 1000	736 per 1000 (559 to 968)	RR 1.87 (1.42 to 2.46)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
Pre-surgery Pancreatitis	0 per 1000	0 per 1000 (0 to 0)	RR 13.83 (0.8 to 238.96)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,9}	
Pre-surgery Cholangitis	21 per 1000	265 per 1000 (65 to 1000)	RR 12.44 (3.04 to 50.89)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
Pre-surgery Post-ERCP Haemorrhage	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.83)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Pre-surgery Perforation	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.83)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Stent Malfunction - Stent Occlusion	11 per 1000	147 per 1000 (20 to 1000)	RR 13.82 (1.86 to 102.63)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
Total Surgery-related Complications	372 per 1000	469 per 1000 (339 to 655)	RR 1.26 (0.91 to 1.76)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,9}	
Total Surgery-related Complications for unresectable PC	179 per 1000	545 per 1000 (232 to 1000)	RR 3.05 (1.3 to 7.17)	61 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgery	Preoperative Endoscopic Biliary Drainage>Surgery				
Surgery-related Haemorrhage	43 per 1000	20 per 1000 (4 to 105)	RR 0.46 (0.09 to 2.46)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Surgery-related Cholangitis	32 per 1000	29 per 1000 (6 to 142)	RR 0.92 (0.19 to 4.45)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Surgery-related Pneumonia	53 per 1000	88 per 1000 (31 to 254)	RR 1.66 (0.58 to 4.77)	196 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Eshuis et al. 2010/van der Gaag 2010: overall unclear risk of bias (unclear allocation concealment and selective reporting).

2 After surgical exploration, sample was found to include 92% pancreatic cancer patients; sample also includes participants with either resectable or unresectable tumours. Five patients in surgery only group also underwent preoperative biliary drainage due to unavailability of surgical facility (3 patients), intercurrent cholangitis after ERCP (1 patient) and hyperglycaemia (1 patient).

3 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).

4 Small sample size for dichotomous (<300 events) or continuous (<400 participants) outcome.

5 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

6 Not statistically significant.

7 Randomisation of patients were not stratified by resectability status.

8 MID for this outcome assumed to be 0.61/-0.61 weeks (0.5 SD of control arm at follow up, calculated from data in van der Gaag et al. 2010).

9 Crosses 1 default MID for dichotomous outcomes (0.8 or 1.25).

1
2

Table 106: Summary clinical evidence profile for endoscopic sphincterotomy then stent versus stent in adults with unresectable pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Stent only for unresectable PC	Endoscopic Sphincterotomy->Stent				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Deaths due to PC progression	780 per 1000	671 per 1000 (562 to 796)	RR 0.86 (0.72 to 1.02)	200 (1 study)	⊕⊕⊕⊖ moderate ¹	
Stent Dysfunction - Stent Occlusion	119 per 1000	108 per 1000 (65 to 181)	RR 0.91 (0.55 to 1.52)	456 (3 studies)	⊕⊖⊖⊖ very low ^{2,3}	
Stent Dysfunction - Stent Migration	31 per 1000	57 per 1000 (23 to 140)	RR 1.84 (0.75 to 4.54)	456 (3 studies)	⊕⊖⊖⊖ very low ^{2,3}	
Early Complications ≤30 days	69 per 1000	86 per 1000 (42 to 173)	RR 1.24 (0.61 to 2.5)	376 (2 studies)	⊕⊖⊖⊖ very low ^{3,4}	
Total stent-related Early Complications (≤30 days)	150 per 1000	150 per 1000 (78 to 289)	RR 1 (0.52 to 1.93)	200 (1 study)	⊕⊕⊖⊖ low ³	
Pancreatitis ≤30 days	44 per 1000	49 per 1000 (22 to 113)	RR 1.11 (0.49 to 2.54)	450 (3 studies)	⊕⊖⊖⊖ very low ^{2,3}	
Pancreatitis ≤30 days related to stent placement	53 per 1000	59 per 1000 (26 to 135)	RR 1.11 (0.49 to 2.54)	376 (2 studies)	⊕⊖⊖⊖ very low ^{3,4}	
Perforation ≤30 days	10 per 1000	3 per 1000 (0 to 84)	RR 0.34 (0.01 to 8.25)	194 (1 study)	⊕⊕⊖⊖ low ³	
Cholecystitis ≤30 days	43 per 1000	11 per 1000 (1 to 96)	RR 0.26 (0.03 to 2.24)	184 (1 study)	⊕⊕⊖⊖ low ³	
Total Late Complications related to stent placement (>30 days)	50 per 1000	60 per 1000 (19 to 190)	RR 1.2 (0.38 to 3.81)	200 (1 study)	⊕⊕⊖⊖ low ³	
Cholangitis >30 days	167 per 1000	173 per 1000 (92 to 330)	RR 1.04 (0.55 to 1.98)	182 (1 study)	⊕⊖⊖⊖ very low ^{3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Cholecystitis >30 days	43 per 1000	11 per 1000 (1 to 96)	RR 0.26 (0.03 to 2.24)	184 (1 study)	⊕⊕⊖⊖ low ³	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Crosses 1 default MID for dichotomous outcomes (0.8 or 1.25).

2 Majority of studies (2 of 3) are unclear or high risk of bias (Artifon et al. 2008; Giorgio et al. 2004): Artifon et al. 2008 (unclear allocation concealment, selective reporting of outcomes); Giorgio et al. 2004 (unclear randomisation method, allocation concealment).

3 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).

4 Unclear risk of bias for Giorgio et al. 2004 (unclear randomisation method, allocation concealment).

5 Final value in controls at relevant time point (data from Hayashi et al. 2015).

1
2

Table 107: Summary clinical evidence profile for endoscopic sphincterotomy then stent versus surgical bypass in adults with unresectable pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass for unresectable PC	Endoscopic Sphincterotomy->Stent				
Relief of biliary obstruction	1000 per 1000	1000 per 1000 (880 to 1000)	RR 1 (0.88 to 1.13)	30 (1 study)	⊕⊕⊖⊖ low ^{1,2}	
Treatment-related morbidity	267 per 1000	200 per 1000 (53 to 744)	RR 0.75 (0.2 to 2.79)	30 (1 study)	⊕⊖⊖⊖ very low ^{1,3}	
Treatment-related hospital readmissions	400 per 1000	600 per 1000 (284 to 1000)	RR 1.5 (0.71 to 3.16)	30 (1 study)	⊕⊖⊖⊖ very low ^{1,3}	
Bilirubin level <2.5 mg/dL on day 30	533 per 1000	533 per 1000 (272 to 1000)	RR 1 (0.51 to 1.95)	30 (1 study)	⊕⊖⊖⊖ very low ^{1,3}	
Serum bilirubin level at 30 days	The mean serum bilirubin level at 30 days in the control groups was 2.2 mg/dL	The mean serum bilirubin level at 30 days in the intervention groups was 0.3 lower		30 (1 study)	⊕⊕⊖⊖ low ^{1,4,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass for unresectable PC	Endoscopic Sphincterotomy->Stent				
		(1.06 lower to 0.46 higher)				
Stent-related complications	0 per 1000	0 per 1000 (0 to 0)	RR 9 (0.53 to 153.79)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Treatment-related early onset complications Definition of 'early' not provided	333 per 1000	200 per 1000 (57 to 690)	RR 0.6 (0.17 to 2.07)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Treatment-related late onset complications Definition of 'late' not provided	267 per 1000	200 per 1000 (53 to 744)	RR 0.75 (0.2 to 2.79)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Post-operative complications	467 per 1000	331 per 1000 (135 to 817)	RR 0.71 (0.29 to 1.75)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Pneumonia	133 per 1000	27 per 1000 (1 to 513)	RR 0.2 (0.01 to 3.85)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Post-ERCP Pancreatitis	0 per 1000	0 per 1000 (0 to 0)	RR 3 (0.13 to 68.26)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,3}	
Quality of Life - SF-36 at 30 days		The mean quality of life - sf-36 at 30 days in the intervention groups was 0.78 standard deviations higher (0.04 to 1.52 higher)		30 (1 study)	⊕⊕⊕⊕ low ^{1,6}	SMD - 0.78 (- 1.52 to - 0.04)
Quality of Life - SF-36 at 60 days		The mean quality of life - sf-36 at 60 days in the intervention groups was		30 (1 study)	⊕⊕⊕⊕ low ^{1,6}	SMD - 0.75 (- 1.49 to - 0.01)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass for unresectable PC	Endoscopic Sphincterotomy->Stent				
		0.75 standard deviations higher (0.01 to 1.49 higher)				

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Artifon et al. 2006: overall high/unclear risk of bias (unclear allocation concealment; selective reporting of survival and QoL outcomes; no power calculation/small sample size).
 2 Small sample size (<300 events).
 3 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).
 4 MIDs for this outcome assumed to be 0.5 SD or -0.5 SD of control arm at baseline calculated as 5.64/-5.64 (from data in Artifon et al. 2006).
 5 Small sample size for continuous outcome (<400 participants).
 6 Crosses 1 default MID for continuous outcomes (0.5 or -0.5).

1
2
3
4

Table 108: Summary clinical evidence profile for endoscopic ultrasound-guided choledochoduodenostomy and stent versus percutaneous transhepatic biliary drainage in adults with an unresectable malignant biliary obstruction where either ERCP or EUS-guided transpapillary rendezvous has failed

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Percutaneous transhepatic biliary drainage	EUS-CD				
Total serum bilirubin - at 7 days		The mean total serum bilirubin - at 7 days in the intervention groups was 0.53 standard deviations lower (1.33 lower to 0.27 higher)		25 (1 study)	⊕⊖⊖⊖ very low ^{1,2,3}	SMD -0.53 (-1.33 to 0.27)
Total serum bilirubin - at 30 days		The mean total serum bilirubin - at 30 days in the intervention groups was 0.42 standard		25 (1 study)	⊕⊖⊖⊖ very low ^{1,2,3}	SMD 0.42 (-0.37 to 1.22)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Percutaneous transhepatic biliary drainage	EUS-CD				
		deviations higher (0.37 lower to 1.22 higher)				
Treatment-related complications - Total	250 per 1000	155 per 1000 (30 to 767)	RR 0.62 (0.12 to 3.07)	25 (1 study)	⊕⊕⊕⊕ very low ^{1,2,4}	
SF-36 Overall - at 7 days		The mean sf-36 overall - at 7 days in the intervention groups was 0.29 standard deviations lower (1.08 lower to 0.5 higher)		25 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	SMD - 0.29 (-1.08 to 0.5)
SF-36 Overall - at 30 days		The mean sf-36 overall - at 30 days in the intervention groups was 0.31 standard deviations lower (1.1 lower to 0.48 higher)		25 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	SMD - 0.31 (-1.1 to 0.48)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Artifon et al. 2012: overall high risk of bias (inadequate randomisation method, unclear allocation concealment, selective reporting of outcomes, no power calculation/small sample size; participants not blinded for QoL outcomes).

2 Sample has 64% pancreatic cancer patients.

3 Crosses 1 default MID for continuous outcomes (0.5 or -0.5).

4 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).

1
2
3

Table 109: Summary clinical evidence profile for endoscopic ultrasound-guided choledochoduodenostomy and stent versus surgical bypass in adults with an unresectable malignant biliary obstruction where ERCP has failed

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
Reduction ≥ 50% from baseline in total serum bilirubin after 7 days	933 per 1000	719 per 1000 (504 to 1000)	RR 0.77 (0.54 to 1.09)	29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Total serum bilirubin - at 7 days	The mean total serum bilirubin - at 7 days in the control groups was 3.43 mg/dL ⁴	The mean total serum bilirubin - at 7 days in the intervention groups was 1.71 higher (0.24 lower to 3.66 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,6}	
Total serum bilirubin - at 30 days	The mean total serum bilirubin - at 30 days in the control groups was 2.17 mg/dL	The mean total serum bilirubin - at 30 days in the intervention groups was 0.26 higher (0.37 lower to 0.89 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,7}	
Total serum bilirubin - at 60 days	The mean total serum bilirubin - at 60 days in the control groups was 1.8 mg/dL ⁴	The mean total serum bilirubin - at 60 days in the intervention groups was 0.06 higher (0.31 lower to 0.43 higher)		25 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,7}	
Total serum bilirubin - at 90 days	The mean total serum bilirubin - at 90 days in the control groups was 1.83 mg/dL ⁴	The mean total serum bilirubin - at 90 days in the intervention groups was 0.01 higher (0.58 lower to 0.6 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,7}	
Treatment-related complications	133 per 1000	215 per 1000 (41 to 1000)	RR 1.61 (0.31 to 8.24)	29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,8}	
Overall Survival 90 days after surgery	600 per 1000	444 per 1000 (190 to 808)	HR 0.64 (0.23 to 1.8)	29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,9,10}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
SF-36 Functional Capacity - at 7 days Scale from: 0 to 100.	The mean sf-36 functional capacity - at 7 days in the control groups was 33.7 ⁴	The mean sf-36 functional capacity - at 7 days in the intervention groups was 6.3 higher (5.12 lower to 17.72 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Functional Capacity - at 30 days Scale from: 0 to 100.	The mean sf-36 functional capacity - at 30 days in the control groups was 40.7 ⁴	The mean sf-36 functional capacity - at 30 days in the intervention groups was 10.7 higher (0.93 to 20.47 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Functional Capacity - at 60 days Scale from: 0 to 100.	The mean sf-36 functional capacity - at 60 days in the control groups was 44.3 ⁴	The mean sf-36 functional capacity - at 60 days in the intervention groups was 9.9 higher (1.04 to 18.76 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Functional Capacity - at 90 days Scale from: 0 to 100.	The mean sf-36 functional capacity - at 90 days in the control groups was 57.5 ⁴	The mean sf-36 functional capacity - at 90 days in the intervention groups was 1.8 lower (9.86 lower to 6.26 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Physical Health - at 7 days Scale from: 0 to 100.	The mean sf-36 physical health - at 7 days in the control groups was 21.7 ⁴	The mean sf-36 physical health - at 7 days in the intervention groups was 1.5 higher (11.76 lower to 14.76 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Physical Health - at 30 days Scale from: 0 to 100.	The mean sf-36 physical health - at 30 days in the control groups was 31.7 ⁴	The mean sf-36 physical health - at 30 days in the intervention groups was 4.9 lower (18.55 lower to 8.75 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
SF-36 Physical Health - at 60 days Scale from: 0 to 100.	The mean sf-36 physical health - at 60 days in the control groups was 28.6 ⁴	The mean sf-36 physical health - at 60 days in the intervention groups was 6.8 higher (5.67 lower to 19.27 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Physical Health - at 90 days Scale from: 0 to 100.	The mean sf-36 physical health - at 90 days in the control groups was 45.8 ⁴	The mean sf-36 physical health - at 90 days in the intervention groups was 10.1 lower (33.62 lower to 13.42 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Pain - at 7 days Scale from: 0 to 100.	The mean sf-36 pain - at 7 days in the control groups was 78 ⁴	The mean sf-36 pain - at 7 days in the intervention groups was 3.7 lower (17.22 lower to 9.82 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,7}	
SF-36 Pain - at 30 days Scale from: 0 to 100.	The mean sf-36 pain - at 30 days in the control groups was 76.7 ⁴	The mean sf-36 pain - at 30 days in the intervention groups was 2.7 higher (9.6 lower to 15 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,7}	
SF-36 Pain - at 60 days Scale from: 0 to 100.	The mean sf-36 pain - at 60 days in the control groups was 70.4 ⁴	The mean sf-36 pain - at 60 days in the intervention groups was 4.4 lower (17.51 lower to 8.71 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Pain - at 90 days Scale from: 0 to 100.	The mean sf-36 pain - at 90 days in the control groups was 88.7 ⁴	The mean sf-36 pain - at 90 days in the intervention groups was 15.3 lower (27.76 to 2.84 lower)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 General Health - at 7 days Scale from: 0 to 100.	The mean sf-36 general health - at	The mean sf-36 general health - at 7 days in the intervention		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
	7 days in the control groups was 42.1 ⁴	groups was 3.4 lower (10.15 lower to 3.35 higher)				
SF-36 General Health - at 30 days Scale from: 0 to 100.	The mean sf-36 general health - at 30 days in the control groups was 40.7 ⁴	The mean sf-36 general health - at 30 days in the intervention groups was 4.1 lower (11.85 lower to 3.65 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 General Health - at 60 days Scale from: 0 to 100.	The mean sf-36 general health - at 60 days in the control groups was 38.4 ⁴	The mean sf-36 general health - at 60 days in the intervention groups was 3.3 lower (10.58 lower to 3.98 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 General Health - at 90 days Scale from: 0 to 100.	The mean sf-36 general health - at 90 days in the control groups was 34.8 ⁴	The mean sf-36 general health - at 90 days in the intervention groups was 4.5 higher (7.44 lower to 16.44 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Vitality - at 7 days Scale from: 0 to 100.	The mean sf-36 vitality - at 7 days in the control groups was 38 ⁴	The mean sf-36 vitality - at 7 days in the intervention groups was 2.7 higher (5.64 lower to 11.04 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Vitality - at 30 days Scale from: 0 to 100.	The mean sf-36 vitality - at 30 days in the control groups was 40.3 ⁴	The mean sf-36 vitality - at 30 days in the intervention groups was 7.6 higher (2.43 lower to 17.63 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Vitality - at 60 days Scale from: 0 to 100.	The mean sf-36 vitality - at 60 days in the control groups was 42.9 ⁴	The mean sf-36 vitality - at 60 days in the intervention groups was 2.1 higher (8.61 lower to 12.81 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
SF-36 Vitality - at 90 days Scale from: 0 to 100.	The mean sf-36 vitality - at 90 days in the control groups was 32.5 ⁴	The mean sf-36 vitality - at 90 days in the intervention groups was 14.6 higher (3.2 lower to 32.4 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Social Role Functioning - at 7 days Scale from: 0 to 100.	The mean sf-36 social role functioning - at 7 days in the control groups was 45.8 ⁴	The mean sf-36 social role functioning - at 7 days in the intervention groups was 0.3 lower (9.69 lower to 9.09 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Social Role Functioning - at 30 days Scale from: 0 to 100.	The mean sf-36 social role functioning - at 30 days in the control groups was 54.2 ⁴	The mean sf-36 social role functioning - at 30 days in the intervention groups was 0.3 higher (7.56 lower to 8.16 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Social Role Functioning - at 60 days Scale from: 0 to 100.	The mean sf-36 social role functioning - at 60 days in the control groups was 43.8 ⁴	The mean sf-36 social role functioning - at 60 days in the intervention groups was 1.1 lower (12.32 lower to 10.12 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Social Role Functioning - at 90 days Scale from: 0 to 100.	The mean sf-36 social role functioning - at 90 days in the control groups was 52.1 ⁴	The mean sf-36 social role functioning - at 90 days in the intervention groups was 1.5 higher (9.73 lower to 12.73 higher)		14 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Emotional Role Functioning - at 7 days Scale from: 0 to 100.	The mean sf-36 emotional role functioning - at 7 days in the control	The mean sf-36 emotional role functioning - at 7 days in the intervention groups was 2.5 higher		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
	groups was 35.6 ⁴	(11.19 lower to 16.19 higher)				
SF-36 Emotional Role Functioning - at 30 days Scale from: 0 to 100.	The mean sf-36 emotional role functioning - at 30 days in the control groups was 46.7 ⁴	The mean sf-36 emotional role functioning - at 30 days in the intervention groups was 0.9 higher (15.69 lower to 17.49 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Emotional Role Functioning - at 60 days Scale from: 0 to 100.	The mean sf-36 emotional role functioning - at 60 days in the control groups was 40.5 ⁴	The mean sf-36 emotional role functioning - at 60 days in the intervention groups was 9.5 higher (11.05 lower to 30.05 higher)		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Emotional Role Functioning - at 90 days Scale from: 0 to 100.	The mean sf-36 emotional role functioning - at 90 days in the control groups was 38.9 ⁴	The mean sf-36 emotional role functioning - at 90 days in the intervention groups was 8.7 higher (15.33 lower to 32.73 higher)		13 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	
SF-36 Mental Health - at 7 days Scale from: 0 to 100.	The mean sf-36 mental health - at 7 days in the control groups was 44 ⁴	The mean sf-36 mental health - at 7 days in the intervention groups was 9.1 higher (1.49 to 16.71 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Mental Health - at 30 days Scale from: 0 to 100.	The mean sf-36 mental health - at 30 days in the control groups was 39.7 ⁴	The mean sf-36 mental health - at 30 days in the intervention groups was 12.9 higher (4.63 to 21.17 higher)		29 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	
SF-36 Mental Health - at 60 days	The mean sf-36 mental health - at	The mean sf-36 mental health - at 60 days in the intervention		26 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,12}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgical bypass	EUS-CD				
Scale from: 0 to 100.	60 days in the control groups was 45.1 ⁴	groups was 8.9 higher (0.92 lower to 18.72 higher)				
SF-36 Mental Health - at 90 days Scale from: 0 to 100.	The mean sf-36 mental health - at 90 days in the control groups was 42.7 ⁴	The mean sf-36 mental health - at 90 days in the intervention groups was 1.9 higher (9.98 lower to 13.78 higher)		14 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5,11}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Artifon et al. 2015: Overall high risk of bias (no power calculation; no blinding for QoL outcomes).

2 Cause of biliary obstruction unclear/number of pancreatic cancer patients unclear

3 Crosses 1 default MID for dichotomous outcomes (0.8 or 1.25).

4 Final value in controls at relevant time point (data from Artifon et al. 2015).

5 MIDs for these outcomes assumed to be 0.5 SD or -0.5 SD of control arm at baseline (calculated from data in Artifon et al. 2015). The MIDs for total bilirubin levels were 2.81/-2.81, 217.68/-217.68 for gamma glutamyl transferase levels, and 127.95/-127.95 for alkaline phosphatase levels. For the SF-36 subscales, the MIDs were calculated to be 4.95/-4.95 for Functional Capacity, 5.5/-5.2 for Physical Health, 17.3/-17.3 for Pain, 5.35/-5.35 for General Health, 5.45/-5.45 for Vitality, 7.75/-7.75 for Social Role Functioning, 7.65/-7.65 for Emotional Role Functioning, and 6.6/-6.6 for Mental Health.

6 Crosses 1 MID for total bilirubin levels (2.81 or -2.81).

7 Small sample size for continuous outcome (<400 participants).

8 Crosses 2 default MIDs for dichotomous outcomes (0.8 and 1.25).

9 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

10 Not statistically significant.

11 Crosses 2 MIDs for relevant SF-36 subscale.

12 Crosses 1 MID for relevant SF-36 subscale.

1 9.1.5 Economic Evidence

2 9.1.5.1 Systematic literature review

3 References to all included studies and evidence tables for all economic evaluations included
4 in the systematic literature review of the economic evidence are presented in Appendix L.
5 Economic evidence profiles of these studies are presented in Appendix K.

6 Two studies (Arguedas et al. 2002; Morris et al. 2014) were included in the current review of
7 published economic evidence for this topic. Both economic evaluations considered different
8 interventions in different patient groups and therefore meaningful comparisons between the
9 studies could not be drawn. A bespoke economic model was also built to help inform
10 recommendations for part of this topic.

1 Morris et al. (2014) compared preoperative biliary drainage (PBD) to direct surgery in
2 patients with potentially resectable pancreatic or periampullary cancer and obstructive
3 jaundice from a UK NHS and PSS perspective. The study was deemed to only have minor
4 methodological limitations.

5 The effectiveness side of the model is nearly entirely based on 1 Cochrane Review of six
6 RCTs comparing PBD to direct surgery. The utility values for the model were taken from
7 patient responses to the EQ-5D questionnaire, scored using the UK population weightings,
8 completed by people with hepatic colorectal metastases. Although this was not the patient
9 group considered by the economic evaluation the study did report that the trends closely
10 matched those reported in disease specific quality of life measures for the relevant patient
11 group. However, the results of the model were not sensitive to this input and it noted that
12 alternative plausible values were unlikely to change the preferred option. Cost inputs for the
13 model were all sourced from NHS reference costs.

14 The model concluded that sending patients directly to surgery led to a cost saving of £2,552
15 per patient. It also led to a small increase in health of 0.006 QALYS. This result was robust to
16 all sensitivity analyses performed with probabilistic sensitivity analysis showing a strategy of
17 PBD prior to surgery being the preferred option in less than 10% of iterations when a
18 £20,000 willingness to pay per QALY is assumed.

19 The economic evaluation did not explicitly consider the issues of capacity (i.e. operating
20 theatres and surgeons being available when needed) although it was unclear if there would
21 be additional costs to having to reorganise services or not. However, unless the increases in
22 cost per patient were significant it would be unlikely to change the conclusions.

23 Arguedas et al. (2002) compared plastic stenting to metal stenting in patients with pancreatic
24 cancer and obstructive jaundice presenting for palliative biliary stenting. The study took a US
25 Societal Perspective and was deemed to have very serious methodological limitations. The
26 study estimated that initial stenting with metal stents would lead to a cost saving of US\$433
27 and a health increase of 0.033 QALYs. This result was robust to all parameters apart from
28 length of survival. Given the age of the study, the US societal perspective, methodological
29 issues and that a contemporary bespoke economic model had been built to answer an
30 almost identical decision problem from a UK NHS and PSS perspective, for the purposes of
31 this guideline it was difficult to give much weight to the conclusions of this economic
32 evaluation.

33 **9.1.5.2 Economic modelling**

34 As this topic was deemed a high economic priority and the previous economic evidence did
35 not fully answer the decision problem, a bespoke economic model was developed. The
36 rationale for economic modelling, methods, results and discussion are reported in full in
37 Chapter 12. This section provides an overview of the methods and results for the bespoke
38 economic model.

39 **9.1.5.3 Overview of methods**

40 A decision-analytical model in the form of a Markov model was developed to evaluate the
41 relative cost effectiveness of different strategies for stenting in people with unresectable or
42 metastatic pancreatic cancer and obstructive jaundice. Three different strategies were
43 considered by the model: a strategy of initial stenting with a plastic stent followed by stenting
44 with a self-expanding metal stent (SEMS) upon dysfunction and initial stenting with SEMS
45 followed by replacement/repositioning upon dysfunction (SEMS/SEMS) compared to a base
46 case strategy of initial plastic stenting replaced with plastic stents upon dysfunction. The
47 model did not consider different types of SEMS (covered, uncovered, partially covered)
48 because it was determined there would not be significant cost differences by type and that
49 the decision of the best type to use would be made wholly on clinical and not economic

1 considerations if the strategies involving SEMs were cost effective. The main outcome of the
2 economic model was incremental cost per QALY compared to the base case strategy. A
3 NHS and PSS perspective was taken. The model had a time horizon of two years which was
4 deemed sufficient to capture the lifetime of the vast majority of the cohort.

5 Clinical data were derived entirely from studies identified in the accompanying systematic
6 review of clinical evidence. All costs were derived from NHS reference costs. The cost of
7 initial stent insertion were taken from NHS reference costs. This figure would include all pre-
8 operative imaging, the unit costs of the stents, the insertion of the stent and any peri-
9 operative treatment and hospital stay.

10 NHS Reference costs gave a difference in total insertion costs between insertion of metal
11 stents and plastic stents of £760, slightly less than the difference in unit cost of the different
12 stents as reported in the NHS Supply Catalogues. Where the insertion of the stent is a
13 secondary or later insertion the costs are assumed to be equal to those above apart from
14 where a person is receiving a secondary SEMs stenting having previously received SEMs
15 stenting (i.e. the SEMs/SEMs strategy). In this case the cost is assumed equal to that of
16 receiving a plastic stent. This is because, unlike plastic stents, SEMs can be reused on
17 migration or occlusion and thus the stent costs are not incurred again.

18 When occlusion or migration is suspected a patient would receive a diagnostic endoscopic
19 procedure to investigate and confirm the suspicion and to rule out any other causes of the
20 associated symptoms. Following this, patients would receive their secondary or later
21 stenting.

22 During the base case analysis hospital days were not costed. Hospital days were not costed
23 as the reference costs for stent placement allow for some days in hospital. It was likely that
24 costing this difference could lead to double counting of this cost. Days in hospital above
25 those in the perioperative period were costed in line with excess bed days for the procedure.
26 In the base case analysis adverse events were not assigned a cost as it was assumed that
27 these adverse events would often be treated as part of surgical treatment follow-up.

28 Quality of life weights were taken from 1 Dutch study (Walter et al. 2017), in an identical
29 patient group, using the EQ-5D questionnaire, administered alongside an RCT. The EQ-5D
30 questionnaire scored using Dutch population values showed no difference in quality of life
31 between the SEMs and plastic stent groups. Therefore, the base case analysis was a de
32 facto cost minimisation study. It was hypothesised that the EQ-5D questionnaire was not
33 sensitive enough to pick up quality of life changes between the groups, therefore a
34 secondary analysis was run using the values from the EQ-5D Visual Analogue Scale (VAS)
35 to measure differences in quality of life between the different strategies.

36 All health and cost outcomes were discounted at a rate of 3.5% per annum.

37 **9.1.5.4 Results of the economic model**

38 In the base case analysis where overall survival and quality of life were assumed equal
39 across the different strategies SEMs/SEMs was the least costly strategy with a cost saving,
40 over the lifetime of one person of over £1500 when compared to the plastic/plastic
41 strategy (Table 110). When scoring from the EQ-5D VAS was included in the secondary
42 model the SEMs/SEMs strategy also lead to the largest amount of QALYs with an additional
43 0.024 QALYS compared to a plastic/plastic strategy. It was also cost saving and health
44 improving compared to the plastic/SEMs strategy making it dominant compared to all other
45 strategies considered in the base case analysis.

1 **Table 110: Deterministic Base Case Results**

	Total Costs	Total QALYs	Incremental Cost	Incremental QALY	ICER
Plastic/Plastic	£11,774	0.1608	Reference	Reference	
Plastic/SEMS	£11,371	0.1721	-£ 402	0.0113	Dominant†
SEMS/SEMS	£11,114	0.1852	-£ 659	0.0244	Dominant
	†Whilst Plastic/SEMS dominated Plastic/Plastic it was dominated by the SEMS/SEMS approach.				

2 This result was only sensitive to overall survival with plastic stenting followed by plastic
3 stenting becoming the least costly for survival less than 24 days. The robustness of the result
4 is supported by the probabilistic sensitivity analysis. The initial stenting with SEMS strategy is
5 cost saving compared to plastic stenting followed by plastic stenting in 98% of iterations.

6 **9.1.5.5 Conclusions**

7 A strategy of SEMS replaced with SEMS upon dysfunction was the preferred option in the
8 base case results for both deterministic and base case results - being cost saving compared
9 to the other two strategies. When quality of life data from the EQ-5D VAS was used this
10 strategy was also health improving.

11 These conclusions were robust to both one way deterministic sensitivity analyses and
12 probabilistic sensitivity analysis. SEMS/SEMS was the preferred option in nearly all
13 deterministic sensitivity analysis. The robustness of these results are further highlighted by
14 the probabilistic sensitivity analysis where a SEMS/SEMS strategy is cost saving in greater
15 than 98% of iterations.

16 The results of this economic model were based on evidence from the clinical evidence
17 review which was derived entirely from RCT evidence. The costings for the model were
18 taken from UK NHS sources and quality of life from a European EQ-5D questionnaire
19 administered alongside an RCT. The results, conclusions and sensitivities are almost
20 identical to the 1 economic evaluation identified by the review of the previous economic
21 evidence review (Arguedas et al. 2002).

22 **9.1.6 Evidence statements**

23 **9.1.6.1 Plastic stent versus self-expanding metal stent in adults with pancreatic cancer and** 24 **biliary obstruction**

25 **Relief of obstruction**

26 Very low quality evidence from 3 RCTS (n=229) showed that, when used as either a primary
27 or secondary stent, there is a clinically important difference favouring SEMS on time to
28 dysfunction in adults with unresectable pancreatic cancer compared to plastic stents: HR
29 2.59 (95% CI 1.67-4.0).

- 30 • Very low quality evidence from 2 RCTS (n=224) showed that when used as a primary
31 stent, there is a clinically important difference favouring covered or partially-covered
32 SEMS on time to dysfunction in adults with unresectable pancreatic cancer compared to
33 plastic stents: HR 2.26 (95% CI 1.45-3.53).
- 34 • Very low quality evidence from 1 RCT (n=117) showed that when used as a primary stent,
35 there is a clinically important difference favouring uncovered SEMS on time to dysfunction
36 in adults with unresectable pancreatic cancer compared to plastic stents: HR 3.0 (95% CI
37 1.45-6.2).

- 1 • Very low quality evidence from 1 RCT (n=33) showed that when used as a secondary
2 stent, there is a clinically important difference favouring partially-covered SEMs plastic
3 stents on time to dysfunction in adults with unresectable pancreatic cancer compared to
4 plastic stents: HR 6.69 (95% CI 1.39-32.07).
- 5 • Very low quality evidence from 1 RCT (n=31) showed that when used as a secondary
6 stent, there is a clinically important difference favouring uncovered SEMs on time to
7 dysfunction in adults with unresectable pancreatic cancer compared to plastic stents: HR
8 9.97 (95% CI 3.46-28.74).
- 9 Low quality evidence from 6 RCTs (n=471) showed that there is a clinically important
10 difference favouring SEMs on the number of adults with pancreatic cancer who experience
11 stent occlusion compared to plastic stents: RR 2.25 (95% CI 1.67-3.02).
- 12 • Very low quality evidence from 4 RCTs (n=258) showed that there is a clinically important
13 difference favouring covered, partially-covered or uncovered SEMs on the number of
14 adults with pancreatic cancer who experience stent occlusion compared to plastic stents:
15 RR 2.2 (95% CI 1.45-3.35).
- 16 • Very low quality evidence from 2 RCTs (n=213) showed that there is a clinically important
17 difference favouring covered SEMs on the number of adults with pancreatic cancer who
18 experience stent occlusion compared to plastic stents: RR 2.3 (95% CI 1.51-3.49).
- 19 • Low quality evidence from 5 RCTs (n=417) showed that there is a clinically important
20 difference favouring SEMs on the number of adults with unresectable pancreatic cancer
21 who experience stent occlusion compared to plastic stents: RR 2.36 (95% CI 1.7-3.28).
- 22 • Low quality evidence from 1 RCT (n=54) showed that there is no clinically important
23 difference between SEMs and plastic stents on the number of adults with resectable,
24 borderline resectable, or locally advanced pancreatic cancer who experience stent
25 occlusion: RR 1.73 (95% CI 0.89-3.34).
- 26 Very low quality evidence from 1 RCT (n=113) showed that there is no clinically important
27 difference between plastic stents and SEMs on the number of adults with pancreatic cancer
28 who experience stent migration: RR 0.19 (95% CI 0.02-1.57).
- 29 Very low quality evidence from 1 RCT (n=117) showed that there is a clinically important
30 difference favouring partially-covered or uncovered SEMs on the number of adults with
31 pancreatic cancer who experience either stent occlusion or stent migration compared to
32 plastic stents: RR 2.42 (95% CI 1.44-4.06).

33 **Relief of symptoms**

34 No evidence was identified to inform this outcome.

35 **Treatment-related mortality**

36 Very low quality evidence from 1 RCT (n=100) showed no clinically important difference
37 between plastic stents and SEMs on treatment-related mortality in adults with unresectable
38 pancreatic cancer: RR 2.88 (95% CI 0.12-69.16).

39 **Treatment-related morbidity**

40 Low quality evidence from 1 RCT (n=34) showed that there is no clinically important
41 difference between wing-shaped plastic stents and SEMs on the number of adults with
42 unresectable biliary obstruction caused by pancreatic cancer whose serum bilirubin levels
43 decrease by 30% or more after their insertion: RR 0.94 (95% CI 0.79-1.1).

44 Low quality evidence from 1 RCT (n=98) showed that there is no clinically important
45 difference between plastic stents and SEMs on the rate of change in total serum bilirubin

1 (SMD 0.23 [95% CI -0.62-0.17]) after their insertion in adults with unresectable pancreatic
2 cancer.

3 **Treatment-related complications**

4 Very low quality evidence from 7 RCTs (n=720) showed that there is no clinically important
5 difference between plastic stents and SEMs on the number of adults with pancreatic cancer
6 who experience pancreatitis after their insertion: RR 0.81 (95% CI 0.32-2.04).

- 7 • Very low quality evidence from 4 RCTs (n=473) showed that there is no clinically
8 important difference between plastic stents and covered, partially covered or uncovered
9 SEMs on the number of adults with pancreatic cancer who experience pancreatitis after
10 their insertion: RR 1.02 (95% CI 0.36-2.92).
- 11 • Very low quality evidence from 2 RCTs (n=213) showed that there is no clinically
12 important difference between plastic stents and covered, partially covered or uncovered
13 SEMs on the number of adults with pancreatic cancer who experience pancreatitis after
14 their insertion: RR 0.32 (95% CI 0.03-3.01).
- 15 • Very low quality evidence from 5 RCTs (n=632) showed that there is no clinically
16 important difference between plastic stents and SEMs on the number of adults with
17 unresectable pancreatic cancer who experience pancreatitis after their insertion: RR 1.52
18 (95% CI 0.51-4.59).
- 19 • Very low quality evidence from 1 RCT (n=54) showed that there is no clinically important
20 difference between plastic stents and SEMs on the number of adults with resectable,
21 borderline resectable or locally advanced pancreatic cancer who experience pancreatitis
22 after their insertion: RR 0.12 (95% CI 0.01-2.01).

23 Low quality evidence from 4 RCTs (n=334) showed that there is a clinically important
24 difference favouring SEMs on the number of adults with unresectable pancreatic cancer who
25 experience cholangitis after their insertion compared to the insertion of plastic stents: RR 3.1
26 (95% CI 1.28-7.48).

- 27 • Very low quality evidence from 2 RCTs (n=152) showed that there is a clinically important
28 difference favouring covered, partially-covered or uncovered SEMs on the number of
29 adults with unresectable pancreatic cancer who experience cholangitis after their insertion
30 compared to the insertion of plastic stents: RR 1.71 (95% CI 0.5-5.89).
- 31 • Very low quality evidence from 1 RCT (n=100) showed that there is no clinically important
32 difference between plastic stents and covered SEMs on the number of adults with
33 unresectable pancreatic cancer who experience cholangitis after their insertion: RR 4.81
34 (95% CI 0.24-97.68).
- 35 • Very low quality evidence from 1 RCT (n=82) showed that there is a clinically important
36 difference favouring partially-covered SEMs on the number of adults with unresectable
37 pancreatic cancer who experience cholangitis after their insertion compared to the
38 insertion plastic stents: RR 5.0 (95% CI 1.17-21.43).

39 Very low quality evidence from 4 RCTs (n=448) showed that there is no clinically important
40 difference between plastic stents and SEMs on the number of adults with unresectable
41 pancreatic cancer who experience cholecystitis after their insertion: RR 0.47 (95% CI 0.15-
42 1.53).

- 43 • Very low quality evidence from 2 RCTs (n=253) showed that there is no clinically
44 important difference between plastic stents and covered, partially-covered or uncovered
45 SEMs on the number of adults with unresectable pancreatic cancer who experience
46 cholecystitis after their insertion: RR 2.56 (95% CI 0.33-20.1).
- 47 • Very low quality evidence from 1 RCT (n=82) showed that there is no clinically important
48 difference between plastic stents and partially-covered SEMs on the number of adults
49 with unresectable pancreatic cancer who experience cholecystitis after their insertion: RR
50 0.2 (95% CI 0.01-4.04).

1 • Very low quality evidence from 1 RCT (n=113) showed that there is no clinically important
2 difference plastic stents and covered SEMs on the number of adults with unresectable
3 pancreatic cancer who experience cholecystitis after their insertion: RR 0.11 (95% CI
4 0.01-1.91).

5 Very low quality evidence from 1 RCT (n=118) showed that there is no clinically important
6 difference between plastic stents and covered SEMs on the number of adults with
7 unresectable pancreatic cancer who experience post-endoscopic sphincterotomy
8 haemorrhage after their insertion: RR 3.0 (95% CI 0.12-72.18).

9 Very low quality evidence from 2 RCTs (n=197) showed that there is no clinically important
10 difference between plastic stents and SEMs on the number of days adults with unresectable
11 pancreatic cancer are hospitalised after their insertion: SMD 0.49 (95% CI 0.21-0.77).

12 **Overall survival**

13 Very low quality evidence from 3 RCTs (n=247) showed no significant difference between
14 plastic stents and SEMs on overall survival in adults with unresectable pancreatic cancer:
15 HR 1 (95% CI 0.75-1.31).

16 **Time to definitive treatment**

17 No evidence was identified to inform this outcome.

18 **Health-related quality of life**

19 No evidence was identified to inform this outcome.

20 **Patient experience**

21 No evidence was identified to inform this outcome.

22 **PROMS**

23 No evidence was identified to inform this outcome.

24 **9.1.6.2 Covered self-expanding metal stent versus uncovered self-expanding metal stent in** 25 **adults with pancreatic cancer and biliary obstruction**

26 **Narrative summary for overall survival**

27 The 5 included RCTs did not report data for overall survival in a way that allowed a meta-
28 analysis. Overall the studies were at high risk of bias due to selective (e.g. incomplete)
29 reporting of outcomes, other sources of bias (such as significant differences at baseline), and
30 insufficient information about the randomisation method or allocation concealment. None of
31 the studies reported the hazard ratios and associated 95% confidence intervals. Unlike the
32 other studies – all of which used ‘standard’ covered SEMs (e.g. with a silicone membrane) -
33 Krokidis 2011 used an SEM with an expanded polytetrafluoroethylene/fluorinated-ethylene-
34 propylene covering. Median overall survival of a covered SEM ranged from 116 days to 285
35 days (1 study reported a mean of 71 days), whilst for an uncovered SEM it ranged from 155
36 to 222 days. One study (Gardner et al., 2016) reported a mean overall survival of 71 (range
37 7-196) days for covered SEM and 242 (range 122-453) days for an uncovered SEM. One
38 study (Krokidis et al., 2011) reported a near significant difference (p=0.06) on overall survival
39 favouring a covered SEM over an uncovered SEM, three studies (Kitano et al., 2013,
40 Kullman et al., 2010, Ung et al., 2013) reported no difference between them, and 1 study did
41 not provide a p-value. However, all of the participants in this study were receiving
42 neoadjuvant therapy.

1 **Narrative summary for relief of obstruction (cumulative stent patency)**

2 The 5 included RCTs did not report data for cumulative stent patency (time to obstruction) in
3 a way that allowed a meta-analysis. Overall the studies were at high risk of bias due to
4 selective (e.g. incomplete) reporting of outcomes, other sources of bias (such as significant
5 differences at baseline), and insufficient information about the randomisation method or
6 allocation concealment. None of the studies reported the hazard ratios and associated 95%
7 confidence intervals. Unlike the other studies – all of which used ‘standard’ covered SEMSS
8 (e.g. with a silicone membrane) - Krokidis 2011 used an SEMS with an expanded
9 polytetrafluoroethylene/fluorinated-ethylene-propylene covering; all of the participants in this
10 study were also receiving neoadjuvant therapy. Median stent patency for a covered SEMS
11 ranged from 153 to 583 days, whilst for an uncovered SEMS it ranged from 127 to 314 days.
12 One study (Gardner et al., 2016) reported a mean stent patency of 220 days (range 21-341)
13 for a covered SEMS and 74 days (range 45-90) for an uncovered SEMS. Two studies
14 (Kitano et al., 2013, Krokidis et al., 2011) reported a significant difference on stent patency
15 favouring a covered SEMS over an uncovered SEMS, two studies (Kullman et al., 2010, Ung
16 et al., 2013), reported no significant difference between them, whilst 1 study (Gardner et al.,
17 2016) did not provide a p-value.

18 **Relief of obstruction**

19 Very low quality evidence from 5 RCTs (n=701) showed that there is no clinically important
20 difference between covered and uncovered SEMS on the number of people experiencing
21 stent dysfunction: RR 0.81 (95% CI 0.61-1.05).

- 22 • Very low quality evidence from 3 RCTs (n=600) showed that there is a clinically important
23 difference favouring uncovered SEMS on the number of stent dysfunctions caused by
24 sludge formation compared to covered SEMS in adults with pancreatic cancer and biliary
25 obstruction: RR 2.43 (95% CI 1.22-4.85).
- 26 • Very low quality evidence from 2 RCTs (n=520) showed that there is no clinically
27 important difference between covered and uncovered SEMS on the number of stent
28 dysfunctions caused by stent migration in adults with pancreatic cancer and biliary
29 obstruction: RR 13 (95% CI 0.74-229.23).
- 30 • Very low quality evidence from 3 RCTs (n=600) showed that there is a clinically important
31 difference favouring covered SEMS on the number of stent dysfunctions caused by
32 tumour ingrowth compared to uncovered SEMS in adults with pancreatic cancer and
33 biliary obstruction: RR 0.36 (95% CI 0.2-0.64).
- 34 • Very low quality evidence from 3 RCTs (n=600) showed that there may be a clinically
35 important difference favouring uncovered SEMS on the number of stent dysfunctions
36 caused by tumour overgrowth compared to covered SEMS in adults with pancreatic
37 cancer and biliary obstruction, although there is some uncertainty: RR 1.88 (95% CI 0.97-
38 3.66).

39 **Relief of symptoms**

40 No evidence was identified to inform this outcome.

41 **Treatment-related mortality**

42 No evidence was identified to inform this outcome.

43 **Treatment-related morbidity**

44 No evidence was identified to inform this outcome.

1 **Treatment-related complications**

2 Very low quality evidence from 4 RCTs (n=668) showed that there is no clinically important
3 difference between covered and uncovered SEMS on the number of adults with pancreatic
4 cancer and biliary obstruction who experience adverse events: RR 0.89 (95% CI 0.52-1.51).

- 5 • Very low quality evidence from 1 RCT (n=400) showed that there is no clinically important
6 difference between covered and uncovered SEMS on the number of adults with
7 pancreatic cancer and biliary obstruction who experience cholangitis (RR 0.67 [95% CI
8 0.28-1.6]) and retroperitoneal perforation (RR 1.0 [95% CI 0.06-15.88]).
- 9 • Very low quality evidence from 2 RCTs (n=520) showed that there is no clinically
10 important difference between covered and uncovered SEMS on the number of adults with
11 pancreatic cancer and biliary obstruction who experience cholecystitis: RR 0.75 (95% CI
12 0.17-3.31).
- 13 • Very low quality evidence from 2 RCTs (n=480) showed that there is no clinically
14 important difference between covered and uncovered SEMS on the number of adults with
15 pancreatic cancer and biliary obstruction who experience haemorrhage: RR 0.71 (95% CI
16 0.14-3.52).
- 17 • Very low quality evidence from 3 RCTs (n=588) showed that there is no clinically
18 important difference between covered and uncovered SEMS on the number of adults with
19 pancreatic cancer and biliary obstruction who experience pancreatitis: RR 1.2 (95% CI
20 0.37-3.89).
- 21 • Very low quality evidence from 1 RCT (n=80) showed that there is no clinically important
22 difference between covered and uncovered SEMS on the number of adults with
23 pancreatic cancer and biliary obstruction who experience peritoneal irritation: RR 1.5
24 (95% CI 0.26-8.5).
- 25 • Very low quality evidence from 1 RCT (n=68) showed that there is no clinically important
26 difference between covered and uncovered SEMS on the number of adults with
27 pancreatic cancer and biliary obstruction who experience sepsis: RR 3.0 (95% CI 0.13-
28 71.15).

29 **Time to definitive treatment**

30 No evidence was identified to inform this outcome.

31 **Health-related quality of life**

32 No evidence was identified to inform this outcome.

33 **Patient experience**

34 No evidence was identified to inform this outcome.

35 **PROMS**

36 No evidence was identified to inform this outcome.

37 **9.1.6.3 Partially-covered self-expanding metal stent versus uncovered self-expanding metal**
38 **stent in adults with pancreatic cancer and biliary obstruction**

39 **Narrative summary for overall survival and relief of obstruction (cumulative stent**
40 **patency)**

41 The 2 included RCTs did not report data for overall survival and cumulative stent patency
42 (time to obstruction) in a way that allowed a meta-analysis. Overall the 2 studies were at
43 high/unclear risk of bias due to selective reporting of outcomes. None of the studies reported

1 the hazard ratios and associated 95% confidence intervals. Only 1 study (Telford et al.,
2 2010) reported median overall survival by group, which was not significant (227 days for a
3 partially covered SEMs and 239 days for an uncovered SEMs). Median stent patency
4 ranged from 285 to 357 days for a partially covered SEMs compared to 268 to 711 days for
5 an uncovered SEMs. One study (Telford et al., 2010) reported no significant difference
6 between partially covered and uncovered SEMs, whilst 1 study (Walter et al, 2015) did not
7 provide a p-value.

8 **Relief of obstruction**

9 Very low quality evidence from 2 RCTs (n=243) showed that there is no clinically important
10 difference between partially-covered and uncovered SEMs on the number of adults with
11 pancreatic cancer and biliary obstruction who experience stent dysfunction from any cause:
12 RR 1.35 (95% CI 0.81-2.23)

13 Very low quality evidence from 1 RCT (n=129) showed that there may be a clinically
14 important difference favouring uncovered SEMs on the number of stent dysfunctions caused
15 by stent migration compared to a partially-covered SEMs in adults with pancreatic cancer
16 and biliary obstruction: RR 15.28 (95% CI 0.9-259.23).

17 **Relief of symptoms**

18 No evidence was identified to inform this outcome.

19 **Treatment-related mortality**

20 No evidence was identified to inform this outcome.

21 **Treatment-related morbidity**

22 No evidence was identified to inform this outcome.

23 **Treatment-related complications**

24 Very low quality evidence from 1 RCT (n=129) showed that there may be a clinically
25 important difference favouring uncovered SEMs on the number of adverse events compared
26 to a partially-covered SEMs in adults with pancreatic cancer and biliary obstruction, although
27 there is some uncertainty: RR 1.4 (95% CI 1.0-1.96).

- 28 • Very low quality evidence from 2 RCTs (n=275) showed that there is no clinically
29 important difference between partially-covered and uncovered SEMs on the number of
30 adults with pancreatic cancer and biliary obstruction who experience pancreatitis (RR 0.97
31 [95% CI 0.14-6.58]) or other adverse events (RR 1.14 [95% CI 0.66-1.99]).
- 32 • Very low quality evidence from 2 RCTs (n=237) showed that there is no clinically
33 important difference between partially-covered and uncovered SEMs on the number of
34 adults with pancreatic cancer and biliary obstruction who experience cholecystitis: RR
35 0.98 (95% CI 0.21-4.59).

36 **Time to definitive treatment**

37 No evidence was identified to inform this outcome.

38 **Health-related quality of life**

39 No evidence was identified to inform this outcome.

1 **Patient experience**

2 No evidence was identified to inform this outcome.

3 **PROMS**

4 No evidence was identified to inform this outcome.

5 **9.1.6.4 Paclitaxel-eluting self-expanding metal stent versus covered self-expanding metal**
6 **stent in adults with an unresectable distal malignant biliary obstruction**

7 **Relief of obstruction**

8 Very low quality evidence from 1 RCT (n=52) showed that there is no clinically important
9 difference between paclitaxel-eluting and covered SEMs on time to stent dysfunction in
10 adults with an unresectable distal malignant biliary obstruction: HR 0.53 (95% CI 0.16-1.78).

- 11 • Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
12 difference between paclitaxel-eluting and covered SEMs on increasing time to stent
13 dysfunction in adults with an unresectable distal malignant biliary obstruction caused by
14 pancreatic cancer: HR 0.52 (95% CI 0.1-3.09).

15 **Relief of symptoms**

16 No evidence was identified to inform this outcome.

17 **Treatment-related mortality**

18 No evidence was identified to inform this outcome.

19 **Treatment-related morbidity**

20 No evidence was identified to inform this outcome.

21 **Treatment-related complications**

22 Very low quality evidence from 1 RCT (n=52) showed that there is no clinically important
23 difference between paclitaxel-eluting and covered SEMs on the number of adults with an
24 unresectable distal malignant biliary obstruction who experience cholangitis symptoms (RR
25 7.28 [95% CI 0.4-133.89]) and pancreatitis (RR 1.04 [95% CI 0.07-15.73]) within 30 days of
26 surgery.

27 **Overall survival**

28 Very low quality evidence from 1 RCT (n=52) showed that there is no clinically important
29 difference between paclitaxel-eluting and covered SEMs on overall survival in adults with an
30 unresectable distal malignant biliary obstruction: HR 1.19 (95% CI 0.65-2.18).

- 31 • Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
32 difference between paclitaxel-eluting and covered SEMs on overall survival in adults with
33 an unresectable distal malignant biliary obstruction caused by pancreatic cancer: HR 0.85
34 (95% CI 0.35-2.06).

35 Very low quality evidence from 1 RCT (n=52) showed that there is no clinically important
36 difference between paclitaxel-eluting and covered SEMs on the number of adults with an
37 unresectable distal malignant biliary obstruction who experience stent occlusion: RR 0.65
38 (95% CI 0.25-1.71).

1 **Time to definitive treatment**

2 No evidence was identified to inform this outcome.

3 **Health-related quality of life**

4 No evidence was identified to inform this outcome.

5 **Patient experience**

6 No evidence was identified to inform this outcome.

7 **PROMS**

8 No evidence was identified to inform this outcome.

9 **9.1.6.5 Preoperative endoscopic biliary drainage (PEBD) then surgery versus surgery in**
10 **adults with suspected pancreatic cancer**

11 **Relief of obstruction**

12 No evidence was identified to inform this outcome.

13 **Relief of symptoms**

14 No evidence was identified to inform this outcome.

15 **Treatment-related mortality**

16 Very low quality evidence from 1 RCT (n=196) showed that there is no clinically important
17 difference between PEBD followed by surgery and surgery only in adults with pancreatic
18 cancer on mortality at 120 days (RR 1.15 [95% CI 0.57-2.33]) nor on treatment-related
19 mortality (RR 2.07 [95% CI 0.66-6.51]).

20 Very low quality evidence from 1 RCT (n=185) showed that there is no clinically important
21 difference between PEBD followed by surgery and surgery only in adults with pancreatic
22 cancer on mortality at 2 years: RR 0.96 (95% CI 0.84-1.09).

23 **Treatment-related morbidity**

24 No evidence was identified to inform this outcome.

25 **Treatment-related complications**

26 Very low quality evidence from 1 RCT (n=196) showed that there is a clinically important
27 difference favouring surgery on the total number of adults with pancreatic cancer who
28 experience protocol-specific complications (RR 1.87 [95% CI 1.42-2.46]), surgery-related
29 complications (RR 1.26 [95% CI 0.91 to 1.76]), pre-surgery cholangitis (RR 12.44 [95% CI
30 3.04 to 50.89]), and the number that are hospitalised due to protocol-specific complications
31 (RR 2.85 [95% CI 1.53-5.2]) compared to PEBD followed by surgery.

32 Very low quality evidence from 1 RCT (n=196) showed that there is a clinically important
33 difference favouring surgery only on the rate of serious complications within 120 days of
34 randomisation compared to PEBD followed by surgery: HR 1.86 (95% CI 1.41-2.45).

35 Very low quality evidence from 1 RCT (n=196) showed that there may be a clinically
36 important difference favouring surgery only on the number of adults with pancreatic cancer

1 who experience pre-surgery pancreatitis compared to PEBD followed by surgery, although
2 there may be some uncertainty: RR 13.83 [95% CI 0.8 to 238.96].

3 Very low quality evidence from 1 RCT (n=196) showed that there is no clinically important
4 difference between PEBD followed by surgery and surgery only on the number of adults with
5 pancreatic cancer who experience pre-surgery post-ERCP haemorrhage (RR 4.61 [95% CI
6 0.22-94.83]), pre-surgery perforation (RR 4.61 [95% CI 0.22 to 94.83]), surgery-related
7 haemorrhage (RR 0.46 [95% CI 0.09-2.46]), surgery-related cholangitis (RR 0.92 (95% CI
8 0.19 to 4.45) and surgery-related pneumonia (RR 1.66 [95% CI 0.58 to 4.77]).

9 **Overall survival**

10 Very low quality evidence from 1 RCT (n=185) showed that there is no clinically important
11 difference between PEBD followed by surgery and surgery only in adults with pancreatic
12 cancer on overall survival at 2 years: HR 0.98 (95% CI 0.72-1.34).

- 13 • Very low quality evidence from 1 RCT (n=113) showed that there is no clinically important
14 difference between PEBD followed by curative surgery and curative surgery only in adults
15 with resectable or borderline resectable pancreatic cancer after undergoing resection on
16 overall survival at 2 years: HR 0.98 (95% CI 0.72-1.34).
- 17 • Very low quality evidence from 1 RCT (n=67) showed that there is no clinically important
18 difference between PEBD followed by palliative surgery and palliative surgery only in
19 adults with unresectable pancreatic cancer on overall survival at 2 years: HR 1.02 (95%
20 CI 0.63-1.67).

21 **Time to definitive treatment**

22 Very low quality evidence from 1 RCT (n=196) showed that there is a clinically important
23 difference favouring surgery only on the delay to surgery in adults with pancreatic cancer
24 compared to PEBD followed by surgery: MD 4.0 (95% CI 3.58-4.42).

25 **Health-related quality of life**

26 No evidence was identified to inform this outcome.

27 **Patient experience**

28 No evidence was identified to inform this outcome.

29 **PROMS**

30 No evidence was identified to inform this outcome.

31 **9.1.6.6 Endoscopic sphincterotomy then stent versus stent in adults with unresectable** 32 **pancreatic cancer**

33 **Relief of obstruction**

34 Very low quality evidence from 3 RCTs (n=454) showed that there is no clinically important
35 difference between endoscopic sphincterotomy followed by a stent and stent only on
36 decreasing the number of adults with unresectable pancreatic cancer who experience stent
37 occlusion (RR 0.91 [95% CI 0.55-1.52]), stent migration (RR 1.84 [95% CI 0.75 to 4.54]).

38 **Relief of symptoms**

39 No evidence was identified to inform this outcome

1 **Treatment-related mortality**

2 No evidence was identified to inform this outcome.

3 **Treatment-related morbidity**

4 Moderate quality evidence from 1 RCT (n=200) showed that there is no clinically important
5 difference between endoscopic sphincterotomy followed by a stent and stent only on the
6 number of adults with unresectable pancreatic cancer that die due to disease progression:
7 RR 0.86 (95% CI 0.72-1.02).

8 **Treatment-related complications**

9 Very low quality evidence from 2 RCTs (n=376) showed that there is no clinically important
10 difference between endoscopic sphincterotomy followed by a stent and stent only on the
11 number of adults with unresectable pancreatic cancer who experience early complications
12 within 30 days (RR 1.24 [95% CI 0.61 to 2.5]) and early stent-related pancreatitis (95% CI
13 RR 1.11 [0.49 to 2.54]).

14 Low quality evidence from 1 RCT (n=200) showed that there is no clinically important
15 difference between endoscopic sphincterotomy followed by a stent and stent only on the
16 number of adults with unresectable pancreatic cancer who experience early stent-related
17 complications within 30 days (RR 1.0 [95% CI 0.52 to 1.93]) and late stent-related
18 complications after 30 days (RR 1.2 [95% CI 0.38 to 3.81]).

19 Very low quality evidence from 3 RCTs (n=450) showed that there is no clinically important
20 difference between endoscopic sphincterotomy followed by a stent and stent only on the
21 number of adults with unresectable pancreatic cancer who experience pancreatitis within 30
22 days: RR 1.11 (95% CI 0.49 to 2.54).

23 Low quality evidence from 1 RCT (n=194) showed that there is no clinically important
24 difference between endoscopic sphincterotomy followed by a stent and stent only on the
25 number of adults with unresectable pancreatic cancer who experience perforation within 30
26 days: RR 0.34 (95% CI 0.01-8.25).

27 Low quality evidence from 1 RCT (n=184) showed that there is no clinically important
28 difference between endoscopic sphincterotomy followed by a stent and stent only on the
29 number of adults with unresectable pancreatic cancer who experience cholecystitis within 30
30 days and after 30 days: RR 0.26 (95% CI 0.03-2.24) for both outcomes.

31 Very low quality evidence from 1 RCT (n=182) showed that there is no clinically important
32 difference between endoscopic sphincterotomy followed by a stent and stent only on the
33 number of adults with unresectable pancreatic cancer who experience cholangitis after 30
34 days: RR 1.04 (95% CI 0.55 to 1.98).

35 **Overall survival**

36 No evidence was identified to inform this outcome.

37 **Time to definitive treatment**

38 No evidence was identified to inform this outcome.

39 **Health-related quality of life**

40 No evidence was identified to inform this outcome.

1 **Patient experience**

2 No evidence was identified to inform this outcome.

3 **PROMS**

4 No evidence was identified to inform this outcome.

5 **9.1.6.7 Endoscopic sphincterotomy then stent versus surgical bypass in adults with**
6 **unresectable pancreatic cancer**

7 **Relief of obstruction**

8 Low to very low quality evidence from 1 RCT (n=30) showed that there is no clinically
9 important difference between endoscopic sphincterotomy followed by a covered stent and
10 surgical bypass on relief of biliary obstruction in adults with unresectable pancreatic cancer:
11 RR 1.0 (95% CI 0.88-1.13).

12 **Relief of symptoms**

13 No evidence was identified to inform this outcome.

14 **Treatment-related mortality**

15 No evidence was identified to inform this outcome.

16 **Treatment-related morbidity**

17 Low to very low quality evidence from 1 RCT (n=30) showed there is no clinically important
18 difference between endoscopic sphincterotomy followed by a covered stent and surgical
19 bypass on the number of people whose bilirubin level is less than 2.5 mg/dL on day 30 (RR 1
20 [95% CI 0.51 to 1.95]) nor on serum bilirubin levels at day 30 (MD -0.3 [95% CI -1.06-0.46])
21 in adults with unresectable pancreatic cancer.

22 Very low quality evidence from 1 RCT (n=30) showed that there is no clinically important
23 difference between endoscopic sphincterotomy followed by a covered stent and surgical
24 bypass on treatment-related morbidity in adults with unresectable pancreatic cancer: RR
25 0.75 (95% CI 0.2-2.79).

26 **Treatment-related complications**

27 Very low quality evidence from 1 RCT (n=30) showed that there is no clinically important
28 difference between endoscopic sphincterotomy followed by a covered stent and surgical
29 bypass on treatment-related hospitalisation (RR 1.5 [95% CI 0.71-3.16]), stent-related
30 complications (RR 9 [95% CI 0.53-153.79]), treatment-related early complications (RR 0.6
31 [95% CI 0.17-2.07]), treatment-related late complications (RR 0.75 [95% CI 0.2- 2.79]), post-
32 operative complications (RR 0.71 [95% CI 0.29-1.75]), pneumonia (RR 0.2 [95% CI 0.01-
33 3.85]), post-ERCP pancreatitis (RR 3 [95% CI 0.13-68.26]) in adults with unresectable
34 pancreatic cancer.

35 **Overall survival**

36 No evidence was identified to inform this outcome.

37 **Time to definitive treatment**

38 No evidence was identified to inform this outcome.

1 **Health-related quality of life**

2 Low quality evidence from 1 RCT (n=30) showed that there is a clinically important difference
3 favouring endoscopic sphincterotomy followed by a covered stent on SF-36 overall quality of
4 life scores at 30 days (SMD 0.78 [0.04-1.52]) and 60 days (SMD 0.75 [0.01-1.49]) in adults
5 with unresectable pancreatic cancer, compared to surgical bypass.

6 **Patient experience**

7 No evidence was identified to inform this outcome.

8 **PROMS**

9 No evidence was identified to inform this outcome.

10 **9.1.6.8 Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) and stent versus**
11 **percutaneous transhepatic biliary drainage (PTBD) in adults with an unresectable**
12 **malignant biliary obstruction where either ERCP or EUS-guided transpapillary**
13 **rendezvous has failed**

14 **Relief of obstruction**

15 No evidence was identified to inform this outcome.

16 **Relief of symptoms**

17 No evidence was identified to inform this outcome.

18 **Treatment-related mortality**

19 No evidence was identified to inform this outcome.

20 **Treatment-related morbidity**

21 Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
22 difference in the effect of EUS-CD compared to PTBD on total serum bilirubin at 7 days
23 (SMD -0.53 [95% CI -1.33-0.27]) and 30 days (SMD 0.42 [95% CI -0.37-1.22]) in adults with
24 unresectable malignant biliary obstruction where ERCP has failed.

25 Very low quality evidence from 1 RCT (n=25) showed that EUS-CD has a clinically significant
26 benefit of lowering gamma glutamyl transferase levels at 7 days in adults with unresectable
27 malignant biliary obstruction where ERCP has failed compared to PTBD: SMD -0.87 (95% CI
28 -1.69- -0.05).

29 Very low quality evidence from 1 RCT (n=25) showed that EUS-CD may have a clinically
30 significant benefit in lowering alkaline phosphatase levels at 7 days in adults with
31 unresectable malignant biliary obstruction where ERCP has failed compared to PTBD,
32 although there is some uncertainty: SMD -0.73 (95% CI -1.54-0.08).

33 **Treatment-related complications**

34 Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
35 difference in the effect of EUS-CD compared to PTBD on the number of adults with
36 unresectable malignant biliary obstruction where ERCP has failed who experience treatment-
37 related complications: RR 0.62 (95% CI 0.12-3.07).

1 **Overall survival**

2 No evidence was identified to inform this outcome.

3 **Time to definitive treatment**

4 No evidence was identified to inform this outcome.

5 **Health-related quality of life**

6 Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
7 difference in the effect of EUS-CD compared to PTBD on SF-36 quality of life scores at 7
8 days (SMD -0.29 [95% CI -1.08-0.5]) and 30 days (SMD -0.31 [95% CI -1.1-0.48]) in adults
9 with unresectable malignant biliary obstruction where ERCP has failed.

10 **Patient experience**

11 No evidence was identified to inform this outcome.

12 **PROMS**

13 No evidence was identified to inform this outcome.

14 **9.1.6.9 Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) and stent versus**
15 **surgical bypass in adults with an unresectable malignant biliary obstruction where**
16 **ERCP has failed**

17 **Relief of obstruction**

18 No evidence was identified to inform this outcome.

19 **Relief of symptoms**

20 No evidence was identified to inform this outcome.

21 **Treatment-related mortality**

22 No evidence was identified to inform this outcome.

23 **Treatment-related morbidity**

24 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
25 difference in the effect of EUS-CD after 7 days on the number of adults with unresectable
26 malignant biliary obstruction (and where ERCP has failed) whose total serum bilirubin levels
27 are reduced 50% or more compared to those who have surgical bypass: RR 0.77 (95% CI
28 0.54-1.09).

29 Very low quality evidence from 1 RCT (n=29) showed that EUS-CD may have a clinically
30 significant effect on decreasing total serum bilirubin at 7 days compared to surgical bypass in
31 adults with unresectable malignant biliary obstruction where ERCP has failed compared to
32 those who have surgical bypass, although there is some uncertainty: MD 1.71 (95% CI -0.24-
33 3.66).

34 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
35 difference in the effect of EUS-CD at 7 days on decreasing gamma glutamyl transferase (MD
36 116.46 [95% CI 34.63 to 198.29]) nor alkaline phosphatase (MD 64.54 [95% CI 16.34 to

1 112.74]), compared to surgical bypass in adults with unresectable malignant biliary
2 obstruction where ERCP has failed.

3 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
4 difference in the effect of EUS-CD at 30 days on decreasing total serum bilirubin (MD 0.26
5 [95% CI -0.37-0.89]), gamma glutamyl transferase (MD 53.83 [95% CI -20.42-128.08], nor
6 alkaline phosphatase (MD 11.39 [95% CI -22.16-44.94]), compared to surgical bypass in
7 adults with unresectable malignant biliary obstruction where ERCP has failed.

8 Very low quality evidence from 1 RCT (n=25) showed that there is no clinically important
9 difference in the effect of EUS-CD at 60 days on decreasing total serum bilirubin (MD 0.06
10 [95% CI -0.31-0.43]), gamma glutamyl transferase (MD 0.22 [95% CI -16.88-17.32]), nor
11 alkaline phosphatase (MD 4.79 [95% CI -7.11-16.69]) compared to surgical bypass in adults
12 with unresectable malignant biliary obstruction where ERCP has failed.

13 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
14 difference in the effect of EUS-CD at 90 days on decreasing total serum bilirubin (MD 0.01
15 [95% CI -0.58-0.6]), gamma glutamyl transferase (MD 14.43 [95% CI -2.3-31.16]) nor
16 alkaline phosphatase (MD 5.4 [95% CI -4.87-15.67]), compared to surgical bypass in adults
17 with unresectable malignant biliary obstruction where ERCP has failed.

18 **Treatment-related complications**

19 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
20 difference in the effect of EUS-CD on the number of treatment-related complications
21 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
22 ERCP has failed: RR 1.61 (95% CI 0.31-8.24).

23 **Overall survival**

24 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
25 difference in the effect of EUS-CD on overall survival, compared to surgical bypass, in adults
26 with unresectable malignant biliary obstruction where ERCP has failed: HR 0.64 (95% CI
27 0.23-1.8).

28 **Time to definitive treatment**

29 No evidence was identified to inform this outcome.

30 **Health-related quality of life**

31 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
32 difference in the effect of EUS-CD on improving SF-36 functional capacity at 7 days (MD 6.3
33 [95% CI -5.12-17.72]) and 30 days (MD 10.7 [95% CI 0.93-20.47]), compared to surgical
34 bypass in adults with unresectable malignant biliary obstruction where ERCP has failed.

35 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
36 difference in the effect of EUS-CD on SF-36 physical health scores at 7 days (MD 1.5 [95%
37 CI -11.76-14.76]) and 30 days (MD -4.9 [95% CI -18.55-8.75]) compared to surgical bypass,
38 in adults with unresectable malignant biliary obstruction where ERCP has failed.

39 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
40 difference in the effect of EUS-CD on improving SF-36 pain scores at 7 days (MD -3.7 [95%
41 CI -17.22-9.82]) and 30 days (MD 2.7 [95% CI -9.6-15.0]) compared to surgical bypass, in
42 adults with unresectable malignant biliary obstruction where ERCP has failed.

43 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
44 difference in the effect of EUS-CD on improving SF-36 general health scores at 7 days (MD -

- 1 3.4 [95% CI -10.15-3.35]) and 30 days (MD -4.1 [95% CI -11.85-3.65]) compared to surgical
2 bypass, in adults with unresectable malignant biliary obstruction where ERCP has failed.
- 3 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
4 difference in the effect of EUS-CD on improving SF-36 vitality scores at 7 days (MD 2.7 [95%
5 CI -5.64-11.04]) and 30 days (MD 7.6 [95% CI -2.43-17.63]) compared to surgical bypass, in
6 adults with unresectable malignant biliary obstruction where ERCP has failed.
- 7 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
8 difference in the effect of EUS-CD on improving SF-36 social role functioning scores at 7
9 days (MD -0.3 [95% CI -9.69-9.09]) and 30 days (MD 0.3 [95% CI -7.56-8.16]) compared to
10 surgical bypass, in adults with unresectable malignant biliary obstruction where ERCP has
11 failed.
- 12 Very low quality evidence from 1 RCT (n=29) showed that there is no clinically important
13 difference in the effect of EUS-CD on improving SF-36 emotional role functioning scores at 7
14 days (MD 2.5 [95% CI -11.19-16.19]) and 30 days (MD 0.9 [95% CI -15.69-17.49]) compared
15 to surgical bypass, in adults with unresectable malignant biliary obstruction where ERCP has
16 failed.
- 17 Very low quality evidence from 1 RCT (n=29) showed that there is a clinically important
18 difference in the effect of EUS-CD on improving SF-36 mental health scores at 7 days (MD
19 9.1 [95% CI 1.49-16.71]) and 30 days (MD 12.9 [95% CI 4.63-21.17]) compared to surgical
20 bypass, in adults with unresectable malignant biliary obstruction where ERCP has failed.
- 21 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
22 difference in the effect of EUS-CD on improving SF-36 functional capacity scores at 60 days
23 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
24 ERCP has failed: MD 9.9 (95% CI 1.04-18.76).
- 25 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
26 difference in the effect of EUS-CD on improving SF-36 functional capacity scores at 90 days
27 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
28 ERCP has failed: MD -1.8 (95% CI -9.86-6.26).
- 29 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
30 difference in the effect of EUS-CD on improving SF-36 physical health scores at 60 days
31 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
32 ERCP has failed: MD 6.8 (95% CI -5.67-19.27).
- 33 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
34 difference in the effect of EUS-CD on improving SF-36 physical health scores at 90 days
35 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
36 ERCP has failed: MD -10.1 (95% CI -33.62-13.42).
- 37 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
38 difference in the effect of EUS-CD on improving SF-36 pain scores at 60 days compared to
39 surgical bypass, in adults with unresectable malignant biliary obstruction where ERCP has
40 failed: MD -4.4 (95% CI -17.51-8.71).
- 41 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
42 difference in the effect of EUS-CD on improving SF-36 functional capacity scores at 90 days
43 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
44 ERCP has failed: MD -15.3 (95% CI -27.76- -2.84).
- 45 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
46 difference in the effect of EUS-CD on improving SF-36 general health scores at 60 days
47 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
48 ERCP has failed: MD -3.3 (95% CI -10.58-3.98).

1 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
2 difference in the effect of EUS-CD on improving SF-36 general health scores at 90 days
3 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
4 ERCP has failed: MD 4.5 (95% CI -7.44-16.44).

5 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
6 difference in the effect of EUS-CD on improving SF-36 vitality scores at 60 days compared to
7 surgical bypass in adults with unresectable malignant biliary obstruction where ERCP has
8 failed: MD 2.14 (95% CI -8.61-12.81).

9 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
10 difference in the effect of EUS-CD on improving SF-36 vitality scores at 90 days compared to
11 surgical bypass, in adults with unresectable malignant biliary obstruction where ERCP has
12 failed: MD 14.6 (95% CI -3.2-32.4).

13 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
14 difference in the effect of EUS-CD on improving SF-36 social role functioning scores at 60
15 days compared to surgical bypass, in adults with unresectable malignant biliary obstruction
16 where ERCP has failed: MD -1.1 (95% CI -12.32-10.12).

17 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
18 difference in the effect of EUS-CD on improving SF-36 social role functioning scores at 90
19 days compared to surgical bypass in adults with unresectable malignant biliary obstruction
20 where ERCP has failed: MD 1.5 (95% CI -9.73-12.73).

21 Very low quality evidence from 1 RCT (n=26) showed that there is no clinically important
22 difference in the effect of EUS-CD on improving SF-36 emotional role functioning scores at
23 60 days compared to surgical bypass, in adults with unresectable malignant biliary
24 obstruction where ERCP has failed: MD 9.5 (95% CI -11.05-30.05).

25 Very low quality evidence from 1 RCT (n=13) showed that there is no clinically important
26 difference in the effect of EUS-CD on improving SF-36 emotional role functioning scores at
27 90 days compared to surgical bypass, in adults with unresectable malignant biliary
28 obstruction where ERCP has failed: MD 8.7 (95% CI -15.33-32.73).

29 Very low quality evidence from 1 RCT (n=26) showed that there may be a clinically important
30 difference in the effect of EUS-CD on improving SF-36 mental health scores at 60 days
31 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
32 ERCP has failed, although there is some uncertainty: MD 8.9 (95% CI 0.92-18.72).

33 Very low quality evidence from 1 RCT (n=14) showed that there is no clinically important
34 difference in the effect of EUS-CD on improving SF-36 mental health scores at 90 days
35 compared to surgical bypass, in adults with unresectable malignant biliary obstruction where
36 ERCP has failed: MD 1.9 (95% CI -9.98-13.78).

37 **Patient experience**

38 No evidence was identified to inform this outcome.

39 **PROMS**

40 No evidence was identified to inform this outcome.

41 **9.1.7 Recommendations**

42 **33. Offer resectional surgery rather than preoperative biliary drainage to people who:**

- 43
 - have resectable pancreatic cancer and obstructive jaundice **and**

- 1 • are well enough for the procedure **and**
- 2 • are not enrolled in a clinical trial that requires preoperative biliary
- 3 drainage.

4 **34. During attempted resection for pancreatic cancer, consider surgical biliary bypass**
5 **if the cancer is found to be unresectable.**

6 **35. If biliary drainage is needed in a person who has resectable pancreatic cancer and**
7 **obstructive jaundice and is not yet fit enough for resectional surgery, offer**
8 **endoscopically placed self-expanding metal stents.**

9 **36. For people with suspected pancreatic cancer who may need their stent removed**
10 **later on, consider endoscopically placed self-expanding fully covered metal**
11 **stents.**

12 **37. Offer endoscopically placed self-expanding metal stents rather than surgical**
13 **biliary bypass to people with unresectable pancreatic cancer.**

14 **9.1.8 Evidence to recommendations**

15 **9.1.8.1 Relative value placed on the outcomes considered**

16 The committee considered relief of obstruction, relief of symptoms, treatment-related
17 mortality, treatment related morbidity, treatment-related complications, overall survival, time
18 to definitive treatment, health-related quality of life, patient experience and PROMS to be the
19 critical outcomes for this question.

20 Patient experience and PROMS were not reported for any comparisons of interest. Relief of
21 obstruction, relief of symptoms, treatment-related mortality and morbidity, time to definitive
22 treatment and quality of life were only reported by a few studies. Treatment related
23 complications and overall survival were reported by the majority of studies. The majority of
24 studies also reported the outcome of stent dysfunction which the committee agreed was a
25 useful outcome to consider.

26 **9.1.8.2 Quality of evidence**

27 The quality of the outcomes for the comparisons identified by this review were as follows:

- 28 • Plastic stent versus self-expanding metal stent (SEMS) – ranged from very low to low
- 29 • Covered SEMS versus uncovered SEMS – very low
- 30 • Partially-covered SEMS versus uncovered SEMS - very low
- 31 • Paclitaxel-eluting SEMS versus covered SEMS - very low
- 32 • Preoperative endoscopic biliary drainage then surgery versus surgery – very low
- 33 • Endoscopic sphincterotomy then stent versus stent – ranged from very low to moderate
- 34 • Endoscopic sphincterotomy then stent versus surgical bypass – ranged from very low to
- 35 low
- 36 • Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) versus percutaneous
- 37 transhepatic biliary drainage – very low
- 38 • Endoscopic ultrasound-guided choledochoduodenostomy (EUS-CD) versus surgical
- 39 bypass – very low

40 The committee noted that several of the studies included people who did not have pancreatic
41 cancer. They agreed to focus on those studies which included at least 66% pancreatic

1 cancer as they considered this proportion would be high enough for the data to be
2 representative of the population under consideration by this guideline.

3 The committee decided to include three studies that either had less than 66% pancreatic
4 cancer patients or did not report the composition of the samples because the studied
5 interventions were deemed to be sufficiently novel to merit consideration. Each of these
6 studies was the only study that contributed data to the relevant three comparisons:
7 paclitaxel-eluting SEMS versus covered SEMS; EUS-CD versus percutaneous transhepatic
8 biliary drainage; and EUS-CD versus surgical bypass. In relation to the two studies on EUS-
9 guided biliary drainage, it was unclear how many patients had pancreatic cancer and the
10 sample sizes were very small so it was difficult to draw conclusions from these data. Given
11 this, and the fact that this is a relatively new technique, the committee agreed not to make
12 any recommendations about this intervention.

13 **9.1.8.3 Consideration of clinical benefits and harms**

14 The committee noted, based on the evidence, that preoperative biliary drainage was
15 associated with an increased delay to surgery, more complications, more serious
16 complications within 120 days, more hospitalisations and more people experiencing pre-
17 surgery pancreatitis compared to surgery alone. Given this evidence, and the results of the
18 published economic analysis showing that going straight to surgery was both cost saving and
19 health improving, the committee made a strong recommendation to offer surgery to people
20 with resectable pancreatic cancer. Based on their clinical knowledge, the committee also
21 noted that there are ongoing clinical trials which require the insertion of a biliary stent to meet
22 the inclusion criteria of the trial protocol. They were conscious that they did not want these
23 recommendations to restrict entry into such clinical trials and therefore agreed to add a
24 caveat that surgery should be offered, when outside of a clinical trial of preoperative biliary
25 drainage.

26 The committee noted, based on the evidence, that the time to dysfunction was shorter with
27 plastic stents compared with SEMS and that there was a decrease in stent occlusion and
28 stent migration with SEMS. Moreover, whilst there was no difference in the number of people
29 experiencing pancreatitis or cholecystitis with the different types of stent, the number of
30 people experiencing cholangitis was lower after the insertion of an SEMS. Given this
31 evidence, and the results of the bespoke economic model showing that SEMS was the most
32 cost effective intervention, the committee made a strong recommendation for the use of
33 SEMS, rather than plastic stents, in people with pancreatic cancer and biliary obstruction.
34 They agreed, based on their knowledge and experience, that stent placement should be
35 done endoscopically as this is safer than percutaneous insertion.

36 The committee noted, based on their experience, that sometimes a stent has to be inserted
37 to relieve the biliary obstruction before it is known whether pancreatic cancer is the cause of
38 this obstruction. In those people where pancreatic cancer does not turn out to be the cause
39 of the obstruction, the stent is likely to need removal. The committee noted that the evidence
40 comparing covered and partially covered SEMS with uncovered SEMS had not identified any
41 clinically significant differences in effects between the two. However, they agreed based on
42 their knowledge, that fully covered metal stents should be considered where it is possible
43 that stent removal may be required, because it can be very difficult to remove uncovered or
44 partially covered metal stents. The committee also acknowledged the importance of fitness
45 for resectional surgery of people who have resectable pancreatic cancer and obstructive
46 jaundice in need of biliary drainage. Based on the evidence on the effectiveness of SEMS
47 committee therefore made a strong recommendation to offer endoscopically placed self-
48 expanding metal stents to people who have resectable pancreatic cancer and obstructive
49 jaundice and are not fit enough for resectable surgery.

50 The committee noted that there would be a group of people who had biliary obstruction but
51 whose pancreatic cancer was unresectable and recommendations were needed for this

1 group too. Based on the evidence, the committee agreed that endoscopic stenting was
2 associated with improvements in quality of life compared to surgical bypass. They, therefore,
3 made a strong recommendation for endoscopic stenting in people with unresectable
4 pancreatic cancer as stent placement would avoid a major operation in someone who was
5 likely to be quite poorly. Based on their knowledge and experience the committee also
6 agreed to recommend that surgical biliary bypass should be considered for people whose
7 pancreatic cancer was deemed unresectable during an attempted resection. This would
8 mean the person would not need to have a potential additional procedure in future to insert a
9 stent.

10 Given that the data for the other comparisons of interest had not demonstrated any
11 difference between interventions, the committee agreed not to make any further
12 recommendations.

13 The committee considered that the potential benefits of the recommendations made would
14 be earlier treatment of biliary obstruction, improved symptom control, a reduction in the
15 complications associated with stent insertion (as metal stents are less likely to occlude or
16 migrate than plastic stents) and avoidance of unnecessary repeat stenting procedures (as
17 metal stents are less likely to become dysfunctional). The committee noted that the potential
18 harms could be duodenal perforation, bleeding and post procedure pancreatitis from stenting
19 or biliary leaking and anastomotic leakage from surgical bypass. However, without these
20 interventions the person would die so they considered that the harms were balanced by the
21 potential benefits.

22 **9.1.8.4 Consideration of economic benefits and harms**

23 The literature search for previous economic evaluations identified 2 relevant economic
24 evaluations (Morris [2015] and Arguedas [2002]). Both economic evaluations considered
25 different interventions in different patient groups and therefore meaningful comparisons
26 between the studies could not be drawn. A bespoke economic model was also built to help
27 inform recommendations.

28 Morris (2015) compared preoperative biliary drainage (PBD) to direct surgery in patients with
29 potentially resectable pancreatic or periampullary cancer and obstructive jaundice from a UK
30 NHS and PSS perspective. The study was deemed to only have minor methodological
31 limitations.

32 The effectiveness side of the model was nearly entirely based on 1 Cochrane Review of 6
33 RCTs comparing PBD to direct surgery. The utility values for the model were taken from
34 patient responses to the EQ-5D questionnaire, scored using the UK population weightings
35 and completed by people with hepatic colorectal metastases. As this was not the patient
36 group considered by the model the committee found it difficult to say whether quality of life
37 would be similar between these groups. The study did report that the trends closely matched
38 those reported in disease specific quality of life measures for pancreatic cancer. However,
39 the results of the model were not sensitive to this input and it was unlikely to change the
40 preferred option. Costs inputs for the model were all sourced from NHS reference costs.

41 The model concluded that sending patients directly to surgery led to a cost saving of £2,552
42 per patient. It led to a small increase in health of 0.006 QALYS. This result was robust to all
43 sensitivity analyses performed. Probabilistic sensitivity analysis showing a strategy of PBD
44 prior to surgery being the preferred option in less than 10% of iterations when a £20,000 per
45 QALY willingness to pay is assumed.

46 The committee were broadly in agreement with the inputs and findings of the economic
47 analysis although raised concerns that issues of capacity (for example, operating theatres
48 and surgeons being available when needed) had not been considered by the model. The
49 committee agreed that this could be dealt with through reorganisation of surgical set-ups with
50 no, or very limited, additional costs as there would be no increase in total number of

1 operations. Whilst this reorganisation could be done in multiple ways, where costs were
2 incurred they were likely to be in employing a coordinator for facilitating immediate access.
3 Even with this wage cost, including on-costs, the conclusions of the economic evaluation
4 were unlikely to be changed. The committee were, therefore, able to make a strong
5 recommendation for sending patients with resectable pancreatic cancer and obstructive
6 jaundice directly to surgery.

7 Arguedas (2002) compared plastic stenting to metal stenting in patients with pancreatic
8 cancer and obstructive jaundice presenting for palliative biliary stenting. The study took a US
9 Societal Perspective and was deemed to have very serious methodological limitations. The
10 study estimated that initial stenting with metal stents would lead to a cost saving of US\$433
11 and a health increase of 0.033 QALYs. This result was robust to all parameters apart from
12 length of survival. Given the age of the study, the US societal perspective, methodological
13 issues, and that a contemporary bespoke economic model had been built to answer an
14 almost identical decision problem from a UK NHS and PSS perspective, the committee did
15 not use this study in informing their recommendations.

16 The bespoke economic model considered 3 possible strategies for biliary stenting in patients
17 with unresectable or metastatic pancreatic cancer and obstructive jaundice. The model
18 compared a strategy of initial stenting with a plastic stent followed by stenting with a self-
19 expanding metal stent (SEMS) upon dysfunction and initial stenting with SEMS
20 replaced/repositioned upon dysfunction with a base case strategy of initial plastic stenting
21 replaced with plastic stents upon dysfunction. The study took a UK NHS and PSS
22 perspective and considered a 2 year time horizon which was adequate to represent the
23 lifetime of over 99% of the patient group.

24 Clinical inputs and baseline values were largely taken from the accompanying clinical
25 evidence review and cost inputs were exclusively taken from NHS reference costs. The utility
26 values in the base-case were taken from a patient group, identical to that considered in the
27 economic model, using the EQ-5D questionnaire and scored using Dutch population values.
28 The questionnaire was completed alongside an RCT identified in the clinical evidence
29 review. The hazard ratio for overall survival between plastic and metal stents in the clinical
30 evidence review was equal to 1 (no difference) and there was no difference in deterioration in
31 EQ-5D reported in the identified study. Therefore, the base case for the model assumed no
32 difference on these parameters between the three strategies and the base case analysis
33 became a de-facto cost minimisation. The committee, however, considered, based on their
34 clinical experience, that quality of life, through reduced adverse events and lower need for
35 repeat surgery would improve and therefore a secondary analysis was performed using the
36 values reported in the same study but using the visual analogue scale. This measure
37 reported that quality of life deteriorated at a lower rate with SEMS compared to plastic stents
38 although this was not statistically significant.

39 In the base case a strategy of initial metal stenting followed by subsequent metal stenting
40 was the least costly with a saving of over £1,500 per patient. When QoL was also considered
41 it led to a small increase in QoL of 0.024 QALYs per patient. This result was only sensitive to
42 overall survival with plastic stenting followed by plastic stenting becoming the least costly
43 when survival was less than 24 days. The robustness of the result is supported by the
44 probabilistic sensitivity analysis. The initial stenting with SEMS strategy is cost saving
45 compared to plastic stenting followed by plastic stenting in 98% of iterations. The conclusions
46 were broadly identical to that of Arguedas (2002), with metal stents being cost saving and
47 results only being sensitive to survival. Although, given the differences between the studies
48 described above, there is little validity to any comparison.

49 The committee, therefore, made a strong recommendation supporting the use of SEMS in
50 this patient group. The economic model attempted to look at the type of SEMS used
51 (covered, partially covered, uncovered) but results disaggregated by SEMS type were
52 reported inconsistently and it was difficult to consider them as separate analyses. The 3

1 types of stents though have almost identical costs and the decision of which type to use was
2 based on clinical and not economic considerations.

3 **9.1.9 References**

- 4 Artifon ELA, Aparicio D, Paione JB et al. (2012) Biliary Drainage in Patients With
5 Unresectable, Malignant Obstruction Where ERCP Fails Endoscopic Ultrasonography-
6 Guided Choledochoduodenostomy Versus Percutaneous Drainage. *Journal of Clinical*
7 *Gastroenterology* 46: 768-774
- 8 Artifon ELA, Loureiro JF, Baron TH et al. (2015) Surgery or EUS-guided
9 choledochoduodenostomy for malignant distal biliary obstruction after ERCP failure.
10 *Endoscopic Ultrasound* 4: 235-43
- 11 Artifon EL, Sakai P, Cunha JE et al. (2006) Surgery or endoscopy for palliation of biliary
12 obstruction due to metastatic pancreatic cancer. *The American Journal of Gastroenterology*
13 101: 2031-7
- 14 Artifon EL, Sakai P, Ishioka S et al. (2008) Endoscopic sphincterotomy before deployment of
15 covered metal stent is associated with greater complication rate: a prospective randomized
16 control trial. *Journal of Clinical Gastroenterology* 42: 815-9
- 17 Eshuis WJ, van der Gaag NA, Rauws EA et al. (2010) Therapeutic delay and survival after
18 surgery for cancer of the pancreatic head with or without preoperative biliary drainage.
19 *Annals of Surgery* 252(5): 840-849
- 20 Gardner TB, Spangler CC, Byanova KL et al. (2016) Cost-effectiveness and clinical efficacy
21 of biliary stents in patients undergoing neoadjuvant therapy for pancreatic adenocarcinoma in
22 a randomized controlled trial. *Gastrointestinal Endoscopy* 84(23): 460-466
- 23 Giorgio PD and Luca LD (2004) Comparison of treatment outcomes between biliary plastic
24 stent placements with and without endoscopic sphincterotomy for inoperable malignant
25 common bile duct obstruction. *World Journal of Gastroenterology* 10(8): 1212-4
- 26 Hayashi T, Kawakami H, Osanai M et al. (2015) No benefit of endoscopic sphincterotomy
27 before biliary placement of self-expandable metal stents for unresectable pancreatic cancer.
28 *Clinical Gastroenterology & Hepatology* 13: 1151-8.e2
- 29 Isayama H, Yasuda I, Ryozaawa S et al. (2011) Results of a Japanese multicenter,
30 randomized trial of endoscopic stenting for non-resectable pancreatic head cancer (JM-test):
31 Covered Wallstent versus DoubleLayer stent. *Digestive Endoscopy* 23, 310-5
- 32 Kaassis M, Boyer J, Dumas R et al. (2003) Plastic or metal stents for malignant stricture of
33 the common bile duct? Results of a randomized prospective study. *Gastrointestinal*
34 *Endoscopy* 57: 178-182
- 35 Kitano M, Yamashita Y, Tanaka K et al. (2013) Covered self-expandable metal stents with an
36 anti-migration system improve patency duration without increased complications compared
37 to uncovered stents for distal biliary obstruction caused by pancreatic carcinoma: a
38 randomized multicenter trial. *The American Journal of Gastroenterology* 108(11): 1713-1722
- 39 Krokidis M, Fanelli F, Orgera G et al. (2011) Percutaneous palliation of pancreatic head
40 cancer: randomized comparison of ePTFE/FEP-covered versus uncovered nitinol biliary
41 stents. *Cardiovascular and Interventional Radiology* 34(2): 352-361
- 42 Kullman E, Frozanpor F, Söderlund C et al. (2010) Covered versus uncovered self-
43 expandable nitinol stents in the palliative treatment of malignant distal biliary obstruction:
44 results from a randomized, multicenter study. *Gastrointestinal Endoscopy* 72(5): 915-923

- 1 Moses PL, Alnaamani KM, Barkun AN et al. (2013) Randomized trial in malignant biliary
2 obstruction: plastic vs partially covered metal stents. *World Journal of Gastroenterology* 19:
3 8638-46
- 4 Schmidt A, Riecken B, Rische S et al. (2015) Wing-shaped plastic stents vs self-expandable
5 metal stents for palliative drainage of malignant distal biliary obstruction: A randomized
6 multicenter study. *Endoscopy* 47(5): 430-436
- 7 Söderlund C and Linder S (2006) Covered metal versus plastic stents for malignant common
8 bile duct stenosis: a prospective, randomized, controlled trial. *Gastrointestinal Endoscopy* 63:
9 986-95
- 10 Song TJ, Lee SS, Yun SC et al. (2011) Paclitaxel-eluting covered metal stents versus
11 covered metal stents for distal malignant biliary obstruction: a prospective comparative pilot
12 study. *Gastrointestinal Endoscopy* 73: 727-733
- 13 Telford JJ, Carr-Locke DL, Baron TH et al. (2010) A randomized trial comparing uncovered
14 and partially covered self-expandable metal stents in the palliation of distal malignant biliary
15 obstruction. *Gastrointestinal Endoscopy* 72(5): 907-914
- 16 Travis S and Nicholson T (1997) Palliation of unresectable pancreatic malignant biliary
17 obstruction: Results of a randomized trial comparing percutaneously placed metal and plastic
18 endoprostheses. *Journal of Interventional Radiology* 12: 17-21
- 19 Ung KA, Stotzer PO, Nilsson Å et al. (2013) Covered and uncovered self-expandable
20 metallic Hanarostents are equally efficacious in the drainage of extrahepatic malignant
21 strictures. Results of a double-blind randomized study. *Scandinavian Journal of*
22 *Gastroenterology*, 48(4): 459-465.
- 23 van der Gaag NA, Rauws EA, van Eijck CH et al. (2010) Preoperative biliary drainage for
24 cancer of the head of the pancreas. *New England Journal of Medicine* 362: 129-37

25 **9.2 Duodenal obstruction**

26 **Review question: What is the optimal treatment of duodenal obstruction?**

27 **9.2.1 Introduction**

28 Tumour invasion into the duodenum can result in obstruction to the flow of ingested food and
29 secretions from the stomach into the duodenum. Gastric outflow obstruction results in
30 recurrent large volume vomiting, fullness, dehydration and malnutrition. Duodenal obstruction
31 is usually associated with advanced and unresectable pancreatic tumours and occurs in up
32 to 20% of patients with pancreatic cancer.

33 When duodenal obstruction occurs in association with an operable tumour the definitive
34 management of the obstruction will occur with resection of the tumour. For the majority of
35 patients with duodenal obstruction who have inoperable disease, the options are between
36 palliative surgery (gastrojejunostomy) to bypass the obstruction or the endoscopic placement
37 of a self-expanding metal stent (SEMS). Placement of a SEMS may be tolerated better by
38 frail individuals and are thought to be associated with faster recovery and symptom
39 improvement, however the improvement may not be as marked or as durable as that
40 achieved with surgery.

41 A proportion of individuals who undergo surgery with curative intent will be found to have
42 inoperable disease at the time of surgery and will therefore not have a resection. Some of
43 these individuals will subsequently develop duodenal obstruction due to disease progression.
44 Prophylactic gastrojejunostomy performed during the operation when curative surgery is
45 deemed not to be feasible may prevent the later development of duodenal obstruction.

1 Guidance is needed on the optimal treatment of duodenal obstruction in people with
2 pancreatic cancer.

3 9.2.1.1 Review protocol summary

4 The review protocol summary used for this question can be found in Table 111. Full details of
5 the review protocol can be found in Appendix C.

6 **Table 111: Clinical review protocol summary for the review of optimal treatment of**
7 **duodenal obstruction**

Population	<ul style="list-style-type: none"> • Patients with duodenal obstruction • Resectable pancreatic cancer • Borderline resectable pancreatic cancer • Unresectable or metastatic pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Duodenal stent placement • Gastric/duodenal bypass surgery (gastrojejunostomy [GJJ]) • Venting gastrostomy • Resectional surgery
Comparison	<ul style="list-style-type: none"> • Each Other • Pharmacological management • Best supportive care
Outcome	<ul style="list-style-type: none"> • Relief of obstruction • Change in symptoms • Nutritional status • Adverse events • Overall Survival • Health-related Quality of Life • Patient experience • PROMS

8 9.2.2 Description of Clinical Evidence

9 Six studies –2 RCTs (Lillemoe et al. 1999; Van Heek et al. 2004) from a recent Cochrane
10 review (Gurusamy et al. 2013), and an additional 4 RCTs (Okuwaki et al. 2016; Jeurnink et
11 al. 2010; Mehta et al. 2006; Shyr et al. 1997) were included in the evidence review. All the
12 studies were in adults. A summary of the included studies is presented in Table 112.

13 Two RCTs (n=157) from a Cochrane review (Gurusamy et al. 2013) that compared
14 prophylactic gastrojejunostomy (GJJ) combined with hepaticojejunostomy with
15 hepaticojejunostomy only in patients with unresectable pancreatic cancer were included
16 (Lillemoe et al. 1999; Van Heek et al. 2004).

17 Two RCTs (n=66) were found that compared laparoscopic GJJ with duodenal stenting as a
18 means of palliating malignant gastric outflow obstruction in patients with pancreatic cancer
19 (Jeurnink et al. 2010; Mehta et al. 2006). The sample in Metha et al. (2006) had only 56%
20 pancreatic cancer patients and was thus downgraded for indirectness.

21 One RCT (n=45) was found that compared three types of GJJ for duodenal obstruction in
22 patients with unresectable periampullary cancer (Shyr et al, 1997). Although the sample had
23 only 51% pancreatic cancer patients, the study was included and downgraded for
24 indirectness. The three types of GJJ differed according to the site of jejunum for the GJJ and
25 the partition of duodenum: Type 1 (GJJ proximal to the Jejunal limb: Ligament of Treitz),
26 Type 2 (Pylorus) and Type 3 (GJJ proximal to Roux-limb Jejunum).

1 One RCT (n=34) was found that compared two types of duodenal stents (WallFlex™
2 duodenal stent [W-group] and Niti-S™ pyloric/duodenal D-type stent) with different axial
3 forces for alleviating duodenal obstruction in patients with pancreatobiliary cancer (Okuwaki
4 et al. 2016). The sample in this study was 74% pancreatic cancer patients.

5 Further information about the search strategy can be found in Appendix D. See study
6 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
7 study evidence tables in Appendix F and list of excluded studies in Appendix G.

8

9

1 **9.2.3 Summary of included studies**

2 A summary of the studies that were included in this review are presented in Table 112.

3 **Table 112: Summary of included studies**

Study	Design	Population	Intervention	Comparison	Outcomes
Gurusamy et al. 2013	Systematic review with meta-analysis (Cochrane review) Searches up to August 2012	Two RCTs from this review were included: Lillemoe et al., 1999 N=87 unresectable pancreatic cancer patients + gastric outlet obstruction Van Heek 2003 N=70 unresectable pancreatic cancer patients + gastric outlet obstruction	Routine prophylactic gastrojejunostomy (open or laparoscopic)	No prophylactic gastrojejunostomy	Relief of obstruction (gastric outlet obstruction) Adverse effects (Peri-operative morbidity) Overall Survival Health-related Quality of Life
Jeurnink et al. 2010	Multicentre non-blinded RCT	N=39 pancreatic cancer patients + gastric outlet obstruction	Gastrojejunostomy (open or laparoscopic and either antecolic or retrocolic)	Duodenal stent placement (Enteral Wallstent)	Relief of obstruction Change in symptoms Nutritional status Adverse events
Metha et al. 2006	Single centre non-blinded RCT	N=27 patients with malignant gastric outflow obstruction (56% pancreatic cancer)	Laparoscopic gastrojejunostomy	Duodenal stent placement (Enteral Wallstent)	Overall Survival Health-related Quality of Life PROMS
Okuwaki et al. 2016	Single centre non-blinded RCT	N=34 patients with pancreatobiliary cancer (74% pancreatic cancer) + duodenal obstruction	WallFlex™ duodenal uncovered SEMS	Niti-S™ pyloric/duodenal D-type uncovered SEMS	Relief of obstruction Change in symptoms Nutritional status Adverse events Overall Survival

Study	Design	Population	Intervention	Comparison	Outcomes
Shyr et al. 1997	Single centre non-blinded RCT	N=45 with unresectable periampullary cancer (51% pancreatic cancer) + gastric outlet obstruction	Type I Gastrojejunostomy proximal to the Jejunal limb: Ligament of Treitz	Type II Gastrojejunostomy beyond pylorus Type III Gastrojejunostomy proximal to Roux-limb Jejunum	Change in symptoms Nutritional status

Source/Note: SEMS, self-expanding metal stent

1
2
3

1 9.2.4 Clinical evidence profile

2 The clinical evidence profiles for this review question are presented in Table 113 to Table
3 118.

4 **Table 113: Summary clinical evidence profile for prophylactic gastrojejunostomy (GJJ)**
5 **and hepaticojejunostomy versus hepaticojejunostomy only in adults with**
6 **unresectable pancreatic cancer and gastric outlet obstruction**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	HJJ only	Prophylactic GJJ + HJJ				
Relief of obstruction (Gastric outlet obstruction) Follow-up: 1 months	278 per 1000	31 per 1000 (8 to 111)	RR 0.11 (0.03 to 0.4)	152 (2 studies ¹)	⊕⊕⊕⊖ low ²	
Adverse events (Perioperative morbidity) - Perioperative mortality Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 2.43 (0.1 to 57.57)	152 (2 studies ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse events (Perioperative morbidity) - Cholangitis Follow-up: 1 months	47 per 1000	91 per 1000 (18 to 471)	RR 1.95 (0.38 to 10.12)	87 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3,4}	
Adverse events (Perioperative morbidity) - Bile leak Follow-up: 1 months	42 per 1000	51 per 1000 (12 to 222)	RR 1.23 (0.28 to 5.34)	152 (2 studies ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse events (Perioperative morbidity) - Gastroenteral leak Follow-up: 1 months	14 per 1000	11 per 1000 (1 to 171)	RR 0.81 (0.05 to 12.33)	152 (2 studies ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse events (Perioperative morbidity) - Delayed gastric emptying Follow-up: 1 months	28 per 1000	75 per 1000 (14 to 391)	RR 2.71 (0.52 to 14.08)	152 (2 studies ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse events (Perioperative morbidity) - Wound infection	14 per 1000	43 per 1000 (7 to 255)	RR 3.09 (0.52 to 18.36)	152 (2 studies ¹)	⊕⊖⊖⊖ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	HJJ only	Prophylactic GJJ + HJJ				
Follow-up: 1 months						
Adverse events (Perioperative morbidity) - Chest complications Follow-up: 1 months	56 per 1000	24 per 1000 (4 to 131)	RR 0.44 (0.08 to 2.35)	152 (2 studies ²)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse events (Perioperative morbidity) - Cardiac complications Follow-up: 1 months	69 per 1000	111 per 1000 (22 to 565)	RR 1.61 (0.32 to 8.19)	65 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Overall survival	403 per 1000	409 per 1000 (351 to 475)	HR 1.02 (0.84 to 1.25)	152 (2 studies)	⊕⊕⊕⊕ low ^{2,5}	
Health Related Quality of Life (EORTC QoL) EORTC	See comment	See comment	No data reported	65 (1 study ⁴)	⊕⊕⊕⊕ low ⁴	No sig. diff. in QoL at any time point
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio; QoL: Quality of Life</p> <p>1 Lillemoe et al. 1999, Van Heek et al. 2003 2 Potential risk of performance bias (no blinding of outcome assessors) in both RCTs. Van Heek et al. 2003 also had incomplete data (3 patients lost to follow up) and potential selective reporting of outcomes (no data provided for quality of life outcomes). 3 95% CI crosses 2 default MIDs (0.8 and 1.25). 4 van Heek et al. 2003 5 The committee decided to downgrade survival outcomes by one level if the difference in survival was not statistically significant.</p>						

1
2

Table 114: Summary clinical evidence profile for GJJ versus duodenal stent placement in adults with pancreatic cancer and gastric outlet obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent placement	GJJ				
Relief of obstruction (Days with GOOSS score >= 2 after	See comment	See comment	Not estimable	39 (1 study ¹)	⊕⊕⊕⊕ low ²	Food intake improved in a long term period after GJJ (median

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent placement	GJJ				
intervention - median)						72[GJJ] vs. 50[Stent] days, P = 0.05).
Change in symptoms - Persistent obstructive symptoms - Persistent obstructive symptoms	143 per 1000	167 per 1000 (39 to 726)	RR 1.17 (0.27 to 5.08)	39 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Change in symptoms - Persistent obstructive symptoms - Recurrent obstructive symptoms	238 per 1000	55 per 1000 (7 to 433)	RR 0.23 (0.03 to 1.82)	39 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Nutritional status - Days to restore ability to eat (median)	See comment	See comment	Not estimable	39 (1 study ¹)	⊕⊕⊕⊕ low ²	Food intake improved more rapidly after stent placement (median 8[GJJ] vs. 5[Stent] days, P < 0.01).
Adverse events - Minor complications	190 per 1000	278 per 1000 (88 to 882)	RR 1.46 (0.46 to 4.63)	39 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse events - Major complications	190 per 1000	25 per 1000 (2 to 427)	RR 0.13 (0.01 to 2.24)	39 (1 study ^{1,4})	⊕⊕⊕⊕ very low ^{2,3}	
Overall survival	400 per 1000	340 per 1000 (130 to 711)	HR 0.81 (0.27 to 2.44)	27 (1 study ⁵)	⊕⊕⊕⊕ very low ^{2,6,7}	
Health Related Quality of Life: SF-36 - Physical Health score Follow-up: 1 months	The mean health related quality of life: sf-36 - physical health score in the control groups	The mean health related quality of life: sf-36 - physical health score in the intervention groups was 7.9 lower (22.74 lower to 6.94 higher)		25 (1 study ⁵)	⊕⊕⊕⊕ very low ^{2,6,8,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent placement	GJJ				
	was 41.2					
Health Related Quality of Life: SF-36 - Mental Health score Follow-up: 1 months	The mean health related quality of life: sf-36 - mental health score in the control groups was 45	The mean health related quality of life: sf-36 - mental health score in the intervention groups was 0.7 higher (18.29 lower to 19.69 higher)		25 (1 study ⁵)	⊕⊕⊕⊕ very low ^{2,6,8,9}	
PROMS - Self-report Pain (Visual Analog Scale) Follow-up: 1 months	The mean proms - self-report pain (visual analogue scale) in the control groups was 2.4	The mean proms - self-report pain (visual analogue scale) in the intervention groups was 2 higher (0.36 lower to 4.36 higher)		25 (1 study ⁵)	⊕⊕⊕⊕ very low ^{2,6,8,10}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Jeurnink et al. 2010

2 The quality of the evidence was downgraded because of the unclear risk of selection bias and the potential risk of performance bias (no blinding of outcome assessors).

3 95% CI crosses 2 default MID (0.8 and 1.25).

4 Follow-up not clear.

5 Metha et al. 2006

6 Metha et al. 2006 sample had less than 66% pancreatic cancer patients.

7 The committee decided to downgrade survival outcomes by one level for imprecision only if the difference in survival was statistically significant.

8 MIDs for SF-36 subscales and pain score were calculated as +/- 0.5 SD of control arm at baseline and were as follows: +/- 6.41 for physical health subscale; +/- 11.78 for mental health subscale; +/- 1.39 for pain score.

9 95% CI crosses 2 MIDs for this outcome.

10 95% CI crosses 1 MID for this outcome.

1
2
3

Table 115: Summary clinical evidence profile for Type I GJJ (proximal to the Jejunal limb: Ligament of Treitz) versus Type II GJJ (Pylorus) in adults with pancreatic cancer and gastric outlet obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Type II GJJ Pylorus	Type I GJJ proximal to the Jejunal limb: Ligament of Treitz				
Change in symptoms - GOO overall GOO Follow-up: 1 months	133 per 1000	467 per 1000 (115 to 1000)	RR 3.5 (0.86 to 14.18)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Change in symptoms (GOO) - Anorexia GOO Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 3 (0.13 to 68.26)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Change in symptoms (GOO) - Epigastric fullness GOO Follow-up: 1 months	67 per 1000	133 per 1000 (13 to 1000)	RR 2 (0.2 to 19.78)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Change in symptoms (GOO) - Nausea GOO Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 3 (0.13 to 68.26)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Change in symptoms (GOO) - Vomiting GOO Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 7 (0.39 to 124.83)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Nutritional status - Gastric emptying time Follow-up: 1 months	The mean nutritional status - gastric emptying time in the control groups was 118.1 min	The mean nutritional status - gastric emptying time in the intervention groups was 40.8 higher (67.85 lower to 149.45 higher)		30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,6,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Type II GJJ Pylorus	Type I GJJ proximal to the Jejunal limb: Ligament of Treitz				
Nutritional status - Patients with delayed gastric emptying Follow-up: 10 days	67 per 1000	200 per 1000 (23 to 1000)	RR 3 (0.35 to 25.68)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2}	

**The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: Confidence interval; RR: Risk ratio;

1 Quality of evidence was downgraded by 1 point owing to unclear risk of performance bias and unclear selective reporting
2 Sample had <66% pancreatic cancer patients.
3 95% CI crosses 1 default MID (0.8 or 1.25).
4 Shyr et al. 1997
5 95% CI crosses 2 default MIDs (0.8 and 1.25).
6 MIDs for nutritional status (gastric emptying time) were calculated as +/- SD of control group immediately after resumption of oral diet and was +/- 75.91 min.
7 95% CI crosses 1 MID for this outcome.

1
2
3

Table 116: Summary clinical evidence profile for Type I GJJ (proximal to the Jejunal limb: Ligament of Treitz) versus Type III GJJ (proximal to Roux-limb Jejunum) in adults with pancreatic cancer and gastric outlet obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Type III GJJ proximal to Roux-limb Jejunum	Type I GJJ proximal to the Jejunal limb: Ligament of Treitz				
Change in symptoms - GOO overall Follow-up: 1 months	133 per 1000	467 per 1000 (115 to 1000)	RR 3.5 (0.86 to 14.18)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
Change in symptoms (GOO) - Anorexia GOO	67 per 1000	67 per 1000 (5 to 970)	RR 1 (0.07 to 14.55)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Change in symptoms (GOO) - Epigastric	67 per 1000	133 per 1000 (13 to 1000)	RR 2 (0.2 to 19.78)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
fullness GOO Follow-up: 1 months						
Change in symptoms (GOO) - Nausea GOO Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 3 (0.13 to 68.26)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Change in symptoms (GOO) - Vomiting GOO Follow-up: 1 months	0 per 1000	0 per 1000 (0 to 0)	RR 7 (0.39 to 124.83)	30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,5}	
Nutritional status - Gastric emptying time Follow-up: 1 months	The mean nutritional status - gastric emptying time in the control groups was 245.3 min	The mean nutritional status - gastric emptying time in the intervention groups was 86.4 lower (192.05 lower to 19.25 higher)		30 (1 study ⁴)	⊕⊕⊕⊕ very low ^{1,2,6,7}	
Nutritional status - Patients with delayed gastric emptying Follow-up: 10 days	67 per 1000	200 per 1000 (23 to 1000)	RR 3 (0.35 to 25.68)	30 (1 study)	⊕⊕⊕⊕ very low ^{1,2,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Quality of evidence was downgraded by 1 point owing to unclear risk of performance bias and unclear selective reporting

2 Sample had <66% pancreatic cancer patients.

3 95% CI crosses 1 default MID (0.8 or 1.25).

4 Shyr et al. 1997

5 95% CI crosses 2 default MIDs (0.8 and 1.25).

6 MIDs for nutritional status (gastric emptying time) were calculated as +/- SD of control group immediately after resumption of oral diet and was +/- 71.65 min.

7 95% CI crosses 1 MID for this outcome.

1
2
3

Table 117: Summary clinical evidence profile for Type II GJJ (Pylorus) versus Type III GJJ (proximal to Roux-limb Jejunum) in adults with pancreatic cancer and gastric outlet obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Type III GJJ proximal to Roux-limb Jejunum	Type II GJJ Pylorus				
Change in symptoms - GOO overall GOO Follow-up: 1 months	133 per 1000	67 per 1000 (7 to 659)	RR 0.5 (0.05 to 4.94)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	
Change in symptoms (GOO) - Anorexia Follow-up: 1 months	See comment	See comment	Not estimable	30 (1 study ¹)	⊕⊕⊕⊕ low ^{2,3}	There were no events in either group
Change in symptoms (GOO) - Epigastric fullness GOO Follow-up: 1 months	67 per 1000	67 per 1000 (5 to 970)	RR 1 (0.07 to 14.55)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Change in symptoms (GOO) - Nausea GOO Follow-up: 1 months	67 per 1000	22 per 1000 (1 to 505)	RR 0.33 (0.01 to 7.58)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Change in symptoms (GOO) - Vomiting GOO Follow-up: 1 months	See comment	See comment	Not estimable	30 (1 study ¹)	⊕⊕⊕⊕ low ^{2,3}	There were no events in either group
Nutritional status - Gastric emptying time Follow-up: 1 months	The mean nutritional status - gastric emptying time in the control groups was 245.3 min	The mean nutritional status - gastric emptying time in the intervention groups was 127.2 lower (232.85 to 21.55 lower)		30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,5,6}	
Nutritional status - Patients	67 per 1000	67 per 1000 (5 to 970)	RR 1 (0.07 to 14.55)	30 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Type III GJJ proximal to Roux-limb Jejunum	Type II GJJ Pylorus				
with delayed gastric emptying Follow-up: 10 days						
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio;</p> <p>1 Shyr et al. 1997 2 Quality of evidence was downgraded by 1 point owing to unclear risk of performance bias and unclear selective reporting 3 Sample had <66% pancreatic cancer patients. 4 95% CI crosses 2 default MIDs (0.8 and 1.25). 5 MIDs for nutritional status (gastric emptying time) were calculated as +/- SD of control group immediately after resumption of oral diet and was +/- 71.65 min. 6 95% CI crosses 1 MID for this outcome.</p>						

1
2

Table 118: Summary clinical evidence profile for duodenal stent-1 versus duodenal stent-2 in adults with pancreatic cancer and duodenal obstruction

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent-2 (Niti-S)	Duodenal stent-1 (WallFlex)				
Relief of obstruction - Mean change in GOO score at 2 weeks	The mean relief of obstruction - mean change in goo score at 2 weeks in the control groups was 1.5 GOO score	The mean relief of obstruction - mean change in goo score at 2 weeks in the intervention groups was 0.37 standard deviations higher (0.34 lower to 1.09 higher)		31 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3,4}	
Relief of obstruction - GOO recurrence Follow-up: 2 weeks	235 per 1000	285 per 1000 (87 to 941)	RR 1.21 (0.37 to 4)	31 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,5}	
Change in symptoms - Mean change	The mean change in symptoms -	The mean change in symptoms -		31 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent-2 (Niti-S)	Duodenal stent-1 (WallFlex)				
in NVSS score	mean change in NVSS score in the control groups was -1.9 NVSS score	mean change in NVSS score in the intervention groups was 0.28 standard deviations higher (0.43 lower to 0.99 higher)				
Nutritional status- Mean change in BMI at 4 weeks	The mean nutritional status- mean change in BMI at 4 weeks in the control groups was 0.1 kg/m ²	The mean nutritional status- mean change in BMI at 4 weeks in the intervention groups was 0.3 lower (1.22 lower to 0.62 higher)		30 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Adverse events (procedure-related) Follow-up: 30 days	235 per 1000	285 per 1000 (87 to 941)	RR 1.21 (0.37 to 4)	31 (1 study ¹)	⊕⊖⊖⊖ very low ^{1,5}	
HRQL - Mean change in Karnofsky performance score at 2 weeks	The mean HRQL - mean change in Karnofsky performance score at 2 weeks in the control groups was 9 KPS score	The mean HRQL - mean change in Karnofsky performance score at 2 weeks in the intervention groups was 5.2 higher (5.47 lower to 15.87 higher)		27 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3,6}	
HRQL - Mean change in Performance score at 2 weeks	The mean HRQL - mean change in performance score at 2 weeks in the control groups was -0.5	The mean HRQL - mean change in performance score at 2 weeks in the intervention groups was 0.1 lower (0.69 lower to 0.49 higher)		31 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3,6}	
Overall survival	-	-	HR 0.53 (0.26 to 1.08)	31 (1 study ¹)	⊕⊕⊖⊖ low ^{2,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Duodenal stent-2 (Niti-S)	Duodenal stent-1 (WallFlex)				

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Okuwaki et al. 2016

2 Unclear randomisation method and whether blinded.

3 MIDs for change in BMI, change in Karnofsky Performance Score and change in Performance Score were calculated as +/- 0.5 SD of control arm at baseline and were as follows: +/- 1.4 kg/m² for change in BMI, +/- 9.5 for Karnofsky Performance Score, and +/- 0.55 for Performance Score. MIDs for change in GOO score and change in NVSS score were assumed to be the default MIDs for continuous outcomes expressed as an SMD (i.e. +/- 0.5) due to insufficient baseline data.

4 95% CI crosses 1 default MID for SMDs (0.5 or -0.5).

5 95% CI crosses 2 default MIDs (0.8 and 1.25).

6 95% CI crosses 1 MID for this outcome.

7 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

1 9.2.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 9.2.6 Evidence Statements

8 9.2.6.1 Prophylactic GJJ and hepaticojejunostomy versus hepaticojejunostomy only

9 Relief of obstruction

10 Low quality evidence from 2 RCTs (n=152) showed that there is a clinically important
11 difference favouring prophylactic gastrojejunostomy combined with hepaticojejunostomy on
12 relief of obstruction compared to hepaticojejunostomy only in adults with unresectable
13 pancreatic cancer and gastric outlet obstruction: RR 0.11 (95% CI 0.03-0.4).

14 Change in symptoms

15 No evidence was identified to inform this outcome.

16 Nutritional status

17 No evidence was identified to inform this outcome.

18 Adverse events

19 Low quality evidence from 2 RCTs (n=152) showed no clinically important difference
20 between prophylactic gastrojejunostomy combined with hepaticojejunostomy and
21 hepaticojejunostomy only on peri-operative mortality (RR 2.43 [95% CI 0.1-57.57]), bile leak
22 (RR 1.23 [95% CI 0.28-5.34]), gastrointestinal leak (RR 0.81 [95% CI 0.05-12.33]), delayed

1 gastric emptying (RR 2.71 [95% CI 0.52-14.08]), wound infection (RR 3.09 [95% CI 0.52-
2 18.36]), and chest complications (RR 0.44 [95% CI 0.08-2.35]) in adults with unresectable
3 pancreatic cancer and gastric outlet obstruction.

4 Very low quality evidence from 1 RCT (n=87) showed no clinically important difference
5 between prophylactic gastrojejunostomy combined with hepaticojejunostomy and
6 hepaticojejunostomy only on cholangitis in adults with unresectable pancreatic cancer and
7 gastric outlet obstruction: RR 1.95 (95% CI 0.38-10.12).

8 Very low quality evidence from 1 RCT (n=65) showed no clinically important difference
9 between prophylactic gastrojejunostomy combined with hepaticojejunostomy and
10 hepaticojejunostomy only on cardiac complications in adults with unresectable pancreatic
11 cancer and gastric outlet obstruction: RR 1.61 (95% CI 0.32-8.19).

12 **Overall survival**

13 Low quality evidence from 2 RCTs (n=152) showed no clinically important difference
14 between prophylactic gastrojejunostomy combined with hepaticojejunostomy and
15 hepaticojejunostomy only on overall survival in adults with unresectable pancreatic cancer
16 and gastric outlet obstruction: HR 1.02 (95% CI 0.84-1.25).

17 **Health-related quality of life**

18 Low quality evidence from 1 RCT (n=65) reported no statistically significant difference
19 between prophylactic gastrojejunostomy combined with hepaticojejunostomy and
20 hepaticojejunostomy only on EORTC quality of life at any time point in adults with
21 unresectable pancreatic cancer and gastric outlet obstruction (no data reported).

22 **Patient experience**

23 No evidence was identified to inform this outcome.

24 **PROMS**

25 No evidence was identified to inform this outcome.

26 **9.2.6.2 GJJ versus duodenal stent placement**

27 **Relief of obstruction**

28 Low quality evidence from 1 RCT (n=39) reported a statistically significant difference
29 favouring duodenal stent placement on the number of days with a Gastric Outlet Obstruction
30 Scoring System score of 2 or more compared to gastrojejunostomy (median 72 days vs 50
31 days, p=0.05) in adults with pancreatic cancer and gastric outlet obstruction.

32 Very low quality evidence from 1 RCT (n=39) showed no clinically important difference
33 between gastrojejunostomy and duodenal stent placement on either persistent obstructive
34 symptoms (RR 1.17 [95% CI 0.27-1.72]) or recurrent obstructive symptoms (RR 0.23 [95%
35 CI 0.03-1.82]) in adults with pancreatic cancer and gastric outlet obstruction.

36 **Change in symptoms**

37 No evidence was identified to inform this outcome.

38 **Nutritional status**

39 Low quality evidence from 1 RCT (n=39) reported a statistically significant difference
40 favouring duodenal stent placement on the number of days to restore the ability to eat
41 compared to gastrojejunostomy (median 8 days vs 5 days, p<0.01) in adults with pancreatic
42 cancer and gastric outlet obstruction.

1 **Adverse events**

2 Very low quality evidence from 1 RCT (n=39) showed no clinically important difference
3 between gastrojejunostomy and duodenal stent placement on either major complications (RR
4 0.13 [95% CI 0.01-2.24]) or minor complications (RR 1.46 [95% CI 0.46-4.63]) in adults with
5 pancreatic cancer and gastric outlet obstruction.

6 **Overall survival**

7 Very low quality evidence from 1 RCT (n=27) showed no clinically important difference
8 between gastrojejunostomy and duodenal stent placement on overall survival in adults with
9 pancreatic cancer and gastric outlet obstruction: HR 0.81 (95% CI 0.27-2.44).

10 **Health-related quality of life**

11 Very low quality evidence from 1 RCT (n=25) showed no clinically important difference
12 between gastrojejunostomy and duodenal stent placement on either the SF-36 physical
13 health (MD -7.9 [95% CI -22.74 to 6.94]) or mental health (MD 0.7 [95% CI -18.29 to 19.69])
14 subscales in adults with pancreatic cancer and gastric outlet obstruction.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **PROMS**

18 Very low quality evidence from 1 RCT (n=25) showed no clinically important difference
19 between gastrojejunostomy and duodenal stent placement on self-reported pain visual
20 analogue scale in adults with pancreatic cancer and gastric outlet obstruction: MD 2.0 (95%
21 CI -0.36 to 4.36).

22 **9.2.6.3 Types of gastrojejunostomy**

23 **9.2.6.3.1 Type I GJJ (proximal to the Jejunal limb: Ligament of Treitz) versus Type II GJJ**
24 **(Pylorus)**

25 **Relief of obstruction**

26 No evidence was identified to inform this outcome.

27 **Change in symptoms**

28 Very low quality evidence from 1 RCT (n=30) showed that there may be a clinically important
29 difference favouring Type I gastrojejunostomy (proximal to the Jejunal limb: Ligament of
30 Treitz) on change in clinical symptoms as assessed by the Gastric Outlet Obstruction
31 Scoring System compared to Type II gastrojejunostomy (Pylorus) in adults with pancreatic
32 cancer and gastric outlet obstruction, although there is some uncertainty: RR 3.5 (95% CI
33 0.86-14.18).

34 Very low quality evidence showed no clinically important difference between Type I
35 gastrojejunostomy (proximal to the Jejunal limb: Ligament of Treitz) and Type II
36 gastrojejunostomy (Pylorus) on change in symptoms of anorexia (RR 3.0 [95% CI 0.13-
37 68.26]), epigastric fullness (RR 2.0 [95% CI 0.2-19.78]), nausea (RR 3.0 [95% CI 0.13-
38 68.26]) and vomiting (RR 7.0 [95% CI 0.39-124.83]) as assessed by the Gastric Outlet
39 Obstruction Scoring System in adults with pancreatic cancer and gastric outlet obstruction.

40 **Nutritional status**

41 Very low quality evidence from 1 RCT (n=30) showed no clinically important difference
42 between Type I gastrojejunostomy (proximal to the Jejunal limb: Ligament of Treitz) and
43 Type II gastrojejunostomy (Pylorus) on either minutes to gastric emptying (MD 40.8 [95% CI -

1 67.85 to 149.45]) or the number of patients with delayed gastric emptying (RR 3.0 [95% CI
2 0.35-25.68]) in adults with pancreatic cancer and gastric outlet obstruction.

3 **Adverse events**

4 No evidence was identified to inform this outcome.

5 **Overall survival**

6 No evidence was identified to inform this outcome.

7 **Health-related quality of life**

8 No evidence was identified to inform this outcome.

9 **Patient experience**

10 No evidence was identified to inform this outcome.

11 **PROMS**

12 No evidence was identified to inform this outcome.

139.2.6.3.2 **Type I GJJ (proximal to the Jejunal limb: Ligament of Treitz) versus Type III GJJ
14 (proximal to Roux-limb Jejunum)**

15 **Relief of obstruction**

16 No evidence was identified to inform this outcome.

17 **Change in symptoms**

18 Very low quality evidence from 1 RCT (n=30) showed that there may be a clinically important
19 difference favouring Type I gastrojejunostomy (proximal to the Jejunal limb: Ligament of
20 Treitz) on change in clinical symptoms as assessed by the Gastric Outlet Obstruction
21 Scoring System compared to Type III gastrojejunostomy (proximal to Roux-limb Jejunum) in
22 adults with pancreatic cancer and gastric outlet obstruction, although there is some
23 uncertainty: RR 3.5 (95% CI 0.86-14.18).

24 Very low quality evidence showed no clinically important difference between Type I
25 gastrojejunostomy (proximal to the Jejunal limb: Ligament of Treitz) and Type III
26 gastrojejunostomy (proximal to Roux-limb Jejunum) on change in symptoms of anorexia (RR
27 1.0 [95% CI 0.07-14.55]), epigastric fullness (RR 2.0 [95% CI 0.2-19.78]), nausea (RR 3.0
28 [95% CI 0.13-68.26]) and vomiting (RR 7.0 [95% CI 0.39-124.83]) as assessed by the
29 Gastric Outlet Obstruction Scoring System in adults with pancreatic cancer and gastric outlet
30 obstruction.

31 **Nutritional status**

32 Very low quality evidence from 1 RCT (n=30) showed no clinically important difference
33 between Type I gastrojejunostomy (proximal to the Jejunal limb: Ligament of Treitz) and
34 Type III gastrojejunostomy (proximal to Roux-limb Jejunum) on either minutes to gastric
35 emptying (MD -86.4 [95% CI -192.05 to 19.25]) or the number of patients with delayed
36 gastric emptying (RR 3.0 [95% CI 0.35-25.68]) in adults with pancreatic cancer and gastric
37 outlet obstruction.

38 **Adverse events**

39 No evidence was identified to inform this outcome.

40 **Overall survival**

1 No evidence was identified to inform this outcome.

2 **Health-related quality of life**

3 No evidence was identified to inform this outcome.

4 **Patient experience**

5 No evidence was identified to inform this outcome.

6 **PROMS**

7 No evidence was identified to inform this outcome.

8 **89.2.6.3.3 Type II GJJ (Pylorus) versus Type III GJJ (proximal to Roux-limb Jejunum)**

9 **Relief of obstruction**

10 No evidence was identified to inform this outcome.

11 **Change in symptoms**

12 Very low quality evidence from 1 RCT (n=30) showed no clinically important difference
13 between Type II gastrojejunostomy (Pylorus) and Type III gastrojejunostomy (proximal to
14 Roux-limb Jejunum) on change in clinical symptoms as assessed by the Gastric Outlet
15 Obstruction Scoring System in adults with pancreatic cancer and gastric outlet obstruction:
16 RR 0.5 (95% CI 0.05-4.94).

17 Very low quality evidence showed no clinically important difference between Type II
18 gastrojejunostomy (Pylorus) and Type III gastrojejunostomy (proximal to Roux-limb Jejunum)
19 on change in symptoms of epigastric fullness (RR 1.0 [95% CI 0.07-14.55]), and nausea (RR
20 0.33 [95% CI 0.01-7.58]) as assessed by the Gastric Outlet Obstruction Scoring System in
21 adults with pancreatic cancer and gastric outlet obstruction. (There were also no events on
22 symptoms of anorexia and vomiting.)

23 **Nutritional status**

24 Very low quality evidence from 1 RCT (n=30) showed that there is a clinically important
25 difference favouring Type II gastrojejunostomy (Pylorus) on minutes to gastric emptying
26 compared to Type III gastrojejunostomy (proximal to Roux-limb Jejunum) in adults with
27 pancreatic cancer and gastric outlet obstruction: MD -127.2 (95% CI -232.85 to -21.55).

28 Very low quality evidence showed no clinically important difference between Type II
29 gastrojejunostomy (Pylorus) and Type III gastrojejunostomy (proximal to Roux-limb Jejunum)
30 on the number of patients with delayed gastric emptying in adults with pancreatic cancer and
31 gastric outlet obstruction: RR 1.0 (95% CI 0.07-14.55).

32 **Adverse events**

33 No evidence was identified to inform this outcome.

34 **Overall survival**

35 No evidence was identified to inform this outcome.

36 **Health-related quality of life**

37 No evidence was identified to inform this outcome.

38 **Patient experience**

39 No evidence was identified to inform this outcome.

1 **PROMS**

2 No evidence was identified to inform this outcome.

3 **9.2.6.4 Duodenal stent-1 versus duodenal stent-2**

4 **Relief of obstruction**

5 Very low quality evidence from 1 RCT (n=31) showed no clinically important difference
6 between WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on the
7 number of people who had recurrence of obstruction as assessed by the Gastric Outlet
8 Obstruction Scoring System at 2 weeks in adults with pancreatic cancer and duodenal
9 obstruction: RR 1.21 (95% CI 0.37-4.0).

10 **Change in symptoms**

11 Low quality evidence from 1 RCT (n=31) showed no clinically important difference between
12 WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on mean change on
13 the Gastric Outlet Obstruction Scoring System at 2 weeks in adults with pancreatic cancer
14 and duodenal obstruction: SMD 0.37 (95% CI -0.34 to 1.09).

15 **Nutritional status**

16 Moderate quality evidence from 1 RCT (n=31) showed no clinically important difference
17 between WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on mean
18 change on BMI at 4 weeks, in adults with pancreatic cancer and duodenal obstruction: MD -
19 0.3 (95% CI -1.22 to 0.62).

20 **Adverse events**

21 Low to very low quality evidence from 1 RCT (n=31) showed no clinically important difference
22 between WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on either
23 mean change in Nausea and Vomiting Scoring System score (SMD 0.28 [95% CI -0.43 to
24 0.99]) or the number of procedure-related adverse events (RR 1.21 [95% CI 0.37-4.0]) in
25 adults with pancreatic cancer and duodenal obstruction.

26 **Overall survival**

27 Low quality evidence from 1 RCT (n=31) showed no clinically important difference between
28 WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on overall survival in
29 adults with pancreatic cancer and duodenal obstruction: HR 0.52 (95% CI 0.26-1.08).

30 **Health-related quality of life**

31 Low quality evidence from 1 RCT (n=31) showed no clinically important difference at 2 weeks
32 between WallFlex™ duodenal stents and Niti-S™ pyloric/duodenal D-type stents on either
33 mean change in Karnofsky Performance Score (MD 5.2 [95% Ci -5.47 to 15.87]) or mean
34 change in Performance Score (MD -0.1 [95% CI -0.69 to 0.49]) in adults with pancreatic
35 cancer and duodenal obstruction

36 **Patient experience**

37 No evidence was identified to inform this outcome.

38 **PROMS**

39 No evidence was identified to inform this outcome.

1 **9.2.7 Recommendations**

2 **38. During attempted resection for head of pancreas cancer, consider prophylactic**
3 **gastrojejunostomy if the cancer is found to be unresectable.**

4 **39. If possible, relieve symptomatic duodenal obstruction caused by unresectable**
5 **pancreatic cancer.**

6 **40. When deciding between gastrojejunostomy and duodenal stent placement,**
7 **consider gastrojejunostomy for people with a more favourable prognosis.**

8 **9.2.8 Evidence to recommendations**

9 **9.2.8.1 Relative value placed on the outcomes considered**

10 Relief of obstruction, change in symptoms, nutritional status, adverse events, overall survival,
11 health-related quality of life, patient reported outcome measures and patient experience were
12 considered to be the critical outcomes for this question.

13 Adverse events, overall survival and health-related quality of life were reported for all
14 comparisons of interest except for gastrojejunostomy with duodenal partition versus other
15 gastrojejunostomy types. Change in symptoms and nutritional status were reported for all
16 comparisons of interest except prophylactic gastrojejunostomy versus no prophylactic
17 gastrojejunostomy.

18 Relief of obstruction was only reported for duodenal stent placement and the comparison of
19 prophylactic gastrojejunostomy with no prophylactic gastrojejunostomy. Patient reported
20 outcome measures was only reported for the comparison of gastrojejunostomy with duodenal
21 stent placement. Patient experience was not reported for any of the comparisons of interest.

22 The committee noted that the data on patient reported outcome measures looked at a self-
23 reported pain score. They agreed that it was not possible to determine whether the pain was
24 generated by the procedure or by the tumour itself, and consequently did not use this
25 outcome when making recommendations.

26 **9.2.8.2 Quality of evidence**

27 The quality of the evidence was assessed by GRADE and the Cochrane risk of bias
28 checklist. The evidence was either very low or low quality for all outcomes across all
29 comparisons of interest.

30 The committee noted that the study looking at gastrojejunostomy with duodenal partition
31 versus other gastrojejunostomy types was conducted in China. They considered that it had
32 limited relevance to the UK setting, particularly because it used a type of gastrojejunostomy
33 which is not done in the UK. The committee, therefore, agreed not to use the results of this
34 study when making their recommendations.

35 The committee agreed that the study comparing different types of stent for relieving duodenal
36 obstruction was not useful when making recommendations. This study was conducted in
37 Japan and so had limited relevance to the UK healthcare setting. In addition, the aim of the
38 study was to compare the effectiveness of two different types of stent. Given that there are
39 several other types of stent available, which the study did not investigate, the committee
40 agreed it would be difficult to draw robust conclusions as to which specific stent should be
41 used.

1 The committee noted that the studies comparing gastrojejunostomy with duodenal stent
2 placement had excluded people who were unfit for surgery. This is not representative of the
3 group of people who get duodenal obstruction.

4 No evidence was found on the effectiveness of venting gastrostomy or resectional surgery
5 for treating duodenal obstruction. Consequently, the committee did not make any
6 recommendations for clinical practice for these interventions. The committee agreed that
7 conducting further research in this area would not be practical because it would not be
8 feasible to randomise people to these interventions and, therefore, did not make any
9 research recommendations either.

10 The committee were not able to make any recommendations for people with resectable
11 pancreatic cancer who have duodenal obstruction as there was no evidence available on this
12 population.

13 **9.2.8.3 Consideration of clinical benefits and harms**

14 Due to the low quality evidence the committee was not able to make any strong
15 recommendations.

16 The committee agreed, based on their knowledge and experience, that it is very important to
17 relieve duodenal obstruction in people with unresectable pancreatic cancer. However they
18 also recognised that people with unresectable pancreatic cancer may have more extensive
19 disease, or may be too unwell for intervention, and this may make it difficult to relieve the
20 obstruction. They, therefore, agreed to recommend that the obstruction should be relieved if
21 possible.

22 The committee noted that the available evidence was of low quality and only covered some
23 of the interventions of interest which made it difficult to specify the most effective method to
24 relieve the obstruction. The evidence indicated a trend that stent placement was more
25 effective in the short term whilst gastrojejunostomy was more effective in the longer term.
26 This accorded with the committee's knowledge and experience that gastrojejunostomy is
27 normally done only in people likely to have longer overall survival because of the morbidity
28 associated with surgery. They, therefore, agreed to recommend both duodenal stents and
29 gastrojejunostomy as options for people with duodenal obstruction with gastrojejunostomy
30 being considered for people with a more favourable prognosis.

31 Based on the evidence, the committee noted that prophylactic gastrojejunostomy was
32 associated with less gastric outlet obstruction and no difference in the proportion of people
33 developing adverse events. The committee noted, based on their knowledge and experience,
34 that duodenal obstruction is a recognised complication of pancreatic cancer. It is associated
35 with significant co-morbidities and is known to have a detrimental effect on quality of life.
36 They, therefore, agreed that, in people with large tumours who were felt to be at risk of
37 duodenal obstruction who were otherwise fit and had a relatively good prognosis, the
38 prophylactic use of gastrojejunostomy could be considered.

39 The committee agreed that the potential benefits of the recommendations made would be
40 symptom relief by an appropriate technique and improved quality of life. The potential harms
41 of the recommendations made would be potential complications of surgery or stent insertion.
42 The committee agreed that the potential benefits for the person would outweigh the risk of
43 harm.

44 **9.2.8.4 Consideration of economic benefits and harms**

45 The committee noted that no relevant published economic evaluations had been identified
46 and no additional economic analysis had been undertaken in this area.

1 The committee noted that current practice is for people with duodenal obstruction to receive
2 a stent or a gastrojejunostomy. Both of these interventions are still options in the
3 recommendations. The committee considered that the costs of stent placement and
4 gastrojejunostomy are broadly similar. The stent insertion procedure is more expensive than
5 a gastrojejunostomy but the length of hospital stay is normally shorter for stent placement
6 and, therefore, associated with less cost than the hospital stay for a gastrojejunostomy.
7 Therefore, whilst it is possible that the balance between stent placement and
8 gastrojejunostomy may alter, the committee agreed this was unlikely to have a significant
9 resource impact. The committee also noted that the recommendation for prophylactic
10 gastrojejunostomy was unlikely to cause significant resource impact because the procedure
11 will be done at the same time as the resectional surgery.

12 **9.2.9 References**

- 13 Gurusamy KS, Kumar S, Davidson BR (2013) Prophylactic gastrojejunostomy for
14 unresectable periampullary carcinoma. *The Cochrane Database of Systematic Reviews* 2
- 15 Jeurnink SM, Polinder S, Steyerberg EW et al. (2010) Cost comparison of gastrojejunostomy
16 versus duodenal stent placement for malignant gastric outlet obstruction. *Journal of*
17 *Gastroenterology* 45(5): 537-43
- 18 Mehta S, Hindmarsh A, Cheong E, et al. (2006) Prospective randomized trial of laparoscopic
19 gastrojejunostomy versus duodenal stenting for malignant gastric outflow obstruction.
20 *Surgical Endoscopy and Other Interventional Techniques* 20(2): 239-42
- 21 Okuwaki K, Kida M, Yamauchi H et al. (2016) Randomized controlled exploratory study
22 comparing the usefulness of two types of metallic stents with different axial forces for the
23 management of duodenal obstruction caused by pancreatobiliary cancer. *Journal of Hepato-*
24 *biliary-pancreatic Sciences* 23(5): 289-97
- 25 Shyr YM, Su CH, King KL et al. (1997) Randomized trial of three types of gastrojejunostomy
26 in unresectable periampullary cancer. *Surgery* 121(5): 506-12

27 **9.2.9.1 Studies included in Gurusamy et al., 2013 (n=1)**

- 28 Lillemoe KD, Cameron JL, Hardacre JM et al. (1999) Is prophylactic gastrojejunostomy
29 indicated for unresectable periampullary cancer?: a prospective randomized trial. *Annals of*
30 *Surgery* 230(3): 322

31

32

10 Management of resectable and borderline resectable pancreatic cancer

10.1 Neoadjuvant treatment

Review question: Is neoadjuvant therapy for people with resectable and borderline resectable pancreatic adenocarcinoma an effective treatment?

10.1.1 Introduction

At best, only around 8% of people with pancreatic cancer are diagnosed early enough to undergo surgical resection of their cancer. However, the outcomes after surgery performed with curative intent are poor. Most people die from metastatic pancreatic cancer, which suggests that most people have disseminated disease before their primary surgery which is not identified by current staging investigations. An additional concern is that, while adjuvant therapy has been shown to improve survival rates, some people are unable to benefit from this treatment because of complications associated with the complex, major surgery involved in removing pancreatic cancer. There is therefore a theoretical justification for offering people non-surgical treatments in advance of primary surgery.

Neoadjuvant therapy aims to improve the success of surgery, increase the proportion of people able to access perioperative treatment, and ultimately improve overall survival from pancreatic cancer. Currently, there is uncertainty about the effectiveness of neoadjuvant therapy for pancreatic cancer, yet some centres offer such treatments routinely. The modalities being used as neoadjuvant treatment for resectable or borderline resectable disease include chemotherapy, radiotherapy, or combinations of these approaches.

Guidance is needed on whether there is a role for neoadjuvant therapy and if so, which type of neoadjuvant therapy is the most effective, compared with standard surgery for resectable and borderline resectable pancreatic cancer.

10.1.1.1 Review protocol summary

The review protocol summary used for this question can be found in Table 119. Full details of the review protocol can be found in Appendix C.

Table 119: Clinical review protocol summary for the review of effectiveness of neoadjuvant therapy

Population	Adults with <ul style="list-style-type: none"> • Resectable pancreatic cancer • Borderline resectable pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Chemotherapy + resectional Surgery • Radiotherapy (stereotactic) + resectional Surgery • Chemoradiotherapy + resectional Surgery • Sequential chemotherapy + chemoradiotherapy + resectional Surgery
Comparison	<ul style="list-style-type: none"> • Resectional surgery
Outcomes	<ul style="list-style-type: none"> • Response to neoadjuvant treatment pre-surgery • Disease-free interval • Relapse-free survival

- Overall Survival
- Resection rate
- Time from initiating treatment to Surgery
- Adverse Events
- Health Related Quality of Life
- Patient experience

1

2 10.1.2 Description of Clinical Evidence

3 Six studies were included in the evidence review: 2 systematic reviews (Festa et al. 2013, Liu
4 et al. 2016), (including a total of 18 studies: Festa et al. (2013) included 10 studies (Le
5 Scodan et al. 2009; Lee et al. 2012; Leone et al. 2013; Magnin et al. 2003; Massucco et al.
6 2006; Mehta et al. 2001; Pipas et al. 2005; Sahara et al. 2011a- 2011b; and Small et al.
7 2011); Liu et al. (2016) included 8 studies (Casadei et al. 2015; Golcher et al. 2008; Golcher
8 et al. 2015; Papalezova et al. 2012; Satoi et al. 2009; Sho et al. 2013; Tzeng et al. 2014;
9 Vento et al. 2007), 1 retrospective review of a prospective database (Grose et al. 2017) and
10 3 prospective single-arm phase II clinical trials (Evans et al. 2008; Taksahaki et al. 2013;
11 Varadhachary et al. 2008). A summary of the included studies is presented in Table 120.

12 One systematic review (Liu et al. 2016) compared neoadjuvant chemoradiotherapy then
13 surgery with surgery only in patients with resectable pancreatic cancer (n=833). This review
14 included 3 randomised phase II/III trials (Casadei et al. 2015; Golcher et al. 2008, 2015) and
15 5 retrospective comparative studies (Papalezova et al. 2012; Satoi et al. 2009; Sho et al.
16 2013; Tzeng et al. 2014; Vento et al. 2007).

17 Two prospective single-arm phase II trials (Evans et al. 2008; Takahashi et al. 2013)
18 evaluated neoadjuvant chemoradiotherapy then surgery in adults with resectable pancreatic
19 adenocarcinoma (n=274).

20 One retrospective review of a prospective database (Grose et al. 2017) compared
21 chemotherapy followed by chemoradiotherapy then surgery followed by chemotherapy with
22 chemotherapy followed by surgery then chemotherapy only in patients with locally advanced
23 pancreatic cancer (n=85), where both arms received neoadjuvant chemotherapy prior and
24 adjuvant chemotherapy (gemcitabine).

25 One systematic review (Festa et al. 2013) and 1 prospective single-arm phase II trial
26 (Takahashi et al. 2013) evaluated chemoradiotherapy delivered pre-operatively in
27 downstaging adults with borderline resectable pancreatic cancer (n=217). Festa et al. (2013)
28 included 7 studies involving this population subgroup: 3 phase II trials (Le Scodan et al.
29 2009; Pipas et al. 2005; Small Jr et al. 2011) and 4 prospective studies (Leone et al. 2012;
30 Magnin et al. 2003; Massucco et al. 2006; Mehta et al. 2001).

31 One prospective single-arm phase II trial (Takahashi et al. 2013) evaluated the safety of
32 neoadjuvant chemoradiotherapy then surgery in adults with resectable or borderline
33 resectable pancreatic cancer (n=268).

34 One systematic review (n=45) evaluated chemotherapy delivered pre-operatively in
35 downstaging adults with borderline resectable pancreatic cancer (Festa et al. 2013). This
36 review included 3 prospective trials involving this population subgroup: 2 phase II trials
37 (Sahora et al. 2011a; Sahara et al. 2011b) and 1 prospective cohort study (Lee et al. 2012).

38 One prospective single-arm phase II trial (n=79) was found that evaluated pre-operative
39 gemcitabine and cisplatin then gemcitabine-based chemoradiotherapy followed by surgery in
40 patients with resectable pancreatic cancer (Varadhachary et al. 2008).

1 Where possible data were extracted from the included systematic reviews (Liu et al. 2016;
2 Festa et al. 2013). When there was not enough detail included in the review, the full copy of
3 the original studies (in the reviews) were checked for accuracy and completeness.

4 The AMSTAR (A Measurement Tool to Assess Systematic Reviews) Checklist was used to
5 assess the methodological quality of systematic reviews; the Cochrane Collaboration's 'Risk
6 of bias' tool was used to assess the risk of bias of randomised phase II/III clinical trials; and
7 the Newcastle-Ottawa Scale (NOS) for assessing the risk of bias of non-randomised studies
8 (i.e. prospective single-arm phase II studies and retrospective comparative studies). Where
9 possible, the risk of bias information was taken from the systematic reviews, though in some
10 cases when there was insufficient detail included in the review, the original study was used to
11 determine risk of bias.

12 Further information about the search strategy can be found in Appendix D. See study
13 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
14 study evidence tables in Appendix F and list of excluded studies in Appendix G.

15

16

1 **10.1.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 120.

3 **Table 120: Summary of included studies**

Study	Study type	Participants	Interventions	Comparison	Outcomes
Evans et al. 2008	Design: single-arm phase II clinical trial Duration: 1998-2001 Country: USA	N=86 patients with resectable PC	CRT before surgery (GEM and 30 Gy in 10 fractions over 2 weeks)	Not applicable	Overall Survival Resection rate Time from initiating treatment to Surgery Adverse Events
Festa et al. 2013	Design: Systematic review with meta-analysis Searches up to September 2012	This review includes 5 phase II trials Pipas et al. 2005 (n=6*) Le Scodan et al. 2009 (n=41) Small et al. 2011 (n=10*) Sahora et al. 2011a (n=12*) Sahora et al. 2011b (n=15*) and 5 prospective observational studies Mehta et al. 2001 (n=15*) Magnin et al. 2003 (n=32) Massucco et al. 2006 (n=18*) Leone et al. 2012 (n=15*) Lee et al. 2012 (n=18*)	Pre-operative administration of chemotherapy, alone or in combination with radiotherapy then surgery^	Not applicable	SR: Response to neoadjuvant treatment pre-surgery Overall Survival Resection rate Adverse Events Included studies: No additional outcomes

Study	Study type	Participants	Interventions	Comparison	Outcomes
Grose et al. 2017	Design: retrospective review of prospective database	N=85 patients with localised pancreatic cancer	Neoadjuvant CT then CRT then surgery then adjuvant CT (gemcitabine)	Neoadjuvant CT then surgery then adjuvant CT (gemcitabine)	Response to neoadjuvant treatment pre-surgery Overall survival Resection rate Adverse events
Liu et al. 2016	Design: Systematic review with meta-analysis Searches up to November 2014	This review includes 3 RCTs Casadei et al. 2015 (n=38) Golcher et al. 2015 (n=66) Golcher et al. 2008 (n=79) and 5 retrospective cohort studies: Papalezova et al. 2012 (n=236) Satoi et al. 2009 (n=68) Sho et al. 2013 (n=132) Tzeng 2014 (n=167) Vento et al. 2007 (n=47)	Neoadjuvant CRT then surgery	Surgery (PD) alone	SR: Overall Survival Resection rate Included studies: Response to neoadjuvant treatment pre-surgery (Casadei et al. 2015, Golcher et al. 2015) Adverse Events (Casadei et al. 2015, Golcher et al. 2015, Sho et al. 2013, Tzeng 2014, Vento et al. 2007)
Takahashi et al. 2013	Design: single-arm phase II clinical trial Duration: 2002-2011 Country: Japan	n= 268 patients with resectable (n=188) and BR resectable (n=80) PC	CRT then surgery [^] Further details: GEM and 50 Gy (with a daily fraction of 2 Gy 5 times per week)	Not applicable	Overall Survival Resection rate Adverse Events
Varadhachary et al. 2008	Design: single-arm phase II clinical trial Duration: 2002-2006 Country: USA	N=90 patients with resectable PC	Chemotherapy then CRT before surgery Further details: GEM + cisplatin then GEM and 30 Gy	Not applicable	Overall Survival Time from initiating treatment to Surgery Adverse Events

Study	Study type	Participants	Interventions	Comparison	Outcomes
<p>* Patients were stratified as (1) unresectable or (2) borderline resectable. The number of patients refers to those participants with borderline resectable disease (those patients included in the meta-analysis)</p> <p>^ only for patients presenting with resectable disease at restaging</p>					

1

1 **10.1.4 Clinical evidence profile**

2 The clinical evidence profiles for this review question are presented in Table 121 to Table
3 128.

4 **Table 121: Summary clinical evidence profile for neoadjuvant chemoradiotherapy**
5 **followed by surgery versus surgery alone in patients with resectable**
6 **pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgery alone in patients with resectable PC	CRT followed by surgery				
Response to neoadjuvant treatment pre-surgery - radiological response RECIST criteria ¹	See comment		Not estimable	47 (2 studies ²)	⊕⊕⊖⊖ low ^{3,11}	Radiological response to CRT was rarely seen, whereas most patients had no change or progression
Response to neoadjuvant treatment pre-surgery - pathological response Rebekah criteria	See comment		Not estimable	18 (1 study ⁸)	⊕⊕⊖⊖ low ^{3,4}	Pathological response to CRT was slightly higher than the radiological (n=0 none; n=2 minimal; n=3 small; n=5 moderate and 1 large response)
Complete resection rate	595 per 1000	690 per 1000 (577 to 826)	RR 1.16 (0.97 to 1.39)	183 (3 studies ⁹)	⊕⊕⊖⊖ low ^{3,5}	
Overall survival	-	-	HR 0.85 (0.58 to 1.25)	104 (2 studies ²)	⊕⊖⊖⊖ very low ^{3,6,11}	
Adverse events - Postoperative complications	774 per 1000	665 per 1000 (364 to 1000)	RR 0.86 (0.47 to 1.57)	104 (2 studies ²)	⊕⊖⊖⊖ very low ^{3,7,11}	
Adverse events - Pancreatic fistula	324 per 1000	181 per 1000 (97 to 340)	RR 0.56 (0.3 to 1.05)	132 (1 study ⁹)	⊕⊖⊖⊖ very low ^{3,7,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Surgery alone in patients with resectable PC	CRT followed by surgery				
Adverse events - Postoperative bleeding	41 per 1000	23 per 1000 (5 to 107)	RR 0.56 (0.12 to 2.65)	346 (3 studies ¹⁵)	⊕⊕⊕⊕ very low ^{3,7,11}	
Adverse events - Acute toxicity of chemoradiotherapy NCI common toxicity criteria v2.0 and RTOG/EORTC recommendations	See comment		Not estimable	18 (1 study ¹²)	⊕⊕⊕⊕ low ^{3,4}	All patients experienced toxicities. 16 patients experienced hematologic toxicities, whereas 15 patients experienced non-hematologic toxicities
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. <i>J Natl Cancer Inst</i> 92:205–216 2 Casadei et al. 2015, Golcher et al. 2015 3 Quality of evidence was downgraded by 1 point owing to unclear risk of performance bias. 4 Numbers are too small for precise results to be obtained 5 95% CI crosses 1 default MID (0.8 and 1.25) 6 The committee decided to downgrade survival outcomes by one level if the difference in survival was not statistically significant. 7 95% CI crosses 2 default MIDs (0.8 and 1.25). 8 Casadei et al. 2015 9 Casadei et al. 2015, Golcher et al. 2015, Golcher et al. 2008 10 Golcher et al. 2008, Golcher et al. 2015 11 Quality of evidence was downgraded by 1 point owing to some inconsistency across studies 12 Sho et al. 2013 13 Retrospective 14 The quality of the evidence was downgraded of one point because of the potential risk of performance bias due to some issues of comparability between comparison groups 15 Sho et al. 2013, Tzeng et al. 2014, Vento et al. 2007</p>						

1
2

Table 122 Summary clinical evidence profile for neoadjuvant chemoradiotherapy then surgery in only adults with resectable pancreatic cancer

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
5 years survival rate- Resectable PC (follow-up 5 years)	The 5-year survival was 57%	Not estimable	188 (1 study ¹)	⊕⊕⊕⊕ low ⁵	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Overall Survival - Resectable PC Follow-up: unclear	Median survival was 34 months for the 64 patients who underwent PD and 7 months for the 22 un-resected patients (P < .001). The 5-year survival for those who did and did not undergo PD was 36% and 0%, respectively.	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Resection rate - Resectable PC Follow-up: mean 8 weeks ³	R0 resection rate was relatively high (99% and 89%, respectively) in those patients who underwent surgery and received the intervention.	Not estimable	250 (2 studies ^{1, 2})	⊕⊕⊖⊖ low ⁵	
Time from initiating treatment to Surgery	The median time from completion of preoperative therapy to surgery in the 73 patients who went to surgery was 5.6 weeks.	Not estimable	73 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Hematologic toxicities (Grade 3 to 4) (Anaemia; Leukopenia; Granulocytopenia; Thrombocytopenia; Neutropenic fever) No of events Follow-up: - unclear	37 patients experienced hematologic toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Constitutional toxicities (Grade 3 to 4) (Fatigue; Anorexia; Pain; Failure to thrive) No of events Follow-up: - unclear	32 patients experienced constitutional toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Gastrointestinal toxicities (Grade 3 to 4) (Nausea; Emesis; Diarrhoea/enteritis; Dehydration; Constipation; Abdominal pain) No of events Follow-up: - unclear	30 patients experienced gastrointestinal toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Adverse effects: Liver and biliary toxicities (Grade 3 to 4) No of events Follow-up: - unclear	24 patients experienced liver and biliary toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Cardiovascular toxicities (Grade 3 to 4) (Deep venous thrombosis) No of events Follow-up: - unclear	4 patients experienced cardiovascular toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Pulmonary embolism toxicities (Grade 3-4) No of events Follow-up: - unclear	No patient experienced pulmonary embolism toxicities (p=no reported)	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
Adverse effects: Other toxicities (Grade 3-4) No of events Follow-up: - unclear	18 patients experienced other toxicities	Not estimable	86 (1 study ²)	⊕⊕⊖⊖ low ⁵	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Takashaki et al. 2013 2 Evans et al. 2008 3 From the initial staging 4 NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. 5 Non-randomised study with no comparator</p>					

1
2
3

Table 123: Summary clinical evidence profile for neoadjuvant chemoradiotherapy followed by surgery in only adults with borderline resectable pancreatic cancer

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Response to neoadjuvant treatment pre-surgery Percent frequency of complete/partial response following neoadjuvant	The fraction of patients with complete/partial response at restaging was 13.5% (95% CI: 7-24.6%)	Not estimable	137 (7 studies ¹)	⊕⊕⊖⊖ low ⁴	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
therapy –RECIST criteria					
5 years survival rate- Resectable PC	The 5-year survival was 34%	Not estimable	43 (1 study ²)	⊕⊕⊕⊖ low ⁴	
Resection rate Percent frequency of pancreatic resection rates following neoadjuvant therapy	R0 resection rate was 78.5 % in those patients who underwent surgery and received the neoadjuvant CRT intervention (95% CI: 62.2-89.1%)	Not estimable	137 (7 studies ¹)	⊕⊕⊕⊖ low ⁴	
Adverse events: toxicity rates (grade 3-4)	28.8% of patients had grade 3-4 toxicities as consequence of the neoadjuvant intervention	Not estimable	137 (7 studies ¹)	⊕⊕⊕⊖ low ⁴	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio</i></p> <p>1 Festa et al. 2013 (included studies: Le Scodan et al. 2009; Leone et al. 2012; Magnin et al. 2003; Massucco et al. 2006; Mehta et al. 2001; Pipas et al. 2005; Small et al. 2011) 2 Takashaki et al. 2013 3 Non-randomised study with no comparator 4 Single-arm prospective clinical trials (non-comparative)</p>					

1
2
3
4
5

Table 124: Summary clinical evidence profile for neoadjuvant chemotherapy before chemoradiotherapy followed by surgery in only adults with borderline resectable pancreatic cancer – outcomes related to type of induction (neoadjuvant) chemotherapy received (FOLFIRINOX or gemcitabine/capecitabine)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEMcap->CRT or GEMcap only then Surgery->Adjuvant CT	FOLFIRINOX->CRT or FOLFIRINOX only->Surgery->Adjuvant CT				
Response to neoadjuvant treatment pre-surgery Follow-up: median 21.2 months	53 per 1000	172 per 1000 (24 to 1000)	RR 3.27 (0.45 to 23.7)	83 (1 study)	⊕⊕⊕⊖ very low ^{1,2}	
Overall survival Follow-up: median 21.2 months	See comment	See comment	HR 1.39 (0.73 to 2.66)	85 (1 study)	⊕⊕⊕⊖ very low ^{1,3,4}	Favours GEMcap but not significantly
Grade 3 Adverse Events - Haematological toxicity Follow-up: median 21.2 months	100 per 1000	77 per 1000 (16 to 367)	RR 0.77 (0.16 to 3.67)	85 (1 study)	⊕⊕⊕⊖ very low ^{1,2}	
Grade 3 Adverse Events - Biochemical toxicity	0 per 1000	0 per 1000 (0 to 0)	RR 1.59 (0.08 to 31.84)	85 (1 study)	⊕⊕⊕⊖ very low ^{1,2}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Follow-up: median 21.2 months Grade 3 Adverse Events - Diarrhoea	0 per 1000	0 per 1000 (0 to 0)	RR 4.14 (0.24 to 70.39)	85 (1 study)	⊕⊕⊕⊕ very low _{1,2}	
Follow-up: median 21.2 months Grade 3 Adverse Events - Nausea/vomiting	0 per 1000	0 per 1000 (0 to 0)	RR 2.23 (0.12 to 41.39)	85 (1 study)	⊕⊕⊕⊕ very low _{1,2}	
Follow-up: median 21.2 months Grade 3 Adverse Events - Fatigue	50 per 1000	77 per 1000 (9 to 620)	RR 1.54 (0.19 to 12.41)	85 (1 study)	⊕⊕⊕⊕ very low _{1,2}	
Follow-up: median 21.2 months Grade 3 Adverse Events - Sepsis	0 per 1000	0 per 1000 (0 to 0)	RR 1.59 (0.08 to 31.84)	85 (1 study)	⊕⊕⊕⊕ very low _{1,2}	
Follow-up: median 21.2 months Grade 4 Adverse Events - Grade 4 Haematological toxicity	0 per 1000	0 per 1000 (0 to 0)	RR 1.59 (0.08 to 31.84)	85 (1 study)	⊕⊕⊕⊕ very low _{1,2}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Grose et al. 2017: High risk of bias for comparability (patients received (i) GEMCAP only if not fit for FOLIRINOX or over 70 years old, and (ii) CRT only if fit.

2 95% CI crosses 2 default MID (0.8 and 1.25).

3 The committee decided to downgrade survival outcomes for imprecision by one level only if there was a statistically significant difference between the interventions. See Chapter 4 for further details.

4 No statistically significant difference between interventions.

1

2

3

4

Table 125: Summary clinical evidence profile for neoadjuvant chemotherapy before chemoradiotherapy followed by surgery in only adults with borderline resectable pancreatic cancer – outcomes related to chemoradiotherapy

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT->Surgery->Adjuvant CT	CT->CRT->Surgery->Adjuvant CT				
Overall survival Follow-up: median 21.2 months	See comment	See comment		85 (1 study)	⊕⊕⊕⊕ very low ₁	Median OS for all patients=17.7 (95% CI 13.2-22.6) mo. Median survival of potentially resectable patients (n=45)=22.2 (95% CI 18.8-25.5) mo; of resected patients (n=30)=37 (95% CI 18.2-55.7) mo.
Complete (R0) resection rate Follow-up: median 21.2 months	467 per 1000	705 per 1000 (378 to 1000)	RR 1.51 (0.81 to 2.82)	32 (1 study)	⊕⊕⊕⊕ very low _{1,2}	
R1 resection rate Follow-up:	533 per 1000	293 per 1000 (123 to 704)	RR 0.55 (0.23 to 1.32)	32 (1 study)	⊕⊕⊕⊕ very low _{1,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
median 21.2 months						
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).						
CI: Confidence interval; RR: Risk ratio;						
1 Grose et al. 2017: High risk of bias for comparability (patients received (i) GEMCAP only if not fit for FOLIRINOX or over 70 years old, and (ii) CRT only if fit.						
2 95% CI crosses 1 default MID (0.8 or 1.25).						
3 95% CI crosses 2 default MID (0.8 and 1.25).						

1

2

3

4

Table 126: Summary clinical evidence profile for neoadjuvant chemoradiotherapy followed by surgery in either adults with borderline resectable or resectable pancreatic cancer

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Adverse events: Leukopenia (Grade 3) - Borderline Resectable and Resectable PC National Cancer Institute Common Toxicity Criteria version 44	Following preoperative CRT there were 132 patients reported associated leukopenia toxicities (grade 3-4)	Not estimable	268 (1 study ¹)	⊕⊕⊖ ⊖ low ⁵	
Adverse events: Thrombocytopenia (Grade 3) - Borderline Resectable and Resectable PC National Cancer Institute Common Toxicity Criteria version 44	Following preoperative CRT there were 14 patients reported associated thrombocytopenia toxicities (grade 3-4)	Not estimable	268 (1 study ¹)	⊕⊕⊖ ⊖ low ⁵	
Adverse events: Gastrointestinal toxicity (Grade 3) - Borderline Resectable and Resectable PC National Cancer Institute Common Toxicity Criteria version 44	Following preoperative CRT there were 4 patients reported associated gastrointestinal toxicities (grade 3-4)	Not estimable	268 (1 study ⁴)	⊕⊕⊖ ⊖ low ⁵	
Adverse events: Delayed gastric emptying (Grade B/C) - Borderline Resectable and	Following preoperative CRT there were 23 patients reported associated delayed	Not estimable	268 (1 studies ¹)	⊕⊕⊖ ⊖ low ⁵	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Resectable PC International study group of pancreatic surgery criteria ⁶	gastric emptying complications				
Adverse events: Delayed gastric emptying (Operative Mortality) - Borderline Resectable and Resectable PC International study group of pancreatic surgery criteria ⁶	There was 1 death following preoperative CRT-associated complications	Not estimable	268 (1 study ¹)	⊕⊕⊖ ⊖ low ⁵	
Adverse events: Pancreatic fistula (Grade B-C) International study group of pancreatic fistula criteria ⁹	Following preoperative CRT there were 15 patients reported pancreatic fistula complications	Not estimable	268 (1 study ¹)	⊕⊕⊖ ⊖ low ⁵	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i> ¹ Takashaki 2013 ⁴ NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. Available at: http://evs.nci.nih.gov/ftp1/CTCAE/About.html. ⁵ Non-randomised study with no comparator ⁶ Wente MN, Bassi C, Dervenis C, et al. Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i>. 2007;142:761–768. ⁸ Numbers are too small for precise results to be obtained ⁹ Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. <i>Surgery</i>. 2005;138:8–13</p>					

1
2
3

Table 127: Summary clinical evidence profile for neoadjuvant chemotherapy followed by surgery in patients with in patients with borderline resectable pancreatic cancer.

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Response to neoadjuvant treatment pre-surgery Percent frequency of complete/partial response following neoadjuvant therapy – RECIST criteria	The weighted fraction of patients with complete/partial response at restaging was 23.6% (95% CI: 8.0-28%)	Not estimable	45 (3 studies ¹)	⊕⊕⊖ ⊖ very low ^{2,3}	
Resection rate	R0 resection rate was 87.6 % in those patients who underwent surgery and received the neoadjuvant CRT	Not estimable	45 (3 studies ¹)	⊕⊕⊖ ⊖ very low ^{2,3}	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	intervention (95% CI: 43.9-98.5%)				
Adverse events: toxicity rates (grade 3-4)	35.9% of patients had grade 3-4 toxicities as consequence of the neoadjuvant intervention (95% CI: 23.1-51.1%)	Not estimable	45 (3 studies ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p><i>1 Festa et al. 2013 (included studies: Lee et al. 2012; Sahora et al. 2011a; Sahora et al. 2011b)</i> <i>2 Non-randomised study with no comparator</i> <i>3 Numbers are too small for precise results to be obtained</i></p>					

1
2
3

Table 128: Summary clinical evidence profile for neoadjuvant chemotherapy then chemoradiotherapy followed by surgery in patients with resectable pancreatic cancer.

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Overall Survival Follow-up: 5 years	Median survival for the patients who completed chemo-CRT was 18.7 months, with a median survival of 31 months for the 52 patients who underwent PD and 10.5 months for the 27 patients who did not undergo surgical resection of their primary tumour	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Resection rate Follow-up: - unclear	R0 resection rate was 96% in those patients who underwent PD and received the intervention	Not estimable	62 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Time from initiating treatment to Surgery Follow-up: - unclear	The median time from completion of the neoadjuvant intervention to surgery in the patients who went to surgery for planned PD was 5.6 weeks	Not estimable	62 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Hematologic toxicities (Grade 3-4) (Anaemia; Leukopenia; Granulocytopenia; Thrombocytopenia;	24 patients experienced hematologic toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	

Outcomes	Effect	Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
Neutropenic fever) No of events Follow-up: - unclear					
Adverse effects: Constitutional toxicities (Grade 3-4) (Fatigue; Anorexia; Pain; Failure to thrive) No of events Follow-up: - unclear	30 patients experienced constitutional toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Gastrointestinal toxicities (Grade 3-4) (Nausea; Emesis; Diarrhoea/enteritis; Dehydration; Constipation; Abdominal pain) No of events Follow-up: - unclear	20 patients experienced gastrointestinal toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Liver and biliary toxicities (Grade 3-4) No of events Follow-up: - unclear	29 patients experienced liver and biliary toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Cardiovascular toxicities(Grade 3-4) (Deep venous thrombosis) No of events Follow-up: - unclear	7 patients experienced cardiovascular toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Pulmonary embolism toxicities (Grade 3-4) No of events Follow-up: - unclear	3 patients experienced pulmonary embolism toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
Adverse effects: Other toxicities (Grade 3-4) No of events Follow-up: - unclear	19 patients experienced other toxicities	Not estimable	79 (1 study ¹)	⊕⊕ ⊖⊖ low ³	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 Varadhachary et al. 2008 2 Single-arm phase II clinical trial (non-comparative) 3 Non-randomised study with no comparator</p>					

1 10.1.5 Economic evidence

2 10.1.5.1 Systematic literature review

- 3 References to all included studies and evidence tables for all economic evaluations included
- 4 in the systematic literature review of the economic evidence are presented in Appendix L.
- 5 Economic evidence profiles of these studies are presented in Appendix K.

1 One study (Abbott et al. 2013) was identified by the review of published economic evidence
2 for this topic. The study was a cost utility analysis of a surgery first approach versus a
3 neoadjuvant therapy approach (either gemcitabine or capecitabine based chemotherapy or
4 chemoradiotherapy) in the treatment of pancreatic head cancer. The study reported the
5 results in terms of both cost and Quality Adjusted Life Month (QALM) gained allowing for
6 incremental analysis to be performed for this review. The study considered a US Health
7 Payer perspective. It was deemed partially applicable to the topic primarily because it did not
8 take a NHS+PSS perspective.

9 Potentially serious limitations were identified with Abbott et al. (2013). Retrospective,
10 observational evidence was used to populate the health outcomes in the economic model
11 from different databases at different centres. It was unlikely that the two patients groups were
12 directly comparable and this may have biased both costs and QALMs. The base case
13 suggested that treating pancreatic head cancer with a neoadjuvant approach would be both
14 less costly and increase QALMs. Deterministic sensitivity analysis suggested this result was
15 robust to alternative clinical assumptions made around the surgery first approach. The
16 deterministic sensitivity analysis did not explore uncertainty around all key clinical
17 assumptions and no probabilistic sensitivity analysis was reported.

18 References to all included studies and evidence tables for all economic evaluations included
19 in the systematic literature review of the economic evidence are presented in Appendix L.
20 Economic evidence profiles of these studies are presented in Appendix K.

21 **10.1.6 Evidence statements**

22 **10.1.6.1 Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone**

23 **Response to neoadjuvant treatment pre-surgery**

24 Low quality evidence from 2 RCTs (n=47) showed that radiological response to neoadjuvant
25 chemoradiotherapy on a restaging CT scan was rarely seen in adults with resectable
26 pancreatic cancer receiving neoadjuvant chemoradiotherapy followed by surgery, whereas
27 most patients had no change or progression (relative effect not estimable).

28 Low quality evidence from 1 RCT (n=18) showed that the most common pathological
29 response to neoadjuvant chemoradiotherapy was small or moderate (n=8) in adults with
30 resectable pancreatic cancer receiving neoadjuvant chemoradiotherapy followed by surgery.
31 By contrast, only 1 patient had a poor pathological response and two patients had a minimal
32 response (relative effect not estimable).

33 **Disease-free interval**

34 No evidence was identified to inform this outcome.

35 **Relapse-free survival**

36 No evidence was identified to inform this outcome.

37 **Overall Survival**

38 Very low quality evidence from 2 RCTs (n=154) showed no clinically important difference
39 between neoadjuvant chemoradiotherapy followed by surgery and surgery alone on long-
40 term survival in adults with resectable pancreatic cancer: HR=0.85 (95% CI, 0.58-1.25),
41 where HR less than 1 favours neoadjuvant chemoradiotherapy group.

42 **Resection rate**

43 Low quality evidence from 3 RCTs (n=183) showed no clinically important difference
44 between neoadjuvant chemoradiotherapy followed by surgery and surgery alone on R0

1 resection rate in adults with resectable pancreatic cancer: RR 1.16 (95% CI, 0.97-1.39),
2 where RR higher than 1 favours neoadjuvant chemoradiotherapy group.

3 **Time from initiating treatment to Surgery**

4 No evidence was identified to inform this outcome.

5 **Adverse Events**

6 Very low quality evidence from 2 RCTs (n=104) showed no clinically important difference
7 between neoadjuvant chemoradiotherapy followed by surgery and surgery alone on post-
8 operative complications in adults with resectable pancreatic cancer: RR 0.86 (95% CI, 0.47-
9 1.57), where RR less than 1 favours neoadjuvant CRT group.

10 Very low quality evidence from 1 retrospective comparative study (n=132) showed that there
11 may be a clinically important difference favouring neoadjuvant chemoradiotherapy followed
12 by surgery on pancreatic fistula compared to surgery alone in adults with resectable
13 pancreatic cancer, although there is some uncertainty: RR 0.56 (95% CI, 0.3-1.05), where
14 RR less than 1 favours neoadjuvant CRT group.

15 Very low quality evidence from 3 retrospective studies (n=346) showed no clinically important
16 difference between neoadjuvant chemoradiotherapy followed by surgery and surgery alone
17 on post-operative bleeding in adults with resectable pancreatic cancer: RR 0.56 (95% CI,
18 0.12-2.65), where RR less than 1 favours neoadjuvant CRT group.

19 **Health Related Quality of Life**

20 No evidence was identified to inform this outcome.

21 **Patient experience**

22 No evidence was identified to inform this outcome.

23 **PROMS**

24 No evidence was identified to inform this outcome.

25 **10.1.6.2 Neoadjuvant chemoradiotherapy followed by surgery**

26 **10.1.6.2.1 Adults with resectable pancreatic cancer**

27 **Response to neoadjuvant treatment pre-surgery**

28 No evidence was identified to inform this outcome.

29 **Disease-free interval**

30 No evidence was identified to inform this outcome.

31 **Relapse-free survival**

32 No evidence was identified to inform this outcome.

33 **Overall Survival**

34 Low quality evidence from 1 single-arm phase II clinical trial (n=188) showed that the 5-year
35 survival rate was 57% in adults with resectable pancreatic cancer who received neoadjuvant
36 chemoradiotherapy and underwent surgery (relative effect not estimable).

37 Low quality evidence from 1 single-arm phase II clinical trial (n=86) showed that adults with
38 resectable pancreatic cancer who received neoadjuvant chemoradiotherapy had an overall
39 median survival of 34 months and a 5-year survival of 36% when they went on to have

1 surgery (n=64) compared to a median survival of 7 months and a 5-year overall survival of
2 0% for those who received neoadjuvant chemoradiotherapy did not have surgery (n=22)
3 (relative effect not estimable).

4 **Resection rate**

5 Low quality evidence from 2 single-arm phase II clinical trial (n=250) showed that the R0
6 resection rate in adults with resectable pancreatic cancer who received neoadjuvant
7 chemoradiotherapy followed by surgery was relatively high (99% and 89%, in the two
8 studies) (relative effect not estimable).

9 **Time from initiating treatment to Surgery**

10 Low quality evidence from 1 single-arm phase II clinical trial (n=73) showed that the median
11 time from completion of neoadjuvant chemoradiotherapy to surgery was 5.6 weeks in adults
12 with resectable pancreatic cancer (relative effect not estimable).

13 **Adverse Events**

14 Low quality evidence from 1 single-arm phase II clinical trial (n=86) showed that the overall
15 Grade 3 or 4 toxicities experienced by adults with resectable pancreatic cancer who received
16 neoadjuvant chemoradiotherapy was relatively high with 37 participants experiencing
17 haematological toxicities, 32 participants experiencing constitutional toxicities, 30 participants
18 experiencing gastrointestinal toxicities, 24 participants experiencing liver and biliary toxicities,
19 4 participants experiencing cardiovascular toxicities, 18 participants experiencing other
20 toxicities, and no patients experiencing pulmonary embolism toxicities (relative effect not
21 estimable).

22 **Health Related Quality of Life**

23 No evidence was identified to inform this outcome.

24 **Patient experience**

25 No evidence was identified to inform this outcome.

26 **PROMS**

27 No evidence was identified to inform this outcome.

28 **1.6.2.2 Adults with borderline resectable pancreatic cancer**

29 **Response to neoadjuvant treatment pre-surgery**

30 Low the percentage of adults with borderline resectable pancreatic cancer with
31 complete/partial response to neoadjuvant chemoradiotherapy before surgery at restaging
32 was 13.5% (95% CI, 7.0-24.6).

33 **Disease-free interval**

34 No evidence was identified to inform this outcome.

35 **Relapse-free survival**

36 No evidence was identified to inform this outcome.

37 **Overall Survival**

38 Low quality evidence from 1 single-arm phase II clinical trial (n=43) showed that the 5-year
39 overall survival in adults with borderline resectable pancreatic cancer who received
40 neoadjuvant chemoradiotherapy then surgery was 34% (relative effect not estimable).

1 **Resection rate**

2 Low quality evidence from 7 single-arm prospective clinical trials (n=137) showed that the R0
3 resection rate was 78.5% (95% CI, 62.2-89.1) in adults with borderline resectable pancreatic
4 cancer who received neoadjuvant chemoradiotherapy followed by surgery (relative effect not
5 estimable).

6 **Time from initiating treatment to Surgery**

7 No evidence was identified to inform this outcome.

8 **Adverse Events**

9 Low quality evidence from 7 single-arm prospective clinical trials (n=137) showed that there
10 was a relatively high incidence of Grade 3 or 4 toxicities of 28.8% (n=39) in adults with
11 borderline resectable pancreatic cancer who received neoadjuvant chemoradiotherapy
12 followed by surgery (relative effect not estimable).

13 **Health Related Quality of Life**

14 No evidence was identified to inform this outcome.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **PROMS**

18 No evidence was identified to inform this outcome.

19 **10.1.6.2.3 Adults with resectable or borderline pancreatic cancer**

20 **Response to neoadjuvant treatment pre-surgery**

21 No evidence was identified to inform this outcome.

22 **Disease-free interval**

23 No evidence was identified to inform this outcome.

24 **Relapse-free survival**

25 No evidence was identified to inform this outcome.

26 **Overall Survival**

27 No evidence was identified to inform this outcome.

28 **Resection rate**

29 No evidence was identified to inform this outcome.

30 **Time from initiating treatment to Surgery**

31 No evidence was identified to inform this outcome.

32 **Adverse Events**

33 Low quality evidence from 1 single-arm phase II clinical trial (n=268) showed that the overall
34 Grade 3 or 4/Grade B/C toxicities was relatively high in adults with resectable or borderline
35 resectable pancreatic cancer who received neoadjuvant chemoradiotherapy followed by
36 surgery, with 132 participants experiencing Grade 3/4 leukopenia. 14 participants
37 experiencing associated Grade 3/4 thrombocytopenia; 4 participants experienced

1 gastrointestinal toxicities (grade 3-4); 23 participants experiencing Grade B/C delayed gastric
2 emptying complications, and 15 participants experiencing Grade B/C pancreatic fistula
3 complications. There was also 1 death following preoperative chemoradiotherapy-associated
4 complications (relative effect not estimable).

5 **Health Related Quality of Life**

6 No evidence was identified to inform this outcome.

7 **Patient experience**

8 No evidence was identified to inform this outcome.

9 **PROMS**

10 No evidence was identified to inform this outcome.

11 **10.1.6.3 Neoadjuvant chemotherapy then chemoradiotherapy followed by surgery then**
12 **adjuvant chemotherapy versus neoadjuvant chemotherapy followed by surgery then**
13 **adjuvant chemotherapy**

14 **Response to neoadjuvant treatment pre-surgery**

15 Very low quality evidence from 1 retrospective review of a prospective database (n=85)
16 showed no clinically significant difference between neoadjuvant FOLFIRINOX and
17 gemcitabine on pre-surgery response to neoadjuvant treatment in adults with localised
18 potentially resectable pancreatic cancer: RR 3.27 (0.45-23.7).

19 **Disease-free interval**

20 No evidence was identified to inform this outcome.

21 **Relapse-free survival**

22 No evidence was identified to inform this outcome.

23 **Overall Survival**

24 Very low quality evidence from 1 retrospective review of a prospective database (n=85)
25 showed no clinically important difference between neoadjuvant FOLFIRINOX and
26 gemcitabine on overall survival in adults with localised potentially resectable pancreatic
27 cancer: HR 1.39 (95% CI 0.73-2.66). In the same study, the median overall survival for all
28 neoadjuvant chemotherapy patients (n=85) was 17.9 months (95% CI 13.2-22.6) and the 12-
29 mo survival rate was 54% (SE 6%). Median survival for all potentially resectable patients
30 (n=45; resection category B) was 22.2 (95% CI 18.8-25.5) months [includes patients who did
31 not have surgery], 18.5 (95% CI 9.3-27.7) months for baseline resection category C (n=19)
32 patients, and 9.0 (95% CI 6.9-11.0) months for resection category D1 (n=19) patients.
33 Median survival of resected patients was 37 months (95% CI 18.2-55.7). At date of
34 censoring, 18 of 34 surgical patients were alive.

35 **Resection rate**

36 Very low quality evidence from 1 retrospective review of a prospective database (n=32)
37 showed a clinically important difference favouring neoadjuvant chemotherapy followed by
38 chemoradiotherapy then surgery compared to neoadjuvant chemotherapy then surgery only
39 on complete (R0) resection rate in adults with localised potentially resectable pancreatic
40 cancer: RR 1.51 (95% CI 0.81-2.82).

41 Very low quality evidence from 1 retrospective review of a prospective database (n=32)
42 showed no clinically important difference between neoadjuvant chemoradiotherapy followed

1 by surgery and surgery only on R1 resection rate in adults with localised potentially
2 resectable pancreatic cancer: RR 0.55 (95% CI 0.23-1.32).

3 **Time from initiating treatment to Surgery**

4 No evidence was identified to inform this outcome.

5 **Adverse Events**

6 Very low quality evidence from 1 retrospective review of a prospective database (n=85)
7 showed no clinically significant difference between neoadjuvant FOLFIRINOX and
8 gemcitabine on Grade 3 and Grade 4 adverse events in adults with localised potentially
9 resectable pancreatic cancer: Grade 3 sepsis, biochemical toxicity (both RR 1.59 [95% CI
10 0.08-31.84]), diarrhoea (RR 4.14 [95% CI 0.24-70.39]), nausea/vomiting (RR 2.23 [95% CI
11 0.12-41.39]), fatigue (RR 1.54 [95% CI 0.19-12.41]) and Grade 4 haematological toxicity RR
12 1.59 [95% CI 0.08-31.84]).

13 **Health Related Quality of Life**

14 No evidence was identified to inform this outcome.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **PROMS**

18 No evidence was identified to inform this outcome.

19 **10.1.6.4 Neoadjuvant chemotherapy followed by surgery**

20 **Response to neoadjuvant treatment pre-surgery**

21 Very low quality evidence from 3 single-arm prospective clinical trials (n=45) showed that the
22 percentage of adults with borderline resectable pancreatic cancer with complete/partial
23 response to neoadjuvant chemotherapy followed by surgery at restaging was 23.6% (95%
24 CI: 8.0-28%).

25 **Disease-free interval**

26 No evidence was identified to inform this outcome.

27 **Relapse-free survival**

28 No evidence was identified to inform this outcome.

29 **Overall Survival**

30 No evidence was identified to inform this outcome.

31 **Resection rate**

32 Very low quality evidence from 3 single-arm prospective clinical trials (n=45) showed that the
33 R0 resection rate in adults with borderline resectable pancreatic cancer who received
34 neoadjuvant chemotherapy followed by surgery was 87.6% (95% CI, 43.9-98.5).

35 **Time from initiating treatment to Surgery**

36 No evidence was identified to inform this outcome.

37 **Adverse Events**

1 Very low quality evidence from 3 single-arm prospective clinical trials (n=45) showed that the
2 incidence of Grade 3 or 4 toxicities was relatively high at 35.9% (95% CI, 23.1-51.1) in adults
3 with borderline resectable pancreatic cancer who received neoadjuvant chemotherapy
4 followed by surgery.

5 **Health Related Quality of Life**

6 No evidence was identified to inform this outcome.

7 **Patient experience**

8 No evidence was identified to inform this outcome.

9 **PROMS**

10 No evidence was identified to inform this outcome.

11 **10.1.6.5 Neoadjuvant chemotherapy then chemoradiotherapy followed by surgery**

12 **Response to neoadjuvant treatment pre-surgery**

13 No evidence was identified to inform this outcome.

14 **Disease-free interval**

15 No evidence was identified to inform this outcome.

16 **Relapse-free survival**

17 No evidence was identified to inform this outcome.

18 **Overall Survival**

19 Low quality evidence from 1 single-arm phase II clinical trial (n=79) showed that the median
20 survival of adults with resectable pancreatic cancer who received neoadjuvant chemotherapy
21 then chemoradiotherapy followed by surgery (n=52) was 31 months compared to a median
22 survival of 10.5 months for adults with resectable pancreatic cancer who received
23 neoadjuvant chemotherapy then chemoradiotherapy and did not have surgery (n=27)
24 (relative effect not estimable).

25 **Resection rate**

26 Low quality evidence from 1 single-arm phase II clinical trial (n=62) showed that the R0
27 resection rate was 96% in adults with resectable pancreatic cancer who received
28 neoadjuvant chemotherapy then chemoradiotherapy followed by surgery (relative effect not
29 estimable).

30 **Time from initiating treatment to Surgery**

31 Low quality evidence from 1 single-arm phase II clinical trial (n=62) showed that the median
32 time from completion of neoadjuvant chemotherapy then chemoradiotherapy to surgery was
33 5.6 weeks (relative effect not estimable).

34 **Adverse Events**

35 Low quality evidence from 1 single-arm phase II clinical trial (n=79) showed that there was a
36 relatively high incidence of adverse events in adults with resectable pancreatic cancer who
37 received neoadjuvant chemotherapy then chemoradiotherapy followed by surgery, with 24
38 participants experiencing haematological toxicities, 30 participants experiencing
39 constitutional toxicities; 20 participants experiencing gastrointestinal toxicities; 29 participants
40 experiencing liver and biliary toxicities; 7 participants experiencing cardiovascular toxicities; 3

1 participants experiencing pulmonary embolism toxicities, and 19 participants experiencing
2 other toxicities (relative effect not estimable).

3 **Health Related Quality of Life**

4 No evidence was identified to inform this outcome.

5 **Patient experience**

6 No evidence was identified to inform this outcome.

7 **PROMS**

8 No evidence was identified to inform this outcome.

9 **10.1.7 Recommendations**

10 **41. Only consider neoadjuvant therapy for people with borderline resectable**
11 **pancreatic cancer as part of a clinical trial.**

12 **42. Only consider neoadjuvant therapy for people with resectable pancreatic cancer**
13 **as part of a clinical trial.**

14 **10.1.8 Evidence to recommendations**

15 **10.1.8.1 Relative value placed on the outcomes considered**

16 Response to neoadjuvant therapy, disease-free survival, relapse-free survival, resection rate,
17 overall survival, time from initiation of treatment to surgery, adverse events, health-related
18 quality of life and patient experience were considered to be the critical outcomes for this
19 question.

20 Resection rate and adverse events were reported for all comparisons of interest. Overall
21 survival was reported for all comparisons except chemotherapy followed by surgery. Time
22 from initiating treatment to surgery was only reported for the comparisons of
23 chemoradiotherapy followed by surgery and chemotherapy followed by chemoradiotherapy
24 before surgery. Response to neoadjuvant treatment pre-surgery was only reported in 1 study
25 for neoadjuvant chemotherapy followed by chemoradiotherapy before surgery and adjuvant
26 chemotherapy compared to neoadjuvant chemotherapy and surgery and adjuvant
27 chemotherapy only. Health-related quality of life, patient experience, patient reported
28 outcome measures, disease free interval or relapse free survival were not reported for any of
29 the comparisons of interest.

30 The committee noted that the evidence of time from initiating treatment to surgery did not
31 help when making recommendations because it was only available for chemoradiotherapy
32 and it wasn't available for the other comparisons of interest.

33 **10.1.8.2 Quality of evidence**

34 The quality of the evidence was assessed by GRADE, the Newcastle Ottawa Scale and the
35 Cochrane risk of bias checklist.

36 The quality of the evidence for the comparison of chemoradiotherapy followed by surgery
37 against surgery alone ranged from very low to moderate quality across all outcomes. The
38 quality of the evidence for chemoradiotherapy followed by surgery, chemotherapy followed
39 by surgery and chemotherapy followed by chemoradiotherapy before surgery was very low
40 for all outcomes. The quality of evidence for chemotherapy then chemoradiotherapy followed

1 by surgery and adjuvant chemotherapy compared to chemotherapy before surgery and
2 adjuvant chemotherapy only was very low for all outcomes.

3 The committee noted that several of the studies were from outside the UK and therefore may
4 have limited relevance to the UK population. They also noted that most of the data came
5 from single arm studies with no comparator. The committee applied less weight to these data
6 as the lack of a comparator made it difficult to evaluate the relative effectiveness of the
7 different interventions. The committee also noted that the 1 comparative study that had been
8 identified used neoadjuvant interventions would be considered sub-optimal compared with
9 current treatments, making it difficult to be certain about the toxicity results. Because of these
10 issues the committee were not able to make any strong recommendations but they agreed to
11 recommend further research in this area to help provide additional data using current
12 treatments.

13 The committee noted, based on the evidence, that the extent of efficacy and toxicity of
14 neoadjuvant treatment was uncertain because the studies used sub-optimal interventions
15 compared with modern non-surgical therapy. Furthermore, the studies were single arm and
16 non-randomised.

17 The committee also noted that the data on pathological assessment of the response to
18 neoadjuvant therapy need to be interpreted with caution. Macroscopically, it can be very
19 difficult to distinguish tumour, fibrotic areas of tumour regression, and the fibrosis of
20 obstructive or chronic pancreatitis in pancreatic resection specimens. Therefore, tissue
21 sampling by the pathologist is critical for evaluating whether residual tumour is present or
22 not. The only way to confirm complete tumour regression is for the pathologist to sample the
23 entire pancreas from the resection specimen. It was not always clear from the evidence
24 whether this has been done. Inadequate sampling can lead to a false impression of complete
25 response, because residual tumour was not sampled.

26 Assessment of resection margin status (R0 or R1) in pancreatic resection specimens post
27 neoadjuvant therapy is also dependent upon tissue sampling. The committee noted that
28 there is no standardised protocol for pancreas resection margin assessment by pathologists
29 and, therefore, R0/R1 rates can be influenced by the number of margins sampled by the
30 pathologist. There is also no universally agreed definition of what constitutes an R1 resection
31 in a pancreatic resection specimen. In pancreatic resections without neoadjuvant therapy,
32 most pathologists use either <1mm clearance or 0mm clearance to define an R1 resection.
33 The clearance required for an R0 resection in a specimen following neoadjuvant therapy is
34 probably much more than 1mm. The evidence does not always specify how R1 has been
35 defined. The R1 rates in pancreatic resection specimens post neoadjuvant therapy range
36 from 0-100%. The variation in specimen/margin sampling by pathologists, and the differing
37 definitions of R1, probably contribute to this wide range of R1 rates.

38 10.1.8.3 Consideration of clinical benefits and harms

39 Given the limited, low quality evidence available and the issues around interpreting the data
40 on resection rates, the committee agreed it was difficult to be certain of the balance of
41 benefits and harms from the use of neoadjuvant therapy. They noted that neoadjuvant
42 therapy is currently being used outside of clinical trials. They agreed that the ideal use of
43 neoadjuvant therapy is in the context of ongoing clinical trials in order to collect the required
44 comparative data for both resectable and borderline resectable disease.

45 10.1.8.4 Consideration of economic benefits and harms

46 The economic evidence review identified 1 study reporting an economic model comparing
47 neoadjuvant therapy (either gemcitabine or capecitabine based chemotherapy or
48 chemoradiotherapy) compared to a surgery first approach in people with resectable
49 pancreatic head cancer from a US health payer perspective. The study concluded that

1 neoadjuvant therapy was both cost saving and health improving and this conclusion was
2 robust to alternative assumptions.

3 The committee noted that retrospective, observational evidence was used to populate the
4 health outcomes in the economic model and from different databases at different centres. It
5 was likely that people receiving neoadjuvant therapy had a better prognosis and were less
6 likely to incur significant costs from adverse events associated with pancreatic cancer than
7 people receiving immediate surgery and this would have counted somewhat towards the cost
8 and health outcome differences in the model. Given this and the low applicability to an NHS
9 setting the committee could not use the study to strongly influence their recommendations.

10 The committee did agree with the study that neoadjuvant therapy could be cost saving if it
11 successfully selected out people who were unlikely to respond well to resection, therefore
12 potentially avoiding unnecessary expensive surgery. The committee noted that this would
13 account for approximately 20% of resections. However, the committee acknowledged that
14 there was not strong evidence to support this.

15 **10.1.9 Research recommendation**

16 **6. Prospective randomised trials should be undertaken to compare preoperative**
17 **(neoadjuvant) therapy with standard postoperative therapy in people with**
18 **resectable pancreatic cancer.**

19 **Why this is important**

20 The survival rate of pancreatic cancer after surgical resection is very low, which suggests
21 that most patients have metastatic disease at the time of surgery. In addition, complications
22 of surgery may stop people from having adjuvant therapy. This makes neoadjuvant therapy
23 an attractive option. However, the evidence for neoadjuvant therapy is limited and low
24 quality. Using neoadjuvant therapy means delaying surgery, and it is possible that during this
25 delay pancreatic cancer will progress and become unresectable in some people, negating
26 any benefit of neoadjuvant therapy.

27 Research is needed to compare neoadjuvant treatments (which might be chemotherapy,
28 radiotherapy or both) with surgery followed by adjuvant chemotherapy. The outcomes of
29 interest are:

- 30 • feasibility of delivering neoadjuvant treatment
- 31 • feasibility of randomising patients
- 32 • objective response rate of neoadjuvant therapy
- 33 • R0 resection rate
- 34 • surgical complications, length of hospital stay, mortality of surgery
- 35 • delivery of planned treatment
- 36 • disease-free survival and overall survival after surgery
- 37 • quality of life, patient experience and patient-reported outcome measures.

38 **10.1.10 References**

39 Evans DB, Varadhachary GR, Crane CH et al. (2008) Preoperative gemcitabine-based
40 chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. *Journal*
41 *of Clinical Oncology* 26: 3496- 3502

42 Festa V, Andriulli A, Valvano MR et al. (2013) Neoadjuvant chemo-radiotherapy for patients
43 with borderline resectable pancreatic cancer: a meta-analytical evaluation of prospective
44 studies. *Journal of the Pancreas* 14(6): 618-25.

- 1 Grose D, McIntosh D, Jamieson N et al. (2017) The role of induction chemotherapy +
2 chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. *Journal of*
3 *Gastrointestinal Oncology* 8(4): 683-695
- 4 Liu W, Fu XL, Yang JY et al. (2016) Efficacy of Neo-Adjuvant chemoradiotherapy for
5 Resectable pancreatic cancer: A PRISMA-Compliant Meta-Analysis and Systematic Review.
6 *Medicine (Baltimore)* 95(15): e3009
- 7 Takahashi H, Ohigashi H, Gotoh K et al. (2013) Preoperative gemcitabine-based
8 chemoradiation therapy for resectable and borderline resectable pancreatic cancer. *Annals*
9 *of Surgery* 258(6): 1040-50
- 10 Varadhachary GR, Wolff RA, Crane CH et al. (2008) Preoperative gemcitabine and cisplatin
11 followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the
12 pancreatic head. *Journal of Clinical Oncology* 26: 3487-3495
- 130.1.10.1 Studies included in Festa et al., 2013 (n=10)**
- 14 Le Scodan R, Mornex F, Girard N et al. (2009) Preoperative chemoradiation in potentially
15 resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic
16 factors, analysis of the SFRO-FFCD 9704 trial and literature review. *Annals of Oncology*
17 20(8): 1387-96
- 18 Lee JL, Kim SC, Kim JH et al. (2012) Prospective efficacy and safety study of neoadjuvant
19 gemcitabine with capecitabine combination chemotherapy for borderline-resectable or
20 unresectable locally advanced pancreatic cancer. *Surgery* 152(5): 851-62
- 21 Leone F, Gatti M, Massucco P et al. (2013) Induction gemcitabine and oxaliplatin therapy
22 followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation
23 for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional
24 experience. *Cancer* 119(2): 277-84
- 25 Magnin V, Moutardier V, Giovannini MH et al. (2003) Neoadjuvant preoperative
26 chemoradiation in patients with pancreatic cancer. *International Journal*
27 *Radiation*Oncology*Biology*Physics* 55(5): 1300-4
- 28 Massucco P, Capussotti L, Magnino A et al. (2006) Pancreatic resections after
29 chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative
30 outcome and survival. *Annals of Surgical Oncology* 13(9): 1201-8
- 31 Mehta VK, Fisher G, Ford JA et al. (2001) Preoperative chemoradiation for marginally
32 resectable adenocarcinoma of the pancreas. *Journal of Gastrointestinal Surgery* 5(1): 27-35
- 33 Pipas JM, Barth RJ Jr, Zaki B et al. (2005) Docetaxel/gemcitabine followed by gemcitabine
34 and external beam radiotherapy in patients with pancreatic adenocarcinoma. *Annals of*
35 *Surgical Oncology* 12(12): 995-1004
- 36 Sahara K, Kuehrer I, Schindl M et al. (2011a) NeogemcitabineTax: gemcitabine and
37 docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic
38 cancer. *World Journal of Surgery* 35(7): 1580-9
- 39 Sahara K, Kuehrer I, Eisenhut A et al. (2011b) NeogemcitabineOx: gemcitabine and
40 oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic
41 cancer. *Surgery* 149(3): 311-20
- 42 Small W Jr, Mulcahy MF, Rademaker A et al. (2011) Phase II trial of full-dose gemcitabine
43 and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy
44 in patients with localized pancreatic cancer. *International Journal*
45 *Radiation*Oncology*Biology*Physics* 80(2): 476-82

10.1.10.2 Studies included in Liu et al., 2016 (n=8)

2 Casadei R, Di Marco M, Ricci C et al. (2015) Neoadjuvant chemoradiotherapy and surgery
3 versus surgery alone in resectable pancreatic cancer: A single-center prospective,
4 randomized, controlled trial which failed to achieve accrual targets. *Journal of*
5 *Gastrointestinal Surgery* 19(10): 1802-12

6 Golcher H, Brunner T, Grabenbauer G et al. (2008) Preoperative chemoradiation in
7 adenocarcinoma of the pancreas: A single centre experience advocating a new treatment
8 strategy. *European Journal of Surgical Oncology* 34(7): 756-64

9 Golcher H, Brunner TB, Witzigmann H et al. (2015) Neoadjuvant chemoradiation therapy
10 with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic
11 cancer: results of the first prospective randomized phase II trial. *Strahlentherapie und*
12 *Onkologie* 191(1): 7-16

13 Papalezova KT, Tyler DS, Blazer DG et al. (2012) Does preoperative therapy optimize
14 outcomes in patients with resectable pancreatic cancer? *Journal of Surgical Oncology*
15 106(1): 111-8

16 Satoi S, Yanagimoto H, Toyokawa H et al. (2009) Surgical results after preoperative
17 chemoradiation therapy for patients with pancreatic cancer. *Pancreas* 38(3): 282-8

18 Sho M, Akahori T, Tanaka T et al. (2013) Pathological and clinical impact of neoadjuvant
19 chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable
20 pancreatic cancer. *Journal of Hepato-biliary Pancreatic Sciences* 20(2): 197-205

21 Tzeng CW, Tran Cao HS, Lee JE et al. (2014) Treatment sequencing for resectable
22 pancreatic cancer: influence of early metastases and surgical complications on multimodality
23 therapy completion and survival. *Journal of Gastrointestinal Surgery* 18(1): 16-24

24 Vento P, Mustonen H, Joensuu T et al. (2007) Impact of preoperative chemoradiotherapy on
25 survival in patients with resectable pancreatic cancer. *World Journal of Gastroenterology*
26 13(21): 2945-51

27 10.2 Resectable and borderline resectable pancreatic cancer

28 **Review question: What is the most effective surgery (type and extent) for adults with**
29 **newly diagnosed resectable and borderline resectable pancreatic cancer?**

30 10.2.1 Introduction

31 Resectional surgery is the only cure for pancreatic cancer and is indicated in a proportion of
32 people with this disease. The possibility of a resection in an individual depends on the stage
33 of the tumour and their fitness for surgery. For surgery to be successful, in terms of
34 improving survival, a complete resection of the tumour is necessary. The type of surgery is
35 therefore important.

36 Prior to surgery the person's tumour is assessed with imaging tests to determine whether the
37 tumour might be resectable. Based on the information provided by these tests it is usually
38 possible to identify whether the tumour might be: resectable (one that would be expected to
39 be removed surgically); borderline resectable (one that might be); locally advanced (not
40 resectable but still confined to the pancreas and surrounding tissues); or metastatic (where
41 the tumour has spread to lymph-nodes or other organs).

42 Resectional surgery is not performed on tumours identified as locally advanced or metastatic.
43 For tumours identified as resectable or borderline resectable, a variety of different types of

1 surgery, surgical access and surgical dissection are used depending on the site of the
2 tumour in the pancreas and involvement of other structures.

3 Guidance is needed on the most effective type and extent surgery for people with resectable
4 and borderline resectable pancreatic cancer in order to standardise practice.

5 10.2.1.1 Review protocol summary

6 The review protocol summary used for this question can be found in Table 129. Full details of
7 the review protocol can be found in Appendix C.

8 **Table 129: Clinical review protocol summary for the review of type and extent of**
9 **surgery**

Population	Adults with <ul style="list-style-type: none"> • Resectable pancreatic cancer • Borderline resectable pancreatic cancer 	
Intervention/Comparator	Minimally invasive surgery <ul style="list-style-type: none"> • Laparoscopic • Robotic 	Open surgery
	Extended surgery (e.g. venous arterial, extent of lymph nodes resection, other organs to be removed)	Standard surgery
Outcomes	<ul style="list-style-type: none"> • Local Recurrence • Distant Recurrence • Overall Survival • Post-operative death (30 day/90 day) • Treatment related morbidity • Treatment related mortality • Lymph node harvest • Health Related Quality of Life • Patient experience • PROMS 	

10 10.2.2 Description of Clinical Evidence

11 Sixteen studies were included in this review: 15 systematic reviews/meta-analyses (de Rooij
12 et al., 2016; Doula et al., 2016; Giovianazzo et al., 2016; Huttner et al., 2016; Ke et al., 2014;
13 Lei et al., 2014; Mollberg et al., 2011; Pedziwiatr et al., 2017; Peng et al., 2016; Shin et al.,
14 2016; Sui et al., 2012; Venkat et al., 2012; Yu et al., 2014; Zhang et al., 2013; Zhou et al.,
15 2012) and 1 RCT (Kawai et al., 2014). A summary of the included studies is presented in
16 Table 130.

17 Five systematic reviews/meta-analyses (de Rooij et al., 2016; Doula et al., 2016; Let et al.,
18 2014; Pedziwiatr et al., 2017; Shin et al., 2016) of 30 cohort studies (n=3870) - 4 prospective
19 cohort studies (n=425; Chen et al., 2015; Cho et al., 2009; Delitto et al., 2016; Hammill et al.,
20 2010) and 26 retrospective cohort studies (n=3445; Asbun & Stauffer 2010; Baker et al.,
21 2016; Bao et al., 2014; Boggi et al., 2016; Buchs et al., 2011; Chalikonda et al., 2012;
22 Croome et al., 2014; Croome et al. 2015; Dokmak et al., 2015; Gumbs et al., 2008; Hakeem
23 et al., 2014; Ito et al., 2009; Kuroki et al., 2012; Lai et al., 2012; Langan et al., 2014; Mesleh
24 et al., 2013; Pugliese et al., 2008; Song et al., 2015; Speicher et al., 2014; Tan et al., 2015;
25 Tee et al., 2015; Wang et al., 2014; Wellner et al., 2014; Zhou et al., 2011; Zureikat et al.,
26 2011; Zureikat et al., 2016) – and 3 Registry studies (n=27,057; Abdelgadir Adam et al.,

- 1 2015; Sharpe et al., 2015; Tran et al., 2016) compared minimally invasive (laparoscopic
2 and/or robotic) pancreatoduodenectomy with open pancreatoduodenectomy .
- 3 One systematic review/meta-analysis (Huttner et al., 2016) of 8 retrospective cohort studies
4 (n=512; Bloechle et al., 1999; Lin & Lin, 1999; Paquet, 1998; Seiler et al., 2005;
5 Srinarmwong et al., 2008; Taher et al., 2015; Tran et al., 2004; Wenger et al., 1999) and 1
6 RCT (n=130; Kawai et al. 2014) compared Pylorus-preserving Whipple with Classic Whipple.
- 7 Two systematic reviews/meta-analyses (Venkat et al., 2012; Sui et al., 2012) of 21
8 retrospective cohort studies (n=1992) compared minimally invasive laparoscopic distal
9 pancreatectomy with open pancreatectomy (Aly et al., 2010; Bruzoni & Sasson, 2008;
10 Casedei et al., 2010; DiNorcia et al., 2010; Eom et al., 2008; Finan et al., 2009; Jayaraman
11 et al., 2010; Kim et al., 2008; Kooby et al., 2010; Matsumoto et al., 2008; Misawa et al.,
12 2007; Nakamura et al., 2009; Shimura et al., 2006; Tang et al., 2007; The et al., 2007;
13 Velanovich et al., 2006; Vijan et al., 2010; Waters et al., 2010; Zhao et al., 2010).
- 14 One systematic review/meta-analysis (Zhang et al., 2013) of 3 cohort studies (n=104; Kang
15 et al., 2011; Walsh et al., 2011; Waters et al., 2010) compared minimally invasive robotic
16 pancreatectomy with open pancreatectomy.
- 17 One systematic review/meta-analysis (Ke et al., 2014) of 4 RCTs (n=428) compared
18 extended lymphadectomy with standard lymphadectomy (Farnell et al., 2005; Nimura et al.,
19 2012; Pedrazzoli et al., 1998; Riall et al., 2005).
- 20 One systematic review/meta-analysis (Mollberg et al., 2011) of 26 retrospective
21 observational studies (n=2609) compared arterial resection with no arterial resection
22 (Allendorf et al., 2008; Amano et al., 2009; Bockhorn et al., 2011; Boggi et al., 2009;
23 Denecke et al., 2010; Fortner et al., 2009; Hartwig W et al., 2009; Hirano et al., 2007;
24 Hishinuma et al., 2007; Kato et al., 2009; Kinoshita et al., 2001; Klempnauer et al., 1996;
25 Martin et al., 2009; Miyakawa et al., 2002; Miyazaki, 2003; Ogata et al., 1997; Ouaiissi et al.,
26 2010; Park et al., 2001; Settmacher et al., 2004; Shimada et al., 2006; Sperti et al., 2010;
27 Stitzenberg et al., 2008; Sugiura et al., 2009; Wang et al., 2008; Wu et al., 2008).
- 28 Three systematic reviews/meta-analyses (Giovinazzo et al., 2016; Yu et al., 2014; Zhou et
29 al., 2012) of 34 retrospective cohort studies (n=9937) compared venous resection with no
30 venous resection (Al-Haddad et al., 2007; Allema et al., 1994; Banz et al., 2012; Bachellier et
31 al., 2001; Carrere et al., 2006; Castleberry et al., 2012; Chakravarty et al., 2010; Furhman et
32 al., 2007; Fukuda et al., 2007; Gong et al., 2013; Harrison et al., 1996; Hartel et al., 2002;
33 Howard et al., 2003; Illumnati et al., 2008; Kaneoka et al., 2009; Kawada et al., 2002; Kelly et
34 al., 2013; Kurosaki et al., 2008; Launois et al., 1999; Leach et al., 1998; Martin et al., 2009;
35 Murakami et al., 2013; Nakagohri et al., 2003; Ouaiissi et al., 2010; Poon et al., 2004;
36 Ravikumar et al., 2014; Riediger et al., 2006; Shibata et al., 2001; Shimada et al., 2006;
37 Shrikhande et al., 2011; Sperti et al., 1996; Tseng et al., 2004; Yang et al., 2016)
- 38 Where possible, the risk of bias information was taken from the systematic reviews. In some
39 cases, where there was not enough detail included in the review (Ke et al., 2014; Zhang et
40 al., 2013), the original study was used to determine risk of bias.
- 41 Further information about the search strategy can be found in Appendix D. See study
42 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
43 study evidence tables in Appendix F and list of excluded studies in Appendix G.
- 44
- 45

10.2.31 Summary of included studies

2 A summary of the studies that were included in this review is presented in Table 130.

3 **Table 130: Summary of included studies**

Study	N	# of studies	Design of studies	Intervention	Comparison	Included outcomes
De Rooij et al. (2016)	706	8 cohort	SR of cohort and registry studies	Minimally invasive laparoscopic pancreatoduodenectomy Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	Post-operative mortality R0 resection rate Operation time Delayed gastric emptying Pancreatic fistula Blood loss Retrieved lymph nodes Length of stay
	27,057	3 registry				
Doula et al. (2016)	68	2	SR of cohort studies	Minimally invasive laparoscopic pancreatoduodenectomy Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	Post-operative mortality R0 resection rate Operation time Delayed gastric emptying Pancreatic fistula Blood loss Retrieved lymph nodes
Lei et al. (2014)	15	1	SR of cohort studies	Minimally invasive laparoscopic pancreatoduodenectomy Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	Operation time Delayed gastric emptying Pancreatic fistula Blood loss
Pędziwiatr et al. (2017)	1382	5	SR of cohort studies	Minimally invasive laparoscopic pancreatoduodenectomy Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	R1 resection rate Operation time Delayed gastric emptying Pancreatic fistula Blood loss Retrieved lymph nodes Length of stay

Study	N	# of studies	Design of studies	Intervention	Comparison	Included outcomes
Peng et al. (2017)	77	1	SR of cohort studies	Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	Post-operative mortality
Shin et al. (2017)	1622	13	SR of cohort studies	Minimally invasive laparoscopic pancreatoduodenectomy Minimally invasive robotic pancreatoduodenectomy	Open pancreatoduodenectomy	Operation time Delayed gastric emptying Pancreatic fistula Blood loss Retrieved lymph nodes Length of stay
Huttner et al. (2016) Kawai et al. (2014) ^a	642	9	SR of RCTs RCT	Pylorus-preserving Whipple	Classic Whipple	Overall survival Post-operative mortality R0 resection rate Operation time Delayed gastric emptying Pancreatic fistula Biliary leakage Reoperation rate Intraoperative blood loss Surgical site infection Length of hospital stay
Venkat et al. (2012); Sui et al. (2012)	1992	21	SRs of retrospective cohort studies	Minimally invasive laparoscopic distal pancreatectomy	Open pancreatectomy	Mortality Positive margin rate Pancreatic fistula Reoperation rate Operative blood loss Surgical site infection Operation time Length of hospital stay Time to oral intake
Zhang et al. (2013)	104	3	SR of cohort studies	Minimally invasive robotic pancreatectomy	Open pancreatectomy	Post-operative mortality Positive margin rate Pancreatic fistula Operation time

Study	N	# of studies	Design of studies	Intervention	Comparison	Included outcomes
						Length of hospital stay
Ke et al. (2014)	428	4	SR of RCTs	Extended lymphadenectomy	Standard lymphadenectomy	Overall survival Positive/negative margin status Positive/negative lymph nodes
Mollberg et al. (2011)	2609	26	SR of retrospective observational studies	Arterial resection	No arterial resection	Overall survival Post-operative mortality Reoperation rate R0 resection rate Positive lymph nodes Post-operative morbidity
Giovinazzo et al. (2016); Zhou et al. (2012); Yu et al. (2014)	9937	34	SRs of retrospective cohort studies	Venous resection	No venous resection	Overall survival Post-operative mortality Reoperation rate R1/R2 resection rate Operative morbidity

1 Notes: ^a, Huttner et al. (2016) is a systematic review/meta-analysis, whilst Kawai et al. (2014) is a single study. Abbreviations: SR, systematic review

1 10.2.4 Clinical Evidence Profile

2 The clinical evidence profiles for this review question are presented in Table 131 to Table
3 137.

4 **Table 131: Summary clinical evidence profile for minimally invasive (laparoscopic or**
5 **robotic) versus open pancreatoduodenectomy**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Open pancreatoduodenectomy	Minimally invasive (laparoscopic or robotic) pancreatoduodenectomy				
Postoperative Mortality (cohort studies)	29 per 1000	28 per 1000 (17 to 45)	RR 0.96 (0.6 to 1.55)	2959 (19 studies)	⊕⊕⊕⊕ very low1,2,3,4	
Postoperative Mortality (Registry studies)	42 per 1000	54 per 1000 (31 to 94)	RR 1.29 (0.74 to 2.25)	27057 (3 studies)	⊕⊕⊕⊕ very low3,4,5,6	
R0 resection rate - laparoscopic or robotic	703 per 1000	753 per 1000 (710 to 795)	RR 1.07 (1.01 to 1.13)	1793 (19 studies)	⊕⊕⊕⊕ very low1,2	
R0 resection rate - laparoscopic	692 per 1000	740 per 1000 (692 to 796)	RR 1.07 (1 to 1.15)	1374 (11 studies)	⊕⊕⊕⊕ very low1,2	
R0 resection rate - robotic	746 per 1000	806 per 1000 (739 to 880)	RR 1.08 (0.99 to 1.18)	419 (8 studies)	⊕⊕⊕⊕ very low1,2	
R0 resection rate (Registry studies)	740 per 1000	799 per 1000 (762 to 843)	RR 1.08 (1.03 to 1.14)	4422 (1 study)	⊕⊕⊕⊕ very low5,6	
R1 resection rate - laparoscopic (fixed effects)	207 per 1000	203 per 1000 (137 to 298)	RR 0.98 (0.66 to 1.44)	610 (3 studies)	⊕⊕⊕⊕ very low1,2,7	
R1 resection rate -	295 per 1000	207 per 1000 (65 to 673)	RR 0.7 (0.22 to 2.25)	612 (5 studies)	⊕⊕⊕⊕ very low1,2,7,8	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
robotic (random effects)			to 2.28)			
Operation Time [mins] - laparoscopic or robotic (random effects)	The mean operation time [mins] - laparoscopic or robotic (random effects) ranged across control groups from 264-555 mins	The mean operation time [mins] - laparoscopic or robotic (random effects) in the intervention groups was 74.31 higher (44.63 to 103.98 higher)		3662 (25 studies)	⊕⊖⊖⊖ very low1,2,9,10,11	
Operation time - laparoscopic (random effects)	The mean operation time - laparoscopic (random effects) ranged across control groups from 264-555 mins	The mean operation time - laparoscopic (random effects) in the intervention groups was 65.83 higher (26.48 to 105.18 higher)		1962 (15 studies)	⊕⊖⊖⊖ very low1,2,9,10,11	
Operation time - robotic (random effects)	The mean operation time - robotic (random effects) ranged across control groups from 265-559 mins	The mean operation time - robotic (random effects) in the intervention groups was 87.47 higher (39.78 to 135.16 higher)		1700 (10 studies)	⊕⊖⊖⊖ very low1,2,9,10,11	
Delayed Gastric Emptying	189 per 1000	136 per 1000 (112 to 167)	RR 0.72 (0.59 to 0.88)	2162 (19 studies)	⊕⊖⊖⊖ very low1,2,12	
Pancreatic Fistula - Grade A-C	158 per 1000	158 per 1000 (136 to 185)	RR 1.0 (0.86 to 1.17)	3296 (25 studies)	⊕⊖⊖⊖ very low1,2	
Pancreatic Fistula (clinically relevant) - Grade B-C	149 per 1000	148 per 1000 (121 to 181)	RR 0.99 (0.81 to 1.21)	2129 (18 studies)	⊕⊖⊖⊖ very low1,2	
Blood loss [ml] - laparoscopic or robotic (random effects)	The mean blood loss [ml] - laparoscopic or robotic (random effects) ranged across control groups from 210-1510 ml	The mean blood loss [ml] - laparoscopic or robotic (random effects) in the intervention groups was 261.75 lower (367.14 to 156.36 lower)		2078 (19 studies)	⊕⊖⊖⊖ very low1,2,9,10,11	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Blood loss [ml] - laparoscopic (random effects)	The mean blood loss [ml] - laparoscopic (random effects) ranged across control groups from 400-1510 ml	The mean blood loss [ml] - laparoscopic (random effects) in the intervention groups was 317.11 lower (495.2 to 139.02 lower)		1525 (11 studies)		
Blood loss [ml] - robotic (random effects)	The mean blood loss [ml] - robotic (random effects) ranged across control groups from 210-827 ml	The mean blood loss [ml] - robotic (random effects) in the intervention groups was 209.89 lower (336.17 to 75.61 lower)		553 (8 studies)	⊕⊕⊕⊕ very low1,2,8,10,11	
Retrieved lymph nodes - laparoscopic or robotic (random effects)	The mean retrieved lymph nodes - laparoscopic or robotic (random effects) ranged across control groups from 10-20 retrieved lymph nodes	The mean retrieved lymph nodes - laparoscopic or robotic (random effects) in the intervention groups was 1.26 higher (0.81 lower to 3.33 higher)		2779 (19 studies)	⊕⊕⊕⊕ very low1,2,9,10	
Retrieved lymph nodes - laparoscopic (random effects)	The mean retrieved lymph nodes - laparoscopic (random effects) ranged across control groups from 10-20 retrieved lymph nodes	The mean retrieved lymph nodes - laparoscopic (random effects) in the intervention groups was 0.84 higher (0.95 lower to 2.63 higher)		1285 (12 studies)	⊕⊕⊕⊕ very low1,2,8,10	
Retrieved lymph nodes - robotic (random effects)	The mean retrieved lymph nodes - robotic (random effects) ranged across control groups from 10-20 retrieved lymph nodes	The mean retrieved lymph nodes - robotic (random effects) in the intervention groups was 2.05 higher (2.28 lower to 6.39 higher)		1494 (7 studies)	⊕⊕⊕⊕ very low1,2,9,10,11	
Retrieved lymph nodes (Registry studies)	The mean retrieved lymph nodes (registry studies) in the control groups was 0	The mean retrieved lymph nodes (registry studies) in the intervention groups was 0.21 standard deviations lower (0.31 to 0.1 lower)		4422 (1 study)	⊕⊕⊕⊕ very low5,6	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Hospital stay [days] - laparoscopic or robotic (random effects)	The mean hospital stay [days] - laparoscopic or robotic (random effects) ranged across control groups from 8-26 days	The mean hospital stay [days] - laparoscopic or robotic (random effects) in the intervention groups was 2.96 lower (4.25 to 1.68 lower)		1700 (17 studies)	⊕⊕⊕⊕ very low1,2,8,10	
Hospital stay [days] - laparoscopic (random effects)	The mean hospital stay [days] - laparoscopic (random effects) ranged across control groups from 8-23 days	The mean hospital stay [days] - laparoscopic (random effects) in the intervention groups was 2.54 lower (4.02 to 1.06 lower)		1246 (11 studies)	⊕⊕⊕⊕ very low1,2,8,10	
Hospital stay [days] - robotic (random effects)	The mean hospital stay [days] - robotic (random effects) ranged across control groups from 8-26 days	The mean hospital stay [days] - robotic (random effects) in the intervention groups was 4.1 lower (6.89 to 1.32 lower)		454 (6 studies)		
Hospital stay [days] (Registry studies)	The mean hospital stay [days] (registry studies) in the control groups was 0	The mean hospital stay [days] (registry studies) in the intervention groups was 0.16 standard deviations lower (0.22 to 0.09 lower)		19996 (2 studies)	⊕⊕⊕⊕ very low5,6	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 All studies included in this outcome are cohort studies and were thus not randomised. High risk of selection bias as type of surgery may be determined by patient's suitability. High risk of performance bias due to centre and operator differences.

2 Study samples were composed of between <1% and 68% pancreatic cancer patients, with majority of studies selecting patients on basis of having had surgery.

3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.

4 No significant difference on this outcome between the two arms.

5 Data is from various US centres performing pancreaticoduodenectomies, with 2 studies using the National Cancer Database and 1 study using the Nationwide Inpatient Sample. No data regarding type of surgery (e.g. laparoscopic or robotic) used available. High risk of selection bias as type of surgery may be determined by patient's suitability. High risk of performance bias due to operator and centre differences.

6 No information on composition of sample available but likely that includes wide variety of patients.

7 95% CI crosses 2 default MIDs (0.8 and 1.25).

8 High heterogeneity ($I^2 > 50\%$).

9 Very high heterogeneity ($I^2 > 80\%$)

10 MIDs for these outcomes are as follows: operation time (laparoscopic or robotic)=+/- 49 mins; operation time (laparoscopic)=+/- 49 mins; operation time (robotic)=+/-51.31 mins; blood loss (laparoscopic or robotic)=+/- 259.5 mls; blood loss (laparoscopic)=+/- 278 mls; blood loss (robotic)=+/- 239.5 mls; retrieved lymph nodes (laparoscopic or robotic)=+/- 4.3 nodes; retrieved lymph nodes (laparoscopic)=+/- 4.59 nodes; retrieved lymph nodes (robotic)=+/- 4 nodes; hospital stay(laparoscopic or robotic)=+/- 4.33 days; hospital stay (laparoscopic)=+/- 4.3 days; hospital stay (robotic)=+/- 5.4 days.

11 95% CI crosses 1 MID for this outcome.

12 95% CI crosses 1 default MID (0.8 or 1.25).

1
2
3

Table 132: Summary clinical evidence profile for pylorus preserving Whipple versus classic Whipple

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Classic Whipple	Pylorus Preserving Whipple				
Overall Survival Follow-up: 1-115 months	625 per 1000	511 per 1000 (344 to 698)	HR 0.73 (0.43 to 1.22)	335 (3 studies)	⊕⊕⊕⊖ low1,2,3,4	
Postoperative Mortality Follow-up: 1-115 months ⁵	60 per 1000	40 per 1000 (19 to 86)	RR 0.66 (0.31 to 1.43)	464 (7 studies)	⊕⊖⊖⊖ very low1,3,4,6	
R0 Resection Rate	819 per 1000	810 per 1000 (737 to 892)	RR 0.99 (0.9 to 1.09)	359 (4 studies)	⊕⊕⊕⊖ low1,6	
Operation Time (random effects)		The mean operation time (random effects) in the intervention groups was 44.96 lower (78.2 to 11.73 lower)		452 (6 studies)	⊕⊖⊖⊖ very low1,6,7,8	
Delayed Gastric Emptying (random effects) Follow-up: 1-115 weeks ⁵	235 per 1000	505 per 1000 (230 to 1000)	RR 2.15 (0.98 to 4.71)	459 (7 studies)	⊕⊖⊖⊖ very low1,6,9,10	
Pancreatic Fistula Follow-up: 1-115 months	93 per 1000	88 per 1000 (51 to 150)	RR 0.94 (0.55 to 1.61)	468 (7 studies)	⊕⊖⊖⊖ very low1,6,11	
Biliary Leakage Follow-up: 1-115 months ⁵	21 per 1000	21 per 1000 (7 to 62)	RR 1.01 (0.35 to 2.91)	380 (5 studies)	⊕⊖⊖⊖ very low1,6,11	
Reoperation rate	115 per 1000	96 per 1000 (52 to 178)	RR 0.84 (0.45 to 1.55)	320 (5 studies)	⊕⊖⊖⊖ very low1,6,11	
Blood Loss (litres) Follow-up: 1-115 months ⁵	The mean blood loss (litres) in the control	The mean blood loss (litres) in the intervention groups was		404 (5 studies)	⊕⊖⊖⊖ very low1,6,8,12	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	groups was 0.1 litres	0.37 lower (0.77 lower to 0.04 higher)				
Surgical site infection	98 per 1000	85 per 1000 (38 to 185)	RR 0.86 (0.39 to 1.88)	251 (4 studies)	⊕⊕⊕⊕ very low ^{1,6,11}	
Hospital Stay (days)		The mean hospital stay (days) in the intervention groups was 0.26 higher (2.04 lower to 2.56 higher)		366 (5 studies)	⊕⊕⊕⊕ low ^{1,3,6,8}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Inadequate reporting of sequence generation and allocation concealment. Small sample size (Lin et al), no power calculations, no intention to treat analysis,

2 Subgroup analysis of pancreatic head carcinoma

3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.

4 No significant difference on this outcome between the two arms.

5 Follow-up not reported in all studies

6 Includes patients with periampullary cancer

7 Very high heterogeneity ($I^2 > 80\%$)

8 Distribution of continuous outcomes is known to be skewed and may introduce bias to the analysis. MID for continuous outcomes, calculated from median SD of control arm at follow up, are as follows: operating time is +/- 26.8 mins; intraoperative blood loss is +/- 0.202 litres; hospital stay is +/- 6.9 days.

9 High heterogeneity ($I^2 > 50\%$)

10 95% CI crosses 1 default MID (0.8 or 1.25).

11 95% CI crosses both default MIDs (0.8 and 1.25).

12 95% CI crosses 1 MID for this outcome.

1
2

Table 133: Summary clinical evidence profile for minimally invasive laparoscopic distal pancreatectomy versus open pancreatectomy

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Open Pancreatectomy	MI laparoscopic distal pancreatectomy				
Mortality	13 per 1000	8 per 1000 (3 to 22)	RR 0.59 (0.21 to 1.65)	1723 (17 studies)	⊕⊕⊕⊕ very low ^{1,2,3,4}	
Positive Margins	52 per 1000	31 per 1000 (17 to 55)	RR 0.59 (0.32 to 1.06)	1331 (7 studies)	⊕⊕⊕⊕ very low ^{1,2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Pancreatic Fistula (All)	205 per 1000	186 per 1000 (153 to 225)	RR 0.91 (0.75 to 1.1)	1814 (18 studies)	⊕⊕⊕⊕ very low1,2,5	
Pancreatic Fistula Grade B-C	150 per 1000	129 per 1000 (90 to 183)	RR 0.86 (0.6 to 1.22)	834 (6 studies)	⊕⊕⊕⊕ very low1,2,5	
Reoperation Rates	31 per 1000	24 per 1000 (10 to 55)	RR 0.76 (0.33 to 1.75)	847 (5 studies)	⊕⊕⊕⊕ very low1,2,6	
Blood Loss [ml] (random effects)		The mean blood loss [ml] (random effects) in the intervention groups was 332.22 lower (480.99 to 183.65 lower)		1341 (16 studies)	⊕⊕⊕⊕ very low1,2,7,8,9	
Surgical Site Infection	79 per 1000	35 per 1000 (20 to 59)	RR 0.44 (0.25 to 0.75)	1127 (11 studies)	⊕⊕⊕⊕ very low1,2	
Operation Time [mins] (random effects)		The mean operation time [mins] (random effects) in the intervention groups was 8.88 higher (6.46 lower to 24.24 higher)		1562 (18 studies)	⊕⊕⊕⊕ very low1,2,7,8	
Hospital stay [days] (random effects)		The mean hospital stay [days] (random effects) in the intervention groups was 3.88 lower (4.92 to 2.83 lower)		1811 (20 studies)	⊕⊕⊕⊕ very low1,2,7,8,9	
Time to Oral Intake (random effects)		The mean time to oral intake (random effects) in the intervention groups was 1.48 lower (2.43 to 0.53 lower)		388 (6 studies)	⊕⊕⊕⊕ very low1,2,8,10	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
CI: Confidence interval; RR: Risk ratio; 1 Not randomised comparisons 2 Population not all pancreatic cancer patients 3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups. 4 No significant difference on this outcome between the two arms. 5 95% CI crosses 1 MID (0.8 or 1.25). 6 95% CI crosses 2 default MIDs (0.8 and 1.25). 7 Very high heterogeneity (I ² >80%). 8 MIDs for continuous outcomes, calculated from median SD of control arm at follow up, are as follows: blood loss is +/- 291.5 litres (Median SD=583 litres); operation time is +/- 33.3 mins (Median SD=66.7 mins); length of hospital stay is +/- 2.9 days (median SD=5.7 days); time to oral intake is +/- 2.8 days (median SD=5.4 days). 9 95% CI crosses 1 MID for this outcome. 10 High heterogeneity (I ² >50%)						

1
2

Table 134: Summary clinical evidence profile for minimally invasive robotic pancreatectomy versus open pancreatectomy

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Open pancreatectomy	MI Robotic pancreatectomy				
Postoperative Mortality			RR 3.0 (0.13 to 70.3)	104 (3 studies)	⊕⊕⊕ ⊖ very low ^{1,2,3}	
Positive Margin Rate	120 per 1000	17 per 1000 (1 to 316)	RR 0.14 (0.01 to 2.63)	50 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2,4}	
Overall Complication Rate	351 per 1000	253 per 1000 (140 to 463)	RR 0.72 (0.4 to 1.32)	104 (3 studies)	⊕⊕⊕ ⊖ very low ^{1,2,4}	
Pancreatic Fistula - Grade A-C (random effects)	148 per 1000	92 per 1000 (4 to 1000)	RR 0.62 (0.03 to 13.52)	50 (2 studies)	⊕⊕⊕ ⊖ very low ^{1,2,4}	
Operation Time [mins]	The mean operation time [mins] in the control groups was 287 mins	The mean operation time [mins] in the intervention groups was 189.5 higher (109.24 to 269.76 higher)		15 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2,5}	
Reoperation rate	229 per 1000	78 per 1000 (21 to 295)	RR 0.34 (0.09 to 1.29)	65 (2 studies)	⊕⊕⊕ ⊖ very low ^{1,2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Blood loss [ml]		The mean blood loss [ml] in the intervention groups was 0.57 standard deviations lower (1.07 to 0.06 lower)		65 (2 studies)	⊕⊕⊕ ⊖ very low ^{1,2,6}	
Hospital stay [days]	The mean hospital stay [days] in the control groups was 22 days	The mean hospital stay [days] in the intervention groups was 7.5 lower (18.15 lower to 3.15 higher)		15 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 All 3 studies included in this comparison from the systematic review of Zhang et al. 2013 were retrospective cohort studies and were thus not randomised. One of the studies was a conference abstract. High risk of selection bias as type of surgery may be determined by patient's suitability. High risk of performance bias due to centre and/or operator differences.

2 Patient samples were not restricted to people with confirmed or suspected pancreatic cancer.

3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.

4 95% CI crosses 2 default MIDs (0.8 and 1.25).

5 MIDs for these outcomes are as follows: Operation time=+/- 45.1 min; Hospital stay=+/- 6.65 days.

6 95% CI crosses 1 default MID for standardised mean difference (+0.5 or -0.5).

1
2

Table 135: Summary clinical evidence profile for extended versus standard lymphadenectomy

Outcome	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Standard lymphadenectomy	Extended lymphadenectomy				
Overall Survival Follow-up: 60-96 months	879 per 1000	902 per 1000 (838 to 948)	HR 1.1 (0.86 to 1.4)	412 (4 studies)	⊕⊕⊕⊕ low ^{1,2,3,4}	
Lymph nodes Positive Follow-up: 60-96 months	936 per 1000	943 per 1000 (876 to 980)	HR 1.04 (0.76 to 1.42)	280 (4 studies)	⊕⊕⊕⊕ very low ^{1,2,5}	
Lymph Nodes Negative Follow-	773 per 1000	792 per 1000 (577 to 944)	HR 1.06 (0.58 to 1.94)	132 (4 studies)	⊕⊕⊕⊕ very low ^{1,2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
up: 60-96 months						
Margin Status Positive	186 per 1000	112 per 1000 (71 to 179)	RR 0.6 (0.38 to 0.96)	428 (4 studies)	⊕⊕⊖⊖ low1,2,6	
Margin Status Negative (random effects)	805 per 1000	853 per 1000 (748 to 974)	RR 1.06 (0.93 to 1.21)	428 (4 studies)	⊕⊕⊖⊖ low1,2,7	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Inadequate reporting of randomisation and allocation concealment, no assessor blinding, incomplete outcome data
2 Only data relevant to patients with pancreatic cancer were extracted and included in the systematic review
3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.
4 No significant difference on this outcome between the two arms.
5 95% CI crosses 2 default MIDs (0.8 and 1.25).
6 95% CI crosses 1 default MID (0.8 or 1.25)
7 High heterogeneity ($i^2 > 50\%$)

1
2**Table 136: Summary clinical evidence profile for arterial resection versus no arterial resection**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No Arterial Resection	Arterial Resection				
1-year Overall survival (random effects)	659 per 1000	547 per 1000 (442 to 672)	RR 0.83 (0.67 to 1.02)	1810 (12 studies)	⊕⊖⊖⊖ very low1,2,3,4	
1-year Overall Survival (arterial versus venous resection)	21 per 1000	165 per 1000 (74 to 367)	RR 7.96 (3.58 to 17.7)	670 (7 studies)	⊕⊖⊖⊖ very low1,3	
3-year Overall survival (random effects)	249 per 1000	115 per 1000 (57 to 234)	RR 0.46 (0.23 to 0.94)	1804 (12 studies)	⊕⊖⊖⊖ very low1,2,3	
Operative morbidity (random effects)	396 per 1000	523 per 1000 (365 to 749)	RR 1.32 (0.92 to 1.89)	1379 (7 studies)	⊕⊖⊖⊖ very low1,2,5	
Postoperative mortality	35 per 1000	155 per 1000 (89 to 271)	RR 4.40 (2.52 to 7.69)	2093 (14 studies)	⊕⊖⊖⊖ very low1	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Reoperation Rate	105 per 1000	244 per 1000 (170 to 350)	RR 2.33 (1.62 to 3.34)	1558 (7 studies)	⊕⊕⊕⊕ very low ¹	
R0 Resection Rate (random effects)	741 per 1000	675 per 1000 (497 to 912)	RR 0.91 (0.67 to 1.23)	1471 (9 studies)	⊕⊕⊕⊕ very low ^{1,5,6}	
Positive lymph nodes	601 per 1000	643 per 1000 (553 to 751)	RR 1.07 (0.92 to 1.25)	1201 (6 studies)	⊕⊕⊕⊕ very low ¹	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Not randomised studies
2 High heterogeneity ($i^2 > 50\%$)
3 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.
4 No significant difference on this outcome between the two arms.
5 95% CI crosses 1 default MID (0.8 or 1.25).
6 Very high heterogeneity ($i^2 > 80\%$)

1

2
3

Table 137: Summary clinical evidence profile for venous resection versus no venous resection

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No venous resection	Venous resection				
1-year overall survival (random effects)	See comment		HR 1.38 (1.04 to 1.83)	2082 (6 studies)	⊕⊕⊕⊕ very low ^{1,2}	Risk not calculable since # of events not provided
5-year overall survival	See comment		HR 3.19 (1.95 to 5.19)	637 (4 studies)	⊕⊕⊕⊕ very low ^{1,2}	Risk not calculable since # of events not provided
5-year overall survival (all studies)	172 per 1000	110 per 1000 (84 to 143)	RR 0.64 (0.49 to 0.83)	1532 (11 studies)	⊕⊕⊕⊕ very low ^{1,2}	
Post operative mortality	32 per 1000	47 per 1000 (35 to 61)	RR 1.45 (1.1 to 1.9)	8624 (28 studies)	⊕⊕⊕⊕ very low ^{1,3}	
Reoperation Rate	90 per 1000	119 per 1000 (99 to 142)	RR 1.32 (1.1 to 1.58)	6398 (11 studies)	⊕⊕⊕⊕ very low ^{1,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
R1-R2 resection rate	345 per 1000	459 per 1000 (414 to 507)	RR 1.33 (1.2 to 1.47)	3303 (18 studies)	⊕⊕⊕⊕ very low ^{1,3}	
Overall morbidity rate (random effects)	330 per 1000	390 per 1000 (333 to 456)	RR 1.18 (1.01 to 1.38)	6249 (16 studies)	⊕⊕⊕⊕ very low ^{1,3,4}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 No randomised, blinding or allocation concealment
2 The committee decided to downgrade mortality/survival outcomes by one level for imprecision only if there was not a significant difference between the groups.
3 95% CI crosses 1 default MID (0.8 or 1.25).
4 High heterogeneity ($i^2 > 50\%$)

1 10.2.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

7 10.2.6 Evidence Statements

8 10.2.6.1 Minimally invasive (laparoscopic or robotic) versus open pancreatoduodenectomy

9 Local or distant recurrence

10 No evidence was identified to inform this outcome.

11 Overall Survival

12 No evidence was identified to inform this outcome.

13 Postoperative Mortality

14 Very low quality evidence from 19 retrospective cohort studies (n=2959) showed no clinically
15 important difference between minimally invasive pancreatoduodenectomy and open
16 pancreatoduodenectomy on post-operative mortality in adults with resectable or borderline
17 resectable pancreatic cancer: RR 0.96 (95% CI, 0.60-1.55).

18 Very low quality evidence from 3 registry studies (n=27,057) showed no clinically important
19 difference between minimally invasive pancreatoduodenectomy and open
20 pancreatoduodenectomy on post-operative mortality in adults with resectable or borderline
21 resectable pancreatic cancer: RR 1.29 (95% CI, 0.74-2.25).

22 R0 Resection Rate

23 Very low quality evidence from 19 retrospective cohort studies (n=1793) showed no clinically
24 important difference between minimally invasive pancreatoduodenectomy and open
25 pancreatoduodenectomy on achieving an R0 resection in adults with resectable or

1 borderline resectable pancreatic cancer: RR 1.07 (95% CI, 1.01-1.13) [random effects
2 analysis].

- 3 • Very low quality evidence from 11 retrospective cohort studies (n=1374) showed no
4 clinically important difference between minimally invasive laparoscopic
5 pancreatoduodenectomy and open pancreatoduodenectomy on achieving an R0
6 resection in adults with resectable or borderline resectable pancreatic cancer: RR 1.07
7 (95% CI, 1.00-1.15) [random effects analysis].
- 8 • Very low quality evidence from 8 retrospective cohort studies (n=419) showed no
9 clinically important difference between minimally invasive robotic
10 pancreatoduodenectomy and open pancreatoduodenectomy on achieving an R0
11 resection in adults with resectable or borderline resectable pancreatic cancer: RR 1.08
12 (95% CI, 0.99-1.18) [random effects analysis].

13 Very low quality evidence from 1 registry study (n=4422) showed no clinically important
14 difference between minimally invasive pancreatoduodenectomy and open
15 pancreatoduodenectomy on achieving an R0 resection in adults with resectable or
16 borderline resectable pancreatic cancer: RR 1.08 (95% CI, 1.03-1.14)

17 **R1 Resection Rate**

18 Very low quality evidence from 3 retrospective cohort studies (n=610) showed no clinically
19 important difference between minimally invasive laparoscopic pancreatoduodenectomy and
20 open pancreatoduodenectomy on achieving an R1 resection in adults with resectable or
21 borderline resectable pancreatic cancer: RR 0.98 (95% CI, 0.66-1.44) [fixed effects analysis].

22 Very low quality evidence from 5 retrospective cohort studies (n=612) showed no clinically
23 important difference between minimally invasive robotic pancreatoduodenectomy and open
24 pancreatoduodenectomy on achieving an R1 resection in adults with resectable or
25 borderline resectable pancreatic cancer: RR 0.70 (95% CI, 0.22-2.28) [random effects
26 analysis].

27 **Operation time (mins)**

28 Very low quality evidence from 25 retrospective cohort studies (n=3662) showed that there is
29 a clinically important difference favouring open pancreatoduodenectomy on operation time
30 (mins) compared to minimally invasive pancreatoduodenectomy in adults with resectable or
31 borderline resectable pancreatic cancer: MD 74.31 (95% CI, 44.63-103.98) [random effects
32 analysis].

- 33 • Very low quality evidence from 15 retrospective cohort studies (n=535) showed that there
34 is a clinically important difference favouring open pancreatoduodenectomy on operation
35 time (mins) compared to minimally invasive laparoscopic pancreatoduodenectomy in
36 adults with resectable or borderline resectable pancreatic cancer: MD 65.83 (95% CI,
37 26.48-105.18) [random effects analysis].
- 38 • Very low quality evidence from 10 retrospective cohort studies (n=535) showed that there
39 is a clinically important difference favouring open pancreatoduodenectomy on operation
40 time (mins) compared to minimally invasive robotic pancreatoduodenectomy in adults
41 with resectable or borderline resectable pancreatic cancer: MD 87.47 (95% CI, 39.78-
42 135.16) [random effects analysis].

43 **Treatment Related Morbidity**

44 *Delayed Gastric Emptying*

45 Very low quality evidence from 19 retrospective cohort studies (n=2162) showed that there is
46 a clinically important difference favouring minimally invasive pancreatoduodenectomy on

1 delayed gastric emptying compared to open pancreatoduodenectomy in adults with
2 resectable or borderline resectable pancreatic cancer: RR 0.72 (95% CI, 0.59-0.88).

3 *Pancreatic Fistula*

4 Very low quality evidence from 25 retrospective cohort studies (n=3296) showed no clinically
5 important difference between minimally invasive pancreatoduodenectomy and open
6 pancreatoduodenectomy on Grade A-C pancreatic fistula formation in adults with resectable
7 or borderline resectable pancreatic cancer: RR 1.00 (95% CI, 0.86-1.17).

8 Very low quality evidence from 18 retrospective cohort studies (n=2129) showed no clinically
9 important difference between minimally invasive pancreatoduodenectomy and open
10 pancreatoduodenectomy on clinically relevant (Grade B-C) pancreatic fistula formation in
11 adults with resectable or borderline resectable pancreatic cancer: RR 0.99 (95% CI, 0.81-
12 1.21).

13 *Reoperation Rate*

14 Very low quality evidence from 12 retrospective cohort studies (n=1215) showed no clinically
15 important difference between minimally invasive pancreatoduodenectomy and open
16 pancreatoduodenectomy on the relative rates of reoperation in adults with resectable or
17 borderline resectable pancreatic cancer: RR 0.80 (95% CI, 0.52-1.21).

18 *Blood Loss (ml)*

19 Very low quality evidence from 19 retrospective cohort studies (n=2078) showed that there is
20 a clinically important difference favouring minimally invasive pancreatoduodenectomy on
21 blood loss compared with open pancreatoduodenectomy in adults with resectable or
22 borderline resectable pancreatic cancer: MD = -261.75 (95% CI, -367.14 to -156.36) [random
23 effects analysis].

- 24 • Very low quality evidence from 11 retrospective cohort studies (n=1525) showed that
25 there is a clinically important difference favouring minimally invasive laparoscopic
26 pancreatoduodenectomy on blood loss compared with open pancreatoduodenectomy in
27 adults with resectable or borderline resectable pancreatic cancer: MD = -317.11 (95% CI,
28 -495.20 to -139.02) [random effects analysis].
- 29 • Very low quality evidence from 8 retrospective cohort studies (n=553) showed that there
30 is a clinically important difference favouring minimally invasive robotic
31 pancreatoduodenectomy on blood loss compared with open pancreatoduodenectomy in
32 adults with resectable or borderline resectable pancreatic cancer: MD = -205.89 (95% CI,
33 -336.17 to -75.61) [random effects analysis].

34 **Hospital Stay (days)**

35 Very low quality evidence from 19 retrospective cohort studies (n=1700) showed no clinically
36 important difference between minimally invasive pancreatoduodenectomy and open
37 pancreatoduodenectomy on hospital stay in adults with resectable or borderline resectable
38 pancreatic cancer: MD = -2.96 (95% CI, -4.25 to -1.68) [random effects analysis].

- 39 • Very low quality evidence from 11 retrospective cohort studies (n=1246) showed showed
40 no clinically important difference between minimally invasive laparoscopic
41 pancreatoduodenectomy and open pancreatoduodenectomy on hospital stay in adults
42 with resectable or borderline resectable pancreatic cancer: MD = -2.54 (95% CI, -4.02 to
43 -1.06) [random effects analysis].
- 44 • Very low quality evidence from 6 retrospective cohort studies (n=454) showed showed no
45 clinically important difference between minimally invasive robotic
46 pancreatoduodenectomy and open pancreatoduodenectomy on hospital stay in adults

1 with resectable or borderline resectable pancreatic cancer: MD = -4.10 (95% CI, -6.89 to
2 -1.32) [random effects analysis].

3 Very low quality evidence from 2 registry studies (n=19,996) showed no clinically important
4 difference between minimally invasive pancreatoduodenectomy and open
5 pancreatoduodenectomy on hospital stay in adults with resectable or borderline resectable
6 pancreatic cancer: SMD = -0.16 (95% CI, -0.22 to -0.09).

7 **Lymph Node Harvest/Retrieval**

8 Very low quality evidence from 19 retrospective cohort studies (n=2779) patients showed no
9 clinically important difference between minimally invasive pancreatoduodenectomy and
10 open pancreatoduodenectomy on lymph node retrieval in adults with resectable or
11 borderline resectable pancreatic cancer: MD 1.26 (95% CI, -0.81 to 3.33).

- 12 • Very low quality evidence from 12 retrospective cohort studies (n=1285) patients showed
13 no clinically important difference between minimally invasive pancreatoduodenectomy
14 and open pancreatoduodenectomy on lymph node retrieval in adults with resectable or
15 borderline resectable pancreatic cancer: MD 0.84 (95% CI, -0.95 to 2.63).
- 16 • Very low quality evidence from 7 retrospective cohort studies (n=1494) patients showed
17 no clinically important difference between minimally invasive pancreatoduodenectomy
18 and open pancreatoduodenectomy on lymph node retrieval in adults with resectable or
19 borderline resectable pancreatic cancer: MD 2.05 (95% CI, -2.28 to 6.39).

20 **Quality of Life**

21 No evidence was identified to inform this outcome.

22 **Patient Experience**

23 No evidence was identified to inform this outcome.

24 **PROMs**

25 No evidence was identified to inform this outcome.

26 **10.2.6.2 Pylorus preserving Whipple (PPW) versus Classic Whipple (CW)**

27 **Local or distant recurrence**

28 No evidence was identified to inform this outcome.

29 **Overall Survival**

30 Low quality evidence from 3 RCTs (n=335) showed no clinically important difference
31 between Pylorus-preserving Whipple and Classic Whipple on overall survival in adults with
32 resectable or borderline resectable pancreatic cancer: HR=0.73 (95% CI, 0.43-1.22).

33 **Postoperative Mortality**

34 Very low quality evidence from 7 RCTs (n=464) showed no clinically important difference
35 between Pylorus-preserving Whipple and Classic Whipple on post-operative mortality in
36 adults with resectable or borderline resectable pancreatic cancer: RR 0.66 (95% CI, 0.31-
37 1.43).

1 **R0 Resection Rate**

2 Low quality evidence from 3 RCTs (n=359) showed no clinically important difference
3 between Pylorus-preserving Whipple and Classic Whipple on achieving an R0 resection in
4 adults with resectable or borderline resectable pancreatic cancer patients: RR 0.99 (95% CI,
5 0.9-1.09).

6 **Operation Time (mins)**

7 Very low quality evidence from 6 RCTs (n=452) showed that there is a clinically important
8 difference favouring Pylorus-preserving Whipple on operation time compared to Classic
9 Whipple in adults with resectable or borderline resectable pancreatic cancer: MD -44.96
10 (95% CI, -78.2 to -11.73) [random effects analysis].

11 **Treatment related morbidity**

12 *Delayed Gastric Emptying*

13 Very low quality evidence from 7 RCTs (n=459) showed that there may be a clinically
14 important difference between Pylorus-preserving Whipple and Classic Whipple on frequency
15 of delayed gastric emptying in adults with resectable or borderline resectable pancreatic
16 cancer, although there is some uncertainty: RR 2.15 (95% CI, 0.98-4.71) [random effects
17 analysis].

18 *Pancreatic Fistula*

19 Very low quality evidence from 7 RCTs (n=468) showed no clinically important difference
20 between Pylorus-preserving Whipple and Classic Whipple on pancreatic fistula formation in
21 adults with resectable or borderline resectable pancreatic cancer: RR 0.94 (95% CI, 0.55-
22 1.61).

23 *Biliary Leakage*

24 Very low quality evidence from 5 RCTs (n=380) showed no clinically important difference
25 between Pylorus-preserving Whipple and Classic Whipple on biliary leakage in adults with
26 resectable or borderline resectable pancreatic cancer: RR 1.01 (95% CI, 0.35-2.91).

27 *Reoperation Rate*

28 Very low quality evidence from 3 RCTs (n=320) showed no clinically important difference
29 between Pylorus-preserving Whipple and Classic Whipple on reoperation rate in adults with
30 resectable or borderline resectable pancreatic cancer: RR 0.84 (95% CI, 0.45-1.55).

31 *Intraoperative Blood Loss (litres)*

32 Very low quality evidence from 5 RCTs (n=404) showed that there is a clinically important
33 difference favouring Pylorus-preserving Whipple on blood loss compared to Classic Whipple
34 in adults with resectable or borderline resectable pancreatic cancer: MD -0.37 (95% CI, -0.77
35 to -0.04).

36 *Surgical Site Infection*

37 Very low quality evidence from 4 RCTs (n=251) showed no clinically important difference
38 between Pylorus-preserving Whipple and Classic Whipple on surgical site infection in adults
39 with resectable or borderline resectable pancreatic cancer: RR 0.86 (95% CI, 0.39-1.88).

1 **Hospital Stay (days)**

2 Low quality evidence from 5 RCTs (366) showed no clinically important difference between
3 Pylorus-preserving Whipple and Classic Whipple on length of hospital stay in adults with
4 resectable or borderline resectable pancreatic cancer: MD 0.26 (95% CI -2.04 to 2.56).

5 **Lymph Node Harvest**

6 No evidence was identified to inform this outcome.

7 **Quality of Life**

8 No evidence was identified to inform this outcome.

9 **Patient Experience**

10 No evidence was identified to inform this outcome.

11 **PROMs**

12 No evidence was identified to inform this outcome.

13 **10.2.6.3 Minimally invasive laparoscopic distal pancreatectomy versus open pancreatectomy**

14 **Local or distant recurrence**

15 No evidence was identified to inform this outcome.

16 **Overall Survival**

17 No evidence was identified to inform this outcome.

18 **Postoperative Mortality**

19 Very low quality evidence from 17 retrospective cohort studies (n=1723) showed no clinically
20 important difference between minimally invasive laparoscopic distal pancreatectomy and
21 open pancreatectomy on post-operative mortality in adults with resectable or borderline
22 resectable pancreatic cancer: RR 0.59 (95% CI, 0.21-1.65).

23 **Treatment Related Morbidity**

24 *Positive Margins*

25 Very low quality evidence from 7 retrospective cohort studies (n=1331) showed there may be
26 a clinically important difference between minimally invasive laparoscopic distal
27 pancreatectomy and open pancreatectomy on positive margin rate in adults with resectable
28 or borderline resectable pancreatic cancer, although there is some uncertainty: RR 0.59
29 (95% CI, 0.32-1.06).

30 *Pancreatic Fistula*

31 Very low quality evidence from 18 retrospective cohort studies (n=1814) showed no clinically
32 important difference between minimally invasive laparoscopic distal pancreatectomy and
33 open pancreatectomy on frequency of any pancreatic fistula formation in adults with
34 resectable or borderline resectable pancreatic cancer: RR 0.91 (95% CI, 0.75-1.1).

35 Very low quality evidence from 6 retrospective cohort studies (n=834) showed no clinically
36 important difference between minimally invasive laparoscopic distal pancreatectomy and

1 open pancreatectomy on frequency of ISGPF Grade B-C pancreatic fistula formation in
2 adults with resectable or borderline resectable pancreatic cancer: RR 0.86 (95% CI, 0.6-
3 1.22).

4 *Reoperation Rate*

5 Very low quality evidence from 5 retrospective cohort studies (n=847) showed no clinically
6 important difference between minimally invasive laparoscopic distal pancreatectomy and
7 open pancreatectomy on reoperation rate in adults with resectable or borderline resectable
8 pancreatic cancer: RR 0.76 (95% CI, 0.33-1.75).

9 *Operative Blood Loss (mls)*

10 Very low quality evidence from 16 retrospective cohort studies (n=1341) showed that there is
11 a clinically important difference favouring minimally invasive laparoscopic distal
12 pancreatectomy on blood loss (mls) compared to open pancreatectomy in adults with
13 resectable or borderline resectable pancreatic cancer: MD -332.2 (95% CI, -480.99 to -
14 183.45) [random effects analysis].

15 *Surgical Site Infection*

16 Very low quality evidence from 11 retrospective cohort studies (n=1127) showed that there is
17 a clinically important difference favouring minimally invasive laparoscopic distal
18 pancreatectomy on rate of surgical site infection compared to open pancreatectomy in adults
19 with resectable or borderline resectable pancreatic cancer: RR 0.44 (95% CI, 0.25-0.75).

20 **Operation Time (mins)**

21 Very low quality evidence from 18 retrospective cohort studies (n=1562) showed no clinically
22 important difference between minimally invasive laparoscopic distal pancreatectomy and
23 open pancreatectomy on operation time (minutes) in adults with resectable or borderline
24 resectable pancreatic cancer: MD 8.88 (95% CI, -6.46 to 24.23) [random effects analysis].

25 **Hospital Stay (days)**

26 Very low quality evidence from 20 retrospective cohort studies (n=1811) showed that there is
27 a clinically important difference favouring minimally invasive laparoscopic distal
28 pancreatectomy on length of hospital stay (days) compared to open pancreatectomy in
29 adults with resectable or borderline resectable pancreatic cancer: MD -3.88 (95% CI, -4.92 to
30 -2.83) [random effects analysis].

31 **Time to Oral Intake**

32 Very low quality evidence from 6 retrospective cohort studies (n=388) showed no clinically
33 important difference between minimally invasive laparoscopic distal pancreatectomy and
34 open pancreatectomy on time to oral intake in adults with resectable or borderline resectable
35 pancreatic cancer: MD -1.48 (95% CI, -2.43 to -0.53) [random effects analysis].

36 **Lymph Node Harvest**

37 No evidence was identified to inform this outcome.

38 **Quality of Life**

39 No evidence was identified to inform this outcome.

1 **Patient Experience**

2 No evidence was identified to inform this outcome.

3 **PROMs**

4 No evidence was identified to inform this outcome.

5 **10.2.6.4 Minimally invasive robotic pancreatectomy versus open pancreatectomy**

6 **Local or distant recurrence**

7 No evidence was identified to inform this outcome.

8 **Overall Survival**

9 No evidence was identified to inform this outcome.

10 **Postoperative Mortality**

11 Very low quality evidence from 3 retrospective cohort studies (n=104) showed no clinically
12 important difference between minimally invasive robotic pancreatectomy and open
13 pancreatectomy on post-operative mortality in adults with resectable or borderline resectable
14 pancreatic cancer: RR 3.0 (95% CI, 0.13-70.30).

15 **Treatment Related Morbidity**

16 *Overall complication rate*

17 Very low quality evidence from 3 retrospective cohort studies (n=104) showed no clinically
18 important difference between minimally invasive robotic pancreatectomy and open
19 pancreatectomy on post-operative mortality in adults with resectable or borderline resectable
20 pancreatic cancer: RR 0.72 (95% CI, 0.40-1.32).

21 *Positive Margins*

22 Very low quality evidence from 1 retrospective cohort study (n=50) showed no clinically
23 important difference between minimally invasive robotic pancreatectomy open
24 pancreatectomy on positive margin rate in adults with resectable or borderline resectable
25 pancreatic cancer: RR 0.31 (95% CI, 0.14-2.63).

26 *Pancreatic Fistula*

27 Very low quality evidence from 2 retrospective cohort studies (n=50) showed no clinically
28 important difference between minimally invasive robotic pancreatectomy and open
29 pancreatectomy on rate of pancreatic fistula formation (Grade A-C) in adults with resectable
30 or borderline resectable pancreatic cancer: RR 0.62 (95% CI, 0.03-13.52) [random effects
31 analysis].

32 *Reoperation Rate*

33 Very low quality evidence from 2 retrospective cohort studies (n=65) showed no clinically
34 important difference between minimally invasive robotic pancreatectomy and open
35 pancreatectomy on reoperation rate in adults with resectable or borderline resectable
36 pancreatic cancer: RR 0.34 (95% CI, 0.09-1.29).

37 *Operative Blood Loss*

1 Very low quality evidence from 2 retrospective cohort studies (n=65) showed that there is a
2 clinically important difference favouring minimally invasive robotic pancreatectomy on
3 reoperation rate compared to open pancreatectomy in adults with resectable or borderline
4 resectable pancreatic cancer: SMD -0.57 (95% CI, -1.07 to -0.06).

5 **Operation Time (mins)**

6 Very low quality evidence from 1 retrospective cohort study (n=114) showed that there is a
7 clinically important difference favouring open pancreatectomy on operative time (mins)
8 compared to minimally invasive robotic pancreatectomy in adults with resectable or
9 borderline resectable pancreatic cancer: MD 189.50 (95% CI, 109.24 to 269.76).

10 **Hospital Stay (days)**

11 Very low quality evidence from 1 retrospective cohort studies (n=15) showed no clinically
12 important difference between minimally invasive robotic pancreatectomy and open
13 pancreatectomy on length of hospital stay (days) in adults with resectable or borderline
14 resectable pancreatic cancer: MD -7.50 (95% CI, -18.15 to 3.15).

15 **Time to Oral Intake**

16 No evidence was identified to inform this outcome.

17 **Lymph Node Harvest**

18 No evidence was identified to inform this outcome.

19 **Quality of Life**

20 No evidence was identified to inform this outcome.

21 **Patient Experience**

22 No evidence was identified to inform this outcome.

23 **PROMs**

24 No evidence was identified to inform this outcome.

25 **10.2.6.5 Extended versus standard lymphadenectomy**

26 **Local or distant recurrence**

27 No evidence was identified to inform this outcome.

28 **Overall Survival**

29 Low quality evidence from 4 RCTs (n=412) showed no clinically important difference
30 between extended lymphadenectomy and standard lymphadenectomy on overall survival in
31 adults with resectable or borderline resectable pancreatic cancer: HR=1.1 (95% CI, 0.86-
32 1.4).

33 *Margin Status*

34 Low quality evidence from 4 RCTs (n=428) showed that there is a clinically important
35 difference favouring extended lymphadenectomy on survival compared to standard

1 lymphadenectomy in adults with a positive margin and resectable or borderline resectable
2 pancreatic cancer: RR 0.6 (95% CI, 0.38-0.96).

3 Low quality evidence from 4 RCTs (n=428) showed no clinically important difference
4 between extended lymphadenectomy and standard lymphadenectomy on survival in adults
5 with a negative margin status and resectable or borderline resectable pancreatic cancer: RR
6 1.06 (95% CI, 0.93-1.21) [random effects analysis].

7 *Lymph Node Status*

8 Very low quality evidence from 4 RCTs showed no clinically important difference between
9 extended lymphadenectomy and standard lymphadenectomy on overall survival in adults
10 with either positive lymph node (n=280; HR=1.04 [95% CI, 0.76-1.42]) or negative lymph
11 node status (n=132; HR=1.06 [95% CI, 0.58-1.94, random effects analysis]) and resectable
12 or borderline resectable pancreatic cancer.

13 **Postoperative Mortality**

14 No evidence was identified to inform this outcome.

15 **Treatment Related Morbidity**

16 *Pancreatic Fistula*

17 No evidence was identified to inform this outcome.

18 *Reoperation Rate*

19 No evidence was identified to inform this outcome.

20 **Operation Time (mins)**

21 No evidence was identified to inform this outcome.

22 **Hospital Stay (days)**

23 No evidence was identified to inform this outcome.

24 **Lymph Node Harvest**

25 No evidence was identified to inform this outcome.

26 **Quality of Life**

27 No evidence was identified to inform this outcome.

28 **Patient Experience**

29 No evidence was identified to inform this outcome.

30 **PROMs**

31 No evidence was identified to inform this outcome.

1 10.2.6.6 Arterial resection versus no arterial resection

2 Local or distant recurrence

3 No evidence was identified to inform this outcome.

4 Overall Survival

5 Very low quality evidence from 12 retrospective observational studies (n=1810) showed no
6 clinically important difference between arterial resection and no arterial resection on 1-year
7 overall survival in adults with resectable or borderline resectable pancreatic cancer: RR 0.83
8 (95% CI, 0.67-1.02) [random effects analysis].

9 Very low quality evidence from 12 retrospective observational studies (n=1787) showed that
10 there is a clinically important difference favouring no arterial resection on 3-year overall
11 survival compared to arterial resection in adults with resectable or borderline resectable
12 pancreatic cancer: RR 0.46 (95% CI, 0.23-0.94) [random effects analysis].

13 Operative Morbidity

14 Very low quality evidence from 7 retrospective observational studies (n=1379) showed no
15 clinically important difference between arterial resection and no arterial resection on post-
16 operative morbidity in adults with resectable or borderline resectable pancreatic cancer: RR
17 1.32 (95% CI, 0.92-1.89) [random effects analysis].

18 Postoperative Mortality

19 Very low quality evidence from 14 retrospective observational studies (n=2093) showed that
20 there is a clinically important difference favouring no arterial resection on post-operative
21 mortality (including in-hospital, 30-day and 60-day mortality) compared to arterial resection
22 (concomitant with pancreatectomy) in adults with resectable or borderline resectable
23 pancreatic cancer: RR 4.40 (95% CI, 2.52-7.69).

24 Treatment Related Morbidity

25 *Reoperation Rate*

26 Very low quality evidence from 7 retrospective observational studies (n=1558) showed there
27 is a clinically important difference favouring no arterial resection on reoperation rate
28 compared to arterial resection in adults with resectable or borderline resectable pancreatic
29 cancer: RR 2.33 (95% CI, 1.62-3.34).

30 R0 Resection Rates

31 Very low quality evidence from 9 retrospective observational studies (n=1471) showed no
32 clinically important difference between arterial resection and no arterial resection on
33 achieving an R0 resection in adults with resectable or borderline resectable pancreatic
34 cancer: RR 0.91 (95% CI, 0.67-1.23) [random effects analysis].

35 Positive Lymph Nodes

36 Very low quality evidence from 6 retrospective observational studies (n=1201) showed no
37 clinically important difference between arterial resection and no arterial resection on positive
38 lymph nodes in adults with resectable or borderline resectable pancreatic cancer: RR 1.07
39 (95% CI, 0.92-1.25).

1 **Quality of Life**

2 No evidence was identified to inform this outcome

3 **Patient Experience**

4 No evidence was identified to inform this outcome

5 **PROMs**

6 No evidence was identified to inform this outcome

7 **10.2.6.7 Venous resection versus no venous resection**

8 **Local or distant recurrence**

9 No evidence was identified to inform this outcome.

10 **Overall Survival**

11 Very low quality evidence from 6 retrospective cohort studies (n=1935) showed that there is
12 a clinically important difference favouring no venous resection on 1-year overall survival
13 compared to venous resection in adults with resectable or borderline resectable pancreatic
14 cancer: HR=1.38 (95% CI, 1.04-1.83) [random effects analysis].

15 Very low quality evidence from 4 retrospective cohort studies (n=525) showed that there is a
16 clinically important difference favouring no venous resection on 5-year overall survival
17 compared to venous resection in adults with resectable or borderline resectable pancreatic
18 cancer: HR=3.18 (95% CI, 1.95-5.19). By contrast, if the raw survival data from all 11
19 observational studies (n=1532) are considered, venous resection is favoured on 5-year
20 overall survival compared to no venous resection: RR 0.64 (95% CI, 0.49-0.83).

21 **Overall Morbidity**

22 Very low quality evidence from 16 retrospective cohort studies (n=6249) showed no clinically
23 important difference between venous resection and no venous resection on post-operative
24 morbidity in adults with resectable or borderline resectable pancreatic cancer: RR 1.18 (95%
25 CI, 1.01-1.38) [random effects analysis].

26 **Postoperative Mortality**

27 Very low quality evidence from 28 retrospective cohort studies (n=8624) showed that there is
28 a clinically important difference favouring no venous resection on post-operative mortality
29 compared to venous resection in adults with resectable or borderline resectable pancreatic
30 cancer: RR 1.45 (95% CI, 1.1-1.9).

31 **Treatment related morbidity**

32 *Reoperation Rates*

33 Very low quality evidence from 11 retrospective cohort studies (n=6398) showed that there is
34 a clinically important difference favouring no venous resection on reoperation rate compared
35 to venous resection in adults with resectable or borderline resectable pancreatic cancer: RR
36 1.32 (95% CI, 1.1-1.58).

1 **R1-2 Resection Rates**

2 Very low quality evidence from 18 retrospective cohort studies (n=3303) showed that there is
3 a clinically important difference favouring no venous resection on R1 and R2 resection rates
4 compared to venous resection in adults with resectable or borderline resectable pancreatic
5 cancer: RR 1.33 (95% CI, 1.2-1.47).

6 **Lymph node harvest**

7 No evidence was identified to inform this outcome.

8 **Quality of Life**

9 No evidence was identified to inform this outcome.

10 **Patient Experience**

11 No evidence was identified to inform this outcome.

12 **PROMs**

13 No evidence was identified to inform this outcome.

14 **10.2.7 Recommendations**

15 **43. For people having surgery for head of pancreas cancer, consider pylorus-**
16 **preserving resection if the tumour can be adequately resected.**

17 **44. Consider standard lymphadenectomy^a rather than extended lymphadenectomy for**
18 **people having head of pancreas resection.**

19 **10.2.8 Evidence to recommendations**

20 **10.2.8.1 Relative value placed on the outcomes considered**

21 Local and distant recurrence, overall survival, post-operative death (30 day/90 day),
22 treatment-related morbidity and mortality, lymph node harvest, health related quality of life,
23 patients experience and PROMs were considered to be the critical outcomes to this question.

24 Lymph node harvest was considered to be a particularly important outcome when comparing
25 the extent of lymphadenectomy as it was a way to determine whether surgery did in fact
26 include extended lymphadenectomy according to current definitions.

27 The outcomes of local/distant recurrence, health-related quality of life, patient experience
28 and patient reported outcome measures were not reported in any of the identified systematic
29 reviews for any of the comparisons of interest.

30 Post-operative mortality and treatment-related morbidity were not reported for the
31 comparison of extended lymphadenectomy against standard lymphadenectomy. Overall
32 survival was not reported for the comparisons of minimally invasive pancreatoduodenectomy
33 against open pancreatoduodenectomy or minimally invasive pancreatectomy (either
34 laparoscopic or robotic) against open pancreatectomy. Lymph node harvest was not reported

^a As defined by Tol et al. (2014) [Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery \(ISGPS\)](#). Surgery 156(3): 591–600

1 for any comparisons other than minimally invasive pancreatoduodenectomy against open
2 pancreatoduodenectomy.

3 R0 resection rates were reported for some of the comparisons of interest, but the Committee
4 did not use this information when agreeing recommendations due to the limitations of the
5 evidence.

6 10.2.8.2 Quality of evidence

7 The quality of the evidence was assessed by GRADE and the Cochrane risk of bias
8 checklist.

9 The quality of the evidence for comparisons of minimally invasive surgery versus open
10 surgery (i.e. pancreatoduodenectomy or pancreatectomy) was very low for all outcomes.
11 The committee noted that the populations included in the studies were not exclusively people
12 with pancreatic cancer and that this mixed population represented a high risk of
13 overestimating the benefit of minimally invasive and/or robotic surgery as people with
14 periampullary cancer, benign disease or other malignancies were likely to have better
15 outcomes. In addition they noted that there was a risk of selection bias - studies included in
16 the review were not randomised trials and therefore it is possible that the people selected for
17 surgery represent the proportion of pancreatic patients who were considered likely to benefit
18 from surgery and have favourable outcomes.

19 Due to the limitations with the evidence, the committee were unable to determine which form
20 of pancreatoduodenectomy was the most effective; whether minimally invasive laparoscopic
21 or open distal pancreatectomy was the most effective; or whether minimally invasive robotic
22 or open pancreatectomy was the most effective. They agreed not to make any
23 recommendations for clinical practice in these areas but to recommend further research
24 instead.

25 The quality of the evidence comparing pylorus preserving Whipple (PPW) with classic
26 Whipple (CW) was very low quality for all outcomes except overall survival which was low
27 quality. In addition, there was not enough detail reported to determine whether the trials were
28 at risk of selective outcome reporting and many of the included trials did not adequately
29 report the randomisation methods or blinding. In addition the populations included in the
30 studies were not exclusively people with pancreatic cancer and there was a risk of selection
31 bias in the non-randomised studies as it was possible that the people selected for surgery
32 represent the proportion of pancreatic cancer patients who were considered likely to benefit
33 from surgery and have favourable outcomes. Therefore the committee were not able to make
34 any strong recommendations.

35 The quality of the evidence for extended lymphadenectomy versus standard
36 lymphadenectomy was low and only reported survival outcomes. The committee noted that
37 whilst this evidence included randomised trials, in a number of cases these trials were
38 underpowered or there was insufficient detail to ascertain whether the study was powered. In
39 addition, there was not enough detail reported to determine whether the trials were at risk of
40 selective outcome reporting and many of the included trials did not adequately report the
41 randomisation methods or blinding. However, the committee considered that the reasons for
42 the low quality evaluation were a result of the randomised trials being small and
43 underpowered. They also noted that the evidence for this comparison was directly relevant
44 as it only included people with pancreatic cancer. The committee considered whether or not
45 to make a recommendation for future research in this area but agreed not to do so as only a
46 small population group are affected and there were likely to be higher priorities for research
47 funding. Therefore the committee agreed to make recommendations for clinical practice but
48 were not able to make any strong recommendations.

49 The quality of the evidence for the comparisons of arterial resection versus no arterial
50 resection and venous resection versus no venous resection was very low for all outcomes.

1 The committee noted that whilst the evidence was a systematic review it only included
2 observational studies, with small sample sizes and high heterogeneity between studies for
3 overall survival and mortality. Given the very low quality of the evidence the committee
4 agreed not to make any recommendations for clinical practice. Arterial resection is a high-risk
5 procedure, the benefits of which are uncertain based on the available evidence so the
6 committee agreed not to make any recommendations for clinical practice about this type of
7 surgery. The committee acknowledged that portal venous resection in an effort to obtain a
8 clear surgical margin (R0) appeared, based on the evidence, to be safe and is an
9 increasingly frequent practice in high-volume centres. However, given the low quality of this
10 evidence, the committee agreed not to make any recommendations for clinical practice. The
11 committee discussed whether or not to make a recommendation for future research but
12 agreed that RCTs would be difficult to construct, and only a small number of people would be
13 suitable for enrolment. It would therefore take too long to collect the necessary data.

14 **10.2.8.3 Consideration of clinical harms and benefits**

15 The committee did not make clinical practice recommendations for a number of the
16 comparisons of interest as they considered the evidence to be of too low quality to allow
17 them to adequately balance the benefits and harms for people with pancreatic cancer.

18 The committee noted, based on the evidence, that blood loss and operative time appeared to
19 be significantly reduced with PPW (compared with CW), but no difference in survival was
20 found between the two techniques. The committee acknowledged there were limitations with
21 the evidence, but agreed that it was possible to make recommendations for clinical practice
22 because although there were mixed populations in the evidence the patient populations were
23 comparable and the differences were in the Whipple's procedure. They recommended PPW
24 based on the evidence of reduced blood loss and operative time and their clinical experience
25 that it is a less extensive procedure and preserving the pylorus and stomach is potentially
26 beneficial to people, particularly in terms of minimising the number or severity of side effects
27 and surgical risks.

28 Whilst the committee acknowledged that there may be some differences between what the
29 evidence reported as 'standard' and 'extended' lymphadenectomy and what is used in
30 current practice, the committee noted, based on the evidence, that no survival difference had
31 been shown between standard and extended lymphadenectomy. Based on their clinical
32 experience that the extended procedure would result in increased morbidity, because it is
33 more complex surgery, the committee agreed to recommend standard lymphadenectomy
34 rather than extended lymphadenectomy (as defined by Tol et al. (2014)).

35 The committee considered standard lymphadenectomy to be sufficient to ensure adequate
36 clearance of lymph nodes. The evidence did not provide any details of the morbidity around
37 the extended procedure. However the committee reported clinical experience which suggests
38 greater morbidity from the extended procedure. The committee therefore considered that
39 recommending the standard procedure should help to standardise the approach to
40 lymphadenectomy and minimise the potential risks associated with the extended procedure.

41 It was agreed that there needs to be a balance between the most effective surgery in terms
42 of achieving the most favourable survival and/or recurrence outcomes while minimising the
43 number or severity of side effects and surgical risks. The committee therefore recommended
44 the less extensive procedure for both Whipple's surgery and lymphadenectomy.

45 **10.2.8.4 Consideration of economic benefits and harms**

46 The committee noted that no relevant published economic evaluations had been identified
47 and no additional economic analysis had been undertaken in this area.

48 The committee considered that the recommendations were unlikely to result in a substantial
49 increase in costs because the less extensive procedure had been recommended in both

1 instances which were likely to have shorter surgery times and reduced morbidity.
2 Consequently the committee considered it was possible that the recommendations could
3 result in a small cost saving compared with current practice.

4 **10.2.8.5 Other considerations**

5 Having reviewed the evidence for the most effective type of surgery for people with
6 resectable or borderline resectable pancreatic cancer, the committee noted that the available
7 data were limited, of low quality and often included mixed populations. Given these issues
8 there was a lot of uncertainty over the effects reported by the evidence which severely
9 restricted the ability of the committee to evaluate the effectiveness of several surgical
10 interventions.

11 **10.2.9 Research Recommendations**

12 **7. Prospective randomised trials should be undertaken to compare the effectiveness** 13 **of minimally invasive pancreatectomy or pancreatoduodenectomy (laparoscopic** 14 **or robotic) with open pancreatectomy or pancreatoduodenectomy in people with** 15 **pancreatic cancer.**

16 Minimally invasive surgery is generally considered to be more acceptable to patients than
17 open surgery. It has been introduced successfully for several other types of cancer and has
18 been shown to improve quality of life. However, there is not enough evidence to determine
19 whether minimally invasive surgery improves morbidity and mortality for people with
20 pancreatic cancer, compared with open surgery. Prospective randomised trials are therefore
21 needed in this area. The outcomes of interest are:

- 22 • conversion rate to open surgery
- 23 • R0 resection rate
- 24 • lymph node yield
- 25 • blood loss
- 26 • duration of surgery
- 27 • complications
- 28 • need for critical care
- 29 • length of hospital stay
- 30 • time to return to normal activity
- 31 • mortality of surgery
- 32 • long-term survival after surgery
- 33 • quality of life, patient experience and patient-reported outcome measures.

34 **10.2.10 References**

- 35 de Rooij T, Lu MZ, Steen MW et al. (2016) Minimally invasive versus open
36 pancreatoduodenectomy: systematic review and meta-analysis of comparative cohort and
37 registry studies. *Annals of Surgery* 264(2): 257-67
- 38 Doula C, Kostakis ID, Damaskos C et al. (2016) Comparison between minimally invasive and
39 open pancreaticoduodenectomy: A systematic review. *Surgical Laparoscopy, Endoscopy*
40 *and Percutaneous Techniques* 26(1): 6-16
- 41 Giovinazzo F, Turri G, Katz MH et al. (2016) Meta-analysis of benefits of portal–superior
42 mesenteric vein resection in pancreatic resection for ductal adenocarcinoma. *British Journal*
43 *of Surgery* 103(3): 179-91

- 1 Huttner FJ, Fitzmaurice C, Schwarzer G et al. (2016) Pylorus-preserving
2 pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic whipple)
3 for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database of
4 Systematic Reviews
- 5 Kawai M, Tani M, Hirono S et al. (2014) Pylorus-resecting pancreaticoduodenectomy offers
6 long-term outcomes similar to those of pylorus-preserving pancreaticoduodenectomy: results
7 of a prospective study. *World journal of surgery* 38(6): 1476-83
- 8 Ke K, Chen W, Chen Y (2014) Standard and extended lymphadenectomy for
9 adenocarcinoma of the pancreatic head: A meta-analysis and systematic review. *Journal of*
10 *Gastroenterology and Hepatology* 29: 453-462
- 11 Lei P, Wei B, Guo W et al. (2014) Minimally invasive surgical approach compared with open
12 pancreaticoduodenectomy: a systematic review and meta-analysis on the feasibility and
13 safety. *Surgical Laparoscopy Endoscopy & Percutaneous Techniques* 24(4): 296-305
- 14 Mollberg N, Rahbari NN, Koch M et al. (2011) Arterial resection during pancreatectomy for
15 pancreatic cancer. A systematic review and meta-analysis. *Annals of Surgery* 25(6): 882-893
- 16 Pędziwiatr M, Małczak P, Pisarska M et al. (2017) Minimally invasive versus open
17 pancreatoduodenectomy—systematic review and meta-analysis. *Langenbeck's Archives of*
18 *Surgery* 402(5): 841-851
- 19 Peng L, Lin S, Li Y et al. (2016) Systematic review and meta-analysis of robotic versus open
20 pancreaticoduodenectomy. *Surgical Endoscopy* 31(8): 3085-3097
- 21 Shin SH, Kim YJ, Song KB et al. (2017) Totally laparoscopic or robot-assisted
22 pancreaticoduodenectomy versus open surgery for periampullary neoplasms: separate
23 systematic reviews and meta-analyses. *Surgical Endoscopy* 31(9): 3459-3474
- 24 Sui CJ, Li B, Yang JM et al. (2012) Laparoscopic versus open distal pancreatectomy: a
25 meta-analysis. *Asian Journal of Surgery* 35: 1-8
- 26 Tol JA, Gouma DJ, Bassi C et al. (2014) Definition of a standard lymphadenectomy in
27 surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International
28 Study Group on Pancreatic Surgery (ISGPS). *Surgery* 156(3): 591-600.
- 29 Venkat R, Edil BH, Schulick RD et al. (2012) Laparoscopic distal pancreatectomy is
30 associated with significantly less overall morbid compared to the open technique. *Annals of*
31 *Surgery* 255(6): 1048-1059
- 32 Yu XZ, Li J, Fu DL et al. (2014) Benefit from synchronous portal-superior mesenteric vein
33 resection during pancreaticoduodenectomy for cancer: a meta-analysis. *European Journal of*
34 *Surgical Oncology* 40: 371-378
- 35 Zhang J, Wu WM, You L et al. (2013) Robotic versus Open Pancreatectomy: A Systematic
36 Review and Meta-analysis. *Annals of Surgical Oncology* 20: 1774-1780
- 37 Zhou Y, Zhang Z, Liu Y et al. (2012) Pancreatectomy combined with superior mesenteric
38 vein-portal vein resection: A meta-analysis. *World Journal of Surgery* 36: 884-891
- 39 0.2.10.1 Studies included in de Rooij et al., 2016 (n=11)**
- 40 Abdelgadir Adam M, Choudhury K, Goffredo P et al. (2015). Minimally Invasive Distal
41 Pancreatectomy for Cancer: Short-Term Oncologic Outcomes in 1,733 Patients. *World*
42 *Journal of Surgery* 39(10): 2564-2572

- 1 Cho A, Yamamoto H, Nagata M (2009) Comparison of laparoscopy-assisted and open
2 pylorus preserving pancreaticoduodenectomy for periampullary disease. *American Journal of*
3 *Surgery* 198: 445-449
- 4 Hakeem AR, Verbeke CS, Cairns A (2014) A matched-pair analysis of laparoscopic versus
5 open pancreaticoduodenectomy: oncological outcomes using Leeds Pathology Protocol.
6 *Hepatobiliary & Pancreatic Diseases International* 13(4): 435-41
- 7 Kuroki T, Adachi T, Okamoto, T et al. (2012) A non randomised comparative study of
8 laparoscopy assisted pancreaticoduodenectomy and open pancreaticoduodenectomy.
9 *HepatoGastroenterology* 59: 570-573
- 10 Langan RC, Graham JA, Chin AB et al. (2014) Laparoscopic assisted versus open
11 pancreaticoduodenectomy: early favourable physical quality of life measures. *Surgery* 156:
12 379-384
- 13 Sharpe SM, Talamonti MS, Wang CE et al. (2015) Early national experience with
14 laparoscopic pancreaticoduodenectomy for ductal adenocarcinoma: a comparison of
15 laparoscopic pancreaticoduodenectomy and open pancreaticoduodenectomy from the
16 National Cancer Data Base. *Journal of the American College of Surgeons* 221(1): 175-84
- 17 Speicher PJ, Nussbaum DP, White RR et al. (2014) Defining the learning curve for team-
18 based laparoscopic pancreaticoduodenectomy. *Annals of Surgical Oncology* 21: 4014-4019
- 19 Tee MC, Croome KP, Shubert CR et al. (2015) Laparoscopic pancreatoduodenectomy does
20 not completely mitigate increased perioperative risks in elderly patients. *HPB* 17(10): 909-18
- 21 Tran TB, Dua MM, Worhunsky DJ et al. (2016) The first decade of laparoscopic
22 pancreaticoduodenectomy in the United States: costs and outcomes using the nationwide
23 inpatient sample. *Surgical Endoscopy* 30(5): 1778-83
- 24 Wang Y, Bergman S, Piedimonte S et al. (2014) Bridging the gap between open and
25 minimally invasive pancreaticoduodenectomy: the hybrid approach. *Canadian Journal of*
26 *Surgery* 57(4): 263-270
- 27 Wellner UF, Küsters S, Sick O et al. (2014) Hybrid laparoscopic versus open pylorus-
28 preserving pancreatoduodenectomy: retrospective matched case comparison in 80 patients.
29 *Langenbeck's Archives of Surgery* 399(7): 849-56

30 10.2.10.2 Studies included in Doula et al., 2016 (n=2)

- 31 Gumbs AA, Gres P, Madureira FA et al. (2008) Laparoscopic vs. open resection of
32 noninvasive intraductal mucinous neoplasms. *Journal of Gastrointestinal Surgery* 12: 707-
33 712
- 34 Pugliese, R, Scandroglio, I, Sansonna, F et al. (2008) Laparoscopic
35 pancreaticoduodenectomy: a retrospective review of 19 cases. *Surgical Laparoscopy,*
36 *Endoscopy and Percutaneous Techniques* 18: 13-18

37 10.2.10.3 Studies included in Giovinazzo et al., 2016 (n=27)

- 38 Al-Haddad M, Martin JK, Nguyen J et al. (2007) Vascular resection and reconstruction for
39 pancreatic malignancy: a single centre survival study. *Journal of Gastrointestinal Surgery* 11:
40 1168-1174
- 41 Bachellier P, Nakano H, Oussoultzoglou PD et al. (2001) Is pancreaticoduodenectomy with
42 mesentericoportal venous resection safe and worthwhile? *American Journal of Surgery* 182:
43 120-129

- 1 Carrere N, Sauvanet A, Goere D et al. (2006) Pancreaticoduodenectomy with
2 mesentericoportal vein resection for adenocarcinoma of the pancreatic head. World Journal
3 of Surgery 30: 1526-1535
- 4 Castleberry AW, White RR, Sebastian G et al. (2012) The impact of vascular resection on
5 early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American
6 College of Surgeons National Surgical Quality Improvement Program Database. Annals of
7 Surgical Oncology 19: 4068-4077
- 8 Chakravarty KD, Hsu JT, Liu KH et al. (2010) Prognosis and feasibility of en bloc vascular
9 resection in stage II pancreatic adenocarcinoma. World Journal of Gastroenterology, 16:
10 997-1002
- 11 Furhman GM, Leach SD, Staley CA et al. (2007) Rationale for en bloc vein resection in the
12 treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein
13 confluence. Annals of Surgery 223: 154-162
- 14 Fukuda S, Oussoultzoglou E, Bachellier P et al. (2007) Significance of the depth of portal
15 vein wall invasion after curative resection for pancreatic adenocarcinoma. Archives of
16 Surgery 142: 172-179
- 17 Gong Y, Zhang L, He T et al. (2013) Pancreaticoduodenectomy combined with vascular
18 resection and reconstruction for patients with locally advanced pancreatic cancer: a
19 multicentre, retrospective analysis. PloS One 8: e70340
- 20 Harrison LF, Klimstra DS, Brennan MF (1996) Isolated portal vein involvement in pancreatic
21 adenocarcinoma: A contraindication for resection. Annals of Surgery 224: 342-347
- 22 Hartel M, Niedergethmann M, Farag-Soliman M et al. (2002) Benefit of venous resection for
23 ductal adenocarcinoma of the pancreatic head. European Journal of Surgery 168, 702-712
- 24 Kawada M, Kondo S, Okushiba S et al. (2002) Reevaluation of the indications for radical
25 pancreatotomy to treat pancreatic carcinoma: is portal vein infiltration a contraindication?
26 Surgery Today 32: 598-601
- 27 Kelly KJ, Winslow E, Kooby D et al. (2013) Vein involvement during
28 pancreaticoduodenectomy: is there a need for redefinition of 'borderline resectable disease'?
29 Journal of Gastrointestinal Surgery 17: 1209-1217
- 30 Kurosaki I, Hatakeyama K, Minagawa M et al. (2008) Portal vein resection in surgery for
31 cancer of biliary tract and pancreas: special reference to the relationship between the
32 surgical outcome and site of primary tumor. Journal of Gastrointestinal Surgery 12: 907-918
- 33 Launois B, Stasik C, Bardaxoglou E et al. (1999) Who benefits from portal vein resection
34 during pancreaticoduodenectomy for pancreatic cancer. World Journal of Surgery 23: 926-
35 929
- 36 Leach SD, Lee JE, Chamsangavej C et al. (1998) Survival following
37 pancreaticoduodenectomy with resection of the superior mesenteric vein-portal vein
38 confluence for adenocarcinoma of the pancreatic head. British Journal of Surgery 85: 611-
39 617
- 40 Martin RC, Scoggins CR, Egnatashvili V et al. (2009) Arterial and venous resection for
41 pancreatic adenocarcinoma operative and long-term outcomes. Archives of Surgery 144:
42 154-159
- 43 Murakami Y, Uemura K, Sudo T et al. (2013) Benefit of portal or superior mesenteric vein
44 resection with adjuvant chemotherapy for patients with pancreatic head carcinoma. Journal
45 of Surgical Oncology 17: 1209-1217

- 1 Nakagohri T, Kinoshita T, Konishi M et al. (2003) Survival benefits of portal vein resection
2 for pancreatic cancer. *American Journal of Surgery* 186: 149-153
- 3 Ouaisi M, Hubert C, Verhelst R et al. (2010) Vascular reconstruction during
4 pancreatoduodenectomy for ductal adenocarcinoma of the pancreas improves resectability
5 but does not achieve patient cure. *World Journal of Surgery* 34, 2648-2661
- 6 Poon RT, Fan ST, Lo CM, et al. (2004) Pancreaticoduodenectomy with en bloc portal vein
7 resection for pancreatic carcinoma with suspected portal vein involvement. *World Journal of*
8 *Surgery* 28: 602-608
- 9 Ravikumar R, Sabin C, Hilal MA et al. (2014) Portal vein resection in borderline resectable
10 pancreatic cancer: a United Kingdom multicentre study. *Journal of the American College of*
11 *Surgeons* 218: 401-411
- 12 Riediger H, Makowiec F, Fischer E, et al. (2006) Postoperative morbidity and long term
13 survival after pancreaticoduodenectomy with superior mesenterico-portal vein resection.
14 *Journal of Gastrointestinal Surgery* 10: 1106-1115
- 15 Shibata C, Kobari M, Tsuchiya T et al. (2001) Pancreatectomy combined with superior
16 mesenteric-portal vein resection for adenocarcinoma in the pancreas. *World Journal of*
17 *Surgery* 25: 1002-1005
- 18 Shimada K, Sano T, Sakamoto Y et al. (2006) Clinical implications of combined portal vein
19 resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for
20 pancreatic head carcinoma. *Annals of Surgical Oncology*, 13: 1569-1578
- 21 Shrikhande SV, Arya S, Barreto SG et al. (2011) Borderline resectable pancreatic tumours:
22 is there a need for further refinement at this stage? *Hepatobiliary & Pancreatic Diseases*
23 *International* 10: 319-324
- 24 Sperti C, Pasquali C, Piccoli A et al. (1996) Survival after resection for ductal
25 adenocarcinoma of the pancreas. *British Journal of Surgery*, 83: 625-631
- 26 Tseng JF, Raut CP, Lee JE et al. (2004) Pancreaticoduodenectomy with vascular resection:
27 margin status and survival duration. *Journal of Gastrointestinal Surgery* 8: 935-949

2810.2.10.4 Studies included in Huttner et al., 2016 (n=8)

- 29 Bloechle C, Broering DC, Latuske C et al. (1999) Prospective randomised study to evaluate
30 quality of life after partial pancreatoduodenectomy according to Whipple versus pylorus
31 preserving pancreatoduodenectomy according to Longmire-Traverso for periampullary
32 cancer. *Deutsche Gesellschaft fur Chirurgie* 1(Suppl. 1): 661-664
- 33 Lin PW and Lin YJ (1999) Prospective randomised comparison between pylorus preserving
34 and standard pancreaticoduodenectomy. *British Journal of Surgery* 86(6): 603-607
- 35 Paquet K-J (1998) Comparison of Whipples pancreaticoduodenectomy with the pylorus
36 preserving pancreaticoduodenectomy - a prospectively controlled randomised long term trial.
37 *Chirurgische Gastroenterologie* 14: 54-58
- 38 Seiler CA, Wagner M, Bachmann T et al. (2005) Randomised clinical trial of pylorus-
39 preserving duodenopancreatectomy versus classical Whipple resection - long term results.
40 *British Journal of Surgery* 92(5): 547-556
- 41 Srinarmwong C, Luechakiettsak P, Prasitvilai W (2008) Standard Whipple's operation versus
42 pylorus preserving pancreaticoduodenectomy: a randomised controlled trial study. *Journal of*
43 *the Medical Association of Thailand* 95(5): 693-698

- 1 Taher MA, Khan ZR, Chowdhury MM et al. (2015) Pylorus preserving
2 pancreaticoduodenectomy versus standard Whipples procedure in case of carcinoma head
3 of the pancreas and periampullary carcinoma. Mymensingh Medical Journal 24(2): 219-325
- 4 Tran KT, Smeenk HG, van Eijck CH et al (2004) Pylorus preserving
5 pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomised,
6 multicentre analysis of 170 patients with pancreatic and periampullary tumours. Annals of
7 Surgery 240(5): 738-745
- 8 Wenger FA, Jacobi CA, Haubold K et al. (1999) Gastrointestinal quality of life after
9 dudodenopancreatectomy in pancreatic carcinoma. Preliminary results of a prospective
10 randomised study: pancreatoduodenectomy. Der Chirurg; Zeitschrift fur alle Gebiete der
11 operativen Medizin 70: 1454-1459

1210.2.10.5 Studies included in Ke et al., 2014 (n=4)

- 13 Farnell M, Pearson RK, Sarr MG et al. (2005) A prospective randomised trial comparing
14 standard pancreaticoduodenectomy with pancreaticoduodenectomy with extended
15 lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 138(4): 618-630
- 16 Nimura Y, Nagino M, Takao S et al. (2012) Standard versus extended lymphadenectomy in
17 radical pancreaticoduodenectomy for ductal adenocarcinoma of the head of the pancreas.
18 Journal of Hepatobiliary Pancreatic Sciences 19: 230-241
- 19 Pedrazzoli S, DiCarlo V, Dionigi R et al. (1998) Standard versus extended
20 lymphadenectomy associated with pancreaticoduodenectomy in the surgical treatment of
21 adenocarcinoma of the head of the pancreas. Annals of Surgery 228(4): 508-517
- 22 Riall T, Cameron JL, Lillemoe KD et al. (2005) Pancreaticoduodenectomy with or without
23 distal gastrectomy and extended retroperitoneal lymphadenectomy for pariampullary
24 adenocarcinoma - part 3: update on 5 year survival. Journal of Gastrointestinal Surgery 9(9):
25 1191-1206

2010.2.10.6 Studies included in Lei et al., 2014 (n=1)

- 27 Ito M, Horiguchi A, Ishihara S et al. (2009) Laparoscopic pancreatic surgery: totally
28 laparoscopic pancreatoduodenectomy and reconstruction. Pancreas 38(8): 1009-1009

2910.2.10.7 Studies included in Mollberg et al., 2011 (n=26)

- 30 Allendorf JD, Lauerma M, Bill A et al. (2008) Neoadjuvant Chemotherapy and radiation for
31 patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy and
32 survival. Journal of Gastrointestinal Surgery 12: 91-100
- 33 Amano H, Miura F, Toyota N et al. (2009) Is pancreatectomy with arterial reconstruction a
34 safe and useful procedure for locally advanced pancreatic cancer? Journal of Hepatobiliary
35 Pancreatic Surgery 16: 850-857
- 36 Bockhorn M, Burdelski C, Bogoevski D et al. (2011) Arterial en bloc resection for pancreatic
37 carcinoma. British Journal of Surgery 98(1): 86-92
- 38 Boggi U, Del Chiaro M, Croce C et al. (2009) Prognostic implications of tumour invasion or
39 adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 146: 869-881
- 40 Denecke T, Andreou A, Podrabsky P et al. (2010) Distal pancreatectomy with en bloc
41 resection of the celiac trunk for extended pancreatic tumour disease: an interdisciplinary
42 approach. Cardiovascular Interventional Radiology 34: 1058-1064

- 1 Fortner JG, Kim DK, Cubilla AN et al. (2009) Regional pancreatectomy: en bloc pancreatic,
2 portal vein and lymph node resection. *Annals of Surgery* 186: 42-50
- 3 Hartwig W, Hackert T, Hinz U et al. (2009) Multivisceral resection for pancreatic
4 malignancies: risk analysis and long-term outcome. *Annals of Surgery* 250: 81-87
- 5 Hirano S, Kondo S, Hara T et al. (2007) Distal pancreatectomy with en bloc celiac axis
6 resection for locally advanced pancreatic body cancer: long term results. *Annals of Surgery*
7 246: 46-51
- 8 Hishinuma S, Ogata Y, Tomikawa M et al. (2007) Stomach preserving distal pancreatectomy
9 with combined resection of the celiac artery: radical procedure for locally advanced cancer of
10 the pancreatic body. *Journal of Gastrointestinal Surgery* 11: 743-749
- 11 Kato K, Yamada S, Sugimoto H et al. (2009) Prognostic factors for survival after extended
12 pancreatectomy for pancreatic head cancer: influence of resection margin status on survival.
13 *Pancreas* 38: 605-612
- 14 Kinoshita H, Hashimoto M, Hashino K et al. (2001) Evaluation of simultaneous excision of
15 pancreatic cancer and the surrounding blood vessels. *Kurume Medical Journal* 48: 21-24
- 16 Klempnauer J, Ridder GJ, Bektas H et al. (1996) Extended resections of ductal pancreatic
17 cancer - impact on operative risk and prognosis. *Oncology* 53: 47-53.
- 18 Martin RC, Scoggins CR, Egnatashvili V et al. (2009) Arterial and venous resection for
19 pancreatic adenocarcinoma: operative and long term outcomes. *Archives of Surgery* 144:
20 154-159
- 21 Miyakawa S, Horiguchi A, Hanai T et al. (2002) Monitoring hepatic venous hemoglobin
22 oxygen saturation during Appleby operation for pancreatic cancer. *Hepatogastroenterology*
23 49: 817-821
- 24 Miyazaki M (2003) Pancreatectomy with the resection of the celiac axis, hepatic artery and
25 superior mesenteric artery. *Gastroenterological Surgery* 26, 1751-1756
- 26 Ogata Y, Hishinuma S, Takahashi S et al. (1997) Indication and results of pancreatectomy
27 with combined resection of vessels for adenocarcinoma of the pancreas. *Nihon Geka Gakkai*
28 *Zasshi* 98: 615-621
- 29 Ouaisi M, Hubert C, Verhelst R et al. (2010) Vascular resection during pancreatectomy for
30 ductal adenocarcinoma of the pancreas improves resectability but does not achieve cure.
31 *World Journal of Surgery* 34: 2648-2661
- 32 Park DI, Lee JK, Kim JE et al. (2001) The analysis of resectability and survival in pancreatic
33 cancer patients with vascular invasion. *Journal of Clinical Gastroenterology* 32: 231-234
- 34 Settmacher U, Langrehr JM, Husmann I et al. (2004) Reconstruction of visceral arteries with
35 homografts in excision of the pancreas. *Chirurg; Zeitschrift fur alle Gebiete der operativen*
36 *Medizin* 75: 1199-1206
- 37 Shimada K, Sakamoto Y, Sano T et al. (2006) Prognostic factors after distal pancreatectomy
38 with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and
39 tail. *Surgery* 139: 288-295
- 40 Sperti C, Berselli M, Pedrazzoli S (2010) Distal pancreatectomy for body-tail pancreatic
41 cancer: is there a role for celiac axis resection. *Pancreatology* 10: 491-498
- 42 Stitzenberg KB, Watson JC, Roberts A et al. (2008) Survival after pancreatectomy with
43 major arterial resection and reconstruction. *Annals of Surgical Oncology* 15: 1399-1406

- 1 Sugiura Y, Horio T, Aiko S et al. (2009) Pancreatectomy for pancreatic cancer with reference
2 to combined resection of the vessels, twenty nine year experience by a single surgeon. The
3 Keio Journal of Medicine 58: 103-109
- 4 Tamura K, Kin S, Ono K et al. (1989) Operative results in cancer of the pancreas, especially
5 complicated with large vascular involvement. Nihon Geka Gakkai Zasshi 90: 1032-1042
- 6 Wang C, Wu H, Xiong J et al. (2008) Pancreaticoduodenectomy with vascular resection for
7 local advanced pancreatic cancer: a single centre retrospective study. Journal of
8 Gastrointestinal Surgery 12: 2183-2190
- 9 Wu X, Tao R, Lei R et al. (2008) Distal pancreatectomy combined with celiac axis resection
10 in treatment of carcinoma of the body/tail of the pancreas: a single -centre experience.
11 Annals of Surgical Oncology 17: 1359-1366

120.2.10.8 Studies included in Pędziwiatr et al., 2017 (n=5)

- 13 Boggi U, Napoli N, Costa F et al. (2016) Robotic-assisted pancreatic resections. World
14 Journal of Surgery 40: 2497–2506
- 15 Buchs NC, Addeo P, Bianco, FM (2011) Robotic versus open pancreaticoduodenectomy: a
16 comparative study at a single institution. World Journal of Surgery 35: 2739-2746
- 17 Delitto D, Luckhurst CM, Black BS et al. (2016) Oncologic and perioperative outcomes
18 following selective application of laparoscopic pancreaticoduodenectomy for periampullary
19 malignancies. Journal of Gastrointestinal Surgery 20(7): 1343-9
- 20 Zhou NX, Chen JZ, Liu Q et al. (2011) Outcomes of pancreaticoduodenectomy with robotic
21 surgery versus open surgery. The International Journal of Medical Robotics and Computer
22 Assisted Surgery 7: 131-137
- 23 Zureikat AH, Postlewait LM, Liu Y et al (2016) A multi-institutional comparison of
24 perioperative outcomes of robotic and open pancreaticoduodenectomy. Annals of Surgery
25 264: 640–649

260.2.10.9 Studies included in Peng et al., 2016 (n=1)

- 27 Hammill C, Cassera M, Swanstrom L et al. (2010) Robotic assistance may provide the
28 technical capability to perform a safe, minimally invasive pancreaticoduodenectomy. HPB
29 12(S1): 198

300.2.10.10 Studies included in Shin et al., 2017 (n=13)

- 31 Asbun HJ and Stauffer JA (2012) Laparoscopic versus open pancreaticoduodenectomy:
32 overall outcomes and severity of complications using the Accordion Severity Grading
33 System. Journal of the American College of Surgeons 215: 810-819
- 34 Baker EH, Ross SW, Seshadri R et al. (2016) Robotic pancreaticoduodenectomy:
35 comparison of complications and cost to the open approach. International Journal of Medical
36 Robotics and Computer Assisted Surgery 12: 554–560
- 37 Bao PQ, Mazirka PO, Watkins KT (2014) Retrospective comparison of robot assisted
38 minimally invasive versus open pancreaticoduodenectomy for periampullary neoplasms.
39 Journal of Gastrointestinal Surgery 18: 682-689
- 40 Chalikonda S, Aguilar-Saavedra JR, Walsh RM (2012) Laparoscopic robotic-assisted
41 pancreaticoduodenectomy: a case matched comparison with open resection. Surgical
42 Endoscopy 26: 2397-2402

- 1 Chen S, Chen J-Z, Zhan Q et al. (2015) Robot-assisted laparoscopic versus open
2 pancreaticoduodenectomy: a prospective, matched, mid-term follow-up study. *Surgical*
3 *Endoscopy* 29: 3698–3711
- 4 Croome KP, Farnell MB, Que FG et al. (2014). Total laparoscopic pancreaticoduodenectomy
5 for pancreatic ductal adenocarcinoma: oncologic advantages over open approaches? *Annals*
6 *of Surgery* 260(4): 633-640
- 7 Croome KP, Farnell MB, Que FG et al. (2015) Pancreaticoduodenectomy with major
8 vascular resection: a comparison of laparoscopic versus open approaches. *Journal of*
9 *Gastrointestinal Surgery* 19(1): 189–194
- 10 Dokmak S, Ftériche FS, Aussilhou B et al. (2015) Laparoscopic pancreaticoduodenectomy
11 should not be routine for resection of periampullary tumors. *Journal of the American College*
12 *of Surgeons* 220(5): 831–838
- 13 Lai EC, Yang GP, Tang CN (2012) Robot assisted laparoscopic pancreaticoduodenectomy
14 versus open pancreaticoduodenectomy - a comparative study. *International Journal of*
15 *Surgery* 10: 475-479
- 16 Mesleh MG, Stauffer JA, Bowers SP et al. (2013) Cost analysis of open and laparoscopic
17 pancreaticoduodenectomy: a single institution comparison. *Surgical Endoscopy* 27(12):
18 4518–4523
- 19 Song KB, Kim SC, Hwang DW et al. (2015) Matched case-control analysis comparing
20 laparoscopic and open pylorus-preserving pancreaticoduodenectomy in patients with
21 periampullary tumors. *Annals of Surgery* 262(1): 146–155
- 22 Tan C-L, Zhang H, Peng B, Li K-Z (2015) Outcome and costs of laparoscopic
23 pancreaticoduodenectomy during the initial learning curve vs laparotomy. *World Journal of*
24 *Gastroenterology* 21(17): 5311–5319
- 25 Zureikat AH, Breaux JA, Steel JL et al. (2011) Can Laparoscopic pancreaticoduodenectomy
26 be safely implemented. *Journal of Gastrointestinal Surgery* 15: 1151-1157

270.2.10.11 Studies included in Sui et al., 2012 (n=3)

- 28 Kooby DA, Hawkins WG, Schmidt CM et al. (2010) A multicentre analysis of distal
29 pancreatectomy for adenocarcinoma: is laparoscopic resection appropriate? *Journal of the*
30 *American College of Surgeons* 62: 171-174
- 31 Shimura T, Suehiro T, Mochida Y et al. (2006) Laparoscopy assisted distal pancreatectomy
32 with mobilisation of the distal pancreas and spleen outside the abdominal cavity. *Surgical*
33 *Laparoscopy, Endoscopy & Percutaneous Techniques* 16: 387-389
- 34 Zhao GD, Hu MG, Liu R (2010) A comparative study of laparoscopic distal pancreatectomy
35 and open distal pancreatectomy. *Nan Fang Yi Ke Da Xue Xue Bao [Journal of Southern*
36 *Medical University]* 30: 2756-2758

370.2.10.12 Studies included in Venkat et al., 2012 (n=18)

- 38 Aly MY, Tsutsumi K, Nakamura M et al. (2010) Comparative Study of laparoscopic and open
39 distal pancreatectomy. *Journal of Laparoendoscopic Advanced Surgical Techniques* 20: 435-
40 440
- 41 Baker MS, Bentrem DJ, Ujiki MB et al. (2009) A prospective single institution comparison of
42 peri-operative outcomes for laparoscopic and open distal pancreatectomy. *Surgery* 146: 635-
43 643

- 1 Bruzoni M and Sasson AR (2008) Open and laparoscopic spleen preserving, splenic vessel
2 preerving distal pancreatectomy: indications and outcomes. *Journal of Gastrointestinal*
3 *Surgery* 12: 1202-1206
- 4 Casesdei R, Ricci C, D'Ambra M et al. (2010) Laparoscopic versus open distal
5 pancreatectomy in pancreatic tumours: a case control study. *Updates in Surgery* 62: 171-174
- 6 DiNorcia J, Schrope BA, Lee MK et al. (2010) Laparoscopic distal pancreatectomy offers
7 shorter hospital stays with fewer complications. *Journal of Gastrointestinal Surgery* 14: 1804-
8 1812
- 9 Eom BW, Jang JY, Lee SE et al. (2008) Clinical outcomes compared between laparoscopic
10 and open distal pancreatectomy. *Surgical Endoscopy* 22: 1334-1338
- 11 Finan KR, Cannon EE, Kim EL et al. (2009) Laparoscopic and open distal pancreatectomy:
12 a comparison of outcomes. *The American Surgeon* 75: 671-679
- 13 Jayaraman S, Gonen M, Brennan MF et al. (2010) Laparoscopic distal pancreatectomy:
14 evaluation of a technique at a single institution. *Journal of the American College of Surgeons*
15 211: 503-509
- 16 Kim SC, Park KT, Hwang JW et al. (2008) Comparative analysis of clinical outcomes for
17 laparoscopic distal pancreatic resection and open distal pancreatic resection at a single
18 institution. *Surgical Endoscopy* 22(10): 2261-2268
- 19 Kooby DA, Gillespie T, Bentrem D et al. (2008) Left sided pancreatectomy: a multicentre
20 comparison of laparoscopic and open approaches. *Annals of Surgery* 248: 438-446
- 21 Matsumoto T, Shibata K, Ohta M et al. (2008) Laparoscopic distal pancreatectomy and open
22 distal pancreatectomy: a non randomised comparative study. *Surgical Laparoscopy,*
23 *Endoscopy & Percutaneous Techniques* 18: 340-343
- 24 Misawa T, Shiba K, Usuba T et al. (2007) Systemic inflammatory response syndrome after
25 hand assisted laparoscopic distal pancreatectomy. *Surgical Endoscopy* 21: 1446-1449
- 26 Nakamura Y, Uchida E, Aimoto T et al. (2009) Clinical outcome of laparoscopic distal
27 pancreatectomy. *Journal of Hepatobiliary Pancreatic Surgery* 16: 35-41
- 28 Tang CN, Tsui KK, Ha JP et al. (2007) Laparoscopic distal pancreatectomy: a comparative
29 study. *Hepatogastroenterology* 54: 265-271
- 30 The SH, Tseng D, Sheppard BC (2007) Laparoscopic and open distal pancreatic resection
31 for benign pancreatic disease. *Journal of Gastrointestinal Surgery* 11: 1120-1125
- 32 Velanovich V (2006) Case control comparison of laparoscopic versus open distal
33 pancreatectomy. *Journal of Gastrointestinal Surgery* 10: 95-98
- 34 Vijan SS, Ahmed KA, Harmsen WS (2010) Laparoscopic versus open distal pancreatectomy:
35 a single institution comparative study. *Archives of Surgery* 145: 616-621
- 36 Waters JA, Canal DF, Wiebke EA et al. (2010) Robotic distal pancreatectomy: cost
37 effective? *Surgery* 148: 814-823

38.2.10.13 Studies included in Yu et al., 2014 (n=4)

- 39 Banz VM, Croagh D, Coldham C et al. (2012) Factors influencing outcome in patients
40 undergoing portal vein resection with adjuvant chemotherapy for adenocarcinoma of the
41 pancreas. *European Journal of Surgical Oncology* 38: 72-9
- 42 Illumnati G, Carboni F, Lorusso R et al. (2008) Results of a pancreatectomy with a limited
43 venous resection for pancreatic cancer. *Surgery Today* 38: 517-523

- 1 Kaneoka Y, Yamaguchi A, Isogai M (2009) Portal or superior mesenteric vein resection for
2 pancreatic head adenocarcinoma: prognostic value of the length of venous resection.
3 Surgery 145: 417-425
- 4 Yang KX, Shi KW, Xi PC et al. (2016) Pancreaticoduodenectomy combined with resection of
5 PV/SMV for carcinoma of the head of the pancreas. Chinese Journal of Hepatobiliary
6 Surgery 16: 176-178

10.2.10.14 Studies included in Zhang et al., 2013 (n=3)

- 8 Kang CM, Kim DH, Lee WJ et al. (2011) Initial experiences using robot assisted central
9 pancreatotomy with pancreaticogastrostomy: a potential way to advanced pancreatotomy.
10 Surgical Endoscopy 25: 1101-1106
- 11 Walsh M, Chalikonda S, Saavedra JRA et al. (2011) Laparoscopic robotic assisted Whipple:
12 early results of a novel technique and comparison with the standard open procedure.
13 Surgical Endoscopy 25(Supp): S221
- 14 Waters JA, Canal DF, Wiebke EA et al. (2010) Robotic Distal Pancreatectomy: cost
15 effective? Surgery 148: 814-823

10.2.10.15 Studies included in Zhou et al., 2012 (n=2)

- 17 Allema JH, Reinders ME, Van Gulik TM et al. (1994) Portal vein resection in patients
18 undergoing pancreaticoduodenectomy for carcinoma of the pancreatic head. British Journal
19 of Surgery 81: 1642-1646
- 20 Howard TJ, Villanustre N, Moore SA et al. (2003) Efficacy of venous reconstruction in
21 patients with adenocarcinoma of the pancreatic head. Journal of Gastrointestinal Surgery 7:
22 1089-1095

23 10.3 Adjuvant treatment

24 **Review question: What is the most effective adjuvant therapy (chemotherapy,**
25 **chemoradiotherapy, biological therapy, immunotherapy, combinations of therapies)**
26 **for adults who have undergone surgical resection of pancreatic adenocarcinoma?**

27 10.3.1 Introduction

28 Outcomes after surgery for pancreatic cancer are very poor. Most people die from metastatic
29 pancreatic cancer, so non-surgical treatments are often used after surgery with the aim of
30 improving patient survival. Clinical trials have been conducted to evaluate a number of
31 different adjuvant treatment strategies and it is generally accepted that adjuvant therapy has
32 increased 5 year survival after surgery for pancreatic cancer.

33 Whilst adjuvant therapy is now established as standard of care, there is still uncertainty
34 regarding what is the optimal treatment modality and regimen. Treatment modalities which
35 have been tested in this setting include chemotherapy, radiotherapy, immunotherapy and
36 combinations of these approaches.

37 Guidance is needed what is the most effective adjuvant therapy for people who have
38 undergone surgical resection of primary pancreatic cancer.

39 10.3.1.1 Review protocol summary

40 The review protocol summary used for this question can be found in Table 138. Full details of
41 the review protocol can be found in Appendix C.

1 **Table 138: Clinical review protocol summary for the review of most effective**
2 **adjuvant therapy**

Population	Patients who have undergone resection of primary pancreatic cancer	
Intervention/comparison	Chemotherapy	<ul style="list-style-type: none"> • Difference chemo types/combination regimens • Chemoradiotherapy • No adjuvant therapy
	Combination chemotherapy with chemoradiotherapy	<ul style="list-style-type: none"> • Combination chemotherapy with chemoradiotherapy • Chemotherapy only • Chemoradiotherapy only • No adjuvant therapy
	Immunotherapy	<ul style="list-style-type: none"> • Other adjuvant therapy
	Biological therapy	<ul style="list-style-type: none"> • No adjuvant therapy
Outcomes	<ul style="list-style-type: none"> • Disease-free survival • Relapse-free survival • Overall Survival • Adverse Events • Health-related quality of life • Patient experience • Patient-reported outcome measures (PROMs) 	

3 10.3.2 Description of clinical evidence

4 Seventeen RCTs (n=4617) were included in the review (Buchler et al. 1991; Kosuge et al.
5 2006; Lygidakis et al. 2002; Neoptolemos 2001; Neoptolemos et al. 2004/2009; Neoptolemos
6 et al. 2010/Valle et al. 2014; Neoptolemos et al. 2017; Oettle et al. 2007/Oettle et al. 2013;
7 Regine et al. 2008/2011; Reni et al. 2012; Schmidt et al. 2012; Takada et al. 2002; Ueno et
8 al. 2009; Uesaka et al. 2016; Valle et al. 2014; van Laethem et al. 2010; Yoshitomi et al.
9 2008). All of the studies were in adults with resected pancreatic cancer.

10 All the included studies were RCTs, several of which were international multicentre studies.
11 Ten direct comparisons were found with the majority of evidence concerning the efficacy of
12 chemotherapy (predominantly a fluorouracil and folinic acid combination, or gemcitabine)
13 compared to no adjuvant therapy. There were only a few identified studies that examined a
14 combined adjuvant option with chemotherapy either preceding or following
15 chemoradiotherapy. Only single studies were found that examined immunotherapy,
16 chemoimmunotherapy, or chemoradioimmunotherapy as adjuvant therapies, whilst no
17 studies were found that examined adjuvant biological therapy. Three of the identified studies
18 were phase II studies (Yoshitomi et al. 2008; Reni et al. 2012; van Laethem et al. 2010).

19 Eight RCTs were found that compared chemotherapy with no adjuvant therapy (Kosuge et al.
20 2006; Lygidakis et al. 2002; Neoptolemos 2001; Neoptolemos et al. 2004, 2009; Oettle et al.
21 2007; Oettle et al. 2013; Takada et al. 2002; Ueno et al. 2009).

22 Four RCTs were found that compared chemotherapy using gemcitabine with another type of
23 chemotherapy (Neoptolemos et al. 2010/Valle et al. 2014; Neoptolemos et al. 2017; Uesaka
24 et al. 2016; Yoshitomi et al. 2008).

25 Two RCTs were found that compared chemotherapy with chemoradiotherapy (Neoptolemos,
26 Stocken et al. 2004; van Laethem, Hammel et al. 2010).

27 One RCT was found that compared chemotherapy with chemoimmunotherapy (Lygidakis,
28 Sgourakis et al. 2002).

- 1 One RCT was found that compared chemotherapy with chemoradioimmunotherapy
2 (Schmidt, Abel et al. 2012).
- 3 One RCT was found that compared chemoradiotherapy followed by chemotherapy with no
4 adjuvant therapy, chemotherapy only and chemoradiotherapy only (Neoptolemos, Stocken et
5 al. 2004).
- 6 Two RCTs were found that compared chemotherapy using gemcitabine followed by
7 chemoradiotherapy with chemotherapy using another type of drug followed by
8 chemoradiotherapy (Regine, Winter et al 2008; Reni, Balzano et al. 2012).
- 9 One RCT was found that compared immunotherapy with no adjuvant therapy (Buchler,
10 Friess et al. 1991).
- 11 One RCT was found that compared chemoimmunotherapy with no adjuvant therapy
12 (Lygidakis, Sgourakis et al. 2002).
- 13 Evidence from these are summarised in the clinical evidence profiles below (Table 140 to
14 Table 150).
- 15
- 16

10.3.31 Summary of included studies

2 A summary of the studies that were included in this review are presented in Table 139.

3 **Table 139: Summary of included studies**

Study (Country/ies)	N	Intervention	Comparison(s)	Outcomes	Overall risk of bias
Büchler et al. 1991 (Germany)	61	Immunotherapy (MoAb 494/32)	No adjuvant therapy	Overall survival Adverse events	HIGH
Kosuge et al. 2006 (Japan)	89	Chemotherapy (cisplatin + 5-FU)	No adjuvant therapy	Overall survival Disease-free survival Adverse events	HIGH
Lygidakis et al. 2002 (Greece)	128	Chemotherapy (gemcitabine, carboplatin + mitoxantrone + mitomycin C + fluororacil + folinic acid)	No adjuvant therapy Chemoimmunotherapy (chemotherapy course followed by interleukin-2)	Overall survival Disease-free survival Adverse events	HIGH
Neoptolemos et al. 2001 [ESPAC-1+] (11 European countries)	192	Chemotherapy (5-FU + FA)	No adjuvant therapy	Overall survival Quality of life	HIGH
Neoptolemos et al. 2004 [ESPAC-1 2x2] (11 European countries)	289	Chemotherapy (5-FU + FA)	No adjuvant therapy Chemoradiotherapy (20 Gy in 10 fractions) Chemoradiotherapy (5-FU with 20 Gy) then chemotherapy (5-FU)	Overall survival Adverse events	HIGH
Neoptolemos et al. 2009 ESPAC-3, v.1 (17 countries)	122	Chemotherapy (5-FU + FA)	No adjuvant therapy	Overall survival	HIGH
Neoptolemos et al. 2010/Valle et al. 2014 [ESPAC-3, v.2]	1088	Chemotherapy (gemcitabine)	Chemotherapy (5-FU + FA)	Overall survival Disease-free survival Adverse events	LOW

Study (Country/ies)	N	Intervention	Comparison(s)	Outcomes	Overall risk of bias
(17 countries)				Quality of life	
Neoptolemos et al. 2017 [ESPAC-4] (6 countries)	730	Chemotherapy (gemcitabine)	Chemotherapy (Gemcitabine + Capecitabine)	Overall Survival Relapse-free Survival Adverse Events	HIGH
Oettle et al. 2007/Oettle et al. 2013 (Germany and Austria)	368	Chemotherapy (gemcitabine)	No adjuvant therapy	Overall survival Disease-free survival Adverse events	HIGH
Regine et al. 2008/2011 (USA and Canada)	451	Chemotherapy (gemcitabine) then chemoradiotherapy (50.4 Gy with 5-FU) then chemotherapy (gemcitabine)	Chemotherapy (5-FU) then chemoradiotherapy (50.4 Gy in 28 fractions with 5-FU) then chemotherapy (5-FU)	Overall survival Adverse events	UNCLEAR
Reni et al. 2012a (Italy)	102	Chemotherapy (gemcitabine) with chemoradiotherapy (54-60 Gy in 27-30 fractions with 5-FU or capecitabine) then chemotherapy (gemcitabine)	Chemotherapy (PEFG) with chemoradiotherapy (54-60 Gy in 27-30 fractions with 5-FU or capecitabine) then chemotherapy (PEFG)	Overall survival Disease-free survival Adverse events	HIGH
Schmidt et al. 2012 (Germany and Italy) ^b	132	Chemotherapy (5-FU + FA)	Chemotherapy with chemoradioimmunotherapy (50.4 Gy in 28 fractions, 5-FU + FA + cisplatin, 3 million units of interferon α -2b)	Overall survival Disease-free survival Adverse events Quality of life	HIGH
Takada et al. 2002 (Japan)	173	Chemotherapy (5-FU and mitomycin C)	No adjuvant therapy	Overall survival Disease-free survival Quality of life	HIGH
Ueno et al. 2009 (Japan)	118	Chemotherapy (gemcitabine)	No adjuvant therapy	Overall survival Disease-free survival Adverse events	LOW
Uesaka et al. 2016 (Japan)	375	Chemotherapy (gemcitabine)	Chemotherapy (S-1)	Overall survival Disease-free survival	LOW

Study (Country/ies)	N	Intervention	Comparison(s)	Outcomes	Overall risk of bias
				Adverse events Quality of life	
Van Laethem et al. 2010 (Various European countries) ^a	90	Chemotherapy (gemcitabine)	Chemoradiotherapy (50.4 Gy in 28 fractions with gemcitabine)	Overall survival Disease-free survival Adverse events	HIGH
Yoshitomi et al. 2008a (Japan)	99	Chemotherapy (gemcitabine)	Chemotherapy (gemcitabine + UFT)	Overall survival Disease-free survival Adverse events	HIGH

Notes: All studies were RCTs; a, phase II trials; b; unclear whether study involved other countries.

1

2

1 10.3.4 Clinical evidence profile

2 The clinical evidence profiles for this review question are presented in Table 140 to Table
3 149.

4 **Table 140: Summary clinical evidence profile for adjuvant chemotherapy versus no**
5 **adjuvant therapy in resected pancreatic cancer patients**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
Overall Survival - Chemotherapy vs No adjuvant therapy	Study population ¹		HR 0.78 (0.69 to 0.89)	1262 (8 studies)	⊕⊕⊕⊖ low ^{2,3}	
	833 per 1000	752 per 1000 (709 to 796)				
	Moderate ¹					
	300 per 1000	243 per 1000 (218 to 272)				
Overall Survival - 5FU+FA vs No adjuvant therapy	Study population ¹		HR 0.69 (0.56 to 0.85)	458 (3 studies)	⊕⊕⊕⊖ low ^{3,4}	
	844 per 1000	723 per 1000 (647 to 794)				
	Moderate ¹					
	300 per 1000	218 per 1000 (181 to 262)				
Overall Survival - Cisplatin+5FU vs No adjuvant therapy	Study population ¹		HR 1.02 (0.64 to 1.62) ⁵	89 (1 study)	⊕⊕⊕⊖ low ^{3,6,7}	
	818 per 1000	824 per 1000 (664 to 937)				
	Moderate ¹					
	300 per 1000	305 per 1000 (204 to 439)				
Overall Survival - Gemcitabine vs No adjuvant therapy	Study population ¹		HR 0.76 (0.63 to 0.93)	472 (2 studies)	⊕⊕⊕⊖ low ^{3,8}	
	906 per 1000	835 per 1000 (775 to 890)				
	Moderate ¹					
	300 per 1000	237 per 1000 (201 to 282)				
Overall Survival - Gemcitabine, Carboplatin, Mitomycin C, 5FU+FA vs No adjuvant therapy	Study population ¹		HR 0.52 (0.27 to 1) ⁵	85 (1 study)	⊕⊖⊖⊖ very low ^{3,7,9}	
	375 per 1000	217 per 1000 (119 to 375)				
	Moderate ¹					
	300 per 1000	169 per 1000 (92 to 300)				
Overall Survival - Mitomycin C+5FU vs No adjuvant therapy	Study population ¹		HR 1.15 (0.82 to 1.61) ⁵	158 (1 study)	⊕⊖⊖⊖ very low ^{3,7,10}	
	818 per 1000	859 per 1000 (753 to 936)				
	Moderate ¹					

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
	300 per 1000	336 per 1000 (254 to 437)				
Disease-free Survival - Chemotherapy vs No adjuvant therapy	Study population ¹		HR 0.79 (0.68 to 0.92)	803 (5 studies)	⊕⊕⊕⊕ very low ^{3,11,12}	
	904 per 1000	843 per 1000 (797 to 884)				
	Moderate ¹					
	200 per 1000	162 per 1000 (141 to 186)				
Disease-free Survival - Cisplatin+5FU vs No adjuvant therapy	Study population ¹		HR 1.06 (0.66 to 1.72) ⁵	88 (1 study)	⊕⊕⊕⊕ low ^{3,6,7}	
	773 per 1000	792 per 1000 (624 to 922)				
	Moderate ¹					
	200 per 1000	211 per 1000 (137 to 319)				
Disease-free Survival - Gemcitabine vs No adjuvant therapy	Study population ¹		HR 0.72 (0.59 to 0.87)	472 (2 studies)	⊕⊕⊕⊕ low ^{3,8}	
	906 per 1000	818 per 1000 (753 to 873)				
	Moderate ¹					
	200 per 1000	148 per 1000 (123 to 176)				
Disease-free Survival - Gemcitabine, Carboplatin, Mitomycin C, 5FU+FA vs No adjuvant therapy	Study population ¹		HR 0.41 (0.21 to 0.81) ⁵	85 (1 study)	⊕⊕⊕⊕ very low ^{3,7,9}	
	375 per 1000	175 per 1000 (94 to 317)				
	Moderate ¹					
	200 per 1000	87 per 1000 (46 to 165)				
Disease-free Survival - Mitomycin C+5FU vs No adjuvant therapy	Study population ¹		HR 0.97 (0.7 to 1.34) ⁵	158 (1 study)	⊕⊕⊕⊕ very low ^{3,7,10}	
	922 per 1000	916 per 1000 (832 to 967)				
	Moderate ¹					
	200 per 1000	195 per 1000 (145 to 258)				
# patients with serious adverse events - Gemcitabine vs No adjuvant therapy	82 per 1000	140 per 1000 (77 to 255)	RR 1.7 (0.93 to 3.1)	368 (1 study)	⊕⊕⊕⊕ very low ^{13,14}	
# patients with any Grade 3 or 4 haematological toxicities - 5FU+FA vs No adjuvant therapy	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.27)	144 (1 study)	⊕⊕⊕⊕ very low ^{4,15}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
UICC Common Toxicity Criteria						
# patients with any Grade 3 or 4 non-haematological toxicities - 5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 17.5 (1.04 to 295.13)	144 (1 study)	⊕⊕⊕⊕ very low ^{4,15}	
# patients with Grade 3 or 4 Abscess - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Alanine Aminotransferase - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 9.47 (0.52 to 171.95)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Anaemia - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 5.26 (0.26 to 107.22)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Anorexia - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 5.26 (0.26 to 107.22)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Aspartate Aminotransferase - Gemcitabine vs No adjuvant therapy NCI Common	0 per 1000	0 per 1000 (0 to 0)	RR 7.36 (0.39 to 139.44)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
Terminology Criteria for Adverse Events						
# patients with Grade 3 or 4 Diarrhoea - Chemotherapy vs No adjuvant therapy UICC Common Toxicity Criteria; NCI Common Terminology Criteria for Adverse Events			RR 3.9 (0.44 to 34.75)	261 (2 studies)	⊕⊕⊕⊕ very low ^{4,15}	
# patients with Grade 3 or 4 Diarrhoea - 5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.27)	144 (1 study)	⊕⊕⊕⊕ very low ^{4,15}	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Fatigue - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Fever - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Granulocytopenia - Cisplatin+5FU vs No adjuvant therapy WHO Toxicity criteria	0 per 1000	0 per 1000 (0 to 0)	RR 10.38 (0.58 to 186.87)	82 (1 study)	⊕⊕⊕⊕ very low ^{6,15}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
# patients with Grade 3 or 4 Hepatic - Cisplatin+5FU vs No adjuvant therapy WHO Toxicity criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.08 (0.43 to 151.56)	82 (1 study)	⊕⊕⊕⊕ very low ^{6,15}	
# patients with Grade 3 or 4 Leukopenia - Chemotherapy vs No adjuvant therapy WHO Toxicity criteria; NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 18.43 (2.45 to 138.47)	199 (2 studies)	⊕⊕⊕⊕ low ^{6,16}	
# patients with Grade 3 or 4 Leukopenia - Cisplatin+5FU vs No adjuvant therapy WHO Toxicity criteria	0 per 1000	0 per 1000 (0 to 0)	RR 5.77 (0.29 to 116.57)	82 (1 study)	⊕⊕⊕⊕ very low ^{6,15}	
# patients with Grade 3 or 4 Leukopenia - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 30.5 (1.86 to 499.65)	117 (1 study)	⊕⊕⊕⊕ moderate ¹⁶	
# patients with Grade 3 or 4 Neutropenia - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 85.19 (5.36 to 1353.55)	117 (1 study)	⊕⊕⊕⊕ moderate ¹⁶	
# patients with Grade 3 or 4 Mucositis - Cisplatin+5FU vs No adjuvant therapy WHO Toxicity criteria	0 per 1000	0 per 1000 (0 to 0)	RR 5.77 (0.29 to 116.57)	82 (1 study)	⊕⊕⊕⊕ very low ^{6,15}	
# patients with Grade 3 or 4 Nausea/Vomiting -	0 per 1000	0 per 1000 (0 to 0)	RR 5.97	284 (3 studies)	⊕⊕⊕⊕ very low ^{6,9,14}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
Chemotherapy vs No adjuvant therapy WHO toxicity criteria; NCI Common Terminology Criteria for Adverse Events			(1.1 to 32.48)			
# patients with Grade 3 or 4 Nausea/Vomiting - Cisplatin+5FU vs No adjuvant therapy WHO toxicity criteria	0 per 1000	0 per 1000 (0 to 0)	RR 12.69 (0.72 to 222.32)	82 (1 study)	⊕⊕⊕⊕ very low ^{6,15}	
# patients with Grade 3 or 4 Nausea/Vomiting - Gemcitabine, Carboplatin, Mitoxantrone, mitomycin C, 5FU+FA vs No adjuvant therapy Not stated in study	0 per 1000	0 per 1000 (0 to 0)	RR 2.67 (0.11 to 63.84)	85 (1 study)	⊕⊕⊕⊕ very low ^{9,15}	
# patients with Grade 3 or 4 Nausea/Vomiting - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
# patients with Grade 3 or 4 Stomatitis - 5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.29 (0.45 to 151.2)	144 (1 study)	⊕⊕⊕⊕ very low ^{4,15}	
# patients with Grade 3 or 4 Thrombocytopenia - Gemcitabine vs No adjuvant therapy NCI Common Terminology Criteria for Adverse Events	0 per 1000	0 per 1000 (0 to 0)	RR 3.16 (0.13 to 75.9)	117 (1 study)	⊕⊕⊕⊕ low ¹⁵	
Quality of life - change scores - 5FU+FA vs No		The mean quality of life - change scores -		473 (1 study)	⊕⊕⊕⊕ very low ^{4,17}	SMD 0 (-0.18 to 0.18)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
adjuvant therapy ESPAC-1 QoL		5fu+fa vs no adjuvant therapy in the intervention groups was 0 standard deviations higher (0.18 lower to 0.18 higher)				
# patients with improving ESPAC-1 QoL Role Functioning scores - 5FU+FA vs No adjuvant therapy		The mean # patients with improving espac-1 QOL role functioning scores - 5fu+fa vs no adjuvant therapy in the intervention groups was 0.27 standard deviations lower (0.46 to 0.09 lower)		473 (1 study)	⊕⊕⊕⊕ very low ^{4,17}	SMD - 0.27 (-0.46 to -0.09)
# patients improved ≥ 1 ECOG PS Grade - Mitomycin C+5FU vs No adjuvant therapy	709 per 1000	709 per 1000 (560 to 893)	RR 1 (0.79 to 1.26)	113 (1 study)	⊕⊕⊕⊕ very low ^{10,15}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Thirty percent 2-year overall survival rate and 20% 2-year disease-free survival rate assumed for no adjuvant therapy control group.

2 Majority of studies have high risk of bias (Lygidakis et al. 2002; Neoptolemos et al. 2001, 2004, 2009; Oettle et al. 2007/2013; Takada et al. 2002). Main reasons include: unclear risk for randomisation method/allocation concealment; unclear or high risk for selective reporting (primary outcomes not fully reported); other sources of bias (Kaplan-Meier curves cross, proportional hazards not satisfied).

3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

4 Overall high risk of bias (Neoptolemos et al. 2001, 2004 and 2009). Main reasons include: unclear risk randomisation method; selective reporting (one or more outcomes of interest reported incompletely); other sources of bias (clinicians chose which ESPAC-1 trial patients were randomised to [ESPAC-1 2x2, ESPAC-1+ chemotherapy only trial, ESPAC-1+ chemoradiotherapy only trials]); other sources of bias (Kaplan-Meier curves for overall survival cross, proportional hazards not satisfied).

5 Hazard ratio estimated from Kaplan-Meier curve and/or summary statistics using method 7 in Tierney et al. (2007).

6 Overall unclear risk of bias for Kosuge et al. 2006 (unclear risk allocation concealment; selective reporting (insufficient information); other sources of bias (Kaplan-Meier curves for overall and disease-free survival

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemotherapy				
<p>cross, proportional hazards not satisfied).</p> <p>7 Not statistically significant ($p>0.5$).</p> <p>8 Overall high risk of bias (Oettle et al. 2007/2013). Main reasons include: selective reporting (one or more outcomes of interest not fully reported; other sources of bias (Kaplan-Meier curves for overall survival cross, proportional hazards not satisfied).</p> <p>9 Overall high risk of bias for Lygidakis et al. 2002. Main reasons include unclear risk randomisation method/allocation method; high risk selective reporting (fails to report survival results in expected manner); other sources of bias (power calculation not reported; Kaplan-Meier curves for overall survival cross, proportional hazards not satisfied).</p> <p>10 Overall high risk of bias for Takada et al. 2002. Main reasons include: unclear randomisation method/allocation concealment; selective reporting (one or more outcomes of interest not fully reported); other sources of bias (No Kaplan-Meier curve, not clear whether proportional hazards satisfied).</p> <p>11 Majority of studies have high risk of bias (Lygidakis et al. 2002; Oettle et al. 2007/2013; Takada et al. 2002). Main reasons include: unclear risk for randomisation method/allocation concealment; high risk for selective reporting (primary outcomes not fully reported);</p> <p>12 High heterogeneity ($i^2>50\%$).</p> <p>13 Overall high risk of bias for Oettle et al. 2007/2013. Main reasons include: selective reporting (one or more outcomes of interest not fully reported).</p> <p>14 Crosses 1 default MID (0.8 or 1.25).</p> <p>15 Crosses 2 default MIDs (0.8 and 1.25).</p> <p>16 Small sample size (<300 events).</p> <p>17 Data from both ESPAC-1 2x2 trial (Neoptolemos et al. 2001, 2004) and ESPAC-1+ (Neoptolemos et al. 2009) trial. Chemotherapy group ($n=238$) includes 72 patients who received both chemotherapy and chemoradiotherapy, in addition to 168 patients who received chemotherapy only. Comparison group ($n=235$) includes 70 patients who received chemoradiotherapy only, in addition to 165 patients who received no treatment after resection.</p>						

1
2
3

Table 141: Summary clinical evidence profile for adjuvant chemotherapy-1 (gemcitabine) versus adjuvant chemotherapy-2 (other) in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
Overall Survival - Gemcitabine vs Other chemotherapy (Random Effects)	Study population ¹		HR 1.15 (0.85 to 1.55)	2302 (4 studies)	⊕⊕⊕⊕ very low ^{2,3,4,5}	
	650 per 1000	701 per 1000 (590 to 803)				
	Moderate ¹					
	400 per 1000	444 per 1000 (352 to 547)				
Overall Survival - Gemcitabine vs 5FU+FA (Fixed Effects)	Study population ¹		HR 0.94 (0.81)	1088 (1 study)	⊕⊕⊕⊕ moderate ^{4,5}	
	704 per 1000	682 per 1000 (627 to 735)				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
	Moderate ¹		to 1.09)			
	400 per 1000	381 per 1000 (339 to 427)				
Overall Survival - Gemcitabine vs S-1 (Fixed Effects)	Study population ¹		HR 1.75 (1.37 to 2.24)	385 (1 study)	⊕⊕⊕⊕ high ⁴	
	594 per 1000	793 per 1000 (709 to 867)				
	Moderate ¹					
	400 per 1000	591 per 1000 (503 to 682)				
Overall Survival - Gemcitabine vs Gemcitabine+UFT (Fixed Effects)	Study population ¹		HR 0.75 (0.45 to 1.26) ⁶	99 (1 study)	⊕⊕⊕⊕ low ^{4,5,7}	
	620 per 1000	516 per 1000 (353 to 705)				
	Moderate ¹					
	400 per 1000	318 per 1000 (205 to 475)				
Overall Survival - Gemcitabine vs Gemcitabine+Capecitabine (Fixed Effects)	Study population ¹		HR 1.22 (1.02 to 1.46) ⁶	730 (1 study)	⊕⊕⊕⊕ moderate ^{4,8}	
	602 per 1000	675 per 1000 (609 to 739)				
	Moderate ¹					
	400 per 1000	464 per 1000 (406 to 526)				
Relapse-Free Survival - Gemcitabine vs Gemcitabine+Capecitabine	648 per 1000	703 per 1000 (641 to 761)	HR 1.16 (0.98 to 1.37)	730 (1 study)	⊕⊕⊕⊕ low ^{4,5,8}	
Disease-free Survival - Gemcitabine vs Other chemotherapy	Study population ¹		HR 1.11 (0.99 to 1.25)	1461 (3 studies)	⊕⊕⊕⊕ very low ^{2,3,4,5}	
	787 per 1000	820 per 1000 (783 to 855)				
	Moderate ¹					
	400 per 1000	433 per 1000 (397 to 472)				
	Study population ¹					

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
Disease-free Survival - Gemcitabine vs 5FU+FA	836 per 1000	833 per 1000 (792 to 872)	HR 0.99 (0.87 to 1.14)	985 (1 study)	⊕⊕⊕⊖ moderate ^{4,5}	
	Moderate ¹					
	400 per 1000	397 per 1000 (359 to 441)				
Disease-free Survival - Gemcitabine vs S-1	Study population ¹		HR 1.67 (1.31 to 2.12)	377 (1 study)	⊕⊕⊕⊕ high ⁴	
	658 per 1000	833 per 1000 (755 to 897)				
	Moderate ¹					
	400 per 1000	574 per 1000 (488 to 661)				
Disease-free Survival - Gemcitabine vs Gemcitabine+UFT	Study population ¹		HR 0.91 (0.58 to 1.43) ⁶	99 (1 study)	⊕⊖⊖⊖ very low ^{4,5,7}	
	780 per 1000	748 per 1000 (584 to 885)				
	Moderate ¹					
	400 per 1000	372 per 1000 (256 to 518)				
# patients with serious treatment-related adverse events - Gemcitabine vs Other (Random Effects)	179 per 1000	138 per 1000 (68 to 272)	RR 0.77 (0.38 to 1.52)	1813 (2 studies)	⊕⊖⊖⊖ very low ^{3,8,9}	
# patients with serious treatment-related adverse events - Gemcitabine vs 5FU+FA (Fixed Effects)	140 per 1000	74 per 1000 (52 to 108)	RR 0.53 (0.37 to 0.77)	1088 (1 study)	⊕⊕⊕⊕ high	
# patients with serious treatment-related adverse events - Gemcitabine vs Gemcitabine+Capecitabine (Fixed Effects)	240 per 1000	256 per 1000 (199 to 331)	RR 1.07 (0.83 to 1.38)	725 (1 study)	⊕⊕⊖⊖ low ^{8,10}	
# patients with Grade 3 or 4 Alanine Aminotransferase/Aspartate Aminotransferase - Gemcitabine vs Other chemotherapy (Random Effects)	174 per 1000	337 per 1000 (45 to 1000)	RR 1.94 (0.26 to 14.2)	1564 (3 studies)	⊕⊖⊖⊖ very low ^{3,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
NCI Common Toxicity Criteria						
# patients with Grade 3 or 4 Alanine Aminotransferase/Aspartate Aminotransferase - Gemcitabine vs S-1 (Fixed Effects) NCI Common Toxicity Criteria	80 per 1000	726 per 1000 (444 to 1000)	RR 9.05 (5.53 to 14.83)	377 (1 study)	⊕⊕⊕⊕ high ¹¹	
# patients with Grade 3 or 4 Alanine Aminotransferase/Aspartate Aminotransferase - Gemcitabine vs 5FU+FA (Fixed Effects) NCI Common Toxicity Criteria	220 per 1000	222 per 1000 (178 to 277)	RR 1.01 (0.81 to 1.26)	1088 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Alanine Aminotransferase/Aspartate Aminotransferase - Gemcitabine vs Gemcitabine+UFT (Fixed Effects) NCI Common Toxicity Criteria	20 per 1000	7 per 1000 (0 to 163)	RR 0.34 (0.01 to 8.15)	99 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Anorexia - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	68 per 1000	50 per 1000 (24 to 103)	RR 0.74 (0.36 to 1.53)	476 (2 studies)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Anorexia - Gemcitabine vs Gemcitabine+UFT NCI Common Toxicity Criteria	20 per 1000	20 per 1000 (1 to 317)	RR 1.02 (0.07 to 15.86)	99 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Anorexia - Gemcitabine vs S-1 NCI Common Toxicity Criteria	80 per 1000	58 per 1000 (27 to 123)	RR 0.72 (0.34 to 1.53)	377 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Bilirubin - Gemcitabine vs S-1 NCI Common Toxicity Criteria	11 per 1000	5 per 1000 (1 to 58)	RR 0.49 (0.05 to 5.38)	377 (1 study)	⊕⊕⊖⊖ low ⁹	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
# patients with Grade 3 or 4 Creatinine - Gemcitabine vs S-1 NCI Common Toxicity Criteria	5 per 1000	5 per 1000 (0 to 84)	RR 0.98 (0.06 to 15.62)	377 (1 study)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	91 per 1000	17 per 1000 (10 to 27)	RR 0.19 (0.11 to 0.3)	2190 (3 studies)	⊕⊕⊕⊕ high ¹¹	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs S-1 NCI Common Toxicity Criteria	48 per 1000	2 per 1000 (0 to 42)	RR 0.05 (0 to 0.88)	377 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria	131 per 1000	22 per 1000 (12 to 41)	RR 0.17 (0.09 to 0.31)	1088 (1 study)	⊕⊕⊕⊕ high ¹¹	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs Gemcitabine+Capecitabine NCI Common Toxicity Criteria	53 per 1000	16 per 1000 (7 to 41)	RR 0.31 (0.13 to 0.77)	725 (1 study)	⊕⊕⊕⊖ moderate ⁸	
# patients with Grade 3 or 4 Fatigue/Tiredness - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	68 per 1000	55 per 1000 (40 to 77)	RR 0.81 (0.58 to 1.12)	2190 (3 studies)	⊕⊕⊕⊖ low ^{8,10}	
# patients with Grade 3 or 4 Fatigue/Tiredness - Gemcitabine vs S-1 NCI Common Toxicity Criteria	53 per 1000	48 per 1000 (20 to 114)	RR 0.89 (0.37 to 2.13)	377 (1 study)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 Fatigue/Tiredness - Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria	82 per 1000	60 per 1000 (38 to 92)	RR 0.73 (0.47 to 1.13)	1088 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Fatigue/Tiredness - Gemcitabine vs Gemcitabine+Capecitabine	56 per 1000	52 per 1000 (28 to 96)	RR 0.93 (0.51	725 (1 study)	⊕⊕⊕⊖ very low ^{8,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
None			to 1.72)			
NCI Common Toxicity Criteria						
# patients with Grade 3 or 4 Febrile Neutropenia - Gemcitabine vs S-1 NCI Common Toxicity Criteria	5 per 1000	16 per 1000 (2 to 150)	RR 2.95 (0.31 to 28.13)	377 (1 study)	⊕⊕⊕⊕ low ⁹	
# patients with Grade 3 or 4 Fever - Gemcitabine vs Other NCI Common Toxicity Criteria	20 per 1000	12 per 1000 (5 to 32)	RR 0.62 (0.24 to 1.6)	1102 (1 study)	⊕⊕⊕⊕ very low ^{8,9}	
# patients with Grade 3 or 4 Fever - Gemcitabine vs S-1 NCI Common Toxicity Criteria	27 per 1000	5 per 1000 (1 to 45)	RR 0.2 (0.02 to 1.67)	377 (1 study)	⊕⊕⊕⊕ low ⁹	
# patients with Grade 3 or 4 Fever - Gemcitabine vs Gemcitabine+Capecitabine NCI Common Toxicity Criteria	17 per 1000	16 per 1000 (5 to 50)	RR 0.98 (0.32 to 3.01)	725 (1 study)	⊕⊕⊕⊕ very low ^{8,9}	
# patients with Grade 3 or 4 Glucose Intolerance - Gemcitabine vs Gemcitabine+UFT NCI Common Toxicity Criteria	980 per 1000	333 per 1000 (10 to 1000)	RR 0.34 (0.01 to 8.15)	99 (1 study)	⊕⊕⊕⊕ low ⁹	
# patients with Grade 3 or 4 Haemoglobin - Gemcitabine vs Gemcitabine+UFT NCI Common Toxicity Criteria	40 per 1000	82 per 1000 (16 to 426)	RR 2.04 (0.39 to 10.64)	99 (1 study)	⊕⊕⊕⊕ low ⁹	
# patients with Grade 3 or 4 Hand-Foot Syndrome	72 per 1000	1 per 1000 (0 to 22)	RR 0.02 (0 to 0.3)	725 (1 study)	⊕⊕⊕⊕ moderate ⁸	
# patients with Grade 3 or 4 Infection - Gemcitabine vs Other NCI Common Toxicity Criteria	20 per 1000	58 per 1000 (29 to 113)	RR 2.86 (1.46 to 5.6)	1102 (2 studies)	⊕⊕⊕⊕ moderate ⁸	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
# patients with Grade 3 or 4 Infection - Gemcitabine vs S-1 NCI Common Toxicity Criteria	11 per 1000	42 per 1000 (9 to 196)	RR 3.94 (0.85 to 18.3)	377 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Infection - Gemcitabine vs Gemcitabine+Capecitabine NCI Common Toxicity Criteria	25 per 1000	66 per 1000 (31 to 139)	RR 2.62 (1.23 to 5.55)	725 (1 study)	⊕⊕⊖⊖ low ^{8,10}	
# patients with Grade 3 or 4 Leukocytes - Gemcitabine vs Gemcitabine+UFT NCI Common Toxicity Criteria	180 per 1000	225 per 1000 (103 to 493)	RR 1.25 (0.57 to 2.74)	99 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Nausea - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	35 per 1000	25 per 1000 (14 to 45)	RR 0.7 (0.39 to 1.27)	1465 (2 studies)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Nausea - Gemcitabine vs S-1 NCI Common Toxicity Criteria	37 per 1000	26 per 1000 (9 to 82)	RR 0.7 (0.23 to 2.18)	377 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Nausea - Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria	34 per 1000	24 per 1000 (12 to 49)	RR 0.7 (0.35 to 1.41)	1088 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Neutrophils - Gemcitabine vs Other chemotherapy (Random Effects) NCI Common Toxicity Criteria	184 per 1000	35 per 1000 (293 to 426)	RR 0.19 (1.59 to 2.31)	1465 (2 studies)	⊕⊕⊖⊖ low ³	
# patients with Grade 3 or 4 Neutrophils - Gemcitabine vs S-1 (Fixed Effects) NCI Common Toxicity Criteria	80 per 1000	726 per 1000 (444 to 1000)	RR 9.05 (5.53 to 14.83)	377 (1 study)	⊕⊕⊕⊕ high ¹¹	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
# patients with Grade 3 or 4 Neutrophils - Gemcitabine vs 5FU+FA (Fixed Effects) NCI Common Toxicity Criteria	220 per 1000	222 per 1000 (178 to 277)	RR 1.01 (0.81 to 1.26)	1088 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	15 per 1000	30 per 1000 (17 to 52)	RR 2.04 (1.17 to 3.53)	2289 (4 studies)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs S-1 NCI Common Toxicity Criteria	48 per 1000	95 per 1000 (44 to 206)	RR 1.97 (0.91 to 4.27)	377 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 17.44 (1.01 to 301.45)	1088 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs Gemcitabine+UFT NCI Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 7.14 (0.38 to 134.71)	99 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs Gemcitabine+Capecitabine NCI Common Toxicity Criteria	22 per 1000	19 per 1000 (7 to 52)	RR 0.86 (0.31 to 2.34)	725 (1 study)	⊕⊖⊖⊖ very low ^{8,9}	
# patients with Grade 3 or 4 Stomatitis - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	80 per 1000	2 per 1000 (1 to 10)	RR 0.03 (0.01 to 0.13)	1465 (2 studies)	⊕⊕⊕⊕ high ¹¹	
# patients with Grade 3 or 4 Stomatitis - Gemcitabine vs S-1 NCI Common Toxicity Criteria	27 per 1000	2 per 1000 (0 to 43)	RR 0.09 (0 to 1.61)	377 (1 study)	⊕⊕⊖⊖ low ⁹	
# patients with Grade 3 or 4 Stomatitis -	98 per 1000	2 per 1000 (0 to 14)	RR 0.02	1088 (1 study)	⊕⊕⊕⊕ high ¹¹	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria			(0 to 0.14)			
# patients with Grade 3 or 4 Vomiting - Gemcitabine vs Other chemotherapy NCI Common Toxicity Criteria	27 per 1000	18 per 1000 (9 to 36)	RR 0.66 (0.33 to 1.32)	1465 (2 studies)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 Vomiting - Gemcitabine vs S-1 NCI Common Toxicity Criteria	16 per 1000	11 per 1000 (2 to 62)	RR 0.66 (0.11 to 3.88)	377 (1 study)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 Vomiting - Gemcitabine vs 5FU+FA NCI Common Toxicity Criteria	31 per 1000	20 per 1000 (10 to 43)	RR 0.66 (0.31 to 1.4)	1088 (1 study)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 White Blood Cell Count - Gemcitabine vs Other chemotherapy (Random Effects) NCI Common Toxicity Criteria	82 per 1000	135 per 1000 (61 to 297)	RR 1.65 (0.75 to 3.63)	2289 (4 studies)	⊕⊖⊖⊖ very low ^{3,9}	
# patients with Grade 3 or 4 White Blood Cell Count - Gemcitabine vs S-1 (Fixed Effects) NCI Common Toxicity Criteria	86 per 1000	389 per 1000 (236 to 643)	RR 4.55 (2.76 to 7.51)	377 (1 study)	⊕⊕⊕⊕ high ¹²	
# patients with Grade 3 or 4 White Blood Cell Count - Gemcitabine vs 5FU+FA (Fixed Effects) NCI Common Toxicity Criteria	58 per 1000	99 per 1000 (64 to 150)	RR 1.7 (1.11 to 2.59)	1088 (1 study)	⊕⊕⊕⊖ moderate ¹⁰	
# patients with Grade 3 or 4 White Blood Cell Count - Gemcitabine vs Gemcitabine+UFT (Fixed Effects) NCI Common Toxicity Criteria	180 per 1000	225 per 1000 (103 to 493)	RR 1.25 (0.57 to 2.74)	99 (1 study)	⊕⊕⊕⊖ low ⁹	
# patients with Grade 3 or 4 White Blood Cell Count - Gemcitabine vs Gemcitabine+Capecitabine	103 per 1000	76 per 1000 (47 to 123)	RR 0.74 (0.46 to 1.11)	725 (1 study)	⊕⊕⊕⊖ low ^{8,10}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
None (Fixed Effects) NCI Common Toxicity Criteria			to 1.19)			
EQ-5D Quality of Life - Gemcitabine vs S-1, 3 months post-randomisation		The mean eq-5d quality of life - gemcitabine vs s-1, 3 months post-randomisation in the intervention groups was 0.15 standard deviations higher (0.08 lower to 0.37 higher)		311 (1 study)	⊕⊖⊖⊖ very low ^{13,14}	SMD 0.15 (-0.08 to 0.37)
EQ-5D Quality of Life - Gemcitabine vs S-1, 6 months post-randomisation		The mean eq-5d quality of life - gemcitabine vs s-1, 6 months post-randomisation in the intervention groups was 0.14 standard deviations higher (0.09 lower to 0.37 higher)		291 (1 study)	⊕⊖⊖⊖ very low ^{13,14}	SMD 0.14 (-0.09 to 0.37)
EQ-5D Quality of Life - Gemcitabine vs S-1, 12 months post-randomisation		The mean eq-5d quality of life - gemcitabine vs s-1, 12 months post-randomisation in the		255 (1 study)	⊕⊖⊖⊖ very low ^{10,13}	SMD 0.4 (0.15 to 0.65)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
		intervention groups was 0.4 standard deviations higher (0.15 to 0.65 higher)				
EQ-5D Quality of Life - Gemcitabine vs S-1, 24 months post-randomisation		The mean eq-5d quality of life - gemcitabine vs s-1, 24 months post-randomisation in the intervention groups was 0.42 standard deviations higher (0.11 to 0.72 higher)		171 (1 study)	⊕⊕⊕⊕ very low ^{10,13}	SMD 0.42 (0.11 to 0.72)
Global Quality of Life - Gemcitabine vs 5FU+FA EORTC QLQ-C30 v3; ESPAC-32		The mean global quality of life - gemcitabine vs 5fu+fa in the intervention groups was 0.15 standard deviations higher (0.01 lower to 0.32 higher)		565 (1 study)	⊕⊕⊕⊕ low ¹⁵	SMD 0.15 (-0.01 to 0.32)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Forty percent 2-year overall survival and disease-free survival rate assumed for other chemotherapy group.

2 Two of 4 studies at high risk of bias: Yoshitomi et al. 2008 (high risk of bias due to other sources of bias (Kaplan-Meier curves for both overall and disease-free survival cross, proportional hazards not satisfied); Neoptolemos et al. 2017 (high risk due to no allocation concealment; no blinding of participants/personnel; relapsed patients received additional chemoradiotherapy, surgery or other treatment).

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)	Chemotherapy-1 (gemcitabine)				
<p>3 High heterogeneity ($I^2 > 80\%$).</p> <p>4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.</p> <p>5 Not statistically significant ($p > 0.5$).</p> <p>6 Hazard ratio estimated from Kaplan-Meier curve and summary statistics using method 7 in Tierney et al. (2007).</p> <p>7 Overall high risk of bias (Yoshitomi et al. 2008) due to high risk other sources of bias (Kaplan-Meier curves for overall and disease-free survival cross, proportional hazards not satisfied).</p> <p>8 Overall high risk of bias (Neoptolemos et al. 2017: no allocation concealment; no blinding of participants/personnel; relapsed patients received additional chemoradiotherapy, surgery or other treatment).</p> <p>9 Crosses 2 default MIDs (0.8 and 1.25).</p> <p>10 Crosses 1 default MID (dichotomous outcomes: 0.8 or 1.25; continuous outcomes: 0.5 or -0.5).</p> <p>11 Very large effect size (Risk Ratio > 5 or < 0.2)</p> <p>12 Large effect size (Risk Ratio > 2 or < 0.5)</p> <p>13 Overall high risk of bias (Uesaka et al. 2016). Main reason: high risk blinding of participants and personnel (participants not blinded, quality of life outcomes likely to be influenced by this).</p> <p>14 Small sample size (< 400 participants).</p> <p>15 Overall high risk of bias (Neoptolemos et al. 2010). Main reason: high risk blinding of participants and personnel (participants not blinded, quality of life outcomes likely to be influenced by this).</p>						

1
2

Table 142: Summary clinical evidence profile for adjuvant chemotherapy versus adjuvant chemoradiotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemoradiotherapy	Chemotherapy				
Overall Survival - Chemotherapy vs Chemoradiotherapy	Study population ¹		HR 0.79 (0.59 to 1.07) ²	238 (2 studies)	⊕⊖⊖ ⊖ very low ^{3,4,5}	
	746 per 1000	661 per 1000 (554 to 769)				
	Moderate ¹					
	500 per 1000	422 per 1000 (336 to 524)				
Overall Survival - 5FU+FA vs Chemoradiotherapy	Study population ¹		HR 0.7 (0.49 to 1.01)	148 (1 study)	⊕⊖⊖ ⊖ very low ^{3,5,6}	
	863 per 1000	751 per 1000 (622 to 866)				
	Moderate ¹					
	500 per 1000	384 per 1000 (288 to 503)				
Overall Survival - Gemcitabine vs Chemoradiotherapy	Study population ¹		HR 1.02 (0.61 to 1.72) ²	90 (1 study)	⊕⊖⊖ ⊖ very low ^{4,5,6}	
	556 per 1000	563 per 1000 (390 to 752)				
	Moderate ¹					
	500 per 1000	507 per 1000 (345 to 696)				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Disease-free survival - Gemcitabine vs Chemoradiotherapy	Study population ¹		HR 0.97 (0.62 to 1.52) ²	90 (1 study)	⊕⊖⊖ ⊖ very low ^{4,5,6}	
	756 per 1000	745 per 1000 (582 to 883)				
	Moderate ¹					
	500 per 1000	489 per 1000 (349 to 651)				
# patients with any Grade 3 or 4 haematological toxicities - 5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 4.87 (0.24 to 99.7)	148 (1 study)	⊕⊖⊖ ⊖ very low ^{3,7}	
# patients with any Grade 3 or 4 non-haematological toxicities - 5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	27 per 1000	120 per 1000 (27 to 537)	RR 4.38 (0.98 to 19.59)	148 (1 study)	⊕⊖⊖ ⊖ very low ^{3,8}	
# patients with Grade 3 or 4 Anorexia - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	47 per 1000	9 per 1000 (0 to 193)	RR 0.2 (0.01 to 4.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Diarrhoea - Chemotherapy vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events; UCCI Common Toxicity Criteria	9 per 1000	13 per 1000 (2 to 77)	RR 1.49 (0.25 to 8.95)	233 (2 studies)	⊕⊖⊖ ⊖ very low ^{3,4,7}	
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine vs Chemoradiotherapy	23 per 1000	7 per 1000 (0 to 189)	RR 0.31 (0.01 to 8.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
NCI Common Terminology Criteria for Adverse Events						
# patients with Grade 3 or 4 Diarrhoea - 5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 4.87 (0.24 to 99.7)	148 (1 study)	⊕⊖⊖ ⊖ very low ^{3,7}	
# patients with Grade 3 or 4 Fatigue - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	70 per 1000	47 per 1000 (8 to 271)	RR 0.68 (0.12 to 3.88)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Fever - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	70 per 1000	10 per 1000 (1 to 192)	RR 0.15 (0.01 to 2.75)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Gastritis - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	47 per 1000	9 per 1000 (0 to 193)	RR 0.2 (0.01 to 4.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Haemoglobin - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	70 per 1000	10 per 1000 (1 to 192)	RR 0.15 (0.01 to 2.75)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
# patients with Grade 3 or 4 Haemorrhage - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	23 per 1000	24 per 1000 (2 to 368)	RR 1.02 (0.07 to 15.84)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Nausea - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	23 per 1000	8 per 1000 (0 to 189)	RR 0.34 (0.01 to 8.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Neutrophils - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	326 per 1000	430 per 1000 (247 to 746)	RR 1.32 (0.76 to 2.29)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Other Gastrointestinal toxicity - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	23 per 1000	8 per 1000 (0 to 189)	RR 0.34 (0.01 to 8.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{3,7}	
# patients with Grade 3 or 4 Platelets - Gemcitabine vs Chemoradiotherapy NCI Common Terminology Criteria for Adverse Events	23 per 1000	8 per 1000 (0 to 189)	RR 0.34 (0.01 to 8.14)	85 (1 study)	⊕⊖⊖ ⊖ very low ^{4,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
# patients with Grade 3 or 4 Serum Glutamicpyruvic Transaminase - Gemcitabine vs Chemoradiotherapy y NCI Common Terminology Criteria for Adverse Events	116 per 1000	119 per 1000 (37 to 381)	RR 1.02 (0.32 to 3.28)	85 (1 study)	⊕⊕⊕ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 Stomatitis - 5FU+FA vs Chemoradiotherapy y UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.76 (0.48 to 159.93)	148 (1 study)	⊕⊕⊕ ⊖ very low ^{3,7}	
# patients with Grade 3 or 4 Vomiting - Gemcitabine vs Chemoradiotherapy y NCI Common Terminology Criteria for Adverse Events	23 per 1000	8 per 1000 (0 to 189)	RR 0.34 (0.01 to 8.14)	85 (1 study)	⊕⊕⊕ ⊖ very low ^{3,7}	
# patients with Grade 3 or 4 Weight Loss - Gemcitabine vs Chemoradiotherapy y NCI Common Terminology Criteria for Adverse Events	23 per 1000	8 per 1000 (0 to 189)	RR 0.34 (0.01 to 8.14)	85 (1 study)	⊕⊕⊕ ⊖ very low ^{4,7}	
# patients with Grade 3 or 4 White Blood Cell count - Gemcitabine vs Chemoradiotherapy () y NCI Common Terminology Criteria for Adverse Events	163 per 1000	143 per 1000 (52 to 391)	RR 0.88 (0.32 to 2.4)	85 (1 study)	⊕⊕⊕ ⊖ very low ^{4,7}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Fifty percent 2-year overall survival and disease-free survival rate assumed for chemoradiotherapy control group. 2 Hazard ratio for van Laethem et al. 2010 estimated using Kaplan-Meier curve and method 10 in Tierney et al. 2010. 3 Overall high risk of bias (Neoptolemos et al. 2004). Main reasons include: unclear risk randomisation method; selective reporting (one or more outcomes of interest reported incompletely); other sources of bias (clinicians chose which ESPAC-1 trial patients were randomised to [ESPAC-1 2x2, ESPAC-1+ chemotherapy only trial, ESPAC-1+ chemoradiotherapy only trials]; Kaplan-Meier curves for separate groups not provided, unclear whether proportional hazards satisfied). 4 Overall high risk of bias (van Laethem et al. 2010). Main reasons include: unclear risk randomisation method/allocation concealment; high risk selective reporting (one or more outcomes of interest not fully reported); other sources of bias (Kaplan-Meier curve cross, proportional hazards not satisfied). 5 Not statistically significant ($p > 0.5$). 6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant. 7 Crosses 2 default MIDs (0.8 and 1.25). 8 Crosses 1 default MID (0.8 or 1.25).</p>						

1
2

Table 143: Summary clinical evidence profile for adjuvant chemotherapy versus adjuvant chemoimmunotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemoimmunotherapy	Chemotherapy				
Overall Survival - Gemcitabine, Carboplatin, Mitomycin C, 5FU+FA vs CT+Interleukin-2	Study population ¹		HR 2.05 (1.12 to 3.76) ²	88 (1 study)	⊕⊕⊖ ⊖ low ^{3,4}	
	465 per 1000	723 per 1000 (504 to 905)				
	Moderate ¹					
	400 per 1000	649 per 1000 (436 to 853)				
Disease-free Survival - Gemcitabine, Carboplatin, Mitomycin C, 5FU+FA vs CT+Interleukin-2	Study population ¹		HR 1.99 (1.07 to 3.7) ²	88 (1 study)	⊕⊕⊖ ⊖ low ^{3,4}	
	488 per 1000	736 per 1000 (512 to 916)				
	Moderate ¹					
	400 per 1000	638 per 1000 (421 to 849)				
# patients with Grade 3 or 4 Nausea - Gemcitabine, Carboplatin, mitoxantrone,	0 per 1000	0 per 1000 (0 to 0)	RR 2.87 (0.12 to 68.58)	88 (1 study)	⊕⊖⊖ ⊖ very low ^{3,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
mitomycin C, 5FU+FA vs CT+Interleukin-2 Not stated in study						
# patients with Grade 3 or 4 Vomiting - Gemcitabine, Carboplatin, mitoxantrone, mitomycin C, 5FU+FA vs CT+Interleukin-2 Not stated in study	47 per 1000	9 per 1000 (0 to 180)	RR 0.19 (0.01 to 3.87)	88 (1 study)	⊕⊖⊖ ⊖ very low ^{3,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.
The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Forty percent 2-year overall and disease-free survival rate assumed for chemoimmunotherapy control group
2 Hazard ratio estimated from Kaplan-Meier curve and summary statistics using method 7 in Tierney et al. (2007).
3 Overall high risk of bias for Lygidakis et al. 2002. Main reasons include unclear risk randomisation method/allocation method; high risk selective reporting (fails to report survival results in expected manner); other sources of bias (power calculation not reported; Kaplan-Meier curves for disease-free survival cross, proportional hazards not satisfied).
4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MID. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.
5 Crosses 2 default MIDs (0.8 and 1.25).

1
2

Table 144: Summary clinical evidence profile for adjuvant chemotherapy versus adjuvant chemoradioimmunotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemoradioimmunotherapy	Chemotherapy				
Overall Survival - 5FU vs 5FU, Cisplatin + Interferon alpha-2b	Study population ¹		HR 0.96 (0.63 to 1.48)	132 (1 study)	⊕⊖⊖ ⊖ very low ^{3,4,5}	
	See comment ²	See comment ²				
	Moderate ¹ 400 per 1000 ²	388 per 1000 (275 to 530) ²				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Disease-free Survival - 5FU vs 5FU, Cisplatin + Interferon alpha-2b (Copy)	Study population ¹		HR 1.02 (0.64 to 1.65) ⁶	132 (1 study)	⊕⊕⊕ ⊖ very low ^{3,4,5}	
	See comment ²	See comment ²				
	Moderate ¹					
	400 per 1000 ²	406 per 1000 (279 to 570) ²				
# patients with any Grade 3 or 4 toxicities - 5FU vs 5FU, Cisplatin + Inteferon alpha-2b Common Toxicity Criteria	789 per 1000	174 per 1000 (95 to 316)	RR 0.22 (0.12 to 0.4)	110 (1 study)	⊕⊕⊕ ⊖ very low ^{3,7}	
EORTC QLQ-30 Quality of Life - Global Health Status	The mean EORTC qlq-30 quality of life - global health status in the control groups was 55.8 AUC	The mean EORTC qlq-30 quality of life - global health status in the intervention groups was 7 higher (0.41 to 13.59 higher)		86 (1 study)	⊕⊕⊕ ⊖ very low ^{3,8}	SMD -0.46 (-0.9 to -0.03)
EORTC QLQ-30 Quality of Life - Nausea/Vomiting	The mean EORTC qlq-30 quality of life - nausea/vomiting in the control groups was -15.9 AUC	The mean EORTC qlq-30 quality of life - nausea/vomiting in the intervention groups was 7.7 higher (1.67 to 13.73 higher)		86 (1 study)	⊕⊕⊕ ⊖ very low ^{3,8}	SMD 0.53 (0.09 to 0.97)
EORTC QLQ-30 Quality of Life - Role functioning	The mean EORTC qlq-30 quality of life - role functioning in the control groups was 55.6 AUC	The mean EORTC qlq-30 quality of life - role functioning in the intervention groups was 13.9 higher (4.16 to 23.64 higher)		85 (1 study)	⊕⊕⊕ ⊖ very low ^{3,8}	SMD 0.61 (0.17 to 1.05)
EORTC QLQ-30 Quality of	The mean EORTC qlq-30 quality of life - social	The mean EORTC qlq-		85 (1 study)	⊕⊕⊕ ⊖	SMD -0.45 (-

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Life - Social functioning	functioning in the control groups was 64.5	30 quality of life - social functioning in the intervention groups was 10 higher (0.75 to 19.25 higher)			very low ^{3,8}	0.88 to -0.01)

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Forty percent 2-year overall survival rate assumed for chemoradioimmunotherapy control group.
 2 The number of observed deaths in each group was not provided in the study (Schmidt et al. 2012).
 3 Overall high risk of bias (Schmidt et al. 2012). Main reasons include: selective reporting (one or more outcomes of interest not fully reported); high risk blinding of participants and personnel (participants not blinded, quality of life outcomes likely to be influenced by this); high risk other sources of bias (Kaplan-Meier curves for overall and disease-free survival cross, proportional hazards not satisfied).
 4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.
 5 Not statistically significant (p>0.5).
 6 Hazard ratio estimated using Kaplan-Meier curve and method 10 of Tierney et al. 2007.
 7 Small sample size (<300 events).
 8 Crosses 1 MID (+5 or -5, from Osoba et al. 1998)

1
2
3

Table 145: Summary clinical evidence profile for adjuvant chemoradiotherapy followed by chemotherapy versus no adjuvant therapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemoradiotherapy->Chemotherapy				
# patients with any Grade 3 or 4 haematological toxicities - Chemoradiotherapy ->5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 10.55 (0.59 to 187.23)	141 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2}	
# patients with any Grade 3 or 4 non-haematological	0 per 1000	0 per 1000 (0 to 0)	RR 22.05 (1.32	141 (1 study)	⊕⊕⊕ ⊖	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
toxicities - Chemoradiotherapy ->5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria			to 367.2)		very low ^{1,3}	
# patients with Grade 3 or 4 Stomatitis - Chemoradiotherapy ->5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.29 (0.45 to 151.2)	144 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2}	
# patients with Grade 3 or 4 Diarrhoea - Chemoradiotherapy ->5FU+FA vs No adjuvant therapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.27)	144 (1 study)	⊕⊕⊕ ⊖ very low ^{1,2}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Overall high risk of bias (Neoptolemos et al. 2004). Main reasons include: unclear risk randomisation method; selective reporting (one or more outcomes of interest reported incompletely); other sources of bias (clinicians chose which ESPAC-1 trial patients were randomised to [ESPAC-1 2x2, ESPAC-1+ chemotherapy only trial, ESPAC-1+ chemoradiotherapy only trials]; Kaplan-Meier overall survival curves for separate groups not provided, unclear whether proportional hazards satisfied).

2 Crosses 2 default MIDs (0.8 and 1.25).

3 Small sample size (<300 events).

1
2
3

Table 146: Summary clinical evidence profile for adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant chemotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy	Chemoradiotherapy->Chemotherapy				
Overall Survival - Chemoradiotherapy->5FU+FA vs 5FU+FA	Study population ¹ 867 per 1000 Moderate ¹	930 per 1000 (837 to 979)	HR 1.32 (0.9 to 1.92)	147 (1 study)	⊕⊕⊕ ⊖ very low ^{2,3,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	400 per 1000	490 per 1000 (369 to 625)				
# patients with any Grade 3 or 4 haematological toxicities - Chemoradiotherapy->5FU+FA vs 5FU+FA UICC Common Toxicity Criteria	27 per 1000	69 per 1000 (14 to 347)	RR 2.6 (0.52 to 13)	147 (1 study)	⊕⊕⊕ ⊖ very low ^{2,5}	
# patients with any Grade 3 or 4 non-haematological toxicities - Chemoradiotherapy->5FU+FA vs 5FU+FA UICC Common Toxicity Criteria	120 per 1000	152 per 1000 (67 to 347)	RR 1.27 (0.56 to 2.89)	147 (1 study)	⊕⊕⊕ ⊖ very low ^{2,5}	
# patients with Grade 3 or 4 Stomatitis - Chemoradiotherapy->5FU+FA vs 5FU+FA UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.29 (0.45 to 151.2)	144 (1 study)	⊕⊕⊕ ⊖ very low ^{2,5}	
# patients with Grade 3 or 4 Diarrhoea - Chemoradiotherapy->5FU+FA vs 5FU+FA UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 5 (0.24 to 102.42)	150 (1 study)	⊕⊕⊕ ⊖ very low ^{2,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Forty percent 2-year overall survival assumed for chemotherapy control group.

2 Overall high risk of bias (Neoptolemos et al. 2004). Main reasons include: unclear risk randomisation method; selective reporting (one or more outcomes of interest reported incompletely); other sources of bias (clinicians chose which ESPAC-1 trial patients were randomised to [ESPAC-1 2x2, ESPAC-1+ chemotherapy only trial, ESPAC-1+ chemoradiotherapy only trials]; Kaplan-Meier overall survival curves for separate groups not provided, unclear whether proportional hazards satisfied).

3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

4 Not statistically significant ($p > 0.5$).

5 Crosses 2 default MIDs (0.8 and 1.25).

1
2
3

Table 147: Summary clinical evidence profile for adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant chemoradiotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemoradiotherapy	Chemoradiotherapy->Chemotherapy				
Overall Survival - Chemoradiotherapy->5FU+FA vs Chemoradiotherapy	Study population ¹		HR 0.67 (0.47 to 0.96)	145 (1 study)	⊕⊕⊕ ⊖ low ^{2,3}	
	890 per 1000	773 per 1000 (646 to 880)				
	Moderate ¹					
	500 per 1000	371 per 1000 (278 to 486)				
# patients with any Grade 3 or 4 haematological toxicities - Chemoradiotherapy->5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 11.15 (0.63 to 198.04)	145 (1 study)	⊕⊕⊕ ⊖ very low ^{2,4}	
# patients with any Grade 3 or 4 non-haematological toxicities - Chemoradiotherapy->5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	27 per 1000	153 per 1000 (35 to 665)	RR 5.58 (1.28 to 24.28)	145 (1 study)	⊕⊕⊕ ⊖ very low ^{2,4}	
# patients with Grade 3 or 4 Stomatitis - Chemoradiotherapy->5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 8.76 (0.48 to 159.93)	148 (1 study)	⊕⊕⊕ ⊖ very low ^{2,4}	
# patients with Grade 3 or 4 Diarrhoea - Chemoradiotherapy->5FU+FA vs Chemoradiotherapy UICC Common Toxicity Criteria	0 per 1000	0 per 1000 (0 to 0)	RR 4.61 (0.22 to 94.27)	144 (1 study)	⊕⊕⊕ ⊖ very low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.</p> <p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Fifty percent 2-year overall survival assumed for chemoradiotherapy control group.</p> <p>2 Overall high risk of bias (Neoptolemos et al. 2004). Main reasons include: unclear risk randomisation method; selective reporting (one or more outcomes of interest reported incompletely); other sources of bias (clinicians chose which ESPAC-1 trial patients were randomised to [ESPAC-1 2x2, ESPAC-1+ chemotherapy only trial, ESPAC-1+ chemoradiotherapy only trials]; Kaplan-Meier overall survival curves for separate groups not provided, unclear whether proportional hazards satisfied).</p> <p>3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.</p> <p>4 Crosses 2 default MIDs (0.8 and 1.25).</p>						

1
2
3
4

Table 148: Summary clinical evidence profile for adjuvant chemotherapy-1 (gemcitabine) followed by chemoradiotherapy versus adjuvant chemotherapy-2 (other) followed by chemoradiotherapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy-2 (other)->Chemoradiotherapy	Chemotherapy-1 (gemcitabine)->Chemoradiotherapy				
Overall Survival - Gemcitabine->CRT->Gemcitabine vs 5-FU->CRT->5FU	817 per 1000	794 per 1000 (725 to 859)	HR 0.93 (0.76 to 1.15)	451 (1 study)	⊕⊕⊖ ⊖ low ^{1,2,3}	
Disease-free Survival - Gemcitabine->CRT vs PEFG->CRT	Study population ⁴		HR 1.33 (0.86 to 2.06) ⁶	100 (1 study)	⊕⊖⊖ ⊖ very low ^{2,3,7}	
	See comment ⁵	See comment ⁵				
	Moderate ⁴	400 per 1000 ⁵				
# patients with any Grade 4 toxicity - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data	13 per 1000	145 per 1000 (45 to 466)	RR 11.1 (3.45 to 35.73)	451 (1 study)	⊕⊕⊕ ⊖ moderate ¹	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Monitoring Committee						
# patients with Grade 3 or 4 Diarrhoea - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data Monitoring Committee	191 per 1000	149 per 1000 (99 to 226)	RR 0.78 (0.52 to 1.18)	451 (1 study)	⊕⊕⊕ ⊖ low ^{1,8}	
# patients with Grade 3 or 4 Neutropenia - Gemcitabine->CRT vs PEFG->CRT NCI Common Terminology Criteria for Adverse Events		The mean # patients with grade 3 or 4 neutropenia - gemcitabine->CRT vs PEFG->CRT in the intervention groups was 0.8 standard deviations lower (1.21 to 0.4 lower)		102 (1 study)	⊕⊕⊕ ⊖ very low ^{7,8}	SMD 0.8 (0.4 to 1.21)
# patients with Grade 3 or 4 Stomatitis - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data Monitoring Committee	152 per 1000	99 per 1000 (61 to 164)	RR 0.65 (0.4 to 1.08)	451 (1 study)	⊕⊕⊕ ⊖ low ^{1,8}	
# patients with Grade 3 or 4 Thrombocytopenia - Gemcitabine->CRT vs PEFG->CRT NCI Common Terminology Criteria for Adverse Events		The mean # patients with grade 3 or 4 thrombocytopenia - gemcitabine->CRT vs PEFG->CRT in the intervention groups was 0.8 standard deviations lower (1.21 to 0.4 lower)		102 (1 study)	⊕⊕⊕ ⊖ very low ^{7,8}	SMD 0.8 (0.4 to 1.21)
# patients with Grade 3 or 4 Worst haematological	96 per 1000	583 per 1000 (386 to 882)	RR 6.1 (4.04)	451 (1 study)	⊕⊕⊕ ⊖	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
AEs - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data Monitoring Committee			to 9.22)		moderate ¹	
# patients with Grade 3 or 4 Worst non-haematological AEs - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data Monitoring Committee	596 per 1000	584 per 1000 (500 to 679)	RR 0.98 (0.84 to 1.14)	451 (1 study)	⊕⊕⊕ ⊖ moderate ¹	
# patients with Grade 3 or 4 Worst overall AEs - Gemcitabine->CRT->gemcitabine vs 5FU->CRT->5FU Monitored by RTOG Data Monitoring Committee	622 per 1000	790 per 1000 (703 to 895)	RR 1.27 (1.13 to 1.44)	451 (1 study)	⊕⊕⊖ ⊖ low ^{1,8}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes.

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

- 1 Overall unclear risk of bias (Regine et al. 2008/2011). Main reasons include: unclear risk randomisation method/allocation concealment (insufficient information).
- 2 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.
- 3 Not statistically significant ($p > 0.5$).
- 4 Forty percent 2-year overall survival and disease-free survival assumed for chemotherapy then chemoradiotherapy group.
- 5 Observed disease-free events not provided by authors (Reni et al. 2012).
- 6 Hazard ratio estimated from Kaplan-Meier survival curve using method 11 in Tierney et al. (2007).
- 7 Overall high risk of bias (Reni et al. 2012) due to high risk selective reporting (primary outcomes not fully reported).
- 8 Crosses 1 default MID (dichotomous outcomes: 0.8 or 1.25; continuous outcomes: 0.5 or -0.5).

1
2

Table 149: Summary clinical evidence profile for immunotherapy versus no adjuvant therapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Immunotherapy				
Overall Survival - IgG1 murine Monoclonal Antibody 494/32 vs Observation	Study population ¹		HR 1.12 (0.21 to 6.03) ²	61 (1 study)	⊕⊕⊕⊕ very low ^{3,4,5}	
	531 per 1000	572 per 1000 (147 to 990)				
	Moderate ¹					
	300 per 1000	329 per 1000 (72 to 884)				
# patients with Grade 3 or 4 Abdominal Pain - IgG1 murine Monoclonal Antibody 494/32 vs No adjuvant therapy	0 per 1000	0 per 1000 (0 to 0)	RR 3.3 (0.14 to 77.95)	61 (1 study)	⊕⊕⊕⊕ very low ^{3,6}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Thirty percent 2-year overall survival rate assumed for no adjuvant therapy control group.
 2 Hazard ratio estimated from Kaplan-Meier curve using method 10 in Tierney et al. (2007).
 3 Overall high risk of bias (Buchler et al. 1991). Main reasons include: unclear randomisation method/allocation concealment (insufficient information); selective reporting (primary outcome not fully reported); other sources of bias (Kaplan-Meier curve crosses, proportional hazards not satisfied).
 4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.
 5 Not statistically significant (p>0.5).
 6 Crosses 2 default MIDs (0.8 and 1.25).

3
4

Table 150: Summary clinical evidence profile for chemoimmunotherapy versus no adjuvant therapy in resected pancreatic cancer patients

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No adjuvant therapy	Chemoimmunotherapy				
Overall Survival - Gemcitabine, Carboplatin, Mitomycin C,	Study population ¹		HR 0.45 (0.23)	83 (1 study)	⊕⊕⊕⊖ low ^{3,4}	
	375 per 1000	191 per 1000 (102 to 339)				
	Moderate ¹					

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
5FU+FA+Interleukin-2 vs No adjuvant therapy	300 per 1000	148 per 1000 (79 to 269)	to 0.88) ²			
Disease-free Survival - Gemcitabine, Carboplatin, Mitomycin C, 5FU+FA+Interleukin-2 vs No adjuvant therapy	Study population ¹		HR 0.33 (0.17 to 0.64) ²	83 (1 study)	⊕⊕⊖ ⊖ low ^{3,4}	
	375 per 1000	144 per 1000 (77 to 260)				
	Moderate ¹					
	200 per 1000	71 per 1000 (37 to 133)				
# patients with Grade 3 or 4 Vomiting - Gemcitabine, Carboplatin, mitoxantrone, mitomycin C, 5FU+FA+Interleukin-2 vs No adjuvant therapy Not stated in study	0 per 1000	0 per 1000 (0 to 0)	RR 4.66 (0.23 to 94.18)	83 (1 study)	⊕⊖⊖ ⊖ very low ^{3,5}	

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Thirty percent 2-year overall survival rate and 20% 2-year disease-free survival rate assumed for no adjuvant therapy control group.
2 Hazard ratio estimated from Kaplan-Meier curve and summary statistics using method 7 in Tierney et al. (2007).
3 Overall high risk of bias for Lygidakis et al. 2002. Main reasons include unclear risk randomisation method/allocation method; high risk selective reporting (fails to report survival results in expected manner); other sources of bias (power calculation not reported).
4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MID. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.
5 Crosses 2 default MIDs (0.8 and 1.25).

1 10.3.5 Economic evidence

2 A literature review of published cost effectiveness analyses did not identify any relevant
3 studies for this topic. Although there were potential implications for resource use associated
4 with making recommendations in this area, other topics in the guideline were agreed as a
5 higher economic priority. Consequently, bespoke economic modelling was not done for this
6 topic.

1 10.3.6 Evidence statements

2 10.3.6.1 Adjuvant chemotherapy versus no adjuvant therapy

3 Disease-free survival

4 Very low quality evidence from 5 RCTs (n=803) showed that there is a clinically important
5 difference favouring adjuvant chemotherapy on disease-free survival compared to no
6 adjuvant therapy in adults with resected pancreatic cancer: HR 0.79 (95% CI 0.68-0.92).

- 7 • Low quality evidence from 1 RCT (n=88) showed no clinically important difference
8 between adjuvant cisplatin combined with fluororacil and no adjuvant therapy on disease-
9 free survival in adults with resected pancreatic cancer: HR 1.06 (95% CI 0.66-1.72).
- 10 • Low quality evidence from 1 RCT (n=) showed that there is a clinically important
11 difference favouring adjuvant gemcitabine on overall survival compared to no adjuvant
12 therapy in adults with resected pancreatic cancer: HR 0.72 (95% CI 0.59-0.87).
- 13 • Very low quality evidence from 1 RCT (n=85) showed that there is a clinically important
14 difference favouring adjuvant gemcitabine combined with carboplatin, mitomycin C,
15 fluororacil and folinic acid on disease-free survival compared to no adjuvant therapy in
16 adults with resected pancreatic cancer: HR 0.41 (95% CI 0.21-0.81).
- 17 • Very low quality evidence from 1 RCT (n=158) showed no clinically important difference
18 between adjuvant mitomycin C combined with fluororacil and no adjuvant therapy on
19 disease-free survival in adults with resected pancreatic cancer: HR 0.97 (95% CI 0.7-
20 1.34).

21 Relapse-free survival

22 No evidence was identified to inform this outcome.

23 Overall survival

24 Low quality evidence from 8 RCTs (n=1262) showed that there is a clinically important
25 difference favouring adjuvant chemotherapy on overall survival compared to no adjuvant
26 therapy in adults with resected pancreatic cancer: HR 0.78 (0.69-0.89).

- 27 • Low quality evidence from 3 RCTs (n=458) showed that there is a clinically important
28 difference favouring adjuvant fluororacil and folinic acid on overall survival compared to no
29 adjuvant therapy in adults with resected pancreatic cancer: HR 0.69 (95% CI 0.56-0.85).
- 30 • Low quality evidence from 1 RCT (n=89) showed no clinically important difference
31 between adjuvant cisplatin and fluororacil and no adjuvant therapy on overall survival in
32 adults with resected pancreatic cancer: HR 1.02 (95% CI 0.64-1.62).
- 33 • Low quality evidence from 2 RCTs (n=472) showed that there is a clinically important
34 difference favouring adjuvant gemcitabine on overall survival compared to no adjuvant
35 therapy in adults with resected pancreatic cancer: HR 0.76 (95% CI 0.63-0.93).
- 36 • Very low quality evidence from 1 RCT (n=85) showed that there is a clinically important
37 difference favouring adjuvant gemcitabine, carboplatin, mitomycin C, fluororacil and folinic
38 acid on overall survival compared to no adjuvant therapy in adults with resected
39 pancreatic cancer: HR 0.52 (95% CI 0.27-1.0).
- 40 • Very low quality evidence from 1 RCT (n=158) showed no clinically important difference
41 between adjuvant mitomycin C combined with fluororacil and no adjuvant therapy on
42 overall survival in adults with resected pancreatic cancer: HR 1.15 (95% CI 0.82-1.61).

1 **Adverse events**

2 Very low quality evidence from 1 RCT (n=368) showed that there may be a clinically
3 important difference favouring no adjuvant therapy on the number of people who experience
4 serious adverse events compared to adjuvant gemcitabine in adults with resected pancreatic
5 cancer, although there is some uncertainty: RR 1.7 (95% CI 0.93-3.1).

6 Very low quality evidence from 1 RCT (n=144) showed that there is a clinically important
7 difference favouring no adjuvant therapy in the number of people who experience grade 3 or
8 4 non-haematological toxicities compared to adjuvant chemotherapy (fluororacil and folinic
9 acid) in adults with resected pancreatic cancer: RR 17.5 (95% CI 1.04-295.13).

10 Very low quality evidence from 1 RCT (n=144) showed no clinically important difference
11 between adjuvant chemotherapy (fluororacil and folinic acid) and no adjuvant therapy on the
12 number of people who experience a grade 3 or 4 haematological toxicity (RR 4.61 [95% CI
13 0.22-94.27]), nor on the number of people who experience grade 3 or 4 stomatitis (RR 8.29
14 [95% CI 0.45-151.2]) in adults with resected pancreatic cancer.

15 Very low quality evidence from 1 RCT (n=82) showed no clinically important difference
16 between adjuvant chemotherapy (cisplatin and fluororacil) and no adjuvant therapy on the
17 number of people who experience a grade 3 or 4 granulocytopenic (RR 10.38 [95% CI 0.58-
18 186.87]), hepatic (RR 8.08 [95% CI 0.43 to 151.56]), or mucositis (RR 5.77 [95% CI 0.29 to
19 116.57]) toxicity in adults with resected pancreatic cancer.

20 Low quality evidence from 2 RCTs (n=199) showed that there is a clinically important
21 difference favouring no adjuvant therapy on the number of people who experience grade 3 or
22 4 leukopenic toxicities compared to adjuvant chemotherapy (cisplatin and fluororacil;
23 gemcitabine) in adults with resected pancreatic cancer: RR 18.43 (95% CI 2.45-138.47).

24 Very low quality evidence from 3 studies (n=284) showed that there is a clinically important
25 difference favouring no adjuvant therapy on the number of people who experience grade 3 or
26 4 nausea/vomiting compared to adjuvant chemotherapy (cisplatin and fluororacil;
27 gemcitabine, carboplatin, mitoxantrone, mitomycin C, fluorouracil, and folinic acid;
28 gemcitabine) in adults with resected pancreatic cancer: RR 5.97 (95% CI 1.1-32.48).

29 Very low quality evidence from 2 RCTs (n=261) showed no clinically important difference
30 between adjuvant chemotherapy (fluorouracil and folinic acid; gemcitabine) and no adjuvant
31 therapy on the number of people who experience grade 3 or 4 diarrhoea in adults with
32 resected pancreatic cancer: RR 3.9 (95% CI 0.44-34.75).

33 Moderate quality evidence from 1 RCT (n=117) that there is a clinically important difference
34 favouring no adjuvant therapy on the number of people who experience grade 3 or 4
35 neutropenic toxicities compared to adjuvant gemcitabine in adults with resected pancreatic
36 cancer: RR 85.19 (95% CI 5.36-1353.55).

37 Low quality evidence from 1 RCT (n=117) showed no clinically important difference between
38 adjuvant chemotherapy (gemcitabine) and no adjuvant therapy on the number of people who
39 experience grade 3 or 4 abscess (RR 3.16 [95% CI 0.13-75.9]), alanine aminotransferase
40 (RR 9.47 [95% CI 0.52-171.95]), anaemia (RR 5.26 [95% CI 0.26-107.22]), anorexia (RR
41 5.26 [95% CI 0.26-107.22]), aspartate aminotransferase (RR 7.36 [95% CI 0.39-139.44]),
42 fatigue (RR 3.16 [95% CI 0.13-75.9]), fever (RR 3.16 [95% CI 0.13-75.9]), and
43 thrombocytopenia (RR 3.16 [95% CI 0.13-75.9]) in adults with resected pancreatic cancer.

44 Very low quality evidence from 3 RCTs (n=284) showed that there is a clinically important
45 difference favouring no adjuvant therapy on the number of people who have grade 3 or 4
46 nausea/vomiting compared to adjuvant chemotherapy in adults with resected pancreatic
47 cancer: RR 5.97 (95% CI 1.1-32.48).

- 48 • Very low quality evidence from 1 RCT (n=82) showed no clinically important difference
49 between adjuvant cisplatin combined with fluororacil and no adjuvant therapy on the

- 1 number of people who experience grade 3 or 4 nausea/vomiting in adults with resected
2 pancreatic cancer: RR 12.69 (95% CI 0.72-222.32).
- 3 • Very low quality evidence from 1 RCT (n=85) showed no clinically important difference
4 between adjuvant gemcitabine combined with adjuvant chemotherapy (carboplatin,
5 mitoxantrone, mitomycin C, fluororacil and folinic acid) and no adjuvant therapy on the
6 number of people who experience grade 3 or 4 nausea/vomiting in adults with resected
7 pancreatic cancer: RR 2.67 (95% CI 0.11-63.84).
- 8 • Very low quality evidence from 1 RCT (n=117) showed no clinically important difference
9 between adjuvant gemcitabine and no adjuvant therapy on the number of people who
10 experience grade 3 or 4 nausea/vomiting in adults with resected pancreatic cancer: RR
11 3.16 (95% CI 0.13-75.9).

12 **Health-related quality of life**

13 Very low quality evidence from 1 RCT (n=473) showed no clinically important difference
14 between adjuvant chemotherapy (fluororacil and folinic acid) and no adjuvant therapy on
15 quality of life (ESPAC-1 QoL) change scores in adults with resected pancreatic cancer: SMD
16 0 (95% CI -0.18 to 0.18).

17 Very low quality evidence from 1 RCT (n=473) showed that no clinically important difference
18 between adjuvant fluororacil combined with folinic acid and no adjuvant therapy on quality of
19 life-role functioning score in adults with resected pancreatic cancer: SMD 0.27 (95% CI -
20 0.46- -0.09).

21 Very low quality evidence from 1 CT (n=113) showed no clinically important difference
22 between adjuvant chemotherapy (mitomycin C and fluororacil) and no adjuvant therapy on
23 the number of people whose ECOG performance status score improved by one or more
24 grade in adults with resected pancreatic cancer: RR 1 (95% CI 0.79-1.26).

25 **Patient experience**

26 No evidence was identified to inform this outcome.

27 **PROMS**

28 No evidence was identified to inform this outcome.

29 **10.3.6.2 Adjuvant chemotherapy-1 (gemcitabine) versus adjuvant chemotherapy-2 (other)**

30 **Disease-free survival**

31 Very low quality evidence from 3 RCTs (n=1461) showed no clinically important difference
32 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on disease-free
33 survival in adults with resected pancreatic cancer: HR 1.11 (95% CI 0.99-1.25).

- 34 • Moderate quality evidence from 1 RCT (n=985) showed no clinically important difference
35 between adjuvant gemcitabine and adjuvant fluororacil and folinic acid on disease-free
36 survival in adults with resected pancreatic cancer: HR 0.99 (95% CI 0.87-1.14).
- 37 • High quality evidence from 1 RCT (n=377) showed that there is a clinically important
38 difference favouring adjuvant S-1 on disease-free survival compared to adjuvant
39 gemcitabine in adults with resected pancreatic cancer: HR 1.67 (95% CI 1.31-2.12).
- 40 • Very low quality evidence from 1 RCT (n=99) showed no clinically important difference
41 between adjuvant gemcitabine only and adjuvant gemcitabine combined with UFT on
42 disease-free survival in adults with resected pancreatic cancer: HR 0.91 (95% CI 0.58-
43 1.43).

1 **Relapse-free survival**

2 Low quality evidence from 1 RCT (n=730) showed no clinically important difference between
3 adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine on relapse-
4 free survival in adults with resected pancreatic cancer: HR 1.16 (95% CI 0.98-1.37).

5 **Overall survival**

6 Very low quality evidence from 4 RCTs (n=2301) showed no clinically important difference
7 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on overall
8 survival compared in adults with resected pancreatic cancer: HR 1.15 (95% CI 0.85-1.55)
9 [random effects analysis].

- 10 • Moderate quality evidence from 1 RCT (n=1088) showed no clinically important difference
11 between adjuvant gemcitabine and adjuvant fluororacil and folinic acid on overall survival
12 in adults with resected pancreatic cancer: HR 0.94 (95% CI 0.81-1.09) [fixed effects
13 analysis].
- 14 • High quality evidence from 1 RCT (n=385) showed that there is clinically important
15 difference favouring adjuvant S-1 on overall survival compared to adjuvant gemcitabine in
16 adults with resected pancreatic cancer: HR 1.75 (95% CI 1.37-2.24) [fixed effects
17 analysis].
- 18 • Very low quality evidence from 1 RCT (n=99) showed no clinically important difference
19 between adjuvant gemcitabine only and adjuvant gemcitabine combined with UFT on
20 overall survival in adults with resected pancreatic cancer: HR 0.75 (95% CI 0.45-1.26)
21 [fixed effects analysis].
- 22 • Moderate quality evidence from 1 RCT (n=730) showed that there is clinically important
23 difference favouring adjuvant gemcitabine combined with capecitabine on overall survival
24 compared to adjuvant gemcitabine only in adults with resected pancreatic cancer: HR
25 1.22 (95% CI 1.02-1.46) [fixed effects analysis].

26 **Adverse events**

27 Very low quality evidence from 2 RCTs (n=1813) showed no clinically important difference
28 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number
29 of people who experience serious treatment-related adverse events in adults with resected
30 pancreatic cancer: RR 0.77 (95% CI 0.38-1.52).

- 31 • High quality evidence from 1 RCT (n=1088) showed that there is a clinically important
32 difference favouring adjuvant gemcitabine on the number of people who experience
33 serious treatment-related adverse events compared to adjuvant fluororacil and folinic acid
34 in adults with resected pancreatic cancer: RR 0.53 (95% CI 0.37-0.77) [fixed effects
35 analysis].
- 36 • Low quality evidence from 1 RCT (n=725) showed no clinically important difference
37 between adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine
38 on the number of people who experience serious treatment-related adverse events in
39 adults with resected pancreatic cancer: RR 1.07 (0.83-1.38) [fixed effects analysis].

40 Very low quality evidence from 3 RCTs (n=1564) showed no clinically important difference
41 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number
42 of people who experience grade 3 or 4 alanine and aspartate aminotransferase toxicities in
43 adults with resected pancreatic cancer: RR 1.94 (95% CI 0.26-14.2) [random effects].

- 44 • High quality evidence from 1 RCT (n=377) showed there is a clinically important difference
45 favouring adjuvant S-1 on the number of people who experience grade 3 or 4 alanine and
46 aspartate aminotransferase toxicities compared to adjuvant gemcitabine in adults with
47 resected pancreatic cancer: RR 9.05 (95% CI 5.53-14.83) [fixed effects].

- 1 • Moderate quality evidence from 1 RCT (n=1088) showed no clinically important difference
2 between adjuvant gemcitabine only and adjuvant fluororacil combined with folinic acid on
3 the number of people who experience grade 3 or 4 alanine and aspartate
4 aminotransferase toxicities in adults with resected pancreatic cancer: RR 1.01 (95% CI
5 0.81-1.26) [fixed effects].
- 6 • Very low quality evidence from 1 RCT (n=99) showed no clinically important difference
7 between adjuvant gemcitabine only and adjuvant gemcitabine combined with UFT on the
8 number of people who experience grade 3 or 4 alanine and aspartate aminotransferase
9 toxicities in adults with resected pancreatic cancer: RR 0.34 (95% CI 0.01-8.15) [fixed
10 effects].
- 11 Low quality evidence from 2 RCTs (n=476) showed no clinically important difference
12 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number
13 of people who experience grade 3 or 4 anorexia in adults with resected pancreatic cancer:
14 RR 0.74 (95% CI 0.36-1.53).
- 15 • Low quality evidence from 1 RCT (n=99) showed no clinically important difference
16 between adjuvant gemcitabine only and adjuvant gemcitabine combined with UFT on the
17 number of people who experience grade 3 or 4 anorexia in adults with resected pancreatic
18 cancer: RR 1.02 (95% CI 0.07-15.86).
- 19 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
20 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
21 grade 3 or 4 anorexia in adults with resected pancreatic cancer: RR 0.72 (95% CI 0.34-
22 1.53).
- 23 Low quality evidence from 1 study (n=377) showed no clinically important difference between
24 adjuvant gemcitabine and adjuvant S-1 on the number of people who experience grade 3 or
25 4 bilirubin (RR 0.49 [95% CI 0.05 to 5.38]), creatinine (RR 0.98 [95% CI 0.06 to 15.62]) and
26 febrile neutropenia (RR 2.95 [95% CI 0.31-28.13]) in adults with resected pancreatic cancer.
- 27 High quality evidence from 3 RCTs (n=2190) showed there is a clinically important difference
28 favouring adjuvant gemcitabine on the number of people who experience grade 3 or 4
29 diarrhoea compared to any other type of adjuvant chemotherapy in adults with resected
30 pancreatic cancer: RR 0.19 (95% CI 0.11-0.3).
- 31 • Moderate quality evidence from 1 RCT (n=377) showed there is a clinically important
32 difference favouring adjuvant gemcitabine on the number of people who experience grade
33 3 or 4 diarrhoea compared to adjuvant S-1 in adults with resected pancreatic cancer: RR
34 0.05 (95% CI 0-0.88).
- 35 • High quality evidence from 1 RCT (n=1088) showed there is a clinically important
36 difference favouring adjuvant gemcitabine on the number of people who experience grade
37 3 or 4 diarrhoea compared to adjuvant fluororacil and folinic acid in adults with resected
38 pancreatic cancer: RR 0.17 (95% CI 0.09-0.31).
- 39 • Moderate quality evidence from 1 RCT (n=725) showed there is a clinically important
40 difference favouring adjuvant gemcitabine only on the number of people who experience
41 grade 3 or 4 diarrhoea compared to adjuvant gemcitabine and capecitabine in adults with
42 resected pancreatic cancer: RR 0.31 (95% CI 0.13-0.77).
- 43 Low quality evidence from 3 RCTs (n=2190) showed no clinically important difference
44 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number
45 of people who experience grade 3 or 4 fatigue/tiredness in adults with resected pancreatic
46 cancer: RR 0.81 (95% CI 0.58-1.12).
- 47 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
48 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
49 grade 3 or 4 fatigue/tiredness in adults with resected pancreatic cancer: RR 0.89 (95% CI
50 0.37-2.13).

- 1 • Moderate quality evidence from 1 RCT (n=1088) showed no clinically important difference
2 between adjuvant gemcitabine and adjuvant fluororacil and folinic acid on the number of
3 people who experience grade 3 or 4 fatigue/tiredness in adults with resected pancreatic
4 cancer: RR 0.73 (95% CI 0.47-1.13).
- 5 • Very low quality evidence from 1 RCT (n=725) showed no clinically important difference
6 between adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine
7 on the number of people who experience grade 3 or 4 fatigue/tiredness in adults with
8 resected pancreatic cancer: RR 0.93 (95% CI 0.51-1.72).
- 9 Very low quality evidence from 2 RCTs (n=1102) showed no clinically important difference
10 between adjuvant gemcitabine and any other adjuvant chemotherapy on the number of
11 people who experience grade 3 or 4 fever in adults with resected pancreatic cancer: RR 0.62
12 (95% CI 0.24-1.6).
- 13 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
14 between adjuvant gemcitabine and adjuvant S-1 on the number of people experience
15 grade 3 or 4 fever in adults with resected pancreatic cancer: RR 0.2 (95% CI 0.02-1.67).
- 16 • Very low quality evidence from 1 RCT (n=725) showed no clinically important difference
17 between adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine
18 on the number of people who experience grade 3 or 4 fever in adults with resected
19 pancreatic cancer: RR 0.98 (95% CI 0.32-3.01).
- 20 Moderate quality evidence from 1 RCT (n=725) showed there is a clinically important
21 difference favouring adjuvant gemcitabine on the number of people who experience grade 3
22 or 4 hand foot syndrome compared to adjuvant gemcitabine and capecitabine in adults with
23 resected pancreatic cancer: RR 0.02 (95% CI 0.0-0.3).
- 24 Moderate quality evidence from 2 RCTs (n=1102) showed there is a clinically important
25 difference favouring any other adjuvant chemotherapy on the number of people who
26 experience grade 3 or 4 infections compared to adjuvant gemcitabine in adults with resected
27 pancreatic cancer: RR 2.86 (95% CI 1.46-5.6).
- 28 • Moderate quality evidence from 1 RCT (n=377) showed that there may be a clinically
29 important difference favouring adjuvant S-1 on the number of people who experience
30 grade 3 or 4 infections compared to adjuvant gemcitabine in adults with resected
31 pancreatic cancer, although there is some uncertainty: RR 3.94 (95% CI 0.85-18.3).
- 32 • Low quality evidence from 1 RCT (n=725) showed that there may be a clinically important
33 difference favouring adjuvant gemcitabine and capecitabine on the number of people who
34 experience grade 3 or 4 infections compared to adjuvant gemcitabine only in adults with
35 resected pancreatic cancer: RR 2.62 (95% CI 1.23-5.55).
- 36 Low quality evidence from 2 RCTs (n=1465) showed no clinically important difference
37 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number
38 of people who experience grade 3 or 4 nausea (RR 0.7 [95% CI 0.39-1.27]) and vomiting
39 (RR 0.66 [95% CI 0.33-1.32]) in adults with resected pancreatic cancer.
- 40 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
41 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
42 grade 3 or 4 nausea in adults with resected pancreatic cancer: RR 0.7 (95% CI 0.23-
43 2.18).
- 44 • Low quality evidence from 1 RCT (n=1088) showed no clinically important difference
45 between adjuvant gemcitabine and adjuvant fluororacil combined with folinic acid on the
46 number of people who experience grade 3 or 4 nausea in adults with resected pancreatic
47 cancer: RR 0.7 (95% CI 0.35-1.41).
- 48 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
49 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
50 grade 3 or 4 vomiting in adults with resected pancreatic cancer: RR 0.66 (95% CI 0.11-
51 3.88).

- 1 • Low quality evidence from 1 RCT (n=1088) showed no clinically important difference
2 between adjuvant gemcitabine and adjuvant fluororacil and folinic acid on the number of
3 people who experience grade 3 or 4 vomiting in adults with resected pancreatic cancer:
4 RR 0.66 (95% CI 0.31-1.4).
- 5 Low quality evidence from 2 RCTs (n=1465) showed that there is a clinically important
6 difference favouring any other type of adjuvant chemotherapy on the number of people who
7 experience grade 3 or 4 neutrophils toxicities compared to adjuvant gemcitabine in adults
8 with resected pancreatic cancer: RR 1.91 (95% CI 1.59-2.31).
- 9 • High quality evidence from 1 RCT (n=377) showed there is a clinically important difference
10 favouring adjuvant S-1 on the number of people who experience grade 3 or 4 neutrophils
11 toxicities compared to adjuvant gemcitabine in adults with resected pancreatic cancer: RR
12 9.05 (95% CI 5.53-14.83).
- 13 • Moderate quality evidence from 1 RCT (n=1088) showed no clinically important difference
14 between adjuvant gemcitabine and adjuvant fluororacil and folinic acid on the number of
15 people who experience grade 3 or 4 neutrophils toxicities in adults with resected
16 pancreatic cancer: RR 1.01 (95% CI 0.81-1.26).
- 17 Moderate quality evidence from 4 RCTs (n=2289) showed there is a clinically important
18 difference favouring any other type of adjuvant chemotherapy on the number of people who
19 experience a grade 3 or 4 platelet toxicity compared to adjuvant gemcitabine in adults with
20 resected pancreatic cancer: RR 2.04 (95% CI 1.17-3.53).
- 21 • Moderate quality evidence from 1 RCT (n=377) showed no clinically important difference
22 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
23 grade 3 or 4 platelet toxicity in adults with resected pancreatic cancer: RR 1.97 (95% CI
24 0.91-4.27).
- 25 • Moderate quality evidence from 1 RCT (n=377) showed there is a clinically important
26 difference favouring adjuvant fluororacil combined with folinic acid on the number of
27 people who experience a grade 3 or 4 platelet toxicity compared to adjuvant gemcitabine
28 in adults with resected pancreatic cancer: RR 17.44 (95% CI 1.01-301.45).
- 29 • Low quality evidence from 1 RCT (n=99) showed no clinically important difference
30 between adjuvant gemcitabine only and adjuvant gemcitabine and UFT on the number of
31 people who experience grade 3 or 4 platelet toxicity in adults with resected pancreatic
32 cancer: RR 7.14 (95% CI 0.38-134.71).
- 33 • Very low quality evidence from 1 RCT (n=725) showed no clinically important difference
34 between adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine
35 on the number of people who experience a grade 3 or 4 platelet toxicity in adults with
36 resected pancreatic cancer: RR 0.86 (95% CI 0.31-2.34).
- 37 High quality evidence from 2 RCTs (n=1465) showed there is a clinically important difference
38 favouring adjuvant gemcitabine leads to a clinically significant decrease in the number of
39 people who experience grade 3 or 4 stomatitis compared to any other type of adjuvant
40 chemotherapy in adults with resected pancreatic cancer: RR 0.03 (95% CI 0.01-0.13).
- 41 • Low quality evidence from 1 RCT (n=377) showed no clinically important difference
42 between adjuvant gemcitabine and adjuvant S-1 on the number of people who experience
43 grade 3 or 4 stomatitis in adults with resected pancreatic cancer: RR 0.09 (95% CI 0-
44 1.61).
- 45 • High quality evidence from 1 RCT (n=1088) showed there is a clinically important
46 difference favouring adjuvant gemcitabine on the number of people who experience grade
47 3 or 4 stomatitis compared to adjuvant fluororacil and folinic acid in adults with resected
48 pancreatic cancer: RR 0.02 (95% CI 0-0.14).
- 49 Very low quality evidence from 4 RCTs (n=2289) showed no clinically important difference
50 between adjuvant gemcitabine and any other type of adjuvant chemotherapy on the number

1 of people who experience a grade 3 or 4 white blood cell count toxicity in adults with
2 resected pancreatic cancer: RR 1.65 (95% CI 0.75-3.63) [random effects analysis].

- 3 • High quality evidence from 1 RCT (n=377) showed there is a clinically important difference
4 favouring adjuvant S-1 leads to a clinically significant increase in the number of people
5 who experience a grade 3 or 4 white blood cell count toxicity compared to adjuvant
6 gemcitabine in adults with resected pancreatic cancer: RR 4.55 (95% CI 2.76-7.51) [fixed
7 effects analysis].
- 8 • Moderate quality evidence from 1 RCT (n=377) showed there is a clinically important
9 difference favouring adjuvant fluororacil and folinic acid on the number of people who
10 experience a grade 3 or 4 white blood cell count toxicity compared to adjuvant
11 gemcitabine in adults with resected pancreatic cancer: RR 1.7 (95% CI 1.11-2.59) [fixed
12 effects analysis].
- 13 • Low quality evidence from 1 RCT (n=99) showed no clinically important difference
14 between adjuvant gemcitabine only and adjuvant gemcitabine combined with UFT on the
15 number of people who experience grade 3 or 4 white blood cell toxicity in adults with
16 resected pancreatic cancer: RR 1.25 (95% CI 0.57-2.74) [fixed effects analysis].
- 17 • Low quality evidence from 1 RCT (n=725) showed no clinically important difference
18 between adjuvant gemcitabine only and adjuvant gemcitabine combined with capecitabine
19 on the number of people who experience grade 3 or 4 white blood cell toxicity in adults
20 with resected pancreatic cancer: RR 0.74 (95% CI 0.46-1.19) [fixed effects analysis].

21 Low quality of evidence from 1 RCT (n=99) showed no clinically important difference
22 between adjuvant gemcitabine and adjuvant gemcitabine combined with UFT on the number
23 of people who experience grade 3 or 4 glucose intolerance (RR 0.34 [95% CI 0.01 to 8.15]),
24 haemoglobin toxicity (RR 2.04 [95% CI 0.39 to 10.64]), leukocytes (RR 1.25 [95% CI 0.57 to
25 2.74]) in adults with resected pancreatic cancer.

26 **Health-related quality of life**

27 Very low quality evidence from 1 RCT (n=311) showed no clinically important difference
28 between adjuvant gemcitabine and adjuvant S-1 on EQ-5D quality of life scores 3 months
29 (n=311; SMD 0.15 [95% CI -0.08 to 0.37] and 6 months (n=291; SMD 0.14 [95% CI -0.09 to
30 0.37]) after randomisation in adults with resected pancreatic cancer.

31 Very low quality evidence from 1 RCT showed no clinically important differences between
32 adjuvant gemcitabine and adjuvant S-1 on EQ-5D quality of life scores at 12 months (n=255;
33 SMD 0.4 [95% CI 0.15-0.65]) and 24 months (n=171; SMD 0.42 [95% CI 0.11-0.72]) after
34 randomisation in adults with resected pancreatic cancer.

35 Low quality evidence from 1 RCT (n=565) showed no clinically important difference between
36 adjuvant gemcitabine and adjuvant fluororacil combined with folinic acid on global quality of
37 life in adults with resected pancreatic cancer: SMD 0.15 (95% CI -0.01 to 0.32).

38 **Patient experience**

39 No evidence was identified to inform this outcome.

40 **PROMS**

41 No evidence was identified to inform this outcome.

1 10.3.6.3 Adjuvant chemotherapy versus adjuvant chemoradiotherapy

2 Disease-free survival

3 Very low quality evidence from 1 RCT (n=90) showed no clinically important difference
4 between adjuvant chemotherapy (gemcitabine) and adjuvant chemoradiotherapy on disease-
5 free survival in adults with resected pancreatic cancer: HR 0.97 (95% CI 0.62-1.52).

6 Relapse-free survival

7 No evidence was identified to inform this outcome.

8 Overall survival

9 Very low quality evidence from 2 RCTs (n=238) showed no clinically important difference
10 between adjuvant chemotherapy (fluororacil and folinic acid; gemcitabine) and adjuvant
11 chemoradiotherapy on overall survival in adults with resected pancreatic cancer: HR 0.79
12 (95% CI 0.59-1.07).

- 13 • Very low quality evidence from 1 RCT (n=148) showed no clinically important difference
14 between adjuvant fluororacil combined with folinic acid and adjuvant chemoradiotherapy
15 on overall survival in adults with resected pancreatic cancer: HR 0.7 (95% CI 0.49-1.01).
- 16 • Very low quality evidence from 1 RCT (n=90) showed no clinically important difference
17 between adjuvant gemcitabine and adjuvant chemoradiotherapy on overall survival in
18 adults with resected pancreatic cancer: HR 1.02 (95% CI 0.61-1.72).

19 Adverse events

20 Very low quality evidence from 1 RCT (n=148) showed no clinically important difference
21 between adjuvant fluororacil combined with folinic acid and adjuvant chemoradiotherapy on
22 the number of people who experience any grade 3 or 4 haematological (RR 4.87 [95% CI
23 0.24-99.7]) or non-haematological (RR 4.38 [95% CI 0.98-19.59]) toxicity in adults with
24 resected pancreatic cancer.

25 Very low quality evidence from 1 RCT (n=85) showed no clinically important difference
26 between adjuvant gemcitabine and adjuvant chemoradiotherapy on the number of people
27 who experience grade 3 or 4 anorexia (RR 0.2 [95% CI 0.01-4.14]), fatigue (RR 0.68 [95% CI
28 0.12-3.88]), fever (RR 0.15 [95% CI 0.01-2.75]), gastritis (RR 0.2 [95% CI 0.01 to 4.14]),
29 haemoglobin (RR 0.15 [95% CI 0.01-2.75]), haemorrhage (RR 1.02 [95% CI 0.07- 15.84]),
30 nausea (RR 0.34 [95% CI 0.01- 8.14]), neutrophils (RR 1.32 [95% CI 0.76- 2.29]), other
31 gastrointestinal toxicities (RR 0.34 [95% CI 0.01- 8.14]), platelets (RR 0.34 [95% CI 0.01-
32 8.14]), serum glutamicpyruvic transaminase (RR 1.02 [95% CI 0.32-3.28]), stomatitis (RR
33 8.76 [95% CI 0.48-159.93]), vomiting (RR 0.34 [95% CI 0.01- 8.14]), weight loss (RR 0.34
34 [95% CI 0.01- 8.14]), white blood cell count (RR 0.88 [95% CI 0.32-2.4]) in adults with
35 resected pancreatic cancer.

36 Very low quality evidence from 2 RCTs (n=233) showed no clinically important difference
37 between adjuvant chemotherapy and adjuvant chemoradiotherapy on the number of people
38 who experience grade 3 or 4 diarrhoea in adults with resected pancreatic cancer: RR 1.49
39 (95% CI 0.25-8.95).

40 Very low quality evidence from 1 RCT (n=85) showed no clinically important difference
41 between adjuvant gemcitabine and adjuvant chemoradiotherapy on the number of people
42 who experience grade 3 or 4 diarrhoea in adults with resected pancreatic cancer: RR 0.31
43 (95% CI 0.01-8.14).

44 Very low quality evidence from 1 RCT (n=148) showed no clinically important difference
45 between adjuvant fluororacil combined with folinic acid and adjuvant chemoradiotherapy on

1 the number of people who experience grade 3 or 4 diarrhoea in adults with resected
2 pancreatic cancer: RR 4.87 (95% CI 0.24-99.7).

3 **Health-related quality of life**

4 No evidence was identified to inform this outcome.

5 **Patient experience**

6 No evidence was identified to inform this outcome.

7 **PROMS**

8 No evidence was identified to inform this outcome.

9 **10.3.6.4 Adjuvant chemotherapy versus adjuvant chemoimmunotherapy**

10 **Disease-free survival**

11 Very low quality evidence from 1 RCT (n=88) showed there is a clinically important difference
12 favouring adjuvant chemoimmunotherapy (interleukin-2) on disease-free survival compared
13 to combined adjuvant chemotherapy (gemcitabine, carboplatin, mitomycin C, fluororacil, and
14 folinic acid) in adults with resected pancreatic cancer: HR 1.99 (95% CI 1.07-3.7).

15 **Relapse-free survival**

16 No evidence was identified to inform this outcome.

17 **Overall survival**

18 Very low quality evidence from 1 RCT (n=88) showed there is a clinically important difference
19 favouring adjuvant chemoimmunotherapy (interleukin-2) on overall survival compared to
20 combined adjuvant chemotherapy (gemcitabine, carboplatin, mitomycin C, fluororacil, and
21 folinic acid) in adults with resected pancreatic cancer: HR 2.05 (95% CI 1.12-3.76).

22 **Adverse events**

23 Very low quality evidence from 1 RCT (n=88) showed no clinically important difference
24 between combined adjuvant chemotherapy (gemcitabine, carboplatin, mitomycin C,
25 fluororacil, and folinic acid) and adjuvant chemoimmunotherapy on the number of people
26 who experience grade 3 or 4 nausea (RR 2.87 [95% CI 0.12-68.58]) or vomiting (RR 0.19
27 [95% CI 0.01-3.87]) in adults with resected pancreatic cancer.

28 **Health-related quality of life**

29 No evidence was identified to inform this outcome.

30 **Patient experience**

31 No evidence was identified to inform this outcome.

32 **PROMS**

33 No evidence was identified to inform this outcome.

1 10.3.6.5 Adjuvant chemotherapy versus adjuvant chemoradioimmunotherapy

2 Disease-free survival

3 Very low quality evidence from 1 RCT (n=132) showed no clinically important difference
4 between adjuvant fluororacil and adjuvant chemoradioimmunotherapy (fluororacil, cisplatin
5 and interferon α -2b) on disease-free survival in adults with resected pancreatic cancer: HR
6 1.02 (95% CI 0.64-1.65).

7 Relapse-free survival

8 No evidence was identified to inform this outcome.

9 Overall survival

10 Very low quality evidence from 1 RCT (n=132) showed no clinically important difference
11 between adjuvant fluororacil and adjuvant chemoradioimmunotherapy (fluororacil, cisplatin
12 and interferon α -2b) on overall survival in adults with resected pancreatic cancer: HR 0.96
13 (95% CI 0.63-1.48).

14 Adverse events

15 Very low quality evidence from 1 RCT (n=110) showed that there is a clinically important
16 difference favouring adjuvant fluororacil on the number of people who experience any grade
17 3 or 4 toxicity compared to adjuvant chemoradioimmunotherapy (fluororacil, cisplatin and
18 interferon α -2b) in adults with resected pancreatic cancer: RR 0.22 (95% CI 0.12-0.4).

19 Health-related quality of life

20 Very low quality evidence from 1 RCT (n=85/86) showed that there is a clinically important
21 difference favouring adjuvant fluororacil on EORTC QLQ-C30 global health status (MD 7.3
22 [95% CI 0.41-13.59]), and the nausea/vomiting (MD 7.7 [95% CI 1.67-13.73]), role
23 functioning (MD 13.9 [95% CI -4.16 to 23.64]) and social functioning subscales (MD 10 [95%
24 CI 0.75-19.25]) compared to adjuvant chemoradioimmunotherapy (fluororacil, cisplatin and
25 interferon α -2b) in adults with resected pancreatic cancer.

26 Patient experience

27 No evidence was identified to inform this outcome.

28 PROMS

29 No evidence was identified to inform this outcome.

30 10.3.6.6 Adjuvant chemoradiotherapy followed by chemotherapy versus no adjuvant therapy

31 10.3.6.7 Disease-free survival

32 No evidence was identified to inform this outcome.

33 Relapse-free survival

34 No evidence was identified to inform this outcome.

35 Overall survival

36 No evidence was identified to inform this outcome.

1 **Adverse events**

2 Very low quality evidence from 1 RCT (n=141) showed no clinically important difference
3 between adjuvant chemoradiotherapy followed by chemotherapy (fluororacil and folinic acid)
4 and no adjuvant therapy on the number of people who experience any grade 3 or 4
5 haematological toxicity (RR 10.55 [95% CI 0.59-187.23]), stomatitis (RR 8.29 [95% CI 0.45-
6 151.2]) and diarrhoea (RR 4.61 [95% CI 0.22-94.27]) in adults with resected pancreatic
7 cancer.

8 Very low quality evidence from 1 RCT (n=144) showed that there is a clinically important
9 difference favouring no adjuvant therapy on the number of people who experience a grade 3
10 or 4 non-haematological toxicity compared to adjuvant chemoradiotherapy followed by
11 chemotherapy (fluororacil and folinic acid) in adults with resected pancreatic cancer: RR
12 22.05 (95% CI 1.32-367.2).

13 **Health-related quality of life**

14 No evidence was identified to inform this outcome.

15 **Patient experience**

16 No evidence was identified to inform this outcome.

17 **PROMS**

18 No evidence was identified to inform this outcome.

19 **10.3.6.8 Adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant**
20 **chemotherapy**

21 **Disease-free survival**

22 No evidence was identified to inform this outcome.

23 **Relapse-free survival**

24 No evidence was identified to inform this outcome.

25 **Overall survival**

26 Very low quality evidence from 1 RCT (n=147) showed no clinically important difference
27 between adjuvant chemoradiotherapy followed by chemotherapy (fluororacil and folinic acid)
28 and adjuvant chemotherapy (fluororacil and folinic acid) on overall survival in adults with
29 resected pancreatic cancer: HR 1.32 (95% CI 0.9-1.92).

30 **Adverse events**

31 Very low quality evidence from 1 RCT showed no clinically important difference between
32 adjuvant chemoradiotherapy followed by chemotherapy (fluororacil and folinic acid) and
33 adjuvant chemotherapy (fluororacil and folinic acid) on the number of people who experience
34 any grade 3 or 4 haematological toxicity (n=147; RR 2.6 [95% CI 0.52 to 13]), non-
35 haematological toxicity (n=147; RR 1.27 [95% CI 0.56-2.89]), stomatitis (n=144; RR 8.29
36 [95% CI 0.45-151.2]), and diarrhoea (n=150; RR 5 [95% CI 0.24-102.42]) in adults with
37 resected pancreatic cancer.

38 **Health-related quality of life**

39 No evidence was identified to inform this outcome.

1 **Patient experience**

2 No evidence was identified to inform this outcome.

3 **PROMS**

4 No evidence was identified to inform this outcome.

5 **10.3.6.9 Adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant**
6 **chemoradiotherapy**

7 **Disease-free survival**

8 No evidence was identified to inform this outcome.

9 **Relapse-free survival**

10 No evidence was identified to inform this outcome.

11 **Overall survival**

12 Low quality evidence from 1 RCT (n=145) showed a clinically important difference favouring
13 adjuvant chemoradiotherapy followed by chemotherapy (fluororacil and folinic acid) on
14 overall survival compared to adjuvant chemoradiotherapy only in adults with resected
15 pancreatic cancer: HR 0.67 (95% CI 0.47-0.96).

16 **Adverse events**

17 Very low quality evidence from 1 RCT (n=147) showed no clinically important difference
18 between adjuvant chemoradiotherapy followed by chemotherapy (fluororacil and folinic acid)
19 and adjuvant chemoradiotherapy only on the number of people who experience any grade 3
20 or 4 haematological toxicity (n=145; RR 11.15 [95% CI 0.63-198.04]), stomatitis (n=148; RR
21 8.76 [95% CI 0.48-159.93]) and diarrhoea (n=144; RR 4.61 [95% CI 0.22-94.27]) in adults
22 with resected pancreatic cancer.

23 Very low quality evidence from 1 RCT (n=145) showed that there is a clinically important
24 difference favouring adjuvant chemoradiotherapy only on the number of people who
25 experience any grade 3 or 4 non-haematological toxicities compared to chemoradiotherapy
26 followed by chemotherapy (fluororacil and folinic acid) in adults with resected pancreatic
27 cancer: RR 5.58 (95% CI 1.28-24.28).

28 **Health-related quality of life**

29 No evidence was identified to inform this outcome.

30 **Patient experience**

31 No evidence was identified to inform this outcome.

32 **PROMS**

33 No evidence was identified to inform this outcome.

10.3.6.10 Adjuvant chemotherapy-1 (gemcitabine) followed by chemoradiotherapy versus adjuvant chemotherapy-2 (other) followed by chemoradiotherapy

3 Disease-free survival

4 Very low quality evidence from 1 RCT (n=100) showed no clinically important difference
5 between adjuvant gemcitabine followed by chemoradiotherapy and adjuvant chemotherapy
6 (PEFG) followed by chemoradiotherapy on prolonging disease-free survival in adults with
7 resected pancreatic cancer: HR 1.33 (95% CI 0.86-2.06).

8 Relapse-free survival

9 No evidence was identified to inform this outcome.

10 Overall survival

11 Low quality evidence from 1 RCT (n=451) showed no clinically important difference between
12 adjuvant gemcitabine followed by chemoradiotherapy and adjuvant chemotherapy
13 (fluororacil) followed by chemoradiotherapy on overall survival in adults with resected
14 pancreatic cancer: HR 0.93 (95% CI 0.76-1.15).

15 Adverse events

16 Low to moderate quality evidence from 1 RCT (n=451) showed that there is a clinically
17 important difference favouring adjuvant chemotherapy (fluororacil) followed by
18 chemoradiotherapy on the number of people who experience grade 4 toxicities (RR 11.1
19 [95% CI 3.45-35.73]), worst grade 3 or 4 haematological toxicities (RR 6.1 [95% CI 4.04-
20 9.22]) and worst grade 3 or 4 overall toxicities (RR 1.27 [95% CI 1.13-1.44]) compared to
21 adjuvant gemcitabine followed by chemoradiotherapy in adults with resected pancreatic
22 cancer.

23 Low quality evidence from 1 RCT (n=451) showed no clinically important difference between
24 adjuvant gemcitabine followed by chemoradiotherapy and adjuvant chemotherapy
25 (fluororacil) followed by chemoradiotherapy on the number of people who experience grade 3
26 or 4 diarrhoea (RR 0.78 [95% CI 0.52-1.18]) or stomatitis (RR 0.65 [95% CI 0.4-1.08]), nor on
27 the number of people who experience worst grade 3 or 4 non-haematological toxicities (RR
28 0.98 [95% CI 0.84-1.14]) in adults with resected pancreatic cancer.

29 Very low quality evidence from 1 RCT (n=102) showed that there is a clinically important
30 difference favouring adjuvant gemcitabine followed by chemoradiotherapy on the number of
31 people who experience a grade 3 or 4 neutropenic or thrombocytopenic toxicity compared to
32 adjuvant chemotherapy (PEFG) followed by chemoradiotherapy in adults with resected
33 pancreatic cancer: SMD -0.8 (95% CI -1.21 to -0.4) for both outcomes.

34 Health-related quality of life

35 No evidence was identified to inform this outcome.

36 Patient experience

37 No evidence was identified to inform this outcome.

38 PROMS

39 No evidence was identified to inform this outcome.

110.3.6.11 Immunotherapy versus no adjuvant therapy

2 **Disease-free survival**

3 No evidence was identified to inform this outcome.

4 **Relapse-free survival**

5 No evidence was identified to inform this outcome.

6 **Overall survival**

7 Very low quality evidence from 1 RCT (n=61) showed no clinically important difference
8 between adjuvant immunotherapy (MoAb 494/32) and no adjuvant therapy on overall survival
9 in adults with resected pancreatic cancer: HR 1.12 (95% CI 0.21-6.03).

10 **Adverse events**

11 Very low quality evidence from 1 RCT (n=61) showed no clinically important difference
12 between adjuvant immunotherapy (MoAb 494/32) and no adjuvant therapy on the number of
13 people who experience grade 3 or 4 abdominal pain in adults with resected pancreatic
14 cancer: RR 3.3 (95% CI 0.14-77.95).

15 **Health-related quality of life**

16 No evidence was identified to inform this outcome.

17 **Patient experience**

18 No evidence was identified to inform this outcome.

19 **PROMS**

20 No evidence was identified to inform this outcome.

2110.3.6.12 Chemoimmunotherapy versus no adjuvant therapy

22 **Disease-free survival**

23 Low quality evidence from 1 RCT (n=83) showed that there is a clinically important difference
24 favouring adjuvant chemoimmunotherapy (interleukin-2) disease-free survival compared to
25 no adjuvant therapy in adults with resected pancreatic cancer: HR 0.33 (95% CI 0.17-0.64).

26 **Relapse-free survival**

27 No evidence was identified to inform this outcome.

28 **Overall survival**

29 Low quality evidence from 1 RCT (n=83) showed that there is a clinically important difference
30 favouring adjuvant chemoimmunotherapy (interleukin-2) on overall survival compared to no
31 adjuvant therapy in adults with resected pancreatic cancer: HR 0.45 (95% CI 0.23-0.88).

32 **Adverse events**

33 Very low quality evidence from 1 RCT (n=83) showed no clinically important difference
34 between chemoimmunotherapy (interleukin-2) and no adjuvant therapy on the number of

1 adults with resected pancreatic cancer who experience grade 3 or 4 vomiting: RR 4.66 (95%
2 CI 0.23-94.18).

3 **Health-related quality of life**

4 No evidence was identified to inform this outcome.

5 **Patient experience**

6 No evidence was identified to inform this outcome.

7 **PROMS**

8 No evidence was identified to inform this outcome.

9 **10.3.7 Recommendations**

10 **45. Give people time to recover from surgery before starting adjuvant therapy. Start**
11 **adjuvant therapy as soon as they are well enough to tolerate all 6 cycles.**

12 **46. Offer adjuvant gemcitabine plus capecitabine² to people who have had sufficient**
13 **time to recover after pancreatic cancer resection.**

14 **47. Consider adjuvant gemcitabine³ for people who are not well enough to tolerate**
15 **combination chemotherapy.**

16 **10.3.8 Evidence to recommendations**

17 **10.3.8.1 Relative value placed on the outcomes considered**

18 Disease free survival, relapse free survival, overall survival, adverse events, health related
19 quality of life, patient experience and patient reported outcome measures were considered to
20 be the critical outcomes for this question.

21 Overall survival and adverse events were reported by all studies. Relapse free survival,
22 disease free survival and health-related quality of life were reported only by some studies. No
23 studies reported on patient experience or patient reported outcome measures.

24 **10.3.8.2 Quality of evidence**

25 The quality of the evidence was assessed by GRADE and the Cochrane risk of bias
26 checklist.

27 The quality of the outcomes for the comparisons identified by this review were as follows:

- 28
- adjuvant gemcitabine versus other adjuvant chemotherapy - ranged from very low to high

² Although this use is common in UK clinical practice, at the time of publication (January 2018) gemcitabine plus capecitabine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

³ Although this use is common in UK clinical practice, at the time of publication (January 2018) gemcitabine did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

- 1 • adjuvant gemcitabine followed by chemoradiotherapy versus other adjuvant
- 2 chemotherapy followed by chemoradiotherapy - ranged from low to moderate.
- 3 • adjuvant chemotherapy with no adjuvant therapy - ranged from very low to moderate
- 4 • adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant
- 5 chemoradiotherapy - ranged from very low to low
- 6 • adjuvant chemoimmunotherapy versus no adjuvant therapy - ranged from very low to low
- 7 • adjuvant chemotherapy with adjuvant chemoradiotherapy – very low
- 8 • adjuvant chemotherapy with adjuvant chemoimmunotherapy – very low
- 9 • adjuvant chemotherapy with adjuvant chemoradioimmunotherapy – very low
- 10 • Adjuvant chemoradiotherapy followed by chemotherapy versus no adjuvant therapy – very
- 11 low
- 12 • Adjuvant chemoradiotherapy followed by chemotherapy versus adjuvant chemotherapy –
- 13 very low
- 14 • Adjuvant immunotherapy versus no adjuvant therapy – very low.

15 The committee noted that the clinical evidence indicates adjuvant S1 is an effective adjuvant
16 chemotherapy. However the committee also noted that the trial reporting this result recruited
17 only in Japan. The committee considered, based on their knowledge and experience, that
18 there are population differences between the Japanese and European populations which
19 mean that these results may not be directly applicable to a western population. Consequently
20 the committee agreed not to make a recommendation for clinical practice about S1. They
21 considered making a recommendation for further research in this area but agreed it was
22 unlikely to be feasible.

23 The committee also noted that the data for the use of adjuvant chemoradiotherapy were
24 limited, of very low to low quality and only reported a restricted set of outcomes.
25 Consequently the committee were not able to make any recommendations about this
26 intervention. They was aware that there were ongoing trials in this area and so they did not
27 make a recommendation for further research.

28 The committee noted that only single studies had been found that examined immunotherapy,
29 chemoimmunotherapy, or chemoradioimmunotherapy as adjuvant therapies. Because of the
30 limited and low quality data on these interventions and the fact that none of these
31 interventions are in regular use, the committee agreed not to make any recommendations for
32 clinical practice. In the absence of any new agents with encouraging preliminary data, the
33 committee recognised this was an unmet need but was not able to prioritise further
34 randomised trials in this area at this time.

35 10.3.8.3 Consideration of clinical benefits and harms

36 The committee noted, based on directly relevant evidence, that adjuvant therapy with
37 gemcitabine plus capecitabine had shown the most benefit to overall survival in people who
38 have had pancreatic resection. The committee also noted that the evidence had shown
39 adjuvant therapy was associated with toxicity. However the committee considered the
40 benefits to overall survival outweighed the potential for increased toxicity and agreed to make
41 a strong recommendation for this intervention.

42 Given that there would be people who may not tolerate the toxicity associated with
43 combination therapy, the committee agreed it was important to make a recommendation for
44 this group of people. The committee noted that adjuvant monotherapy with gemcitabine had
45 also shown a benefit to overall survival, but not as much as the combination of gemcitabine
46 and capecitabine. They therefore agreed to make a recommendation on adjuvant
47 gemcitabine.

1 The committee also noted that Valle et al's (2010) analysis of ESPAC3 showed that overall
2 survival favoured people receiving all 6 cycles of adjuvant therapy (compared with only 1-5
3 cycles). This study also demonstrated that delaying adjuvant therapy did not negatively affect
4 outcomes. Therefore the committee agreed to recommend that commencement of adjuvant
5 chemotherapy should be delayed until the person had fully recovered from surgery in order
6 to maximize the chance of delivering all 6 cycles.

7 **10.3.8.4 Consideration of economic benefits and harms**

8 The committee noted that no relevant published economic evaluations had been identified
9 and no additional economic analysis had been undertaken in this area.

10 The committee agreed that current practice is to use gemcitabine as adjuvant therapy.
11 Therefore there are likely to be additional costs associated with the recommendation to offer
12 gemcitabine in combination with capecitabine. However, since capecitabine is now generic
13 and can be provided orally, rather than requiring daily injection, the committee thought that
14 any increase in costs was unlikely to be significant. In addition, the proportion of people with
15 pancreatic cancer who have resection and therefore are able to receive adjuvant therapy is
16 small. The committee also considered that there were likely to be cost savings as a result of
17 the recommendations because provision of adjuvant therapy would reduce the number of
18 people who relapse, hence saving the costs of investigations for relapse and second line
19 therapies.

20 **10.3.9 References**

21 Büchler M, Friess H, Schultheiss KH et al. (1991) A randomized controlled trial of adjuvant
22 immunotherapy (murine monoclonal antibody 494/32) in resectable pancreatic cancer.
23 *Cancer* 68(7): 1507-1512

24 Kosuge T, Kiuchi T, Mukai K et al. (2006) A multicenter randomized controlled trial to
25 evaluate the effect of adjuvant cisplatin and 5-fluorouracil therapy after curative resection in
26 cases of pancreatic cancer. *Japanese Journal of Clinical Oncology* 36(3): 159-165

27 Lygidakis NJ, Sgourakis G, Georgia D et al. (2002) Regional targeting chemoimmunotherapy
28 in patients undergoing pancreatic resection in an advanced stage of their disease: a
29 prospective randomized study. *Annals of Surgery* 236(6): 806-813

30 Neoptolemos JP (2001) ESPAC-1: A European randomized controlled study of adjuvant
31 chemoradiation and chemotherapy in resectable pancreatic cancer. *The Lancet* 358(9293):
32 1576-1585

33 Neoptolemos JP, Palmer DH, Ghaneh P et al. (2017) Comparison of adjuvant gemcitabine
34 and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer
35 (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. *The Lancet* 389(10073):
36 1011-1024

37 Neoptolemos JP, Stocken DD, Friess H et al. (2004) A randomized trial of
38 chemoradiotherapy and chemotherapy after resection of pancreatic cancer. *New England*
39 *Journal of Medicine* 350(12): 1200-1210

40 Neoptolemos JP, Stocken DD, Smith CT et al. (2009) Adjuvant 5-fluorouracil and folinic acid
41 vs observation for pancreatic cancer: composite data from the ESPAC-1 and-3 (v1) trials.
42 *British Journal of Cancer* 100(2): 246-250

43 Neoptolemos JP, Stocken DD, Bassi, C et al. (2010) Adjuvant chemotherapy with fluorouracil
44 plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized
45 controlled trial. *JAMA* 304(10): 1073-1081

- 1 Oettle H, Neuhaus P, Hochhaus A et al. (2013) Adjuvant chemotherapy with gemcitabine
2 and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001
3 randomized trial. *JAMA* 310(14): 1473-1481
- 4 Oettle H, Post S, Neuhaus P et al. (2007) Adjuvant chemotherapy with gemcitabine vs
5 observation in patients undergoing curative-intent resection of pancreatic cancer: a
6 randomized controlled trial. *JAMA* 297(3): 267-277
- 7 Regine WF, Winter KA, Abrams RA et al. (2008) Fluorouracil vs gemcitabine chemotherapy
8 before and after fluorouracil-based chemoradiation following resection of pancreatic
9 adenocarcinoma: a randomized controlled trial. *JAMA* 299(9): 1019-1026
- 10 Regine WF, Winter KA, Abrams R et al. (2011) Fluorouracil-based chemoradiation with either
11 gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-
12 year analysis of the US Intergroup/RTOG 9704 phase III trial. *Annals of Surgical Oncology*
13 18(5): 1319-1326
- 14 Reni M, Balzano G, Aprile G et al. (2012) Adjuvant pefg (cisplatin, epirubicin, 5-fluorouracil,
15 gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized
16 phase ii trial. *Annals of Surgical Oncology* 19(7): 2256-2263
- 17 Schmidt J, Abel U, Debus J et al. (2012) Open-label, multicenter, randomized phase III trial
18 of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for
19 patients with resected pancreatic adenocarcinoma. *Journal of Clinical Oncology* 30(33):
20 4077-4083
- 21 Takada T, Amano H, Yasuda H et al. (2002) Is postoperative adjuvant chemotherapy useful
22 for gallbladder carcinoma? *Cancer* 95(8): 1685-1695
- 23 Ueno H, Kosuge T, Matsuyama Y et al. (2009) A randomised phase III trial comparing
24 gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study
25 Group of Adjuvant Therapy for Pancreatic Cancer. *British Journal of Cancer* 101(6): 908-915
- 26 Uesaka K, Boku N, Fukutomi A, et al. (2016) Adjuvant chemotherapy of S-1 versus
27 gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-
28 inferiority trial (JASPAC 01). *The Lancet* 388(10041): 248-257
- 29 Valle JW, Palmer D, Jackson R et al. (2014) Optimal duration and timing of adjuvant
30 chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing
31 lessons from the ESPAC-3 study. *Journal of Clinical Oncology* 32(6): 504-512
- 32 Van Laethem JL, Hammel P, Mornex F et al. (2010) Adjuvant gemcitabine alone versus
33 gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a
34 randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. *Journal of Clinical*
35 *Oncology* 28(29): 4450-4456
- 36 Yoshitomi H, Togawa A, Kimura F et al. (2008) A randomized phase II trial of adjuvant
37 chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with
38 resected pancreatic cancer. *Cancer* 113(9): 2448-2456

1 10.4 Follow-up for people with resected pancreatic cancer

2 **Review question: What is the optimal follow-up protocol for people with resected**
3 **pancreatic adenocarcinoma?**

4 10.4.1 Introduction

5 Pancreatic surgery is both technically challenging and highly specialist in terms of pre and
6 post-operative care. Previous UK guidelines specified that pancreatic cancer surgery should
7 be performed in specialised units covering a geographical population of over 2 million
8 people, but they did not stipulate optimal follow-up after surgery. Surgical resection followed
9 by adjuvant chemotherapy is the only hope of cure for pancreatic cancer patients. Post-
10 surgery, for those people with suitable performance status, a 6 month course of adjuvant
11 chemotherapy is recognised as the gold standard treatment.

12 The question of how best to follow up people thereafter varies regionally, nationally and
13 internationally, not least due to lack of a high quality evidence base.

14 There are 3 main reasons to follow-up people after they have had their pancreatic cancer
15 resected to:

- 16 1. manage post-surgical morbidity, including pain, change in bowel habit, pancreatic
17 exocrine insufficiency, other nutrition requirements and diabetes;
- 18 2. diagnose disease recurrence with a view to expediting subsequent treatment and
- 19 3. support people and their families coping with a cancer diagnosis that is associated with
20 one of the worst outcomes.

21 Most post-surgical morbidity is managed over the first 6 months but the ways in which this is
22 done are variable.

23 There is also wide variation in how surveillance for disease recurrence is conducted across
24 the UK. This ranges from intensive, 3 monthly clinic reviews involving surgeons, oncologists,
25 specialist nurses and dieticians, to no formal clinic review at all. The latter approach may be
26 justified because recurrence of pancreatic cancer is almost never resectable and the
27 treatment options for unresectable disease remain very limited. There is also variation in
28 what the surveillance involves (for example clinical examination, holistic needs assessment,
29 monitoring of the serum CA19.9 tumour marker, cross sectional imaging such as CT, MRI or
30 FDG-PET/CT), the intervals at which these are done or whether they are done at all.

31 Guidance is needed on the most effective follow-up protocol for people with resected
32 pancreatic cancer.

33 10.4.1.1 Review protocol summary

34 The review protocol summary used for this question can be found in Table 151. Full details of
35 the review protocol can be found in Appendix C.

36 **Table 151: Clinical review protocol summary for the review of follow-up protocols**

Population	Patients who have undergone surgical resection for pancreatic adenocarcinoma with curative intent
Intervention	<ul style="list-style-type: none">• Gastro-intestinal or endocrine, psychological, oncological• Follow-up packages [including combinations of follow-up elements such as clinical assessment (including Holistic Needs Assessment (HNA) and clinical examination), imaging, blood tests including ca19.9, including the frequency of follow up]

Population	Patients who have undergone surgical resection for pancreatic adenocarcinoma with curative intent
Comparison	No active/scheduled follow-up or one of the interventions listed
Outcome	<ul style="list-style-type: none">• Survival• Time to detection of recurrence• Proportion of asymptomatic recurrence (imaging)• Fitness for further intervention• Health Reported Quality of Life• Adverse events• Risk of increased radiation (following repeated imaging)• Patient Reported Outcome Measures• Patient acceptability

1 **10.4.2 Description of clinical evidence**

2 Two studies were included in this review (Reeder-Hayes et al. 2014; Vaccaro et al. 2010). A
3 summary of the included studies is presented in Table 2. One study was an abstract
4 (Vaccaro et al. 2010) and only a limited amount of data about this study could be extracted.

5 One study (n=4652) provided evidence on the overall mortality between various imaging
6 approaches (PET, CT/MRI, and none) in pancreatic cancer (Reeder-Hayes et al. 2014). The
7 other study (n=296) investigated the value of CT imaging compared to clinical symptoms and
8 CA 19-9 levels in detecting cancer recurrence in pancreatic cancer (Vaccaro et al. 2010).

9 Further information about the search strategy can be found in Appendix D. See study
10 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
11 study evidence tables in Appendix F and list of excluded studies in Appendix G.

12
13

1 **10.4.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 152.

3 **Table 152: Summary of included studies**

Study	Population	Intervention	Comparator	Outcomes
Reeder-Hayes, et al. (2014)	Individuals with a new, single primary cancer diagnosis of pancreatic malignancy (ICD-O-2 codes C250-C259) between 2003-2007. Included individuals were >66 years at diagnosis and continuously enrolled in Medicare part A and B for 1 year prior to diagnosis forward to death or end of the study period. Patients stratified into: Surgery, Borderline, Metastatic, and Unknown n= 6691; only n=4652 analysed	CT/MRI imaging No imaging follow-up	PET imaging	Mortality Survival beyond 180 days
Vaccaro, et al. (2010)	Pancreatic cancer patients who underwent potentially curative surgery n= 476; only n=296 analysed	CT imaging	Clinical symptoms and CA 19-9 blood levels	Cancer recurrence

4
 5
 6

1 10.4.4 Clinical evidence profile

2 The clinical evidence profiles for this review question are presented in Table 153 to Table
3 156.

4 10.4.4.1 CT/MRI versus PET

5 **Table 153: Summary clinical evidence profile for CT/MRI versus PET on survival**
6 **beyond 180 days**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT/MRI on Survival Beyond 180 days	PET				
Surgical Group Follow-up: 180 days	Study population		HR 0.8 (0.57 to 1.14)	372 (1 study)	⊕⊕⊕⊕ very low ^{1,2}	
	See comment ⁴	See comment ⁴				
	Moderate					
Borderline Group Follow-up: 180 days	Study population		HR 1.04 (0.82 to 1.33)	969 (1 study)	⊕⊕⊕⊕ very low ^{1,2,3}	
	See comment ⁴	See comment ⁴				
	Moderate					

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; HR: Hazard ratio;

1 Unclear if population confounders were accounted for in the analyses. High dropout rate 57%

2 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.

3 Unclear if participants in the borderline population underwent resection

4Not calculable due to paucity of data

7 **Table 154: Summary clinical evidence profile for CT/MRI versus PET on overall**
8 **mortality**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT/MRI on Mortality (time-varying exposure model)	PET				
Mortality in Surgical Group Time-varying exposure model	Study population		HR 0.66 (0.52 to 0.83)	372 (1 study)	⊕⊕⊕⊕ very low ^{2,3}	
	See comment ¹	See comment ¹				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Mortality in Borderline Group Time-varying exposure model	Study population See comment ¹	See comment ¹	HR 0.95 (0.81 to 1.13)	969 (1 study)	⊕⊖⊖⊖ very low ^{2,3,4}	
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; HR: Hazard ratio;</p> <p>1 Not calculable due to paucity of data</p> <p>2 Unclear if confounders between cohorts were accounted for in the analyses. 31% dropout in the analyses.</p> <p>3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant</p> <p>4 Not clear if participants included in the borderline analyses have undergone surgical resection</p>						

1 10.4.4.2 No imaging versus PET

2 **Table 155: Summary clinical evidence profile for no follow-up imaging versus PET**
3 **on survival beyond 180 days**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No follow-up on Survival Beyond 180 days	PET				
Surgical Group Follow-up: 180 days	Study population See comment ⁴ Moderate	See comment ⁴	HR 0.56 (0.37 to 0.85)	190 (1 study)	⊕⊖⊖⊖ very low ¹	
Borderline group Follow-up: 180 days	Study population See comment ⁴ Moderate	See comment ⁴	HR 0.9 (0.69 to 1.19)	709 (1 study)	⊕⊖⊖⊖ very low ^{1,2,3}	
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; HR: Hazard ratio;</p> <p>1 Unclear if confounders in the population were accounted for in the analyses. High dropout rate 57%.</p> <p>2 Unclear if participants in the borderline population underwent resection</p> <p>3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant.</p> <p>4 Not calculable due to paucity of data</p>						

1
2

Table 156: Summary clinical evidence profile for no follow-up imaging versus PET on overall mortality

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	No follow-up on mortality (time-varying exposure model)	PET				
Mortality in Surgical Group Time-varying exposure model	Study population		HR 0.17 (0.1 to 0.28)	190 (1 study)	⊕⊖⊖⊖ very low	
	See comment ¹	See comment ¹				
	Moderate					
Mortality in Borderline Group Time-varying exposure model	Study population		HR 1.02 (0.84 to 1.24)	709 (1 study)	⊕⊖⊖⊖ very low ^{2,3,4}	
	See comment ¹	See comment ¹				
	Moderate					

**The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).*

CI: Confidence interval; HR: Hazard ratio;

1 Not calculable due to paucity of data

2 Unclear if population confounders between cohorts were accounted for in the analyses. High dropout rate 31% in the analyses

3 Unclear if participants in the borderline analyses have undergone surgical resection

4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant

3 10.4.5 Economic evidence

4 One study (Tzeng et al. 2013) was identified by the review of published economic evidence
5 for this topic. The study compared different strategies of follow-up for people who had
6 undergone surgical resection of the pancreas.

7 The study compared four follow-up strategies in total:

- 8 • 6 Monthly follow-up with CA 19-9 with routine CT Scan and chest x-ray (CT/CXR)
- 9 • 6 Monthly follow-up with CA 19-9 without routine CT/CXR
- 10 • 3 Monthly follow-up with CA 19-9 with routine CT/CXR
- 11 • 3 Monthly follow-up with CA 19-9 without routine CT/CXR

12 These were compared to a base case of no routine follow-up, with testing and imaging being
13 initiated by patient symptoms. The study concluded that the most cost effective follow-up
14 strategy was the least intensive (6 monthly follow-up with CA 19-9 without routine CT/CXR)
15 with other strategies adding significant costs but only marginal survival advantage.

16 The study was deemed only partially applicable to the topic as it took a non-NHS +PSS
17 perspective and potentially serious methodological issues were identified. For example, the
18 survival parameters of the model were populated using retrospective, observational data

1 from 1 centre reporting survival following cancer recurrence identified through routine follow-
2 up and that which was symptom initiated. The difference in survival (8 months) reported was
3 included in the model unadjusted as the estimated survival difference between routine and
4 symptom-led follow-up resulting in a potentially significant lead time bias. The study was also
5 limited in its exploration of quality of life and sources of data were not adequately discussed
6 or referenced.

7 References to all included studies and evidence tables for all economic evaluations included
8 in the systematic literature review of the economic evidence are presented in Appendix L.
9 Economic evidence profiles of these studies are presented in Appendix K.

10 **10.4.6 Evidence statements**

11 **10.4.6.1 Follow-up imaging with CT/MRI versus PET Survival beyond 180 days**

12 Very low quality evidence from 1 retrospective cohort study (n=372) showed no clinically
13 important difference between follow-up imaging with CT/MRI and follow-up imaging with PET
14 on survival beyond 180 days in a 'surgical group' of pancreatic cancer patients: HR=0.80
15 (95% CI 0.57-1.14)

16 Very low quality evidence from 1 retrospective cohort study (n=969) showed no clinically
17 important difference between follow-up imaging with CT/MRI and follow-up imaging with PET
18 on survival beyond 180 days in a 'borderline group' of pancreatic patients: HR=1.04 (95% CI
19 0.82-1.33)

20 **Overall mortality**

21 Very low quality evidence from 1 retrospective cohort study (n=372) showed that there was a
22 clinically important difference favouring follow-up imaging with CT/MRI on mortality
23 compared to follow-up imaging with PET in a 'surgical group' of pancreatic cancer patients:
24 HR=0.66 (95% CI 0.52-0.83)

25 Very low quality evidence from 1 retrospective cohort study (n=969) showed there was no
26 clinically important difference between follow-up imaging with CT/MRI and follow-up imaging
27 with PET on mortality in a 'borderline group' of pancreatic cancer patients: HR=0.95 (95% CI
28 0.81-1.13)

29 **Time to detection of recurrence**

30 No evidence was identified to inform this outcome.

31 **Proportion of asymptomatic recurrence**

32 No evidence was identified to inform this outcome.

33 **Fitness for further intervention**

34 No evidence was identified to inform this outcome.

35 **Health related quality of life**

36 No evidence was identified to inform this outcome.

37 **Adverse events**

38 No evidence was identified to inform this outcome.

39 **Risk of increased radiation**

40 No evidence was identified to inform this outcome.

1 **Patient reported outcome measures**

2 No evidence was identified to inform this outcome.

3 **Patient acceptability**

4 No evidence was identified to inform this outcome.

5 **10.4.6.2 No follow-up imaging versus PET**

6 **Survival beyond 180 days**

7 Very low quality evidence from 1 retrospective cohort study (n=190) showed that there was a
8 clinically important difference favouring no follow-up imaging on survival beyond 180 days
9 compared to follow-up imaging with PET in a 'surgical group' of pancreatic cancer patients:
10 HR=0.56 (95% CI 0.37-0.85)

11 Very low quality evidence from 1 retrospective cohort study (n=709) showed no clinically
12 important difference between no follow-up imaging compared to follow-up imaging with PET
13 on survival beyond 180 days in a 'borderline group' of pancreatic cancer patients: HR=0.90
14 (95% CI 0.69-1.19)

15 **Overall mortality**

16 Very low quality evidence from 1 retrospective cohort study (n=190) showed that there was a
17 clinically important difference favouring no follow-up imaging on mortality compared to follow-
18 up imaging with PET in a 'surgical group' of pancreatic cancer patients: HR=0.17 (95% CI
19 0.10-0.28)

20 Very low quality evidence from 1 retrospective cohort study (n=709) showed no clinically
21 important difference between no follow-up imaging and follow-up imaging with PET on
22 mortality in a 'borderline group' of pancreatic cancer patients: HR=1.02 (95% CI 0.84-1.24)

23 **Time to detection of recurrence**

24 No evidence was identified to inform this outcome.

25 **Proportion of asymptomatic recurrence**

26 No evidence was identified to inform this outcome.

27 **Fitness for further intervention**

28 No evidence was identified to inform this outcome.

29 **Health related quality of life**

30 No evidence was identified to inform this outcome.

31 **Adverse events**

32 No evidence was identified to inform this outcome.

33 **Risk of increased radiation**

34 No evidence was identified to inform this outcome.

1 **Patient reported outcome measures**

2 No evidence was identified to inform this outcome.

3 **Patient acceptability**

4 No evidence was identified to inform this outcome.

5 **10.4.6.3 Follow-up imaging of CT versus symptoms and CA 19-9**

6 **Proportion of asymptomatic recurrence**

7 Very low quality evidence from 1 abstract of a retrospective cohort study (n=296) showed
8 that 15% of cancer recurrence was noted only on follow-up imaging of CT in the absence of
9 symptoms or elevation of CA 19-9, however the uncertainty around this could not be
10 calculated.

11 **Survival**

12 No evidence was identified to inform this outcome.

13 **Time to detection of recurrence**

14 No evidence was identified to inform this outcome.

15 **Fitness for further intervention**

16 No evidence was identified to inform this outcome.

17 **Health related quality of life**

18 No evidence was identified to inform this outcome.

19 **Adverse events**

20 No evidence was identified to inform this outcome.

21 **Risk of increased radiation**

22 No evidence was identified to inform this outcome.

23 **Patient reported outcome measures**

24 No evidence was identified to inform this outcome.

25 **Patient acceptability**

26 No evidence was identified to inform this outcome.

27 **10.4.7 Recommendations**

28 **48. For people who have had resection, offer ongoing specialist assessment and care**
29 **to identify and manage any problems resulting from surgery.**

30 **49. For people who have new, unexplained or unresolved symptoms after treatment,**
31 **provide access to specialist investigation and support services.**

1 10.4.8 Evidence to recommendations

2 10.4.8.1 Relative value placed on the outcomes considered

3 Survival, time to detection of recurrence, proportion of asymptomatic recurrence, fitness for
4 further intervention, health-related quality of life, adverse events, risk of increased radiation,
5 patient reported outcome measures and patient acceptability were considered to be the
6 critical outcomes for this question. Evidence was only reported for the outcomes of survival,
7 mortality and recurrence. No evidence was available for the other outcomes of interest.

8 10.4.8.2 Quality of evidence

9 Evidence was available for the comparisons of follow-up imaging with CT/MRI versus PET,
10 no follow-up imaging versus PET and follow-up imaging with CT versus symptoms and
11 CA19-9. The evidence for all comparisons was very low quality.

12 The committee noted that there was a variety of limitations with the evidence base. In the
13 comparison of CT/MRI versus PET only 12% of people received PET, 97% of which had
14 MRI/CT during follow-up. PET imaging after an attempted curative resection may indicate an
15 attempt to confirm recurrence with poor prognosis. It was not possible to distinguish between
16 scans performed as routine surveillance and those obtained to confirm or monitor
17 recurrence.

18 Since the evidence base for this question was limited, of very low quality and only evaluated
19 imaging and blood tests as potential investigations, it was not useful to the committee in
20 identifying the optimal follow up protocol for people with resected pancreatic cancer. They,
21 therefore, based the recommendations on their clinical knowledge and experience.

22 Given the limited evidence available, the committee noted that it would be useful to have
23 more data on the effectiveness of follow up. However, they also noted that such a research
24 study would take 10-15 years to complete, during which time the technologies used in follow
25 up were likely to have moved on. This would mean the results of the study would then not be
26 helpful in making recommendations for clinical practice. They, therefore, agreed not to make
27 a recommendation for research in this area as it was unlikely to be practical. However, the
28 committee noted that existing and new trials of interventions are likely to include collection of
29 follow-up data which may help to resolve some of the uncertainty.

30 10.4.8.3 Consideration of clinical benefits and harms

31 The committee noted that there are 3 main reasons for following up people after resection of
32 their pancreatic cancer – to manage any post-operative sequelae, to detect recurrence of the
33 cancer and to provide psychological support. The patient perspective was that there are
34 inevitably consequences resulting from resectional surgery and it is important that these are
35 managed effectively. The committee unanimously agreed that specialist post-operative
36 assessment was essential to achieving this. They agreed that, even though this
37 recommendation was based on their experience and knowledge rather than high quality
38 evidence, it should be a strong recommendation as it would be negligent not to offer
39 assessment for the purpose of managing post-operative sequelae.

40 The committee noted the patient perspective following surgery was that new or persistent
41 symptoms are often a source of concern for people. They, therefore, recommended that
42 additional open access to specialist services should be available to provide information and
43 support. The committee noted that this recommendation was in line with advice from NHS
44 England's enhanced recovery programmes.

45 There was no evidence to show whether detecting recurrence has any utility in terms of
46 improving overall survival. The committee was, therefore, unable to make any
47 recommendations about what tests should be done to detect recurrence, the frequency of

1 testing or the duration of follow-up. The committee discussed that tests and follow-up
2 frequency would vary depending on too many factors (e.g. complexity of surgery, types of
3 symptoms, age of patient) and therefore wanted to leave this to clinical judgement.

4 The committee agreed that the benefits of the recommendations made would be a clearer
5 route back to specialist teams. This clarity should lead to better management of post-
6 operative sequelae and more timely, and accurate, identification of new or persistent
7 symptoms. In turn, this would likely lead to avoidance of acute hospital admission and reduce
8 primary care visits. The potential harms of the recommendations would be an increased
9 number of visits. However, the committee agreed that the benefits in terms of better
10 addressing the needs of people with pancreatic cancer and providing reassurance
11 outweighed the potential harms.

12 **10.4.8.4 Consideration of economic benefits and harms**

13 The committee noted that the survival parameters of the model, in the 1 identified economic
14 evaluation were populated using retrospective, observational data from 1 centre. This
15 reported survival following cancer recurrence identified through routine follow-up and that
16 which was symptom initiated. The study estimated an increase in survival of 8 months
17 between recurrence identified by routine follow-up and that identified through changes in
18 symptoms outside of routine follow-up. This was used as the survival difference between
19 routine and symptom-led follow-up in the economic model. The committee noted that this
20 value was likely to have significant lead time bias and that it was not supported by the clinical
21 evidence review. As the survival difference in the model was a key driver of the results it was
22 difficult to draw strong conclusions to support making recommendations. This uncertainty
23 was reinforced by the non-NHS perspective of the economic evaluation as well as potentially
24 serious methodological issues.

25 The committee did consider that any economic evaluation, including the one identified, would
26 not pick up important justifications for follow-up such as a route back into secondary care and
27 reduction in anxiety through routine imaging for recurrence. Therefore, despite there being
28 no strong cost effectiveness evidence for routine follow-up, the committee still felt it was a
29 worthwhile and efficient use of resources, especially as it was unlikely to result in any
30 significant resource impact, as follow-up for the purposes of managing post-operative
31 sequelae is already standard. The committee agreed that there may be some increased
32 staffing costs associated with more people having specialist post-operative assessment.
33 However, this is likely to be balanced by a reduction in costs associated with better
34 management of post-operative sequelae leading to avoidance of emergency hospital
35 admissions.

36 **10.4.9 References**

37 Reeder-Hayes KE, Freburger J, Feagnanes J et al. (2014) Comparative effectiveness of
38 follow-up imaging approaches in pancreatic cancer. *Journal of Comparative Effectiveness*
39 *Research* 3(5): 491-502

40 Tzeng CW, Abbott DE, Cantor SB et al. (2013) Frequency and intensity of postoperative
41 surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis.' *Ann*
42 *Surg Oncol* 20(Suppl 3): 2197-203

43 Vaccaro V, Fleming JB, Wolff RA (2010) Role of surveillance CT scans in resected PC:
44 Correlation with CA19-9 and symptoms. *Journal of Clinical Oncology* 28(15 - supplement):
45 4113

11 Management of unresectable pancreatic cancer

11.1 Management of locally advanced pancreatic cancer

Review question: What is the most effective treatment (chemotherapy, chemoradiotherapy, radiotherapy, combination of chemotherapy and chemoradiotherapy, biological therapies or other local therapies) for adults with newly diagnosed or recurrent unresectable locally advanced non-metastatic pancreatic cancer?

11.1.1 Introduction

Approximately 30-40% of the people present with locally advanced pancreatic cancer, which is unresectable, but without evidence of metastatic spread. Unlike people with borderline resectable disease, people with locally advanced pancreatic cancer can sometimes be downstaged to resectability with chemotherapy or chemoradiotherapy. They comprise a distinct subset of advanced disease, as the overall survival is significantly better than for people with metastatic disease (10-12 months versus 5-6 months).

Competing risks of locoregional progression versus systemic progression influence overall prognosis in this patient group. In addition to overall survival, management of local symptoms are an important consideration. Autopsy series suggest that about a third of these people die with local progression alone without evidence of metastatic spread. Both systemic therapy alone or in combination with loco-regional therapy (radiotherapy) has been widely used, but the optimal treatment strategy, particularly the role of radiation therapy, remains controversial.

Guidance is needed on what is the most effective treatment for people with locally advanced pancreatic cancer.

11.1.1.1 Review protocol summary

The review protocol summary used for this question can be found in Table 157. Full details of the review protocol can be found in Appendix C.

Table 157: Clinical review protocol summary for the review of most effective treatment of locally advanced, non-metastatic pancreatic cancer

Population	Patients with unresectable non-metastatic locally advanced pancreatic cancer	
Intervention/Comparison	• Chemotherapy	<ul style="list-style-type: none"> • CT • different types/regimens/combinations of chemotherapy • best supportive care
	• Radiotherapy/ SBRT +/- chemotherapy	
	• Immunotherapy	
	• Biological therapies	
	• Other local therapies (RFA, microwave)	
	• CRT +/- CT (either sequence)	Chemoradiotherapy Best supportive care chemotherapy
Outcomes	<ul style="list-style-type: none"> • Objective Response (CR/PR/PD/SD/) • Resection rate 	

- Progression Free Survival (local, distant)
- Overall Survival
- Adverse Events
- Health Related Quality of Life
- Pain control
- Patient experience
- PROMS

1

2 11.1.2 Description of Clinical Evidence

3 Eighteen studies were included in the review: ten phase III RCTs (Cantore et al. 2005;
4 Chauffert et al. 2008; Chung et al. 2004; Cohen et al. 2005; Hammel et al. 2016; Herman et
5 al. 2013; Li et al. 2003; Loehrer et al. 2011; Shinchi et al. 2002; Sunamura et al. 2004),
6 seven phase II RCTs including five studies (Heinemann et al. 2013; Hurt et al. 2015; Hurt et
7 al. 2017; Khan et al. 2016; Mukherjee et al. 2013; Rich et al. 2012; Wilkowski et al. 2009)
8 and 1 prospective cohort study (Cantore et al. 2012). A summary of the included studies is
9 presented in Table 158.

10 Three RCTs (n=175) compared different chemoradiotherapy (CRT) regimens (gemcitabine
11 based CRT versus paclitaxel-based CRT (Chung et al. 2004); gemcitabine-based CRT
12 versus 5FU-based CRT (Li et al. 2003); gemcitabine/cisplatin-based CRT versus 5FU-based
13 CRT (Wilkowski et al. 2009) in patients with locally advanced pancreatic cancer.

14 Two phase II RCTs (n=127) compared different CRT regimens after induction chemotherapy:
15 gemcitabine-CRT versus capecitabine-CRT after induction chemotherapy (Mukherjee et al.
16 2013; Hurt et al. 2015); capecitabine-CRT + cetuximab versus capecitabine-CRT alone after
17 induction chemotherapy (Khan et al. 2016) for patients with locally advanced pancreatic
18 cancer.

19 One RCT (n=31) evaluated whether 5FU-based CRT affected the length and quality of
20 survival in patients with locally advanced pancreatic cancer (Shinchi et al. 2002).

21 One RCT (n=95) compared gemcitabine/cisplatin-based CRT against the same CRT regimen
22 followed by a sequential full-dose of gemcitabine and cisplatin in patients with locally
23 advanced pancreatic cancer (Wilkowski et al. 2009).

24 One RCT (n=195) compared the effect of gemcitabine/paclitaxel-based CRT [low-dose
25 gemcitabine plus paclitaxel and concurrent radiation] against the same CRT regimen
26 followed by R115777 [a farnesyl transferase inhibitor] in patients with locally advanced
27 pancreatic cancer (Rich et al. 2012).

28 One RCT (n=304) compared CRT + TNFerade with CRT alone in patients with locally
29 advanced pancreatic cancer (Herman et al. 2013).

30 Two RCTs (n=182) compared CRT with chemotherapy in patients with locally advanced
31 pancreatic cancer. One trial compared an intensified induction phase with CRT, followed by
32 maintenance gemcitabine with gemcitabine alone (Chauffert et al. 2008); the other trial
33 examined whether CRT improves survival or provides additional benefit compared with
34 gemcitabine-based chemotherapy alone (Loehrer et al. 2011).

35 One phase III RCT (n=268) compared chemoradiotherapy with chemotherapy alone (after 4
36 months of gemcitabine-based induction chemotherapy in patients with locally advanced
37 pancreatic cancer controlled (Hammel et al. 2016 - 2nd randomization).

38 One RCT (n=105) compared CRT (using 5FU and mytomycin C) against radiotherapy alone
39 in patients with locally advanced pancreatic cancer (Cohen et al. 2005).

1 Two RCTs (n=617) compared the effect of different chemotherapy regimens in patients with
2 locally advanced pancreatic cancer. One trial evaluated the FLEC regimen (5-fluoruracil +
3 leucovorin + epirubicin + carboplatin) compared with the gold standard chemotherapy
4 (Cantore et al. 2005); the other trial compared gemcitabine-based chemotherapy against
5 gemcitabine+erlonitib based chemotherapy.

6 One RCT (n=95) compared the urokinase plasminogen activator (uPA) inhibitor upmostat in
7 combination with gemcitabine-based chemotherapy against gemcitabine-based
8 chemotherapy alone in locally advanced pancreatic cancer (Heinemann et al. 2013).

9 One RCT (n=48) compared radiotherapy plus a novel radiosensitiser (PR-350) against
10 radiotherapy plus placebo in patients with locally advanced pancreatic cancer (Sunamura et
11 al. 2004).

12 One observational study (n=107) compared giving radiofrequency ablation as a primary
13 treatment against giving radiofrequency ablation after another primary treatment in patients
14 with locally advanced pancreatic cancer (Cantore et al. 2012).

15 The Cochrane Collaboration's 'Risk of bias' tool was used for assessing risk of bias of
16 randomised trials, the Newcastle-Ottawa Scale (NOS) was used for assessing the risk of
17 bias of non-randomised studies (i.e. prospective cohort studies).

18 Further information about the search strategy can be found in Appendix D. See study
19 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
20 study evidence tables in Appendix F and list of excluded studies in Appendix G.

21

22

1 **11.1.3 Summary of included studies**

2 A summary of the studies that were included in this review is presented in Table 158.

3 **Table 158: Summary of included studies**

Study	Sample size	Intervention	Comparison	Outcomes	Study design & setting	Overall risk of bias
Cantore et al. 2005	N= 175 (138 randomised)	CT [FLEC -based] (n=71)	CT [GEM-based] (n=67)	Adverse Events	Design: Phase III RCT Setting: Italy Duration/follow-up: every 2 months until patients' death	Very serious
Cantore et al. 2012	N= 107	RFA as primary treatment (n=47)	RFA after other primary treatment (CT and/or CRT and/or IASC) (n=60)	Overall Survival	Design: Prospective cohort study. Setting: Italy Duration/follow-up: after 30 days and every 3 months – until 1 July 2011	Low
Chauffert et al. 2008	N= 111	CRT (n=59)	CT [GEM-based] (n=52)	Adverse Events	Design: Phase III RCT Setting: France Duration/follow-up: Median follow-up was 31 months in the CRT arm and 33 months in the GEM arm.	Very serious
Chung et al. 2004	N= 46	CRT [GEM-based] (n=22)	CRT [Paclitaxel-based] (n=24)	Objective Response Overall Survival Adverse Events	Design: Phase III RCT Setting: South Korea Duration/follow-up: every 3 months until patients death	Very serious
Cohen et al. 2005	N= 114	CRT (n=55)	Radiotherapy (n=49)	Adverse Events	Design: Open label phase III RCT Setting: USA Duration/follow-up: unclear	Very serious
	N= 268	RANDOMISATION 1				Low

Study	Sample size	Intervention	Comparison	Outcomes	Study design & setting	Overall risk of bias
Hammel et al. 2016		CT [GEM-based] (n=223)	CT [GEM+ERLONITIB] (n=219)	Adverse Events	Design: Multicentre, open label, phase III RCT Setting: France Duration/follow-up: until patients' death	
		RANDOMISATION 2		Progression Free Survival Overall Survival Adverse Events		
Heinemann et al. 2013	N= 95	Gemcitabine + 200mg upmostat (n=31) Gemcitabine + 400mg upmostat (n=33)	CT [GEM-based] (n=31)	Adverse Events	Design: Open label, proof of concept, phase II RCT Setting: Germany Duration/follow-up: every 8 weeks until patients death	Serious
Herman et al. 2013	N= 304	CRT (standard of care) + TNFerade (n=187)	Standard of care (n=90)	Adverse Events	Design: Open label phase III RCT Setting: USA Duration/follow-up: "Median follow-up was 9.1 months"	Serious
Hurt et al. 2015	N= 114 (N=78 patients were randomly allocated)	CRT after induction CT [GEM-based] (n=38)	CRT after induction CT [Capecitabine-based] (n=36)	Health Related Quality of Life	Design: Multi-centre, open label, phase II RCT Setting: UK Duration/follow-up: : "until progression, death, or 12-month follow-up assessment"	Serious
Khan et al. 2016	N= 13	CRT + cetuximab after induction CT (n=6)	CRT alone after induction CT (n=7)	Objective Response Overall Survival Adverse Events	Design: Phase II RCT Setting: UK Duration/follow-up: median follow-up of 61.2 months	Very serious
Li et al. 2003	N= 34	CRT [GEM-based] (n=16)	CRT [5FU-based] (n=18)	Adverse Events Pain control	Design: Open label phase III RCT Setting: Taiwan	Very serious

Study	Sample size	Intervention	Comparison	Outcomes	Study design & setting	Overall risk of bias
				HQRL: Average monthly Karnofsky performance score	Duration/follow-up: until patients' death	
Loehrer et al. 2011	N= 71	CRT (n=34)	CT (n=37)	Adverse Events Health Related Quality of Life	Design: Phase III RCT Setting: USA Duration/follow-up: week 6, week 15/16 and 9 months post baseline	Very serious
Mukherjee et al. 2013	N= 114 (N=78 patients were randomly allocated)	CRT after induction CT [GEM-based] (n=38)	CRT after induction CT [Capecitabine-based] (n=36)	Objective Response Progression Free Survival Overall Survival Adverse Events	Design: Multi-centre, open label, Phase II RCT Setting: UK Duration/follow-up: : "until progression, death, or 12-month follow-up assessment"	Serious
Rich et al. 2012	N=195	CRT + R115777 (n=94)	CRT alone (n=91)	Overall Survival Adverse Events	Design: Phase II RCT Setting: USA Duration/follow-up: unclear	Serious
Shinchi et al. 2002	N=31	CRT (n=16)	BSC [no intervention] (n=15)	Health Related Quality of Life	Design: Phase III RCT Setting: Japan Duration/follow-up: monthly until patients' date	Very serious
Sunamura et al. 2004	N=48	PR-350 + radiotherapy (n=25)	Placebo + radiotherapy (n=22)	Objective Response Overall Survival Adverse Events	Design: Double-blind phase III RCT Setting: Japan Duration/follow-up: 6 months	Very serious
Wilkowski et al. 2009	N=95	CRT [GEM/Cisplatin] followed by Gemcitabine/Cisplatin-CT (n=31)	CRT [GEM/Cisplatin] (n=32) CRT [5-FU]	Adverse Events	Design: Multicentre phase II RCT Setting: Germany	Very serious

Study	Sample size	Intervention	Comparison (n=31)	Outcomes	Study design & setting Duration/follow-up: until patients' death	Overall risk of bias

1
2
3
4
5

1 11.1.4 Clinical evidence profile

2 The clinical evidence profiles for this review question are presented in Table 159 to Table
3 176.

4 **Table 159: Summary clinical evidence profile for gemcitabine-based**
5 **chemoradiotherapy versus paclitaxel-based chemoradiotherapy in adults**
6 **with unresectable non-metastatic locally advanced pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Paclitaxel-based CRT	GEM-based CRT				
Overall response rates (CR+PR) - 1 month follow-up	250 per 1000	138 per 1000 (38 to 480)	RR 0.55 (0.15 to 1.92)	46 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Overall response rates (CR+PR) - 1 year follow-up	167 per 1000	182 per 1000 (52 to 640)	RR 1.09 (0.31 to 3.84)	46 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Overall survival ⁴	Median survival = 14 (95%CI 12.0-16.0) months	Median survival = 12 (95%CI 8.8-15.2) months	HR 0.98 (0.52 to 1.85) ⁴	46 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,6}	
Adverse effects - Grade 3/4 toxicities - Haematological	208 per 1000	227 per 1000 (75 to 681)	RR 1.09 (0.36 to 3.27)	46 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Non-haematological	417 per 1000	817 per 1000 (492 to 1000)	RR 1.96 (1.18 to 3.28)	46 (1 study ¹)	⊕⊕⊕⊕ low ²	

CI: Confidence interval; RR: Risk ratio;

1 Chung et al. 2004

2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial

3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

4 The median survival was 12 months in the gemcitabine group vs. 14 months in the paclitaxel group. There was no statistically significant difference in survival between the 2 groups ($p=0.951$, log-rank test). Relative effect was calculated by the NGA staff by means of the Tieney et al. 2007 methods.

5 The quality of the evidence was downgraded by 2 because the unclear risk of selection bias (no details given about the randomisation and allocation methods). Furthermore no research protocol was published for this trial and no sample size calculations were provided.

6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant

1
2
3

Table 160: Summary clinical evidence profile for gemcitabine-based chemoradiotherapy versus 5FU-based chemoradiotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	5FU-based CRT	GEM-based CRT				
Overall pain control - follow-up not reported	62 per 1000	389 per 1000 (54 to 1000)	RR 6.22 (0.86 to 45.25)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{1,2,3}	
Adverse effects - Grade 3/4 toxicities - Neutropenia	188 per 1000	334 per 1000 (99 to 1000)	RR 1.78 (0.53 to 5.97)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Thrombocytopenia	62 per 1000	19 per 1000 (1 to 428)	RR 0.3 (0.01 to 6.84)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Anaemia	188 per 1000	223 per 1000 (58 to 846)	RR 1.19 (0.31 to 4.51)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Anorexia	312 per 1000	334 per 1000 (125 to 884)	RR 1.07 (0.4 to 2.83)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Nausea	312 per 1000	334 per 1000 (125 to 884)	RR 1.07 (0.4 to 2.83)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Vomiting	188 per 1000	167 per 1000 (39 to 712)	RR 0.89 (0.21 to 3.8)	34 (1 study ¹)	⊕⊕⊕ ⊖ low ⁴	
Adverse effects - Grade 3/4 toxicities - GI bleeding	62 per 1000	56 per 1000 (4 to 817)	RR 0.89 (0.06 to 13.08)	34 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{1,4}	
HQRL: Average monthly Karnofsky performance score - follow-up not reported		The mean HQRL: average monthly Karnofsky performance score - follow-up not reported in the intervention groups was 9 higher		34 (1 study ¹)	⊕⊕⊕ ⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		(6.98 to 11.02 higher)				
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio</p> <p>1 Li et al. 2003 2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial 3 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 4 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2
3

Table 161: Summary clinical evidence profile for gemcitabine/Cisplatin-based chemoradiotherapy versus 5FU-based chemoradiotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	5FU-based CRT	GEM/Cisplatin-based CRT				
Adverse effects - Grade 3/4 toxicities - Leukocytopenia	34 per 1000	516 per 1000 (73 to 1000)	RR 14.97 (2.12 to 105.82)	60 (1 study ¹)	⊕⊕⊖⊖ low ²	
Adverse effects - Grade 3/4 toxicities - Thrombocytopenia	34 per 1000	516 per 1000 (73 to 1000)	RR 14.97 (2.12 to 105.82)	60 (1 study ¹)	⊕⊕⊖⊖ low ²	
Adverse effects - Grade 3/4 toxicities - Anaemia	0 per 1000	0 per 1000 (0 to 0)	RR 4.69 (0.23 to 93.7)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Lower GI tract	34 per 1000	97 per 1000 (11 to 879)	RR 2.81 (0.31 to 25.48)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Upper GI tract	0 per 1000	0 per 1000 (0 to 0)	RR 12.19 (0.72 to 207.14)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Non-haematological ⁴	276 per 1000	356 per 1000 (166 to 756)	RR 1.29 (0.6 to 2.74)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
<p>CI: Confidence interval; RR: Risk ratio;</p> <p>1 Wilkowski et al. 2009 2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial and no sample size calculations were provided. 3 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 1- Fatigue; 2-Weight loss; 3- Diarrhoea; 4- Nausea; 5-Febrile neutropenia; 6-Infection without neutropenia.</p>						

1
2
3
4

Table 162: Summary clinical evidence profile for gemcitabine-chemoradiotherapy after induction chemotherapy versus capecitabine-chemoradiotherapy after induction chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Capecitabine-CRT	GEM-CRT versus				
Overall response rates (CR+PR) ¹	229 per 1000	194 per 1000 (80 to 480)	RR 0.85 (0.35 to 2.1)	71 (1 study ²)	⊕⊕⊕⊖ very low ^{3,4}	
Progression Free Survival ⁵	Median PFS = 12 (95%CI 10.2-14.2) months	Median PFS = 10.4 (95%CI 8.9-12.5) months	HR 0.6 (0.32 to 1.12)	72 (1 study ²)	⊕⊕⊕⊖ moderate ⁶	
Overall Survival	1 year overall survival = 79.2% (95% CI 61.1–89.5)	1 year overall survival = 64.2% (95% CI 46.4–77.5)	HR 0.39 (0.18 to 0.85)	72 (1 study ²)	⊕⊕⊕⊕ high	
Adverse effects - Grade 3/4 toxicities - Haematological	0 per 1000	0 per 1000 (0 to 0)	RR 13.46 (0.8 to 227.22)	72 (1 study ²)	⊕⊕⊕⊖ low ^{3,7}	
Adverse effects - Grade 3/4 toxicities - Non-haematological	118 per 1000	264 per 1000 (91 to 762)	RR 2.24 (0.77 to 6.48)	72 (1 study ²)	⊕⊕⊕⊖ very low ^{3,4}	
Adverse effects - Grade 3/4 toxicities - Other	59 per 1000	79 per 1000 (14 to 445)	RR 1.34 (0.24 to 7.56)	72 (1 study ²)	⊕⊕⊕⊖ very low ^{2,8}	
HQRL - 23 -26 -39 - 52 weeks follow-up ⁹	See comment	See comment	Not estimable ⁹	48 (1 study ²)	⊕⊕⊕⊖ low ⁸	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 GEM-CRT group: no complete responses; CAP-CRT group: 2 complete responses

2 Mukherjee et al. 2013

3 The quality of the evidence was downgraded of one point because the high risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the high risk of detection bias (no masking of outcome assessors)

4 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

5 Median progression-free survival was 12.0 months (95% CI 10.2–14.6) in the capecitabine group and 10.4 months (95% CI 8.9–12.5) in the gemcitabine group

6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.

7 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

8 The quality of the evidence was downgraded of two points because the high risk of performance bias and the high risk of detection bias

9 Differences in changes in HQRL scores between trial arms rarely reached statistical significance; however, where they did, they favoured capecitabine therapy.

5
6

Table 163 Summary clinical evidence profile for capecitabine-chemoradiotherapy + cetuximab versus capecitabine-chemoradiotherapy alone after induction

1
2

chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Capecitabine-CRT alone	Capecitabine-CRT + cetuximab				
Objective response rate	333 per 1000	167 per 1000 (13 to 757)	RR 0.5 (0.06 to 4.15)	12 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Overall survival ⁴	See comment	See comment	Not estimable ⁴	12 (1 study ¹)	⊕⊕⊕ ⊖ low ⁵	
Adverse effects - Grade 3/4 toxicities - Hyponatraemia ⁶	167 per 1000	55 per 1000 (3 to 1000)	RR 0.33 (0.02 to 6.86)	12 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Fatigue ⁶	167 per 1000	55 per 1000 (3 to 1000)	RR 0.33 (0.02 to 6.86)	12 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Abdominal pain ⁶	167 per 1000	55 per 1000 (3 to 1000)	RR 0.33 (0.02 to 6.86)	12 (1 study ¹)	⊕⊕⊕ ⊖ low ³	

CI: Confidence interval; RR: Risk ratio;
¹ Khan et al. 2016
² The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore sample size not achieved as the trial was closed pre-maturely -following emergent data from LAP-07
³ Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs
⁴ median OS was 15.8 months and 22.0 months in arms capecitabine-CRT alone and capecitabine-CRT + cetuximab respectively (p > 0.05)
⁵ The quality of the evidence was downgraded because of the unclear risk of selection bias. Furthermore sample size not achieved as the trial was closed pre-maturely -following emergent data from LAP-07
⁶ no grade 3-4 toxicity was registered

3
4
5

Table 164 Summary clinical evidence profile for chemoradiotherapy versus best supportive care in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Best supportive care	CRT				
Average of monthly Karnofsky scores		The mean average of monthly Karnofsky score in the intervention groups		31 (1 study ¹)	⊕⊕⊕⊕ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		was 11.6 higher (6.61 to 16.59 higher)				
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; 1 Shinchi et al. 2002 2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial and no sample size calculations were provided.</p>						

1
2
3

Table 165 Summary clinical evidence profile for chemoradiotherapy followed by chemotherapy versus chemoradiotherapy alone in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CRT	CRT followed by CT				
Adverse effects - Grade 3/4 toxicities - Leukocytopenia	34 per 1000	630 per 1000 (90 to 1000)	RR 18.26 (2.6 to 128.02)	56 (1 study ¹)	⊕⊕⊖⊖ low ²	
Adverse effects - Grade 3/4 toxicities - Thrombocytopenia	34 per 1000	370 per 1000 (51 to 1000)	RR 10.74 (1.47 to 78.39)	56 (1 study ¹)	⊕⊖⊖⊖ very low ²	
Adverse effects - Grade 3/4 toxicities - Anaemia	0 per 1000	0 per 1000 (0 to 0)	RR 3.21 (0.14 to 75.68)	56 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Upper GI tract	0 per 1000	0 per 1000 (0 to 0)	RR 5.36 (0.27 to 106.78)	56 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Lower GI tract	34 per 1000	12 per 1000 (1 to 290)	RR 0.36 (0.02 to 8.41)	56 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Non-haematological ⁴	276 per 1000	74 per 1000 (17 to 317)	RR 0.27 (0.06)	56 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 1.15)			
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Wilkowski et al. 2009 2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial and no sample size calculations were provided. 3 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 1- Fatigue; 2-Weight loss; 3- Diarrhoea; 4- Nausea; 5-Febrile neutropenia; 6-Infection without neutropenia. 5 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</p>						

1
2
3

Table 166 Summary clinical evidence profile for chemoradiotherapy + R115777 versus chemoradiotherapy alone in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CRT	CRT + R115777				
Overall survival ¹	1-year overall survival = 46.2% (95%CI 35.7%-43.6%) months	1-year overall survival = 34.0% (95%CI 24.7%-43.6%) months	Not estimable ¹	185 (1 study ²)	⊕⊕⊕⊖ moderate ³	
Adverse effects - Grade 3/4 toxicities - Allergy/immunology ⁴	33 per 1000	21 per 1000 (4 to 124)	RR 0.65 (0.11 to 3.77)	185 (1 study ²)	⊕⊖⊖⊖ very low ^{5,6}	
Adverse effects - Grade 3/4 toxicities - Blood/bone marrow ⁴	330 per 1000	458 per 1000 (316 to 659)	RR 1.39 (0.96 to 2)	185 (1 study ²)	⊕⊕⊖⊖ low ^{5,7}	
Adverse effects - Grade 3/4 toxicities - Cardiovascular (general) ⁴	33 per 1000	75 per 1000 (20 to 279)	RR 2.26 (0.6 to 8.47)	185 (1 study ²)	⊕⊖⊖⊖ very low ^{3,6}	
Adverse effects - Grade 3/4 toxicities - Coagulation ⁴	11 per 1000	4 per 1000 (0 to 86)	RR 0.32 (0.01 to 7.82)	185 (1 study ²)	⊕⊖⊖⊖ very low ^{5,6}	
Adverse effects - Grade 3/4 toxicities - Constitutional symptoms ⁴	88 per 1000	149 per 1000 (66 to 338)	RR 1.69 (0.75 to 3.84)	185 (1 study ²)	⊕⊖⊖⊖ very low ^{5,6}	
Adverse effects - Grade 3/4 toxicities - Endocrine ⁴	11 per 1000	4 per 1000 (0 to 86)	RR 0.32 (0.01 to 7.82)	185 (1 study ²)	⊕⊖⊖⊖ very low ^{5,6}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Adverse effects - Grade 3/4 toxicities - Haemorrhage	330 per 1000	20 per 1000 (7 to 86)	RR 0.06 (0.02 to 0.26)	185 (1 study ^{2,4})	⊕⊕⊕⊖ very low ^{5,6}	
Adverse effects - Grade 3/4 toxicities - Gastrointestinal	352 per 1000	394 per 1000 (271 to 573)	RR 1.12 (0.77 to 1.63)	185 (1 study ^{2,6})	⊕⊕⊕⊖ very low ^{5,6}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 All patients included in this analysis have died, the median survival time was 11.5 months (95% CI: 8.2–12.6) for the CXRT arm and 8.9 months (95% CI: 7.3–10.4) for the CXRT+R115777 arm (non-significant difference: p value not reported) 2 Rich et al. 2012 3 The quality of the evidence was downgraded of one point because of the unclear risk of selection bias (no details given about the randomisation and allocation methods) 4 No 3-4 grade toxicities were reported for the following outcomes in both intervention groups: Auditory/hearing; Cardiovascular (arrhythmia); Dermatology/skin; Ocular/visual/ renal/genitourinary 5 The quality of the evidence was downgraded of one point because of the unclear risk of selection bias (no details given about the randomisation and allocation methods), the unclear risk of performance and detection bias (no details given in the text) 6 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID's 7 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</p>						

1
2
3

Table 167 Summary clinical evidence profile for chemoradiotherapy + TNFerade versus chemoradiotherapy alone in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CRT	CRT + TNFerade				
Adverse effects - Grade 3/4 toxicities - Gastrointestinal ¹	111 per 1000	182 per 1000 (94 to 351)	RR 1.64 (0.85 to 3.16)	277 (1 study ²)	⊕⊕⊕⊖ low ^{3,4}	
Adverse effects - Grade 3/4 toxicities - Haematological ⁵	356 per 1000	320 per 1000 (228 to 455)	RR 0.9 (0.64 to 1.28)	277 (1 study ²)	⊕⊕⊕⊖ very low ^{3,5}	
Adverse effects - Grade 3/4 toxicities - Non-gastrointestinal/non-haematologic ⁶	78 per 1000	117 per 1000 (52 to 265)	RR 1.51 (0.67 to 3.41)	277 (1 study ²)	⊕⊕⊕⊖ very low ^{3,5}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 In descending order of frequency, the most commonly occurring GI toxicities were nausea/vomiting, abdominal pain, and anorexia in the SOC TNFerade arm versus nausea/vomiting, diarrhoea, and anorexia in the SOC arm. 2 Herman et al. 2013 3 The quality of the evidence was downgraded of one point because of the unclear risk of selection bias (no</p>						

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>details given about the randomisation and allocation methods) and the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions)</p> <p>4 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</p> <p>5 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p> <p>6 In both arms, the majority of hematologic toxicities (85%) took place during gemcitabine-based maintenance therapy following chemoradiotherapy.</p> <p>7 In descending order of frequency, the most commonly occurring non-GI/ nonhematologic toxicities were fatigue, chills/rigors/sweats, pyrexia, and dehydration in the SOC TNFerade arm versus fatigue, dehydration, dermatitis, and hypokalaemia in the SOC arm.</p>						

1
2
3

Table 168 Summary clinical evidence profile for chemoradiotherapy versus chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT	CRT				
Adverse effects - Grade 3/4 toxicities - Haemoglobin	57 per 1000	177 per 1000 (38 to 814)	RR 3.09 (0.67 to 14.25)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Leukocytes	143 per 1000	323 per 1000 (126 to 833)	RR 2.26 (0.88 to 5.83)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Neutrophils	343 per 1000	384 per 1000 (206 to 717)	RR 1.12 (0.6 to 2.09)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Nausea	86 per 1000	294 per 1000 (88 to 977)	RR 3.43 (1.03 to 11.4)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Vomiting	86 per 1000	265 per 1000 (78 to 895)	RR 3.09 (0.91 to 10.44)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Hypokalaemia	57 per 1000	118 per 1000 (23 to 601)	RR 2.06 (0.4 to 10.51)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Fatigue	57 per 1000	323 per 1000 (77 to 1000)	RR 5.66 (1.35)	69 (1 study ¹)	⊕⊕⊕⊕ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 23.68)			
Adverse effects - Grade 3/4 toxicities - Anorexia	29 per 1000	177 per 1000 (22 to 1000)	RR 6.18 (0.78 to 48.64)	69 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
HQRL - Trial outcome index [mean difference of change from baseline] - Change at week 6		The mean HQRL - trial outcome index [mean difference of change from baseline] - change at week 6 in the intervention groups was 12.2 lower (17.98 to 6.42 lower)		71 (1 study ¹)	⊕⊕⊕⊕ low ^{2,5}	
HQRL - Trial outcome index [mean difference of change from baseline] - Change at week 15/16		The mean HQRL - trial outcome index [mean difference of change from baseline] - change at week 15/16 in the intervention groups was 3.3 lower (9.08 lower to 2.48 higher)		71 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4,5}	
HQRL - Trial outcome index [mean difference of change from baseline] - Change at 9 months		The mean HQRL - trial outcome index [mean difference of change from baseline] - change at 9 months in the intervention groups was 2.7 higher (3.08 lower to 8.48 higher)		71 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4,5}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Loehrer et al. 2011

2 The quality of the evidence was downgraded of two points point because the high risk of bias: 1) Sample size calculation required a sample size of 316 patients however recruitment was stopped early due to poor accrual rates; 2) 46% of patients in Arm A and 21% of patients in Arm B did not have CT scans performed at adequate intervals to appropriately assess duration of treatment response; and 3) Comparison of progression was compromised as precise tumour measurement was difficult in many patients due to margins being obscured by local inflammatory processes. Additionally quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text).

3 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID

4 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

5 Quality of life data should be taken with caution due to high rate of attrition from baseline (high risk of attrition bias)

1
2
3

Table 169 Summary clinical evidence profile chemoradiotherapy versus chemotherapy followed by maintenance chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT followed by maintenance CT	CRT followed by maintenance CT				
Adverse effects - Grade 3/4 haematological toxicities - Induction phase	250 per 1000	288 per 1000 (160 to 522)	RR 1.15 (0.64 to 2.09)	119 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 haematological toxicities - Maintenance phase	200 per 1000	492 per 1000 (278 to 868)	RR 2.46 (1.39 to 4.34)	119 (1 study ¹)	⊕⊕⊕⊕ low ²	
Adverse effects - Grade 3/4 non-haematological toxicities - Induction phase	167 per 1000	407 per 1000 (213 to 775)	RR 2.44 (1.28 to 4.65)	119 (1 study ¹)	⊕⊕⊕⊕ low ²	
Adverse effects - Grade 3/4 non-haematological toxicities - Maintenance phase	183 per 1000	204 per 1000 (97 to 424)	RR 1.11 (0.53 to 2.31)	119 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
¹ *Chauffert et al. 2008*
² *The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions), the potential risk of detection bias (no details about the blinding of outcome assessors) and unclear risk of selection bias (no details given about the concealment allocation methods). Furthermore no research protocol was published for this trial, no sample size calculations were provided. and the trial was stopped before completion of recruitment*
³ *Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID*

4
5
6

Table 170 Summary clinical evidence profile for chemoradiotherapy versus chemotherapy after chemotherapy induction therapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	CT after CT	CRT after CT induction therapy				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	induction therapy					
Overall survival ¹	Median overall survival = 16.5 (95% CI, 14.5-18.5) months	Median overall survival = 15.2 (95% CI, 13.9-17.3) months	HR 1.03 (0.79 to 1.14)	269 (1 study ²)	⊕⊕⊕⊖ moderate ³	
Progression-free survival ⁴	Median PFS = 8.4 (95%CI 7.8-9.4) months	PFS = 9.9 (95%CI 8.8-10.4) months	HR 0.78 (0.61 to 1)	269 (1 study ²)	⊕⊕⊕⊖ moderate ³	
Adverse effects - Grade 3/4 toxicities - Hematological ⁵	30 per 1000	88 per 1000 (29 to 267)	RR 2.93 (0.97 to 8.87)	269 (1 study ²)	⊕⊕⊖⊖ low ^{6,7}	
Adverse effects - Grade 3/4 toxicities - Non-hematological ⁸	180 per 1000	170 per 1000 (101 to 285)	RR 0.94 (0.56 to 1.58)	269 (1 study ²)	⊕⊖⊖⊖ very low ^{6,9}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 no difference in survival with median overall survival from the date of the first randomization of 15.2 months (95%CI, 13.9-17.3 months) in the CRT group vs 16.5 months (95%CI, 14.5-18.5 months) in the CT group

2 Hammel et al. 2016 -2nd randomisation

3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.

4 no difference in progression-free survival from the date of the first randomization between CT group (median, 8.4 months; 95% CI, 7.8-9.4 months) and the CRT group (median, 9.9 months; 95%CI, 8.8-10.4 months)

5 Including neutrophils, platelets, haemoglobin, and febrile neutropenia

6 The quality of the evidence was downgraded of one point because the high risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the high risk of detection bias (no masking of outcome assessors)

7 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

8 Including Nausea, vomiting, diarrhoea, mucositis, acne, rash, dyspnoea, allergic reaction, fever, aspartate transaminase, bilirubin, and γ -glutamyl transpeptidase and creatinine. Nausea 3-4 grade toxicity differed: N/n=133/6; N/n=136/0; p=0.008

9 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

1
2
3

Table 171 Summary clinical evidence profile for chemoradiotherapy versus radiotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Radiotherapy	CRT				
Adverse effects - Grade 3/4 toxicities - Gastrointestinal	19 per 1000	6 per 1000 (0 to 146)	RR 0.32 (0.01 to 7.72)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Vomiting	75 per 1000	54 per 1000 (13 to 232)	RR 0.72 (0.17 to 3.08)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Diarrhoea	See comment	See comment	Not estimable	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Adverse effects - Grade 3/4 toxicities - Infection	0 per 1000	0 per 1000 (0 to 0)	RR 2.89 (0.12 to 69.47)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Haemorrhage	See comment	See comment	Not estimable	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Skin, mucous membrane	0 per 1000	0 per 1000 (0 to 0)	RR 4.82 (0.24 to 98.13)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Neurologic	19 per 1000	73 per 1000 (8 to 630)	RR 3.85 (0.45 to 33.38)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Respiratory	See comment	See comment	Not estimable	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Genitourinary	19 per 1000	18 per 1000 (1 to 283)	RR 0.96 (0.06 to 15.01)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Hematologic	94 per 1000	255 per 1000 (98 to 658)	RR 2.7 (1.04 to 6.97)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Liver	94 per 1000	37 per 1000 (8 to 179)	RR 0.39 (0.08 to 1.9)	108 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Adverse effects - Grade 3/4 toxicities - Other ⁴	19 per 1000	36 per 1000 (3 to 389)	RR 1.93 (0.18 to 20.63)	108 (1 study ¹)	⊕⊕⊕⊖ very low ^{2,3}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i> ¹ Cohen et al. 2005 ² The quality of the evidence was downgraded two points because of the unclear risk of selection bias (no sufficient details given about the randomisation method), the high of performance and detection bias (no blinding of patients/ care providers delivering the interventions; and no masking of outcome assessors). Furthermore no research protocol was published for this trial and no sample size calculations were provided. ³ Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs ⁴ Includes constipation, cardiac, fever.</p>						

1
2
3

Table 172 Summary clinical evidence profile for gemcitabine+erlonitib-based chemotherapy versus gemcitabine-based chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM-based CT	GEM+erlonitib-based CT				
Adverse effects - Grade 3/4 toxicities - haematological ¹	332 per 1000	388 per 1000 (302 to 498)	RR 1.17 (0.91 to 1.5)	442 (1 study ²)	⊕⊕⊖ ⊖ low ^{3,4}	
Adverse effects - Grade 3/4 toxicities - Non-haematological ¹	395 per 1000	399 per 1000 (316 to 501)	RR 1.01 (0.8 to 1.27)	442 (1 study ²)	⊕⊕⊖ ⊖ very low ^{3,5}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i> ¹ Including neutrophils, platelets, haemoglobin, and febrile neutropenia ² Hammel et al. 2016 -1st randomisation ³ The quality of the evidence was downgraded of one point because the high risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the high risk of detection bias (no masking of outcome assessors) ⁴ Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID ⁵ Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2
3

Table 173 Summary clinical evidence profile for FLEC-based chemotherapy versus gemcitabine-based chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM-based CT	FLEC-based CT				
Adverse effects - Grade 3/4 toxicities ¹	224 per 1000	479 per 1000 (289 to 795)	RR 2.14 (1.29 to 3.55)	138 (1 study ²)	⊕⊕⊖⊖ low ³	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio;</p> <p>1 Any 3-4 grade toxicity including: leukopenia, vomiting, diarrhoea, anaemia, thrombocytopenia, fever, mucositis, and gastrointestinal bleeding. 2 Cantore et al. 2005 3 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), the unclear risk of performance and detection bias (no details given in the text). Furthermore no research protocol was published for this trial and the required sample size (103 patients per) was not achieved</p>						

4
5
6

Table 174: Summary clinical evidence profile for gemcitabine-based chemotherapy + upmostat versus gemcitabine-based chemotherapy alone in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM-based CT	GEM-based CT + upmostat				
Adverse effects - Grade 3/4 toxicities - Patients with any grade 3/4 toxicity - GEM + 200mg upmostat	433 per 1000	568 per 1000 (338 to 949)	RR 1.31 (0.78 to 2.19)	60 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Adverse effects - Grade 3/4 toxicities - Patients with any grade 3/4 toxicity - GEM + 400mg upmostat	433 per 1000	667 per 1000 (416 to 1000)	RR 1.54 (0.96 to 2.47)	63 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio;</p> <p>1 Heinemann et al. 2013 2 The quality of the evidence was downgraded because of the high risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the high risk of detection bias (no masking of outcome assessors) 3 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</p>						

1
2
3

Table 175: Summary clinical evidence profile for radiotherapy + PR-350 radiosensitiser versus radiotherapy + placebo in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Radiotherapy + Placebo	Radiotherapy + PR-350 Radiosensitiser				
Objective Response - Effective response	217 per 1000	474 per 1000 (191 to 1000)	RR 2.18 (0.88 to 5.41)	42 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Overall survival ⁴	See comment	See comment	Not estimable ⁴	47 (1 study ¹)	⊕⊕⊖⊖ low ⁵	
Adverse effects - Grade 3/4 toxicities ⁶	40 per 1000	15 per 1000 (1 to 352)	RR 0.38 (0.02 to 8.8)	47 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,7}	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;*

1 Sunamura et al. 2004
2 The quality of the evidence was downgraded of two points because the potential risk of performance bias (no details about blinding of patients/ care providers delivering the interventions), the unclear risk of detection bias (no information provided in the text) and the unclear risk of selection bias (no details given about the randomisation and allocation methods). Furthermore no research protocol was published for this trial and no sample size calculations were provided.
3 Evidence was further downgraded by 1 due to serious imprecision as 95%CI crossed one default MID
4 The median survival period of the PR-350 group was 318.5 days and that of control group was 303.0 days (no difference between the 2 groups, p value not reported)
5 The quality of the evidence was downgraded of one because the unclear risk of selection bias (no details given about the randomisation and allocation methods). Furthermore no research protocol was published for this trial and no sample size calculations were provided.
6 All patients, except 1 from the control group, were determined to be negative for toxicity, and the PR-350 compound was considered to be safe
7 Evidence was further downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

4
5
6

Table 176 Summary clinical evidence profile for radiofrequency ablation as primary treatment versus radiofrequency ablation after other primary treatments in adults with unresectable non-metastatic locally advanced pancreatic cancer

Outcome s	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	RFA after other primary treatments	RFA as primary treatment				
Overall Survival ¹	See comment	See comment	Not estimable ¹	107 (1 study ²)	⊕⊕⊖⊖ low	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval;*

1 Median overall survival was shorter in the primary RFA group than in control group -RFA following any other primary treatment (14.7 versus 25.6 months; P = 0.004)
2 Cantore et al. 2012

7

1 11.1.5 Economic evidence

2 11.1.5.1 Systematic literature review

3 A literature review of published cost effectiveness analyses did not identify any relevant
4 studies for this topic.

5 11.1.5.2 Economic modelling

6 As there were potential implications for resource use associated with making
7 recommendations in this area and it was deemed a high economic priority by the committee
8 a network meta-analysis (NMA) and economic model was developed to aid in making
9 recommendations in this area. The full methods and results of the NMA and economic model
10 can be found in Chapter 13.

11 11.1.5.3 Overview of methods

12 A NMA was developed to consider the effectiveness of treatments for unresectable locally
13 advanced non-metastatic pancreatic cancer (LAPC). The NMA includes all studies, identified
14 by the accompanying clinical evidence review, which are phase II or phase III randomised
15 comparative trials that compared treatments which fit into the broad groups of:

- 16 • chemotherapy,
- 17 • chemoradiotherapy,
- 18 • combination of chemotherapy and chemoradiotherapy,
- 19 • radiotherapy
- 20 • biological therapies

21 with another treatment or to placebo, best supportive care or no treatment. Only studies
22 published in the year 2000 or later were included in the NMA. Studies were excluded from
23 the NMA if they included cancers other than pancreatic cancer or included populations that
24 had both locally advanced and metastatic disease and the locally advanced group were not
25 analysed and reported separately. Studies which considered a previously treated patient
26 group with responding or stable disease were also excluded from the NMA, unless they were
27 randomised before receiving treatment.

28 The systematic review identified 9 trials involving 1294 patients considering 12 different
29 treatments which were eligible for inclusion in the NMA. From the evidence reported it was
30 decided that 1 primary NMA considering overall survival (OS) could be created as this
31 outcome was reported by or could be derived from all trials. Two secondary NMAs were
32 created looking at progression-free survival and objective response. As these outcomes were
33 not reported by all trials not all studies could be included in these secondary NMAs. All three
34 NMAs had gemcitabine as the reference treatment. Outcomes were reported in terms of a
35 hazard ratio for overall survival and progression-free survival and in absolute terms and odds
36 ratio for objective response.

37 Results from the NMAs were used to inform an economic model again comparing the cost
38 effectiveness of treatments for unresectable LAPC. The model was a partitioned survival
39 analysis considering three states 'alive and not progressed', 'alive and progressed' and
40 'death'. The economic evaluation considered all treatments included in the primary NMA
41 apart from best supportive care, TNFerade and Upamostat. FOLFIRINOX was also added as
42 part of a secondary economic analysis despite no evidence being identified which matched
43 the inclusion criteria for it to be included in any of the NMAs or the clinical evidence review.
44 The clinical inputs for this intervention were informed by 1 systematic review and patient level
45 meta-analysis. The study identified 13 studies of 653 patients, 355 of which had LAPC. A
46 secondary analysis was included in the economic model to compare a change in treatment
47 for disease which had not progressed. Three interventions were considered for this economic

1 model. This covered all interventions that were investigated in studies which were solely
2 excluded from the NMA on account of being in people with responding or stable disease. The
3 model was configured so that change in treatment happened 12 weeks into the model.

4 The main outcome of the economic model was incremental cost per QALY compared to the
5 base case strategy. A NHS and PSS perspective was taken. The model had a time horizon
6 of three years which was deemed sufficient to capture the lifetime of the vast majority of the
7 cohort. All health outcomes were discounted at a rate of 3.5% per annum in line with the
8 [NICE guidelines manual](#).

9 All chemotherapy and radiotherapy were costed in line with the trial protocols identified in the
10 accompanying clinical evidence review. All patients in the cohort were assumed to complete
11 the regimens as per the trial protocols. Given the relatively low life expectancy of the model
12 cohort, the high probability of progression and the potential for serious adverse events this
13 assumption was likely to be an unrealistic assumption. However it was likely to bias against
14 interventions with the lower adverse events and higher overall survival and progression-free
15 survival i.e. the more clinically effective interventions.

16 The cost of chemotherapy drugs were taken from the Drugs and Pharmaceutical Electronic
17 Market Information Tool (eMIT). Where the cost of the chemotherapy regimens were not
18 available on eMIT the drugs were costed using the BNF (BNF 72). The costs of drug
19 procurement and administration were based on NHS reference costs. Radiotherapy and
20 surgery were also costed using NHS reference costs. For radiotherapy, the model cohort
21 were assumed to complete the regimen specified in the trial protocols. The cost of surgery
22 was estimated assuming a probability of complications of 39.6%.

23 No UK costs were identified for the specific adverse events considered by the economic
24 model. In the absence of this evidence it was assumed that the adverse events could be
25 treated during one face-to-face consultant follow-up meeting and was costed as such using
26 NHS reference costs. Only one cost was assumed for any combination of the four
27 considered adverse events. Again this assumption was likely to bias against the more
28 effective treatments.

29 Each of these health states were given a quality of life weighting based on those reported in
30 a previous economic evaluation of LAPC. This study used expert opinion to estimate a utility
31 weight of 0.68 for patients without progressed disease. Based on a review of the literature a
32 detriment of 0.12 was estimated for disease progression. This gave an estimate of 0.56 for
33 patients with progressed disease. These estimates were considered low quality and were
34 therefore given a wide range during PSA. In the base case analysis no quality of life
35 detriment was assigned to adverse events as these were considered to be straight forward to
36 treat and would only occur for a short period.

37 11.1.5.4 Results of the NMA and economic model

38 The studies included in the NMA had a serious risk of bias and the quality of inputs for the
39 model ranged from very low to good quality across all outcomes and comparisons, with most
40 of the evidence being of low quality. The NMAs for progression-free survival and objective
41 response had very wide credible intervals and all crossed the line of no effect therefore it was
42 difficult to conclude anything based solely on these. In all three analyses only one treatment,
43 chemoradiotherapy with gemcitabine, reported a hazard ratio or odds ratio, which had a 95%
44 credible interval that did not pass the line of no effect. This effect would have been
45 completely driven by 1 trial, Loehrer et al. 2012. The estimated hazard ratios and credible
46 intervals compared to gemcitabine for the treatments in the overall survival NMA are reported
47 in Table 177. Results of all other NMAs are reported in Chapter 13.

1 **Table 177: Estimated Hazard Ratios and Credible Intervals for overall survival**
2 **compared to gemcitabine**

Treatment	median (HR)	2.5%CrI	97.5%CrI	sd
Chemorad (GEM)	0.58	0.37	0.92	0.14
Chemorad (Gem) + Cisplatin	0.62	0.26	1.50	0.33
Chemorad (Gem) +CisplatinX2	0.63	0.26	1.56	0.34
Chemorad(5-fu)+TNFerade	0.69	0.30	1.59	0.34
Gem+400 Upamostat	0.75	0.49	1.15	0.17
FLEC	0.75	0.55	1.02	0.12
Chemorad(5-fu)	0.77	0.36	1.67	0.34
Gem+ 200 Upamostat	0.90	0.61	1.32	0.18
Best Supportive Care	0.99	0.29	3.41	0.84
Gemcitabine	1	Reference		
Gemcitabine + Erlotinib	1.19	0.98	1.45	0.12
Chemorad(5-fu) + Cisplatin	1.45	0.88	2.39	0.39

3 For the economic model in the primary base case analysis, considering only interventions
4 included in the NMA, chemoradiotherapy with gemcitabine came out as the preferred option
5 with an incremental net monetary benefit (INMB) of £786 when a £20,000 per QALY
6 willingness to pay was assumed. Full results of the primary base case analysis are shown in
7 Table 178.

8 **Table 178: Primary Base Case Analysis Results**

	Total Cost	Total QALY	Incremental Cost	Incremental QALYs	INMB £20k per QALY	INMB £50k per QALY
Gemcitabine	£3,157	0.80	Reference	Reference	Reference	Reference
Chemorad (Gem)	£6,713	1.01	£3,556	0.22	£786	£7,299
Chemorad (Gem) + Cisplatin	£6,397	0.98	£3,240	0.18	£374	£5,794
Chemorad (Gem) +CisplatinX2	£6,554	0.98	£3,397	0.18	£251	£5,724
Chemorad(5-fu)	£6,336	0.88	£3,179	0.08	-£1,601	£767
Chemorad(5-fu) + Cisplatin	£6,651	0.63	£3,494	-0.17	-£6,875	-£11,946
FLEC	£6,310	0.92	£3,152	0.12	-£753	£2,846
Gemcitabine + Erlotinib	£10,373	0.71	£7,216	-0.08	-£8,861	-£11,330

9 Considerable uncertainty around this conclusion was identified during probabilistic sensitivity
10 analysis with only a 14% probability of chemoradiotherapy with gemcitabine being the most
11 cost effective therapy at a £20,000 per QALY willingness to pay. Chemoradiotherapy with
12 gemcitabine and cisplatin becomes the preferred treatment option at the £20,000 per QALY
13 threshold with a 24% chance of being the preferred option. Chemoradiotherapy with
14 gemcitabine, the preferred choice in the deterministic analysis now has a 16% probability of
15 being the most cost effective option. Gemcitabine alone had a 17% probability of being the
16 preferred option in this scenario. As the only monotherapy in the analysis this corresponds to
17 an 83% probability that some form of combination therapy is the most cost effective option.
18 Again the plateauing lines for all interventions suggests there is significant uncertainty
19 around the clinical inputs for the model. This suggests that interventions were likely to be
20 cost effective if the regimens were effective at NICE's conventional thresholds. It was also

1 acknowledged that there may be scope to consider a higher £50,000 per QALY threshold
2 given the potential benefits and short life expectancy of the interventions and population. The
3 use of either a £20,000 or £50,000 threshold did not alter the conclusions of the model.

4 When FOLFIRINOX was considered this regimen came out as the preferred option with an
5 INMB of £5,992 compared to gemcitabine alone at a willingness to pay of £20,000 per QALY.
6 During probabilistic sensitivity analysis FOLFIRINOX had a >40% chance of being the
7 preferred option compared to all other regimens for all willingness to pay per QALY above
8 £15,000. During this analysis gemcitabine alone has a 3% and zero probability of being cost
9 effective for a willingness to pay per QALY of £20,000 and £50,000 respectively. Again, this
10 strongly suggests that a combination therapy approach is almost certainly the most cost
11 effective treatment option.

12 The secondary analysis around the use of chemoradiotherapy in stable and responding
13 patients predicted that the use of chemoradiotherapy with capecitabine in this patient
14 population would be cost effective. Again this result was robust to sensitivity analysis.

15 11.1.5.5 Conclusions

16 Of the interventions considered in the NMA, chemoradiotherapy with gemcitabine was the
17 preferred option in the deterministic results but chemoradiotherapy with gemcitabine and
18 cisplatin was the preferred option in the largest number of iterations in the PSA. However, it
19 never had a greater than 25% probability compared to all other interventions at a willingness
20 to pay per QALY values of £20,000 and £50,000 respectively. It was therefore again difficult
21 to strongly conclude for any intervention to be the preferred option from this group. The
22 economic model suggested that gemcitabine alone was unlikely to be the preferred option for
23 any conventionally used willingness to pay threshold suggesting that a form combination
24 therapy.

25 FOLFIRINOX was the preferred option in the when included in the analysis and in over 40%
26 of the iterations of the probabilistic sensitivity analysis. However, despite its prevalent usage
27 for treatment of LAPC across England no direct, randomised comparative evidence was
28 identified for this intervention. The comparability of FOLFIRINOX to other interventions
29 considered in the NMA and economic model is not strong. Whilst FOLFIRINOX was robust to
30 the probabilistic sensitivity analysis, as the overall survival and progression-free survival for
31 FOLFIRINOX were reduced closer to those of other interventions in the NMA, the strength of
32 this conclusion was largely reduced. Comparative randomised evidence comparing
33 FOLFIRINOX with other interventions in the NMA, would increase the comparability of this
34 intervention and the strength of any conclusions drawn. Additional randomised clinical trials
35 which would strengthen and increase the power of the NMA would likely reduce this
36 uncertainty and increase the strength of any recommendations made from the model.

37 It is difficult to draw comparisons between the NMA and economic model above with the
38 economic model used in [Guidance on the use of gemcitabine for the treatment of pancreatic
39 cancer](#) (TA25). The cost effectiveness evidence for TA25 compared 5-FU chemotherapy with
40 gemcitabine chemotherapy. The two economic evaluations for this technology assessment
41 were largely based around 1 RCT (Burris et al. 1997) comparing gemcitabine monotherapy
42 to 5-FU monotherapy in patients with either locally advanced or metastatic pancreatic
43 cancer. The models submitted estimated a cost per QALY for gemcitabine compared to 5-FU
44 of between £7,200 and £18,700. Given that 5-FU monotherapy was not a comparison
45 considered in the NMA and economic model above, due to an absence of identified trials,
46 direct comparisons of results could not be made. The costs of gemcitabine are also now
47 likely to be much reduced compared to those considered in TA25 given that the treatment is
48 now 'off patent' for this condition.

49 Despite the TA25 models not being strictly comparable to the economic model above the
50 most pertinent difference is that gemcitabine monotherapy is now very unlikely to be the
51 preferred option with the PSA estimating an almost 0% probability of being cost effective.

1 This however is compared to regimens that were not considered by TA25. However,
2 interventions that have a component of gemcitabine, in particular chemoradiation with
3 gemcitabine, perform favourably in the economic model.

4 **11.1.6 Evidence Statements for pair-wise comparisons**

5 **11.1.6.1 Different chemoradiotherapy regimens**

6 **Objective Response**

7 Very low quality evidence from 1 phase III RCT (n=46) showed no clinically important
8 difference between gemcitabine-based chemoradiotherapy (CRT) and paclitaxel-based
9 chemoradiotherapy about the relative probability of objective response rate (CR + PR) in
10 adults with unresectable non-metastatic locally advanced pancreatic cancer: RR 0.55 (95%
11 CI 0.15-1.92), where RR higher than 1 favours the gemcitabine-based CRT group.

12 **Resection rate**

13 No evidence was identified to inform this outcome.

14 **Progression Free Survival**

15 No evidence was identified to inform this outcome.

16 **Overall Survival**

17 Very low quality evidence from 1 phase III RCT (n=46) showed no clinically important
18 difference between gemcitabine-based CRT and paclitaxel-based CRT on survival rates in
19 adults with unresectable non-metastatic locally advanced pancreatic cancer: HR=0.98 (95%
20 CI 0.52-1.85), where RR higher than 1 favours the GEM-based CRT group.

21 **Adverse Events**

22 Very low and low quality evidence from 1 phase III RCT (n=46) showed no clinically
23 important difference between gemcitabine-based CRT and paclitaxel-based CRT about the
24 relative risk of grade 3/4 toxicities (including haematological and non-haematological) in
25 adults with unresectable non-metastatic locally advanced pancreatic cancer: RR 1.09 (95%
26 CI 0.36-3.27) and RR 1.96 (95% CI 1.18-3.28) respectively, where RR higher than 1 favours
27 the paclitaxel-based CRT group.

28 Very low and low quality evidence from 1 open label phase III RCT (n=34) showed no
29 clinically important difference between gemcitabine-based CRT and 5FU-based CRT about
30 the relative risk of grade 3/4 toxicities (including nausea, vomiting, anorexia, anaemia,
31 neutropenia, thrombocytopenia and GI bleeding) in adults with unresectable non-metastatic
32 locally advanced pancreatic cancer (relative effect not estimable).

33 Low quality evidence from 1 multicentre phase II RCT (n=60) showed a clinical important
34 difference favouring 5FU-based CRT in drug-related grade 3/4 toxicities (leukocytopenia and
35 thrombocytopenia) compared to gemcitabine/cisplatin-based CRT in adults with unresectable
36 non-metastatic locally advanced pancreatic cancer: RR 14.97 (95% CI 2.12-105.82) and RR
37 14.97 (95% CI 2.12-105.82) respectively.

38 Very low quality evidence from 1 multicentre phase II RCT (n=60) showed no clinically
39 important difference between 5FU-CRT and gemcitabine/cisplatin-CRT about the relative risk
40 of grade 3/4 toxicities (including non-haematological, lower GI tract, upper GI tract, anaemia)
41 in adults with unresectable non-metastatic locally advanced pancreatic cancer (relative effect
42 not estimable).

1 **Health Related Quality of Life**

2 Low quality evidence from 1 open label phase III RCT (n=34) showed a clinically important
3 difference favouring gemcitabine-based CRT on global quality of life scores compared to
4 5FU-based CRT in adults with unresectable non-metastatic locally advanced pancreatic
5 cancer: MD = 9.00 (95% CI 6.98-11.03).

6 **Pain control**

7 Very low quality evidence from 1 open label phase III RCT (n=34) showed a clinically
8 important difference favouring gemcitabine-based CRT on pain control compared to 5FU-
9 based CRT in adults with unresectable non-metastatic locally advanced pancreatic cancer:
10 RR 6.22 (95% CI 0.86-45.25).

11 **Patient experience and PROMS**

12 No evidence was identified to inform this outcome.

13 **11.1.6.2 Different chemoradiotherapy regimens after induction chemotherapy**

14 **Objective Response**

15 Very low quality evidence from 1 open label phase II RCT (n=71) showed no clinically
16 important difference between gemcitabine-CRT and capecitabine-CRT after induction
17 chemotherapy on the relative probability of objective response rate (CR + PR) in adults with
18 unresectable non-metastatic locally advanced pancreatic cancer: RR 0.85 (95% CI 0.35-
19 2.10), where RR higher than 1 favours the GEM-CRT group.

20
21 Very low quality evidence from 1 Phase II RCT (n=13) showed no clinically important
22 difference between CRT + cetuximab and CRT alone after induction chemotherapy on the
23 relative probability of objective response rate (CR + PR) in adults with unresectable non-
24 metastatic locally advanced pancreatic cancer: RR 0.50 (95% CI 0.06-4.15), where RR
25 higher than 1 favours the CRT + cetuximab group.

26 **Resection rate**

27 No evidence was identified to inform this outcome.

28 **Progression Free Survival**

29 Moderate quality evidence from 1 open label phase II RCT (n=72) showed no clinically
30 important difference between gemcitabine-CRT and capecitabine-CRT after induction
31 chemotherapy on time to progression rates in adults with unresectable non-metastatic locally
32 advanced pancreatic cancer: HR=0.60 (95% CI 0.32-1.12), where HR higher than 1 favours
33 the gemcitabine-CRT arm.

34 **Overall Survival**

35 Moderate quality evidence from 1 open label phase II RCT (n=72) indicates that
36 capecitabine-CRT after induction chemotherapy is associated with a clinically important
37 difference in overall survival compared to gemcitabine-CRT after induction chemotherapy in
38 adults with unresectable non-metastatic locally advanced pancreatic cancer: HR=0.39 (95%
39 CI 0.18-0.85)

40 Low quality evidence from 1 phase II RCT (n=13) showed no clinically important difference
41 between CRT + cetuximab and CRT alone after induction chemotherapy on survival rates in
42 adults with unresectable non-metastatic locally advanced pancreatic cancer (relative effect
43 not estimable).

1 **Adverse Events**

2 Very low and low quality evidence from 1 open label phase II RCT (n=72) showed no
3 clinically important difference between gemcitabine-CRT and capecitabine-CRT after
4 induction chemotherapy on the relative risk of grade 3/4 toxicities (including haematological
5 and non-haematological toxicities) in adults with unresectable non-metastatic locally
6 advanced pancreatic cancer: RR 13.46 (95% CI 0.8-227.22) and 2.24 (95% CI 0.77-6.48)
7 respectively, where RR less than 1 favours the gemcitabine-CRT arm.

8 Very low and low quality evidence from 1 phase II RCT (n=13) showed no clinically important
9 difference between CRT + cetuximab and CRT alone after induction chemotherapy on
10 relative risk of grade 3/4 toxicities (including hyponatremia, fatigue and abdominal pain) in
11 adults with unresectable non-metastatic locally advanced pancreatic cancer: RR 0.33 (95%
12 CI 0.02-6.86) for all outcomes, where RR less than 1 favours the CRT + cetuximab group.

13 **Health Related Quality of Life**

14 Low quality evidence from 1 open label phase II RCT (n=48) showed no clinically important
15 difference between gemcitabine-CRT and capecitabine-CRT after induction chemotherapy
16 on the improvement of quality of life (measured as mean of the EORTC QLQ-C30) in adults
17 with unresectable non-metastatic locally advanced pancreatic cancer (relative effect not
18 estimable).

19 **Pain control**

20 No evidence was identified to inform this outcome.

21 **Patient experience and PROMS**

22 No evidence was identified to inform this outcome.

23 **11.1.6.3 Chemoradiotherapy versus best supportive care**

24 **Objective Response**

25 No evidence was identified to inform this outcome.

26 **Resection rate**

27 No evidence was identified to inform this outcome.

28 **Progression Free Survival**

29 No evidence was identified to inform this outcome.

30 **Overall Survival**

31 No evidence was identified to inform this outcome.

32 **Adverse Events**

33 No evidence was identified to inform this outcome.

34 **Health Related Quality of Life**

35 Low quality evidence from 1 phase III RCT (n=31) indicates a clinically important difference
36 favouring CRT on global quality of life scores (measured as mean of the Karnofsky

1 performance status) compared to best supportive care [no CRT] in adults with unresectable
2 non-metastatic locally advanced pancreatic cancer: MD = 11.60 (95% CI 6.61-15.69).

3 **Pain control**

4 No evidence was identified to inform this outcome.

5 **Patient experience and PROMS**

6 No evidence was identified to inform this outcome.

7 **11.1.6.4 Chemoradiotherapy versus chemoradiotherapy followed by chemotherapy**

8 **Objective Response**

9 No evidence was identified to inform this outcome.

10 **Resection rate**

11 No evidence was identified to inform this outcome.

12 **Progression Free Survival**

13 No evidence was identified to inform this outcome.

14 **Overall Survival**

15 No evidence was identified to inform this outcome.

16 **Adverse Events**

17 Low quality evidence from 1 multicentre phase II RCT (n=56) showed a clinically important
18 difference favouring CRT [5FU-CRT] on the relative risk of drug-related grade 3/4 toxicities
19 (leukocytopenia and thrombocytopenia) compared to CRT followed by chemotherapy
20 [gemcitabine/cisplatin-CRT followed by gemcitabine chemotherapy] in adults with
21 unresectable non-metastatic locally advanced pancreatic cancer: RR 18.26 (95% CI 2.60-
22 128.02) and 10.74 (95% CI 1.47-78.39) respectively, where RR less than 1 favours the CRT
23 followed by chemotherapy arm.

24 Very low quality evidence from 1 multicentre phase II RCT (n=56) showed no clinically
25 important difference between CRT [5FU-CRT] and CRT followed by chemotherapy
26 [gemcitabine/cisplatin-CRT followed by gemcitabine chemotherapy] on the relative risk of
27 grade 3/4 toxicities (including non-haematological, lower GI tract, upper GI tract, anaemia) in
28 adults with unresectable non-metastatic locally advanced pancreatic cancer.

29 **Health Related Quality of Life**

30 No evidence was identified to inform this outcome.

31 **Pain control**

32 No evidence was identified to inform this outcome.

33 **Patient experience and PROMS**

34 No evidence was identified to inform this outcome.

1 11.1.6.5 Chemoradiotherapy + R115777 versus chemoradiotherapy alone

2 **Objective Response**

3 No evidence was identified to inform this outcome.

4 **Resection rate**

5 No evidence was identified to inform this outcome.

6 **Progression Free Survival**

7 No evidence was identified to inform this outcome.

8 **Overall Survival**

9 Moderate quality evidence from 1 phase II RCT (n=185) showed no clinically important
10 difference between CRT+R115777 and CRT alone in survival rates after induction
11 chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic cancer
12 (relative effect not estimable).

13 **Adverse Events**

14 Very low and low quality evidence from 1 phase II RCT (n=185) showed no clinically
15 important difference between CRT+R115777 and CRT alone on the relative risk of grade 3/4
16 toxicities (including allergy/immunology, blood/bone marrow, cardiovascular, coagulation,
17 constitutional, endocrine, and gastrointestinal) in adults with unresectable non-metastatic
18 locally advanced pancreatic cancer: RR 0.65 (95% CI 0.11-3.77); RR 1.39 (95% CI 0.96-2.0);
19 RR 2.26 (95% CI 0.6-8.47); RR 0.32 (95% CI 0.01-7.82); RR 1.69 (95% CI 0.75-3.84); RR
20 0.32 (95% CI 0.01-7.82); and RR 1.12 (95% CI 0.77-1.63) respectively, where RR less than
21 1 favours the CRT+R115777 arm.

22 No grade 3/4 toxicities were reported for the following outcomes in both intervention groups:
23 auditory/hearing, cardiovascular (arrhythmia), dermatology/skin, and ocular/visual/
24 renal/genitourinary.

25 Moderate quality evidence from 1 phase II RCT (n=185) suggests a clinically important
26 difference favouring CRT+R115777 on the relative risk of drug-related grade 3/4 toxicities
27 (haemorrhage) compared to CRT alone: RR 0.06 (95% CI 0.02-0.26).

28 **Health Related Quality of Life**

29 No evidence was identified to inform this outcome.

30 **Pain control**

31 No evidence was identified to inform this outcome.

32 **Patient experience and PROMS**

33 No evidence was identified to inform this outcome.

34 11.1.6.6 Chemoradiotherapy + TNFerade versus chemoradiotherapy alone

35 **Objective Response**

36 No evidence was identified to inform this outcome.

1 **Resection rate**

2 No evidence was identified to inform this outcome.

3 **Progression Free Survival**

4 No evidence was identified to inform this outcome.

5 **Overall Survival**

6 No evidence was identified to inform this outcome.

7 **Adverse Events**

8 Very low quality evidence from 1 open label phase III RCT (n=304) showed no clinically
9 important difference between CRT + TNFerade and CRT alone on the relative risk of grade
10 3/4 toxicities (including gastrointestinal, haematological, and non-
11 gastrointestinal/haematological) in adults with unresectable non-metastatic locally advanced
12 pancreatic cancer: RR 1.64 (95% CI 0.85-3.16); RR 0.90 (95% CI 0.64-1.28); and RR 1.51
13 (95% CI 0.67-3.41) respectively, where RR less than 1 favours the CRT + TNFerade arm.

14 **Health Related Quality of Life**

15 No evidence was identified to inform this outcome.

16 **Pain control**

17 No evidence was identified to inform this outcome.

18 **Patient experience and PROMS**

19 No evidence was identified to inform this outcome.

20 **11.1.6.7 Chemoradiotherapy versus chemotherapy**

21 **Objective Response**

22 No evidence was identified to inform this outcome.

23 **Resection rate**

24 No evidence was identified to inform this outcome.

25 **Progression Free Survival**

26 No evidence was identified to inform this outcome.

27 **Overall Survival**

28 No evidence was identified to inform this outcome.

29 **Adverse Events**

30 Low quality evidence from 1 phase III RCT (n=71) showed a clinically important difference
31 favouring CRT on the relative risk of drug-related grade 3/4 toxicities (fatigue) compared to
32 chemotherapy in adults with unresectable non-metastatic locally advanced pancreatic
33 cancer: RR 5.66 (95% CI 1.35-33.68)

1 Very low quality evidence from 1 phase III RCT (n=71) showed no clinically important
2 difference between CRT and chemotherapy on the relative risk of grade 3/4 toxicities
3 (including haemoglobin, leukocytes, neutrophils, nausea, vomiting, hypokalaemia, and
4 anorexia) in adults with unresectable non-metastatic locally advanced pancreatic cancer: RR
5 3.09 (95% CI 0.67-14.25); RR 2.26 (95% CI 0.88-5.83); RR 1.12 (95% CI 0.60-2.09); RR
6 3.43 (95% CI 1.03-11.40); RR 3.09 (95% CI 0.91-10.44); RR 2.06 (95% CI 0.40-10.51); and
7 RR 6.18 (95% CI 0.78-48.64) respectively, where RR less than 1 favours the CRT arm.

8 **Health Related Quality of Life**

9 Low and very low quality evidence from 1 phase III RCT (n=71) showed a clinically important
10 difference favouring CRT on the improvement of global quality of life scores compared to
11 chemotherapy at 6 weeks follow-up in adults with unresectable non-metastatic locally
12 advanced pancreatic cancer: MD = -12.20 (95% CI -17.98 to -6.42, measured as mean
13 difference of changes from baseline).

14 The same study showed no clinically important difference between CRT and chemotherapy
15 on the improvement in global quality of life scores (measured as mean difference of changes
16 from baseline) at 16 week and 9 month follow-up in adults with unresectable non-metastatic
17 locally advanced pancreatic cancer: MD = -3.30 (95% CI -9.08 to 2.48) and 2.70 (95% CI -
18 3.08 to 8.48), where MD less than 1 favours the GEM-CRT arm.

19 **Patient experience and PROMS**

20 No evidence was identified to inform this outcome.

21 **11.1.6.8 Chemotherapy versus chemoradiotherapy after induction chemotherapy**

22 **Objective Response**

23 No evidence was identified to inform this outcome.

24 **Resection rate**

25 No evidence was identified to inform this outcome.

26 **Progression Free Survival**

27 Moderate quality evidence from 1 open label phase III RCT (n=368) showed no clinically
28 important difference between chemotherapy and CRT after induction chemotherapy on time
29 to progression rates in adults with unresectable non-metastatic locally advanced pancreatic
30 cancer: HR=0.78 (95% CI 0.61-1.00), where HR higher than 1 favours the CT arm.

31 **Overall Survival**

32 Moderate quality evidence from 1 open label phase III RCT (n=368) showed no clinically
33 important difference between chemotherapy and CRT after induction chemotherapy on
34 overall survival rates in adults with unresectable non-metastatic locally advanced pancreatic
35 cancer: HR=1.03 (95% CI 0.79-1.14), where HR higher than 1 favours the CT arm.

36 **Adverse Events**

37 Very low and low quality evidence from 1 open label phase III RCT (n=368) showed no
38 clinically important difference between chemotherapy and CRT after induction chemotherapy
39 on the relative risk of grade 3/4 toxicities (including haematological and non-haematological)
40 in adults with unresectable non-metastatic locally advanced pancreatic cancer: RR = 2.93

1 (95% CI 0.97-8.87) and 0.94 (95% CI 0.56-1.58), where RR less than 1 favours the CRT
2 arm.

3 **Health Related Quality of Life**

4 No evidence was identified to inform this outcome.

5 **Pain control**

6 No evidence was identified to inform this outcome.

7 **Patient experience and PROMS**

8 No evidence was identified to inform this outcome.

9 **11.1.6.9 Chemoradiotherapy versus radiotherapy**

10 **Objective Response**

11 No evidence was identified to inform this outcome.

12 **Resection rate**

13 No evidence was identified to inform this outcome.

14 **Progression Free Survival**

15 No evidence was identified to inform this outcome.

16 **Overall Survival**

17 No evidence was identified to inform this outcome.

18 **Adverse Events**

19 Very low quality evidence from 1 open label phase III RCT (n=114) showed no clinically
20 important difference between CRT and radiotherapy on the relative risk of grade 3/4 toxicities
21 (including gastrointestinal, vomiting, infection, skin, mucous, neurologic, genitourinary,
22 hematologic, liver, constipation, cardiac, and fever) in adults with unresectable non-
23 metastatic locally advanced pancreatic cancer: RR 0.32 (95% CI 0.01-7.72); RR 0.72 (95%
24 CI 0.17-3.08); RR 2.89 (95% CI 0.12-69.47); RR 4.82 (95% CI 0.24-98.13); RR 3.85 (95% CI
25 0.45-33.38); RR 0.96 (95% CI 0.06-15.01); RR 2.70 (95% CI 1.04-6.97); RR 0.39 (95% CI
26 0.08-1.90) and RR 1.93 (95% CI 0.18-20.63) respectively, where RR less than 1 favours the
27 CRT arm.

28 No grade 3/4 toxicities were reported for the following outcomes in both intervention groups:
29 diarrhoea, haemorrhage, and respiratory system.

30 **Health Related Quality of Life**

31 No evidence was identified to inform this outcome.

32 **Pain control**

33 No evidence was identified to inform this outcome.

1 **Patient experience and PROMS**

2 No evidence was identified to inform this outcome.

3 **31.1.6.10 Different chemotherapy regimens**

4 **Objective Response**

5 No evidence was identified to inform this outcome.

6 **Resection rate**

7 No evidence was identified to inform this outcome.

8 **Progression Free Survival**

9 No evidence was identified to inform this outcome.

10 **Overall Survival**

11 No evidence was identified to inform this outcome.

12 **Adverse Events**

13 Very low quality evidence from 1 open label phase III RCT (n=443) showed no clinically
14 important difference between the gemcitabine chemotherapy and gemcitabine/erlotinib
15 chemotherapy on the relative risk of grade 3/4 toxicities (including haematological and non-
16 haematological) in adults with unresectable non-metastatic locally advanced pancreatic
17 cancer: RR = 1.17 (95% CI 0.91-1.5) and 1.01 (95% CI 0.8-1.27) respectively, where RR less
18 than 1 favours the gemcitabine/erlotinib chemotherapy arm.

19 Low quality evidence from 1 phase III RCT (n=138) showed a clinically important difference
20 favouring gemcitabine chemotherapy on drug-related grade 3/4 toxicities (including
21 leukopenia, vomiting, diarrhoea, anaemia, thrombocytopenia, fever, microsites, and
22 gastrointestinal bleeding) compared to FLEC chemotherapy in adults with unresectable non-
23 metastatic locally advanced pancreatic cancer: RR = 2.14 (95% CI 1.29-3.55).

24 **Health Related Quality of Life**

25 No evidence was identified to inform this outcome.

26 **Pain control**

27 No evidence was identified to inform this outcome.

28 **Patient experience and PROMS**

29 No evidence was identified to inform this outcome.

30 **31.1.6.11 Gemcitabine- based chemotherapy + upmostat versus gemcitabine-based
31 chemotherapy alone**

32 **Objective Response**

33 No evidence was identified to inform this outcome.

1 **Resection rate**

2 No evidence was identified to inform this outcome.

3 **Progression Free Survival**

4 No evidence was identified to inform this outcome.

5 **Overall Survival**

6 No evidence was identified to inform this outcome.

7 **Adverse Events**

8 Very low and low quality evidence from 1 open label phase II RCT (n=95) showed no
9 clinically important difference between gemcitabine-based chemotherapy and gemcitabine-
10 based chemotherapy + upmostat on the relative risk of grade 3/4 toxicities (any type) in
11 adults with unresectable non-metastatic locally advanced pancreatic cancer: RR = 1.31 (95%
12 CI 0.78-2.19)- 200mg upmostat and RR 1.54 (95% CI 0.96-2.74)- 400mg upmostat, where
13 RR less than 1 favours the gemcitabine-based chemotherapy + upmostat arm.

14 **Health Related Quality of Life**

15 No evidence was identified to inform this outcome.

16 **Pain control**

17 No evidence was identified to inform this outcome.

18 **Patient experience and PROMS**

19 No evidence was identified to inform this outcome.

20**1.1.6.12 Radiotherapy + PR-350 Radiosensitiser versus Radiotherapy + Placebo**

21 **Objective Response**

22 Very low quality evidence from 1 double-blind phase III RCT (n=48) showed no clinically
23 important difference between radiotherapy + PR-350 and radiotherapy + placebo on the
24 relative probability of objective response rate (CR + PR) in adults with unresectable non-
25 metastatic locally advanced pancreatic cancer: RR 2.18 (95% CI 0.88-5.41), where RR
26 higher than 1 favours the radiotherapy + PR-350 group.

27 **Resection rate**

28 No evidence was identified to inform this outcome.

29 **Progression Free Survival**

30 No evidence was identified to inform this outcome.

31 **Overall Survival**

32 Low quality evidence from 1 double-blind phase III RCT (n=48) showed no clinically
33 important difference between radiotherapy + PR-350 and radiotherapy + placebo on survival
34 rates in adults with unresectable non-metastatic locally advanced pancreatic cancer (relative
35 effect not estimable).

1 **Adverse Events**

2 Very low quality evidence from 1 double-blind phase III RCT (n=48) showed no clinically
3 important difference between radiotherapy + PR-350 and radiotherapy + placebo on the
4 relative risk of grade 3/4 toxicities (including any type) in adults with unresectable non-
5 metastatic locally advanced pancreatic cancer: RR 0.38 (95% CI 0.02-8.80), where RR
6 higher than 1 favours the radiotherapy + PR-350 group.

7 **Health Related Quality of Life**

8 No evidence was identified to inform this outcome.

9 **Pain control**

10 No evidence was identified to inform this outcome.

11 **Patient experience and PROMS**

12 No evidence was identified to inform this outcome.

13**1.1.6.13** **Radiofrequency ablation (RFA) as primary treatment versus RFA after other primary**
14 **treatments.**

15 **Objective Response**

16 No evidence was identified to inform this outcome.

17 **Resection rate**

18 No evidence was identified to inform this outcome.

19 **Progression Free Survival**

20 No evidence was identified to inform this outcome.

21 **Overall Survival**

22 Low quality evidence from 1 prospective cohort study (n=107) indicates a clinical important
23 difference favouring RFA as primary treatment on overall survival compared to RFA following
24 any other primary treatment (relative effect not estimable).

25 **Adverse Events**

26 No evidence was identified to inform this outcome.

27 **Health Related Quality of Life**

28 No evidence was identified to inform this outcome.

29 **Pain control**

30 No evidence was identified to inform this outcome.

31 **Patient experience and PROMS**

32 No evidence was identified to inform this outcome.

1 **11.1.7 Recommendations**

2 **50. Offer systemic combination chemotherapy to people with locally advanced**
3 **pancreatic cancer who are well enough to tolerate it.**

4 **51. Consider gemcitabine for people with locally advanced pancreatic cancer who are**
5 **not well enough to tolerate combination chemotherapy.**

6 **52. When using chemoradiotherapy, consider capecitabine as the radiosensitiser.**

7 **11.1.8 Evidence to recommendations**

8 **11.1.8.1 Relative value placed on the outcomes considered**

9 Overall survival, progression free survival, objective response, resection rate, adverse
10 events, health related quality of life, pain control, patient experience and PROMS were
11 considered to be the critical outcomes for this question. Objective response was reported by
12 eleven studies, progression free survival was reported by nine studies and overall survival
13 was reported by sixteen studies.

14 **11.1.8.2 Quality of evidence**

15 **Network meta-analysis (NMA)**

16 Given the variation in practice for this topic and the potential for a significant resource impact
17 from any recommendations, a network meta-analysis (NMA) was developed to help inform
18 recommendations.

19 All identified phase III and phase II randomised clinical trials in pure locally advanced
20 pancreatic cancer populations were considered in the network meta-analysis as long as the
21 intervention in a given trial was also considered by another study and could therefore form
22 part of the network. Studies where the patient group had received induction chemotherapy
23 and were randomised only if they had responding or stable disease, were excluded. Three
24 NMAs were built based on the outcomes of overall survival, progression free survival and
25 objective response with gemcitabine monotherapy being used as the reference standard.
26 The committee noted that most of the studies included in the NMA had a serious risk of bias
27 and that the quality of inputs for the economic model ranged from very low to good quality
28 across all outcomes and comparisons, with most of the evidence being of low quality.

29 The committee noted that the results of the NMA for progression free survival and objective
30 response had very wide credible intervals and all crossed the line of no effect. They therefore
31 agreed that no conclusions could be drawn from these outcomes.

32 The committee also noted that the results of the NMA for overall survival had 1 intervention,
33 chemoradiotherapy with Gemcitabine, for which the 95% credible intervals did not pass the
34 line of no effect (HR=1). They also noted that 1 RCT (Loehrer 2011) which was identified as
35 having a serious risk of bias was independently driving the results of the NMA in this way. All
36 other credible intervals crossed 1, although the credible intervals were much narrower than
37 for the other NMAs. The committee agreed that the NMA considering overall survival would
38 be somewhat useful for informing recommendations, but they noted great uncertainty and
39 that caution in interpreting results was needed.

40 Usually this would mean making a weaker recommendation, but the committee agreed that
41 because a very high proportion of people with locally advanced disease will go on to develop
42 metastatic disease unless they have treatment, a stronger recommendation should be made.

1 The committee also noted that chemotherapy used in the identified studies would no longer
2 be considered standard for either metastatic or locally advanced pancreatic cancer. There
3 were no randomised clinical trials of FOLFIRINOX, which is frequently offered as standard of
4 care, so it was not possible for this intervention to be included in the NMA. It was agreed that
5 FOLFIRINOX should be investigated as a secondary economic analysis instead. The clinical
6 data for FOLFIRINOX came from Suler 2016, which was a non-comparative patient level
7 meta-analysis of 13 studies. The committee noted that this is a lower level of evidence than
8 the RCT data on other interventions that went into the NMA, so used caution when
9 interpreting the results. The committee noted that FOLFIRINOX is only suitable for fit
10 patients.

11 **Pairwise comparison**

12 Pairwise comparisons were conducted for outcomes in the review question that were not
13 covered by the NMA. Pairwise comparisons were also conducted for studies which did not
14 meet the inclusion criteria for the NMA. The evidence for the outcomes of pairwise
15 comparisons ranged from very low to moderate quality across all outcomes and
16 comparisons, with most of the evidence being either very low or low quality. The committee
17 noted that the overall trend being reported by the evidence was that more chemotherapy (in
18 the form of combination regimens) was associated with more adverse events.

19 Very little evidence was found on ablative therapies so the committee agreed not to make
20 any recommendations for clinical practice about this intervention. They did not recommend
21 further research on any of the ablative therapies investigated in this question as they did not
22 think they were a priority for research funding.

23 **11.1.8.3 Consideration of clinical benefits and harms**

24 Based on the results of the NMA and economic analysis the committee agreed that
25 combination chemotherapy was more clinically effective than monotherapy in terms of overall
26 survival and the most cost effective option.

27 The health economic analysis showed FOLFIRINOX was cost effective but there was
28 uncertainty about the clinical data used to inform the model. Therefore they agreed not to
29 make a specific recommendation on FOLFIRINOX but noted that the offer of combination
30 chemotherapy allowed FOLFIRINOX to be considered. Given the potential toxicity with
31 combination chemotherapy and difficulty for less fit patients to tolerate it, the committee also
32 recommended gemcitabine as an option for people who are unlikely to tolerate combination
33 therapy.

34 The committee noted that consolidation chemoradiotherapy was relatively safe, improved
35 local control and may be cost effective but that survival was not superior to chemotherapy
36 alone. Therefore they agreed that they were unable to make a specific recommendation on
37 the use of consolidation chemoradiotherapy. Based on data from pairwise comparisons that
38 there was improved overall survival and less haematological toxicity with capecitabine-based
39 chemoradiotherapy compared with gemcitabine-based chemoradiotherapy, the committee
40 agreed to recommend capecitabine as the radiosensitiser for people in whom the decision to
41 offer chemoradiotherapy has been made.

42 **11.1.8.4 Consideration of economic benefits and harms**

43 The estimates and distributions from the NMA were used to inform a bespoke economic
44 model. The committee raised concerns that there were important elements for this topic not
45 considered by the NMA, most notably the role of chemoradiotherapy in patients with stable
46 and responding disease and the use of FOLFIRINOX (for which no randomised evidence
47 was identified and thus was excluded from the NMA). Two secondary economic analyses
48 were therefore performed to consider these.

1 In the primary base case analysis, considering only interventions included in the NMA,
2 chemoradiotherapy with gemcitabine came out as the preferred option with an incremental
3 net monetary benefit (INMB) of £786 when a £20,000 per QALY willingness to pay was
4 assumed. However, considerable uncertainty around this conclusion was identified during
5 probabilistic sensitivity analysis with only a 14% probability of being the most cost effective
6 therapy at a £20,000 per QALY willingness to pay. Above a willingness to pay of £10,000 per
7 QALY there was never more than a few percentage difference in being the preferred option
8 between the top four therapies. It was therefore difficult for the committee to conclude which
9 regimen was most cost effective.

10 When FOLFIRINOX was considered, this regimen came out as the preferred option with an
11 INMB of £5,992 compared to gemcitabine alone. During probabilistic sensitivity analysis
12 FOLFIRINOX had a >40% chance of being the preferred option compared to all other
13 regimens for all willingness to pay per QALY above £15,000. The committee noted that this
14 was based on observational data and that the likely associated biases would mean that
15 inputs into the economic model would overestimate the true effectiveness of FOLFIRINOX.
16 However, these results were robust to deterministic sensitivity analyses which reduced the
17 effectiveness of FOLFIRINOX. The committee therefore agreed, based on the results of the
18 economic model that whilst FOLFIRINOX appeared to be cost effective, the clinical data was
19 very weak and therefore did not make a recommendation for this intervention.

20 The secondary analysis around the use of chemoradiotherapy in stable and responding
21 patients predicted that the use of chemoradiotherapy with capecitabine in this patient
22 population would be cost effective. Again this result was robust to sensitivity analysis. The
23 committee noted that from the clinical evidence that whilst consolidation chemoradiotherapy
24 appeared to be relatively safe and improve local control, that survival was not superior to
25 chemotherapy alone. Therefore they agreed that they were unable to make a specific
26 recommendation on the use of consolidation chemoradiotherapy.

27 It was also acknowledged by the committee that most of the uncertainty in the model was
28 driven by clinical factors with the lines of the cost-effectiveness acceptability curve running
29 almost horizontal for values above a willingness to pay of £15,000 per QALY. This suggested
30 that interventions were likely to be cost effective if the regimens were effective at NICE's
31 conventional thresholds. It was also acknowledged that there may be scope to consider a
32 higher £50,000 per QALY threshold given the potential benefits and short life expectancy of
33 the interventions and population. Whilst the use of either a £20,000 or £50,000 threshold did
34 not alter the conclusions, it does strengthen the argument that the recommendations made
35 around the model are cost effective.

36 The committee agreed that there was unlikely to be any significant resource impact as a
37 result of the recommendations made since the interventions are already widely used as
38 treatment in this patient group.

39 **11.1.8.5 Other considerations**

40 The committee noted that there was existing NICE Interventional Procedure guidance on the
41 use of irreversible electroporation for treating pancreatic cancer (IPG579). It concluded that
42 current evidence on its safety and efficacy is inadequate in quantity and quality, and
43 therefore recommended that this procedure should only be used in the context of research.
44 Consequently this intervention was not investigated by this guideline and the committee were
45 not able to make any recommendations on it.

46 **11.1.9 References**

47 Cantore M, Fiorentini G, Luppi G et al. (2004) Gemcitabine versus FLEC regimen given intra-
48 arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase

- 1 Ill trial of the Italian Society for Integrated Locoregional Therapy in Oncology. *Journal of*
2 *Chemotherapy* 16(6): 589-94
- 3 Cantore M, Girelli R, Mambrini A et al. (2012) Combined modality treatment for patients with
4 locally advanced pancreatic adenocarcinoma. *British Journal of Surgery* 99(8): 1083-8
- 5 Chauffert B, Mornex F, Bonnetain F et al. (2008) Phase III trial comparing intensive induction
6 chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by
7 maintenance gemcitabine with gemcitabine alone for locally advanced unresectable
8 pancreatic cancer Definitive results of the 2000-01 FFCD/SFRO study. *Annals of Oncology*
9 19(9): 1592-9
- 10 Chung HW, Bang SM, Park SW et al. (2004) A prospective randomized study of gemcitabine
11 with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for
12 locally advanced pancreatic cancer. *International Journal of Radiation*Oncology*Biology**
13 *Physics* 60(5): 1494-501
- 14 Cohen SJ, Dobelbower R Jr et al. (2005) A randomized phase III study of radiotherapy alone
15 or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of
16 the pancreas: Eastern Cooperative Oncology Group study E8282. *International Journal of*
17 *Radiation*Oncology*Biology* Physics* 62(5): 1345-50
- 18 Hammel P, Huguet F, van Laethem JL et al. (2016) Effect of Chemoradiotherapy vs
19 Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled
20 After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical
21 Trial. *JAMA* 315(17): 1844-53
- 22 Heinemann V, Ebert MP, Laubender RP et al. (2013) Phase II randomised proof-of-concept
23 study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine
24 compared with gemcitabine alone in patients with non-resectable, locally advanced
25 pancreatic cancer. *British Journal of Cancer* 108(4): 766-70
- 26 Herman JM, Wild AT, Wang H et al. (2013) Randomized phase III multi-institutional study of
27 TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer:
28 final results. *Journal of Clinical Oncology* 31(7): 886-94
- 29 Hurt CN, Mukherjee S, Bridgewater J et al. (2015) Health-Related Quality of Life in SCALOP,
30 a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally
31 Advanced Pancreatic Cancer. *International Journal of Radiation*Oncology*Biology*Physics.*
32 93(4): 810-8
- 33 Hurt CN, Falk S, Crosby T et al. (2017) Long-term results and recurrence patterns from
34 SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-chemoradiation for
35 locally advanced pancreatic cancer. *British Journal of Cancer* 116(10): 1264-1270
- 36 Khan K, Cunningham D, Peckitt C et al. (2016) miR-21 expression and clinical outcome in
37 locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux,
38 radiotherapy and UFT (PERU) trial. *Oncotarget* 7(11): 12672-81
- 39 Li CP, Chao Y, Chi KH et al. (2003) Concurrent chemoradiotherapy treatment of locally
40 advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled
41 study. *International Journal of Radiation*Oncology*Biology*Physics* 57(1): 98-104
- 42 Loehrer PJ Sr, Feng Y, Cardenes H et al. (2011) Gemcitabine alone versus gemcitabine plus
43 radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative
44 Oncology Group trial. *Journal of Clinical Oncology* 29(31): 4105-12
- 45 Mukherjee S, Hurt CN, Bridgewater J et al. (2013) Gemcitabine-or capecitabine-
46 chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre,
47 randomised, phase 2 trial. *Lancet Oncology* 14(4): 317-26

- 1 Rich TA, Winter K, Safran H et al. (2012) Weekly paclitaxel, gemcitabine, and external
2 irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally
3 advanced pancreatic cancer. *OncoTargets and Therapy* 5: 161-70
- 4 Shinci H, Takao S, Noma H et al. (2002) Length and quality of survival after external-beam
5 radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable
6 pancreatic cancer. *International Journal of Radiation*Oncology*Biology*Physics* 53(1): 146-
7 50
- 8 Sunamura M, Karasawa K, Okamoto A et al. & PR-350 study group (2004) Phase III trial of
9 radiosensitiser PR-350 combined with intraoperative radiotherapy for the treatment of locally
10 advanced pancreatic cancer. *Pancreas* 28(3): 330-4
- 11 Wilkowski R, Boeck S, Ostermaier S et al. (2009) Chemoradiotherapy with concurrent
12 gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin
13 vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced
14 pancreatic cancer--a multi-centre randomised phase II study. *British Journal of Cancer*
15 101(11): 1853-9

16 11.2 Management of metastatic pancreatic cancer

17 **Review question: What are the most effective interventions for adults with newly**
18 **diagnosed or recurrent metastatic pancreatic cancer (Chemotherapy, surgery,**
19 **radiotherapy)?**

20 11.2.1 Introduction

21 At presentation, the majority of pancreatic cancer patients have locally advanced or
22 metastatic disease. The prognosis of those with metastatic pancreatic cancer is measured in
23 months, which may be extended, albeit to a limited extent by systemic chemotherapy.
24 Pancreatic cancer frequently affects older people and metastatic disease is associated with
25 multiple problems, including pain, weight loss, anorexia, cachexia, jaundice, nausea,
26 vomiting, altered bowel habit, dyspepsia, mood disturbance and depression and increased
27 risk of thromboembolic events.

28 Despite recent advances in chemotherapy, with interventions such as FOLFIRNOX and other
29 combination regimes providing a prolonged median survival, the prognosis for people
30 diagnosed with metastatic pancreatic cancer remains poor and any subsequent treatment is
31 deemed palliative (for example not curative). People with metastatic pancreatic cancer may
32 experience distressing symptoms that require ongoing and specialist support. In respect of
33 this, it is important that people diagnosed with metastatic pancreatic cancer have their
34 physical and psychological needs assessed at the time of diagnosis. General and specialist
35 palliative care services have an important role in introducing the person with pancreatic
36 cancer, and their family if applicable, to a range of services and support available to ease the
37 burden of physical and psychological distress through the trajectory of their cancer diagnosis
38 towards end of life. If a person presents with end stage metastatic disease with a poor
39 performance status and no treatment can be offered to them, the support of specialist
40 palliative care is essential.

41 Individuals with significant comorbidities or poor performance status due to advancing
42 disease may not tolerate chemotherapy. For those people fit for treatment, various single
43 agent and combination chemotherapy regimens are in routine use, few of which have
44 undergone NICE technology appraisal. Those interventions where there is existing NICE
45 technology appraisal guidance will not be reviewed here, [paclitaxel as albumin-bound](#)
46 [nanoparticles in combination with gemcitabine for previously untreated metastatic pancreatic](#)
47 [cancer](#) (TA476, 2017) and [pegylated liposomal irinotecan for treating pancreatic cancer after](#)
48 [gemcitabine](#) (TA440, 2017).

1 Metastatic disease results in a significant symptom burden for the individual which requires
2 active management to achieve symptom control, with the intention of improving quality of life,
3 patient and family experience. Radiotherapy with or without chemotherapy has been used to
4 reduce local tumour volume (including at the coeliac plexus) with the intention of improving
5 pain control. Pharmacological interventions including analgesia, antiemetics, pancreatic
6 enzyme replacement, blood sugar management, corticosteroid and other hormonal agents
7 as well as anticoagulants play a role in symptom management and may influence overall
8 outcomes. An area of current uncertainty is whether isolated metastases can be effectively
9 targeted by surgery or local ablative techniques.

10 While most randomised trials have focussed on evaluating first line chemotherapy, there is
11 uncertainty regarding the role of second line chemotherapy in a subgroup of people who are
12 sufficiently fit to receive it.

13 Guidance is needed on the most effective interventions for people with metastatic pancreatic
14 cancer.

15 11.2.1.1 Review protocol summary

16 The review protocol summary used for this question can be found in Table 179. Full details of
17 the review protocol can be found in Appendix C.

18 **Table 179: Clinical review protocol summary for review of management of**
19 **metastatic pancreatic cancer**

Population	Patients with advanced and/or metastatic pancreatic cancer
Intervention	<ul style="list-style-type: none"> • Chemotherapy (1st line, 2nd line) • Surgery for metastatic disease +/- chemotherapy • Radiotherapy
Comparison	<ul style="list-style-type: none"> • Different Chemo types/regimens • Best supportive care • No surgery • Ablative techniques for metastases • Best supportive care • Best supportive care
Outcomes	<ul style="list-style-type: none"> • Response rate • Overall Survival • Progression Free Survival • Adverse Events • Health Related Quality of Life • Patient experience and PROMs • Symptom control

20 11.2.2 Description of Clinical Evidence

21 Thirty-nine phase II/III RCTs and 1 network-meta analysis of 23 RCTs (Gresham et al. 2014)
22 were included in this review. A summary of the studies included in pairwise comparisons is
23 presented in Table 180. A summary of the studies included in the NMA is presented in Table
24 181.

25 Two RCTs were found that compared chemotherapy with chemoimmunotherapy in adults
26 with advanced/metastatic pancreatic cancer (Middleton et al. 2014; Wang et al. 2013). One
27 of the studies assessed the efficacy and safety of sequential or simultaneous telomerase

1 vaccination (GV1001) in combination with chemotherapy as first-line therapy in adults with
2 advanced/metastatic pancreatic cancer (Middleton et al. 2014). The other study compared S-
3 1 combined with cytokine-induced killer cells (CIK) with S-1 only in adults with
4 advanced/metastatic pancreatic cancer who had previously received gemcitabine-based
5 therapy (Wang et al. 2013).

6 A total of 15 RCTs (Bernhard et al. 2008; Burris et al. 1997; Chao et al. 2013; Deplanque et
7 al. 2015; Eckhardt et al. 2009; Fuchs et al. 2015; Gourgou-Bourgade et al. 2013; Irigoyen et
8 al. 2017; Lee et al. 2017; Kindler et al. 2010; Moinpour et al. 2010; Rougier et al. 2013; Sudo
9 et al. 2014; Ueno et al. 2013; Yamaue et al. 2015) and 1 NMA (Gresham et al. 2014) of 23
10 RCTs (Abou-Alfa et al. 2006; Berlin et al. 2002; Bramhall et al. 2002; Colucci et al. 2010;
11 Conroy et al. 2011; Cunningham et al. 2009; Gonçalves et al. 2012; Heinemann et al. 2006;
12 Heinemann et al. 2012; Herrmann et al. 2007; Kindler et al. 2011; Louvet et al. 2005; Moore
13 et al. 2007; Oettle et al. 2005; Philip et al. 2010; Poplin et al. 2006; Reni et al. 2005; Riess et
14 al. 2005; Rocha Lima et al. 2004; Stathopoulos et al. 2006; Van-Cutsem et al. 2004; Van-
15 Cutsem et al. 2009; Von-Hoff et al. 2013) were found that compared gemcitabine with other
16 chemotherapy regimens. Ten of the 15 RCTs included in this review were in a mixed
17 population that included adults with either locally advanced or metastatic pancreatic cancer,
18 whilst the remaining 5 were in adults with metastatic pancreatic cancer only (Chao et al.
19 2013; Fuchs et al. 2015; Gourgou-Bourgade et al. 2013; Irigoyen et al. 2017; Rougier et al.
20 2013). The majority of the studies in the NMA by Gresham et al. 2014 included adults with
21 either locally advanced or metastatic pancreatic cancer. A summary of the characteristics of
22 the 15 included RCTs studies are presented in Table 180, whilst a summary of the
23 characteristics of the 23 RCTs in the included NMA of Gresham et al. 2014 are presented in
24 Table 181.

25 Data were extracted from the NMA for overall survival only. Data on response rate,
26 progression-free survival, adverse events, and health-related quality of life were extracted
27 from the original studies included in the NMA (pairwise evidence review). The NMA included
28 a study (Von Hoff et al. 2013) that is part of a NICE TA evaluation of nab-Paclitaxel plus
29 Gemcitabine; [TA476](#) [see NICE 2017]). Although the results of this study were included in
30 the NMA - to increase its precision and decrease heterogeneity - it was excluded from the
31 pairwise comparisons presented to the committee (and hence its decision making).

32 Three RCTs were found that compared gemcitabine with novel gemcitabine-based
33 treatments in adults with locally advanced or metastatic pancreatic cancer (Middleton et al.
34 2017; Moore et al. 2003; Smith et al. 2003).

35 One RCT was identified that compared a low-dose gemcitabine infusion with a standard-
36 dose gemcitabine infusion in adults with locally advanced or metastatic pancreatic cancer
37 (Sakamoto et al. 2006).

38 Four RCTs were found that compared 5-FU with combination 5-FU in adults with metastatic
39 pancreatic cancer (Cullinan et al. 1985; Cullinan et al. 1990; Ducreux et al. 2002; Maisey et
40 al. 2002). Two of these studies were in adults with metastatic pancreatic cancer (Cullinan et
41 al. 1985; Maisey et al. 2002), whilst two of them were in adults with locally advanced or
42 metastatic pancreatic cancer (Cullinan et al. 1990; Ducreux et al. 2002).

43 Two RCTs, which were both in adults with locally advanced or metastatic pancreatic cancer,
44 compared first-line combination 5-FU with other chemotherapy regimens (Bukowski et al.
45 1983; Oster et al. 1986). One of the studies compared FAM (a combination of 5-FU,
46 Adriamycin [Doxorubicin], and Mitomycin) with FSM (a combination of 5-FU, Streptozotocin,
47 and Mitomycin) (Oster et al. 1986); whilst the other study compared FSM with MF (a
48 combination of Mitomycin C and 5-FU) (Bukowski et al. 1983).

49 Three RCTs were found that compared regional intra-arterial chemotherapy (RIAC) with
50 systemic chemotherapy in adults with locally advanced or metastatic pancreatic cancer
51 (Aigner et al. 1998; Cantore et al. 2004; Ji et al. 2003).

1 Two RCTs were found that compared a combination of chemotherapy and a prophylactic
2 anticoagulant with chemotherapy only in adults with locally advanced or metastatic
3 pancreatic cancer. One study compared a combination of gemcitabine and weight-adjusted
4 dalteparin (WAD) with gemcitabine only (Maraveyas et al. 2012), whilst 1 study compared a
5 combination of first-line chemotherapy and prophylactic enoxaparin with chemotherapy only
6 (Pelzer et al. 2015).

7 One RCT was found that compared second-line glufosfamide with best supportive care
8 (BSC) in adults with metastatic pancreatic cancer (Ciuleanu et al. 2009).

9 Six RCTs were found that compared two types of second-line chemotherapy with 1 another
10 in adults with locally advanced or metastatic pancreatic cancer who had previously received
11 gemcitabine-based chemotherapy (Azmy et al. 2013; Dahan et al. 2010; Gill et al. 2016;
12 Heinemann et al. 2012; Oettle et al. 2014; Ulrich-Pur et al. 2003).

13 The ISPOR checklist was used for the quality assessment of the NMA (Jansen et al. 2014),
14 whilst the GRADE tool was used for assessing risk of bias and overall quality of the phase
15 II/III RCTs.

16 Further information about the search strategy can be found in Appendix D. See study
17 selection flow chart in Appendix E, forest plots in Appendix H, GRADE tables in Appendix I,
18 study evidence tables in Appendix F and list of excluded studies in Appendix G.

19

1 11.2.3 Summary of included studies

2 A summary of the studies that were included in this review is presented in Table 180.

3 **Table 180: Summary table of included RCT studies**

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Aigner et al. 1998 Germany	Multicentre phase III RCT	14 patients with locally advanced/metastatic PC	Regional intra-arterial chemotherapy	Systemic chemotherapy	Overall response rate (CR + PR)
Azmy et al. 2013 Egypt	Phase III RCT	48 patients with locally advanced/metastatic PC	Second-line Oxaliplatin + 5- FU	Second-line bolus folinic acid + bolus 5-FU	Overall response rate (CR + PR) Progression Free Survival* Overall Survival* Adverse Events
Bernhard et al. 20081 Switzerland, Italy, Austria, Germany	Multicentre phase III RCT	319 patients with locally advanced/metastatic PC	Gemcitabine + Capecitabine	Gemcitabine	Response rate Overall Survival Adverse Events Health-related quality of life
Bukowski et al. 1983 USA	Phase III RCT	181 patients with locally advanced/metastatic PC	First-line Streptozotocin, Mitomycin C + 5-FU	First-line Mitomycin C + 5-FU	Overall response rate (CR + PR) Overall Survival* Adverse Events Drug-related deaths
Burris et al. 1997 USA	Phase III RCT	160 patients with locally advanced/metastatic PC	5-FU	Gemcitabine	Response rate Overall Survival Adverse Events
Cantore et al. 2004	Phase III RCT	138 patients with locally	Regional Intra-Arterial Chemotherapy - FLEC	Gemcitabine single-agent	Overall response rate (CR + PR)

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Italy		advanced/metastatic PC			Overall Survival Adverse Events
Chao et al. 2013 Taiwan	RCT	46 patients with metastatic PC	Gemcitabine + Cisplatin	Gemcitabine	Response rate Progression-free Survival Overall Survival Adverse Events Health-related quality of life
Ciuleanu et al. 2009 Argentina, Brazil, Czech Republic, Hungary, India, Russia	Multicentre phase III RCT	303 patients with metastatic PC	Second-line chemotherapy + best supportive care	Best supportive care	Progression-free Survival Overall Survival Adverse effects
Cullinan et al. 1990 USA	Phase III RCT	123 patients with metastatic PC	5-FU, Doxorubicin, + Cisplatin	5-FU	Overall response rate (CR + PR) Overall Survival Adverse Events
Cullinan et al. 1985 USA	Multicentre phase III RCT	100 patients with metastatic PC	5-FU, Doxorubicin + Mitomycin	5-FU	Overall response rate (CR + PR) Overall Survival
Dahan et al. 2010 France	Multicentre phase III RCT	202 patients with metastatic PC	5-FU, Folinic Acid + Cisplatin (LV5FU2-CDDP) then Gemcitabine after progression	Gemcitabine then LV5FU2-CDDP after progression	Overall response rate (CR + PR) Progression-free survival Overall Survival Adverse Events
Deplanque et al. 2015 France, Czech Republic, USA	Multicentre phase III RCT	348 patients with locally advanced/metastatic PC	Gemcitabine + Masitinib	Gemcitabine + Placebo	Progression-free Survival Overall Survival Adverse Events
Ducreux et al. 2002	Phase III RCT	207 patients with metastatic PC	5-FU + Cisplatin	5-FU	Overall response rate (CR + PR)

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
France					Progression-free survival Overall Survival Adverse Events
Eckhardt et al. 2009 Australia, Austria, France, Germany, Portugal, Spain, Sweden, UK, USA	Multicentre phase III RCT	244 patients with locally advanced/metastatic PC (mixed population)	Gemcitabine + Tipifarnib	Gemcitabine + Placebo	Response rate Overall Survival Adverse Events
Fuchs et al. 2015 Australia, Canada, Japan, Brazil, Czech Republic, Poland, Spain, UK, US	Multicentre phase III RCT	800 patients with metastatic PC	Gemcitabine + Ganitumab 12 mg/kg	Gemcitabine + Ganitumab 20 mg/kg Gemcitabine + Placebo	Response rate Progression-free Survival Overall Survival Adverse Events
Gill et al. 2016 Canada	Multicentre phase III RCT	108 patients with locally advanced/metastatic PC	Second-line modified FOLFOX6 (infusional 5-FU, folinic acid + Oxaliplatin)	Second-line infusional 5- FU and folinic acid	Overall response rate (CR + PR) Progression-free Survival Overall Survival Adverse Events Health-related quality of life
Gourgou- Bourgade et al. 20132 France	Multicentre phase III RCT	342 patients with metastatic PC	FOLFIRINOX (Oxaliplatin, Irinotecan, 5-FU + Leucovorin)	Gemcitabine	Health-related quality of life

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Gresham et al. 2014	Network meta-analysis of 23 RCTs	23 RCTs with total of 9,989 patients with either metastatic PC or locally advanced/metastatic PC (see Table 181 for more details)	FOLFIRINOX PEFG Gemcitabine with 5-FU 5-FU + Folinic Acid Axitinib Capecitabine Cetuximab Cisplatin Erlotinib Erlotinib + Bevacizumab Exatecan Irinotecan Marimastat Nab-Paclitaxel Oxaliplatin Pemetrexed Sorafenib Tipifarnib	Capecitabine + Erlotinib Gemcitabine Gemcitabine + Erlotinib	Overall Survival
Irigoyen et al. 2017 Spain	Phase IIb RCT	120 patients with metastatic PC	Gemcitabine, Capecitabine + Erlotinib	GEM + Erlotinib	Overall response rate (CR + PR) Progression-free Survival Overall Survival Adverse Events
Ji et al. 2003 China	Multicentre phase III RCT	29 patients with metastatic PC	Regional intra-arterial Chemotherapy	Systemic Chemotherapy	Overall response rate (CR + PR) Overall Survival*
Kindler et al. 2010 USA	Multicentre phase III RCT	602 patients with locally advanced/metastatic PC	Gemcitabine + Bevacizumab	Gemcitabine + Placebo	Response rate Overall Survival Adverse Events

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Lee et al. 2017 South Korea	Multicentre phase III RCT	214 patients with locally advanced/metastatic PC	Gemcitabine + Capecitabine	Gemcitabine	Overall response rate (CR + PR) Progression-free Survival Overall Survival Adverse Events
Maisey et al. 2002 UK	Phase III RCT	209 patients with locally advanced/metastatic PC	5-FU + Mitomycin	5-FU	Overall response rate (CR + PR) Progression free survival Overall Survival Adverse Events
Maraveyas et al. 2012 UK	Phase IIb RCT	123 patients with advanced/metastatic	Gemcitabine + weight-adjusted Dalteparin	Gemcitabine	Overall Survival* Adverse Events
Middleton et al. 2014 UK	Multicentre phase III RCT	1062 patients with locally advanced/metastatic PC	Sequential ICT: Chemotherapy then GV1001 Concurrent ICT: Chemotherapy + GV1001	Chemotherapy	Overall response rate (CR + PR) at 8 weeks Time to progression Overall Survival Adverse Events Health-related quality of life
Middleton et al. 2017 UK	Multicentre phase II RCT	142 patients with locally advanced/metastatic PC	Gemcitabine + Vandetanib	Gemcitabine + Placebo	Overall response rate (CR + PR) Progression-free Survival Overall Survival Adverse Events
Moinpour et al. 2010 Canada, USA	Multicentre phase III RCT	720 patients with locally advanced/metastatic PC	Gemcitabine + Cetuximab	Gemcitabine	Health-related quality of life Patient experience and PROMs
Moore et al. 2003 Canada	Multicentre phase III RCT	277 patients with locally advanced/metastatic PC	BAY 12-9566	Gemcitabine	Overall response rate (CR + PR) Progression-free Survival

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
					Overall Survival Adverse Events Health-related quality of life
Oettle et al. 2014 Germany	Multicentre phase III RCT	160 patients with locally advanced/metastatic PC	Second-line Folinic Acid + 5-FU	Second-line Oxaliplatin + 5-FU	Progression-free Survival Overall Survival Adverse Events
Oster et al. 1986 USA	Phase III RCT	184 patients with locally advanced/metastatic PC	5-FU, Adriamycin (Doxorubicin) + Mitomycin	5-FU, Streptozotocin, Mitomycin (n=94)	Overall response rate (CR + PR) Overall Survival* Adverse Events
Pelzer et al. 2015 Germany	Multicentre phase III RCT	312 patients with locally advanced/metastatic PC	Chemotherapy + Prophylactic Enoxaparin	Chemotherapy	Progression-free Survival Overall Survival Adverse Events
Rougier et al. 2013 Belgium, France, Germany, Czech Republic, US	Multicentre phase III RCT	546 patients with metastatic PC	Gemcitabine + Aflibercept	Gemcitabine + Placebo	Progression-free Survival Overall Survival Adverse Events
Sakamoto et al. 2006 Japan	Phase III RCT	21 patients with locally advanced/metastatic PC	Gemcitabine infusion at a low dose	Gemcitabine infusion at a standard dose	Overall response rate (CR + PR) until disease progression Overall Survival* Adverse Events
Smith et al. 2003 France, Germany, Sweden,	Multicentre phase II/III RCT	55 patients with locally advanced/metastatic PC	ZD9331	Gemcitabine	Overall response rate (CR + PR) until disease progression Adverse Events

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Netherlands, Norway, UK					
Sudo et al. 2014 Japan	Multicentre phase III RCT	101 patients with locally advanced/metastatic PC	Gemcitabine + S-1	Gemcitabine	Response rate Progression-free Survival Overall Survival Adverse Events
Ueno et al. 2013 Japan, Taiwan	Multicentre phase III RCT	834 patients with locally advanced/metastatic PC	Gemcitabine + S-1	Gemcitabine S-1	Response rate Progression-free Survival Overall Survival Adverse Events Health-related quality of life
Ulrich-Pur et al. 2003 Austria	RCT	38 patients with metastatic PC	Irinotecan + Raltitrexed	Raltitrexed	Objective/complete response Adverse Events
Wang et al. 2013 China	Multicentre phase III RCT	58 patients with locally advanced/metastatic PC	Second-line S-1 + Cytokine- induced killer cells	Second-line S-1	Response rate Overall Survival* Adverse Events
Yamaue et al. 2015 Japan	Multicentre phase III RCT	153 patients with locally advanced/metastatic PC	Gemcitabine + Elpamotide	Gemcitabine + Placebo	Progression-free Survival* Overall Survival Adverse Events

Notes: See Table 181 for characteristics of the RCTs included in the NMA (Gresham et al. 2014); *, indicates incompletely reported results

1 See also Table 181, entry for Herrmann et al. 2007;

2 See also Table 181, entry for Conroy et al. 2011;

3 See also Table 181, entry for Philip et al., 2010.

Table 181: Summary of studies included in Gresham et al. 2014 Network Meta-Analysis

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Abou-Alfa et al. 2006	Multicentre phase III RCT	349 patients with locally	Gemcitabine + Exatecan	Gemcitabine	Response rate Progression-free Survival

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
USA		advanced/metastatic PC			Adverse Events
Berlin et al. 2002 USA	Multicentre phase III RCT	322 patients with locally advanced/metastatic PC	Gemcitabine + 5-FU	Gemcitabine	Response rate Progression-free Survival Adverse Events
Bramhall et al. 2002 UK	Multicentre double-blind phase III RCT	239 patients with locally advanced/metastatic PC	Gemcitabine + Marimastat	Gemcitabine	Response rate Progression-free Survival Adverse Events
Colucci et al. 2010 Italy	Multicentre phase III RCT	400 patients with metastatic PC	Gemcitabine + Cisplatin	Gemcitabine	Response rate Progression-free Survival Adverse Events
Conroy et al. 2011 France	Multicentre phase III RCT	342 patients with metastatic PC	FOLFIRINOX (Oxaliplatin, Irinotecan, 5-FU + Leucovorin)	Gemcitabine	Response rate Progression-free Survival Adverse Events Health-related quality of life ¹
Cunningham et al. 2009 UK, Switzerland, Austria	Multicentre non-blinded phase III RCT	533 patients with locally advanced/metastatic PC	Gemcitabine + Capecitabine	Gemcitabine	Response rate Progression-free Survival Adverse Events
Gonçalves et al. 2012 France	Multicentre double-blind phase III RCT	104 patients with locally advanced/metastatic PC	Gemcitabine + Sorafenib	Gemcitabine	Response rate Progression-free Survival Adverse Events
Heinemann et al. 2006 Germany	Multicentre non-blinded phase III RCT	194 patients with locally advanced/metastatic PC	Gemcitabine + Cisplatin	Gemcitabine	Response rate Progression-free Survival Adverse Events Health-related quality of life
Heinemann et al. 2012	Multicentre non-blinded phase III RCT	284 patients with locally	Gemcitabine + Erlotinib then Capecitabine	Capecitabine + Erlotinib then Gemcitabine	Response rate Adverse Events

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Germany		advanced/metastatic PC			
Herrmann et al. 2007 Switzerland, Italy, Austria, Germany	Multicentre non-blinded phase III RCT	319 patients with locally advanced/metastatic PC	Gemcitabine + Capecitabine	Gemcitabine	Response rate Progression-free Survival Adverse Events Health-related quality of life ²
Kindler et al. 2011 USA	Multicentre double-blind phase III RCT	313 patients with locally advanced/metastatic PC	Gemcitabine + Axitinib	Gemcitabine	Response rate Progression-free Survival Adverse Events Health-related quality of life
Louvet et al. 2005 France, Italy	Multicentre phase III RCT	313 patients with locally advanced/metastatic PC	Gemcitabine + Oxaliplatin	Gemcitabine	Response rate Progression-free Survival Adverse Events
Moore et al. 2007 Canada	Multicentre double-blind phase III RCT	569 patients with locally advanced/metastatic PC	Gemcitabine + Erlotinib	Gemcitabine	Response rate Progression-free Survival Adverse Events
Oettle et al. 2005 Argentina, Australia, Austria, Belgium, France, Germany, Greece, Italy, The Netherlands, Peru, Portugal, Spain, Sweden, Taiwan, UK, US, Venezuela	Multicentre non-blinded phase III RCT	565 patients with locally advanced/metastatic PC	Gemcitabine + Pemetrexed	Gemcitabine	Response rate Progression-free Survival Adverse Events
Philip et al. 2010 USA	Multicentre non-blinded phase III RCT	741 patients with locally	Gemcitabine + Cetuximab	Gemcitabine	Response rate Progression-free Survival Adverse Events

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
		advanced/metastatic PC			Health-related quality of life ³
Poplin et al. 2006 (2009) USA	Multicentre phase III RCT	547 patients with locally advanced/metastatic PC	Gemcitabine + oxaliplatin	Gemcitabine	Response rate Progression-free Survival Adverse Events
Reni et al. 2005 Italy	Multicentre non-blinded phase III RCT	99 patients with locally advanced/metastatic PC	PEFG	Gemcitabine	Response rate Progression-free Survival Health-related quality of life ⁴
Riess et al. 2005 Germany	Multicentre phase III RCT	463 patients with locally advanced/metastatic PC	Gemcitabine, 5-FU + Folinic Acid	Gemcitabine	Unclear (coinference abstract)
Rocha Lima et al. 2004 New Zealand, USA	Multicentre phase III RCT	360 patients with locally advanced/metastatic PC	Gemcitabine + Irinotecan	Gemcitabine	Response rate Progression-free Survival Health-related quality of life
Stathopoulos et al. 2006 Greece	Multicentre phase III RCT	130 patients with locally advanced/metastatic PC	Gemcitabine + Irinotecan	Gemcitabine	Response rate Progression-free Survival Adverse Events
Van-Cutsem et al. 2004 Belgium, Germany, Czech Republic, Netherlands, Poland, USA	Multicentre double-blind phase III RCT	688 patients with locally advanced/metastatic PC	Gemcitabine + Tipifarnib	Gemcitabine	Response rate Progression-free Survival Adverse Events Health-related quality of life
Van-Cutsem et al. 2009 Australia, Austria, Belgium, Canada, China, Czech	Multicentre double-blind phase III RCT	607 patients with metastatic PC	Gemcitabine + Erlotinib	Gemcitabine, Erlotinib + Bevacizumab	Response rate Progression-free Survival Adverse Events

Study ID Country	Study design	Participants	Intervention	Comparison	Outcomes
Republic, France, Germany, Italy, Netherlands, Peru, Poland, Singapore, Sweden, Taiwan, UK					
Von-Hoff et al. 2013 Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, , Italy, Poland, Russia, Spain, Ukraine, USA	Multicentre non- blinded phase III RCT	871 patients with metastatic PC	Gemcitabine + Nab- paclitaxel	Gemcitabine	Response rate Progression-free Survival Adverse Events

Notes: 1 See Table 180, data from Gourgou-Bourgade et al. 2013;

2 See Table 180, data from Bernhard et al. 2008;

3 See Table 180, data from Moinpour et al. 2010;

1
2
3
4
5

1 11.2.4 Clinical evidence profile

2 The clinical evidence profiles for this review question are presented in Table 182 to Table
3 214.

4 11.2.4.1 Chemotherapy versus chemoimmunotherapy

5 11.2.4.1.1 First-line chemotherapy with sequential or concurrent immunotherapy versus 6 chemotherapy

7 **Table 182: Summary clinical evidence profile for first-line chemotherapy with**
8 **sequential or concurrent immunotherapy versus chemotherapy in adults**
9 **with locally advanced or metastatic pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy alone	1st-line chemotherapy + sequential/concurrent immunotherapy				
Overall response rate (CR + PR) at 8 weeks - Sequential ICT	73 per 1000	71 per 1000 (42 to 121)	RR 0.98 (0.58 to 1.67)	708 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Overall response rate (CR + PR) at 8 weeks - Concurrent ICT	73 per 1000	82 per 1000 (49 to 137)	RR 1.13 (0.68 to 1.88)	712 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Time to progression - Sequential ICT	Median time: 6.4 (4.8 to 7.1) months	Median time: 4.5 (4.3 to 4.6) months	HR 1.5 (1.26 to 1.79)	708 (1 study ¹)	⊕⊕⊕ ⊖ moderate ²	
Time to progression - Concurrent ICT	Median time: 6.4 (4.8 to 7.1) months	Median time: 4.5 (4.3 to 4.6) months	HR 1 (0.84 to 1.19)	712 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,4}	
Overall Survival - Sequential ICT	Median time: 7.9 (7.1 to 8.8) months	Median time: 6.9 (6.4 to 7.6) months	HR 1.19 (0.97 to 1.48)	708 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,4}	
Overall Survival - Concurrent ICT	Median time: 7.9 (7.1 to 8.8) months	Median time: 6.6 (5.0 to 7.3) months	HR 1.05 (0.85 to 1.29)	712 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,4}	
Grade 3/4/5 toxicities: Nausea - Sequential ICT	36 per 1000	43 per 1000 (21 to 89)	RR 1.18 (0.57	708 (1 study ¹)	⊕⊕⊕ ⊖	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 2.44)		very low ^{2,3}	
Grade 3/4/5 toxicities: Nausea - Concurrent ICT	36 per 1000	57 per 1000 (29 to 112)	RR 1.56 (0.79 to 3.08)	712 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Vomiting - Sequential ICT	47 per 1000	51 per 1000 (27 to 98)	RR 1.08 (0.57 to 2.07)	708 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Vomiting - Concurrent ICT	47 per 1000	62 per 1000 (34 to 115)	RR 1.31 (0.71 to 2.42)	712 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Diarrhoea - Sequential ICT	47 per 1000	31 per 1000 (15 to 66)	RR 0.66 (0.31 to 1.39)	708 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Diarrhoea - Concurrent ICT	47 per 1000	31 per 1000 (15 to 66)	RR 0.65 (0.31 to 1.38)	712 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Fatigue - Sequential ICT	75 per 1000	103 per 1000 (64 to 166)	RR 1.36 (0.85 to 2.2)	708 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Fatigue - Concurrent ICT	75 per 1000	124 per 1000 (78 to 196)	RR 1.65 (1.04 to 2.6)	712 (1 study ¹)	⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4/5 toxicities: Neutropenia - Sequential ICT	190 per 1000	165 per 1000 (120 to 228)	RR 0.87 (0.63 to 1.2)	708 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,3}	
Grade 3/4/5 toxicities: Neutropenia - Concurrent ICT	190 per 1000	222 per 1000 (167 to 298)	RR 1.17 (0.88 to 1.57)	712 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,5}	
Grade 3/4/5 toxicities: Pain - Sequential ICT	95 per 1000	111 per 1000 (72 to 172)	RR 1.17 (0.76 to 1.81)	708 (1 study ¹)	⊕⊕⊕ ⊖ low ^{2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4/5 toxicities: Pain - Concurrent ICT	95 per 1000	119 per 1000 (77 to 182)	RR 1.25 (0.81 to 1.92)	712 (1 study ¹)	⊕⊕⊖ ⊖ low ^{2,5}	
Health Related Quality of Life at 20 weeks (EORTC QLQ-C30) - Sequential ICT		The mean health related quality of life at 20 weeks (EORTC QLQ-C30) - sequential ICT in the intervention groups was 11.1 lower (24.28 lower to 2.08 higher)		708 (1 study ¹)	⊕⊕⊖ ⊖ low ^{2,5}	
Health Related Quality of Life at 20 weeks (EORTC QLQ-C30) - Concurrent ICT		The mean health related quality of life at 20 weeks (EORTC QLQ-C30) - concurrent ICT in the intervention groups was 1.7 higher (10.46 lower to 13.86 higher)		704 (1 study ¹)	⊕⊕⊖ ⊖ low ^{2,5}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

¹ Middleton et al., 2014

² The quality of the evidence was downgraded because of the high risk of performance bias (no blinding of patients/ care providers delivering the interventions)

³ Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

⁴ The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.

⁵ Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

11.2.4.1.2 Second-line chemoimmunotherapy versus chemotherapy

2
3
4
Table 183: Summary clinical evidence profile for second-line chemoimmunotherapy versus chemotherapy in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy alone	2nd-line chemotherapy + concurrent immunotherapy				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Overall response rate (CR + PR) - unclear follow-up	67 per 1000	71 per 1000 (11 to 473)	RR 1.07 (0.16 to 7.1)	58 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	
Progression Free Survival	-	-	Not estimable ⁴	58 (1 study ¹)	⊕⊕⊖ ⊖ low ⁵	
Overall Survival	-	-	Not estimable ⁴	58 (1 study ¹)	⊕⊕⊖ ⊖ low ²	
Grade 3/4 toxicities - Neutropenia	33 per 1000	36 per 1000 (2 to 544)	RR 1.07 (0.07 to 16.32)	58 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	
Grade 3/4 toxicities - Nausea/vomiting	33 per 1000	12 per 1000 (1 to 280)	RR 0.36 (0.02 to 8.4)	58 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	
Grade 3/4 toxicities - Diarrhoea	67 per 1000	71 per 1000 (11 to 473)	RR 1.07 (0.16 to 7.1)	58 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	
Grade 3/4 toxicities - Fatigue	33 per 1000	12 per 1000 (1 to 280)	RR 0.36 (0.02 to 8.4)	58 (1 study ¹)	⊕⊖⊖ ⊖ very low ^{2,3}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Wang et al., 2013

2 The quality of the evidence was downgraded of two points because of the unclear risk of selection bias, the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the unclear risk of detection bias (no masking of outcome assessors)

3 The quality of the evidence was further downgraded from low to very low due to serious imprecision as 95%CI crossed two default MIDs

4 The median time to progression was 2.5 (95 % CI 2.3–2.8) and 2.9 (95 % CI 2.6–3.2) months ($p = 0.037$) for CT group and ICT group, respectively. The median overall survival was 6.1 (95 % CI 5.7–6.5) and 6.6 (95 % CI 6.1–7.1) months ($p = 0.09$) for CT group and ICT group, respectively.

5 The quality of the evidence was downgraded because of the unclear risk of selection bias and the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions). Furthermore, for this outcome the findings were reported only narratively (potential bias due to selective reporting)

1 11.2.4.2 Gemcitabine versus other chemotherapy

2 1.2.4.2.1 Adults with metastatic pancreatic cancer

3 Table 184: Summary clinical evidence profile for gemcitabine versus other
4 chemotherapy (Response rate, overall survival and progression-free
5 survival)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Overall response rate (CR + PR) - FOLFIRINOX	94 per 1000	316 per 1000 (188 to 529)	RR 3.38 (2.01 to 5.65)	342 (1 study ¹)	⊕⊕⊕⊕ high	
Overall response rate (CR + PR) - GEM + Cisplatin	98 per 1000	122 per 1000 (71 to 207)	RR 1.25 (0.73 to 2.12)	445 (2 studies ^{2,3})	⊕⊖⊖⊖ very low ^{4,5}	
Overall response rate (CR + PR) - GEM + Ganitumab 12 mg/kg	102 per 1000	161 per 1000 (106 to 244)	RR 1.58 (1.04 to 2.39)	619 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
Overall response rate (CR + PR) - GEM + Ganitumab 20 mg/kg	102 per 1000	147 per 1000 (89 to 244)	RR 1.44 (0.87 to 2.39)	464 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁷	
Progression Free Survival - FOLFIRINOX	Median time: 6.4 (n.r) months	Median time: 3.3(n.r) months	HR 0.47 (0.32 to 0.69)	342 (1 study ¹)	⊕⊕⊕⊕ high	
Progression Free Survival - GEM + Aflibercept	Median time: 3.7(n.r) months	Median time: 3.7(n.r) months	HR 1.02 (0.83 to 1.25)	546 (1 study ⁸)	⊕⊕⊕⊖ moderate ⁹	
Progression Free Survival - GEM + Cisplatin	Median time: 3.8 (n.r) months	Median time: 3.9(n.r) months	HR 0.97 (0.8 to 1.18)	400 (1 study ³)	⊕⊕⊖⊖ low ^{9,10}	
Progression Free Survival - GEM + Ganitumab - 12 mg/kg	Median time: 3.7 (3.6 to 4.4) months	Median time: 3.6 (3.4 to 3.8) months	HR 1 (0.84 to 1.19)	650 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁹	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Progression Free Survival - GEM + Ganitumab - 20 mg/kg	Median time: 3.7 (3.6 to 4.4) months	Median time: 3.7 (3.2 to 5.0) months	HR 0.97 (0.77 to 1.22)	482 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁹	
Overall Survival - GEM + Afibercept	Median time: 6.5 (5.6 to 7.9) months	Median time: 7.8 (6.8 to 8.6) months	HR 1.17 (0.92 to 1.49)	546 (1 study ⁸)	⊕⊕⊕⊖ moderate ⁹	
Overall Survival - GEM + Cisplatin	-	-	HR 0.92 (0.76 to 1.11)	400 (2 studies ^{2,3})	⊕⊕⊖⊖ low ^{9,10}	
Overall Survival - GEM + Ganitumab - 12 mg/kg	Median time: 7.0 (6.2 to 8.5) months	Median time: 7.2 (6.3 to 8.2) months	HR 1 (0.82 to 1.22)	650 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁹	
Overall Survival - GEM + Ganitumab - 20 mg/kg	Median time: 7.1 (6.3 to 8.5) months	Median time: 7.2 (6.3 to 8.2) months	HR 0.97 (0.76 to 1.24)	482 (1 study ⁶)	⊕⊕⊕⊖ moderate ⁹	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;*

1 Conroy et al., 2011
2 Chao et al., 2013
3 Colucci et al., 2010
4 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text) in one study (Chao et al., 2013), besides the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), and detection bias in both pooled studies
5 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs
6 Fuchs et al., 2015
7 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID
8 Rougier et al., 2013
9 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant
10 The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the potential risk of detection bias (no details about the blinding of outcome assessors)

1
2

Table 185: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities: Diarrhoea - FOLFIRINOX	18 per 1000	127 per 1000 (39 to 419)	RR 7.17 (2.18 to 23.58)	334 (1 study ¹)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Diarrhoea - GEM + Aflibercept	11 per 1000	11 per 1000 (2 to 55)	RR 1 (0.2 to 4.93)	541 (1 study ²)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Diarrhoea - GEM + Cisplatin	14 per 1000	5 per 1000 (1 to 45)	RR 0.34 (0.04 to 3.23)	421 (2 studies ^{4,5})	⊕⊕⊕⊖ very low ^{3,6}	
Grade 3/4 toxicities: Diarrhoea - GEM + Ganitumab 12 mg/kg	3 per 1000	10 per 1000 (1 to 91)	RR 3.02 (0.32 to 28.87)	632 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Diarrhoea - GEM + Ganitumab 20 mg/kg	3 per 1000	12 per 1000 (1 to 137)	RR 3.96 (0.36 to 43.37)	477 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Fatigue - FOLFIRINOX	178 per 1000	236 per 1000 (154 to 362)	RR 1.33 (0.87 to 2.04)	334 (1 study ¹)	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities: Fatigue - GEM + Cisplatin	32 per 1000	54 per 1000 (20 to 145)	RR 1.69 (0.63 to 4.57)	375 (1 study ⁵)	⊕⊕⊕⊖ very low ^{3,9}	
Grade 3/4 toxicities: Fatigue - GEM + Ganitumab 12 mg/kg	38 per 1000	60 per 1000 (30 to 122)	RR 1.59 (0.79 to 3.23)	632 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Fatigue - GEM + Ganitumab 20 mg/kg	38 per 1000	50 per 1000 (21 to 120)	RR 1.32 (0.55 to 3.17)	477 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Neutropenia - FOLFIRINOX	210 per 1000	457 per 1000 (327 to 641)	RR 2.18 (1.56 to 3.06)	331 (1 study ¹)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Neutropenia - GEM + Aflibercept	240 per 1000	305 per 1000 (230 to 401)	RR 1.27 (0.96)	541 (1 study ²)	⊕⊕⊕⊖ moderate ⁸	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 1.67)			
Grade 3/4 toxicities: Neutropenia - GEM + Cisplatin	131 per 1000	241 per 1000 (158 to 366)	RR 1.84 (1.21 to 2.8)	421 (2 studies ^{4,5})	⊕⊕⊕⊖ low ^{6,8}	
Grade 3/4 toxicities: Neutropenia - GEM + Ganitumab 20 mg/kg	205 per 1000	463 per 1000 (353 to 609)	RR 2.26 (1.72 to 2.97)	477 (1 study ⁷)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Neutropenia - GEM + Ganitumab 12 mg/kg	205 per 1000	98 per 1000 (66 to 146)	RR 0.48 (0.32 to 0.71)	632 (1 study ⁷)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Nausea/Vomiting - FOLFIRINOX	83 per 1000	145 per 1000 (78 to 270)	RR 1.75 (0.94 to 3.26)	335 (1 study ¹)	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Aflibercept	37 per 1000	78 per 1000 (37 to 162)	RR 2.11 (1.01 to 4.39)	541 (1 study ²)	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Cisplatin	19 per 1000	34 per 1000 (10 to 116)	RR 1.83 (0.54 to 6.2)	421 (2 studies ^{4,5})	⊕⊕⊕⊖ very low ^{3,6}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Ganitumab 12 mg/kg	63 per 1000	61 per 1000 (33 to 111)	RR 0.96 (0.52 to 1.76)	632 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Ganitumab 20 mg/kg	63 per 1000	32 per 1000 (12 to 82)	RR 0.5 (0.19 to 1.3)	477 (1 study ⁷)	⊕⊕⊕⊖ low ³	
Grade 3/4 toxicities: Thrombocytopenia - FOLFIRINOX	36 per 1000	91 per 1000 (36 to 229)	RR 2.55 (1.01 to 6.4)	333 (1 study ¹)	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Aflibercept	63 per 1000	111 per 1000 (63 to 196)	RR 1.77 (1 to 3.13)	541 (1 study ²)	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities:	51 per 1000	164 per 1000 (86 to 316)	RR 3.2 (1.67	421 (2 studies ^{4,5})	⊕⊕⊕⊖ moderate ⁶	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Thrombocytopenia - GEM + Cisplatin			to 6.14)			
Grade 3/4 toxicities: Thrombocytopenia - GEM + Ganitumab 12 mg/kg	66 per 1000	85 per 1000 (50 to 148)	RR 1.29 (0.75 to 2.24)	632 (1 study ⁷)	⊕⊕⊖⊖ low ³	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Ganitumab 20 mg/kg	66 per 1000	75 per 1000 (38 to 148)	RR 1.13 (0.57 to 2.24)	477 (1 study ⁷)	⊕⊕⊖⊖ low ³	
Grade 3/4 toxicities: Leucopenia - GEM + Cisplatin	47 per 1000	88 per 1000 (42 to 186)	RR 1.89 (0.9 to 3.98)	421 (2 studies ^{4,5})	⊕⊕⊖⊖ low ^{6,8}	
Grade 3/4 toxicities: Leucopenia - GEM + Ganitumab 12 mg/kg	28 per 1000	48 per 1000 (21 to 107)	RR 1.68 (0.74 to 3.78)	632 (1 study ⁷)	⊕⊕⊖⊖ low ³	
Grade 3/4 toxicities: Leucopenia - GEM + Ganitumab 20 mg/kg	28 per 1000	25 per 1000 (8 to 80)	RR 0.88 (0.28 to 2.82)	477 (1 study ⁷)	⊕⊕⊖⊖ low ³	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Conroy et al., 2011 2 Rougier et al., 2013 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 Chao et al., 2013 5 Colucci et al., 2010 6 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text) in one study (Chao et al., 2013), besides the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), and detection bias in both pooled studies 7 Fuchs et al., 2015 8 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 9 The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the potential risk of detection bias (no details about the blinding of outcome assessors)</p>						

1
2

Table 186: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Health-related quality of life)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Global health status	204 per 1000	79 per 1000 (43 to 147)	RR 0.39 (0.21 to 0.72)	320 (1 study ¹)	⊕⊕⊕⊕ high	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Physical functioning	236 per 1000	165 per 1000 (106 to 259)	RR 0.7 (0.45 to 1.1)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Role functioning	274 per 1000	164 per 1000 (107 to 255)	RR 0.6 (0.39 to 0.93)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Emotional functioning	89 per 1000	86 per 1000 (42 to 174)	RR 0.96 (0.47 to 1.95)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Cognitive functioning	102 per 1000	67 per 1000 (33 to 141)	RR 0.66 (0.32 to 1.38)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Social functioning	255 per 1000	140 per 1000 (89 to 224)	RR 0.55 (0.35 to 0.88)	320 (1 study ¹)	⊕⊕⊕⊕ high	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Fatigue	312 per 1000	222 per 1000 (153 to 318)	RR 0.71 (0.49 to 1.02)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Nausea/vomiting	191 per 1000	117 per 1000 (69 to 199)	RR 0.61 (0.36 to 1.04)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Pain	140 per 1000	74 per 1000 (38 to 144)	RR 0.53 (0.27 to 1.03)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Dyspnea	242 per 1000	196 per 1000 (131 to 298)	RR 0.81 (0.54 to 1.23)	320 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Insomnia	96 per 1000	122 per 1000 (65 to 231)	RR 1.28 (0.68 to 2.42)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Loss of appetite	178 per 1000	148 per 1000 (89 to 243)	RR 0.83 (0.5 to 1.36)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Constipation	134 per 1000	111 per 1000 (62 to 199)	RR 0.83 (0.46 to 1.49)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 - Diarrhoea	204 per 1000	226 per 1000 (149 to 344)	RR 1.11 (0.73 to 1.69)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	
HRQL - Number of patients with a clinically significant (10 point) deterioration QLQ-C30 -	51 per 1000	135 per 1000 (62 to 294)	RR 2.65 (1.22 to 5.77)	320 (1 study ¹)	⊕⊕⊖⊖ low ³	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Financial difficulties Follow-up: - between baseline and the end of treatment (6 months). ³						
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Gourgou-Bourgade et al., 2013 2 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 between baseline and the end of treatment (6 months)</p>						

1
2

Table 187: Summary clinical evidence profile for gemcitabine and erlotinib versus gemcitabine, erlotinib and capecitabine

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM + erlotinib + capecitabine	GEM + erlotinib				
Overall response rate (CR + PR)	183 per 1000	216 per 1000 (106 to 446)	RR 1.18 (0.58 to 2.43)	120 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Progression Free Survival	Median time: 4.3 (n.r.) months	Median time: 3.8 (n.r.) months	HR 0.88 (0.58 to 1.34)	120 (1 study ¹)	⊕⊕⊕⊕ moderate ⁴	
Overall survival	Median time: 6.8 (n.r.) months	Median time: 7.7 (n.r.) months	HR 1.09 (0.72 to 1.65)	120 (1 study ¹)	⊕⊕⊕⊕ moderate ⁴	
Grade 3/4 toxicities: any ⁵	567 per 1000	725 per 1000 (550 to 952)	RR 1.28 (0.97 to 1.68)	118 (1 study ¹)	⊕⊕⊕⊕ low ^{2,4}	
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Irigoyen et al., 2017 2 The quality of the evidence was downgraded because of the unclear risk of selection bias and potential risk of performance bias (open-label trial) 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant. 5 including asthenia, diarrhoea, neutropenia, reduced appetite, thrombocytopenia, nausea, anaemia, rash, constipation, mucositis, vomiting, pyrexia, elevated GGT, hand - foot syndrome, and peripheral oedema)</p>						

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
6 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID						

11.2.4.2.2 Adults with locally advanced or metastatic pancreatic cancer

2
3 **Table 188: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Response rate)**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Overall response rate (CR + PR) - 5-FU single-agent	48 per 1000	7 per 1000 (0 to 129)	RR 0.14 (0.01 to 2.71)	126 (1 study ¹)	⊕⊕⊕⊕ low ²	
Overall response rate (CR + PR) - S-1 single-agent	133 per 1000	210 per 1000 (141 to 313)	RR 1.58 (1.06 to 2.36)	489 (1 study ³)	⊕⊕⊕⊕ moderate ⁴	
Overall response rate (CR + PR) - GEM + 5-FU	56 per 1000	69 per 1000 (29 to 162)	RR 1.24 (0.53 to 2.91)	322 (1 study ⁵)	⊕⊕⊕⊕ very low ^{2,6}	
Overall response rate (CR + PR) - GEM + Axitinib	13 per 1000	39 per 1000 (13 to 121)	RR 3.03 (0.99 to 9.29)	613 (1 study ⁷)	⊕⊕⊕⊕ moderate ⁴	
Overall response rate (CR + PR) - GEM + Bevacizumab	100 per 1000	129 per 1000 (82 to 202)	RR 1.29 (0.82 to 2.02)	602 (1 study ⁸)	⊕⊕⊕⊕ low ²	
Overall response rate (CR + PR) - GEM + Capecitabine	116 per 1000	198 per 1000 (148 to 264)	RR 1.70 (1.27 to 2.27)	1050 (3 studies ^{9,10,11})	⊕⊕⊕⊕ moderate ⁴	
Overall response rate (CR + PR) - GEM + Cetuximab	69 per 1000	85 per 1000 (50 to 145)	RR 1.22 (0.72 to 2.08)	660 (1 study ¹²)	⊕⊕⊕⊕ very low ^{2,13}	
Overall response rate (CR +	82 per 1000	102 per 1000 (42 to 247)	RR 1.24	195 (1 study ¹⁴)	⊕⊕⊕⊕ very low ^{2,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
PR) - GEM + Cisplatin			(0.51 to 3)			
Overall response rate (CR + PR) - PEFG	85 per 1000	385 per 1000 (142 to 1000)	RR 4.52 (1.67 to 12.27)	99 (1 study ¹⁵)	⊕⊕⊕⊖ moderate ¹¹	
Overall response rate (CR + PR) - GEM + Exatecan	52 per 1000	69 per 1000 (29 to 159)	RR 1.33 (0.57 to 3.07)	349 (1 study)	⊕⊖⊖⊖ very low ^{2,6}	
Overall response rate (CR + PR) - GEM + Irinotecan	64 per 1000	160 per 1000 (92 to 281)	RR 2.5 (1.43 to 4.39)	490 (2 studies ^{16,17})	⊕⊕⊖⊖ low ^{11,18}	
Overall response rate (CR + PR) - GEM + Marimastat	118 per 1000	92 per 1000 (44 to 194)	RR 0.78 (0.37 to 1.65)	239 (1 study ¹⁹)	⊕⊕⊖⊖ low ¹⁹	
Overall response rate (CR + PR) - GEM + Oxaliplatin	173 per 1000	268 per 1000 (175 to 412)	RR 1.55 (1.01 to 2.38)	313 (1 study)	⊕⊕⊖⊖ low ^{4,11}	
Overall response rate (CR + PR) - GEM + Pemetrexed	71 per 1000	148 per 1000 (89 to 246)	RR 2.09 (1.26 to 3.47)	565 (1 study ²⁰)	⊕⊕⊕⊖ moderate ²¹	
Overall response rate (CR + PR) - GEM + Sorafenib	231 per 1000	125 per 1000 (51 to 307)	RR 0.54 (0.22 to 1.33)	100 (1 study ²²)	⊕⊕⊖⊖ low ²	
Overall response rate (CR + PR) - GEM + Tipifarnib	81 per 1000	59 per 1000 (34 to 102)	RR 0.73 (0.42 to 1.26)	688 (1 study ²³)	⊕⊕⊖⊖ low ²	
Overall response rate (CR + PR) - GEM + S-1	120 per 1000	280 per 1000 (195 to 402)	RR 2.33 (1.62 to 3.34)	584 (2 studies ^{3,24})	⊕⊕⊕⊕ high	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Burris et al., 1997

2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

3 Ueno et al., 2013

4 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
5 Berlin et al., 2002						
6	The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias					
7 Kindler et al., 2011						
8 Kindler et al., 2010						
9 Cunningham et al., 2009						
10 Herrmann et al., 2007						
11	The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias					
12 Philip et al., 2010						
13	The quality of the evidence was downgraded because of the unclear risk of detection bias and the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions)					
14 Heinemann et al., 2006						
15 Reni et al., 2005						
16 Rocha Lima et al., 2004						
17 Stathopoulos et al., 2006						
18	Serious heterogeneity. I-squared = 39%					
19 Bramhall et al., 2002						
20 Oettle et al., 2005						
21	The quality of the evidence was downgraded because of the high risk of detection bias (no blinding of outcome assessors) and the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions)					
22 Gonçalves et al., 2012						
23 Van-Cutsem et al., 2004						
24 Sudo et al., 2014						
25 Lee et al., 2017						

1
2

Table 189: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Progression-free survival, overall survival)

Outcome s	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Other Chemotherapy	GEM alone				
Progression Free Survival - S-1 single-agent	Median time: 4.1 (3.0 to 4.4) months	Median time: 3.8 (2.9 to 4.2) months	HR 1.09 (0.9 to 1.32)	834 (1 study ¹)	⊕⊕⊕⊖ moderate ⁶	
Progression Free Survival - GEM + 5-FU	Median time: 3.4 (n.r.) months	Median time: 2.2 (n.r.) months	HR 0.77 (0.62 to 0.96)	322 (1 study ³)	⊕⊕⊕⊖ moderate ⁴	
Progression Free Survival - GEM + Axitinib	Median time: 4.4 (4.0 to 5.6) months	Median time: 4.4 (3.7 to 5.2) months	HR 1.01 (0.78 to 1.3)	632 (1 study ⁵)	⊕⊕⊕⊖ moderate ⁶	
Progression Free Survival -	-	-	HR 0.80 (0.72 to 0.90)	1050 (3)	⊕⊕⊖⊖ low ^{4,11}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
GEM + Capecitabine				studies ^{7,8,29)}		
Progression Free Survival - GEM + Bevacizumab	Median time: 3.8 (2.4 to 3.7) months	Median time: 2.9 (2.4 to 3.7) months	HR 0.96 (0.81 to 1.15) ⁹⁾	602 (1 study ²⁷⁾)	⊕⊕⊕⊖ moderate ⁶⁾	
Progression Free Survival - GEM + Cetuximab	Median time: 3.4 (n.r.) months	Median time: 3.0 (n.r.) months	HR 1.07 (0.93 to 1.23)	766 (1 study ¹⁰⁾)	⊕⊕⊕⊖ low ^{6,11)}	
Progression Free Survival - GEM + Cisplatin	Median time: 5.3 (n.r.) months	Median time: 3.1 (n.r.) months	HR 0.69 (0.5 to 0.95)	195 (1 study ¹²⁾)	⊕⊕⊕⊖ moderate ¹¹⁾	
Progression Free Survival - PEFG	Median time: 3.9 (IQR: 2.1-7.1) months	Median time: 3.8 (IQR: 2.7-8.2) months	HR 0.51 (0.33 to 0.78)	104 (1 study ¹³⁾)	⊕⊕⊕⊖ moderate ¹¹⁾	
Progression Free Survival - GEM + Elpamotide ¹⁴⁾	-	-	Not estimable ¹⁴⁾	153 (1 study ¹⁵⁾)	⊕⊕⊕⊖ moderate ^{14,16,17)}	
Progression Free Survival - GEM + Erlotinib	Median time: 3.75 (n.r.) months	Median time: 3.55 (n.r.) months	HR 0.77 (0.65 to 0.92)	569 (1 study ¹⁸⁾)	⊕⊕⊕⊕ high ¹⁴⁾	
Progression Free Survival - GEM + Irinotecan	Median time: 3.5 (2.8 to 4.2) months	Median time: 3.0 (2.5 to 3.7) months	HR 0.98 (0.77 to 1.25)	180 (1 study ¹⁹⁾)	⊕⊕⊕⊖ moderate ⁶⁾	
Progression Free Survival - GEM + Marimastat	Median Time: 92.5 (n.r.) days	Median time: 90.0 (n.r.) days	HR 0.95 (0.73 to 1.23)	239 (1 study ²⁰⁾)	⊕⊕⊕⊖ moderate ⁶⁾	
Progression Free Survival - GEM + Oxaliplatin	-	-	HR 0.83 (0.72 to 0.97)	1128 (2 studies ^{21,22)})	⊕⊕⊕⊖ moderate ⁶⁾	

Outcome s	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Progression Free Survival - GEM + Sorafenib	Median time: 3.8 (3.1 to 6) months	Median time: 5.7 (3.7 to 7.5) months	HR 1.04 (0.7 to 1.55)	104 (1 study ²³)	⊕⊕⊕⊖ moderate ²	
Progression Free Survival - GEM + Tipifarnib	Median Time: 109 (n.r.) days	Median time: 112 (n.r.) days	HR 1.03 (0.87 to 1.22)	688 (1 study ²⁴)	⊕⊕⊕⊖ moderate ⁶	
Progression Free Survival - GEM + S-1	-	-	HR 0.65 (0.57 to 0.75)	658 (2 studies ^{1,25})	⊕⊕⊕⊕ high	
Overall Survival - 29	-	-30	See comment	9989 (23 studies ³¹)	⊕⊕⊕⊕ high	FOLFIRINOX, PEFG, GEM/erlotinib+/-bevacizumab, GEM/capecitabine, and GEM/oxaliplatin were associated with significant improvements in overall survival ³²
Overall Survival - 5-FU single-agent	-	-	HR 1.75 (1.21-2.54)	126 (1 study ²⁶)	⊕⊕⊕⊕ high	
Overall Survival - S-1 single-agent	Median time: 9.7 (7.6 to 10.8) months	Median time: 8.8 (8.0 to 9.7) months	HR 0.96 (0.71 to 1.3)	834 (1 study ¹)	⊕⊕⊕⊖ moderate ⁶	
Overall Survival - GEM + Bevacizumab	Median time: 5.0 (n.r.) months	Median time: 5.5 (n.r.) months	HR 0.96 (0.81 to 1.15)	602 (1 study ²⁷)	⊕⊕⊕⊖ moderate ⁶	
Overall Survival - GEM + Elpamotide	Median time: 8.4 (7.5 to 10.2) months	Median time: 8.5 (7.3 to 9.7) months	HR 0.87 (0.49 to 1.56)	153 (1 study ¹⁵)	⊕⊕⊕⊖ moderate ⁶	
Overall Survival - GEM + Masitinib	Median time: 7.7 (6.1 to 10.6) months	Median time: 7.0 (6.1 to 10.6) months	HR 0.89 (0.7 to 1.13)	353 (1 study ²⁸)	⊕⊕⊕⊖ moderate ⁶	

Outcome s	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Overall Survival - GEM + S-1	-	-	HR 0.89 (0.74 to 1.08)	0 (2 studies ^{1,25})	⊕⊕⊕⊖ moderate ⁶	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; HR: Hazard ratio;</p> <p>1 Ueno et al., 2013 3 Berlin et al., 2002 4 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), besides the unclear risk of performance bias (no details given in the text) 5 Kindler et al., 2011 6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant. 7 Cunningham et al., 2009 8 Herrmann et al., 2007 9 The median PFS was 3.8 months (95% CI, 3.4 to 4.0 months) and 2.9 months (95% CI, 2.4 to 3.7 months) for the bevacizumab and placebo arms, respectively (P .075). 10 Philip et al., 2010 11 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors) 12 Heinemann et al., 2006 13 Reni et al., 2005 14 The quality of the evidence was downgraded because of the potential risk of selective findings reporting for this outcome. 15 Yamaue et al., 2015 16 The median PFS length was 3.71 months (95% CI, 2.10 – 3.98) in the Active group and 3.75 months (95% CI, 2.27 – 5.59) in the Placebo group. There were no significant differences found between the two groups (log – rank P-value, 0.332). 17 From data provided by the authors about this outcome is not possible estimate the precision in the effect size estimates. 18 Moore et al., 2007 19 Rocha Lima et al., 2004 20 Bramhall et al., 2002 21 Louvet et al., 2005 22 Poplin et al., 2006 (2009) 23 Gonçalves et al., 2012 24 Van-Cutsem et al., 2004 25 Sudo et al., 2014 26 Burris et al., 1997 27 Kindler et al., 2010 28 Deplanque et al., 2015 29 FOLFIRINOX; Gemcitabine + 5-FU; Gemcitabine + Axitinib; Gemcitabine + Capecitabine; Gemcitabine + Capecitabine; Gemcitabine + Cetuximab; Gemcitabine + Cisplatin; Gemcitabine + Cisplatin; Gemcitabine + Erlotinib; Gemcitabine + Erlotinib; Gemcitabine + Erlotinib then Capecitabine; Gemcitabine + Exatecan; Gemcitabine + Irinotecan; Gemcitabine + Irinotecan; Gemcitabine + Marimastat; Gemcitabine + Nab-paclitaxel; Gemcitabine + Oxaliplatin; Gemcitabine + oxaliplatin; Gemcitabine + Pemetrexed; Gemcitabine + Sorafenib; Gemcitabine + Tipifarnib; Gemcitabine, 5-FU + Folinic Acid; and PEFG 30 The majority of the trials compared Gemcitabine single-agent to an experimental treatment. 31 Abou-Alfa et al. 2006; Berlin et al. 2002; Bramhall et al. 2002; Colucci et al. 2010; Conroy et al. 2011; Cunningham et al. 2009; Gonçalves et al. 2012; Heinemann et al. 2006; Heinemann et al. 2012; Herrmann et al. 2007; Kindler et al. 2011; Louvet et al. 2005; Moore et al. 2007; Oettle et al. 2005; Philip et al. 2010; Poplin et al. 2006 (2009) ; Reni et al. 2005; Riess et al. 2005; Rocha Lima et al. 2004; Stathopoulos et al. 2006; Van-Cutsem et al. 2004; Van-Cutsem et al. 2009; Von-Hoff et al. 2013 32 Please use the following hyperlinks for details on the findings: http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-14-471/MediaObjects/12885_2013_Article_4675_Fig2_HTML.jpg: Figure 2-Network of eligible trials where center node represents the reference comparator: Gemcitabine. http://media.springernature.com/full/springer-static/image/art%3A10.1186%2F1471-2407-14-471/MediaObjects/12885_2013_Article_4675_Fig3_HTML.jpg: Figure 3-Indirect comparisons for overall survival: HRs and 95% CIs for various treatment comparisons.</p>						

1
2

Table 190: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - nausea/vomiting)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Nausea/Vomiting - 5-FU single-agent	127 per 1000	48 per 1000 (13 to 171)	RR 0.38 (0.1 to 1.35)	126 (1 study ¹)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Nausea/Vomiting - S-1 single-agent	26 per 1000	33 per 1000 (13 to 88)	RR 1.29 (0.49 to 3.42)	545 (1 study ³)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + 5-FU	120 per 1000	95 per 1000 (51 to 180)	RR 0.79 (0.42 to 1.5)	316 (1 study ⁵)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Axitinib	58 per 1000	82 per 1000 (46 to 147)	RR 1.4 (0.78 to 2.52)	613 (1 study ⁶)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Capecitabine	89 per 1000	107 per 1000 (74 to 155)	RR 1.20 (0.83 to 1.74)	1017 (3 studies ^{7,8,29})	⊕⊖⊖⊖ very low ^{2,9}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Cetuximab	54 per 1000	92 per 1000 (53 to 158)	RR 1.71 (0.99 to 2.95)	716 (1 study ¹⁰)	⊕⊕⊕⊖ low ^{9,11}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Cisplatin	62 per 1000	225 per 1000 (95 to 529)	RR 3.63 (1.54 to 8.56)	195 (1 study ¹²)	⊕⊕⊕⊕ moderate ⁹	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Elpamotide	38 per 1000	20 per 1000 (3 to 138)	RR 0.53 (0.08 to 3.66)	153 (1 study ¹⁵)	⊕⊕⊕⊖ low ¹¹	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Exatecan	57 per 1000	89 per 1000 (40 to 198)	RR 1.56 (0.7 to 3.46)	325 (1 study ¹⁶)	⊕⊖⊖⊖ very low ^{2,17}	
Grade 3/4 toxicities: Nausea/Vomiting	142 per 1000	228 per 1000 (155 to 331)	RR 1.6 (1.09 to 2.3)	472 (2 studies ^{18,19})	⊕⊕⊕⊖ low ^{11,20}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
g - GEM + Irinotecan			to 2.33)			
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Marimastat	218 per 1000	109 per 1000 (59 to 201)	RR 0.5 (0.27 to 0.92)	239 (1 study ²¹)	⊕⊕⊕⊖ moderate ¹	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Oxaliplatin	62 per 1000	171 per 1000 (112 to 263)	RR 2.77 (1.81 to 4.25)	840 (2 studies ^{22,23})	⊕⊕⊕⊖ moderate ²⁰	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Pemetrexed	66 per 1000	66 per 1000 (35 to 124)	RR 1 (0.53 to 1.88)	546 (1 study ²⁴)	⊕⊖⊖⊖ very low ^{2,25}	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + Tipifarnib	183 per 1000	137 per 1000 (100 to 184)	RR 0.75 (0.55 to 1.01)	915 (2 studies ^{26,27})	⊕⊕⊕⊖ moderate ¹	
Grade 3/4 toxicities: Nausea/Vomiting - GEM + S-1	31 per 1000	94 per 1000 (47 to 188)	RR 2.99 (1.49 to 5.99)	636 (2 studies ^{3,28})	⊕⊕⊕⊕ high	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Burris et al., 1997

2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

3 Ueno et al., 2013

4 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), besides the unclear risk of performance bias (no details given in the text)

5 Berlin et al., 2002

6 Kindler et al., 2011

7 Cunningham et al. 2009

8 Herrmann et al. 2007

9 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors)

10 Philip et al. 2010

11 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

12 Heinemann et al. 2006

14 The quality of the evidence was downgraded because of the potential risk of performance bias (no detail on blinding of patients/ care providers delivering the interventions) and the high detection bias (not masking of outcome assessors)

15 Yamaue et al. 2015

16 Abou-Alfa et al. 2006

17 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias

18 Rocha Lima et al. 2004

19 Stathopoulos et al. 2006

20 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
21 Bramhall et al. 2002 22 Louvet et al. 2005 23 Poplin et al. 2006 (2009) 24 Oettle et al. 2005 25 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and high risk of detection bias 26 Eckhardt et al. 2009 27 Van-Cutsem et al. 2004 28 Sudo et al. 2014 29 Lee et al. 2017						

1
2

Table 191: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - diarrhoea)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Diarrhoea - 5-FU single-agent	16 per 1000	48 per 1000 (5 to 446)	RR 3 (0.32 to 28.07)	126 (1 study ¹)	⊕⊕⊕⊕ low ²	
Grade 3/4 toxicities: Diarrhoea - S-1 single-agent	11 per 1000	55 per 1000 (16 to 188)	RR 5.02 (1.47 to 17.14)	545 (1 study ³)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Diarrhoea - GEM + 5-FU	25 per 1000	63 per 1000 (20 to 197)	RR 2.5 (0.8 to 7.8)	316 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,5}	
Grade 3/4 toxicities: Diarrhoea - GEM + Axitinib	16 per 1000	13 per 1000 (4 to 48)	RR 0.81 (0.22 to 2.98)	613 (1 study ⁷)	⊕⊕⊕⊕ low ²	
Grade 3/4 toxicities: Diarrhoea - GEM + Capecitabine	28 per 1000	42 per 1000 (22 to 81)	RR 1.53 (0.80 to 2.91)	1017 (3 studies ⁸)	⊕⊕⊕⊕ very low ^{2,9}	
Grade 3/4 toxicities: Diarrhoea - GEM + Cetuximab	25 per 1000	28 per 1000 (11 to 67)	RR 1.09 (0.45 to 2.66)	716 (1 study ¹⁰)	⊕⊕⊕⊕ very low ²	
Grade 3/4 toxicities: Diarrhoea -	52 per 1000	30 per 1000 (8 to 125)	RR 0.59 (0.15	195 (1 study ¹¹)	⊕⊕⊕⊕ very low ^{2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
GEM + Cisplatin			to 2.42)			
Grade 3/4 toxicities: Diarrhoea - GEM + Erlotinib	7 per 1000	21 per 1000 (4 to 105)	RR 2.98 (0.61 to 14.63)	562 (1 study)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Diarrhoea - GEM + Exatecan	6 per 1000	12 per 1000 (1 to 130)	RR 1.87 (0.17 to 20.41)	325 (1 study ¹³)	⊕⊕⊕⊖ very low ^{2,14}	
Grade 3/4 toxicities: Diarrhoea - GEM + Irinotecan	21 per 1000	145 per 1000 (57 to 370)	RR 6.92 (2.71 to 17.67)	472 (2 studies ^{15,16})	⊕⊕⊕⊖ low ^{17,18}	
Grade 3/4 toxicities: Diarrhoea - GEM + Oxaliplatin	24 per 1000	60 per 1000 (29 to 123)	RR 2.5 (1.22 to 5.15)	840 (2 studies ^{19,20})	⊕⊕⊕⊖ low ^{6,17}	
Grade 3/4 toxicities: Diarrhoea - GEM + Pemetrexed	7 per 1000	29 per 1000 (6 to 137)	RR 4 (0.86 to 18.67)	546 (1 study ²¹)	⊕⊕⊕⊖ low ^{6,17}	
Grade 3/4 toxicities: Diarrhoea - GEM + Sorafenib	58 per 1000	40 per 1000 (7 to 230)	RR 0.69 (0.12 to 3.98)	102 (1 study ²²)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Diarrhoea - GEM + Tipifarnib	22 per 1000	29 per 1000 (13 to 66)	RR 1.34 (0.6 to 3.02)	915 (2 studies ^{23,24})	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Diarrhoea - GEM + S-1	16 per 1000	41 per 1000 (15 to 112)	RR 2.59 (0.94 to 7.14)	636 (2 studies ^{3,25})	⊕⊕⊕⊖ moderate ⁶	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Burris et al. 1997

2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MID

3 Ueno et al. 2013

4 Berlin et al. 2002

5 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), besides the unclear risk of performance bias (no details given in the text)

6 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

7 Kindler et al. 2011

8 Herrmann et al. 2007, Cunningham et al., 2009 and Lee et al. 2017

9 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
						<p>patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors)</p> <p>10 Philip et al. 2010</p> <p>11 Heinemann et al. 2006</p> <p>13 Abou-Alfa et al. 2006</p> <p>14 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias</p> <p>15 Rocha Lima et al. 2004</p> <p>16 Stathopoulos et al. 2006</p> <p>17 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias</p> <p>18 Serious heterogeneity. I-squared = 73%</p> <p>19 Louvet et al. 2005</p> <p>20 Poplin et al. 2006 (2009)</p> <p>21 Oettle et al. 2005</p> <p>22 Gonçalves et al. 2012</p> <p>23 Eckhardt et al. 2009</p> <p>24 Van-Cutsem et al. 2004</p> <p>25 Sudo et al. 2014</p>

1
2

Table 192: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - fatigue)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Fatigue - S-1 single-agent	37 per 1000	66 per 1000 (31 to 141)	RR 1.81 (0.85 to 3.84)	545 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Grade 3/4 toxicities: Fatigue - GEM + Axitinib	68 per 1000	89 per 1000 (51 to 153)	RR 1.3 (0.75 to 2.25)	613 (1 study ³)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities: Fatigue - GEM + Cetuximab	180 per 1000	200 per 1000 (148 to 270)	RR 1.11 (0.82 to 1.5)	716 (1 study ⁵)	⊕⊕⊖⊖ low ^{2,6}	
Grade 3/4 toxicities: Fatigue - GEM + Erlotinib	54 per 1000	53 per 1000 (26 to 107)	RR 0.99 (0.49 to 1.99)	562 (1 study ⁷)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities: Fatigue -	32 per 1000	83 per 1000 (31 to 226)	RR 2.62 (0.96 to 7.1)	325 (1 study ⁸)	⊕⊖⊖⊖ very low ^{2,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
GEM + Exatecan						
Grade 3/4 toxicities: Fatigue - GEM + Irinotecan	154 per 1000	168 per 1000 (103 to 272)	RR 1.09 (0.67 to 1.77)	342 (1 study ¹⁰)	⊕⊕⊕⊖ very low ^{10,11}	
Grade 3/4 toxicities: Fatigue - GEM + Marimastat	59 per 1000	116 per 1000 (49 to 279)	RR 1.98 (0.83 to 4.74)	239 (1 study ¹²)	⊕⊕⊕⊖ low ⁴	
Grade 3/4 toxicities: Fatigue - GEM + Oxaliplatin	189 per 1000	170 per 1000 (119 to 246)	RR 0.9 (0.63 to 1.3)	527 (1 study ¹³)	⊕⊕⊕⊖ low ^{2,9}	
Grade 3/4 toxicities: Fatigue - GEM + Pemetrexed	66 per 1000	150 per 1000 (88 to 255)	RR 2.28 (1.34 to 3.86)	546 (1 study ¹⁴)	⊕⊕⊕⊖ moderate ¹⁵	
Grade 3/4 toxicities: Fatigue - GEM + Tipifarnib	133 per 1000	121 per 1000 (86 to 168)	RR 0.91 (0.65 to 1.27)	915 (2 studies ^{16,17})	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities: Fatigue - GEM + S-1	34 per 1000	41 per 1000 (19 to 89)	RR 1.19 (0.55 to 2.57)	636 (2 studies ^{1,18})	⊕⊕⊕⊖ low ⁴	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

1 Ueno et al. 2013

2 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

3 Kindler et al. 2011

4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

5 Philip et al. 2010

6 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors)

7 Moore et al. 2007

8 Abou-Alfa et al. 2006

9 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias

10 Rocha Lima et al. 2004

11 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias

12 Bramhall et al. 2002

13 Poplin et al. 2006 (2009)

14 Oettle et al. 2005

15 No explanation was provided

16 Eckhardt et al. 2009

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
17 Van-Cutsem et al. 2004						
18 Sudo et al. 2014						

1
2

Table 193: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - neutropenia)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Neutropenia - 5-FU single-agent	254 per 1000	48 per 1000 (15 to 155)	RR 0.19 (0.06 to 0.61)	126 (1 study ¹)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Neutropenia - S-1 single-agent	410 per 1000	90 per 1000 (57 to 131)	RR 0.22 (0.14 to 0.32)	545 (1 study ²)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Neutropenia - GEM + Axitinib	3 per 1000	1 per 1000 (0 to 27)	RR 0.34 (0.01 to 8.23)	613 (1 study ³)	⊕⊕⊕⊖ low ⁴	
Grade 3/4 toxicities: Neutropenia - GEM + Bevacizumab	110 per 1000	119 per 1000 (75 to 191)	RR 1.08 (0.68 to 1.73)	540 (1 study ³)	⊕⊕⊕⊖ low ⁴	
Grade 3/4 toxicities: Neutropenia - GEM + Capecitabine	190 per 1000	274 per 1000 (219 to 345)	RR 1.44 (1.15 to 1.81)	1017 (3 studies ^{5,6,25})	⊕⊕⊕⊖ low ^{7,8}	
Grade 3/4 toxicities: Neutropenia - GEM + Cetuximab	239 per 1000	232 per 1000 (180 to 302)	RR 0.97 (0.75 to 1.26)	716 (1 study ⁹)	⊕⊕⊕⊖ very low ^{4,10}	
Grade 3/4 toxicities: Neutropenia - GEM + Elpamotide	566 per 1000	481 per 1000 (351 to 657)	RR 0.85 (0.62 to 1.16)	153 (1 study ¹¹)	⊕⊕⊕⊖ moderate 8	
Grade 3/4 toxicities: Neutropenia - GEM + Exatecan	146 per 1000	303 per 1000 (195 to 472)	RR 2.07 (1.33 to 3.22)	325 (1 study ¹²)	⊕⊕⊕⊖ low ¹³	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities: Neutropenia - GEM + Irinotecan	157 per 1000	267 per 1000 (134 to 530)	RR 1.7 (0.85 to 3.37)	130 (1 study ¹⁴)	⊕⊕⊕⊖ low ^{8,15}	
Grade 3/4 toxicities: Neutropenia - GEM + Oxaliplatin	281 per 1000	242 per 1000 (194 to 306)	RR 0.86 (0.69 to 1.09)	840 (2 studies ^{16,17})	⊕⊖⊖⊖ very low ^{8,18,19}	
Grade 3/4 toxicities: Neutropenia - GEM + Pemetrexed	128 per 1000	450 per 1000 (322 to 631)	RR 3.51 (2.51 to 4.92)	546 (1 study ²⁰)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Neutropenia - GEM + Sorafenib	288 per 1000	260 per 1000 (138 to 490)	RR 0.9 (0.48 to 1.7)	102 (1 study ²¹)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities: Neutropenia - GEM + Tipifarnib	324 per 1000	408 per 1000 (347 to 486)	RR 1.26 (1.07 to 1.5)	915 (2 studies ^{22,23})	⊕⊕⊕⊖ moderate ⁸	
Grade 3/4 toxicities: Neutropenia - GEM + S-1	379 per 1000	596 per 1000 (504 to 706)	RR 1.57 (1.33 to 1.86)	636 (2 studies ^{2,24})	⊕⊕⊕⊕ high	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1 Burris et al. 1997

2 Ueno et al. 2013

3 Kindler et al. 2010

4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

5 Cunningham et al. 2009

6 Herrmann et al. 2007

7 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors) in Cunningham et al. 2009, and the unclear risk of selection bias in Herrmann et al. 2007.

8 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

9 Philip et al. 2010

10 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors)

11 Yamaue et al. 2015

12 Abou-Alfa et al. 2006

13 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>the interventions), besides the unclear risk of detection bias</p> <p>14 Stathopoulos et al. 2006#</p> <p>15 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias and the potential risk of attrition bias</p> <p>16 Louvet et al. 2005</p> <p>17 Poplin et al. 2006 (2009)</p> <p>18 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias</p> <p>19 Serious heterogeneity. I-squared = 89%</p> <p>20 Oettle et al. 2005</p> <p>21 Gonçalves et al. 2012</p> <p>22 Eckhardt et al. 2009</p> <p>23 Van-Cutsem et al. 2004</p> <p>24 Sudo et al. 2014</p> <p>25 Lee et al. 2017</p>						

1
2

Table 194: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - thrombocytopenia)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Thrombocytopenia - GEM + 5-FU	105 per 1000	190 per 1000 (109 to 331)	RR 1.81 (1.04 to 3.15)	320 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3}	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Axitinib	3 per 1000	1 per 1000 (0 to 27)	RR 0.34 (0.01 to 8.23)	613 (1 study ⁴)	⊕⊕⊖⊖ low ⁵	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Bevacizumab	46 per 1000	43 per 1000 (20 to 95)	RR 0.95 (0.43 to 2.08)	540 (1 study ⁶)	⊕⊕⊖⊖ low ⁵	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Capecitabine	62 per 1000	70 per 1000 (44 to 112)	RR 1.14 (0.72 to 1.82)	1017 (3 studies ^{7,8,24})	⊕⊖⊖⊖ very low ^{3,9,10}	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Cisplatin	103 per 1000	41 per 1000 (13 to 126)	RR 0.4 (0.13 to 1.22)	195 (1 study ¹¹)	⊕⊕⊖⊖ low ³	
Grade 3/4 toxicities:	151 per 1000	149 per 1000 (68 to 331)	RR 0.99	153 (1 study ¹²)	⊕⊕⊖⊖ low ⁵	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Thrombocytopenia - GEM + Elpamotide			(0.45 to 2.19)			
Grade 3/4 toxicities: Thrombocytopenia - GEM + Exatecan	45 per 1000	155 per 1000 (69 to 346)	RR 3.47 (1.55 to 7.77)	325 (1 study ¹³)	⊕⊕⊕⊖ low ¹⁴	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Irinotecan	0 per 1000	0 per 1000 (0 to 0)	RR 8.15 (0.43 to 154.64)	130 (1 study ¹⁵)	⊕⊖⊖⊖ very low ⁵	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Oxaliplatin	32 per 1000	140 per 1000 (54 to 361)	RR 4.37 (1.7 to 11.25)	313 (1 study ¹⁶)	⊕⊕⊕⊖ moderate ¹⁷	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Pemetrexed	62 per 1000	179 per 1000 (106 to 304)	RR 2.88 (1.7 to 4.88)	546 (1 study ¹⁸)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Sorafenib	115 per 1000	60 per 1000 (16 to 227)	RR 0.52 (0.14 to 1.97)	102 (1 study ¹⁹)	⊕⊕⊕⊖ low ⁵	
Grade 3/4 toxicities: Thrombocytopenia - GEM + Tipifarnib	135 per 1000	164 per 1000 (120 to 224)	RR 1.22 (0.89 to 1.66)	915 (2 studies ^{20,21})	⊕⊕⊕⊖ moderate ¹⁰	
Grade 3/4 toxicities: Thrombocytopenia - GEM + S-1	16 per 1000	53 per 1000 (21 to 136)	RR 3.4 (1.33 to 8.7)	636 (2 studies ^{22,23})	⊕⊕⊕⊕ high	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

1 Berlin et al. 2002

2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), besides the unclear risk of performance bias (no details given in the text)

3 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

4 Kindler et al. 2011

5 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
6 Kindler et al. 2010						
7 Cunningham et al. 2009						
8 Herrmann et al. 2007						
9 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors) in Cunningham et al. 2009, and the unclear risk of selection bias in Herrmann et al. 2007.						
10 Serious heterogeneity. I-squared = 80%						
11 Heinemann et al. 2006						
12 Yamaue et al. 2015						
13 Abou-Alfa et al. 2006						
14 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details provided in the text), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias						
15 Stathopoulos et al. 2006						
16 Louvet et al. 2005						
17 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias						
18 Oettle et al. 2005						
19 Gonçalves et al. 2012						
20 Eckhardt et al. 2009						
21 Van-Cutsem et al. 2004						
22 Sudo et al. 2014						
23 Ueno et al. 2013						
24 Lee et al. 2017						

1
2

Table 195: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Adverse events - leucopenia)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
Grade 3/4 toxicities: Leucopenia - S-1 single-agent	187 per 1000	37 per 1000 (19 to 71)	RR 0.2 (0.1 to 0.38)	545 (1 study ¹)	⊕⊕⊕⊕ high	
Grade 3/4 toxicities: Leucopenia - GEM + 5-FU	101 per 1000	183 per 1000 (104 to 324)	RR 1.81 (1.03 to 3.2)	316 (1 study ²)	⊕⊕⊕⊖ low ^{3,4}	
Grade 3/4 toxicities: Leucopenia - GEM + Axitinib	See comments	See comments	Not estimable	613 (1 study ⁵)	⊕⊕⊕⊕ high	None event was registered
Grade 3/4 toxicities: Leucopenia - GEM + Cetuximab	146 per 1000	111 per 1000 (75 to 163)	RR 0.76 (0.51 to 1.11)	716 (1 study ⁶)	⊕⊕⊕⊖ low ^{4,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities: Leucopenia - GEM + Cisplatin	82 per 1000	102 per 1000 (42 to 247)	RR 1.24 (0.51 to 3)	195 (1 study ⁸)	⊕⊕⊕⊕ very low ^{7,9}	
Grade 3/4 toxicities: Leucopenia - GEM + Elpamotide	434 per 1000	308 per 1000 (204 to 473)	RR 0.71 (0.47 to 1.09)	153 (1 study ¹⁰)	⊕⊕⊕⊕ moderate ⁴	
Grade 3/4 toxicities: Leucopenia - GEM + Oxaliplatin	159 per 1000	121 per 1000 (80 to 186)	RR 0.76 (0.5 to 1.17)	527 (1 study ¹¹)	⊕⊕⊕⊕ moderate ⁴	
Grade 3/4 toxicities: Leucopenia - GEM + S-1	185 per 1000	326 per 1000 (202 to 525)	RR 1.76 (1.09 to 2.84)	636 (2 studies ^{1,12})	⊕⊕⊕⊕ moderate ¹³	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Ueno et al. 2013 2 Berlin et al. 2002 3 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about the allocation method), besides the unclear risk of performance bias (no details given in the text) 4 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 5 Kindler et al. 2011 6 Philip et al. 2010 7 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors) 8 Heinemann et al. 2006 9 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 10 Yamaue et al. 2015 11 Poplin et al. 2006 (2009) 12 Sudo et al. 2014 13 Serious heterogeneity. I-squared = 36%</p>						

1
2

Table 196: Summary clinical evidence profile for gemcitabine versus other chemotherapy (Health-related quality of life)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy	GEM alone				
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment)		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-		319 (1 study ¹)	⊕⊕⊕⊕ low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
[LASA] indicators - Physical well-being		assessment [LASA] indicators - physical well-being in the intervention groups was 5 higher (4.8 lower to 14.8 higher)				
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Mood		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - mood in the intervention groups was 6 higher (3.8 lower to 15.8 higher)		319 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Pain		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - pain in the intervention groups was 8 higher (1.8 lower to 17.8 higher)		319 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Tiredness		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators -		319 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		tiredness in the intervention groups was 2 higher (7.8 lower to 11.8 higher)				
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Functional performance		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - functional performance in the intervention groups was 8 higher (1.8 lower to 17.8 higher)		319 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3}	
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Coping effort		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - coping effort in the intervention groups was 4 higher (5.8 lower to 13.8 higher)		319 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3}	
HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - Treatment burden		The mean HRQL: GEM + Capecitabine versus GEM - mean score difference at 6 months (linear-analogue self-assessment [LASA] indicators - treatment burden in the intervention		319 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		groups was 4 higher (5.8 lower to 13.8 higher)				
HRQL: GEM + Cetuximab versus alone - Emotional Well-Being Score at 5, 13, and 17 weeks follow-up - 5 weeks follow-up		The mean HRQL: GEM + cetuximab versus alone - emotional well-being score at 5, 13, and 17 weeks follow-up in the intervention groups was 0.3 lower (0.69 lower to 0.09 higher)		540 (1 study ⁵)	⊕⊕⊖⊖ low ^{3,6}	
HRQL: GEM + Cetuximab versus alone - Emotional Well-Being Score at 5, 13, and 17 weeks follow-up - 13 weeks follow-up		The mean HRQL: GEM + cetuximab versus alone - emotional well-being score at 5, 13, and 17 weeks follow-up in the intervention groups was 0.2 higher (0.34 lower to 0.74 higher)		340 (1 study ⁵)	⊕⊕⊖⊖ low ^{3,6}	
HRQL: GEM + Cetuximab versus alone - Emotional Well-Being Score at 5, 13, and 17 weeks follow-up - 17 weeks follow-up		The mean HRQL: GEM + cetuximab versus alone - emotional well-being score at 5, 13, and 17 weeks follow-up in the intervention groups was 0.5 higher (0.01 lower to 1.01 higher)		288 (1 study ⁵)	⊕⊕⊖⊖ low ^{3,6}	
HRQL: GEM + cisplatin versus GEM alone at 6 treatment cycles (Spitzer 5-Item Index)		The mean HRQL: GEM + cisplatin versus GEM alone at 6 treatment cycles (spitzer		195 (1 study ⁷)	⊕⊕⊕⊖ moderate ⁶	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		5-item index) in the intervention groups was 0.4 lower (0.66 to 0.14 lower)				
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Global health status	286 per 1000	551 per 1000 (251 to 1000)	RR 1.93 (0.88 to 4.22)	41 (1 study ⁸)	⊕⊕⊖⊖ low ^{3,4}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Physical functioning	87 per 1000	261 per 1000 (58 to 1000)	RR 3 (0.67 to 13.34)	46 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Role functioning	318 per 1000	216 per 1000 (80 to 582)	RR 0.68 (0.25 to 1.83)	45 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Emotional functioning	182 per 1000	429 per 1000 (155 to 1000)	RR 2.36 (0.85 to 6.5)	43 (1 study ⁸)	⊕⊕⊖⊖ low ^{3,4}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 -	208 per 1000	217 per 1000 (73 to 652)	RR 1.04 (0.35 to 3.13)	47 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Cognitive functioning						
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Social functioning	294 per 1000	332 per 1000 (129 to 865)	RR 1.13 (0.44 to 2.94)	38 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Fatigue	250 per 1000	410 per 1000 (175 to 962)	RR 1.64 (0.7 to 3.85)	46 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Nausea/vomiting	53 per 1000	95 per 1000 (9 to 968)	RR 1.81 (0.18 to 18.39)	40 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Pain	409 per 1000	638 per 1000 (352 to 1000)	RR 1.56 (0.86 to 2.82)	44 (1 study ⁸)	⊕⊕⊖⊖ low ^{3,4}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Dyspnea	130 per 1000	173 per 1000 (44 to 691)	RR 1.33 (0.34 to 5.3)	46 (1 study)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement	333 per 1000	347 per 1000 (157 to 770)	RR 1.04 (0.47 to 2.31)	47 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
QLQ-C30 - Insomnia						
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Loss of appetite	292 per 1000	260 per 1000 (102 to 659)	RR 0.89 (0.35 to 2.26)	47 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Constipation	304 per 1000	304 per 1000 (128 to 730)	RR 1 (0.42 to 2.4)	46 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Diarrhoea	87 per 1000	190 per 1000 (39 to 935)	RR 2.19 (0.45 to 10.75)	44 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
HRQL: PEFG versus GEM - Number of patients with a clinically significant improvement QLQ-C30 - Financial difficulties	95 per 1000	90 per 1000 (14 to 588)	RR 0.95 (0.15 to 6.17)	43 (1 study ⁸)	⊕⊖⊖⊖ very low ^{3,9}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio;</i></p> <p>1 Bernhard et al. 2008 2 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias (no details on allocation concealment and randomization) 3 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 4 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and unclear risk of detection bias (not information given on masking of outcome assessors) 5 Moinpour et al. 2010 6 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors) 7 Heinemann et al. 2006 8 Reni et al. 2005 9 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2

Table 197: Summary clinical evidence profile for gemcitabine and erlotinib versus gemcitabine, erlotinib and bevacizumab

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy (GEM + erlotinib + bevacizumab) (pure metastatic)	GEM + erlotinib				
Overall response rate (CR + PR) - GEM + erlotinib + bevacizumab	83 per 1000	130 per 1000 (81 to 210)	RR 1.57 (0.98 to 2.53)	607 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Progression Free Survival - GEM + erlotinib + bevacizumab	Median time: 4.6 (n.r.) months	Median time: 3.6 (n.r.) months	HR 0.73 (0.61 to 0.87)	607 (1 study ¹)	⊕⊕⊕⊖ moderate ³	
Grade 3/4 toxicities - Thrombocytopenia	59 per 1000	78 per 1000 (43 to 142)	RR 1.31 (0.72 to 2.4)	583 (1 study ¹)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities - Neutropenia	171 per 1000	166 per 1000 (116 to 237)	RR 0.97 (0.68 to 1.39)	583 (1 study ¹)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities - Diarrhoea	59 per 1000	40 per 1000 (20 to 84)	RR 0.68 (0.33 to 1.41)	583 (1 study ¹)	⊕⊕⊖⊖ low ⁴	
Grade 3/4 toxicities - Nausea/Vomiting	59 per 1000	91 per 1000 (51 to 163)	RR 1.54 (0.86 to 2.76)	583 (1 study ¹)	⊕⊕⊖⊖ low ⁴	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

GRADE Working Group grades of evidence

High quality: Further research is very unlikely to change our confidence in the estimate of effect.

Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

Very low quality: We are very uncertain about the estimate.

¹ Van-Cutsem et al. 2009

² Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID

³ The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant

⁴ Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

1
2

Table 198: Summary clinical evidence profile for gemcitabine and erlotinib versus capecitabine and erlotinib

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Exp. Chemotherapy (capecitabine + erlotinib)	GEM + erlotinib				
Overall response rate (CR + PR) - Capecitabine + erlotinib	53 per 1000	154 per 1000 (68 to 348)	RR 2.88 (1.27 to 6.52)	274 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Grade 3/4 toxicities - Leukocytopenia	0 per 1000	0 per 1000 (0 to 0)	RR 15.98 (0.93 to 273.93)	256 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3}	
Grade 3/4 toxicities - Thrombocytopenia	16 per 1000	83 per 1000 (19 to 369)	RR 5.17 (1.17 to 22.85)	256 (1 study ¹)	⊕⊕⊖⊖ low ^{2,3}	
Grade 3/4 toxicities - Diarrhoea	97 per 1000	53 per 1000 (21 to 131)	RR 0.55 (0.22 to 1.35)	256 (1 study)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4 toxicities - Nausea/Vomiting	73 per 1000	99 per 1000 (44 to 222)	RR 1.36 (0.6 to 3.06)	256 (1 study)	⊕⊖⊖⊖ very low ^{2,4}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i></p> <p><i>CI: Confidence interval; RR: Risk ratio;</i></p> <p><i>1 Heinemann et al. 2012</i></p> <p><i>2 The quality of the evidence was downgraded because of the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (not masking of outcome assessors)</i></p> <p><i>3 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID</i></p> <p><i>4 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs</i></p>						

3 11.2.4.3 Gemcitabine versus novel agents

4
5

Table 199: Summary clinical evidence profile for gemcitabine versus BAY 12-9566/ ZD9331 in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Novel agent	GEM alone				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Overall response rate (CR + PR) at 8 weeks of therapy - BAY 12-9566	52 per 1000	9 per 1000 (1 to 76)	RR 0.18 (0.02 to 1.45)	223 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Overall response rate (CR + PR) at 8 weeks of therapy - ZD9331	80 per 1000	34 per 1000 (3 to 346)	RR 0.42 (0.04 to 4.33)	55 (1 study ⁵)	⊕⊕⊕⊕ very low ^{3,6}	
Progression Free Survival - BAY 12-9566	Median time: 1.7 (n.r.) months	Median time: 3.5 (n.r.) months	HR 0.53 (0.41 to 0.68)	277 (1 study ¹)	⊕⊕⊕⊕ moderate ²	
Overall Survival - BAY 12-9566	Median time: 3.74 (n.r.) months	Median time: 6.59 (n.r.) months	HR 0.57 (0.44 to 0.74)	277 (1 study ¹)	⊕⊕⊕⊕ moderate ²	
Grade 3/4 toxicities: Nausea - BAY 12-9566	36 per 1000	80 per 1000 (28 to 223)	RR 2.22 (0.79 to 6.21)	277 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities: Nausea - ZD9331	40 per 1000	67 per 1000 (6 to 693)	RR 1.67 (0.16 to 17.32)	55 (1 study ⁴)	⊕⊕⊕⊕ very low ^{3,6}	
Grade 3/4 toxicities: Vomiting - BAY 12-9566	50 per 1000	29 per 1000 (9 to 97)	RR 0.58 (0.17 to 1.92)	277 (1 study ¹)	⊕⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4 toxicities: Vomiting - ZD9331	0 per 1000	0 per 1000 (0 to 0)	RR 4.19 (0.21 to 83.5)	55 (1 study ⁴)	⊕⊕⊕⊕ very low ^{3,6}	
Grade 3/4 toxicities: Diarrhoea - BAY 12-9566	22 per 1000	14 per 1000 (2 to 85)	RR 0.67 (0.11 to 3.96)	277 (1 study ¹)	⊕⊕⊕⊕ ⊖ very low ^{2,3}	
Grade 3/4 toxicities: Diarrhoea - ZD9331	40 per 1000	67 per 1000 (6 to 693)	RR 1.67 (0.16 to 17.32)	55 (1 study ⁵)	⊕⊕⊕⊕ very low ^{3,6}	
Grade 3/4 toxicities: Fatigue - ZD9331	0 per 1000	0 per 1000 (0 to 0)	RR 5.87 (0.32 to ...)	55 (1 study ⁵)	⊕⊕⊕⊕ very low ^{3,6}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 108.53)			
Grade 3/4 toxicities: Neutropenia - ZD9331	40 per 1000	167 per 1000 (21 to 1000)	RR 4.17 (0.52 to 33.37)	55 (1 study ⁵)	⊕⊕⊕⊕ very low ^{3,6}	
Health Related Quality of Life (EORTC C30, Domains) - Mean change From Baseline at 8 weeks follow-up - Physical		The mean health related quality of life (EORTC C30, domains) - mean change from baseline at 8 weeks follow-up - physical in the intervention groups was 13.2 lower (24.46 to 1.94 lower)		111 (1 study ¹)	⊕⊕⊕⊕ moderate ²	
Health Related Quality of Life (EORTC C30, Domains) - Mean change From Baseline at 8 weeks follow-up - Role		The mean health related quality of life (EORTC C30, domains) - mean change from baseline at 8 weeks follow-up - role in the intervention groups was 20.6 lower (34.97 to 6.23 lower)		111 (1 study ¹)	⊕⊕⊕⊕ moderate ²	
Health Related Quality of Life (EORTC C30, Domains) - Mean change From Baseline at 8 weeks follow-up - Emotional		The mean health related quality of life (EORTC C30, domains) - mean change from baseline at 8 weeks follow-up - emotional in the intervention groups was 7 lower (14.96 lower to 0.96 higher)		111 (1 study ¹)	⊕⊕⊕⊕ low ^{2,4}	
Health Related Quality of Life (EORTC C30, Domains) - Mean change From Baseline at		The mean health related quality of life (EORTC C30, domains) - mean change from baseline at 8 weeks follow-up - cognitive in the		111 (1 study ¹)	⊕⊕⊕⊕ moderate ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
8 weeks follow-up - Cognitive		intervention groups was 11.8 lower (20.18 to 3.42 lower)				
Health Related Quality of Life (EORTC C30,Domains) - Mean change From Baseline at 8 weeks follow-up - Social		The mean health related quality of life (EORTC C30,domains) - mean change from baseline at 8 weeks follow-up - social in the intervention groups was 11.5 lower (24.19 lower to 1.19 higher)		111 (1 study ¹)	⊕⊕⊕⊖ low ^{4,7}	
Health Related Quality of Life (EORTC C30,Domains) - Mean change From Baseline at 8 weeks follow-up - Global		The mean health related quality of life (EORTC C30,domains) - mean change from baseline at 8 weeks follow-up - global in the intervention groups was 12.6 lower (20.87 to 4.33 lower)		111 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Fatigue		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - fatigue in the intervention groups was 13.1 higher (2.32 to 23.88 higher)		111 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Nausea		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - nausea in the intervention groups was 6.7 higher		111 (1 study ¹)	⊕⊕⊕⊖ low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
		(2.39 lower to 15.79 higher)				
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Pain		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - pain in the intervention groups was 14.1 higher (3.17 to 25.03 higher)		111 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Dyspnea		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - dyspnea in the intervention groups was 7.3 higher (3.47 lower to 18.07 higher)		111 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Insomnia		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - insomnia in the intervention groups was 9.8 higher (3.51 lower to 23.11 higher)		111 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Health Related Quality of Life (EORTC C30,Symptoms) - Mean change From Baseline at 8 weeks follow-up - Constipation		The mean health related quality of life (EORTC C30,symptoms) - mean change from baseline at 8 weeks follow-up - constipation in the intervention groups was 19.3 higher (5.55 to 33.05 higher)		111 (1 study ¹)	⊕⊕⊕⊖ moderate ⁷	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Health Related Quality of Life (EORTC C30, Symptoms) - Mean change From Baseline at 8 weeks follow-up - Diarrhoea		The mean health related quality of life (EORTC C30, symptoms) - mean change from baseline at 8 weeks follow-up - diarrhoea in the intervention groups was 1.4 lower (11.13 lower to 8.33 higher)		111 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Health Related Quality of Life (EORTC C30, Symptoms) - Mean change From Baseline at 8 weeks follow-up - Financial		The mean health related quality of life (EORTC C30, symptoms) - mean change from baseline at 8 weeks follow-up - financial in the intervention groups was 0.7 lower (9.62 lower to 8.22 higher)		111 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Moore et al. 2003 2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given about randomization and allocation methods) 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 4 Evidence was downgraded by 1 due to serious imprecision as 95%CI crossed one default MID 5 Smith et al. 2003 6 The quality of the evidence was downgraded because of the unclear risk of selection bias and the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions). Furthermore due to unclear risk of selective outcome reporting and potential risk of detection bias, the quality of the evidence was further downgraded to low</p>						

1
2
3

Table 200: Summary clinical evidence profile for gemcitabine and placebo versus gemcitabine and vandetanib in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM + vandetanib	GEM + placebo				
Overall response rate (CR + PR)	129 per 1000	139 per 1000 (60 to 321)	RR 1.08 (0.47 to 2.5)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Progression Free Survival	Median time: 8.0 (4.5 to 10.1) months	Median time: 6.09 (5.0 to 9.9) months	HR 1.11 (0.87 to 1.41)	142 (1 study ¹)	⊕⊕⊕⊖ moderate ³	
Overall survival	Median time: 8.8 (7.1 to 11.6) months	Median time: 8.95 (6.6 to 11.7) months	HR 1.21 (0.96 to 1.53)	142 (1 study ¹)	⊕⊕⊕⊖ moderate ³	
Grade 3/4 toxicities - Thrombocytopenia	229 per 1000	279 per 1000 (158 to 491)	RR 1.22 (0.69 to 2.15)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Neutropenia	314 per 1000	487 per 1000 (321 to 739)	RR 1.55 (1.02 to 2.35)	142 (1 study ¹)	⊕⊕⊕⊖ moderate ⁴	
Grade 3/4 toxicities - Fatigue	214 per 1000	236 per 1000 (129 to 435)	RR 1.1 (0.6 to 2.03)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Leucopenia	186 per 1000	167 per 1000 (82 to 340)	RR 0.9 (0.44 to 1.83)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Hypertension	157 per 1000	126 per 1000 (55 to 283)	RR 0.8 (0.35 to 1.8)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - ALT increased	157 per 1000	112 per 1000 (47 to 259)	RR 0.71 (0.3 to 1.65)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Hyponatraemia	114 per 1000	125 per 1000 (51 to 305)	RR 1.09 (0.45 to 2.67)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - ALP increased	143 per 1000	111 per 1000 (47 to 266)	RR 0.78 (0.33 to 1.86)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Lethargy	100 per 1000	125 per 1000 (49 to 317)	RR 1.25 (0.49 to 3.17)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	
Grade 3/4 toxicities - Lymphocyte count decreased	86 per 1000	125 per 1000 (47 to 333)	RR 1.46 (0.55 to 4.0)	142 (1 study ¹)	⊕⊕⊖⊖ low ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
			to 3.88)			
Grade 3/4 toxicities - Diarrhoea	57 per 1000	97 per 1000 (30 to 318)	RR 1.7 (0.52 to 5.56)	142 (1 study ¹)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities - Blood bilirubin increased	29 per 1000	55 per 1000 (11 to 294)	RR 1.94 (0.37 to 10.28)	142 (1 study ¹)	⊕⊕⊕⊖ low ²	
Grade 3/4 toxicities - Abdominal pain	71 per 1000	28 per 1000 (6 to 139)	RR 0.39 (0.08 to 1.94)	142 (1 study ¹)	⊕⊕⊕⊖ low ²	
<p>*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</p> <p>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio; GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate.</p> <p>1 Middleton et al. 2017 2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant. 4 Evidence was downgraded by 1 due to very serious imprecision as 95%CI crossed one default MID</p>						

1 11.2.4.4 Standard-dose versus low-dose gemcitabine

2
3 **Table 201: Summary clinical evidence profile for standard-dose versus low-dose gemcitabine in adults with locally advanced or metastatic pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Low-dose GEM	Standard-dose GEM				
Overall response rate (CR + PR)	200 per 1000	182 per 1000 (32 to 1000)	RR 0.91 (0.16 to 5.3)	21 (1 study ¹)	⊕⊕⊕⊖ very low ^{2,3}	
Overall Survival	Median time: 7.2 (2.9 to	Median time: 5.2 (2 to 24.6) months	Not estimable ⁴	21 (1 study ¹)	⊕⊕⊕⊖ low ^{2,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	21.5) months					
Grade 3/4 toxicities. - Neutropenia	300 per 1000	90 per 1000 (12 to 738)	RR 0.3 (0.04 to 2.46)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities. - Anaemia	300 per 1000	39 per 1000 (3 to 678)	RR 0.13 (0.01 to 2.26)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities. - Thrombocytopenia	300 per 1000	39 per 1000 (3 to 678)	RR 0.13 (0.01 to 2.26)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities. - General fatigue	500 per 1000	275 per 1000 (85 to 860)	RR 0.55 (0.17 to 1.72)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities. - Nausea/vomiting	200 per 1000	90 per 1000 (10 to 856)	RR 0.45 (0.05 to 4.28)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities. - Diarrhoea	400 per 1000	92 per 1000 (12 to 684)	RR 0.23 (0.03 to 1.71)	21 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
<p><i>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).</i> <i>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</i></p> <p>1 Sakamoto et al. 2006 2 The quality of the evidence was downgraded because of the unclear risk of performance bias (no information on blinding of patients/ care providers delivering the interventions) and detection bias. 3 The quality of the evidence was further downgraded from moderate to very low due to very serious imprecision as 95%CI crossed two default MIDs 4 Survival did not differ significantly between the two groups (P = 0.47). 5 From data provided by the authors about this outcome., is not possible estimate the precision in the effect size estimates.</p>						

1 11.2.4.5 5-FU versus combination 5-FU

2
3 **Table 202: Summary clinical evidence profile for 5-FU versus combination 5-FU in adults with metastatic pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	5-FU combination chemotherapy	5-FU alone				
Overall response rate (CR + PR)	6 per 1000	53 per 1000 (10 to 291)	RR 8.62 (1.57 to 47.22)	319 (2 studies ^{1,2})	⊕⊕⊕⊕ low ^{3,4}	
Overall response rate	16 per 1000	34 per 1000 (3 to 364)	RR 2.17	123 (1 study ¹)	⊕⊕⊕⊕ very low ^{5,6}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
(CR + PR) - 5-FU + doxorubicin + cisplatin			(0.2 to 23.31)			
Overall response rate (CR + PR) - 5-FU + cisplatin	0 per 1000	0 per 1000 (0 to 0)	RR 21 (1.25 to 353.49)	196 (1 study)	⊕⊕⊕⊕ very low ^{5,6}	
Progression Free Survival - 5-FU + cisplatin	Median time: 73 (n.r.) days	Median time: 7.2 (n.r.) days	HR 0.55 (0.41 to 0.74)	207 (1 study ²)	⊕⊕⊕⊕ moderate ⁷	
Overall Survival	-	-	HR 0.97 (0.79 to 1.2)	319 (2 studies ^{1,2})	⊕⊕⊕⊕ low ^{3,6}	
Grade 3/4 toxicities: Nausea - 5-FU + doxorubicin + cisplatin	47 per 1000	220 per 1000 (71 to 511)	RR 4.7 (1.51 to 10.91)	123 (1 study ¹)	⊕⊕⊕⊕ low ⁵	
Grade 3/4 toxicities: Vomiting	43 per 1000	160 per 1000 (74 to 312)	RR 3.75 (1.73 to 7.32)	320 (2 studies ^{1,2})	⊕⊕⊕⊕ moderate ³	
Grade 3/4 toxicities: Vomiting - 5-FU + doxorubicin + cisplatin	47 per 1000	152 per 1000 (44 to 412)	RR 3.25 (0.94 to 8.78)	123 (1 study ¹)	⊕⊕⊕⊕ very low ^{5,13}	
Grade 3/4 toxicities: Vomiting - 5-FU + cisplatin	40 per 1000	165 per 1000 (60 to 381)	RR 4.12 (1.49 to 9.52)	197 (1 study ²)	⊕⊕⊕⊕ moderate ⁷	
Grade 3/4 toxicities: Diarrhoea - 5-FU + cisplatin	20 per 1000	51 per 1000 (10 to 223)	RR 2.57 (0.51 to 11.15)	197 (1 study ²)	⊕⊕⊕⊕ low ^{6,7}	
Grade 3/4 toxicities: Leucopenia - 5-FU + doxorubicin + cisplatin	312 per 1000	525 per 1000 (347 to 697)	RR 1.68 (1.11 to 2.23)	123 (1 study ¹)	⊕⊕⊕⊕ low ⁵	
Grade 3/4 toxicities: Stomatitis	85 per 1000	102 per 1000 (51 to 194)	RR 1.2 (0.6 to 2.27)	320 (2 studies ^{1,2})	⊕⊕⊕⊕ very low ^{3,6,9}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities: Stomatitis - 5-FU + doxorubicin + cisplatin	141 per 1000	51 per 1000 (13 to 172)	RR 0.36 (0.09 to 1.22)	123 (1 study ¹)	⊕⊖⊖⊖ very low ^{5,6}	
Grade 3/4 toxicities: Stomatitis - 5-FU + cisplatin	50 per 1000	134 per 1000 (50 to 312)	RR 2.68 (1.01 to 6.23)	197 (1 study)	⊕⊕⊖⊖ low ^{6,13}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Cullinan et al. 1990 2 Ducreux et al. 2002 3 The quality of the evidence was downgraded because of the unclear risk of selection bias and performance bias in pooled studies 4 Serious heterogeneity. I-squared = 40% 5 The quality of the evidence was downgraded because of the unclear risk of selection bias and the high risk of performance bias (no blinding of patients/ care providers delivering the interventions). 6 The quality of the evidence was downgraded due to very serious imprecision as 95%CI crossed two default MIDs 7 The quality of the evidence was downgraded because of the unclear risk of selection bias and performance bias (no details given in the text to ascertain these criteria) 8 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant 9 Very serious heterogeneity. I-squared = 84% 10 Spitzer's index values assessing quality of life were initially available at 1 and 2 months for 114 patients. Values was missing initially in 16% of patients. Mean index values in the FU group were 7.1 (initially), and 6.6 and 5.9 at 1 and 2 months, respectively (n = 54). For the FUP group values were 7.6, 7.4 and 7.0, respectively (n = 56). 11 The quality of the evidence for this outcome. was downgraded because of the high risk of selective reporting of study findings. 12 From data provided by the authors about this outcome., is not possible estimate the precision in the effect size estimates. 13 Evidence was downgraded by 1 due to very serious imprecision as 95%CI crossed one default MID</p>						

1
2

Table 203: Summary clinical evidence profile for 5-FU versus combination 5-FU in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	5-FU combination chemotherapy	5-FU alone				
Overall response rate (CR + PR)	104 per 1000	177 per 1000 (92 to 344)	RR 1.7 (0.88 to 3.3)	220 (2 studies ^{1,2})	⊕⊖⊖⊖ very low ^{3,4,5}	
Overall response rate (CR + PR) - 5-	300 per 1000	78 per 1000 (9 to 633)	RR 0.26 (0.03	23 (1 study ¹)	⊕⊖⊖⊖ very low ^{3,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
FU + doxorubicin + mitomycin			to 2.11)			
Overall response rate (CR + PR) - 5-FU + mitomycin	86 per 1000	195 per 1000 (93 to 414)	RR 2.28 (1.08 to 4.83)	144 (1 study ¹)	⊕⊕⊕⊕ moderate ⁵	
Progression Free Survival - 5-FU + mitomycin	-	-	HR 0.81 (0.62 to 1.06)	144 (1 study ¹)	⊕⊕⊕⊕ moderate ⁶	
Overall Survival	-	-	HR 0.97 (0.79 to 1.20)	353 (2 studies ^{1,2})	⊕⊕⊕⊕ low ^{4,6}	
Grade 3/4 toxicities: Diarrhoea - 5-FU + mitomycin	47 per 1000	49 per 1000 (14 to 155)	RR 1.05 (0.31 to 3.32)	209 (1 study ²)	⊕⊕⊕⊕ low ⁷	
Grade 3/4 toxicities: Neutropenia - 5-FU + mitomycin	0 per 1000	0 per 1000 (0 to 0)	RR 7.34 (0.38 to 140.36)	209 (1 study)	⊕⊕⊕⊕ low ⁷	
Grade 3/4 toxicities: Stomatitis - 5-FU + mitomycin	75 per 1000	108 per 1000 (45 to 257)	RR 1.44 (0.6 to 3.44)	209 (1 study ²)	⊕⊕⊕⊕ low ⁷	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio; HR: Hazard ratio;

1 Cullinan et al. 1985

2 Maisey et al. 2002

3 The quality of the evidence was downgraded because of the potential risk of selection bias and performance bias in one pooled study (Cullinan et al. 1985)

4 Very serious heterogeneity. I-squared = 73%

5 The quality of the evidence was downgraded due to serious imprecision as 95%CI crossed one default MID

6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.

7 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

1 11.2.4.6 **Combination 5-FU (FSM) versus other chemotherapy**

2 **Table 204: Summary clinical evidence profile for combination 5-FU (FSM) versus other**
 3 **chemotherapy regimens in adults with locally advanced or metastatic**
 4 **pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Control	5-FU combination chemotherapy (FSM)				
Overall response rate (CR + PR) - FAM: 5-FU, Adriamycin, mitomycin	100 per 1000	32 per 1000 (9 to 114)	RR 0.32 (0.09 to 1.14)	184 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Overall response rate (CR + PR) - Mitomycin + 5-FU	71 per 1000	271 per 1000 (107 to 686)	RR 3.8 (1.5 to 9.61)	140 (1 study ⁴)	⊕⊕⊕⊕ low ²	
Overall Survival - FAM: 5-FU, Adriamycin, mitomycin ⁵	-	-	Not estimable ⁵	196 (1 study ¹)	⊕⊕⊕⊕ low ^{2,6}	
Overall Survival - Mitomycin + 5-FU ⁷	-	-	Not estimable ⁷	106 (1 study ⁴)	⊕⊕⊕⊕ low ^{2,6}	
Grade 3/4 toxicities: Diarrhoea - Mitomycin + 5-FU	29 per 1000	14 per 1000 (1 to 141)	RR 0.50 (0.05- 5.39)	140 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities: Nausea/vomiting - FAM: 5-FU, Adriamycin, mitomycin	133 per 1000	160 per 1000 (79 to 321)	RR 1.2 (0.59 to 2.41)	184 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities: Nausea/vomiting - Mitomycin + 5-FU	257 per 1000	414 per 1000 (255 to 674)	RR 1.61 (0.99 to 2.62)	140 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,8}	
Grade 3/4 toxicities: Leukopenia - FAM: 5-FU, Adriamycin, mitomycin	267 per 1000	128 per 1000 (69 to 240)	RR 0.48 (0.26 to 0.9)	184 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,8}	
Grade 3/4 toxicities: Leukopenia - Mitomycin + 5-FU	157 per 1000	129 per 1000 (57 to 291)	RR 0.82 (0.36 to 1.85)	140 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities: Thrombocytopenia - FAM: 5-FU, Adriamycin, mitomycin	367 per 1000	213 per 1000 (132 to 341)	RR 0.58 (0.36 to 0.93)	184 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,8}	
Grade 3/4 toxicities: Thrombocytopenia - Mitomycin + 5-FU	229 per 1000	142 per 1000 (71 to 293)	RR 0.62 (0.31 to 1.28)	140 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Drug-related deaths - Mitomycin + 5-FU	57 per 1000	14 per 1000 (2 to 125)	RR 0.25 (0.03 to 2.18)	140 (1 study ⁴)	⊕⊕⊕⊕ very low ^{2,3}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;</p> <p>1 Oster et al. 1986 2 The quality of the evidence was downgraded because of the unclear risk of selection bias and performance bias (no details given in the text to ascertain these criteria), and likely selective reporting of study findings/outcomes 3 The quality of the evidence was downgraded due to very serious imprecision as 95%CI crossed two default MIDs 4 Bukowski et al. 1983 5 Overall survival did not differ significantly between the treatments (median, 18.3 weeks on FSM; 26.4 weeks on FAM; P = 0.21). 6 From data provided by the authors about this outcome is not possible estimate the precision in the effect size estimates. 7 no differences between groups (Median survival (wks, measurable and non-measurable disease): SFM= 18-21, MF=17-18) 8 The quality of the evidence was downgraded due to serious imprecision as 95%CI crossed one default MID</p>						

1 11.2.4.7 Intra-arterial chemotherapy versus systemic chemotherapy

2
3
4
Table 205: Summary clinical evidence profile for intra-arterial chemotherapy versus systemic chemotherapy in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Systemic chemotherapy	Intra-arterial chemotherapy				
Overall response rate (CR + PR)	72 per 1000	252 per 1000 (113 to 560)	RR 2.76 (1.23-6.18)	181 (3 studies ^{1,2,3})	⊕⊕⊕⊕ low ⁴	
Overall Survival	-	-	HR 1.02 (0.63 to 1.66)	138 (1 study ²)	⊕⊕⊕⊕ low ^{5,6}	
Grade 3/4 toxicities - Thrombocytopenia	15 per 1000	239 per 1000 (33 to 1000)	RR 16.04 (2.2 to 117.24)	138 (1 study ²)	⊕⊕⊕⊕ moderate ⁵	
Grade 3/4 toxicities - Nausea/vomiting	45 per 1000	6 per 1000 (0 to 115)	RR 0.13 (0.01 to 2.56)	138 (1 study ²)	⊕⊕⊕⊕ very low ^{5,7}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities - Diarrhoea	30 per 1000	6 per 1000 (0 to 115)	RR 0.19 (0.01 to 3.86)	138 (1 study ²)	⊕⊕⊕⊕ very low ^{5,7}	
Grade 3/4 toxicities - Leukopenia	75 per 1000	197 per 1000 (75 to 518)	RR 2.64 (1.01 to 6.94)	138 (1 study ²)	⊕⊕⊕⊕ low ^{5,8}	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;*

1 Aigner et al. 1998
2 Cantore et al. 2004
3 Ji et al. 2003
4 The quality of the evidence was downgraded because of the unclear risk of selection bias in two studies (Aigner et., 1998 and Ji 2003), the potential risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias in all studies included in the meta-analysis.
5 The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions) and detection bias (no blinding of investigators/outcome assessors).
6 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant
7 The quality of the evidence was downgraded due to very serious imprecision as 95%CI crossed two default MIDs
8 The quality of the evidence was downgraded due to serious imprecision as 95%CI crossed one default MID

1 11.2.4.8 Chemotherapy versus chemotherapy and prophylactic anticoagulant

2 **Table 206: Summary clinical evidence profile for gemcitabine versus gemcitabine and**
3 **weight-adjusted dalteparin in adults with locally advanced or metastatic**
4 **pancreatic cancer**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Weight-adjusted dalteparin + gemcitabine	GEM alone				
Overall Survival	-	-	Not estimable ¹	121 (1 study ²)	⊕⊕⊕⊕ moderate ^{2,3,4}	
Adverse effects: Grade 3/4 toxicities - Haematological	424 per 1000	369 per 1000 (233 to 581)	RR 0.87 (0.55 to 1.37)	116 (1 study ²)	⊕⊕⊕⊕ very low ^{3,5}	
Adverse effects: Grade 3/4 toxicities -	305 per 1000	333 per 1000 (195 to 567)	RR 1.09 (0.64 to 1.86)	116 (1 study)	⊕⊕⊕⊕ very low ^{3,5}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Hepatic function impairment						
Adverse effects: vascular thromboembolism (VTE) - Total patients with VTEs	306 per 1000	120 per 1000 (55 to 260)	RR 0.39 (0.18 to 0.85)	121 (1 study)	⊕⊕⊕⊖ moderate ³	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Median OS was 9.7 months for GEM and 8.7 months for GEMWAD (p = 0.682) 2 Maraveyas et al. 2012 3 The quality of the evidence was downgraded because of the unclear risk of performance bias (no blinding of patients/ care providers delivering the interventions). Furthermore due to unclear risk of selective outcome reporting and potential risk of detection bias, the quality of the evidence was further downgraded to moderate. 4 From data provided by the authors about this outcome is not possible estimate the precision in the effect size estimates. 5 The quality of the evidence was further downgraded from moderate to low due to very serious imprecision as 95%CI crossed two default MIDs</p>						

1
2

Table 207: Summary clinical evidence profile for gemcitabine and enoxaparin versus gemcitabine in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM	Enoxaparin + GEM				
Progression Free Survival	Median time: 5.4 (4.2 to 5.8) months	Median time: 5.0 (3.7 to 5.5) months	HR 1.06 (0.84 to 1.34)	312 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
Overall Survival	Median time: 8.0 (6.8 to 9.7) months	Median time: 8.5 (7.0 to 9.8) months	HR 1.1 (0.87 to 1.39)	312 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
Adverse effects: vascular thromboembolism (VTE) - Symptomatic VTE	145 per 1000	62 per 1000 (30 to 127)	RR 0.43 (0.21 to 0.88)	312 (1 study ¹)	⊕⊕⊕⊖ low ^{2,5}	
Adverse effects: vascular thromboembolism (VTE) - Major haemorrhages	66 per 1000	82 per 1000 (37 to 180)	RR 1.24 (0.56 to 2.73)	312 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,4}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</p> <p>1 Pelzer et al. 2015</p>						

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>2 The quality of the evidence was downgraded because of the high risk of performance bias (no blinding of patients/ care providers delivering the interventions) and the unclear risk of detection bias (no details about the blinding of outcome assessors)</p> <p>3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.</p> <p>4 The quality of the evidence was downgraded from moderate to very low due to very serious imprecision as 95%CI crossed two default MIDs</p> <p>5 The quality of the evidence was downgraded from moderate to low due to serious imprecision as 95%CI crossed one default MID</p>						

1 11.2.4.9 Second-line chemotherapy versus best supportive care

2 **Table 208: Summary clinical evidence profile for second-line chemotherapy versus**
3 **best supportive care**

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Chemotherapy (second-line)	BSC				
Progression Free Survival	Median time: 46 (1-351) days	Median time: 43 (1-372) days	HR 0.76 (0.57 to 1.01)	286 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
Overall Survival	Median time: 105 (5–875) days	Median time: 84 (2-271) days	HR 0.85 (0.66 to 1.09)	286 (1 study ¹)	⊕⊕⊕⊖ low ^{2,3}	
Grade 3/4/5 adverse effects - Asthenia/fatigue	76 per 1000	85 per 1000 (39 to 187)	RR 1.12 (0.51 to 2.46)	286 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4/5 adverse effects - Abdominal pain	90 per 1000	78 per 1000 (36 to 169)	RR 0.87 (0.4 to 1.88)	286 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4/5 adverse effects - Anaemia	21 per 1000	50 per 1000 (13 to 188)	RR 2.4 (0.63 to 9.1)	286 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,4}	
Grade 3/4/5 adverse effects - Vomiting	14 per 1000	50 per 1000 (10 to 235)	RR 3.6 (0.76 to 17.03)	286 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,4}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4/5 adverse effects - Nausea	14 per 1000	43 per 1000 (9 to 207)	RR 3.09 (0.63 to 15.03)	286 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Grade 3/4/5 adverse effects - Deep vein thrombosis	7 per 1000	35 per 1000 (4 to 300)	RR 5.14 (0.61 to 43.46)	286 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Grade 3/4/5 adverse effects - Renal failure	0 per 1000	0 per 1000 (0 to 0)	RR 11.31 (0.63 to 202.65)	286 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Grade 3/4/5 adverse effects - Hyperbilirubinemia	14 per 1000	28 per 1000 (5 to 152)	RR 2.06 (0.38 to 11.05)	286 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	
Grade 3/4/5 adverse effects - Leucopenia	0 per 1000	0 per 1000 (0 to 0)	RR 9.25 (0.5 to 170.31)	286 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,4}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;
¹ Ciuleanu et al. 2009
² The quality of the evidence was downgraded because of the unclear risk of selection bias and the potential risk of performance bias (no blinding of patients/ care providers)
³ The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.
⁴ The quality of the evidence was further downgraded from moderate to low due to very serious imprecision as 95%CI crossed two default MIDs

11.2.4.10 Second-line chemotherapy versus other chemotherapy regimens

2
3
4
Table 209: Summary clinical evidence profile for LV5FU2-CDDP then gemcitabine versus gemcitabine then LV5FU2-CDDP in adults with metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM followed by LV5FU2-CDDP	LV5FU2-CDDP followed by gemcitabine				

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Overall response rate (CR + PR)	220 per 1000	187 per 1000 (108 to 323)	RR 0.85 (0.49 to 1.47)	202 (1 study ¹)	⊕⊕⊖⊖ low ²	
Progression free-survival	Median time: 3.4 (2.4 to 4.4) months	Median time: 3.5 (2.4 to 4.1) months	HR 1.06 (0.80 to 1.40)	202 (1 study ¹)	⊕⊕⊕⊖ moderate ³	
Overall survival	Median time: 6.7 (5.4 to 8.6) months	Median time: 8.03 (5.9 to 9.8) months	HR 0.97 (0.73 to 1.79)	202 (1 study ¹)	⊕⊕⊕⊖ moderate ³	
Grade 3/4 toxicities: Nausea/vomiting	150 per 1000	138 per 1000 (70 to 270)	RR 0.92 (0.47 to 1.8)	202 (1 study ¹)	⊕⊕⊖⊖ low ²	

*The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;*

*1 Dahan et al. 2010
2 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs
3 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant.*

1
2

Table 210: Summary clinical evidence profile for irinotecan and raltitrexed versus raltitrexed in adults with metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Raltitrexed alone	Irinotecan + raltitrexed				
Objective response	158 per 1000	22 per 1000 (2 to 409)	RR 0.14 (0.01 to 2.59)	38 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Leukocytopenia	211 per 1000	263 per 1000 (84 to 832)	RR 1.25 (0.4 to 3.95)	38 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Neutropenia	158 per 1000	210 per 1000 (54 to 816)	RR 1.33 (0.34 to 5.17)	38 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Thrombocytopenia	-	-	Not estimable	38 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	There were no cases of thrombocytopenia in either group

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities - Nausea/vomiting	53 per 1000	53 per 1000 (4 to 782)	RR 1 (0.07 to 14.85)	38 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Stomatitis	-	-	Not estimable	38 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	There were no cases of stomatitis in either group
Grade 3/4 toxicities - Fatigue	-	-	Not estimable	38 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	There were no cases of fatigue in either group
Grade 3/4 toxicities - Diarrhoea	105 per 1000	105 per 1000 (17 to 672)	RR 1 (0.16 to 6.38)	38 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
<p>The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio;</p> <p>1 Ulrich-Pur et al. 2003 2 The quality of the evidence was downgraded because of the unclear risk of performance bias (no details given about the blinding of patients/ care providers delivering the interventions), besides the unclear risk of detection bias (no details given in the text) 3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs 5 The quality of the evidence was downgraded because of the unclear risk of performance bias and the unclear risk of detection bias (no details given in the text), besides the potential risk of selective findings reporting for this outcome. 6 From data provided by the authors about this outcome it was not possible estimate the precision in the effect size estimates.</p>						

1
2
3

Table 211: Summary clinical evidence profile for Oxaliplatin and 5-FU versus bolus 5-FU and bolus folinic acid in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Bolus leucovorin + bolus 5-FU	Oxaliplatin + 5-FU				
Overall response rate (CR + PR)	83 per 1000	125 per 1000 (23 to 682)	RR 1.5 (0.27 to 8.19) ⁴	48 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Progression Free Survival ⁵	-	-	Not estimable ⁵	48 (1 study ¹)	⊕⊕⊕⊕ low ^{2,6}	
Overall Survival ⁵	-	-	Not estimable ⁵	48 (1 study ¹)	⊕⊕⊕⊕ low ^{2,6}	
Grade 3/4 toxicities - Diarrhoea	208 per 1000	208 per 1000 (69 to 627)	RR 1 (0.33 to 3.01)	48 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities - Nausea/vomiting	125 per 1000	166 per 1000 (41 to 666)	RR 1.33 (0.33 to 5.33)	48 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Stomatitis	42 per 1000	42 per 1000 (3 to 628)	RR 1 (0.07 to 15.08)	48 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Haematological	83 per 1000	125 per 1000 (23 to 682)	RR 1.5 (0.27 to 8.19)	48 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio

1 Azmy et al. 2013

2 The quality of the evidence was downgraded because of the unclear risk of detection bias (no details given in the text to ascertain these criteria) and the high risk of performance bias (no blinding of patients/ care providers delivering the interventions).

3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

4 No complete response in both groups

5 There was no statistical significance in progression-free survival between the 2 regimens (p value by log rank test = .4619), and so was the situation in overall survival (p-value by log rank test = .5248).

6 From data provided by the authors about this outcome., is not possible estimate the precision in the effect size estimates

7 The quality of the evidence was downgraded because of the unclear risk of detection bias (no details given in the text to ascertain these criteria), the high risk of performance bias (no blinding of patients/ care providers delivering the interventions), and the potential risk of selective reporting of findings for this outcome.

1
2

Table 212: Summary clinical evidence profile for mFOLFOX6 versus 5-FU and folinic acid in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Leucovorin /5-FU	mFOLFOX6 (5-FU + leucovorin + oxaliplatin)				
Overall response rate (CR + PR)	93 per 1000	130 per 1000 (44 to 383)	RR 1.4 (0.47 to 4.14)	108 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Progression Free Survival	Median time: 2.9 (n.r.) months	Median time: 3.1 (n.r.) months	HR 1 (0.66 to 1.52)	108 (1 study ¹)	⊕⊕⊖⊖ low ^{2,4}	
Overall Survival	Median time: 9.9 (n.r.) months	Median time: 3.1 (n.r.) months	HR 1.78 (1.08 to 2.93)	108 (1 study ¹)	⊕⊕⊕⊖ moderate ⁵	
Grade 3/4 toxicities - Neutropenia	38 per 1000	326 per 1000 (79 to 1000)	RR 8.65 (2.1 to 35.72)	102 (1 study ¹)	⊕⊕⊕⊖ moderate ²	

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
Grade 3/4 toxicities - Febrile neutropenia	0 per 1000	0 per 1000 (0 to 0)	RR 5.4 (0.27 to 109.76)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Fatigue	19 per 1000	143 per 1000 (18 to 1000)	RR 7.57 (0.97 to 59.34)	102 (1 study ¹)	⊕⊕⊕⊕ low ^{2,5}	
Grade 3/4 toxicities - Thrombocytopenia	19 per 1000	82 per 1000 (9 to 705)	RR 4.33 (0.5 to 37.39)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Dehydration	0 per 1000	0 per 1000 (0 to 0)	RR 9.72 (0.54 to 176)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Pulmonary embolism	0 per 1000	0 per 1000 (0 to 0)	RR 5.4 (0.27 to 109.76)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Vomiting	0 per 1000	0 per 1000 (0 to 0)	RR 5.4 (0.27 to 109.76)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Hypokalaemia	0 per 1000	0 per 1000 (0 to 0)	RR 5.4 (0.27 to 109.76)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Peripheral neuropathy	0 per 1000	0 per 1000 (0 to 0)	RR 5.4 (0.27 to 109.76)	102 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Health Related Quality of Life	See comment	See comment	Not estimable	0 (1 study ¹)	⊕⊕⊕⊕ low ^{4,6}	No significant differences were observed in time to deterioration on the EORTC QLQ-C30 global health scale.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Gill et al. 2016

2 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given in the text about methods of allocation) and potential risk of performance bias (open-label trial)

3 Evidence was downgraded by 2 due to very serious imprecision as 95%CI crossed two default MIDs

4 The quality of the evidence was downgraded because of the unclear risk of selection bias (no details given in the text about methods of allocation), potential risk of performance bias (open-label trial) and the high risk of selective reporting of study findings for this outcome.

5 The committee decided to consider all survival outcomes that were statistically significant, regardless of

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<p>whether the 95% confidence interval crossed the default MIDs. Survival outcomes were therefore downgraded for imprecision by one level only if they were not statistically significant</p> <p>6 From data provided by the authors about this outcome is not possible estimate the precision in the effect size estimates.</p>						

1
2
3

Table 213: Summary clinical evidence profile for capecitabine and erlotinib then gemcitabine versus gemcitabine and erlotinib then capecitabine in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	GEM + erlotinib followed by capecitabine	Capecitabine + erlotinib followed by GEM				
Overall response rate (CR + PR)	65 per 1000	32 per 1000 (6 to 149)	RR 0.49 (0.1 to 2.29)	140 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Overall survival	Median time: 6.2 (n.r.) months	Median time: 6.9 (n.r.) months	HR 1.02 (0.79 to 1.31)	274 (1 study ¹)	⊕⊕⊕⊕ low ^{2,4}	
Grade 3/4 toxicities - Nausea/vomiting	130 per 1000	113 per 1000 (45 to 279)	RR 0.87 (0.35 to 2.15)	139 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Diarrhoea	39 per 1000	7 per 1000 (0 to 131)	RR 0.18 (0.01 to 3.36)	139 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Leukocytopenia	52 per 1000	32 per 1000 (6 to 170)	RR 0.62 (0.12 to 3.28)	139 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	
Grade 3/4 toxicities - Thrombocytopenia	65 per 1000	32 per 1000 (6 to 160)	RR 0.5 (0.1 to 2.47)	139 (1 study ¹)	⊕⊕⊕⊕ very low ^{2,3}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;

1 Heinemann et al. 2012

2 The quality of the evidence was downgraded because of the high risk of detection bias (no masking of investigators/outcome assessors) and the high risk of performance bias (no blinding of patients/ care providers)

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<i>delivering the interventions).</i>						
3 The quality of the evidence was downgraded due to very serious imprecision as 95%CI crossed two default MIDs						
4 The committee decided to consider all survival outcomes that were statistically significant, regardless of whether the 95% confidence interval crossed the default MIDs. The quality of the evidence for this outcome was therefore downgraded for imprecision by one level as it was not statistically significant						

1
2
3

Table 214: Summary clinical evidence profile for 5-FU and folinic acid versus oxaliplatin and 5-FU in adults with locally advanced or metastatic pancreatic cancer

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
	Oxaliplatin + 5-FU	FA + 5-FU				
Progression Free Survival	Median time: 2.9 (2.4 to 3.2) months	Median time: 2.0 (0.5 to 0.9) months	HR 0.68 (0.49 to 0.94)	160 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Overall Survival	Median time: 5.9 (4.1 to 7.4) months	Median time: 3.3 (2.7 to 4.0) months	HR 0.66 (0.48 to 0.91)	160 (1 study ¹)	⊕⊕⊕⊖ moderate ²	
Grade 3/4 toxicities - Anaemia	24 per 1000	40 per 1000 (7 to 230)	RR 1.66 (0.28 to 9.66)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Nausea/emesis	36 per 1000	13 per 1000 (1 to 124)	RR 0.37 (0.04 to 3.47)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Paresthesia	0 per 1000	0 per 1000 (0 to 0)	RR 7.73 (0.41 to 147.21)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Pain	405 per 1000	316 per 1000 (206 to 482)	RR 0.78 (0.51 to 1.19)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Leucopenia	-	-	Not estimable	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	No cases of leucopenia occurred in either group
Grade 3/4 toxicities - Thrombocytopenia	0 per 1000	0 per 1000 (0 to 0)	RR 3.31 (0.14 to 80.09)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	
Grade 3/4 toxicities - Diarrhoea	0 per 1000	0 per 1000 (0 to 0)	RR 3.31 (0.14 to 80.09)	160 (1 study ¹)	⊕⊖⊖⊖ very low ^{2,3}	

The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison

Outcomes	Illustrative comparative risks* (95% CI)		Relative effect (95% CI)	No of Participants (studies)	Quality of the evidence (GRADE)	Comments
	Assumed risk	Corresponding risk				
<i>group and the relative effect of the intervention (and its 95% CI).</i>						
<i>CI: Confidence interval; RR: Risk ratio; HR: Hazard ratio;</i>						
<i>1 Oettle et al. 2014</i>						
<i>2 The quality of the evidence was downgraded because of the unclear risk of detection bias (no details given in the text to ascertain these criteria) and the high risk of performance bias (no blinding of patients/ care providers delivering the interventions).</i>						
<i>3 The quality of the evidence was downgraded due to very serious imprecision as 95%CI crossed two default MIDs</i>						

1 11.2.5 Economic evidence

2 11.2.5.1 Systematic literature review

3 Two studies (Tam et al. 2013, Attard et al. 2014) were included in the review of published
4 economic evidence for this topic. Both papers reported cost-utility studies of chemotherapy
5 interventions in people with metastatic pancreatic cancer from a Canadian health payer
6 perspective and reported outcomes in terms of cost (Canadian dollars) per QALY. Both
7 studies used gemcitabine chemotherapy as the base case compared to FOLFIRINOX. Tam
8 2013 also included gemcitabine with the addition of capecitabine and gemcitabine with the
9 addition of erlotinib in their analysis. Effectiveness data to inform both economic models were
10 based on phase III randomised trials and the same trial was used to inform the effectiveness
11 of FOLFIRINOX and gemcitabine in both studies. Tam 2013 used a cost year of 2010
12 compared to Attard 2014 which used a cost year of 2013. Both studies were deemed partially
13 applicable to the decision problem that we are evaluating. This is because they did not take a
14 NHS+PSS perspective.

15 Potentially serious limitations were identified with both studies. There were potential conflicts
16 of interest with the studies either being funded by, or the authors having received funding
17 from a manufacturer of 1 of the interventions considered. Both studies performed
18 probabilistic sensitivity analyses although these were inadequately reported with descriptions
19 of the distributions missing.

20 The base cases in Tam 2013 and Attard 2014 suggested an ICER of CA\$133,184 and
21 CA\$57,858 for FOLFIRINOX compared to gemcitabine. This discrepancy can largely be
22 explained by Tam 2013 having an upper limit for the number of cycles of FOLFIRINOX, a
23 more detailed costing and used a different method for estimating quality of life weightings.

24 Deterministic sensitivity analysis suggested these results were robust to alternative clinical
25 assumptions. Probabilistic sensitivity analyses suggested that in Tam 2013, FOLFIRINOX
26 had a less than 5% chance of being cost effective compared to gemcitabine under the
27 conventionally held Canadian willingness to pay threshold of CA\$100,000. Alternatively,
28 Attard 2014 reported an 85% chance of being cost effective at the same WTP threshold. This
29 again can be accounted for by the more favourable assumptions towards FOLFIRINOX in
30 Attard 2014.

31 References to all included studies and evidence tables for all economic evaluations included
32 in the systematic literature review of the economic evidence are presented in Appendix L.
33 Economic evidence profiles of these studies are presented in Appendix K.

1 11.2.6 Evidence statements

2 11.2.6.1 Chemotherapy versus chemoimmunotherapy

3 11.2.6.1.1 First-line chemotherapy and sequential/concurrent immunotherapy versus 4 chemotherapy

5 Response rate

6 Very low quality evidence from 1 multicentre phase III RCT (n=1062) showed no clinically
7 important difference between 1st-line chemotherapy with sequential GV1001, first-line
8 chemotherapy with concurrent GV1001 and first-line chemotherapy alone about the relative
9 probability of objective response rate (CR + PR) in adults with locally advanced or metastatic
10 pancreatic cancer: RR 0.98 (95% CI 0.58-1.67- sequential group) and RR 1.13 (95% CI 0.68-
11 1.88 - concurrent group), where RR less than 1 favours the chemotherapy alone arm.

12 Progression-free survival

13 Low quality evidence from 1 multicentre phase III RCT (n=712) showed no clinically
14 important difference between first-line chemotherapy with concurrent GV1001 and first-line
15 chemotherapy alone in time to progression rates in adults with locally advanced or metastatic
16 pancreatic cancer: HR 1.00 (95% CI 0.84-1.19), where HR higher than 1 favours the
17 chemotherapy alone arm.

18 Moderate quality evidence from 1 multicentre phase III RCT (n=708) showed that there is a
19 clinically important difference favouring first-line chemotherapy alone on PFS rates when
20 compared with first-line chemotherapy plus sequential GV1001 in adults with locally
21 advanced or metastatic pancreatic cancer: HR 1.5 (95% CI 1.26-1.79)

22 Overall Survival

23 Low quality evidence from 1 multicentre phase III RCT (n=712) showed no clinically
24 important difference between first-line chemotherapy with concurrent GV1001 and first-line
25 chemotherapy alone in overall survival rates in adults with locally advanced or metastatic
26 pancreatic cancer: HR 1.05 (95% CI 0.85-1.29), where HR higher than 1 favours the
27 chemotherapy alone arm.

28 Low quality evidence from 1 multicentre phase III RCT (n=708) showed no clinically
29 important difference between first-line chemotherapy with sequential GV1001 and first-line
30 chemotherapy alone in overall survival rates in adults with locally advanced or metastatic
31 pancreatic cancer: HR 1.19 (95% CI 0.97-1.48), where HR higher than 1 favours the
32 chemotherapy alone arm.

33 Adverse Events

34 Very low and low quality evidence from 1 multicentre phase III RCT (n=1062) showed no
35 clinically important difference between first-line chemotherapy with sequential GV1001, first-
36 line chemotherapy with concurrent GV1001 and first-line chemotherapy alone about the
37 relative risk of grade 3/4/5 toxicities (including nausea, vomiting, diarrhoea, fatigue,
38 neutropenia, and pain) in adults with locally advanced or metastatic pancreatic cancer.

39 Health-related quality of life

40 Low quality evidence from 1 multicentre phase III RCT (n=1062) showed no clinically
41 important difference between first-line chemotherapy with sequential GV1001, first-line
42 chemotherapy with concurrent GV1001 and first-line chemotherapy alone on the
43 improvement of quality of life (measured as mean of the EORTC QLQ-C30) in adults with
44 locally advanced or metastatic pancreatic cancer.

11.2.6.1.2 **Second-line chemoimmunotherapy versus chemotherapy**

2 **Response rate**

3 Very low quality evidence from 1 phase III RCT (n=58) showed no clinically important
4 difference between chemotherapy + concurrent ICT [CIK - Cytokine-induced killer cells] and
5 chemotherapy as second-line treatments on the relative probability of objective response rate
6 (CR + PR) in adults with locally advanced/metastatic pancreatic cancer: RR 1.07 (95% CI
7 0.16-7.1), where RR less than 1 favours the chemotherapy alone arm.

8 **Progression-free survival**

9 Very low quality evidence from 1 phase III RCT (n=58) showed no clinically important
10 difference between chemotherapy + concurrent ICT [CIK - Cytokine-induced killer cells] and
11 chemotherapy alone as second-line treatments on progression-free survival in adults with
12 locally advanced/metastatic pancreatic cancer (relative effect not estimable).

13 **Overall Survival**

14 Very low quality evidence from 1 phase III RCT (n=58) showed no clinically important
15 difference between chemotherapy + concurrent ICT [CIK - Cytokine-induced killer cells] and
16 chemotherapy alone as second-line treatments on survival rates in adults with locally
17 advanced/metastatic pancreatic cancer (relative effect not estimable).

18 **Adverse Events**

19 Very low quality evidence from 1 phase III RCT (n=58) showed no clinically important
20 difference between chemotherapy + concurrent ICT [CIK - Cytokine-induced killer cells] and
21 chemotherapy alone as second-line treatments on the relative risk of grade 3/4 toxicities
22 (including neutropenia, nausea/vomiting, diarrhoea, and fatigue) in adults with locally
23 advanced/metastatic pancreatic cancer: RR 1.07 (95% CI 0.07-16.32), RR 0.36 (95% CI
24 0.02-8.4), RR 1.07 (95% CI 0.16-7.1), and RR 0.36 (95% CI 0.02-8.4) where RR less than 1
25 favours the chemotherapy + concurrent ICT arm.

26 **Health-related quality of life**

27 No evidence was identified to inform this outcome.

28 11.2.6.2 **Gemcitabine versus other chemotherapy**

29 11.2.6.2.1 **In adults with metastatic disease**

30 **Response rate**

31 High quality evidence from 1 multicentre phase III RCT (n=342) showed that there is a
32 clinically important difference favouring gemcitabine single-agent on objective response rate
33 (CR + PR) compared to FOLFIRINOX in adult with metastatic pancreatic cancer: RR 3.38
34 (95% CI 2.01-5.65).

35 Very low quality evidence from a meta-analysis of 2 phase III RCTs (n=425) showed no
36 clinically important difference between gemcitabine + Cisplatin and gemcitabine single-agent
37 about the relative probability of objective response rate (CR + PR) in adult with metastatic
38 pancreatic cancer: RR 1.25 (95% CI 0.73-2.12), where RR higher less 1 favours the
39 gemcitabine arm.

40 Moderate quality evidence from 1 phase III RCT (n=619) showed no clinically important
41 difference between gemcitabine + Ganitumab [12 mg/kg] and in the gemcitabine single-agent
42 about the relative probability of objective response rate (CR + PR) in adult with metastatic
43 pancreatic cancer: RR 1.58 (95% CI 1.04-2.39), where RR less than 1 favours the
44 gemcitabine arm.

1 Moderate quality evidence from 1 phase III RCT (n=464) showed no clinically important
2 difference between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent about
3 the relative probability of objective response rate (CR + PR) in adult with metastatic
4 pancreatic cancer: RR 1.44 (95% CI 0.87-2.39), where RR less than 1 favours the
5 gemcitabine arm.

6 Moderate quality evidence from 1 phase III RCT (n=607) showed no clinically important
7 difference between gemcitabine + erlotinib + bevacizumab group and gemcitabine + erlotinib
8 about the relative probability of objective response rate (CR + PR) in adult with metastatic
9 pancreatic cancer: RR 1.57 (95% CI 0.98-2.53), where RR less than 1 favours the
10 gemcitabine + erlotinib arm.

11 Low quality evidence from 1 phase IIb RCT (n=120) showed no clinically important difference
12 between gemcitabine + capecitabine + erlotinib group and gemcitabine + erlotinib about the
13 relative probability of objective response rate (CR + PR) in adult with metastatic pancreatic
14 cancer: RR 1.18 (95% CI 0.58-2.43), where RR higher than 1 favours the gemcitabine +
15 erlotinib + capecitabine arm.

16 **Progression-free survival**

17 High quality evidence from 1 multicentre phase III RCT (n=342) showed that there is a
18 clinically important difference favouring FOLFIRINOX in PFS compared to gemcitabine
19 single-agent in adult with metastatic pancreatic cancer: HR 0.47 (95% CI 0.32-0.69)

20 Moderate quality evidence from 1 phase III RCT (n=411) showed no clinically important
21 difference between gemcitabine + Aflibercept and gemcitabine single-agent in PFS rates in
22 adult with metastatic pancreatic cancer: HR 1.02 (95% CI 0.83-1.25), where HR less than 1
23 favours the gemcitabine + Aflibercept arm.

24 Low quality evidence from 1 phase III RCT (n=375) showed no clinically important difference
25 between gemcitabine + Cisplatin and gemcitabine single-agent in PFS rates in adult with
26 metastatic pancreatic cancer: HR 0.97 (95% CI 0.8-1.18), where HR less than 1 favours the
27 gemcitabine + Cisplatin arm.

28 Moderate quality evidence from 1 phase III RCT (n=619) showed no clinically important
29 difference between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent in
30 PFS rates in adult with metastatic pancreatic cancer: HR 1 (95% CI 0.84-1.19), where HR
31 less than 1 favours the gemcitabine + Ganitumab arm.

32 Moderate quality evidence from 1 phase III RCT (n=464) showed no clinically important
33 difference between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent in
34 PFS rates in adult with metastatic pancreatic cancer: HR 0.97 (95% CI 0.77-1.22), where HR
35 less than 1 favours the gemcitabine + Ganitumab arm.

36 Moderate1.35) quality evidence from 1 phase III RCT (n=707) showed that there is a clinically
37 important difference favouring gemcitabine + erlotinib + bevacizumab in PFS compared to
38 gemcitabine + erlotinib in adult with metastatic pancreatic cancer: HR 0.73 (95% CI 0.61-
39 0.87).

40 Low quality evidence from 1 phase IIb RCT (n=120) showed no clinically important difference
41 between gemcitabine + capecitabine + erlotinib and gemcitabine + erlotinib in PFS rates in
42 adult with metastatic pancreatic cancer: HR 0.88 (95% CI 0.58-1.34), where HR less than 1
43 favours the gemcitabine + erlotinib + capecitabine arm.

44 **Overall Survival**

45 Moderate quality evidence from 1 phase III RCT (n=411) showed no clinically important
46 difference between gemcitabine + Aflibercept and gemcitabine single-agent in overall

1 survival in adult with metastatic pancreatic cancer: HR 1.17 (95% CI 0.92-1.49), where HR
2 less than 1 favours the gemcitabine + Aflibercept arm.

3 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=425) showed no clinically
4 important difference between gemcitabine + Cisplatin and gemcitabine single-agent in overall
5 survival in adult with metastatic pancreatic cancer: HR 0.92 (95% CI 0.76-1.11), where HR
6 less than 1 favours the gemcitabine + Cisplatin arm.

7 Moderate quality evidence from 1 phase III RCT (n=619) showed no clinically important
8 difference between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent in
9 overall survival in adult with metastatic pancreatic cancer: HR 1 (95% CI 0.82-1.22), where
10 HR less than 1 favours the gemcitabine + Ganitumab arm.

11 Moderate quality evidence from 1 phase III RCT (n=464) showed no clinically important
12 difference between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent in
13 overall survival in adult with metastatic pancreatic cancer: HR 0.97 (95% CI 0.76-1.24),
14 where HR less than 1 favours the gemcitabine + Ganitumab arm.

15 Low quality evidence from 1 phase IIb RCT (n=120) showed no clinically important difference
16 between gemcitabine + capecitabine + erlotinib and gemcitabine + erlotinib in overall survival
17 in adult with metastatic pancreatic cancer: HR 1.09 (95% CI 0.72-1.65), where HR less than
18 1 favours the gemcitabine + erlotinib + capecitabine arm.

19 **Adverse Events**

20 **a) Grade 3/4 toxicities: diarrhoea**

21 High quality evidence from 1 multicentre phase III RCT (n=342) showed that there is a
22 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
23 related grade 3/4 toxicities (diarrhoea) compared to FOLFIRINOX in adult with metastatic
24 pancreatic cancer: RR 7.17 (95% CI 2.18-23.58)

25 Low quality evidence from 1 phase III RCT (n=541 patients: 270) showed no clinically
26 important difference between gemcitabine + Aflibercept and gemcitabine single-agent on the
27 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adult with metastatic pancreatic
28 cancer: RR 1 (95% CI 0.2-4.93), where RR less than 1 favours the gemcitabine + Aflibercept
29 arm.

30 Very low quality evidence from a meta-analysis of 2 phase III RCTs (n=421) showed no
31 clinically important difference between gemcitabine + Cisplatin and gemcitabine single-agent
32 on the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adult with metastatic
33 pancreatic cancer: RR 0.34 (95% CI 0.04-3.23), where RR less than 1 favours the
34 gemcitabine + Cisplatin arm.

35 Low quality evidence from 1 phase III RCT (n=632) showed no clinically important difference
36 between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent on the relative
37 risk of drug-related grade 3/4 toxicities (diarrhoea) in adult with metastatic pancreatic cancer:
38 RR 3.02 (95% CI 0.32-28.87), where RR less than 1 favours the gemcitabine + Ganitumab
39 arm.

40 Low quality evidence from 1 phase III RCT (n=477) showed no clinically important difference
41 between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent on the relative
42 risk of drug-related grade 3/4 toxicities (diarrhoea) in adult with metastatic pancreatic cancer:
43 RR 3.96 (95% CI 0.36-43.37), where RR less than 1 favours the gemcitabine + Ganitumab
44 arm.

45 **b) Grade 3/4 toxicities: fatigue**

46 Moderate quality evidence from 1 multicentre phase III RCT (n=334) showed no clinically
47 important difference between FOLFIRINOX and gemcitabine single-agent on the relative risk

1 of drug-related grade 3/4 toxicities (fatigue) in adult with metastatic pancreatic cancer: RR
2 1.33 (95% CI 0.87-2.04), where RR less than 1 favours the FOLFIRINOX arm.

3 Very low quality evidence from 1 phase III RCT (n=375) showed no clinically important
4 difference between gemcitabine + Cisplatin and gemcitabine single-agent on the relative risk
5 of drug-related grade 3/4 toxicities (fatigue) in adult with metastatic pancreatic cancer: RR
6 1.69 (95% CI 0.63-4.57), where RR less than 1 favours the gemcitabine + Cisplatin arm.

7 Low quality evidence from 1 phase III RCT (n=632) showed no clinically important difference
8 between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent on the relative
9 risk of drug-related grade 3/4 toxicities (fatigue) in adult with metastatic pancreatic cancer:
10 RR 1.59 (95% CI 0.79-3.23), where RR less than 1 favours the gemcitabine + Ganitumab
11 arm.

12 Low quality evidence from 1 phase III RCT (n=477) showed no clinically important difference
13 between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent on the relative
14 risk of drug-related grade 3/4 toxicities (fatigue) in adult with metastatic pancreatic cancer:
15 RR 1.32 (95% CI 0.55-1.17), where RR less than 1 favours the gemcitabine + Ganitumab
16 arm.

17 **c) Grade 3/4 toxicities: Neutropenia**

18 High quality evidence from 1 Multicentre phase III RCT (n=331) showed that there is a
19 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
20 related grade 3/4 toxicities (Neutropenia) compared to FOLFIRINOX in adult with metastatic
21 pancreatic cancer: RR 2.18 (95% CI 1.56-3.06)

22 Moderate quality evidence from 1 phase III RCT (n=541) showed no clinically important
23 difference between gemcitabine + Aflibercept and gemcitabine single-agent on the relative
24 risk of drug-related grade 3/4 toxicities (neutropenia) in adult with metastatic pancreatic
25 cancer: RR 1.27 (95% CI 0.96-1.67), where RR less than 1 favours the gemcitabine +
26 Aflibercept arm.

27 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=421) showed no clinically
28 important difference between gemcitabine + Cisplatin and gemcitabine single-agent on the
29 relative risk of drug-related grade 3/4 toxicities (neutropenia) in adult with metastatic
30 pancreatic cancer: RR 1.84 (95% CI 1.21-2.8), where RR less than 1 favours the
31 gemcitabine + Cisplatin arm.

32 High quality evidence from 1 phase III RCT (n=632) showed that there is a clinically
33 important difference favouring gemcitabine + Ganitumab [12 mg/kg] on the relative risk of
34 drug-related grade 3/4 toxicities (neutropenia) compared to gemcitabine single-agent in adult
35 with metastatic pancreatic cancer: RR 0.48 (95% CI 0.32-0.71)

36 High quality evidence from 1 phase III RCT (n=477) showed that there is a clinically
37 important difference favouring gemcitabine single-agent on the relative risk of drug-related
38 grade 3/4 toxicities (neutropenia) compared to those treated with gemcitabine + Ganitumab
39 [20 mg/kg] in adult with metastatic pancreatic cancer: RR 2.26 (95% CI 1.72-2.97)

40 Low quality evidence from 1 phase III RCT (n=583) showed no clinically important difference
41 between gemcitabine + erlotinib + bevacizumab and gemcitabine + erlotinib on the relative
42 risk of drug-related grade 3/4 toxicities (neutropenia) in adult with metastatic pancreatic
43 cancer: RR 0.97 (95% CI 0.68-1.39), where RR less than 1 favours the gemcitabine +
44 erlotinib arm.

45

46

47 **d) Grade 3/4 toxicities: Nausea/vomiting**

1 Moderate quality evidence from 1 multicentre phase III RCT (n=335) showed no clinically
2 important difference between FOLFIRINOX and gemcitabine single-agent on the relative risk
3 of drug-related grade 3/4 toxicities (nausea/vomiting) in adult with metastatic pancreatic
4 cancer: RR 1.75 (95% CI 0.94-3.26), where RR less than 1 favours the FOLFIRINOX arm.

5 Moderate quality evidence from 1 phase III RCT (n=541) showed no clinically important
6 difference between gemcitabine + Aflibercept and gemcitabine single-agent on the relative
7 risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adult with metastatic pancreatic
8 cancer: RR 2.11 (95% CI 1.01-4.39), where RR less than 1 favours the gemcitabine +
9 Aflibercept arm.

10 Very low quality evidence from a meta-analysis of 2 phase III RCTs (n=421) showed no
11 clinically important difference between gemcitabine + Cisplatin and gemcitabine single-agent
12 on the relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adult with
13 metastatic pancreatic cancer: RR 1.83 (95% CI 0.54-6.2), where RR less than 1 favours the
14 gemcitabine + Cisplatin arm.

15 Low quality evidence from 1 phase III RCT (n=632) showed no clinically important between
16 gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent on the relative risk of
17 drug-related grade 3/4 toxicities (nausea/vomiting) in adult with metastatic pancreatic cancer:
18 RR 0.96 (95% CI 0.52-1.76), where RR less than 1 favours the gemcitabine + Ganitumab
19 arm.

20 Low quality evidence from 1 phase III RCT (n=477) showed no clinically important difference
21 between Ganitumab [20 mg/kg] and gemcitabine single-agent on the relative risk of drug-
22 related grade 3/4 toxicities (nausea/vomiting) in adult with metastatic pancreatic cancer: RR
23 0.5 (95% CI 0.19-1.3), where RR less than 1 favours the gemcitabine + Ganitumab arm.

24 Low quality evidence from 1 phase III RCT (n=583) showed no clinically important difference
25 between gemcitabine + erlotinib + bevacizumab and gemcitabine + erlotinib on the relative
26 risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adult with metastatic pancreatic
27 cancer: RR 1.54 (95% CI 0.86-2.79), where RR less than 1 favours the gemcitabine +
28 erlotinib arm.

29 **e) Grade 3/4 toxicities: Thrombocytopenia**

30 Moderate quality evidence from 1 multicentre phase III RCT (n=333) showed no clinically
31 important difference between FOLFIRINOX and gemcitabine single-agent on the relative risk
32 of drug-related grade 3/4 toxicities (thrombocytopenia) in adult with metastatic pancreatic
33 cancer: RR 2.55 (95% CI 1.01-6.4), where RR less than 1 favours the FOLFIRINOX arm.

34 Moderate quality evidence from 1 phase III RCT (n=541) showed no clinically important
35 difference between gemcitabine + Aflibercept and gemcitabine single-agent on the relative
36 risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adult with metastatic pancreatic
37 cancer: RR 1.77 (95% CI 1-3.13), where RR less than 1 favours the gemcitabine +
38 Aflibercept arm.

39 Moderate quality evidence from a meta-analysis of 2 phase III RCTs (n=421) showed that
40 there is a clinically important difference favouring gemcitabine single-agent on the relative
41 risk of drug-related grade 3/4 toxicities (Thrombocytopenia) compared to gemcitabine +
42 Cisplatin: RR 3.2 (95% CI 1.67-6.14), where RR less than 1 favours the gemcitabine +
43 Cisplatin arm.

44 Low quality evidence from 1 phase III RCT (n=632) showed no clinically important difference
45 between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent on the relative
46 risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adult with metastatic pancreatic
47 cancer: RR 1.29 (95% CI 0.75-2.24), where RR less than 1 favours the gemcitabine +
48 Ganitumab arm.

1 Low quality evidence from 1 phase III RCT (n=477) showed no clinically important difference
2 between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent on the relative
3 risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adult with metastatic pancreatic
4 cancer: RR 1.13 (95% CI 0.57-2.24), where RR less than 1 favours the gemcitabine +
5 Ganitumab arm.

6 Low quality evidence from 1 phase III RCT (n=583) showed no clinically important difference
7 between gemcitabine + erlotinib + bevacizumab and gemcitabine + erlotinib on the relative
8 risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adult with metastatic pancreatic
9 cancer: RR 1.31 (95% CI 0.72-2.40), where RR less than 1 favours the gemcitabine +
10 erlotinib arm.

11 **f) Grade 3/4 toxicities: Leucopenia**

12 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=421) suggests not
13 significant differences between gemcitabine + Cisplatin and gemcitabine single-agent on the
14 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adult with metastatic
15 pancreatic cancer: RR 1.89 (95% CI 0.9-3.98)

16 Low quality evidence from 1 phase III RCT (n=632) showed no clinically important difference
17 between gemcitabine + Ganitumab [12 mg/kg] and gemcitabine single-agent on the relative
18 risk of drug-related grade 3/4 toxicities (leucopenia) in adult with metastatic pancreatic
19 cancer: RR 1.68 (95% CI 0.74-3.78), where RR less than 1 favours the gemcitabine +
20 Ganitumab arm.

21 Low quality evidence from 1 phase III RCT (n=477) showed no clinically important difference
22 between gemcitabine + Ganitumab [20 mg/kg] and gemcitabine single-agent on the relative
23 risk of drug-related grade 3/4 toxicities (leucopenia) in adult with metastatic pancreatic
24 cancer: RR 0.88 (95% CI 0.28-2.82), where RR less than 1 favours the gemcitabine +
25 Ganitumab arm.

26 **g) Grade 3/4 toxicities: Any**

27 Low quality evidence from 1 phase IIb RCT (n=118) showed no clinically important difference
28 between gemcitabine + capecitabine + erlotinib and gemcitabine + erlotinib on the relative
29 risk of drug-related grade 3/4 toxicities (including asthenia, diarrhoea, neutropenia, reduced
30 appetite, thrombocytopenia, nausea, anaemia, rash, constipation, mucositis, vomiting,
31 pyrexia, elevated GGT, hand - foot syndrome, and peripheral oedema): RR 1.28 (95% CI
32 0.97-1.68), where RR less than 1 favours the gemcitabine + erlotinib + capecitabine arm.

33 **Health-related quality of life**

34 High quality evidence from 1 multicentre phase III RCT (n=320) showed that there is a
35 clinically important difference favouring gemcitabine single-agent on quality of life scores
36 (global health status, measured as mean of the QLQ-C30 questionnaire) compared to
37 FOLFIRINOX at the end of the treatment (6 months) in adult with metastatic pancreatic
38 cancer: RR 0.39 (95% CI 0.21-0.72)

39 High to low quality evidence from 1 multicentre phase III RCT (n=320) showed that there is a
40 clinically important difference favouring gemcitabine single-agent on quality of life scores
41 (including social functioning, role functioning, and financial difficulties - measured as mean of
42 the QLQ-C30) compared to FOLFIRINOX at the end of the treatment (6 months) in adult
43 with metastatic pancreatic cancer.

44 Moderate and low quality evidence from 1 multicentre phase III RCT (n=333) showed no
45 clinically important difference between FOLFIRINOX and gemcitabine single-agent at the
46 end of the treatment (6 months) on the improvement of quality of life in physical functioning,
47 emotional functioning, cognitive functioning, fatigue, nausea/vomiting, pain, dyspnoea,

1 insomnia, loss of appetite, constipation and diarrhoea (measured as mean of the QLQ-C30)
2 in adult with metastatic pancreatic cancer.

31.2.6.2.2 *In adults with locally advanced and metastatic pancreatic cancer*

4 **Response rate**

5 Low quality evidence from 1 multicentre phase III RCT (n=126) showed no clinically
6 important difference between 5-FU single agent and gemcitabine single-agent about the
7 relative probability of objective response rate (CR + PR) in adults with locally
8 advanced/metastatic pancreatic cancer: RR 0.14 (95% CI 0.01-2.71), where RR less than 1
9 favours the gemcitabine arm.

10 Moderate quality evidence from 1 multicentre phase III RCT (n=489) showed that there is a
11 clinically important difference favouring S-1 chemotherapy about the relative probability of
12 objective response rate compared to gemcitabine alone in adults with locally
13 advanced/metastatic pancreatic cancer: RR 1.58 (95% CI 1.06-2.36)

14 Very low quality evidence from 1 multicentre phase III RCT (n=322) showed no clinically
15 important difference between gemcitabine + 5-FU and gemcitabine single-agent about the
16 relative probability of objective response rate (CR + PR) in adults with locally
17 advanced/metastatic pancreatic cancer: RR 1.24 (95% CI 0.53-2.91), where RR less than 1
18 favours the gemcitabine arm.

19 Moderate quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
20 important difference between gemcitabine + Axitanib group and gemcitabine single-agent
21 about the relative probability of objective response rate (CR + PR) in adults with locally
22 advanced/metastatic pancreatic cancer: RR 3.03 (95% CI 0.99-9.29), where RR less than 1
23 favours the gemcitabine arm.

24 Low quality evidence from 1 multicentre phase III RCT (n=602) showed no clinically
25 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent
26 about the relative probability of objective response rate (CR + PR) in adults with locally
27 advanced/metastatic pancreatic cancer: RR 1.29 (95% CI 0.82-2.02), where RR less than 1
28 1 favours the gemcitabine arm.

29 Low quality evidence from a meta-analysis of 3 multicentre phase III RCTs (n=1050) showed
30 that there is a clinically important difference favouring gemcitabine + Capecitabine about the
31 relative probability of objective response rate (CR + PR) compared to gemcitabine alone in
32 adults with locally advanced/metastatic pancreatic cancer: RR 1.70 (95% CI 1.27-2.27)

33 Very low quality evidence from 1 multicentre phase III RCT (n=660) showed no clinically
34 important difference between gemcitabine + Cetuximab and gemcitabine single-agent about
35 the relative probability of objective response rate (CR + PR) in adults with locally
36 advanced/metastatic pancreatic cancer: RR 1.22 (95% CI 0.72-2.08), where RR less than 1
37 1 favours the gemcitabine arm.

38 Very low quality evidence from 1 multicentre phase III RCT (n=195) showed no clinically
39 important difference between gemcitabine + Cisplatin and gemcitabine single-agent about
40 the relative probability of objective response rate (CR + PR) in adults with locally
41 advanced/metastatic pancreatic cancer: RR 1.24 (95% CI 0.51-3.00), where RR less than 1
42 1 favours the gemcitabine arm.

43 Moderate quality evidence from 1 phase III RCT (n=99) showed that there is a clinically
44 important difference favouring PEFG about the relative probability of objective response rate
45 (CR + PR) compared to gemcitabine alone in adults with locally advanced/metastatic
46 pancreatic cancer: RR 4.52 (95% CI 1.67-12.27)

- 1 Very low quality evidence from 1 multicentre phase III RCT (n=349) showed no clinically
2 important difference between gemcitabine + Exatecan and gemcitabine single-agent about
3 the relative probability of objective response rate (CR + PR) in adults with locally
4 advanced/metastatic pancreatic cancer: RR 1.33 (95% CI 0.57-3.07), where RR less than 1
5 favours the gemcitabine arm.
- 6 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=490) showed
7 that there is a clinically important difference favouring gemcitabine + Irinotecan
8 chemotherapy about the relative probability of objective response rate (CR + PR) compared
9 to gemcitabine alone in adults with locally advanced/metastatic pancreatic cancer: RR 2.50
10 (95% CI 1.43-4.39).
- 11 Low quality evidence from 1 phase III RCT (n=319) showed no clinically important difference
12 between gemcitabine + Marimastat and gemcitabine single-agent about the relative
13 probability of objective response rate (CR + PR) in adults with locally advanced/metastatic
14 pancreatic cancer: RR 0.78 (95% CI 0.37-1.65), where RR less than 1 favours the
15 gemcitabine arm.
- 16 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=313) showed
17 that there is a clinically important difference favouring gemcitabine + Oxaliplatin
18 chemotherapy about the relative probability of objective response rate (CR + PR) compared
19 to gemcitabine alone in adults with locally advanced/metastatic pancreatic cancer: RR 1.55
20 (95% CI 1.01-2.38).
- 21 Moderate quality evidence from 1 multicentre phase III RCT (n=565) showed that there is a
22 clinically important difference favouring gemcitabine + Pemetrexed chemotherapy about the
23 relative probability of objective response rate (CR + PR) compared to gemcitabine alone in
24 adults with locally advanced/metastatic pancreatic cancer: RR 2.09 (95% CI 1.26-3.47).
- 25 Low quality evidence from 1 phase III RCT (n=104) showed no clinically important difference
26 between gemcitabine + Sorafenib and gemcitabine single-agent about the relative probability
27 of objective response rate (CR + PR) in adults with locally advanced/metastatic pancreatic
28 cancer: RR 0.54 (95% CI 0.22-1.33), where RR less than 1 favours the gemcitabine arm.
- 29 Low quality evidence from 1 phase III RCT (n=688) showed no clinically important difference
30 between gemcitabine + Tipifarnib and gemcitabine single-agent about the relative probability
31 of objective response rate (CR + PR) in adults with locally advanced/metastatic pancreatic
32 cancer: RR 0.73 (95% CI 0.42-1.26), where RR less than 1 favours the gemcitabine arm.
- 33 High quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=584) showed
34 that there is a clinically important difference favouring gemcitabine + S-1 chemotherapy
35 about the relative probability of objective response rate (CR + PR) compared to gemcitabine
36 alone in adults with locally advanced/metastatic pancreatic cancer: RR 2.33 (95% CI 1.62-
37 3.34).
- 38 Moderate quality evidence from 1 phase III RCT (n=274) showed that there is a clinically
39 important difference favouring gemcitabine + erlotinib chemotherapy about the relative
40 probability of objective response rate (CR + PR) compared to Capecitabine + erlotinib in
41 adults with locally advanced/metastatic pancreatic cancer: RR 2.88 (95% CI 1.27-6.52).
- 42 **Progression free survival**
- 43 Moderate quality evidence from 1 multicentre phase III RCT (n=489) showed no clinically
44 important difference between S-1 single agent and gemcitabine single-agent in PFS rates in
45 adults with locally advanced/metastatic pancreatic cancer: HR 1.09 (95% CI 0.9-1.32), where
46 HR less than 1 favours the S-1 arm.
- 47 Moderate quality evidence from 1 multicentre phase III RCT (n=322) showed that there is a
48 clinically important difference favouring gemcitabine + 5-FU in PFS rates compared to

- 1 gemcitabine single-agent in adults with locally advanced/metastatic pancreatic cancer: HR
2 0.77 (95% CI 0.62-0.96)
- 3 Moderate quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
4 important difference between gemcitabine + Axitanib and gemcitabine single-agent in PFS
5 rates in adults with locally advanced/metastatic pancreatic cancer: HR 1.01 (95% CI 0.78-
6 1.30), where HR less than 1 favours the gemcitabine + Axitanib arm.
- 7 Moderate quality evidence from a meta-analysis of 3 multicentre phase III RCTs (n=1050)
8 showed that there is a clinically important difference favouring gemcitabine + Capecitabine in
9 PFS rates compared to gemcitabine single-agent in adults with locally advanced/metastatic
10 pancreatic cancer: HR 0.80 (95% CI 0.72-0.90)
- 11 Moderate quality evidence from 1 multicentre phase III RCT (n=602) showed no clinically
12 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent in
13 PFS rates in adults with locally advanced/metastatic pancreatic cancer: HR 0.96 (95% CI
14 0.81-1.15), where HR less than 1 favours the gemcitabine + Bevacizumab arm.
- 15 Low quality evidence from 1 multicentre phase III RCT (n=660) showed no clinically
16 important difference between gemcitabine + Cetuximab and gemcitabine single-agent in PFS
17 rates in adults with locally advanced/metastatic pancreatic cancer: HR 1.07 (95% CI 0.93-
18 1.23), where HR less than 1 favours the gemcitabine + Cetuximab arm.
- 19 Moderate quality evidence from 1 multicentre phase III RCT (n=195) showed that there is a
20 clinically important difference favouring gemcitabine + Cisplatin in PFS rates compared to
21 gemcitabine single-agent in adults with locally advanced/metastatic pancreatic cancer: HR
22 0.69 (95% CI 0.50-0.95)
- 23 Moderate quality evidence from 1 phase III RCT (n=99) showed that there is a clinically
24 important difference favouring PEFG in PFS rates compared to gemcitabine single-agent in
25 adults with locally advanced/metastatic pancreatic cancer: HR 0.51 (95% CI 0.33-0.78)
- 26 High quality evidence from 1 multicentre phase III RCT (n=569) showed that there is a
27 clinically important difference favouring gemcitabine + Erlotinib in PFS rates compared to
28 gemcitabine single-agent in adults with locally advanced/metastatic pancreatic cancer: HR
29 0.77 (95% CI 0.65-0.92)
- 30 Moderate quality evidence from 1 multicentre phase III RCT (n=360) showed no clinically
31 important difference between gemcitabine + Irinotecan and gemcitabine single-agent in PFS
32 rates in adults with locally advanced/metastatic pancreatic cancer: HR 0.98 (95% CI 0.77-
33 1.25), where HR less than 1 favours the gemcitabine + Irinotecan arm.
- 34 Moderate quality evidence from 1 phase III RCT (n=319) showed no clinically important
35 difference between gemcitabine + Marimastat and gemcitabine single-agent in PFS rates in
36 adults with locally advanced/metastatic pancreatic cancer: HR 0.95 (95% CI 0.73-1.23),
37 where HR less than 1 favours the gemcitabine + Marimastat arm.
- 38 Moderate quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=313)
39 showed that there is a clinically important difference favouring gemcitabine + Oxaliplatin in
40 PFS rates when compared to gemcitabine single-agent in adults with locally
41 advanced/metastatic pancreatic cancer: HR 0.83 (95% CI 0.72-0.97)
- 42 Moderate quality evidence from 1 phase III RCT (n=104) showed no clinically important
43 difference between gemcitabine + Sorafenib and gemcitabine single-agent in PFS rates in
44 adults with locally advanced/metastatic pancreatic cancer: HR 1.04 (95% CI 0.70-1.55),
45 where HR less than 1 favours the gemcitabine + Sorafenib arm.
- 46 Moderate quality evidence from 1 phase III RCT (n=688) showed no clinically important
47 difference between gemcitabine + Tipifarnib and gemcitabine single-agent in PFS rates in

1 adults with locally advanced/metastatic pancreatic cancer: HR 1.03 (95% CI 0.87-1.22),
2 where HR less than 1 favours the gemcitabine + Tipifarnib arm.

3 High quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=584) showed
4 that there is a clinically important difference favouring gemcitabine + S-1 group in PFS rates
5 when compared to gemcitabine single-agent in adults with locally advanced/metastatic
6 pancreatic cancer: HR 0.65 (95% CI 0.57-0.75)

7 **Overall survival**

8 High quality evidence from a network meta-analysis of 23 phase III RCTs involving 9.989
9 patients with locally advanced/metastatic pancreatic cancer showed that there is a clinically
10 important difference favouring FOLFIRINOX, PEFG, gemcitabine + erlotinib+/-bevacizumab,
11 gemcitabine+capecitabine, and gemcitabine+oxaliplatin in OS when compared to
12 gemcitabine single-agent and several other gemcitabine-based chemotherapy treatments in
13 adults with locally advanced/metastatic PC.

14 High quality evidence from 1 multicentre phase III RCT (n=126) showed that there is a
15 clinically important difference favouring gemcitabine single-agent chemotherapy in long-term
16 survival compared with the 5-FU single-agent in adults with locally advanced/metastatic
17 pancreatic cancer: HR 1.75 (95% CI 1.21-0.2.54)

18 Moderate quality evidence from 1 multicentre phase III RCT (n=489) showed no clinically
19 important difference between S-1 single agent and gemcitabine single-agent in long-term
20 survival rates in adults with locally advanced/metastatic pancreatic cancer: HR 0.96 (95% CI
21 0.71-1.30), where HR less than 1 favours the S-1 arm.

22 Moderate quality evidence from 1 multicentre phase III RCT (n=602) showed no clinically
23 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent in
24 long-term survival rates in adults with locally advanced/metastatic pancreatic cancer: HR
25 0.96 (95% CI 0.81-1.15), where HR less than 1 favours the gemcitabine + Bevacizumab arm.

26 Moderate quality evidence from 1 multicentre phase III RCT (n=159) showed no clinically
27 important difference between gemcitabine + elpamotide and gemcitabine single-agent in
28 long-term survival rates in adults with locally advanced/metastatic pancreatic cancer: HR
29 0.87 (95% CI 0.49-1.56), where HR less than 1 favours the gemcitabine + elpamotide arm.

30 Moderate quality evidence from 1 multicentre phase III RCT (n=602) showed no clinically
31 important difference between gemcitabine + masitinib and gemcitabine single-agent in long-
32 term survival rates in adults with locally advanced/metastatic pancreatic cancer: HR 0.89
33 (95% CI 0.70-1.13), where HR less than 1 favours the gemcitabine + masitinib arm.

34 Moderate quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=584)
35 showed no clinically important difference between gemcitabine + S-1 and gemcitabine single-
36 agent in long-term survival rates in adults with locally advanced/metastatic pancreatic
37 cancer: HR 0.89 (95% CI 0.74-1.08), where HR less than 1 favours the gemcitabine + S-1
38 arm.

39 **Adverse Events**

40 **a) Grade 3/4 toxicities: Nausea/Vomiting**

41 Low quality evidence from 1 multicentre phase III RCT (n=126) showed no clinically
42 important difference between 5-FU single agent and gemcitabine single-agent on the relative
43 risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
44 advanced/metastatic pancreatic cancer: RR 0.38 (95% CI 0.1-1.35), where RR less than 1
45 favours the 5-FU arm.

46 Very low quality evidence from 1 multicentre phase III RCT (n=545) showed no clinically
47 important difference between S-1 single agent and gemcitabine single-agent on the relative

- 1 risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
2 advanced/metastatic pancreatic cancer: RR 1.29 (95% CI 0.49-3.42), where RR less than 1
3 favours the S-1 arm.
- 4 Very low quality evidence from 1 multicentre phase III RCT (n=316) showed no clinically
5 important difference between gemcitabine + 5-FU and gemcitabine single-agent on the
6 relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
7 advanced/metastatic pancreatic cancer: RR 0.79 (95% CI 0.42-1.50), where RR less than 1
8 favours the gemcitabine + 5-FU arm.
- 9 Low quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
10 important difference between gemcitabine+ Axitanib and gemcitabine single-agent on the
11 relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
12 advanced/metastatic pancreatic cancer: RR 1.40 (95% CI 0.78-2.52), where RR less than 1
13 favours the gemcitabine + Axitanib arm.
- 14 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=1017) showed
15 no clinically important difference between gemcitabine + Capecitabine and gemcitabine
16 single-agent on the relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in
17 adults with locally advanced/metastatic pancreatic cancer: RR 1.20 (95% CI 0.83-1.74),
18 where RR less than 1 favours the gemcitabine + Capecitabine arm.
- 19 Low quality evidence from 1 multicentre phase III RCT (n=726) showed no clinically
20 important difference between gemcitabine + Cetuximab and gemcitabine single-agent on the
21 relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
22 advanced/metastatic pancreatic cancer: RR 1.71 (95% CI 0.99-2.95), where RR less than 1
23 favours the gemcitabine + Cetuximab arm.
- 24 Moderate quality evidence from 1 multicentre phase III RCT (n=195) showed that there is a
25 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
26 related grade 3/4 toxicities (Nausea/vomiting) compared to gemcitabine + Cisplatin in adults
27 with locally advanced/metastatic pancreatic cancer: RR 3.63 (95% CI 1.54-8.56)
- 28 Low quality evidence from 1 multicentre phase III RCT (n=153) showed no clinically
29 important difference between gemcitabine + elpamotide and gemcitabine single-agent on the
30 relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
31 advanced/metastatic pancreatic cancer: RR 0.53 (95% CI 0.08-3.66), where RR less than 1
32 favours the gemcitabine + elpamotide arm.
- 33 Very low quality evidence from 1 multicentre phase III RCT (n=325) showed no clinically
34 important difference between gemcitabine + Exatecan and gemcitabine single-agent on the
35 relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
36 advanced/metastatic pancreatic cancer: RR 1.56 (95% CI 0.70-3.46), where RR less than 1
37 favours the gemcitabine + Exatecan arm.
- 38 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=472) showed
39 no clinically important difference between gemcitabine + Irinotecan and gemcitabine single-
40 agent on the relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with
41 locally advanced/metastatic pancreatic cancer: RR 1.60 (95% CI 1.09-2.33), where RR less
42 than 1 favours the gemcitabine + Irinotecan arm.
- 43 Moderate quality evidence from 1 phase III RCT (n=319) showed no clinically important
44 difference between gemcitabine + Marimastat and gemcitabine single-agent on the relative
45 risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
46 advanced/metastatic pancreatic cancer: RR 0.50 (95% CI 0.27-0.92), where RR less than 1
47 favours the gemcitabine + Marimastat arm.
- 48 Moderate evidence [GRADE] from a meta-analysis of 2 multicentre phase III RCTs (n=840)
49 showed that there is a clinically important difference favouring gemcitabine single-agent on

- 1 the relative risk of drug-related grade 3/4 toxicities (Nausea/vomiting) compared to
2 gemcitabine + Oxaliplatin in adults with locally advanced/metastatic pancreatic cancer: RR
3 2.77 (95% CI 1.81-4.25)
- 4 Very low quality evidence from 1 multicentre phase III RCT (n=546) showed no clinically
5 important difference between gemcitabine + Pemetrexed and gemcitabine single-agent on
6 the relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
7 advanced/metastatic pancreatic cancer: RR 1 (95% CI 0.53-1.88), where RR less than 1
8 favours the gemcitabine + Pemetrexed arm.
- 9 Moderate quality evidence from a meta-analysis of 2 phase III RCTs (n=915) showed no
10 clinically important difference between gemcitabine + Tipifarnib and gemcitabine single-agent
11 on the relative risk of drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
12 advanced/metastatic pancreatic cancer: RR 0.75 (95% CI 0.55-1.01), where RR less than 1
13 favours the gemcitabine + Tipifarnib arm.
- 14 High quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636) showed
15 that there is a clinically important difference favouring gemcitabine single-agent on the
16 relative risk of drug-related grade 3/4 toxicities (Nausea/vomiting) compared to gemcitabine +
17 S-1 in adults with locally advanced/metastatic pancreatic cancer: RR 2.99 (95% CI 1.49-
18 5.99)
- 19 Moderate quality evidence from 1 phase III RCT (n=256) showed no clinically important
20 difference between Capecitabine + erlotinib and gemcitabine + erlotinib on the relative risk of
21 drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally advanced/metastatic
22 pancreatic cancer: RR 15.98 (95% CI 0.93-273.93), where RR less than 1 favours the
23 gemcitabine + erlotinib
- 24 **b) Grade 3/4 toxicities: diarrhoea**
- 25 Low quality evidence from 1 multicentre phase III RCT (n=126) showed no clinically
26 important difference between 5-FU single-agent and gemcitabine single-agent on the relative
27 risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally advanced/metastatic
28 pancreatic cancer: RR 3 (95% CI 0.32-28.07), where RR less than 1 favours the 5-FU arm.
- 29 High quality evidence from 1 multicentre phase III RCT (n=545) showed that there is a
30 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
31 related grade 3/4 toxicities (diarrhoea) compared to S-1 single-agent in adults with locally
32 advanced/metastatic pancreatic cancer: RR 5.02 (95% CI 1.47-17.14)
- 33 Very low quality evidence from 1 multicentre phase III RCT (n=316) showed no clinically
34 important difference between gemcitabine + 5-FU and gemcitabine single-agent on the
35 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
36 advanced/metastatic pancreatic cancer: RR 2.5 (95% CI 0.8-7.8), where RR less than 1
37 favours the gemcitabine + 5-FU arm.
- 38 Low quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
39 important difference between gemcitabine + Axitanib and gemcitabine single-agent on the
40 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
41 advanced/metastatic pancreatic cancer: RR 0.81 (95% CI 0.22-2.98), where RR less than 1
42 favours the gemcitabine + Axitanib arm.
- 43 Low quality evidence from 1 multicentre phase III RCT (n=602) showed no clinically
44 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent on
45 the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
46 advanced/metastatic pancreatic cancer: RR 1 (95% CI 0.22-2.98), where RR less than 1
47 favours the gemcitabine + Bevacizumab arm.

- 1 Very low quality evidence from a meta-analysis of 3 multicentre phase III RCTs (n=1017)
2 showed no clinically important difference between gemcitabine + Capecitabine and
3 gemcitabine single-agent on the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in
4 adults with locally advanced/metastatic pancreatic cancer: RR 1.53 (95% CI 0.80-2.91),
5 where RR less than 1 favours the gemcitabine + Capecitabine arm.
- 6 Very low quality evidence from 1 multicentre phase III RCT (n=716) showed no clinically
7 important difference between gemcitabine + Cetuximab and gemcitabine single-agent on the
8 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
9 advanced/metastatic pancreatic cancer: RR 1.09 (95% CI 0.45-2.66), where RR less than 1
10 favours the gemcitabine + Cetuximab arm.
- 11 Very low quality evidence from 1 multicentre phase III RCT (n=195) showed no clinically
12 important difference between gemcitabine + Cisplatin and gemcitabine single-agent on the
13 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
14 advanced/metastatic pancreatic cancer: RR 0.59 (95% CI 0.15-2.42), where RR less than 1
15 favours the gemcitabine + Cisplatin arm.
- 16 Low quality evidence from 1 multicentre phase III RCT (n=562) showed no clinically
17 important difference between gemcitabine + Erlotinib and gemcitabine single-agent on the
18 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
19 advanced/metastatic pancreatic cancer: RR 2.98 (95% CI 0.61-14.63), where RR less than 1
20 favours the gemcitabine + Erlotinib arm.
- 21 Very low quality evidence from 1 multicentre phase III RCT (n=325) showed no clinically
22 important difference between gemcitabine + Exatecan and gemcitabine single-agent on the
23 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
24 advanced/metastatic pancreatic cancer: RR 1.87 (95% CI 0.17-20.41), where RR less than 1
25 favours the gemcitabine + Exatecan arm.
- 26 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=472) showed
27 that there is a clinically important difference favouring gemcitabine single-agent on the
28 relative risk of drug-related grade 3/4 toxicities (diarrhoea) compared to gemcitabine +
29 Irinotecan in adults with locally advanced/metastatic pancreatic cancer: RR 6.92 (95% CI
30 2.71-17.67)
- 31 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=840) showed
32 no clinically important difference between gemcitabine + Oxaliplatin and gemcitabine single-
33 agent on the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
34 advanced/metastatic pancreatic cancer: RR 2.50 (95% CI 1.22-5.11), where RR less than 1
35 favours the gemcitabine + Oxaliplatin arm.
- 36 Low quality evidence from 1 multicentre phase III RCT (n=546) showed no clinically
37 important difference between gemcitabine + Pemetrexed and gemcitabine single-agent on
38 the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
39 advanced/metastatic pancreatic cancer: RR 4 (95% CI 0.86-18.67), where RR less than 1
40 favours the gemcitabine + Pemetrexed arm.
- 41 Low quality evidence from 1 phase III RCT (n=102) showed no clinically important difference
42 between gemcitabine + Sorafenib and gemcitabine single-agent on the relative risk of drug-
43 related grade 3/4 toxicities (diarrhoea) in adults with locally advanced/metastatic pancreatic
44 cancer: RR 0.69 (95% CI 0.12-3.98), where RR less than 1 favours the gemcitabine +
45 Sorafenib arm.
- 46 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=915) showed no clinically
47 important difference between gemcitabine + Tipifarnib and gemcitabine single-agent on the
48 relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
49 advanced/metastatic pancreatic cancer: RR 1.34 (95% CI 0.60-3.02), where RR less than 1
50 favours the gemcitabine + Tipifarnib arm.

1 Moderate quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636)
2 showed no clinically important difference between gemcitabine + S-1 and gemcitabine single-
3 agent on the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults with locally
4 advanced/metastatic pancreatic cancer: RR 2.59 (95% CI 0.94-7.14), where RR less than 1
5 favours the gemcitabine + S-1 arm.

6 Moderate quality evidence from 1 phase III RCT (n=256) showed no clinically important
7 difference between Capecitabine + erlotinib and gemcitabine + erlotinib on the relative risk of
8 drug-related grade 3/4 toxicities (diarrhoea) in adults with locally advanced/metastatic
9 pancreatic cancer: RR 0.55 (95% CI 0.22-1.35), where RR less than 1 favours the
10 gemcitabine + erlotinib arm.

11 **c) Grade 3/4 toxicities in adults with locally advanced/metastatic pancreatic cancer:**
12 **Fatigue**

13 Moderate quality evidence from 1 multicentre phase III RCT (n=545) showed no clinically
14 important difference between S-1 single agent and gemcitabine single-agent on the relative
15 risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally advanced/metastatic
16 pancreatic cancer: RR 1.81 (95% CI 0.85-3.84), where RR less than 1 favours the S-1 arm.

17 Low quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
18 important difference between gemcitabine + Axitanib and gemcitabine single-agent on the
19 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
20 advanced/metastatic pancreatic cancer: RR 1.3 (95% CI 0.75-2.25), where RR less than 1
21 favours the gemcitabine + Axitanib arm.

22 Low quality evidence from 1 multicentre phase III RCT (n=716) showed no clinically
23 important difference between gemcitabine + Cetuximab and gemcitabine single-agent on the
24 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
25 advanced/metastatic pancreatic cancer: RR 1.11 (95% CI 0.82-1.5), where RR less than 1
26 favours the gemcitabine + Cetuximab arm.

27 Low quality evidence from 1 multicentre phase III RCT (n=362) showed no clinically
28 important difference between gemcitabine + Erlotinib and gemcitabine single-agent on the
29 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
30 advanced/metastatic pancreatic cancer: RR 0.99 (95% CI 0.49-1.99), where RR less than 1
31 favours the gemcitabine + Erlotinib arm.

32 Very low quality evidence from 1 multicentre phase III RCT (n=325) showed no clinically
33 important difference between gemcitabine + Exatecan and gemcitabine single-agent on the
34 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
35 advanced/metastatic pancreatic cancer: RR 2.62 (95% CI 0.96-7.10), where RR less than 1
36 favours the gemcitabine + Exatecan arm.

37 Very low quality evidence from 1 multicentre phase III RCT (n=342) showed no clinically
38 important difference between gemcitabine + Irinotecan and gemcitabine single-agent on the
39 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
40 advanced/metastatic pancreatic cancer: RR 1.09 (95% CI 0.67-1.77), where RR less than 1
41 favours the gemcitabine + Irinotecan arm.

42 Low quality evidence from 1 phase III RCT (n=319) showed no clinically important difference
43 between gemcitabine + Marimastat and gemcitabine single-agent on the relative risk of drug-
44 related grade 3/4 toxicities (fatigue) in adults with locally advanced/metastatic pancreatic
45 cancer: RR 1.98 (95% CI 0.83-4.74), where RR less than 1 favours the gemcitabine +
46 Marimastat arm.

47 Low quality evidence from 1 multicentre phase III RCT (n=527) showed no clinically
48 important difference between gemcitabine + Oxaliplatin and gemcitabine single-agent on the
49 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally

1 advanced/metastatic pancreatic cancer: RR 0.90 (95% CI 0.63-1.30), where RR less than 1
2 favours the gemcitabine + Oxaliplatin arm.

3 Moderate quality evidence from 1 multicentre phase III RCT (n=546) showed that there is a
4 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
5 related grade 3/4 toxicities (fatigue) compared to gemcitabine + Pemetrexed in adults with
6 locally advanced/metastatic pancreatic cancer: RR 2.28 (95% CI 1.34-3.86)

7 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=915) showed no clinically
8 important difference between gemcitabine + Tipifarnib and gemcitabine single-agent on the
9 relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
10 advanced/metastatic pancreatic cancer: RR 0.91 (95% CI 0.65-1.27), where RR less than 1
11 favours the gemcitabine + Tipifarnib arm.

12 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636) showed
13 no clinically important difference between gemcitabine + S-1 and gemcitabine single-agent
14 on the relative risk of drug-related grade 3/4 toxicities (fatigue) in adults with locally
15 advanced/metastatic pancreatic cancer: RR 1.19 (95% CI 0.55-2.57), where RR less than 1
16 favours the gemcitabine + S-1 arm.

17 **d) Grade 3/4 toxicities: Neutropenia**

18 High quality evidence from 1 multicentre phase III RCT (n=126) showed that there is a
19 clinically important difference favouring 5-FU single-agent on the relative risk of drug-related
20 grade 3/4 toxicities (Neutropenia) compared to gemcitabine single-agent in adults with locally
21 advanced/metastatic pancreatic cancer: RR 0.19 (95% CI 0.06-0.61)

22 High quality evidence from 1 multicentre phase III RCT (n=545) showed that there is a
23 clinically important difference favouring S-1 single-agent on the relative risk of drug-related
24 grade 3/4 toxicities (Neutropenia) compared to gemcitabine single-agent in adults with locally
25 advanced/metastatic pancreatic cancer: RR 0.22 (95% CI 0.14-0.32)

26 Low quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
27 important difference between gemcitabine + Axitanib and gemcitabine single-agent on the
28 relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally
29 advanced/metastatic pancreatic cancer: RR 0.34 (95% CI 0.01-8.23), where RR less than 1
30 favours the gemcitabine + Axitanib arm.

31 Low quality evidence from 1 multicentre phase III RCT (n=530) showed no clinically
32 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent on
33 the relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally
34 advanced/metastatic pancreatic cancer: RR 1.08 (95% CI 0.68-1.73), where RR less than 1
35 favours the gemcitabine + Bevacizumab arm.

36 Low quality evidence from a meta-analysis of 3 multicentre phase III RCTs (n=1017) showed
37 no clinically important difference between gemcitabine + Capecitabine and gemcitabine
38 single-agent on the relative risk of drug-related grade 3/4 toxicities (Neutropenia) in patients
39 treated with gemcitabine compared to those treated with gemcitabine + Capecitabine in
40 adults with locally advanced/metastatic pancreatic cancer: RR 1.44 (95% CI 1.15-1.81)

41 Very low quality evidence from 1 multicentre phase III RCT (n=716) showed no clinically
42 important difference between gemcitabine + Cetuximab and gemcitabine single-agent on the
43 relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally
44 advanced/metastatic pancreatic cancer: RR 0.97 (95% CI 0.75-1.26), where RR less than 1
45 favours the gemcitabine + Cetuximab arm.

46 Moderate quality evidence from 1 multicentre phase III RCT (n=159) showed no clinically
47 important difference between gemcitabine + elpamotide and gemcitabine single-agent on the
48 relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally

1 advanced/metastatic pancreatic cancer: RR 0.85 (95% CI 0.62-1.16), where RR less than 1
2 favours the gemcitabine + elpamotide arm.

3 Low quality evidence from 1 multicentre phase III RCT (n=325) showed that there is a
4 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
5 related grade 3/4 toxicities (Neutropenia) compared to in adults with locally
6 advanced/metastatic pancreatic cancer: RR 2.07 (95% CI 1.33-3.22)

7 Low quality evidence from 1 multicentre phase III RCT (n=130) showed no clinically
8 important difference between gemcitabine + Irinotecan and gemcitabine single-agent on the
9 relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally
10 advanced/metastatic pancreatic cancer: RR 1.70 (95% CI 0.85-3.37), where RR less than 1
11 favours the gemcitabine + Irinotecan arm.

12 Very low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=840)
13 showed no clinically important difference between gemcitabine + Oxaliplatin and gemcitabine
14 single-agent on the relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults
15 with locally advanced/metastatic pancreatic cancer: RR 0.86 (95% CI 0.69-1.09), where RR
16 less than 1 favours the gemcitabine + Oxaliplatin arm.

17 Moderate quality evidence from 1 multicentre phase III RCT (n=546) showed that there is a
18 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
19 related grade 3/4 toxicities (Neutropenia) compared to gemcitabine + Pemetrexed in adults
20 with locally advanced/metastatic pancreatic cancer: RR 3.51 (95% CI 2.51-4.92)

21 Low quality evidence from 1 phase III RCT (n=102) showed no clinically important difference
22 between gemcitabine + Sorafenib and gemcitabine single-agent on the relative risk of drug-
23 related grade 3/4 toxicities (neutropenia) in adults with locally advanced/metastatic
24 pancreatic cancer: RR 0.9 (95% CI 0.48-1.70), where RR less than 1 favours the
25 gemcitabine + Sorafenib arm.

26 Moderate quality evidence from a meta-analysis of 2 phase III RCTs (n=915) showed no
27 clinically important difference between gemcitabine + Tipifarnib and gemcitabine single-agent
28 on the relative risk of drug-related grade 3/4 toxicities (neutropenia) in adults with locally
29 advanced/metastatic pancreatic cancer: RR 1.26 (95% CI 1.07-1.5), where RR less than 1
30 favours the gemcitabine + Tipifarnib arm.

31 High quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636) showed
32 that there is a clinically important difference favouring gemcitabine single-agent on the
33 relative risk of drug-related grade 3/4 toxicities (Neutropenia) compared to gemcitabine + S-1
34 in adults with locally advanced/metastatic pancreatic cancer: RR 1.57 (95% CI 1.33-1.86)

35

36

37 **e) Grade 3/4 toxicities: Thrombocytopenia**

38 Low quality evidence from 1 multicentre phase III RCT (n=320) showed no clinically
39 important difference between gemcitabine+ 5-FU and gemcitabine single-agent gemcitabine
40 compared to those treated with gemcitabine + 5-FU: RR 1.81 (95% CI 1.04-3.15), where RR
41 less than 1 favours the gemcitabine + 5-FU arm.

42 Low quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
43 important difference between gemcitabine + Axitanib and gemcitabine single-agent on the
44 relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with locally
45 advanced/metastatic pancreatic cancer: RR 0.34 (95% CI 0.01-8.23), where RR less than 1
46 favours the gemcitabine + Axitanib arm.

- 1 Low quality evidence from 1 multicentre phase III RCT (n=540) showed no clinically
2 important difference between gemcitabine + Bevacizumab and gemcitabine single-agent on
3 the relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with locally
4 advanced/metastatic pancreatic cancer: RR 0.95 (95% CI 0.43-2.08), where RR less than 1
5 favours the gemcitabine + Bevacizumab arm.
- 6 Very low quality evidence from a meta-analysis of 3 multicentre phase III RCTs (n=1017)
7 showed no clinically important difference between gemcitabine + Capecitabine and
8 gemcitabine single-agent on the relative risk of drug-related grade 3/4 toxicities
9 (thrombocytopenia) in adults with locally advanced/metastatic pancreatic cancer: RR 1.14
10 (95% CI 0.72-1.82), where RR less than 1 favours the gemcitabine + Capecitabine arm.
- 11 Low quality evidence from 1 multicentre phase III RCT (n=195) showed no clinically
12 important difference between gemcitabine + Cisplatin and gemcitabine single-agent on the
13 relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with locally
14 advanced/metastatic pancreatic cancer: RR 0.4 (95% CI 0.13-1.22), where RR less than 1
15 favours the gemcitabine + Cisplatin arm.
- 16 Low quality evidence from 1 multicentre phase III RCT (n=153) showed no clinically
17 important difference between gemcitabine + elpamotide and gemcitabine single-agent on the
18 relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with locally
19 advanced/metastatic pancreatic cancer: RR 0.99 (95% CI 0.45-2.19), where RR less than 1
20 favours the gemcitabine + elpamotide arm.
- 21 Low quality evidence from 1 multicentre phase III RCT (n=325) showed that there is a
22 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
23 related grade 3/4 toxicities (Thrombocytopenia) compared to gemcitabine + Exatecan in
24 adults with locally advanced/metastatic pancreatic cancer: RR 3.47 (95% CI 1.55-7.77)
- 25 Very low quality evidence from 1 multicentre phase III RCT (n=130) showed no clinically
26 important difference between gemcitabine + Irinotecan and gemcitabine single-agent on the
27 relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with locally
28 advanced/metastatic pancreatic cancer: RR 8.15 (95% CI 0.43-154.64), where RR less than
29 1 favours the gemcitabine + Irinotecan arm.
- 30 Moderate quality evidence from 1 multicentre phase III RCT (n=313) showed that there is a
31 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
32 related grade 3/4 toxicities (Thrombocytopenia) compared to gemcitabine + Oxaliplatin in
33 adults with locally advanced/metastatic pancreatic cancer: RR 4.37 (95% CI 1.7-11.25),
34 where RR less than 1 favours the gemcitabine + Oxaliplatin arm
- 35 High quality evidence from 1 multicentre phase III RCT (n=546) showed that there is a
36 clinically important difference favouring gemcitabine single-agent on the relative risk of drug-
37 related grade 3/4 toxicities (Thrombocytopenia) compared to gemcitabine + Pemetrexed in
38 adults with locally advanced/metastatic pancreatic cancer: RR 2.88 (95% CI 1.70-4.88)
- 39 Low quality evidence from 1 phase III RCT (n=102) showed no clinically important difference
40 between gemcitabine + Sorafenib and gemcitabine single-agent on the relative risk of drug-
41 related grade 3/4 toxicities (thrombocytopenia) in adults with locally advanced/metastatic
42 pancreatic cancer: RR 0.52 (95% CI 0.14-1.97), where RR less than 1 favours the
43 gemcitabine + Sorafenib arm.
- 44 Moderate quality evidence from a meta-analysis of 2 phase III RCTs (n=915) showed no
45 clinically important difference between gemcitabine + Tipifarnib and gemcitabine single-agent
46 on the relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in adults with
47 locally advanced/metastatic pancreatic cancer: RR 1.22 (95% CI 0.89-1.66), where RR less
48 than 1 favours the gemcitabine + Tipifarnib arm.

1 High quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636) showed
2 that there is a clinically important difference favouring gemcitabine single-agent on the
3 relative risk of drug-related grade 3/4 toxicities (Thrombocytopenia) compared to gemcitabine
4 + S-1 in adults with locally advanced/metastatic pancreatic cancer: RR 3.4 (95% CI 1.33-8.7)

5 Low quality evidence from 1 phase III RCT (n=256) showed no clinically important difference
6 between Capecitabine + erlotinib and gemcitabine + erlotinib on the relative risk of drug-
7 related grade 3/4 toxicities (thrombocytopenia) in adults with locally advanced/metastatic
8 pancreatic cancer: RR 5.17 (95% CI 1.17-22.85), where RR less than 1 favours the
9 gemcitabine + erlotinib arm

10 **f) Grade 3/4 toxicities: Leucopenia**

11 High quality evidence from 1 multicentre phase III RCT (n=545) showed that there is a
12 clinically important difference favouring S-1 single-agent on the relative risk of drug-related
13 grade 3/4 toxicities (Leucopenia) compared to gemcitabine single-agent in adults with
14 locally advanced/metastatic pancreatic cancer: RR 0.2 (95% CI 0.1-0.38)

15 Low quality evidence from 1 multicentre phase III RCT (n=316) showed no clinically
16 important difference between gemcitabine + 5-FU and gemcitabine single-agent on the
17 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
18 advanced/metastatic pancreatic cancer: RR 1.81 (95% CI 1.03-3.2), where RR less than 1
19 favours the gemcitabine + 5-FU arm.

20 High quality evidence from 1 multicentre phase III RCT (n=613) showed no clinically
21 important difference between gemcitabine + Axitanib and gemcitabine single-agent on the
22 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
23 advanced/metastatic pancreatic cancer: no drug-related grade 3/4 toxicities (Leucopenia)
24 were reported.

25 Low quality evidence from 1 multicentre phase III RCT (n=716) showed no clinically
26 important difference between gemcitabine + Cetuximab and gemcitabine single-agent on the
27 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
28 advanced/metastatic pancreatic cancer: RR 0.76 (95% CI 0.51-1.11), where RR less than 1
29 favours the gemcitabine + Cetuximab arm.

30 Very low quality evidence from 1 multicentre phase III RCT (n=195) showed no clinically
31 important difference between gemcitabine + Cisplatin and gemcitabine single-agent on the
32 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
33 advanced/metastatic pancreatic cancer: RR 1.24 (95% CI 0.51-3), where RR less than 1
34 favours the gemcitabine + Cisplatin arm.

35 Moderate quality evidence from 1 multicentre phase III RCT (n=153) showed no clinically
36 important difference between gemcitabine + elpamotide and gemcitabine single-agent on the
37 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
38 advanced/metastatic pancreatic cancer: RR 0.71 (95% CI 0.47-1.09), where RR less than 1
39 favours the gemcitabine + elpamotide arm.

40 Moderate quality evidence from 1 multicentre phase III RCT (n=527) showed no clinically
41 important difference between gemcitabine + Oxaliplatin and gemcitabine single-agent on the
42 relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with locally
43 advanced/metastatic pancreatic cancer: RR 0.76 (95% CI 0.5-1.17), where RR less than 1
44 favours the gemcitabine + Oxaliplatin arm.

45 Moderate quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=636)
46 showed no clinically important difference between gemcitabine + S-1 and gemcitabine single-
47 agent between patients treated with gemcitabine compared to those treated with gemcitabine
48 + S-1 on the relative risk of drug-related grade 3/4 toxicities (leucopenia) in adults with

1 locally advanced/metastatic pancreatic cancer: RR 1.76 (95% CI 1.09-2.84), where RR less
2 than 1 favours the gemcitabine + S-1 arm.

3 Low quality evidence from 1 phase III RCT (n=256) showed no clinically important difference
4 between Capecitabine + erlotinib and gemcitabine + erlotinib on the relative risk of drug-
5 related grade 3/4 toxicities (leucopenia) in adults with locally advanced/metastatic
6 pancreatic cancer: RR 15.98 (95% CI 0.93-273.93), where RR less than 1 favours the
7 gemcitabine + erlotinib arm

8 **Health-related quality of life**

9 Low quality evidence from a meta-analysis of 2 multicentre phase III RCTs (n=319) showed
10 no clinically important difference between gemcitabine + Capecitabine and gemcitabine
11 single-agent on the improvement of quality of life in physical well-being, mood, pain,
12 tiredness, functional performance, coping effort, and treatment burden (measured as mean
13 of the linear-analogue self-assessment [LASA] indicators) in adults with locally
14 advanced/metastatic pancreatic cancer at 6 months follow-up.

15 Low quality evidence from 1 multicentre phase III RCT (n=540) showed no clinically
16 important difference between gemcitabine + Cetuximab and gemcitabine single-agent group
17 at 5, 13, and 17 weeks follow-up on the improvement of quality of life in emotional well-being
18 (measured as mean of the linear-analogue self-assessment [LASA] indicators) in adults with
19 locally advanced/metastatic pancreatic cancer.

20 Moderate low quality evidence from 1 multicentre phase III RCT (n=195) showed that there is
21 a clinically important difference favouring gemcitabine + Cisplatin on quality of life (measured
22 as mean of the Spitzer 5-Item Index) compared to gemcitabine alone at the end of treatment
23 in adults with locally advanced/metastatic pancreatic cancer: MD -0.40 (95% CI -0.66 to -
24 0.14)

25 Very low and low quality evidence from 1 phase III RCT (n=46) indicates showed no clinically
26 important difference between PEFG and gemcitabine single-agent on the relative probability
27 of improving quality of life in adults with locally advanced/metastatic pancreatic cancer at 6
28 months follow-up (measured as mean of the number of patients with a clinically significant
29 improvement QLQ-C30).

30 **11.2.6.3 Gemcitabine versus novel agents**

31 **Response rate**

32 Low quality evidence from 1 multicentre phase II RCT (n=142) showed no clinically important
33 difference between gemcitabine + novel agents [vandetanib] and gemcitabine + placebo
34 about the relative probability of objective response rate (CR + PR) in adults with locally
35 advanced/metastatic pancreatic cancer: RR 1.08 (95% CI 0.47-2.50), where RR less than 1
36 favours the gemcitabine + vandenitab arm.

37 Very low quality evidence from 1 multicentre phase III RCT (n=277) showed no clinically
38 important difference between novel agents [BAY 12-9566] and gemcitabine single-agent
39 chemotherapy for patients treated with the BAY 12-9566 when compared to those who
40 received gemcitabine about the relative probability of objective response rate (CR + PR) in
41 adults with locally advanced/metastatic pancreatic cancer: RR 0.18 (95% CI 0.02-1.45),
42 where RR less than 1 favours the gemcitabine single-agent chemotherapy arm.

43 Very low quality evidence from 1 multicentre phase III RCT (n=55) showed no clinically
44 important difference between novel agents [ZD9331] and gemcitabine single-agent
45 chemotherapy for patients treated with the ZD9331 when compared to those who received
46 gemcitabine about the relative probability of objective response rate (CR + PR) in adults with
47 locally advanced/metastatic pancreatic cancer: RR 0.42 (95% CI 0.04-4.33), where RR less
48 than 1 favours the gemcitabine single-agent chemotherapy arm.

1 **Progression-free survival**

2 Moderate quality evidence from 1 multicentre phase II RCT (n=142) showed no clinically
3 important difference between gemcitabine + novel agents [vandetanib] and gemcitabine +
4 placebo in progression-free survival rates in adults with locally advanced/metastatic
5 pancreatic cancer: HR 1.11 (95% CI 0.87-1.41), where HR less than 1 favours the
6 gemcitabine + placebo arm.

7 Moderate quality evidence from 1 multicentre phase III RCT (n=277) showed that there is a
8 clinically important difference favouring gemcitabine single-agent chemotherapy in
9 progression-free survival rates when compared with the BAY 12-9566: HR 0.53 (95% CI
10 0.41-0.68)

11 **Overall Survival**

12 Moderate quality evidence from 1 Multi multicentre phase RCT (n=142) showed no clinically
13 important difference between gemcitabine + novel agents [vandetanib] and gemcitabine +
14 placebo in overall survival in adults with locally advanced/metastatic pancreatic cancer: HR
15 1.21 (95% CI 0.96-1.53), where HR less than 1 favours the gemcitabine + vandenitab arm.

16 Moderate quality evidence from 1 multicentre phase III RCT (n=277) showed that there is a
17 clinically important difference favouring gemcitabine single-agent chemotherapy in overall
18 survival rates compared to BAY 12-9566 in adults with locally advanced/metastatic
19 pancreatic cancer: HR 0.57 (95% CI 0.44-0.74), where HR less than 1 favours the
20 gemcitabine single-agent chemotherapy arm.

21 **Adverse Events**

22 Moderate quality evidence from 1 multicentre phase II RCT (n=142) showed no clinically
23 important difference between gemcitabine + novel agents [vandetanib] and gemcitabine +
24 placebo about the relative risk of grade 3/4 toxicities (neutropenia) in adults with locally
25 advanced/metastatic pancreatic cancer: RR 1.55 (95% CI 1.02-2.35), where RR less than 1
26 favours the gemcitabine + vandenitab arm

27 Low quality evidence from 1 multicentre phase II RCT (n=142) showed no clinically important
28 difference between gemcitabine + novel agents [vandetanib] and gemcitabine + placebo
29 about the relative risk of grade 3/4 toxicities (including thrombocytopenia, fatigue,
30 leucopenia, hypertension, ALT increased, hyponatraemia, ALP increased, lethargy,
31 lymphocyte count decreased, diarrhoea, blood bilirubin increased, and abdominal pain) in
32 adults with locally advanced/metastatic pancreatic cancer.

33 Very low quality evidence from 1 multicentre phase III RCT (n=277) showed no clinically
34 important difference between novel agents [BAY 12-9566] and gemcitabine single-agent
35 chemotherapy the relative risk of grade 3/4 toxicities (including nausea, vomiting, and
36 diarrhoea) in adults with locally advanced/metastatic pancreatic cancer.

37 Very low quality evidence from 1 multicentre phase III RCT (n=55) showed no clinically
38 important difference between novel agents [ZD9331] and gemcitabine single-agent
39 chemotherapy about the relative risk of grade 3/4 toxicities (including nausea, vomiting,
40 diarrhoea, fatigue, and neutropenia) in adults with locally advanced/metastatic pancreatic
41 cancer.

42 **Health-related quality of life**

43 Moderate quality evidence from 1 multicentre phase III RCT (n=277) showed that there is a
44 clinically important difference favouring novel agents [BAY 12-9566] on global quality of life
45 and several functional domains: including physical, role and cognitive (measured as mean of
46 the EORTC QLQ C-30) compared to gemcitabine single-agent chemotherapy in adults with
47 locally advanced/metastatic pancreatic cancer at 8 weeks follow-up.

1 Moderate quality evidence from 1 multicentre phase III RCT (n=277) showed that there is a
2 clinically important difference favouring novel agents [BAY 12-9566] on perceived symptom
3 burden: including fatigue, pain and constipation (measured as mean of the EORTC QLQ C-
4 30) compared to gemcitabine single-agent chemotherapy in adults with locally
5 advanced/metastatic pancreatic cancer at 8 weeks follow-up

6 Low quality evidence from 1 multicentre phase III RCT (n=277) showed no clinically
7 important difference between novel agents [BAY 12-9566] and gemcitabine single-agent
8 chemotherapy in quality of life: including emotional and social functional domains; and
9 nausea, dyspnoea, insomnia, diarrhoea, and financial perceived symptom burden (measured
10 as mean of the EORTC QLQ C-30) in adults with locally advanced/metastatic pancreatic
11 cancer at 8 weeks follow-up.

12 **11.2.6.4 Standard-dose gemcitabine versus low-dose**

13 **Response rate**

14 Very low quality evidence from 1 phase III RCT (n=21) showed no clinically important
15 difference between gemcitabine infusion at a standard dose and gemcitabine infusion at a
16 low dose chemotherapy about the relative probability of objective response rate (CR + PR) in
17 adults with locally advanced/metastatic pancreatic cancer: RR 0.91 (95% CI 0.16-5.3) where
18 RR higher than 1 favours the standard dose arm.

19 **Progression-free survival**

20 No evidence was identified to inform this outcome.

21 **Overall Survival**

22 Moderate quality evidence from 1 phase III RCT (n=21) showed no clinically important
23 difference in between survival rates gemcitabine infusion at a standard dose and
24 gemcitabine infusion at a low dose chemotherapy in adults with locally advanced/metastatic
25 pancreatic cancer.

26 **Adverse Events**

27 Very low quality evidence from 1 phase III RCT (n=21) showed no clinically important
28 difference between gemcitabine infusion at a standard dose and gemcitabine infusion at a
29 low dose chemotherapy about the relative risk of grade 3/4 toxicities (including neutropenia,
30 anaemia, thrombocytopenia, general fatigue, nausea/vomiting, and diarrhoea) in adults with
31 locally advanced/metastatic pancreatic cancer.

32 **Health-related quality of life**

33 No evidence was identified to inform this outcome.

34 **11.2.6.5 5-FU versus combination 5-FU**

35 **11.2.6.5.1 In adults with metastatic disease**

36 **Response rate**

37 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=319) showed that there is
38 a clinically important difference favouring 5-FU combination chemotherapy on objective
39 response rate (CR + PR) compared to 5-FU single-agent chemotherapy in adults with
40 metastatic pancreatic cancer: RR 8.62 (95% CI 1.57-47.22)

41 Very low quality evidence from 1 phase III RCT (n=123) showed no clinically important
42 difference between 5-FU single-agent chemotherapy and 5-FU combination chemotherapy
43 [5-FU + doxorubicin + cisplatin] in objective response rate (CR + PR) in adults with

1 metastatic pancreatic cancer: RR 2.17 (95% CI 0.2-23.31), where RR higher than 1 favours
2 the 5-FU combination arm.

3 Very low quality evidence from 1 phase III RCT (n=196) showed no clinically important
4 difference between 5-FU single-agent chemotherapy and 5-FU combination chemotherapy
5 [5-FU + cisplatin] in objective response rate (CR + PR) in adults with metastatic pancreatic
6 cancer: RR 21 (95% CI 1.25-353.49), where RR higher than 1 favours the 5-FU combination
7 arm.

8 **Progression-free survival**

9 Low quality evidence from 1 phase III RCT (n=196) showed that there is a clinically important
10 difference favouring 5-FU + cisplatin chemotherapy in progression-free survival rates
11 compared to 5-FU single-agent chemotherapy in adults with metastatic pancreatic cancer:
12 HR 0.55 (95% CI 0.41-0.74)

13 **Overall Survival**

14 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=319) showed no clinically
15 important difference between 5-FU single-agent chemotherapy and 5-FU combination
16 chemotherapy in overall survival rates in adults with metastatic pancreatic cancer: HR 0.97
17 (95% CI 0.79-1.2), where HR less than 1 favours the 5-FU combination arm.

18 **Adverse Events**

19 Very low quality evidence from 1 phase III RCT (n=123) showed that there is a clinically
20 important difference favouring 5-FU single-agent chemotherapy on the relative risk of grade
21 3/4 toxicities (nausea) compared to 5-FU + doxorubicin + cisplatin in adults with metastatic
22 pancreatic cancer: RR 4.70 (95% CI 1.51-10.91)

23 Moderate quality evidence from a meta-analysis of III phase III RCTs (n=319) showed that
24 there is a clinically important difference favouring 5-FU combination chemotherapy on the
25 relative risk of grade 3/4 toxicities (vomiting) compared to 5-FU single-agent chemotherapy in
26 adults with metastatic pancreatic cancer: RR 3.75 (95% CI 1.73-7.32)

27 Very low quality evidence from 1 phase III RCT (n=123) showed no clinically important
28 difference between 5-FU single-agent chemotherapy and 5-FU combination chemotherapy
29 [5-FU + doxorubicin + cisplatin] about the relative risk of grade 3/4 toxicities (vomiting) in
30 adults with metastatic pancreatic cancer: RR 3.25 (95% CI 0.94-8.78), where RR higher than
31 1 favours the 5-FU single-agent arm.

32 Moderate quality evidence from 1 phase III RCT (n=196) showed that there is a clinically
33 important difference favouring 5-FU combination [5-FU + cisplatin] chemotherapy on the
34 relative risk of grade 3/4 toxicities (vomiting) compared to 5-FU single-agent chemotherapy in
35 adults with metastatic pancreatic cancer: RR 4.12 (95% CI 1.49-9.52)

36 Very low quality evidence from 1 phase III RCT (n=196) showed no clinically important
37 difference between 5-FU single-agent chemotherapy group & 98 in the 5-FU combination
38 chemotherapy [5-FU + cisplatin] about the relative risk of grade 3/4 toxicities diarrhoea
39 between intervention groups in adults with metastatic pancreatic cancer: RR 2.57 (95% CI
40 0.51-11.15), where RR higher than 1 favours the 5-FU single-agent arm.

41 Very low quality evidence from 1 phase III RCT (n=123) showed no clinically important
42 difference between 5-FU single-agent chemotherapy and 5-FU combination chemotherapy
43 [5-FU + doxorubicin + cisplatin] about the relative risk of grade 3/4 toxicities (leucopenia) in
44 adults with metastatic pancreatic cancer: RR 1.68 (95% CI 1.11-2.23), where RR higher than
45 1 favours the 5-FU single-agent arm.

46 Very low quality evidence from a meta-analysis of 2 phase III RCTs (n=320) showed no
47 clinically important difference between 5-FU single-agent chemotherapy and 5-FU

1 combination chemotherapy about the relative risk of grade 3/4 toxicities (stomatitis) in adults
2 with metastatic pancreatic cancer: RR 1.2 (95% CI 0.6-2.27), where RR higher than 1
3 favours the 5-FU single-agent arm.

4 Very low quality evidence from 1 phase III RCT (n=123) showed no clinically important
5 difference between 5-FU single-agent chemotherapy and 5-FU combination chemotherapy
6 [5-FU + doxorubicin + cisplatin] about the relative risk of grade 3/4 toxicities (stomatitis) in
7 adults with metastatic pancreatic cancer: RR 0.36 (95% CI 0.09-1.22), where RR higher than
8 1 favours the 5-FU single-agent arm.

9 Low quality evidence from 1 phase III RCT (n=197) showed no clinically important difference
10 5-FU single-agent chemotherapy and 5-FU combination chemotherapy [5-FU + cisplatin]
11 about the relative risk of grade 3/4 toxicities (stomatitis) in adults with metastatic pancreatic
12 cancer: RR 2.68 (95% CI 1.01-6.23), where RR higher than 1 favours the 5-FU single-agent
13 arm.

14 **Health-related quality of life**

15 No evidence was identified to inform this outcome.

16 **1.2.6.5.2 In adults with locally advanced and metastatic pancreatic cancer**

17 **Response rate**

18 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=220) showed no clinically
19 important difference between 5-FU single-agent and 5-FU combination chemotherapy in
20 objective response rate (CR + PR) in adults with locally advanced/metastatic pancreatic
21 cancer: RR 1.7 (95% CI 0.88-3.3), where RR higher than 1 favours the 5-FU combination
22 arm.

23 Very low quality evidence from 1 phase III RCT (n=23) showed no clinically important
24 difference between 5-FU single-agent and 5-FU combination chemotherapy [5-FU +
25 doxorubicin + mitomycin] on objective response rate (CR + PR) in adults with locally
26 advanced/metastatic pancreatic cancer: RR 0.26 (95% CI 0.03-2.11), where RR higher than
27 1 favours the 5-FU combination arm.

28 Moderate quality evidence from 1 phase III RCT (n=197) showed no clinically important
29 difference between 5-FU single-agent and 5-FU combination chemotherapy [5-FU +
30 mitomycin] the 5-FU combination chemotherapy when compared to those who received 5-FU
31 chemotherapy alone objective response rate (CR + PR) in adults with locally
32 advanced/metastatic pancreatic cancer: RR 2.28 (95% CI 1.08-4.83), where RR higher than
33 1 favours the 5-FU combination arm.

34 **Progression-free survival**

35 Moderate quality evidence from 1 phase III RCT (n=197) showed no clinically important
36 difference between 5-FU single-agent and 5-FU combination chemotherapy [5-FU +
37 mitomycin] on progression-free survival rates in adults with locally advanced/metastatic
38 pancreatic cancer: HR 0.81 (95% CI 0.62-1.06), where HR less than 1 favours the 5-FU
39 combination arm.

40 **Overall Survival**

41 Low quality evidence from a meta-analysis of 2 phase III RCTs (n=220) showed no clinically
42 important difference between 5-FU single-agent and 5-FU combination chemotherapy on
43 overall survival in adults with locally advanced/metastatic pancreatic cancer: HR 0.97 (95%
44 CI 0.79-1.20), where HR less than 1 favours the 5-FU combination arm.

45 **Adverse Events**

1 Low quality evidence from 1 phase III RCT (n=197) showed no clinically important difference
2 between 5-FU single-agent and 5-FU combination chemotherapy [5-FU + mitomycin] about
3 the relative risk of grade 3/4 toxicities (diarrhoea) in adults with locally advanced/metastatic
4 pancreatic cancer: RR 1.05 (95% CI 0.31-3.52) where RR higher than 1 favours the 5-FU
5 combination arm.

6 Low quality evidence from 1 phase III RCT (n=197) showed no clinically important difference
7 between 5-FU single-agent and 5-FU combination chemotherapy [5-FU + mitomycin] about
8 the relative risk of grade 3/4 toxicities (neutropenia) in adults with locally
9 advanced/metastatic pancreatic cancer: RR 7.34 (95% CI 0.38-140.36) where RR higher
10 than 1 favours the 5-FU combination arm.

11 Low quality evidence from 1 phase III RCT (n=209) showed no clinically important difference
12 between about the relative risk of grade 3/4 toxicities (stomatitis) 5-FU single-agent and 5-FU
13 combination chemotherapy [5-FU + mitomycin] in adults with locally advanced/metastatic
14 pancreatic cancer: RR 1.44 (95% CI 0.60-3.44) where RR higher than 1 favours the 5-FU
15 combination arm.

16 **Health-related quality of life**

17 No evidence was identified to inform this outcome.

18 **11.2.6.6 Combination 5-FU (FSM) versus other chemotherapy**

19 **Response rate**

20 Very low quality evidence from 1 phase III RCT (n=184) showed no clinically important
21 difference between FSM [5-FU+ streptozotocin + mitomycin] and FAM chemotherapy [5-FU +
22 Adriamycin + mitomycin] about the relative probability of objective response rate (CR + PR)
23 in adults with locally advanced/metastatic pancreatic cancer: RR 0.32 (95% CI 0.09-1.14),
24 where RR higher than 1 favours the FSM arm.

25 Low quality evidence from 1 phase III RCT (n=140) showed that there is a clinically important
26 difference favouring FSM group [5-FU+ streptozotocin + mitomycin] in objective response
27 rate (CR + PR) compared to FM chemotherapy [5-FU + mitomycin] in adults with locally
28 advanced/metastatic pancreatic cancer: RR 3.8 (95% CI 1.5-9.61)

29

30 **Progression-free survival**

31 No evidence was identified to inform this outcome.

32 **Overall Survival**

33 Low quality evidence from 1 phase III RCT (n=184) showed no clinically important difference
34 between FSM [5-FU+ streptozotocin + mitomycin] and FAM chemotherapy [5-FU +
35 Adriamycin + mitomycin] in overall survival rates.

36 Low quality evidence from 1 phase III RCT (n=140) showed no clinically important difference
37 between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin] chemotherapy
38 in overall survival rates.

39 **Adverse Events**

40 Very low quality evidence from 1 phase III RCT (n=140) showed no clinically important
41 difference between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin]
42 chemotherapy about the relative risk of drug-related grade 3/4 toxicities (diarrhoea) in adults
43 with locally advanced/metastatic pancreatic cancer: RR 0.50 (95% CI 0.05-5.39) where RR
44 less than 1 favours the FSM arm.

1 Very low quality evidence from 1 phase III RCT (n=184) showed no clinically important
2 difference between FSM [5-FU+ streptozotocin + mitomycin] and FAM chemotherapy [5-FU +
3 Adriamycin + mitomycin] about the relative risk of drug-related grade 3/4 toxicities
4 (nausea/vomiting) in adults with locally advanced/metastatic pancreatic cancer: RR 1.20
5 (95% CI 0.59-2.41) where RR less than 1 favours the FSM arm.

6 Very low quality evidence from 1 phase III RCT (n=140) showed no clinically important
7 difference between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin]
8 chemotherapy about drug-related grade 3/4 toxicities (nausea/vomiting) in adults with locally
9 advanced/metastatic pancreatic cancer: RR 1.61 (95% CI 0.99-2.62), where RR less than 1
10 favours the FSM arm.

11 Very low quality evidence from 1 phase III RCT (n=184) showed no clinically important
12 difference between FSM [5-FU+ streptozotocin + mitomycin] and FAM chemotherapy [5-FU +
13 Adriamycin + mitomycin] on the relative risk of drug-related grade 3/4 toxicities (leukopenia)
14 in adults with locally advanced/metastatic pancreatic cancer: RR 0.48 (95% CI 0.26-0.90),
15 where RR less than 1 favours the FSM arm.

16 Very low quality evidence from 1 phase III RCT (n=140) showed no clinically important
17 difference between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin]
18 chemotherapy in the relative risk of drug-related grade 3/4 toxicities (leukopenia) in adults
19 with locally advanced/metastatic pancreatic cancer: RR 0.82 (95% CI 0.36-1.85) where RR
20 less than 1 favours the FSM arm.

21 Very low quality evidence from 1 phase III RCT (n=184) showed no clinically important
22 difference between FSM [5-FU+ streptozotocin + mitomycin] and FAM chemotherapy [5-FU +
23 Adriamycin + mitomycin] on the relative risk of drug-related grade 3/4 toxicities
24 (thrombocytopenia) in adults with locally advanced/metastatic pancreatic cancer: RR 0.58
25 (95% CI 0.36-0.93), where RR less than 1 favours the FSM arm

26 Very low quality evidence from 1 phase III RCT (n=140) showed no clinically important
27 difference between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin]
28 chemotherapy in the relative risk of drug-related grade 3/4 toxicities (thrombocytopenia) in
29 adults with locally advanced/metastatic pancreatic cancer: RR 0.62 (95% CI 0.31-1.28)
30 where RR less than 1 favours the FSM arm.

31 Very low quality evidence from 1 phase III RCT (n=140) showed no clinically important
32 difference between FSM [5-FU+ streptozotocin + mitomycin] and FM [5-FU + mitomycin]
33 chemotherapy in the relative risk of drug-related deaths in adults with locally
34 advanced/metastatic pancreatic cancer: RR 0.25 (95% CI 0.03-2.18) where RR less than 1
35 favours the FSM arm.

36 **Health-related quality of life**

37 No evidence was identified to inform this outcome.

38 **11.2.6.7 Intra-arterial chemotherapy versus systemic chemotherapy**

39 **Response rate**

40 Low quality evidence from a meta-analysis of 3 phase III RCTs (n=181) showed that there is
41 a clinically important difference favouring intra-arterial chemotherapy on objective response
42 rate (CR + PR) compared to systemic chemotherapy in adults with locally
43 advanced/metastatic pancreatic cancer: RR 2.76 (95% CI 1.23-6.18)

44 **Progression-free survival**

45 No evidence was identified to inform this outcome.

46 **Overall Survival**

1 Low quality evidence from 1 phase III RCT (n=138) showed no clinically important difference
2 between intra-arterial and systemic chemotherapy in overall survival rates in adults with
3 locally advanced/metastatic pancreatic cancer: HR 1.02 (95% CI 0.63-1.66), where HR less
4 than 1 intra-arterial chemotherapy arm.

5 **Adverse Events**

6 Moderate quality evidence from 1 phase III RCT (n=138) showed that there is a clinically
7 important difference favouring intra-arterial chemotherapy on the relative risk of drug-related
8 grade 3/4 toxicities (thrombocytopenia) compared to systemic chemotherapy in adults with
9 locally advanced/metastatic pancreatic cancer: RR 16.04 (95% CI 2.20-117.24)

10 Low and very low quality evidence from 1 phase III RCT (n=138) showed no clinically
11 important difference between the intra-arterial and systemic chemotherapy about the relative
12 risk of drug-related grade 3/4 toxicities (including nausea/vomiting, diarrhoea, and
13 leucopenia) in adults with locally advanced/metastatic pancreatic cancer: RR 0.13 (95% CI
14 0.01-2.56), RR 0.19 (95% CI 0.01-3.86), and RR 2.64 (95% CI 1.01-6.94); where RR less
15 than 1 favours the intra-arterial chemotherapy arm.

16 **Health-related quality of life**

17 No evidence was identified to inform this outcome.

18 **11.2.6.8 Chemotherapy versus chemotherapy and prophylactic anticoagulant**

19 **Response rate**

20 No evidence was identified to inform this outcome.

21 **Progression-free survival**

22 Low quality evidence from 1 multicentre phase III RCT (n=312) showed no clinically
23 important difference between gemcitabine combined with enoxaparin and gemcitabine only
24 on progression-free survival in adults with locally advanced or metastatic pancreatic cancer:
25 HR 1.06 (95% CI 0.84-1.34), where HR less than 1 favours the gemcitabine + enoxaparin
26 arm.

27 **Overall Survival**

28 Moderate quality evidence from 1 phase IIb RCT (n=121) showed no clinically important
29 difference between gemcitabine with weight-adjusted dalteparin and gemcitabine only on
30 overall survival in adults with locally advanced or metastatic pancreatic cancer.

31 Low quality evidence from 1 phase III RCT (n=312) showed no clinically important difference
32 between gemcitabine combined with enoxaparin and gemcitabine only on overall survival in
33 adults with locally advanced or metastatic pancreatic cancer: HR 1.10 (95% CI 0.87-1.39),
34 where HR less than 1 favours the gemcitabine + enoxaparin arm.

35 **Adverse Events**

36 Very low quality evidence from 1 phase IIb RCT (n=116) showed no clinically important
37 difference between gemcitabine with weight-adjusted dalteparin and gemcitabine only on
38 drug-related Grade 3/4 haematological impairment (RR 0.87 [95% CI 0.55-1.37]) and hepatic
39 functional impairment (RR 1.09 [95% CI 0.64-1.86]) in adults with locally advanced or
40 metastatic pancreatic cancer, where RR less than 1 favours the gemcitabine and weight-
41 adjusted dalteparin arm.

42 Moderate quality evidence from 1 phase IIb RCT (n=123) showed no clinically important
43 difference between gemcitabine combined with weight-adjusted dalteparin and gemcitabine
44 only on vascular thromboembolism in adults with locally advanced or metastatic pancreatic

1 cancer: RR 0.39 (95% CI 0.18-0.85), where RR less than 1 favours the gemcitabine and
2 weight-adjusted dalteparin arm.

3 Very low and low quality evidence from 1 multicentre phase III RCT (n=312) showed no
4 clinically important difference between gemcitabine combined with enoxaparin and
5 gemcitabine only on symptomatic VTE (RR 0.43 [95% CI 0.21-0.88]) and major
6 haemorrhages (RR 1.24 [95% CI 0.56-2.73]) in adults with locally advanced or metastatic
7 pancreatic cancer, where RR less than 1 favours the gemcitabine and weight-adjusted
8 dalteparin arm.

9 **Health-related quality of life**

10 No evidence was identified to inform this outcome.

11 **111.2.6.8.1 Second-line chemotherapy versus best supportive care**

12 **Response rate**

13 No evidence was identified to inform this outcome.

14 **Progression-free survival**

15 Low quality evidence from 1 multicentre phase III RCT (n=303) showed no clinically
16 important difference between second-line chemotherapy and best supportive care on
17 progression-free survival in adults with metastatic pancreatic cancer: HR 0.76 (95% CI 0.57-
18 1.01), where HR less than 1 favours the chemotherapy arm.

19 **Overall Survival**

20 Low quality evidence from 1 multicentre phase III RCT (n=303) showed no clinically
21 important difference between second-line chemotherapy and best supportive care on overall
22 survival in adults with metastatic pancreatic cancer: HR 0.85 (95% CI 0.66-1.09), where HR
23 less than 1 favours the chemotherapy arm.

24 **Adverse Events**

25 Very quality evidence from 1 multicentre phase III RCT (n=286) showed no clinically
26 important difference between second-line chemotherapy and best supportive care on Grade
27 3, 4 or 5 toxicities (including asthenia/fatigue, abdominal pain, anaemia, vomiting, nausea,
28 deep vein thrombosis, renal failure, hyperbilirubinemia, and leukopenia) in adults with
29 metastatic pancreatic cancer: RR 1.12 (95% CI 0.51-2.46), RR 0.87 (95% CI 0.4-1.88), RR
30 2.4 (95% CI 0.63-9.1), RR 3.6 (95% CI 0.76-17.03), RR 3.09 (95% CI 0.63-15.03), RR 5.14
31 (95% CI 0.61-43.46), RR 11.31 (95% CI 0.63-202.65), RR 2.06 (95% CI 0.38-11.05), and RR
32 9.25 (95% CI 0.5-170.31), where RR less than 1 favours the chemotherapy arm.

33 **Health-related quality of life**

34 No evidence was identified to inform this outcome.

35 **111.2.6.8.2 Second-line chemotherapy versus other chemotherapy**

36 **In adults with metastatic disease**

37 *Response rate*

38 Low quality evidence from 1 multicentre phase III RCT (n=202) showed no clinically
39 important difference between LV5FU2-CDDP followed by gemcitabine single-agent
40 [LV5FU2-CDDP/Gem] and gemcitabine single-agent followed by LV5FU2-CDDP
41 [Gem/LV5FU2-CDDP] about the relative probability of objective response rate (CR + PR) in
42 adults with metastatic pancreatic cancer: RR 0.85 (95% CI 0.49-1.47), where RR higher than
43 1 favours the LV5FU2-CDDP/Gem arm.

1 Very low quality evidence from 1 multicentre phase III RCT (n=38) showed no clinically
2 important difference between irinotecan + raltitrexed and raltitrexed single-agent as second-
3 line chemotherapy about the relative probability of objective response rate (CR + PR) in
4 adults with metastatic pancreatic cancer: RR 0.14 (95% CI 0.01-2.59), where RR higher than
5 1 favours the irinotecan + raltitrexed arm.

6 *Progression-free survival*

7 Moderate quality evidence from 1 multicentre phase III RCT (n=202) showed no clinically
8 important difference between LV5FU2-CDDP followed by gemcitabine single-agent
9 [LV5FU2-CDDP/Gem] and gemcitabine single-agent followed by LV5FU2-CDDP
10 [Gem/LV5FU2-CDDP] in PFS rates between intervention groups in adults with metastatic
11 pancreatic cancer: HR 1.06 (95% CI 0.80-1.40), where HR less than 1 favours the LV5FU2-
12 CDDP/Gem arm.

13 *Overall Survival*

14 Moderate quality evidence from 1 multicentre phase III RCT (n=202) showed no clinically
15 important difference between LV5FU2-CDDP followed by gemcitabine single-agent
16 [LV5FU2-CDDP/Gem] and gemcitabine single-agent followed by LV5FU2-CDDP
17 [Gem/LV5FU2-CDDP] in long-term survival rates in adults with metastatic pancreatic cancer:
18 HR 1.06 (95% CI 0.80-1.40), where HR less than 1 favours the LV5FU2-CDDP/Gem arm.

19 *Adverse Events*

20 Low quality evidence from 1 multicentre phase III RCT (n=202) showed no clinically
21 important difference between LV5FU2-CDDP followed by gemcitabine single-agent
22 [LV5FU2-CDDP/Gem] and gemcitabine single-agent followed by LV5FU2-CDDP
23 [Gem/LV5FU2-CDDP] about the relative risk of drug-related grade 3/4 toxicities (including
24 nausea/vomiting) in adults with metastatic pancreatic cancer: RR 0.92 (95% CI 0.47-1.80),
25 where RR less than 1 favours the LV5FU2-CDDP/Gem arm.

26 Very low quality evidence from 1 multicentre phase III RCT (n=38) showed no clinically
27 important difference between irinotecan + raltitrexed and raltitrexed single-agent as second-
28 line chemotherapy about the relative risk of drug-related grade 3/4 toxicities in adults with
29 metastatic pancreatic cancer, including leukocytopenia (RR 1.25 [95% CI 0.4-3.95]),
30 neutropenia (RR 1.33 [95% CI 0.34-5.17]), nausea/vomiting (RR 1.0 [95% CI 0.07-14.85]),
31 and diarrhoea (RR 1.0 [95% CI 0.16-6.38]), where RR less than 1 favours the raltitrexed
32 alone arm. (There were no cases of thrombocytopenia, stomatitis, and fatigue).

33 *Health-related quality of life*

34 No evidence was identified to inform this outcome.

35 **In adults with locally advanced and metastatic pancreatic cancer**

36 ***Response rate***

37 Very low quality evidence from 1 phase III RCT (n=110) showed no clinically important
38 difference between the oxaliplatin + 5-FU and folinic acid + 5-FU second-line chemotherapy
39 in adults with locally advanced/metastatic pancreatic cancer: RR 1.5 (95% CI 0.27-8.19),
40 where RR higher than 1 favours the oxaliplatin + 5-FU arm.

41 Very low quality evidence from 1 multicentre phase III RCT (n=274) showed no clinically
42 important difference between gemcitabine + erlotinib followed by capecitabine [Gem+E/Cap]
43 and capecitabine + erlotinib followed by gemcitabine [Cap+E/ Gem] second-line
44 chemotherapy about the relative probability of objective response rate (CR + PR) in adults
45 with locally advanced/metastatic pancreatic cancer: RR 0.49 (95% CI 0.1-2.29), where RR
46 higher than 1 favours the Gem+E/Cap arm.

1 Very low quality evidence from 1 phase III RCT (n=108) showed no clinically important
2 difference between 5-FU + folinic acid + oxaliplatin [mFOLFOX6] and folinic acid/5-FU
3 second-line chemotherapy about the relative probability of objective response rate (CR + PR)
4 in adults with locally advanced/metastatic pancreatic cancer: RR 1.4 (95% CI 0.47-4.14),
5 where RR higher than 1 favours the mFOLFOX6 arm.

6 *Progression-free Survival*

7 Low quality evidence from 1 phase III RCT (n=110) showed no clinically important difference
8 between oxaliplatin + 5-FU and folinic acid + 5-FU second-line chemotherapy in PFS rates in
9 adults with locally advanced/metastatic pancreatic cancer.

10 Low quality evidence from 1 multicentre phase III RCT (n=168) showed that there is a
11 clinically important difference favouring OFF is associated with a marked improvement in
12 PFS when compared with FF in adults with locally advanced/metastatic pancreatic cancer:
13 HR 0.68 (95% CI 0.49-0.94), where HR less than 1 favours the OFF group.

14 Moderate quality evidence from 1 phase III RCT (n=108) showed no clinically important
15 difference between 5-FU + folinic acid + oxaliplatin [mFOLFOX6] and folinic acid/5-FU
16 second-line chemotherapy in PFS rates in adults with locally advanced/metastatic pancreatic
17 cancer: HR 1.00 (95% CI 0.66-1.52), where HR less than 1 favours the mFOLFOX6 arm.

18 *Overall Survival*

19 Low quality evidence from 1 phase III RCT (n=110) showed no clinically important difference
20 between oxaliplatin + 5-FU and folinic acid + 5-FU second-line chemotherapy in survival
21 rates in adults with locally advanced/metastatic pancreatic cancer.

22 Moderate quality evidence from 1 multicentre phase III RCT (n=168) showed that there is a
23 clinically important difference favouring oxaliplatin + 5-FU group [OFF] second-line
24 chemotherapy in overall survival compared to FA + 5-FU group [FF] second-line
25 chemotherapy in adults with locally advanced/metastatic pancreatic cancer: HR 0.66 (95% CI
26 0.48-0.91), where HR less than 1 favours the OFF group.

27 Low quality evidence from 1 multicentre phase III RCT (n=274) showed no clinically
28 important difference between gemcitabine + erlotinib followed by capecitabine [Gem+E/Cap]
29 and capecitabine + erlotinib followed by gemcitabine [Cap+E/ Gem] second-line
30 chemotherapy in survival rates.

31 Moderate quality evidence from 1 phase III RCT (n=108) showed that there is a clinically
32 important difference favouring folinic acid/5-FU second-line chemotherapy in overall survival
33 compared to 5-FU + folinic acid + oxaliplatin [mFOLFOX6] second-line chemotherapy in
34 adults with locally advanced/metastatic pancreatic cancer: HR 1.78 (95% CI 1.08-2.93),
35 where HR less than 1 favours the mFOLFOX6 arm.

36 *Adverse Events*

37 Very low quality evidence from 1 phase III RCT (n=110) showed no clinically important
38 difference between oxaliplatin + 5-FU and folinic acid + 5-FU second-line chemotherapy
39 about the relative risk of drug-related grade 3/4 toxicities (including nausea/vomiting,
40 diarrhoea, stomatitis and haematological -neutropenia, anaemia, thrombocytopenia).

41 Low quality evidence from 1 multicentre phase III RCT (n=168) showed no clinically
42 important difference between oxaliplatin + 5-FU [OFF] and FA + 5-FU group [FF] second-line
43 chemotherapy about the relative risk of drug-related grade 3/4 toxicities (including anaemia,
44 nausea/emesis, paresthesia, pain, leucopenia, thrombocytopenia, and diarrhoea).

45 Very low quality evidence from 1 multicentre phase III RCT (n=274) showed no clinically
46 important difference between gemcitabine + erlotinib followed by capecitabine [Gem+E/Cap]
47 and capecitabine + erlotinib followed by gemcitabine [Cap+E/ Gem] second-line

1 chemotherapy about the relative risk of drug-related grade 3/4 toxicities (including
2 nausea/vomiting, leucopenia, thrombocytopenia, and diarrhoea).

3 Low to very low quality evidence from 1 phase III RCT (n=102) showed no clinically important
4 difference between 5-FU + folinic acid + oxaliplatin [mFOLFOX6] and folinic acid/5-FU
5 second-line chemotherapy about the relative risk of drug-related grade 3/4 toxicities
6 (including febrile neutropenia, fatigue, thrombocytopenia, dehydration, pulmonary embolism,
7 vomiting, hypokalaemia, and peripheral neuropathy).

8 Moderate quality evidence from 1 phase III RCT (n=102) showed that there is a clinically
9 important difference favouring 5-FU + folinic acid + oxaliplatin [mFOLFOX6] second-line
10 chemotherapy on the relative risk of drug-related grade 3/4 toxicities (neutropenia) compared
11 to folinic acid/5-FU in adults with locally advanced/metastatic pancreatic cancer: RR 8.65
12 (95% CI 2.10-35.72)

13 *Health-related quality of life*

14 Very low quality evidence from 1 phase III RCT (n=108) showed no clinically important
15 difference between 5-FU + folinic acid + oxaliplatin [mFOLFOX6] and folinic acid/5-FU
16 second-line chemotherapy in health related quality of life in adults with locally
17 advanced/metastatic pancreatic cancer.

18 **11.2.7 Recommendations**

19 **First-line treatment**

20 **53. Offer FOLFIRINOX⁴ to people with metastatic pancreatic cancer and an Eastern**
21 **Cooperative Oncology Group (ECOG) performance status of 0–1.**

22 **54. Consider gemcitabine combination therapy⁵ for people who are not well enough to**
23 **tolerate FOLFIRINOX. For guidance on combination therapy with gemcitabine and**
24 **nab–paclitaxel, see the NICE technology appraisal guidance on [paclitaxel as](#)**
25 **[albumin-bound nanoparticles with gemcitabine for untreated metastatic](#)**
26 **[pancreatic cancer](#).**

27 **55. Offer gemcitabine to people who are not well enough to tolerate combination**
28 **chemotherapy.**

29 **Second-line treatment**

30 **56. Consider oxaliplatin-based chemotherapy⁶ as second-line treatment for people**
31 **who have not had first-line oxaliplatin.**

⁴ Although this use is common in UK clinical practice, at the time of publication (January 2018) FOLFIRINOX did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

⁵ Although this use is common in UK clinical practice, at the time of publication (January 2018) many gemcitabine combination therapies did not have a UK marketing authorisation covering the first-line treatment of adults with metastatic pancreatic cancer. The prescriber should follow relevant professional guidance, taking full responsibility for the decision to prescribe. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

⁶ Although this use is common in UK clinical practice, at the time of publication (January 2018) oxaliplatin-based chemotherapy did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

1 **57. Consider gemcitabine-based chemotherapy⁷ as second-line treatment for people**
2 **whose cancer has progressed after first-line FOLFIRINOX.**

3 **Venous thromboembolism prophylaxis**

4 **The updated NICE guideline on venous thromboembolism will cover venous**
5 **thromboembolism prophylaxis for people with pancreatic cancer. This guideline is**
6 **due to be published in March 2018, and the [draft recommendations](#) are available**
7 **now.**

8 **11.2.8 Evidence to recommendations**

9 **11.2.8.1 Relative value placed on the outcomes considered**

10 Response rate, progression free survival, overall survival, adverse events, health related
11 quality of life, patient experience, PROMS and symptom control were considered the critical
12 outcomes for this question.

13 Overall survival and adverse events were reported by all studies. Response rate was
14 reported for all studies except 1. Health related quality of life and progression free survival
15 were reported only by some studies. The outcomes of patient experience/patient reported
16 outcome measures and symptom control were not reported by any studies.

17 **11.2.8.2 Quality of evidence**

18 The quality of the evidence was assessed by GRADE and the Cochrane risk of bias
19 checklist. AMSTAR was used for assessing the methodological quality of systematic reviews.

20 The quality of the outcomes for the comparisons identified by this review were as follows:

- 21 • Chemotherapy versus immunochemotherapy for second line treatment - very low.
- 22 • 5-FU combination chemotherapy versus other chemotherapy regimens – ranged from
23 very low to low
- 24 • Second-line chemotherapy versus other chemotherapy regimens for metastatic disease –
25 ranged from very low to low
- 26 • Gemcitabine versus novel agents – ranged from very low to moderate
- 27 • 5-FU alone versus 5-FU combination chemotherapy (both metastatic and locally
28 advanced disease) – ranged from very low to moderate
- 29 • Second-line chemotherapy versus other chemotherapy regimens for mixed metastatic and
30 locally advanced disease – ranged from low to moderate
- 31 • Chemotherapy versus immunochemotherapy for first line treatment - ranged from low to
32 moderate quality.
- 33 • Chemotherapy (second-line) versus best supportive care – ranged from low to moderate
- 34 • Standard-dose versus low-dose gemcitabine – ranged from low to moderate
- 35 • Intra-arterial chemotherapy versus systemic chemotherapy – ranged from low to moderate
- 36 • Chemotherapy versus prophylactic anticoagulation + chemotherapy – ranged from low to
37 moderate

⁷ Although this use is common in UK clinical practice, at the time of publication (January 2018) gemcitabine-based chemotherapy did not have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See the General Medical Council's [Prescribing guidance: prescribing unlicensed medicines](#) for further information.

- 1 • Gemcitabine versus other chemotherapy regimens for locally advanced disease - ranged
2 from very low to high.
3 • Gemcitabine versus other chemotherapy regimens for metastatic disease - ranged from
4 low to high

5 A substantial number of studies in the evidence base included mixed locally advanced and
6 metastatic cancer populations, but did not report the subgroups separately. Given that there
7 is a continuum between locally advanced and metastatic disease, the committee agreed it
8 was appropriate to use evidence with mixed populations to base their recommendations on.
9 However, during their discussions the committee applied more weight to those studies that
10 had exclusively metastatic populations or had reported metastatic populations separately.

11 The committee noted that no RCT evidence was identified which evaluated surgical resection
12 of metastases in people with pancreatic cancer. The committee therefore agreed to
13 recommend further research in this area, as the role of surgery in managing metastatic
14 pancreatic cancer is a common question asked by patients.

15 11.2.8.3 Consideration of clinical benefits and harms

16 **First line treatment**

17 The committee noted that high quality evidence from a network meta-analysis of 23 RCTs
18 had shown improvements in overall survival with the use of FOLFIRINOX in people with
19 metastatic disease and ECOG performance status 0-1. They also noted the potential for
20 increased toxicity with FOLFIRINOX chemotherapy, and that its use was contraindicated for
21 people with significantly impaired liver function. However, the committee agreed that the
22 benefits in overall survival from this intervention outweighed the potential side effects
23 experienced by those fitter people receiving it and made a strong recommendation for its use
24 in the appropriate subgroup of people reported by the PRODIGE4/ACCORD11 trial.

25 Given the potential for toxicity with FOLFIRINOX, the committee agreed to make additional
26 recommendations that covered first line treatment for those people who would be unlikely to
27 tolerate FOLFIRINOX. They noted that the evidence for both gemcitabine combination
28 therapy and gemcitabine monotherapy had shown improved overall survival and progression
29 free survival in people with metastatic disease. Whilst the survival advantage for gemcitabine
30 combination therapy was larger compared with monotherapy, this needed to be balanced
31 against the potential for increased side effects and a recognition that some patients were not
32 sufficiently fit to tolerate combination chemotherapy. Gemcitabine monotherapy is
33 remarkably well tolerated, even in relatively unfit people. The committee therefore agreed to
34 make a weaker recommendation on gemcitabine combination and monotherapy as the
35 balance between the benefits and harms was less certain.

36 It was not possible, based on the evidence, to determine the optimal gemcitabine
37 combination therapy as several were shown to have some benefits. Therefore the committee
38 did not recommend a particular regimen.

39 The committee noted that the potential benefits of the recommendations made could be
40 improvements in overall survival, progression free survival and quality of life. The potential
41 harms were considered to be side effects from chemotherapy. The committee agreed that
42 the potential benefits of offering chemotherapy outweighed the harms of not doing so.

43 **Second line treatment**

44 The committee noted, based on the evidence, that oxaliplatin-based chemotherapy had
45 shown improved progression-free survival when given second line. However the results for
46 overall survival were inconsistent, with 1 study showing a statistically significant benefit on

1 overall survival whilst another showed no difference. The committee therefore agreed it was
2 only possible to make a weak recommendation for this intervention.

3 Based on their clinical knowledge and experience the committee also agreed to recommend
4 gemcitabine or gemcitabine-based chemotherapy as second line treatment for those people
5 who progress on first line FOLFIRINOX. The committee noted that 80% of patients treated in
6 the PRODIG4/ACCORD11 trial of first line FOLFIRINOX received gemcitabine or
7 gemcitabine-based combination chemotherapy second line, and that they had based their
8 first line treatment recommendations on results of this clinical trial. It is also the current
9 standard of care.

10 Based on their knowledge and experience, the committee noted that treatment options for
11 metastatic disease are currently very limited and second line treatment is often not
12 considered as an option due to the poor prognosis of the disease. These factors generate an
13 impression of futility which has a significant negative psychological impact on people with
14 pancreatic cancer. The committee considered that making recommendations for second line
15 treatment would help promote the active treatment of people with metastatic disease thereby
16 helping to alleviate some of this psychological impact. They noted that other more tangible
17 benefits could be improvements in overall survival, progression free survival and quality of
18 life. The potential harms of the recommendations made were considered to be side effects
19 from chemotherapy. The committee agreed that the potential benefits outweighed the harms
20 of treatment.

21 **11.2.8.4 Consideration of economic benefits and harms**

22 The economic evidence review identified two previous economic evaluations for this topic
23 both from a Canadian public healthcare payer perspective. Both studies compared
24 FOLFIRINOX to gemcitabine in a metastatic population with 1 study also comparing
25 gemcitabine in combination with erlotinib and gemcitabine in combination with capecitabine.

26 Whilst both studies reported broadly similar incremental improvements in health of
27 approximately 0.25 QALYs, when comparing FOLFIRINOX to gemcitabine the reported
28 lifetime incremental costs were double in 1 study compared to the other. These resulted in
29 the studies concluding differently as to the cost effectiveness of FOLFIRINOX from a
30 Canadian perspective. The committee acknowledged that the study that concluded that
31 FOLFIRINOX was not cost effective incorporated the more realistic assumptions. They also
32 noted that FOLFIRINOX was significantly more expensive in Canada (approximately by a
33 factor of 10) where the oxaliplatin component is still on patent.

34 The committee acknowledged the low applicability of the studies given the differing
35 perspective to that used by NICE although they agreed that the QALY values reported were
36 believable in a NHS setting and were in line with the evidence from the clinical evidence
37 review. With the lower costs associated with using FOLFIRINOX in a NHS setting it was
38 strongly thought that FOLFIRINOX would be cost effective from a NHS+PSS perspective
39 compared to gemcitabine alone. It was also noted that FOLFIRINOX is currently standard of
40 care for eligible people and that this recommendation would be cost neutral.

41 Both gemcitabine with capecitabine and gemcitabine with erlotinib were health improving and
42 more costly than gemcitabine alone. Given that the increase in QALYs were lower in this
43 group compared to FOLFIRINOX, the committee found it more difficult to generalise these
44 results to an NHS setting. Whilst the committee thought combination therapies were health
45 improving compared to gemcitabine alone it would also be cost increasing through increased
46 use of additional chemotherapies - although the committee did not think this cost would be
47 significant. It was difficult to draw any conclusions from the evidence identified about cost
48 effectiveness from a NHS+PSS perspective and a weaker recommendation was made
49 around combination therapies.

1 No published economic evidence was identified for the other interventions in the review
2 question. The committee agreed that recommendations for second line treatment would
3 probably cause an increase in costs as the current standard of care was best supportive
4 care. Given the relatively short life expectancy and limited number of people receiving
5 second line treatment it was felt that any cost increases were unlikely to be significant.

6 11.2.8.5 Other considerations

7 The committee were aware that there was existing NICE guidance on the use of [paclitaxel as
8 albumin-bound nanoparticles in combination with gemcitabine for previously untreated
9 metastatic pancreatic cancer](#) (TA476, 2017) and [pegylated liposomal irinotecan for treating
10 pancreatic cancer after gemcitabine](#) (TA440, 2017), in metastatic pancreatic cancer.
11 Consequently and in line with NICE processes, the committee did not investigate the use of
12 nab-paclitaxel or liposomal irinotecan in this population or make any recommendations on
13 these interventions. Committee members also noted that the [venous thromboembolism in
14 over 16s](#) is in the process of being updated (to be published in March 2018) and contains a
15 new recommendation related to pancreatic cancer. The committee cross-referenced to
16 TA476 (related to gemcitabine combinations for first line treatment) and noted in the
17 recommendation section that the venous thromboembolism guideline is being updated with
18 a link to the version that is in consultation. They did not cross-refer to TA440 because it does
19 not recommend the use of pegylated liposomal irinotecan and the committee decided that a
20 cross-reference would therefore not be appropriate.

21 11.2.9 Research recommendation

22 **8. A randomised phase II feasibility study should be undertaken comparing
23 surgery/ablative treatment (in combination with chemotherapy) against
24 chemotherapy in people with hepatic oligometastatic potentially resectable
25 pancreatic cancer.**

26 The role of surgery in controlling metastatic pancreatic cancer is of considerable interest.
27 Debulking surgery is established in some other forms of advanced cancer and, combined
28 with chemotherapy, helps to prolong life. No RCT evidence exists which evaluates the role of
29 surgical resection of metastatic pancreatic cancer and compares it against standard non-
30 surgical treatment. More data in this area may enable recommendations to be made about this
31 intervention. Outcomes of interest are feasibility of recruitment, recurrence/progression free
32 survival, quality of life and PROMS.

33 11.2.10 References

- 34 Aigner KR, Gailhofer S, Kopp S (1998) Regional versus systemic chemotherapy for
35 advanced pancreatic cancer: a randomized study. *Hepatogastroenterology* 45(22): 1125-9
- 36 Attard CL, Brown S, Alloul K et al. (2014) Cost-effectiveness of folfirinix for first-line
37 treatment of metastatic pancreatic cancer. *Current Oncology* 21: e41-51
- 38 Azmy A, Abdelwahab S, Yassen M (2013) Oxaliplatin and Bolus-Modulated 5-Fluorouracil as
39 a Second-Line Treatment for Advanced Pancreatic Cancer: Can Bolus Regimens Replace
40 FOLFOX When Considered for Second Line? *ISRN Oncology* Article ID 358538
- 41 Bernhard J, Dietrich D, Scheithauer W et al. (2008) Clinical benefit and quality of life in
42 patients with advanced pancreatic cancer receiving Gemcitabine + capecitabine versus
43 Gemcitabine single-agent : a randomized multicenter phase III clinical trial--SAKK 44/00-
44 CECOG/PAN13001. *Journal of Clinical Oncology* 26(22): 3695-701

- 1 Bukowski RM, Balcerzak SP, O'Bryan RM et al. (1983) Randomized trial of 5-fluorouracil and
2 mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest
3 Oncology Group study. *Cancer* 52(9): 1577-82
- 4 Burris HA, Moore MJ, Andersen J et al. (1997) Improvements in survival and clinical benefit
5 with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a
6 randomized trial. *Journal of Clinical Oncology* 15(6): 2403-13
- 7 Cantore M, Fiorentini G, Luppi G et al. (2004) Gemcitabine versus FLEC regimen given intra-
8 arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase
9 III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. *Journal of*
10 *Chemotherapy* 16(6): 589-94
- 11 Chao Y, Wu CY, Wang JP et al. (2013) A randomized controlled trial of Gemcitabine plus
12 cisplatin versus Gemcitabine single-agent in the treatment of metastatic pancreatic cancer.
13 *Cancer Chemotherapy and Pharmacology* 72(3): 637-42
- 14 Ciuleanu TE, Pavlovsky AV, Bodoky G et al. (2009) A randomised Phase III trial of
15 glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma
16 previously treated with Gemcitabine . *European Journal of Cancer* 45(9): 1589-96
- 17 Cullinan S, Moertel CG, Wieand HS, et al. (1990) A phase III trial on the therapy of advanced
18 pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil,
19 doxorubicin, and cisplatin. *Cancer* 65(10): 2207-12
- 20 Cullinan SA, Moertel CG, Fleming TR et al. (1985) A comparison of three chemotherapeutic
21 regimens in the treatment of advanced pancreatic and gastric carcinoma: Fluorouracil vs
22 fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. *JAMA* 253(14):
23 2061-7
- 24 Dahan L, Bonnetain F, Ychou M et al. (2010) Combination 5-fluorouracil, folinic acid and
25 cisplatin (LV5FU2-CDDP) followed by Gemcitabine or the reverse sequence in metastatic
26 pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). *Gut*
27 59(11): 1527-34
- 28 Deplanque G, Demarchi M, Hebbar M et al. (2015) A randomized, placebo-controlled phase
29 III trial of masitinib + Gemcitabine in the treatment of advanced pancreatic cancer. *Annals of*
30 *Oncology* 26(6): 1194-200
- 31 Ducreux M, Rougier P, Pignon JP et al. (2002). A randomised trial comparing 5-FU with 5-FU
32 plus cisplatin in advanced pancreatic carcinoma. *Annals of Oncology* 13(8): 1185-91
- 33 Eckhardt SG, De Porre P, Smith D et al. (2009) Patient-reported outcomes as a component
34 of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic
35 cancer. *Journal of Pain Symptom Management* 37(2): 135-43
- 36 Fuchs CS, Azevedo S, Okusaka T et al. (2015) A phase 3 randomized, double-blind,
37 placebo-controlled trial of ganitumab or placebo in combination with Gemcitabine as first-line
38 therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. *Annals of*
39 *Oncology* 26(5): 921-7
- 40 Gill S, Ko YJ, Cripps C et al. (2016) PANCREOX: A Randomized Phase III Study of 5-
41 Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic
42 Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. *Journal of*
43 *Clinical Oncology*. 2016
- 44 Gourgou-Bourgade S, Bascoul-Mollevi C, Desseigne F et al. (2013) Impact of FOLFIRINOX
45 compared with Gemcitabine on quality of life in patients with metastatic pancreatic cancer:
46 results from the PRODIGE 4/ACCORD 11 randomized trial. *Journal of Clinical Oncology*
47 31(1): 23-9

- 1 Gresham GK, Wells GA, Gill S et al. (2014) Chemotherapy regimens for advanced
2 pancreatic cancer: a systematic review and network meta-analysis. *BMC Cancer* 14: 471
- 3 Irigoyen A, Gallego J, Ponce CG et al. (2017) Gemcitabine-erlotinib versus gemcitabine-
4 erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer:
5 Efficacy and safety results of a phase IIb randomised study from the Spanish TTD
6 Collaborative Group. *European Journal of Cancer* 75: 73-82.
- 7 Jansen JP, Trikalinos T, Cappelleri JC et al. (2014) Indirect treatment comparison/network
8 meta-analysis study questionnaire to assess relevance and credibility to inform health care
9 decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. *Value in Health*
10 17(2): 157-73
- 11 Ji Z, Wang Y, Chen X et al. (2003) Peripancreatic artery ligation and artery infusion
12 chemotherapy for advanced pancreatic carcinoma. *Chinese Medical Journal* 116(1): 89-92
- 13 Kindler HL, Niedzwiecki D, Hollis D et al. (2010) Gemcitabine plus bevacizumab compared
14 with Gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of
15 the Cancer and Leukemia Group B (CALGB 80303). *Journal of Clinical Oncology* 28(22):
16 3617-22
- 17 Lee HS, Chung MJ, Park JY et al. (2017) A randomized, multicenter, phase III study of
18 gemcitabine combined with capecitabine versus gemcitabine alone as first-line
19 chemotherapy for advanced pancreatic cancer in South Korea. *Medicine* 96(1): e5702
- 20 Maisey N, Chau I, Cunningham D et al. (2002) Multicenter randomized phase III trial
21 comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin
22 in inoperable pancreatic cancer. *Journal of Clinical Oncology* 20(14): 3130-6
- 23 Maraveyas A, Waters J, Roy R et al. (2012) Gemcitabine versus Gemcitabine plus dalteparin
24 thromboprophylaxis in pancreatic cancer. *European Journal of Cancer* 48(9): 1283-92
- 25 Middleton G, Palmer DH, Greenhalf W et al. (2017) Vandetanib plus gemcitabine versus
26 placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a
27 prospective, randomised, double-blind, multicentre phase 2 trial. *Lancet Oncology* 18(4):
28 486-499
- 29 Middleton G, Silcocks P, Cox T et al. (2014) Gemcitabine and capecitabine with or without
30 telomerase peptide vaccine GV1001 in patients with LA or metastatic pancreatic cancer
31 (TeloVac): an open-label, randomised, phase 3 trial. *Lancet Oncology* 15(8): 829-40
- 32 Moinpour CM, Vaught NL, Goldman B et al. (2010) Pain and emotional well-being outcomes
33 in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing
34 Gemcitabine plus cetuximab versus Gemcitabine as first-line therapy in patients with
35 advanced pancreas cancer. *Journal of Clinical Oncology* 28(22): 3611-6
- 36 Moore MJ, Hamm J, Dancey J et al. (2003) Comparison of Gemcitabine versus the matrix
37 metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic
38 adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada
39 Clinical Trials Group. *Journal of Clinical Oncology* 21(17): 3296-302
- 40 NICE (2017). Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated
41 metastatic pancreatic cancer. *Technology Appraisal Guidance TA476*. London, UK: National
42 Institute for Health and Care Excellence
- 43 Oettle H, Riess H, Stieler JM et al. (2014) Second-line oxaliplatin, folinic acid, and
44 fluorouracil versus folinic acid and fluorouracil alone for Gemcitabine-refractory pancreatic
45 cancer: outcomes from the CONKO-003 trial. *Journal of Clinical Oncology* 32(23): 2423-9

- 1 Oster MW, Gray R, Panasci L et al. (1986) Chemotherapy for advanced pancreatic cancer A
2 comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil,
3 streptozotocin, and mitomycin (FSM). *Cancer* 57(1): 29-33
- 4 Pelzer U, Opitz B, Deuschinoff G et al. (2015) Efficacy of Prophylactic Low-Molecular
5 Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From
6 the CONKO-004 Trial. *Journal of Clinical Oncology* 33(18): 2028-34
- 7 Rougier P, Riess H, Manges R et al. (2013) Randomised, placebo-controlled, double-blind,
8 parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment
9 with Gemcitabine for metastatic pancreatic cancer. *European Journal of Cancer* 49(12):
10 2633-42
- 11 Sakamoto H, Kitano M, Suetomi Y et al. (2006) Comparison of standard-dose and low-dose
12 Gemcitabine regimens in pancreatic adenocarcinoma patients: a prospective randomized
13 trial. *Journal of Gastroenterology* 41(1): 70-6
- 14 Smith D and Gallagher N (2003) A phase II/III study comparing intravenous ZD9331 with
15 Gemcitabine in patients with pancreatic cancer. *European Journal of Cancer* 39(10): 1377-83
- 16 Sudo K, Ishihara T, Hirata N et al. (2014) Randomized controlled study of Gemcitabine plus
17 S-1 combination Chemotherapy versus Gemcitabine for unresectable pancreatic cancer.
18 *Cancer Chemotherapy and Pharmacology* 73(2): 389-96
- 19 Tam VC, Ko YJ, Mittmann N et al. (2013) Cost-effectiveness of systemic therapies for
20 metastatic pancreatic cancer. *Current Oncology* 20: e90-e106
- 21 Ueno H, Ioka T, Ikeda M et al. (2013) Randomized phase III study of Gemcitabine plus S-1,
22 S-1 alone, or Gemcitabine single-agent in patients with LA and metastatic pancreatic cancer
23 in Japan and Taiwan: GEST study. *Journal of Clinical Oncology* 31(13): 1640-8
- 24 Ulrich-Pur H, Raderer M, Kornek GV et al. (2003) Irinotecan plus raltitrexed vs raltitrexed
25 alone in patients with Gemcitabine -pretreated advanced pancreatic adenocarcinoma. *British*
26 *Journal of Cancer* 88(8): 1180-4
- 27 Wang M, Shi SB, Qi JL et al. (2013) S-1 plus CIK as second-line treatment for advanced
28 pancreatic cancer. *Medical Oncology* 30(4): 747
- 29 Yamaue H, Tsunoda T, Tani M et al. (2015) Randomized phase II/III clinical trial of
30 elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. *Cancer*
31 *Science* 106(7): 883-90

32 1.2.10.1 Included studies in Gresham et al., 2014 (n=23)

- 33 Abou-Alfa GK, Letourneau R, Harker G et al. (2006) Randomized phase III study of exatecan
34 and Gemcitabine compared with Gemcitabine single-agent in untreated advanced pancreatic
35 cancer. *Journal of Clinical Oncology* 24(27): 4441-7
- 36 Berlin JD, Catalano P, Thomas JP et al. (2002) Phase III study of Gemcitabine in
37 combination with fluorouracil versus Gemcitabine single-agent in patients with advanced
38 pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. *Journal of Clinical*
39 *Oncology* 20(15): 3270-5
- 40 Bramhall SR, Schulz J, Nemunaitis J et al. (2002) A double-blind placebo-controlled,
41 randomised study comparing Gemcitabine and marimastat with Gemcitabine and placebo as
42 first line therapy in patients with advanced pancreatic cancer. *British Journal of Cancer* 87(2):
43 161-7
- 44 Colucci G, Labianca R, Di Costanzo F et al. (2010) Randomized phase III trial of
45 Gemcitabine plus cisplatin compared with single-agent Gemcitabine as first-line treatment of

- 1 patients with advanced pancreatic cancer: the GIP-1 study. *Journal of Clinical Oncology*
2 28(10): 1645-51
- 3 Conroy T, Desseigne F, Ychou M et al. (2011) FOLFIRINOX versus Gemcitabine for
4 metastatic pancreatic cancer. *New England Journal of Medicine* 364(19): 1817-25
- 5 Cunningham D, Chau I, Stocken DD et al. (2009) Phase III randomized comparison of
6 Gemcitabine versus Gemcitabine plus capecitabine in patients with advanced pancreatic
7 cancer. *Journal of Clinical Oncology* 27(33): 5513-8
- 8 Gonçalves A, Gilibert M, François E et al. (2012) BAYPAN study: a double-blind phase III
9 randomized trial comparing Gemcitabine plus sorafenib and Gemcitabine plus placebo in
10 patients with advanced pancreatic cancer. *Annals of Oncology* 23(11): 2799-805
- 11 Heinemann V, Quietzsch D, Gieseler F et al. (2006) Randomized phase III trial of
12 Gemcitabine plus cisplatin compared with Gemcitabine single-agent in advanced pancreatic
13 cancer. *Journal of Clinical Oncology* 24(24): 3946-52
- 14 Heinemann V, Ursula V-K, Dirk W et al. (2012) Gemcitabine plus erlotinib followed by
15 capecitabine versus capecitabine plus erlotinib followed by Gemcitabine in advanced
16 pancreatic cancer: final results of a randomised phase 3 trial of the 'Arbeitsgemeinschaft
17 Internistische Onkologie' (AIO-PK0104). *Gut* 62(5): 751-9
- 18 Herrmann R, Bodoky G, Ruhstaller T et al. (2007) Gemcitabine plus capecitabine compared
19 with Gemcitabine single-agent in advanced pancreatic cancer: a randomized, multicenter,
20 phase III trial of the Swiss Group for Clinical Cancer Research and the Central European
21 Cooperative Oncology Group. *Journal of Clinical Oncology* 25(16): 2212-7
- 22 Kindler HL, Ioka T, Richel DJ et al. (2011) Axitinib plus Gemcitabine versus placebo plus
23 Gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind
24 randomised phase 3 study. *Lancet Oncology* 12(3): 256-62
- 25 Louvet C, Labianca R, Hammel P et al. (2005). Gemcitabine in combination with oxaliplatin
26 compared with Gemcitabine single-agent in LA or metastatic pancreatic cancer: results of a
27 GERCOR and GISCAD phase III trial. *Journal of Clinical Oncology* 23(15): 3509-16
- 28 Moore MJ, Goldstein D, Hamm J et al. (2007) Erlotinib plus Gemcitabine compared with
29 Gemcitabine single-agent in patients with advanced pancreatic cancer: a phase III trial of the
30 National Cancer Institute of Canada Clinical Trials Group. *Journal of Clinical Oncology*
31 25(15): 1960-6
- 32 Oettle H, Richards D, Ramanathan RK et al. (2006) A phase III trial of pemetrexed plus
33 Gemcitabine versus Gemcitabine in patients with unresectable or metastatic pancreatic
34 cancer. *Annals of Oncology* 16(10): 1639-45
- 35 Philip PA, Benedetti J, Corless CL et al. (2010) Phase III study comparing Gemcitabine plus
36 cetuximab versus Gemcitabine in patients with advanced pancreatic adenocarcinoma:
37 Southwest Oncology Group-directed intergroup trial S0205. *Journal of Clinical Oncology*
38 28(22): 3605-10
- 39 Poplin E, Levy DE, Berlin J et al. (2006) Phase III trial of Gemcitabine (30-minute infusion)
40 versus Gemcitabine (fixed-dose-rate infusion [FDR]) versus Gemcitabine oxaliplatin
41 (GEMOX) in patients with advanced pancreatic cancer (E6201). *Journal of Clinical Oncology*
42 24: 933S
- 43 Reni M, Cordio S, Milandri C et al. (2005) Gemcitabine versus cisplatin, epirubicin,
44 fluorouracil, and Gemcitabine in advanced pancreatic cancer: a randomised controlled
45 multicentre phase III trial. *Lancet Oncology* 6(6): 369-76

- 1 Riess H, Helm A, Niedergethmann M et al. (2005) A randomised, prospective, multicenter,
2 phase III trial of Gemcitabine, 5-fluorouracil (5-FU), folinic acid versus Gemcitabine single-
3 agent in patients with advanced pancreatic cancer. *Journal of Clinical Oncology* 23(16
4 suppl): 4009
- 5 Rocha Lima CM, Green MR, Rotche R et al. (2004) Irinotecan plus Gemcitabine results in no
6 survival advantage compared with Gemcitabine monotherapy in patients with LA or
7 metastatic pancreatic cancer despite increased tumor response rate. *Journal of Clinical*
8 *Oncology* 22(18): 3776-83
- 9 Stathopoulos GP, Syrigos K, Aravantinos G et al. (2006) A multicenter phase III trial
10 comparing irinotecan-Gemcitabine (IG) with Gemcitabine (G) monotherapy as first-line
11 treatment in patients with LA or metastatic pancreatic cancer. *British Journal of Cancer* 95(5):
12 587-92
- 13 Van Cutsem E, van de Velde H, Karasek P et al. (2004) Phase III trial of Gemcitabine plus
14 tipifarnib compared with Gemcitabine plus placebo in advanced pancreatic cancer. *Journal of*
15 *Clinical Oncology* 15;22(8): 1430-8
- 16 Van Cutsem E, Vervenne WL, Bennouna J et al. (2009) Phase III trial of bevacizumab in
17 combination with Gemcitabine and erlotinib in patients with metastatic pancreatic cancer.
18 *Journal of Clinical Oncology* 27(13): 2231–7
- 19 Von Hoff DD, Ervin T, Arena FP et al. (2013) Increased survival in pancreatic cancer with
20 nab-paclitaxel plus Gemcitabine. *New England Journal of Medicine* 369(18): 1691-703
- 21

12 Economic modelling: cost effectiveness of different types of stent for the management of biliary obstruction in people with unresectable pancreatic cancer

12.1 Introduction

Biliary obstruction causing obstructive jaundice is the most visible manifestation of pancreatic malignancy in the head of pancreas. The main symptom associated with the obstructive jaundice is an itch which can be severe and debilitating but is not present in all patients. Other symptoms that may be caused/exacerbated by biliary obstruction include early satiety and nausea. The visible signs of biliary obstruction include yellow sclera and skin and may be of most concern to the individual. Biliary obstruction leads to malabsorption of the fat soluble vitamins, resulting in a vitamin k deficiency if obstruction is prolonged and consequent derangement of blood clotting.

In people with unresectable pancreatic cancer causing biliary obstruction clarity is needed around the most cost effective stent to use in palliation of this blockage. Historically, inexpensive plastic stents (with a small diameter lumen) have been used for managing biliary obstruction. In the last few years more expensive self-expanding mesh metal stents (SEMS) have become widely available and there is a perception that use of these stents may cause less morbidity than plastic stents and may have a longer time to dysfunction. Therefore, they may be cost effective or cost saving through improved quality of life and reduced costs from reducing the need for further surgery following dysfunction and through reducing the need to treat other adverse events.

12.2 Methods

12.2.1 Interventions considered

12.2.1.1 Interventions and comparator

This economic model compared two stenting strategies for biliary obstruction in patients with unresectable pancreatic cancer:

- Initial stenting with plastic stents replaced with SEMS on dysfunction (Plastic/SEMS)
- Initial stenting with SEMS replaced with SEMS on dysfunction (SEMS/SEMS)

to a basecase of:

- Initial stenting with plastic stents replaced with plastic stents on dysfunction (Plastic/Plastic)

A strategy of initial stenting with metal stents replaced with plastic stents on dysfunction was not considered by the model as this was a strategy that was not deemed clinically appropriate as metal stents can be reused upon dysfunction and would be used again.

All people in the model would receive initial stenting for palliation of the bile duct blockage by insertion of the stent (either plastic or SEMS) during endoscopic retrograde cholangiopancreatography (ERCP). It is also assumed for the simplicity of modelling that the initial insertion attempt had been successful and that patients would enter the model at this

1 point. Other placement methods are possible (e.g. percutaneous transhepatic
2 cholangiography (PTC) but these were not considered by the economic model. ERCP is the
3 most widely used method within the NHS for the insertion of biliary stents and was used by
4 all but 1 study included in the accompanying clinical evidence review. Whilst the issue of
5 method of insertion is not considered by the economic model it is considered more widely as
6 part of the recommendations for this topic. Whilst there will be differences between the
7 methods in terms of both costs and adverse events, the use of either SEMS or plastic stent
8 would not influence this choice. Therefore, the costs of initial insertion, excluding the cost of
9 the stent, are likely to be identical between the interventions considered and would not
10 influence which strategy is cost effective. Whilst the model assumes otherwise, in a small
11 proportion of cases multiple methods of insertion will be attempted or the same method used
12 more than once in initial insertion when the original attempt has not been successful. Whilst
13 this will ultimately mean the model will underestimate costs, no evidence was identified and it
14 was deemed unlikely by the committee that the need for second or further procedures during
15 initial stenting would differ between strategies. Therefore, this assumption would not have
16 any effect upon the preferred strategy.

17 12.2.1.2 Type of stent

18 There are three broad types of SEMS: covered, uncovered and partially uncovered
19 describing the extent to which the SEMS is covered by plastic. It is possible that the different
20 types of covering have a different rate of migration and occlusion, with the plastic covering
21 believed to reduce occlusion but potentially increase migration. The cost of these different
22 broad stent types are almost identical and the choice of which type is preferable would be
23 based on clinical factors, not economic and consequently this question is not addressed by
24 this economic model.

25 For this model where parameters have been informed by the clinical evidence review the
26 pooled estimates from studies including all types of SEMS has been used. To test the
27 robustness of this assumption these estimates have been replaced with those estimates for
28 solely covered and solely partially covered SEMS. Given the evidence that was identified by
29 the clinical evidence review it was not possible to calculate estimates for solely uncovered
30 metal stents and this analysis was not performed.

31 The clinical evidence review also identified randomised controlled evidence on paclitaxel-
32 eluting SEMS. These, as well as other drug-eluting SEMS are relatively new and seldom
33 used in an NHS setting. It is unclear currently how these would fit into the clinical pathway for
34 this patient group and more discussion and research is needed in this area. Therefore drug
35 eluting SEMS were not considered by this economic model.

36 Plastic stents are, by themselves, of insignificant cost and there is little variation in design
37 amongst different variations and consequently unlikely to be any difference in effectiveness
38 and costs between different manufacturers and types.

39 12.2.2 Model structure


40 A simple Markov model was created which included three states to try and estimate the
41 number of stents received by the three different strategies considered. The Markov model
42 has three displayed states: initial stent placement, subsequent stent placement and death.
43 The model cohort remained in the initial stent placement state until they either experienced
44 stent dysfunction and received a secondary stenting or died. In Figure 3 the 2nd
45 insertion/subsequent' represents multiple states where patients can receive a third or in very
46 limited cases fourth and fifth stentings. The model cohort can transit to the death state from
47 any of these subsequent stenting states.

48 The Markov model had a cycle length of 1 month. When patients transitioned between a 1st
49 and 2nd/sub stent insertion states (i.e. their stent became dysfunctional) there is 1 cycle

1 length, not depicted in the diagram, where patients would receive their diagnostic work-up
 2 and surgery to replace or reposition their stent. Whilst this allowed the simple Markov model
 3 to allow these transitions it also accurately mirrored clinical practice where the process of
 4 becoming symptomatic, having the diagnostic work up and scheduling surgery can take
 5 approximately 3-6 weeks or approximately 1 month.

6 Quality of life, adverse events, hospital stay and other important components of the
 7 estimates of costs and QALYs were not estimated through the Markov model and were
 8 added to the outcomes of the model directly. This was because given the short life
 9 expectancy of this patient group most of the evidence reported primary outcomes, such as
 10 death, and these did not need to be estimated, for the different strategies, through modelling.
 11 All modelling was performed in Microsoft Excel 2013.

Figure 3: Simple Markov model for estimating number of stent insertions



12 12.2.3 Population

13 The model covers all people with an increased bilirubin level and/or clinical symptoms of
 14 jaundice caused by an obstructive inoperable malignancy of the bile duct resulting from
 15 pancreatic cancer presenting in a NHS secondary care setting. The model only covers
 16 people of sufficient health for palliative stenting and the model assumes that all patients
 17 would receive a successful stenting.

18 12.2.4 Model parameters

19 12.2.4.1 Overall survival

20 In the accompanying clinical evidence review the hazard ratio for overall survival was 1.0
 21 (95%CI 0.75-1.31) based on three RCTs (n=247) when comparing SEMS to plastic stents.
 22 This suggests that there is no difference in overall survival between the differing stenting
 23 interventions. Whilst this was based on low quality evidence, the committee considered it
 24 reasonable that there would be no difference in overall survival between the three
 25 interventions considered. Therefore, in our analysis survival was assumed identical between
 26 all interventions.

1 For the purposes of the model we used a mean overall survival for the model cohort of 109
2 days as reported in Walter et al. (2015) the most recent study reported in the clinical
3 evidence review for patients with unresectable blockage. Walter et al. (2015) was a three
4 armed RCT comparing two types of SEMS (uncovered and partially covered) to plastic
5 stenting in 219 patients across 18 hospitals in The Netherlands. Only three quarters of
6 patients had a blocking malignancy resulting from pancreatic cancer in this trial which may
7 impact upon the accuracy of the estimate for overall survival for this patient group. Mixed
8 populations were reported in all but 1 study (Travis & Nicholson 1997), which published two
9 decades ago, identified for this patient group. It is difficult to tell which direction any bias
10 resulting from these mixed populations would be as the type of other malignancies are not
11 reported in detail. However, the committee agreed this was a reasonable estimate of life
12 expectancy for this patient group. The model assumes a constant probability of survival at all
13 time points.

14 Given this uncertainty, overall survival was varied during both deterministic and probabilistic
15 sensitivity analysis (PSA). For the purposes of the PSA, overall survival was altered over the
16 range of survivals reported in the clinical evidence review (108-149 days) using a uniform
17 distribution.

18 12.2.4.2 Time to dysfunction

19 The clinical evidence review estimated a hazard ratio of dysfunction of plastic stents of 2.59
20 (95%CI 1.67-4.0) compared to SEMS when used as either a first or secondary stent. For the
21 base case the economic model used a mean time to dysfunction of a primary plastic stent of
22 172 days and for a secondary stent of 170 days based on that reported by Walter et al.
23 (2015) described above. These mean times were adjusted in the model, using the reported
24 hazard ratio, to estimate corresponding times to dysfunction. Mean time to dysfunction was
25 not adjusted for death in the Walter et al (2015) trial and was only counted in those patients
26 who survived and consequently experienced a dysfunction. The mean time in the model will
27 likely be shorter as a large proportion of the model cohort will die before dysfunction. The
28 probability of dysfunction was assumed constant at all time points. When adjusting for
29 relative risk a proportional hazard assumption was made throughout.

30 For PSA the hazard ratios were varied across their reported distribution using a Log Normal
31 distribution. Time to dysfunction of plastic stents was varied across the 95% CI using a
32 uniform distribution.

33 12.2.4.3 Adverse events

34 The economic model only included adverse events which occurred after the operative and
35 peri-operative period. Adverse events of the placement of a stent can cause significant
36 detriments in quality of life and can be costly to treat. These include, in particular, wound
37 infection and wound perforation. In some cases the ERCP to place the stent can lead to
38 procedural related mortality although this would be picked up by our survival estimates.
39 There was no evidence identified that these differed by type of stent used and the committee
40 thought it most likely be identical between stent type. As these costs and quality of life
41 detriments would cancel out in this incremental analysis their inclusion in the model is very
42 unlikely to alter the preferred option.

43 Pancreatitis, cholangitis, stent migration and stent occlusion were the only adverse events
44 widely reported in the evidence review. Stent migration and stent occlusion are the two
45 leading causes of stent dysfunction and consequently the need to reposition or reinsert a
46 stent. Therefore, to prevent double counting alongside time to dysfunction, migration and
47 occlusion were not individually considered in the economic model leaving only cholangitis
48 and pancreatitis to be considered by the model. Other adverse events are possible from
49 stent placement but are uncommon and no evidence was identified to estimate the
50 differences between stent types.

1 Both pancreatitis and cholangitis occur more frequently in people who have had a plastic
2 stent placement. Compared to SEMs, people with a plastic stent placement have a relative
3 risk of 1.52 (95%CI 0.51-4.59) of pancreatitis and a relative risk of 3.1 (95%CI 1.28-7.48) of
4 cholangitis post placement. The relative risk of cholangitis were high for people with plastic
5 stents when compared to partially covered and covered SEMs alone (Table 215). Baseline
6 rates of pancreatitis and cholangitis for those with plastic stents were taken from the mean
7 prevalence of all the studies included in the accompanying evidence review.

8 For the PSA the relative risks were varied across their reported distribution using a Log
9 Normal distribution and the baseline probability of both pancreatitis and cholangitis varied
10 across a beta distribution.

11 12.2.4.4 Time in hospital

12 Time in hospital was again identical between plastic and SEMs in the post-operative period
13 and as these would cancel out during the incremental analysis and were likely to be picked
14 up in the stenting costs, they were not included by the model. However, time in hospital for
15 treating adverse events arising from stent placement are included. Total number of days in
16 hospital were not reported in Walter et al. (2015) and were back calculated by dividing
17 reported total costs of hospitalisation by unit costs to get an estimate of the unreported
18 hospital days from the trial. This estimated that after discharge from the primary stenting
19 people with plastic stents spend a mean 3.82 days in hospital compared to 3.48 days for
20 SEMs. For patients with a secondary stenting this was 5.18 and 2.51 days for plastic and
21 SEMs respectively again ignoring the immediate post-operative period.

22 The post-operative length of stay was not varied during PSA as this uncertainty would be
23 picked up by the variation in costs of the stenting procedures and consequently would lead to
24 an overstatement of this uncertainty. The length of stay in hospital was varied across a
25 uniform distribution from zero to double the base case estimate during PSA.

26 12.2.4.5 Health related quality of life

27 The literature search for the clinical evidence review was conducted to identify any evidence
28 comparing Health Related Quality of Life (HrQoL) in people with pancreatic cancer with an
29 inoperable malignancy receiving either a plastic stent or SEMs. Only 1 study was identified
30 during this search. (Walter et al. 2017)

31 This study of HrQoL was conducted in parallel with the Walter et al. (2015) study described
32 above. Of the 219 patients in the original RCT, 140 patients completed two general health
33 related QoL questionnaires (the EQ-5D-3L and QLQ-C30) alongside a disease specific one.
34 The EQ-5D-3L gives a utility weighting up to 1 (representing perfect health) with a score of 0
35 assumed to be equal to death. In some cases the utility weighting score can be below zero
36 representing health states worse than death. This utility weighting can be used to adjust life
37 expectancy in an economic model, by multiplying the time lived in each health state by its
38 utility weighting, to give quality adjusted life years (QALYs).

39 As the preferred measure of QoL in NICE economic modelling, the EQ-5D-3L took
40 precedence for populating the model over the disease specific measures. The EQ-5D-3L is a
41 non-disease specific survey assessing health related QoL across five health domains
42 (mobility, self-care, daily activities, pain and anxiety/depression) with the severity rated on 1
43 of 3 levels (No Problems, Moderate Problems, Extreme Problems). This is given alongside a
44 visual analogue scale ranging from 'worst imaginable health' and 'best imaginable health'
45 with a 0 to 100 scale on which responders can rate their current health. These responses
46 were amalgamated into a health profile and given a QoL score, between 0 and 1 based upon
47 Dutch general population sample. NICE prefer EQ-5D scores valued using the UK general
48 population sample but no QoL data was identified using this measure. QoL scores are likely
49 to differ between countries through both a differing national way of valuing health and

1 through differing demographics leading to sampling differences. These Dutch population
2 values may therefore differ from UK ratings. The committee however thought the values for
3 QoL reported in the paper were consistent with their own clinical experience around treating
4 this patient group.

5 The people who responded to the QoL questionnaires in the trial had a baseline EQ-5D-3L
6 score of 0.6. Unsurprisingly, given the short life expectancy and debilitating nature of
7 unresectable pancreatic cancer QoL in both the plastic and SEMS cohorts decreased over
8 time with a near identical change (-0.1) between the two stent types for every 6 months of
9 follow-up. This value was used in the base case and as no difference in either survival or
10 QoL is assumed in the primary base case analysis in this model, the analysis becomes a de-
11 facto cost minimisation.

12 This equal QoL score was inconsistent with the clinical experience of the committee who
13 thought that quality of life, through both reduction in adverse events and through the longer
14 time to dysfunction, would be higher (or at least decrease less rapidly) in people receiving
15 SEMS. It was hypothesised that as a result of only having three levels of severity for each
16 domain the EQ-5D-3L was not sensitive enough to identify any differences in QoL between
17 the groups. The results of the more sensitive visual analogue scale show a similar baseline
18 utility value of 0.53 with a change of -0.25 and -0.11 every six months for plastic stents and
19 SEMS respectively. This shows a more pronounced difference between the two groups and
20 although it is more consistent with the committee's clinical experience the difference does not
21 become statistically significant (p-value=0.08). The VAS is known to be unreliable in the
22 measurement of QoL values. It is also difficult to estimate the likely direction of any biases
23 introduced by this method. Given these problems and higher quality evidence being identified
24 it was decided not to try to incorporate these values into the primary analysis even if it more
25 closely matched the committee's clinical experience.

26 These values were used as part of a secondary analysis to account for an improved quality
27 of life for SEMS. These changes were converted into monthly deteriorations assuming that
28 the deterioration between the two points was constant. QoL was not reported separately by
29 type of SEMS and therefore was not differed for the relevant secondary analyses. Quality of
30 life was not stratified by whether a patient was receiving an initial or subsequent stent
31 placement and therefore we assumed that the deterioration for patients in the plastic/SEMS
32 strategy would follow the deterioration based on the type of stent they currently have
33 inserted.

34 The rate of deterioration of QoL weights above were varied across a triangular distribution
35 between the reported range during probabilistic sensitivity analysis. Baseline utilities were
36 not varied as this parameter would not influence the preferred option.

37 **12.2.4.6 Costs**

38 All costs were taken from NHS Reference Costs (Department of Health 2016) unless
39 otherwise stated. During PSA all costs were varied using their reported range and a Gamma
40 distribution.

41 **12.2.4.6.1 Stent insertion costs**

42 The cost of initial stent insertion were taken from NHS reference costs. (NHS Reference
43 Costs 2016) The model cohort was assumed to all have a complications and comorbidity
44 (CC) score of 4+ given that the entirety of the cohort will have either unresectable or
45 metastatic pancreatic cancer. This figure would include all pre-operative imaging, the unit
46 costs of the stents, the insertion of the stent and any peri-operative treatment and hospital
47 stay.

1 NHS Reference costs gave a difference in total insertion costs between insertion of SEMS
2 and plastic stents of £760; slightly less than the difference in unit cost of the different stents
3 as reported in the NHS Supply Catalogues of £820 (Table 215). The slightly lower cost is
4 consistent with our modelling assumption that non-stent costs between patients receiving
5 plastic stents or SEMS would be picked up by the difference in NHS reference costs. We
6 would hypothesise that the difference between the costs in the insertion of SEMS over plastic
7 stents would be the difference in stent costs minus the savings from a reduction in short term
8 adverse events associated with SEMS.

9 Where the insertion of the stent is a secondary or later insertion the costs are assumed to be
10 equal to those above apart from where a person is receiving a secondary SEMS stenting
11 having previously received SEMS stenting (i.e. the SEMS/SEMS strategy). In this case the
12 cost is assumed equal to that of receiving a plastic stent. This is because, unlike plastic
13 stents, SEMS can be reused on migration or occlusion and thus the stent costs are not
14 incurred again. During PSA the random number assigned for the distributions for the three
15 insertion types were identical. This was to avoid widely different costs, during the random
16 iterations, for operations which are broadly similar apart from the type of stent inserted.

172.2.4.6.2 **Occlusion and migration costs**

18 When occlusion or migration is suspected a patient would receive a diagnostic endoscopic
19 procedure to investigate and confirm the suspicion and to rule out any other causes of the
20 associated symptoms. Following this patients would receive their secondary or later stenting.
21 This procedure was again costed using NHS Reference Costs.

222.2.4.6.3 **Adverse events and hospitalisation costs**

23 During the base case analysis hospital days were not costed. Hospital days were not costed
24 as the reference costs for stent placement allow for some days in hospital and it was likely
25 that costing the differences could lead to double counting of this cost.

26 Days in hospital above those in the perioperative period were costed in line with excess bed
27 days for the procedure, as reported by NHS reference costs during PSA and varied across
28 their reported range using a gamma distribution

29 In the base case analysis adverse events were not assigned a cost as it was assumed that
30 these adverse events would often be treated as part of surgical treatment follow-up. A
31 sensitivity analysis was carried out where adverse events were assigned a cost, again from
32 NHS reference costs, in line with one consultant led outpatient appointment. Again this value
33 was varied across its reported range using a gamma distribution.

342.2.4.6.4 **Cost of death**

35 Studies of resource use in cancer show a peak in costs towards the final months of life. This
36 is likely to be true for this model cohort. However, as the model assumes no difference in
37 survival between the interventions the preferred option would not change for any value for
38 the cost of death. Therefore, this was not costed in the economic model.

39 12.2.4.7 **Discounting**

40 All health and cost outcomes were discounted at a rate of 3.5% per annum in line with the
41 [NICE guidelines manual](#). This was not varied during sensitivity analyses. Costs for the model
42 were not inflated and as they were all reported and inputted in 2016 costs.

43 **Table 215: List of parameters used in the economic model and PSA distribution**

	Value	Source	PSA Distribution
Overall Survival (Days)			

	Value	Source	PSA Distribution
All stent types	109	Clinical Evidence Review	Uniform(108,149)
Time to dysfunction primary stenting (days)			
Plastic	172	Walter 2015	Uniform(126,219)
SEMS (Hazard Ratio)	2.59	Clinical Evidence Review	Log normal
Time to dysfunction primary stenting (days)			
Plastic	170	Clinical Evidence Review	Uniform(85,255)
SEMS (Hazard Ratio)	2.59	Clinical Evidence Review	Log normal
Adverse events			
Pancreatitis-plastic	2.6%	Clinical Evidence Review	BETA
Pancreatitis-Relative Risk	1.52	Clinical Evidence Review	Log normal
Cholangitis-plastic	6.7%	Clinical Evidence Review	BETA
Cholangitis-Relative Risk	3.10	Clinical Evidence Review	Log normal
Hospital Days			
Plastic Primary	3.8	Walter 2015	Uniform(0,7.6)
SEMS primary	3.5	Walter 2015	Uniform(0,7.0)
Plastic Secondary	5.2	Walter 2015	Uniform(0,10.4)
SEMS secondary	2.5	Walter 2015	Uniform(0,5.0)
Costs			
Insertion Plastic Stent	£7,176.47	NHS Reference Costs(YG05A)	Gamma
Insertion Metal Stent	£7,936.64	NHS Reference Costs(YG04A)	Gamma
Insertion Secondary Metal Stent	£7,176.47	NHS Reference Costs(YG05A)	Gamma
Diagnostic Endoscope	£770.51	NHS Reference Costs(FZ60Z)	Gamma
Adverse Event	£162.84	NHS Reference Costs(WF01A)	Gamma
Hospital day	£191.01	NHS Reference Costs(YG03A)	Gamma
Utility			
Baseline EQ-5D	0.60	Walter 2017	Not varied
Baseline EQ-5D VAS	0.53	Walter 2017	Not varied
Change Quality of Life (180 days)			
EQ-5D VAS Plastic	-0.25	Walter 2017	Triangular(-0.39,-0.11)
EQ-5D VAS metal	-0.11	Walter 2017	Triangular(-0.19,-0.03)
Discount (per annum)			
Costs		NICE	Not varied
QALYs		NICE	Not varied

1 12.3 Results

2 12.3.1 Deterministic base case results

3 In the base case analysis where overall survival and quality of life were assumed equal
 4 across the different strategies (a de-facto cost-minimisation) SEMS/SEMS was the least
 5 costly strategy with a cost saving, over the lifetime of 1 person of over £1,500 when
 6 compared to the plastic/plastic strategy (Table 216). Given the assumptions of the model all
 7 costs are driven by the surgical procedure to insert/adjust the stent and the diagnostic work
 8 up prior to the operation. The SEMS/SEMS strategy reduced the number of surgical
 9 operations by 0.32 per patient, saving 1 additional operation for every three patients needing
 10 biliary drainage. This is slightly lower than the number of subsequent surgeries prevented
 11 reported in Walter et al. (2015) although their estimated hazard ratio for stent dysfunction
 12 was of a larger magnitude than the 1 estimated in the clinical evidence review. Considering
 13 all patients must receive at least 1 stenting, a SEMS/SEMS strategy more than halves the
 14 number of subsequent insertions. Less than 1% of insertions were 3rd or subsequent
 15 operations and these did not significantly contribute towards costs. As expected given the
 16 relative risks included in the model both pancreatitis and cholangitis was less common in the
 17 SEMS/SEMS strategy.

18 **Table 216: Deterministic Base Case Results**

	Mean Number Insertions	Pancreatitis (%)	Cholangitis (%)	Total Costs	Incremental Cost
Plastic/Plastic	1.57	2.6	6.7	£11,697	Reference
Plastic/SEMS	1.48	2.6	6.7	£11,267	-£ 430
SEMS/SEMS	1.25	1.7	2.2	£10,117	-£ 1,580

19 12.3.2 Stochastic base case results

20 When the stochastic results (means of the iterations of the probabilistic sensitivity analysis)
 21 are considered the same conclusion can be drawn with the SEMS/SEMS strategy again
 22 being dominant (Table 217). Total costs are greater for all strategies. This is as a result of a
 23 probabilistic distribution around survival which is skewed towards increased survival and the
 24 inclusion of hospital and adverse event costs.

25 **Table 217: Stochastic Base Case Results**

	Total Costs	Incremental Cost	ICER
Plastic/Plastic	£13,836	Reference	
Plastic/SEMS	£12,828	-£ 1,009	Dominant†
SEMS/SEMS	£11,286	-£ 2,551	Dominant

26 †Whilst Plastic/SEMS dominated Plastic/Plastic it was dominated by the SEMS/SEMS approach. QALYs were
 27 assumed equal between the groups.

28 12.3.3 Deterministic one way sensitivity analysis

29 A number of one way sensitivity analyses were conducted, where the impact of a change on
 30 one variable, to the overall conclusion of the model is assessed (Table 218). During all
 31 deterministic sensitivity analyses the SEMS/SEMS strategy remains the preferred or least
 32 costly option.

1 One threshold analysis was conducted around overall survival. For the plastic/plastic strategy
 2 to become the preferred option overall survival in the patient group needed to be less than 24
 3 days.

4 **Table 218: One Way Deterministic Sensitivity Analysis Results**

Parameter	Change Made	Lowest lifetime costs
Stent Functional time days- Plastic Primary	Lower 95% Confidence Interval=126 days	SEMS/SEMS
	Higher 95% Confidence Interval=219 days	SEMS/SEMS
Stent Functional time Relative Risk- Plastic Secondary	Lower 95% Confidence Interval=85 days	SEMS/SEMS
	Higher 95% Confidence Interval=255 days	SEMS/SEMS
Stent Functional Relative Risk – SEMS Primary	Lower 95% Confidence Interval=1.67	SEMS/SEMS
	Higher 95% Confidence Interval=4.00	SEMS/SEMS
Stent Functional Relative Risk – SEMS Secondary	Lower 95% Confidence Interval=1.67	SEMS/SEMS
	Higher 95% Confidence Interval=4.00	SEMS/SEMS
Adverse Events Pancreatitis Plastic	Lower 95% Confidence Interval=1.5%	SEMS/SEMS
	Higher 95% Confidence Interval=4.0%	SEMS/SEMS
Adverse Events Pancreatitis SEMS Relative Risk	Lower 95% Confidence Interval=0.51	SEMS/SEMS
	Higher 95% Confidence Interval=4.59	SEMS/SEMS
Adverse Events Cholangitis Plastic	Lower 95% Confidence Interval=7.2%	SEMS/SEMS
	Higher 95% Confidence Interval=11.7%	SEMS/SEMS
Adverse Events Cholangitis SEMS	Lower 95% Confidence Interval=1.28	SEMS/SEMS
	Higher 95% Confidence Interval=7.48	SEMS/SEMS
Cost Insertion Plastic	Lower 95% Confidence Interval=£6,813	SEMS/SEMS
	Higher 95% Confidence Interval=£7,066	SEMS/SEMS
Cost Insertion SEMS	Lower 95% Confidence Interval=£7,214	SEMS/SEMS
	Higher 95% Confidence Interval=£8,857	SEMS/SEMS
Adverse Event Cost added	=£163	SEMS/SEMS
Hospital Day Cost added	=£191 per day	SEMS/SEMS
EQ-5D VAS change 180 days plastic	Lower 95% Confidence Interval=-0.39	SEMS/SEMS

Parameter	Change Made	Lowest lifetime costs
	Higher 95% Confidence Interval=-0.11	SEMS/SEMS
EQ-5D VAS change 180 days SEMS	Lower 95% Confidence Interval=-0.19	SEMS/SEMS
	Higher 95% Confidence Interval=-0.03	SEMS/SEMS

1 12.3.4 Secondary Analysis including VAS Quality of Life Values

2 When scoring from the EQ-5D VAS was included in the secondary analysis the SEMS/SEMS
3 strategy also led to the largest amount of QALYs with an additional 0.0245 QALYS compared
4 to plastic/plastic. It was also cost saving and health improving compared to the plastic/SEMS
5 strategy making it dominant compared to all other strategies considered in the base case
6 analysis.

7 **Table 219: Secondary Analysis Results Including VAS Quality of Life Values**


	Total Costs	Total QALYs	Incremental Cost	Incremental QALY	ICER
Plastic/Plastic	£11,696.79	0.093	Reference	Reference	
Plastic/SEMS	£11,266.63	0.106	−£430	0.0128	Dominant†
SEMS/SEMS	£10,117.00	0.118	−£1,580	0.0245	Dominant

8 †Whilst Plastic/SEMS dominated Plastic/Plastic it was dominated by the SEMS/SEMS approach.

9 12.3.5 Probabilistic sensitivity analyses


10 Figure 4 shows the cost effectiveness plane for the SEMS/SEMS strategy compared to a
11 plastic/plastic strategy. Where no difference in survival or quality of life is assumed the
12 SEMS/SEMS strategy is cost saving in 98.8% of iterations. When a difference between
13 quality of life is included in less than 1% of iterations is the SEMS/SEMS strategy health
14 decreasing. When a willingness to pay per QALY threshold is assumed of £20,000 per
15 QALY, NICE's conventionally held threshold for approving technologies, over 99% of
16 iterations would be cost effective.

Figure 4: Cost Effectiveness Plane: Plastic/Plastic vs SEM/SEM




1 A similar conclusion can be drawn for when a plastic/SEMS strategy is compared to plastic
 2 plastic strategy (Figure 5). In this comparison the results are less strong with 95.0% of
 3 iterations being cost saving. Again when differences in survival and quality of life are
 4 considered, less than 1% of iterations shows the plastic/SEMS strategy being health
 5 decreasing.

Figure 5: Cost Effectiveness Plane: Plastic/Plastic vs Plastic/SEMS




6 When comparing a SEMS/SEMS strategy to a plastic/SEMS strategy the SEMS/SEMS
 7 strategy is cost saving in over 97% of iterations. At a £20,000 willingness to pay threshold
 8 over 99% of iterations are cost-effective (Figure 6).

Figure 6: Cost Effectiveness Plane: Plastic/SEMS vs SEMS/SEMS




9

Figure 7: Cost Effectiveness Acceptability Curve




1

Figure 6: Cost Effectiveness Plane: Plastic/SEMS vs SEMS/SEMS



2

Figure 7: Cost Effectiveness Acceptability Curve

1 The above conclusions for a SEMS/SEMS strategy are strongly supported by the Cost
 2 Effectiveness Acceptability Curve (Figure 7) which shows the SEMS/SEMS strategy having a
 3 greater than 98% probability of being cost saving (the preferred option).

4 12.4 Discussion

5 A strategy of SEMS/SEMS was the preferred option in the base case results for both
 6 deterministic and stochastic results. When no difference in survival between the different
 7 strategies was considered a SEMS/SEMS strategy was cost saving through reducing the
 8 number of surgeries for subsequent placement or adjustment of stents. Despite the best
 9 available evidence identified around quality of life showing no difference between the
 10 different strategies when a more sensitive instrument although with large biases (EQ-5D
 11 VAS) was used a SEMS/SEMS strategy also appeared to be health improving.

12 This conclusion was robust to both one way deterministic sensitivity analyses and
 13 probabilistic sensitivity analysis. SEMS/SEMS was the preferred option in all deterministic
 14 sensitivity analyses apart from when plastic stent or SEMS insertion were varied to their
 15 lower and upper confidence interval respectively when plastic/plastic becomes the preferred
 16 option. Given the similarity of the two procedures this wide variation in costs is unlikely to
 17 represent any plausible difference in cost which may be observed. The robustness of these
 18 results are further highlighted by the probabilistic sensitivity analysis where a SEMS/SEMS
 19 strategy is cost saving in greater than 98% of iterations.

20 The results of this economic model were based on evidence from the clinical evidence
 21 review which was derived entirely from RCT evidence. The costings for the model were
 22 taken from UK NHS sources and quality of life from a European EQ-5D questionnaire given
 23 alongside an RCT. The results, conclusions and sensitivities are almost identical to the one
 24 economic evaluation identified by the review of the previous economic evidence (Arguedas
 25 et al. 2002). The conclusions of the model could be strengthened by finding UK-based quality
 26 of life evidence measured using a sensitive but validated scale (i.e. the EQ-5D-5L). However,
 27 even in these circumstances a SEMS/SEMS strategy will remain cost saving and it is likely,
 28 given the favourable clinical outcomes of a SEMS/SEMS strategy that it will remain health
 29 improving. Therefore, it is unlikely that the conclusions of the model would change if this
 30 evidence was available.

1 **12.5 References**

2 Arguedas MR, Heudebert GH, Stinnett AA et al. (2002) Biliary stents in malignant obstructive
3 jaundice due to pancreatic carcinoma: a cost-effectiveness analysis. *American Journal of*
4 *Gastroenterology* 97(4): 898-904

5 Department of Health (2016) NHS reference costs 2015 to 2016. Reference costs 2015-
6 2016. UK Government

7 NICE (2014) Developing NICE guidelines: the manual. London, UK: National Institute of
8 Health and Care Excellence

9 Travis S and Nicholson T (1997) Palliation of unresectable pancreatic malignant biliary
10 obstruction: Results of a randomized trial comparing percutaneously placed metal and plastic
11 endoprotheses. *Journal of Interventional Radiology* 12: 17-21

12 Walter D, van Boeckel PG, Groenen MJ et al. (2015) Cost Efficacy of Metal Stents for
13 Palliation of Extrahepatic Bile Duct Obstruction in a Randomized Controlled Trial.
14 *Gastroenterology* 149(1): 130-8

15 Walter D, van Boeckel PG, Groenen MJ et al. (2017) Higher quality of life after metal stent
16 placement compared with plastic stent placement for malignant extrahepatic bile duct
17 obstruction: a randomized controlled trial. *European Journal of Gastroenterology &*
18 *Hepatology* 29(2): 231-237

19

20

21

13 Network Meta-Analysis (Mixed Treatment Comparison) and Economic Model on treatment of unresectable locally advanced non-metastatic pancreatic cancer

13.1 Methods

13.1.1 Clinical data considered in the network meta-analyses

The Network Meta-Analysis (NMA) considered the effectiveness of treatments for unresectable locally advanced non-metastatic pancreatic cancer (LAPC). The NMA includes all studies, identified by the accompanying clinical evidence review, which are phase II or phase III randomised comparative trials that compared treatments which fit into the broad groups of:

- chemotherapy,
- chemoradiotherapy,
- combination of chemotherapy and chemoradiotherapy,
- radiotherapy
- biological therapies

with another treatment or to placebo, best supportive care or no treatment. Other local therapies (such as microwaves, radiofrequency ablation) were not considered in the NMA although it was unlikely that randomised evidence would be identified to allow inclusion. Treatments not in these broad groups (as well as the excluded interventions) were only considered if they provided indirect evidence to the network via a closed loop of treatment effects for included interventions. Studies in which all investigated treatments were not considered in any other study, and therefore could not be usefully statistically synthesised into either the main NMAs or a smaller alternative one were not considered in this analysis.

Only studies published in the year 2000 or later were included in the NMA as it was considered evidence published prior to this date would not adequately represent current practice. Studies were excluded from the NMA if they included cancers other than pancreatic cancer or included populations that had both locally advanced and metastatic disease and the locally advanced group were not analysed and reported separately. Studies which considered a previously treated patient group with responding or stable disease were also excluded from the NMA, unless they were randomised before receiving treatment, as it was considered that this patient group would have better outcomes than for studies which included treatment naïve patients.

All data were derived from trials identified in the accompanying systematic reviews.

13.1.2 Review Strategy and Evidence Synthesis

Inspection of the data in the accompanying clinical evidence review identified 9 trials involving 1294 patients considering 12 different treatments. The only outcome reported in all these trials was overall survival (OS). It was therefore decided that the primary NMA would consider OS. OS was inputted into the model in the form of a hazard ratio comparing the intervention to the control. Where hazard ratios had not been reported in the original paper

these were calculated using methods outlined in Parmar et al. (2008). Consequently outcomes were also reported in terms of hazard ratio using gemcitabine as the control. This was because gemcitabine was the most widely used control treatment in the studies identified. It is also widely used within England for the treatment of LAPC and is covered by TA25 for use in the treatment of both locally advanced unresectable and metastatic pancreatic cancer.

Inspection of the other outcome measures reported, identified both progression-free survival (PFS) and objective response (complete response or partial response) as outcomes that would form usefully sized networks although these would be smaller (less participants and interventions) and would be considered as secondary NMAs. The NMA for PFS considered 7 studies looking at 10 treatments involving 1125 patients. The NMA for objective response looked at 6 studies involving 706 patients. As with OS, PFS was included in the NMA in the form of hazard ratios. Again where hazard ratios had not been reported these were calculated using the same methods as for OS. Outcomes were again reported in terms of hazard ratio with gemcitabine as control. All studies included in the objective response NMA reported this information or it was able to be easily calculated from the partial response and complete response data. However, there were differences in studies between what criteria was used to assess resectability or this was not reported. It was therefore difficult to say how strictly comparable this outcome was between studies. This data was included in the NMA as count data. Outcomes from this secondary analysis were reported in terms of odds ratios, again with gemcitabine as the control.

Treatment related adverse events were also reported widely in the literature. However, due to the definitions used for recording these and uncertainty about whether an unreported event had not occurred or had not been included in the data, it was decided that an NMA looking at adverse events would not be useful. Therefore, this analysis was not performed. Other outcomes identified by the committee in the clinical evidence review protocol were either too sparsely or inconsistently reported to make any sort of evidence synthesis worthwhile. Minimally important differences were not considered in any of the NMAs as the results of both the primary and secondary analyses fed directly into a cost effectiveness model.

The following studies were included in the accompanying clinical evidence review but were excluded in both the primary or secondary NMAs (Table 220):

- Chung et al. (2014) and Rich et al. (2012): these studies only included interventions which were not considered by other studies. It was therefore not possible to include them in a useful way in any of the NMA analyses.
- Mukherjee et al (2013), Khan et al. (2016) and the 2nd randomisation in Hammel et al. (2016): these randomisations only considered previously treated patients with responding or stable disease.

Table 220: List of studies included in the Clinical Evidence review but excluded from the primary and secondary NMA analyses.

Study	Control	Intervention
Chung et al. (2004)	CRT(Gem) plus docetaxel	CRT(Paclitaxel) plus docetaxel
Hammel et al. (2016)†	Gem± erlotinib	CRT (Gem) ± erlotinib
Khan et al. (2016)	Cap or UFT plus radiotherapy	Cap or UFT plus cetuximab and radiotherapy
Mukherjee et al. (2013)	CRT(Gem)	CRT(Cap)
Rich et al. (2012)	CRT(Gem)+Paclitaxel	CRT(Gem)+paclitaxel+tipifarnib

†Only the second randomisation from Hammel et al. (2016) was excluded from the analysis
 CRT=Chemoradiotherapy Gem=Gemcitabine Cap=Capecitabine

1 Of the studies included in the primary analysis only Shinci et al. (2001) was not included in
2 any of the secondary analyses as both PFS and objective response were not reported. The
3 list of studies included in the primary and secondary analyses are reported in Table 221.
4 Where hazard ratios or counts have been inputted as not reported (NR) these studies have
5 not been included in the corresponding secondary analysis. The sole reason for studies not
6 being included in the secondary analysis was that the outcome of interest was not reported in
7 the study.

8

9


1 Table 221: List of studies included in the primary NMA and where sufficient data has been reported the relevant secondary NMAs

Study	Control	Intervention	N (control)	N (intervention)	HR OS (SD)	HR PFS (sd)	Objective response Control	Objective response Intervention
Cantore et al. (2004)	Gemcitabine	FLEC	67	71	0.75 (0.1569)	NR	6.0%	14.1%
Chauffert et al. (2008)	Chemorad(5-fu)+Cisplatin	Gemcitabine	59	60	0.69 (0.2562)	0.72(0.2521)	NR	NR
Hammel et al. (2016)	Gemcitabine	Gemcitabine+Erlotinib	223	219	1.19 (0.1008)	1.12 (0.0911)	NR	NR
Heinemann et a. (2013)	Gemcitabine	Gemcitabine+400mg Upamostat Gemcitabine+ 200mg Upamostat	31	33 31	0.75(0.2181) 0.90(0.1954)	0.87(0.1334) 0.92(0.1270)	3.8%	7.1% 12.9%
Herman et a. (2013)	Chemorad(5-fu)	Chemorad(5-fu)+TNFerade	90	187	0.90(0.1552)	0.96(0.1625)	8.2%	12.0%
Li et al. (2003)	Chemorad(Gem)	Chemorad(5-fu)	18	16	1.33(0.3138)	1.87(0.3523)	50.0%	12.5%
Loehrer et al. (2011)	Gemcitabine	Chemorad(Gem)	37	34	0.58(0.2354)	1.16(0.2436)	5.4%	5.9%
Shinchi et al. (2002)	Best Supportive Care	Chemorad(5-fu)	16	15	0.78(0.4930)	NR	NR	NR
Wilkowski et al. (2009)	Chemorad(5-fu)	Chemorad (Gem) + cisplastin X 2 Chemorad (Gem) + cisplastin	31	31 32	0.82(0.2351) 0.81(0.2090)	0.75(0.1907) 0.85(0.1802)	19.4%	12.9% 21.9%

13.1.32 Network meta-analysis Model structure

- 3 The network for the primary and two secondary NMAs including studies which did not connect to the main network are shown in Figure 8 to 4 Figure 10 The area of the nodes are in proportion with the number of patients, in the NMAs, receiving that treatment.

Figure 8: Network for overall survival



1

2

Figure 9: Network for Progression Free Survival





Figure 10: Network for Objective response



- 1
- 2
- 3

1 Fixed effects models were run for all 3 NMAs considered. It was not possible to run an
 2 alternative random effects model, to compare goodness of fit, as no two trials in the NMA
 3 compared the same interventions and both random and fixed effect models would give
 4 identical results. The fixed effects model was created to estimate the hazard ratio for OS and
 5 PFS and the odds ratio for overall response compared to the reference treatment
 6 gemcitabine for use in the economic model.

7 For the OS and PFS models the log hazard ratio for each trial j comprised a normal
 8 likelihood:

$$9 \quad \gamma_{ik} \sim N(\theta_{ik}, se_{ik}^2)$$

10 Where γ_{ik} represents the log hazard ratio of treatment k relative to the control arm of trial i ,
 11 se_{ik} represents the standard error of the log hazard ratios and θ_{ik} represents the trial-specific
 12 log hazard ratio. As the data used in the NMA is relative to other treatments, no baseline
 13 values can be predicted and the linear predictor is reduced to:

$$14 \quad \theta_{ik} = \delta_{i,bk}$$

15 Where $\delta_{i,bk}$ is the trial specific log hazard ratio for treatment k compared to a control of
 16 treatment b in trial i . As fixed effects are assumed then:

$$17 \quad \delta_{i,bk} = d_{12}$$

18 Where d_{12} is the log hazard ratio of treatment 2 compared to a baseline of treatment 1.

19 For the objective response model, the data for each trial j comprised a binomial likelihood:

$$20 \quad r_{jk} \sim \text{Bin}(p_{jk}, n_{jk})$$

21 where p_{jk} is the probability of an objective response in trial j under treatment k , r_{jk} is the
 22 number of people experiencing the event in trial j under treatment k , and n_{jk} is the total
 23 number of people at risk of the event in trial j under treatment k .

24 Since the parameters of interest, p_{jk} , are probabilities and therefore can only take values
 25 between 0 and 1, a transformation (link function) was used that mapped these probabilities
 26 into a continuous measure between plus infinity and minus infinity. Also, since this was a
 27 binomial likelihood the logit link function was used. The probabilities of success p_{jk} were
 28 modelled on the logit scale as:

$$29 \quad \text{logit}(p_{ik}) = \mu_i + d_{12} \times I_{\{k \neq 1\}}$$

30 where

$$I_{\{u\}} = \begin{cases} 1 & \text{if } u \text{ is true} \\ 0 & \text{otherwise} \end{cases}$$

31 In the fixed effects model the between-trial heterogeneity σ^2 was set to 0 which was
 32 equivalent to assuming homogeneity of the underlying true treatment effects.

33 The analysis was undertaken following Bayesian statistical principles. The goodness of fit of
 34 the models was tested using the total residual deviance in the model. All models were
 35 created in WinBUGS 14 and the code for the OS and PFS models is provided in Table 222
 36 and the objective response model in Table 223. All code was based on that reported by Dias
 37 et al. (2016).

1 **Table 222: WinBUGS code used to estimate the hazard ratio for overall survival and**
 2 **progression free survival for all treatment options compared to gemcitabine**
 3 **for people with LAPC – fixed effects model**

```

# Normal likelihood,
# Trial-level data given as Hazard Ratios
# Fixed effects model for multi-arm trials
model{
  for(i in 1:ns2) {
    y[i,2] ~ dnorm(delta[i,2],prec[i,2])
  }
  #Deviance contribution for trial i
  resdev[i] <- (y[i,2]-delta[i,2])*(y[i,2]-delta[i,2])*prec[i,2]
}
for(i in (ns2+1):(ns2+ns3)) {
  for (k in 1:(na[i]-1)) {
    for (j in 1:(na[i]-1)) {
      Sigma[i,j,k] <- V[i]*(1-equals(j,k)) + var[i,k+1]*equals(j,k)
    }
  }
  Omega[i,1:(na[i]-1),1:(na[i]-1)] <- inverse(Sigma[i,,])
  y[i,2:na[i]] ~ dnmnorm(delta[i,2:na[i]],Omega[i,1:(na[i]-1),1:(na[i]-1)])
  #Deviance contribution for trial i
  for (k in 1:(na[i]-1)){ # multiply vector & matrix
    ydiff[i,k]<- y[i,(k+1)] - delta[i,(k+1)]
    z[i,k]<- inprod2(Omega[i,k,1:(na[i]-1)], ydiff[i,1:(na[i]-1)])
  }
  resdev[i]<- inprod2(ydiff[i,1:(na[i]-1)], z[i,1:(na[i]-1)])
}
for(i in 1:(ns2+ns3)){
  for (k in 2:na[i]) {
    var[i,k] <- pow(se[i,k],2)
    prec[i,k] <- 1/var[i,k]
    delta[i,k] <- d[t[i,k]] - d[t[i,1]]
  }
}
totresdev <- sum(resdev[])
d[1]<-0
for (k in 2:nt){ d[k] ~ dnorm(0,.0001) }

# pairwise HRs and LHRs for all possible pair-wise comparisons
for (c in 1:(nt-1)) { for (k in (c+1):nt) {
  LHR[c,k] <- (d[k] - d[c])
  HR[c,k] <- exp(d[k] - d[c])
}
}

# ranking
for (k in 1:nt) {
  rk[k] <- rank(d[],k)
  best[k] <- equals(rk[k],1)
  best3[k] <- equals(rk[k],3) + equals(rk[k],2) + equals(rk[k],1)
}
}
# *** PROGRAM ENDS

```

4

1 **Table 223: WinBUGS code used to estimate the odds ratio for objective response**
 2 **for all treatment options for people with LAPC – fixed effects model**

```

# Binomial likelihood, logit link, MTC
# Fixed effect model
model{
  for(i in 1:ns){
    mu[i] ~ dnorm(0,.0001)
    for(k in 1:na[i]){
      r[i,k] ~ dbin(p[i,k],n[i,k])
      logit(p[i,k]) <- mu[i] + d[t[i,k]]-d[t[i,1]]
      rhat[i,k] <- p[i,k] * n[i,k]
      dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])))
        + (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
    }
    resdev[i] <- sum(dev[i,1:na[i]])
  }
  totresdev <- sum(resdev[])
  d[1] <- 0
  for(k in 2:nt) { d[k] ~ dnorm(0,.0001) }

# pairwise ORs and LORs for all possible pair-wise comparisons
for(c in 1:(nt-1)) { for(k in (c+1):nt) {
  or[c,k] <- exp(d[k] - d[c])
  lor[c,k] <- (d[k]-d[c])
}
}

# ranking
for(k in 1:nt) {
  rk[k] <- nt+1-rank(d[],k)
  best[k] <- equals(rk[k],1)
  best3[k] <- equals(rk[k],3) + equals(rk[k],2) + equals(rk[k],1)
}

# *** PROGRAM ENDS

```

3

4 13.2 Network Meta-analysis Results

5 13.2.1 Estimated Hazard Ratios and Odds Ratios

6 Table 224 to Table 226 show the results of the three NMAs compared to gemcitabine as the
 7 reference case. In all three analyses only 1 treatment, chemoradiotherapy with gemcitabine,
 8 reported a hazard ratio or odds ratio, which had a 95% credible interval that did not pass the
 9 line of no effect. This effect would have been completely driven by 1 trial, Loehrer et al.
 10 (2012). Table 227 shows the direct trial results and the NMA indirect results in the form of a
 11 matrix. Given that there were no independent closed loops in the NMA and only 1 trial
 12 identified for each comparison, where both indirect and direct evidence is available the HR is
 13 identical although inverted.

14 The results presented for progression free survival in Table 225 may seem counterintuitive
 15 with PFS being most favourable for the gemcitabine and gemcitabine and upamostat
 16 therapies. This is despite them performing relatively more poorly in the OS NMA. It may be
 17 expected that interventions which delay progression in cancer also lead to an increase in
 18 overall survival and there is strong evidence in advanced pancreatic cancer of a strong
 19 correlation between OS and PFS (Hamada 2016). The great uncertainty with the PFS NMA

1 should be noted in that all of the 95% credible intervals for all interventions in this NMA
 2 passed the line of no effect and could all plausibly have higher or lower PFS than the
 3 reference treatment gemcitabine.

4 **Table 224 Estimated Hazard Ratios and Credible Intervals for overall survival**
 5 **compared to gemcitabine**

Treatment	median (HR)	2.5%CrI	97.5%CrI	sd
Chemorad (GEM)	0.58	0.37	0.92	0.14
Chemorad (Gem) + Cisplatin	0.62	0.26	1.50	0.33
Chemorad (Gem) +CisplatinX2	0.63	0.26	1.56	0.34
Chemorad(5-fu)+TNFerade	0.69	0.30	1.59	0.34
Gem+400 Upamostat	0.75	0.49	1.15	0.17
FLEC	0.75	0.55	1.02	0.12
Chemorad(5-fu)	0.77	0.36	1.67	0.34
Gem+ 200 Upamostat	0.90	0.61	1.32	0.18
Best Supportive Care	0.99	0.29	3.41	0.84
Gemcitabine	1	Reference		
Gemcitabine + Erlotinib	1.19	0.98	1.45	0.12
Chemorad(5-fu) + Cisplatin	1.45	0.88	2.39	0.39

6 **Table 225 Estimated Hazard Ratios and Credible Intervals for progression free survival**
 7 **compared to gemcitabine.**

Treatment	median (HR)	2.5%CrI	97.5%CrI	sd
Gem+400 Upamostat	0.75	0.49	1.15	0.17
Gem+ 200 Upamostat	0.90	0.61	1.32	0.18
Gemcitabine	1.00	Reference		
Chemorad (Gem) +CisplatinX2	1.16	0.49	2.75	0.59
Chemorad (GEM)	1.16	0.72	1.87	0.30
Gemcitabine + Erlotinib	1.19	0.98	1.45	0.12
Chemorad (Gem) + Cisplatin	1.31	0.56	3.09	0.66
Chemorad(5-fu)+TNFerade	1.39	0.60	3.21	0.68
Chemorad(5-fu) + Cisplatin	1.45	0.88	2.39	0.39
Chemorad(5-fu)	1.54	0.71	3.37	0.69

8 **Table 226 Estimated Odds ratio and Credible Intervals for objective response.**

Treatment	median (OR)	2.5%CrI	97.5%CrI	sd
Gem+ 200 Upamostat	4.97	0.57	157.00	1394
FLEC	2.73	0.84	10.82	3
Gem+400 Upamostat	2.35	0.17	82.64	552
Chemorad (GEM)	1.10	0.11	10.85	64
Gemcitabine	1	Reference		
Chemorad (Gem) + Cisplatin	0.15	0.01	3.55	26
Chemorad(5-fu)	0.13	0.01	2.31	13
Chemorad(5-fu)+TNFerade	0.09	0.00	1.93	11
Chemorad (Gem) +CisplatinX2	0.08	0.00	1.91	12

1 Table 227: Indirect and direct comparisons for overall survival.

Gemcita bine	0.84(0.69,1.02)			1.33(0.98,1.81)	1.73(1.09,2.74)					1.11(0.76,1.63)	1.33(0.87,2.04)
0.84(0.69,1.02)	Gemcita bine + Erlotinib							0.69(0.42,1.14)			
1.3(0.6,2.82)	1.54(0.69,3.44)	Chemorad(5-fu)	1.11(0.82,1.51)		0.9(0.71,1.14)	0.78(0.3,2.04)		1.23(0.82,1.86)	1.22(0.77,1.94)		
1.44(0.63,3.32)	1.71(0.73,4.04)	1.11(0.82,1.51)	Chemorad(5-fu)+TNFrade								
1.33(0.98,1.81)	1.59(1.1,2.29)	1.03(0.45,2.36)	0.93(0.38,2.24)	FLEC							
1.73(1.09,2.74)	2.05(1.24,3.39)	1.33(0.72,2.46)	1.2(0.6,2.38)	1.29(0.74,2.26)	Chemorad (GEM)						
1.01(0.29,3.48)	1.21(0.34,4.2)	0.78(0.3,2.04)	0.7(0.26,1.92)	0.76(0.21,2.7)	0.59(0.19,1.84)	Best Supportive Care					
0.69(0.42,1.14)	0.82(0.48,1.41)	0.53(0.21,1.34)	0.48(0.18,1.27)	0.52(0.2,0.93)	0.4(0.2,0.79)	0.68(0.18,2.59)	Chemorad(5-fu) + Cisplatin				
1.6(0.67,3.84)	1.9(0.77,4.67)	1.23(0.82,1.86)	1.11(0.67,1.85)	1.2(0.48,3.04)	0.93(0.44,1.95)	1.58(0.56,4.52)	2.32(0.84,6.37)	Chemorad (Gem) + Cisplatin	0.7(0.26,1.87)		
1.58(0.64,3.89)	1.88(0.75,4.73)	1.22(0.77,1.94)	1.1(0.63,1.91)	1.19(0.46,3.08)	0.92(0.42,1.98)	1.56(0.54,4.55)	2.29(0.81,6.45)	0.99(0.64,1.53)	Chemorad (Gem) +CisplatinX 2		
1.11(0.76,1.63)	1.32(0.86,2.03)	0.86(0.36,2.03)	0.77(0.31,1.92)	0.83(0.51,1.36)	0.64(0.35,1.17)	1.1(0.3,4.02)	1.61(0.86,3.03)	0.69(0.27,1.81)	0.7(0.26,1.87)	Gem+ 200 Upamostat	1.2(0.8,1.8)
1.33(0.87,2.04)	1.59(0.99,2.54)	1.03(0.45,2.48)	0.93(0.36,2.35)	1(0.59,1.69)	0.77(0.41,1.45)	1.32(0.36,4.88)	1.93(1.3,7.4)	0.83(0.31,2.21)	0.84(0.31,2.29)	1.2(0.8,1.8)	Gem+400 Upamostat

Lower half displays indirect NMA results. Upper half displays direct results from included studies. Results, read horizontally, show the Hazard ratio for experimental vs control for indirect results and control vs experimental for direct results. Results in bold show results where the 95% credible intervals do not pass 1.

1

13.2.21 Model Fit

2 The goodness of model fit, evaluated using total residual deviance, for the OS NMA was
3 12.01 almost identical to the number of data points. The same is seen with the PFS NMA
4 (9.003 for 9 data points) this suggested a good model fit. For the objective response NMA
5 the residual deviance (16.08) is much larger than the number of data points suggesting a
6 poor model fit. Given this and the wide credible intervals (given the large number of 0 or
7 small number of events in the data) around the estimates it would be difficult make any
8 strong conclusions around this NMA.

13.3⁹ Economic Model

13.3.10 Interventions Considered

11 An economic model was created to consider the interventions identified by and connected in
12 the primary network meta-analysis for overall survival described above. Given its wide use
13 across England in NHS settings for the treatment of LAPC, FOLFIRINOX was also included
14 in a secondary economic analysis despite no evidence being identified which matched the
15 inclusion criteria for it to be included in any of the NMAs or the clinical evidence review.
16 Gemcitabine was chosen as the comparator for the included interventions in the economic
17 model for identical reasons for using it as the comparator in the NMAs.

18 Best supportive care was not considered by the economic model. Where there are already
19 established treatments for a disease it is not deemed appropriate to recommend a no
20 treatment strategy based on cost effectiveness alone. If best supportive care is deemed to be
21 the optimal treatment strategy, on clinical effectiveness grounds, it is likely to be both cost
22 saving as well as health improving making the need for economic modelling redundant.
23 Interventions which had components of TNFerade and Upamostat were also not considered
24 in the analysis. This is because they were seldom or never used in the NHS for any condition
25 and did not appear in either the BNF or EMIT database of drug prices. The review of the
26 costing literature failed to identify any costs for these two interventions for any condition in
27 any country. It was therefore agreed that any meaningful estimate of cost effectiveness
28 would be near impossible and of little use in making recommendations. Given both these
29 drugs are 'on patent' they are likely to be associated with drug costs much higher than other
30 drug interventions considered in this analysis. These interventions are therefore unlikely to
31 have strong evidence of cost effectiveness without strong evidence of clinical effectiveness.
32 This was not provided by the accompanying NMA.

33 Interventions in patients with stable and responding disease having been previously treated
34 were explicitly excluded from the NMA. However, subsequent different (or further) treatment
35 of patients with stable and responding disease form a vital part of treatment and widely
36 happens in practice for treatment of LAPC across the NHS. Therefore, a secondary analysis
37 was included in the economic model to compare treatments for stable disease. Three
38 interventions (chemoradiotherapy (gemcitabine), chemoradiotherapy (capecitabine) and
39 continued gemcitabine) were considered for this economic model. This covered all
40 interventions that were investigated in studies which were solely excluded from the NMA on
41 account of being in people with responding or stable disease. The model was configured so
42 that change in treatment happened 12 weeks into the model. This analysis was performed
43 using the same methodology as for all other interventions but treatment was only altered in
44 patients with disease that had not progressed during initial treatment. Given a paucity of
45 evidence around the topic the outcomes of this secondary analysis were independent of the
46 initial treatment received. For the purposes of modelling this secondary analysis was
47 performed in people with stable disease from the gemcitabine alone group although given
48 the assumptions made above the results would be identical for any initial treatment.
49 Continued gemcitabine was used as the basecase comparative treatment in this analysis


13.3.21 Model Structure

2 A partitioned survival analysis was developed to estimate the expected life time quality
3 adjusted life years (QALYs) and costs associated with the competing interventions in the
4 patient population. A partitioned survival analysis divides the model cohort between different
5 health states based on the parametric survival functions derived in the NMAs for OS and
6 PFS. The expected OS and PFS are then calculated from the area under the respective
7 curves. For our model three mutually exclusive health states were derived for the cohort to
8 be partitioned into:

- 9 • Alive without progressed disease (equal to the difference between area under the PFS
10 curve)
- 11 • Alive with progressed disease (equal to the area between the PFS curve and OS curve)
- 12 • Death (area above the OS curve)

13 An illustrative example of the structure of the partitioned survival analysis is shown in Figure
14 11.

Figure 11: Illustrative example of partitioned survival analysis



15 A partitioned survival analysis approach was chosen over other modelling approaches, for
16 example a state transition model. This approach is not widely used in models of the cost-
17 effectiveness of oncology interventions. A review of recent oncology NICE Technology
18 Appraisals found that this approach was used in 73% of submissions (Woods 2017). This
19 approach was chosen given the properties of the accompanying NMAs. As both hazard
20 ratios for OS and PFS were estimated in separate mutually exclusive NMAs these values
21 were independent of each other. Consequently, as the survival functions of the included
22 interventions in the model are informed by these hazard ratios the survival curves were also
23 independent of each other. In the absence of evidence of the relationship between OS and
24 PFS a partitioned survival analysis approach allowed for these estimates to feed directly into
25 the model. Given the modelling assumptions made about other events in the model, such as
26 adverse events and receiving resection, do no impact upon OS and PFS, the curves do not

1 need to account for these factors. Such events are a potential source of bias in partitioned
2 survival analysis.

3 Whilst not a consideration in choosing the most appropriate modelling approach, a
4 partitioned survival analysis is a more intuitive modelling approach for LAPC. Evidence from
5 trials and observational studies where survival is a key outcome are almost exclusively
6 reported as median overall and progression free survival with accompanying hazard ratio
7 and Kaplan Meier survival curves. As these are the primary inputs for partitioned survival
8 analysis the inputs can be easily compared with those observed in the included trials and
9 other external sources.

10 A partitioned survival analysis was performed for each intervention considered in the
11 economic evaluation and total time spent in each health state for the model cohort was
12 recorded. Each health state was assigned a quality of life weighting so that QALYs could be
13 calculated.

14 A proportion of the cohort (informed by the secondary NMA) will have an objective response
15 to treatment and will have a probability of becoming eligible for and receive resection of the
16 pancreas with curative intent. This will incur costs associated with the surgical procedure.
17 Surgery will have no impact upon health outcomes in the model as any benefit of surgery
18 would have been picked up in the OS and PFS of the studies included in the NMA and thus
19 any inclusion in the economic model will lead to double counting and overestimation of the
20 costs and effectiveness of treatments.

21 Independently of the partitioned survival analysis the model cohort also has a probability of
22 having treatment-related adverse events. The model considered four adverse events which
23 were the most widely reported in the clinical evidence used to inform the NMA and economic
24 model. These were neutropenia, thrombocytopenia, diarrhoea and fatigue. Adverse events
25 were only considered by the model if they were either rated grade III or grade IV as these
26 were considered the severity in which significant costs and quality of life (QoL) detriments
27 were likely to occur. People in the cohort with treatment-related adverse events were given
28 both quality of life detriment and cost at the start of the model. It was acknowledge by the
29 committee that other adverse events were likely to be associated with both QoL detriments
30 and costs, however as these were not consistently reported across the literature it was
31 difficult to include in the model. However, sensitivity analysis was performed to test the
32 robustness of this structural assumption.

33 The economic component of the model was built and run in Microsoft Excel 2013.

13.3.34 Model Parameters

13.3.3.15 Overall and Progression Free Survival

36 OS and PFS hazard ratios used in the economic model were estimated in the NMA. As the
37 outcomes of the NMA were reported as relative and not absolute values, an assumption had
38 to be made around absolute overall survival and progression free survival for 1 of the
39 interventions. As gemcitabine is the reference treatment in both the NMA and economic
40 evaluation it was deemed most appropriate to assign an absolute value of OS and PFS for
41 this treatment. OS and PFS hazard ratios used in the economic model were estimated in the
42 NMAs. As the outcomes of the NMA were reported as relative and not absolute values, an
43 assumption had to be made around absolute overall survival and progression free survival
44 for 1 of the interventions. As gemcitabine is the reference treatment in both the NMA and
45 economic evaluation it was deemed most appropriate to assign an absolute value of OS and
46 PFS for this treatment. For the base case analysis a survival curve was fitted based on the
47 summary Kaplan Meier curves reported in Hammel 2016. This trial was chosen for modelling
48 the baseline OS and PFS as it was both the most recent and largest trial reporting OS and
49 PFS for gemcitabine treatment in patients with LAPC. The curve was fitted using methods

1 detailed in Hoyle 2011. The curves were fitted in R Statistical package using code made
2 publicly available by the authors. The shape and scale parameters were taken directly from
3 the R package results and added to the excel model. The covariance for these parameters
4 were also calculated in the form of a Cholesky Decomposition Matrix and used to inform the
5 probabilistic sensitivity analysis (PSA). These parameters are summarised in Table 228.
6 Weibull and exponential models were considered using Akaike Information Criteria with
7 weibull distribution estimated to be the best fit for both the OS and PFS data.

8 OS and PFS for the interventions were calculated from the hazard ratios reported in the NMA
9 relative to the survival for gemcitabine. The usual proportional hazard assumptions were
10 made about the hazard ratios for both OS and PFS. During PSA these hazard ratios were
11 drawn at random from the iterations of the NMA to reflect uncertainty. PFS was constrained
12 in the model so that it could not be greater than OS and cause a logistical inconsistency.
13 Whilst this might constrict the range of PFS, potentially underestimating the true endpoint for
14 PFS, this logical inconsistency happens in only a tiny number of cases and is unlikely to
15 impact upon the conclusions of the model.

16 Where PFS was not reported for an intervention and therefore could not be calculated in the
17 NMA it was assumed to be identical to PFS for gemcitabine in the absence of the alternative.
18 As no values for OS and PFS for FOLFIRINOX had been calculated by the NMAs, excluded
19 papers from the clinical evidence were searched for the best available evidence to inform this
20 parameter. In the absence of randomised comparative evidence in a pure LAPC population,
21 observational data was considered. From this, 1 systematic review and patient level meta-
22 analysis of the use of FOLFIRINOX in people with LAPC was identified (Suker et al. 2016).
23 The study identified 13 studies of 653 patients, 355 of which had LAPC. No studies were
24 identified which were both randomised and comparative. The meta-analysis reported a
25 median OS of 24.2 months (95% CI 21.7-26.8) and a median PFS of 15.0 months (95% CI
26 13.8-16.2). As FOLFIRINOX was the only intervention considered in this meta-analysis no
27 comparative analysis was performed with any other intervention and therefore a hazard ratio
28 was not and could not be calculated. FOLFIRINOX was therefore incorporated into the
29 secondary analysis using the summary Kaplan Meier curves reported in Suker 2016.
30 Identical methods were used for estimating the survival curves for FOLFIRINOX as used for
31 gemcitabine and again a Weibull distribution was estimated to be the most appropriate fit for
32 both OS and PFS. Shape, scale and Cholesky Decomposition Matrix parameters are
33 reported in Table 231.

34 The shape and scale of both the OS and PFS curves for gemcitabine and FOLFIRINOX were
35 varied during PSA using the estimated Cholesky Decomposition Matrices calculated above.
36 This uncertainty is again estimated using methods discussed in Hoyle 2011.

37 The model used a time horizon of 5 years at which point over 99% of the cohort had died.
38 This meant the survival curves were extrapolated out past three years reported by both
39 Hammel 2016 and Suker 2016 using the shape and scale parameters estimated. It is difficult
40 to say how accurate this extrapolation is in the absence of longer term follow-up data
41 although any uncertainty should be picked up in the PSA. The extrapolation is only relevant
42 to a small proportion of the trial cohort so the impact of any inaccuracy should be limited.

13.3.3.23 Proportion Adverse Events

44 The proportion of treatment related adverse events were taken from the accompanying
45 clinical evidence review using the combined estimate for adverse events from the summary
46 forest plots. Where the adverse events considered by the model were not reported in the
47 clinical evidence they were assumed to be equal to that of gemcitabine. The proportion of
48 adverse events for FOLFIRINOX were taken from Suker et al. (2016). During probabilistic
49 sensitivity analysis, adverse events were varied using a binomial distribution when reported
50 by the evidence. Where adverse events were not reported they were given a wide uniform
51 distribution between 0% and 100% to reflect the large uncertainty.

13.3.3.31 Proportion receiving resection

2 The model assumed that a patient would go on to receive resection if their cancer had had
3 an objective response to treatment. Given the difficulties discussed above with different
4 criteria being used to estimate objective response it was difficult to give any weight to the
5 absolute estimates of objective response estimated by the model and these were
6 disregarded by the committee as they had little face validity. Therefore, the proportion of
7 patients receiving gemcitabine becoming eligible for resection was assumed to be 3% based
8 upon the committee's clinical opinion. The resection rate for other treatments were then
9 estimated using the Odds Ratios estimated in the objective response NMA. During PSA
10 these hazard ratios were drawn at random from the iterations of the NMA to reflect
11 uncertainty. Where an intervention was not included in the objective response NMA it was
12 assumed to have an objective response rate equal to that of gemcitabine but was varied over
13 a uniform distribution between 0% and 6% during PSA.

14 The proportion receiving resection following FOLFIRINOX was again taken from Suker et al
15 (2016). During probabilistic sensitivity analysis the proportion receiving resection was
16 randomly drawn from the iterations of the NMA. Where this had not reported a wide uniform
17 distribution was assigned around this variable ranging from 0% to 25%. The estimates for
18 FOLFIRINOX were varied along a beta distribution.

19 Whilst it was acknowledge that the results of initial treatment may influence further treatment;
20 not only with resection but also by chemotherapy and radiotherapy these were not
21 considered in the base case analysis. The economic model considers chemoradiotherapy
22 (gemcitabine), chemoradiotherapy (capecitabine) and continued treatment with gemcitabine
23 in patients with stable and responding disease although the model will assume the
24 effectiveness of this is independent of the previous treatment received. It will be the case that
25 those patients receiving interventions with greater effectiveness will be more likely to receive
26 further treatment downstream whether considered by the model or not. The model will
27 underestimate both effectiveness and costs for the interventions. There is a paucity of
28 evidence around 2nd and 3rd line treatments and the relationship with first line treatment,
29 therefore any relationship between the two could not be accurately modelled and was
30 therefore not considered in the analysis. As the bias will be in both costs and health
31 outcomes it is not possible to say in which direction the bias will be on the overall cost
32 effectiveness. Given the relatively short life expectancy of the cohort and the small number of
33 patients able to receive 2nd and 3rd line treatments, in practice the more effective treatments
34 will likely be given without consideration of future treatment.

13.3.45 Costs

13.3.4.36 Treatment costs

37 All chemotherapy and radiotherapy were costed in line with the trial protocols identified in the
38 accompanying clinical evidence review. These are presented in the clinical evidence review.
39 Patients were assumed to have a body surface area of 1.79m² based on a retrospective
40 study of 3,613 adult cancer patients in the UK (Sacco et al., 2010). All patients in the cohort
41 were assumed to complete the regimens as per the trial protocols. Given the relatively low
42 life expectancy of the model cohort, the high probability of progression and the potential for
43 serious adverse events this assumption was likely to be an unrealistic assumption. However
44 it was likely to bias against interventions with the lower adverse events and higher OS and
45 PFS for example, the more clinically effective interventions.

46 The cost of chemotherapy drugs were taken from the Drugs and Pharmaceutical Electronic
47 Market Information Tool (eMIT). All regimens were costed assuming no wastage. Where the
48 cost of the chemotherapy regimens were not available on eMIT the drugs were costed using
49 the BNF (BNF 72). It was noted that this was likely to overestimate the true cost paid by the
50 NHS for these drugs. The costs of drug procurement and administration were based on NHS

1 reference costs. Chemotherapy regimens which required a longer infusion were costed at the
2 higher complex tariff.

3 Radiotherapy and surgery were also costed using NHS reference costs. For radiotherapy the
4 model cohort were assumed to complete the regimen specified in the trial protocols. The cost
5 for radiotherapy included an initial set-up cost followed by a cost per fraction administered.
6 Two costs are presented in the NHS reference costs for resection surgery, for surgeries with
7 and without complications. The cost of surgery was estimated assuming a probability of
8 complications of 39.6% based on the value estimated, from the literature, of a previous
9 costing for a UK economic evaluation of preoperative biliary drainage in pancreatic cancer
10 (Morris et al. 2014).

11 Total resource use, in line with the trial protocols are reported in Table 231. These were not
12 varied during the PSA. All treatment costs were varied using a gamma distribution and the
13 reported standard deviations during the PSA.

14 **Table 228: Total resource use assumed by the model for each intervention**
15 **considered.**

	Total Resource Use Treatment Protocol
Gemcitabine	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment • 11 subsequent chemotherapy appointments • 20760mg gemcitabine
FOLFIRINOX	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 176.46mg oxaliplatin • 8304mg leucovorin • 3736.8mg irinotecan • 58128mg fluoracil
Chemorad (Gem)	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 20760mg gemcitabine • 28 fraction radiotherapy
Chemorad (Gem) + Cisplatin	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 20760mg gemcitabine • 28 fractions radiotherapy • 346mg cisplatin
Chemorad (Gem) +CisplatinX2	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 20760mg gemcitabine • 28 fractions radiotherapy • 692mg cisplatin
Chemorad(5-fu)	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 58128mg fluoracil • 28 fractions radiotherapy
Chemorad(5-fu) + Cisplatin	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 20760mg gemcitabine • 346mg cisplatin • 28 fractions radiotherapy

	Total Resource Use Treatment Protocol
FLEC	<ul style="list-style-type: none"> • 1 initial complex chemotherapy appointment, • 7 subsequent chemotherapy appointments • 8304mg epirubicin • 8304mg leucovorin • 4152mg carboplatin • 58128mg fluoracil
Gemcitabine + Erlotinib	<ul style="list-style-type: none"> • 1 initial chemotherapy appointment, • 11 subsequent chemotherapy appointments • 20760mg gemcitabine • 12 tablets erlotinib

13.3.4.21 Cost of adverse events.

2 No UK costs were identified for the specific adverse events considered by the economic
3 model. In the absence of this evidence it was assumed that the adverse events could be
4 treated during 1 face-to-face consultant follow-up meeting and was costed as such using
5 NHS reference costs. Only 1 cost was assumed for any combination of the four considered
6 adverse events included as part of the model structure. Again this assumption was likely to
7 bias against treatments with a lower proportion of adverse events. The cost of adverse
8 events was varied during PSA using a gamma distribution.

13.3.4.39 Cost of death

10 Studies of resource use in cancer show a peak in costs towards the final months of life.
11 Given that over 99% of the model cohort died during the time horizon of the model no
12 terminal cost was assigned to death in the model as this cost was likely to be borne by all
13 patients regardless of intervention received. As costs after year 1 in the model are
14 discounted this assumption again is likely to bias against the clinically effective interventions
15 with the higher OS.

13.3.56 Quality of Life

17 As above three different, mutually exclusive health states were created in the partitioned
18 survival analysis:

- 19 • Alive without progressed disease
- 20 • Alive with progressed disease
- 21 • Death

22 Each of these health states were given a quality of life (QoL) weighting based on those
23 reported in a previous economic evaluation of LAPC (Murphy et al. 2012). This study used
24 expert opinion to estimate a utility weight of 0.68 for patients without progressed disease.
25 Based on a review of the literature a detriment of 0.12 was estimated for disease
26 progression. This gave an estimate of 0.56 for patients with progressed disease. As these
27 estimates were based on expert opinion and were considered very low quality evidence for
28 informing this parameter, QoL weightings were given a large uniform distribution during
29 sensitivity analysis, under the assumption that the QoL without progressed disease was
30 higher or equal to that of progressed disease.

31 No evidence was identified around adverse events and they were therefore difficult to
32 accurately build into the model. These adverse events were relatively easy to treat and only
33 occurred for a short period of time and therefore the overall impact on QoL was likely to be
34 small. Therefore, in the base case analysis no QoL detriment was assigned to adverse
35 events. The committee acknowledged however that such adverse events are not negligible

1 for patients receiving treatment for LAPC and some effort should be made to capture these in
 2 the QoL measures. Therefore, during probabilistic sensitivity analysis a 0.1 QoL weight
 3 detriment was assigned to all adverse events. During PSA this value was varied along a
 4 uniform distribution between this value and zero.

13.3.65 Discounting

6 All health outcomes were discounted at a rate of 3.5% per annum in line with the [NICE](#)
 7 [guidelines manual](#). The way the model is structured no costs are considered after year 1.
 8 Therefore no discounting is necessary around costs.

13.3.79 Probabilistic sensitivity analysis

10 Probabilistic sensitivity analysis was also conducted to assess the combined parameter
 11 uncertainty in the model. In this analysis, the mean values that are utilised in the base case
 12 are replaced with values drawn from distributions around the mean values. The distributions
 13 used are presented in Table 229

13.3.84 Net Monetary Benefit

15 All results are presented as incremental net monetary benefit (INMB). INMB is a
 16 representation of cost effectiveness where incremental QALY gains, compared to the
 17 comparator intervention, are converted into a monetary value by multiplying by a willingness
 18 to pay per QALY. For example if an intervention had a QALY gain of 0.5 compared to the
 19 comparator and the willingness to pay per QALY was £20,000, the monetary value of the
 20 QALY gain would equal £10,000. INMB is then calculated by subtracting total incremental
 21 cost from this incremental monetary value of the QALYs gained. For our analysis the
 22 'willingness to pay' per QALY is set equal to £20,000 the cost per QALY below which NICE
 23 conventionally recommends interventions and £50,000, a higher willingness to pay which
 24 NICE consider for interventions which increase life expectancy by at least three months in
 25 people in their final 24 months of life relative to current treatment. Interventions which report
 26 a positive INMB are cost effective compared to the comparator (gemcitabine) with those
 27 reporting a negative value not being cost effective. The 'preferred' intervention would be the
 28 one which reports the highest INMB.

29 **Table 229 List of parameters used in the economic model and PSA distribution**

	Value	Source	PSA Distribution
Overall Survival (Weibull Function)			
Gemcitabine Intercept	2.89	Hammel 2016	Cholesky
Gemcitabine Log Scale	-0.43	Hammel 2016	Cholesky
FOLFIRINOX Intercept	3.25	Suker 2016	Cholesky
FOLFIRINOX Log Scale	-0.75	Suker 2016	Cholesky
Hazard ratio (vs Gemcitabine)		See NMA results	NMA
Progression Free Survival (Weibull Function)			
Gemcitabine Intercept	2.38	Hammel 2016	Cholesky
Gemcitabine Log Scale	-1.15	Hammel 2016	Cholesky
FOLFIRINOX Intercept	2.99	Suker 2016	Cholesky
FOLFIRINOX Log Scale	-0.30	Suker 2016	Cholesky
Hazard ratio (vs Gemcitabine)		See NMA Results	NMA
Proportion Adverse Events			

	Value	Source	PSA Distribution
Gemcitabine	39.5%	Clinical Evidence Review	BETA(88,135)
FOLFIRINOX	60.4%	Suker et al (2016)	BETA(296,194)
Chemorad (Gem)	79.4%	Clinical Evidence Review	BETA(27,7)
Chemorad (Gem) + Cisplatin	51.6%	Clinical Evidence Review	BETA(16,15)
Chemorad (Gem) +CisplatinX2	63.0%	Clinical Evidence Review	BETA(17,10)
Chemorad(5-fu)	35.6%	Clinical Evidence Review	BETA(32,58)
Chemorad(5-fu) + Cisplatin	61.0%	Clinical Evidence Review	BETA(36,59)
FLEC	47.9%	Clinical Evidence Review	BETA(34,37)
Gemcitabine + Erlotinib	39.7%	Clinical Evidence Review	BETA(87,132)
Proportion Resection			
FOLFIRINOX	25.9%	Suker et al (2016)	BETA(81,313)
Other Interventions		See NMA Results	
Proportion Complications Resection	39.6%	Morris 2014	BETA(98,167)
Costs			
Total intervention Costs		EMIT, BNF, NHS Reference Costs	
Gemcitabine	£4,963.34		Gamma (individual components)
FOLFIRINOX	£7,172.59		Gamma (individual components)
Chemorad (Gem)	£8,342.37		Gamma (individual components)
Chemorad (Gem) + Cisplatin	£10,867.62		Gamma (individual components)
Chemorad (Gem) +CisplatinX2	£13,418.24		Gamma (individual components)
Chemorad(5-fu)	£5,686.62		Gamma (individual components)
Chemorad(5-fu) + Cisplatin	£8,211.87		Gamma (individual components)
FLEC	£6,618.30		Gamma (individual components)
Gemcitabine + Erlotinib	£5,493.00		Gamma (individual components)
Other Costs			
Adverse Event	£162.84	NHS Reference Costs	Gamma(162,6.0)
Cost resection no complications	£8,117.84	NHS Reference Costs	Gamma(8118,11.0)
Cost resection complications	£10,576.46	NHS Reference Costs	Gamma(10,576,13.3)
Utility (Month)			
Stable Disease	0.057	Morris 2014	Uniform(0.023,0.080)
Disease Progression	0.047	Morris 2014	Uniform(0.023,0.080)

	Value	Source	PSA Distribution
Death	0		Not Varied
Discount (per annum)			
Costs	3.5%	NICE	Not varied
QALYs	3.5%	NICE	Not varied

13.4.1 Results Economic Model

13.4.1.2 Overall and Progression Free Survival

3 Figure 12 and Figure 13 show the estimated OS and PFS estimated by the model for the
 4 interventions considered. FOLFIRINOX has greater OS up to 27 months and greater PFS
 5 throughout. This result is expected given the greater median OS and PFS reported by Suker
 6 2016. The committee did not expect OS to be higher at any time point for the non-
 7 FOLFIRINOX interventions. This may be because the proportional hazard assumptions
 8 made for survival may not hold for the tail end of the survival curves. Of the other
 9 interventions considered in the primary analysis of interventions included in the NMA,
 10 chemoradiotherapy with gemcitabine had the greatest OS and gemcitabine the greatest PFS.
 11 This is consistent with the magnitude of the hazard ratios estimated by the NMAs.

Figure 12: Estimated Overall Survival for all interventions in the model





Figure 13: Estimated Progression Free Survival for all interventions in the model



13.4.21 Deterministic Base Case Results

13.4.2.12 Clinical Outcomes

3 As expected given the magnitude of the hazard ratios estimated in the accompanying NMAs,
 4 chemoradiotherapy with gemcitabine had the largest mean OS and gemcitabine the largest
 5 mean PFS (Table 230). FLEC was estimated to have identical PFS to gemcitabine in the
 6 basecase analysis however given no evidence was identified to include FLEC in the PFS
 7 NMA this was directly as a result of the assumptions made in the model. The mean OS and
 8 PFS values are larger than the median values reported in the clinical evidence. Given the
 9 tails of the survival curves this is not unexpected.

10 FLEC resulted in the largest percentage of patients going on to receive resection, although
 11 these figures should be interpreted with caution given the large uncertainty and other
 12 weaknesses associated with the OR NMA highlighted above.

13 Table 230: Primary Base Case Analysis Results- Clinical Outcomes

	Mean PFS (Months)	Mean OS (Months)	Percentage receiving resection
Gemcitabine	9.6	15.0	3.0%
Chemorad (Gem)	8.4	19.9	3.3%
Chemorad (Gem) + Cisplatin	7.6	19.3	0.5%
Chemorad (Gem) +CisplatinX2	8.4	19.2	0.2%
Chemorad(5-fu)	6.6	17.4	0.4%

	Mean PFS (Months)	Mean OS (Months)	Percentage receiving resection
Chemorad(5-fu) + Cisplatin	6.9	12.0	3.0%
FLEC	9.6	17.6	8.0%
Gemcitabine + Erlotinib	8.2	13.5	3.0%

1

13.4.2.22 Economic Outcomes

3 Table 231 shows the base case results for the different interventions for LAPC considered by
 4 both the NMA and economic model. At the higher £50,000 per QALY threshold all
 5 interventions with a positive incremental QALY compared to gemcitabine returned a positive
 6 INMB and therefore could be considered cost effective compared to gemcitabine alone.
 7 Chemoradiotherapy with gemcitabine was the preferred option with an INMB of £7,299 per
 8 patient or a cost per QALY of £16,378 compared to gemcitabine alone. At a £20,000 per
 9 QALY threshold chemoradiotherapy with gemcitabine still remained the preferred option
 10 although of the interventions considered in the NMA. Using the means of the probabilistic
 11 results rather than deterministic results did not impact significantly upon the results and did
 12 not change the conclusions.

13 **Table 231: Primary Base Case Analysis Results Economic Outcomes**

	Total Cost	Total QALY	Incremental Cost	Incremental QALYs	INMB £20k per QALY	INMB £50k per QALY
Gemcitabine	£3,157	0.80	Reference	Reference	Reference	Reference
Chemorad (Gem)	£6,713	1.01	£3,556	0.22	£786	£7,299
Chemorad (Gem) + Cisplatin	£6,397	0.98	£3,240	0.18	£374	£5,794
Chemorad (Gem) +CisplatinX2	£6,554	0.98	£3,397	0.18	£251	£5,724
Chemorad(5-fu)	£6,336	0.88	£3,179	0.08	-£1,601	£767
Chemorad(5-fu) + Cisplatin	£6,651	0.63	£3,494	-0.17	-£6,875	-£11,946
FLEC	£6,310	0.92	£3,152	0.12	-£753	£2,846
Gemcitabine + Erlotinib	£10,373	0.71	£7,216	-0.08	-£8,861	-£11,330

13.4.34 Deterministic one way sensitivity analysis

15 A number of one way sensitivity and scenario analyses were carried out to test the
 16 robustness of the model (Table 232). Broad scenarios were chosen for sensitivity analysis
 17 over individual sensitivity analyses as these are difficult to interpret for a large number of
 18 interventions and uncertainty is better displayed by the probabilistic results.

19 Chemoradiotherapy with gemcitabine remained the preferred option in the majority of
 20 scenarios. Importantly it was robust to assumptions around PFS and baseline OS.

21 Resection rates account for a large cost in the model with interventions with a large resection
 22 rate likely to have relatively larger costs. It was also acknowledged that estimates from the
 23 objective response NMA had great uncertainty and point estimates should be interpreted with
 24 caution. However, when resection rates and consequently costs are equal across all
 25 interventions the preferred intervention remained the same.

- 1 Only a handful of scenario analyses resulted in a different preferred therapy to the basecase.
 2 Halving the progressed disease state QALY resulted in gemcitabine becoming the preferred
 3 option. This is due largely to its point estimate performing well, comparative to other
 4 treatments, in the PFS NMA. Again these point estimates should be interpreted with caution
 5 given the large uncertainty and potentially counterintuitive results they produced.
- 6 When a one-off QALY detriment of 0.1 is added for adverse events, chemoradiotherapy with
 7 gemcitabine and cisplatin becomes the preferred option at a £20,000 willingness to pay
 8 threshold, reflecting its lower number of adverse events reported in the accompanying
 9 clinical evidence review. FLEC becomes the preferred option when treatment administration
 10 costs are not included although FLEC is a relatively complex chemotherapy to administer
 11 attracting higher tariffs, so it is not clear how realistic this scenario is.

12 Table 232: One Way Deterministic Sensitivity Analysis Results

Parameter	Change Made	Cost Effective £20,000 QALY	Cost Effective £50,000 QALY
Survival	Gemcitabine OS upper 95%	Chemorad(Gem)	Chemorad(Gem)
	Gemcitabine OS lower 95%	Chemorad(Gem)	Chemorad(Gem)
	PFS same proportion as gemcitabine for all interventions	Chemorad(Gem)	Chemorad(Gem)
Resection Rate	Equal 3% all intervention	Chemorad(Gem)	Chemorad(Gem)
Adverse Events	Equal 40% all interventions	Chemorad(Gem)	Chemorad(Gem)
Quality of Life	Life years used instead of QALYs	Chemorad(Gem)	Chemorad(Gem)
	Progression QALY halved	Gemcitabine	Gemcitabine
	0.05 QALY detriment from adverse events	Chemorad(Gem)	Chemorad(Gem)
	0.1 QALY detriment from adverse events	Chemorad(Gem)	Chemorad(Gem)+Cisplatin
Costs	Chemo and radiotherapy administration costs remove	FLEC	Chemorad(Gem)
	No adverse event costs	Chemorad(Gem)	Chemorad(Gem)
	25% reduction in cost of gemcitabine	Chemorad(Gem)	Chemorad(Gem)
	50% reduction in cost of gemcitabine	Chemorad(Gem)	Chemorad(Gem)
	75% reduction in cost of gemcitabine	Chemorad(Gem)	Chemorad(Gem)

13.4.43 Secondary analysis of treatment for patients with stable or responding disease

- 14 In the secondary analysis, based on the results of the two trials identified during the clinical
 15 evidence review, continued gemcitabine alone dominated chemoradiotherapy, with
 16 gemcitabine being both health improving and less costly. Chemoradiotherapy with
 17 capecitabine was cost effective at a willingness to pay per QALY of both £20,000 and

- 1 £50,000. Compared to continued treatment with gemcitabine it returned a cost per QALY of
 2 £13,052 again below both the £20,000 and £50,000 willingness to pay thresholds.

3 Table 233: Secondary analysis base case results


	Total Cost	Total QALY	Incremental Cost	Incremental QALYs	INMB £20k per QALY	INMB £50k per QALY
Gemcitabine	£3,992	0.73	Reference	Reference	Reference	Reference
Chemorad (Gem)	£6,342	0.71	£2,350	-0.02	−£2,750	£3,350
Chemorad (Cap)	£6,472	0.92	£2,480	0.19	£1,320	£7,020

13.4.54 Probabilistic Sensitivity Analysis

5 When only interventions included in the NMA are considered (Figure 14) chemoradiotherapy
 6 with gemcitabine and cisplatin becomes the preferred treatment option at the £20,000 per
 7 QALY threshold with a 24% chance of being the preferred option. Chemoradiotherapy with
 8 gemcitabine, the preferred choice in the deterministic analysis now has a 16% probability of
 9 being the most cost effective option. Gemcitabine alone had a 17% probability of being the
 10 preferred option in this scenario. As the only monotherapy in the analysis this corresponds to
 11 an 83% probability that some form of combination therapy is the most cost effective option.

12 At a £50,000 per QALY threshold chemoradiotherapy with gemcitabine becomes the
 13 preferred option with a 30% probability of being the most cost effective option. At this
 14 £50,000 per QALY threshold, gemcitabine has a 5% probability of being the preferred option
 15 corresponding to a probability of 95% that some form of combination therapy is the most cost
 16 effective option. The plateauing lines for all interventions suggests there is significant
 17 uncertainty around the clinical inputs for the model.

Figure 14: Cost effectiveness acceptability curve for all interventions included in the NMAs



13.4.61 Secondary Analysis Including FOLFIRINOX

13.4.6.12 Clinical Outcomes

3 Values for FOLFIRINOX in the economic model were taken from Suker 2016 and no
 4 modelling was performed around these clinical outcomes (Table 234). When FOLFIRINOX
 5 was included as part of the secondary economic analysis the values for median OS and PFS
 6 were greater than for any intervention in any trial reported in the NMA. It was therefore
 7 expected that FOLFIRINOX would also report a greater mean OS and PFS. The reported
 8 25.9% of patients receiving resection was much higher than anything predicted by the NMAs
 9 and economic model.

10 **Table 234: Secondary Analysis Results- Clinical Outcomes**

	Mean PFS (Months)	Mean OS (Months)	Percentage receiving resection
Gemcitabine	9.6	15.0	3.0%
FOLFIRINOX	18.9	21.0	25.9%
Chemorad (Gem)	8.4	19.9	3.3%
Chemorad (Gem) + Cisplatin	7.6	19.3	0.5%
Chemorad (Gem) +CisplatinX2	8.4	19.2	0.2%
Chemorad(5-fu)	6.6	17.4	0.4%
Chemorad(5-fu) + Cisplatin	6.9	12.0	3.0%
FLEC	9.6	17.6	8.0%
Gemcitabine + Erlotinib	8.2	13.5	3.0%

13.4.6.21 Economic Outcomes

12 Table 235 shows the results of the secondary analysis which considers FOLFIRINOX as part
 13 of the secondary analysis. FOLFIRINOX has greater lifetime costs, other than gemcitabine
 14 with erlotinib, but also reports greater lifetime QALYs. FOLFIRINOX also becomes the
 15 preferred option for both a £20,000 and £50,000 per QALY willingness to pay thresholds.

16 **Table 235: Secondary Analysis Results-Economic Outcomes**

	Total Cost	Total QALY	Incremental Cost	Incremental QALYs	INMB £20k per QALY	INMB £50k per QALY
Gemcitabine	£3,157	0.80	Reference	Reference	Reference	Reference
FOLFIRINOX	£7,718	1.58	£4,561	0.53	£5,992	£21,823
Chemorad (Gem)	£6,713	1.01	£3,556	0.22	£786	£7,299
Chemorad (Gem) + Cisplatin	£6,397	0.98	£3,240	0.18	£374	£5,794
Chemorad (Gem) +CisplatinX2	£6,554	0.98	£3,397	0.18	£251	£5,724
Chemorad(5-fu)	£6,336	0.88	£3,179	0.08	-£1,601	£767
Chemorad(5-fu) + Cisplatin	£6,651	0.63	£3,494	-0.17	-£6,875	-£11,946

	Total Cost	Total QALY	Incremental Cost	Incremental QALYs	INMB £20k per QALY	INMB £50k per QALY
FLEC	£6,310	0.92	£3,152	0.12	-£753	£2,846
Gemcitabine + Erlotinib	£10,373	0.71	£7,216	-0.08	-£8,861	-£11,330

13.4.71 Threshold Sensitivity Analysis around FOLFIRINOX

2 Given the potential biases discussed around the data used to populate FOLFIRINOX (Table
3 236) a range of threshold sensitivity analyses were performed to try to capture at which
4 values for FOLFIRINOX the intervention is no longer the preferred option in the secondary
5 analysis. FOLFIRINOX remains the preferred option for OS and PFS much below that
6 reported in Suker 2016. Even if the identified biases do lead to a large overestimate of these
7 important parameters FOLFIRINOX may still be a cost effective option.

8 FOLFIRINOX remains the preferred choice for all values of adverse events. FOLFIRINOX is a
9 relatively toxic chemotherapy. Even if treatment does lead to a large number of patients
10 experiencing adverse events it is still likely to remain the preferred option.


11 Table 236: Threshold sensitivity analyses for FOLFIRINOX

Variable	WTP £20k per QALY	WTP £50k per QALY
Overall Survival	<13.1 months	<11.3 months
Progression Free Survival	<9 months	<8.3 months
Adverse Events	All Values	All values
Total Drug Costs	£7,885	£18,322

13.4.82 Probabilistic Sensitivity Analysis

13 It can be seen from Figure 15 that the cost effective acceptability curve changes significantly
14 when FOLFIRINOX is included as part of the analysis. FOLFIRINOX is now the most likely
15 preferred option for all willingness to pay thresholds above £10,000 per QALY. The
16 probability of FOLFIRINOX being the preferred option remains constant with a 51% and 56%
17 chance of being cost effective at a willingness to pay per QALY of £20,000 and £50,000
18 respectively. At the same willingness to pay values there is only a few percentage points
19 separating the other interventions (considered in the NMA) at both £20,000 and £50,000 with
20 a less than 14% probability of any single intervention being the preferred option at both
21 thresholds. Gemcitabine alone has a 3% and zero probability of being cost effective for a
22 willingness to pay per QALY of £20,000 and £50,000 respectively. Again, this strongly
23 suggests that a multimodal therapy approach is almost certainly the most cost effective
24 treatment option.

Figure 15: Cost effectiveness acceptability curve for all interventions including FOLFIRINOX



13.4.91 Discussion

2 Of the interventions considered in the NMA chemoradiotherapy with gemcitabine was the
 3 preferred option during the deterministic base case results and, chemoradiotherapy with
 4 gemcitabine and cisplatin was the preferred option in the largest number of iterations in the
 5 PSA in line with the results of the NMA. However, it never had a greater than 25% probability
 6 compared to all other interventions at a willingness to pay per QALY values of £20,000 and
 7 £50,000 respectively. It was therefore difficult to strongly conclude for any intervention to be
 8 the preferred option from this group. The economic model suggested that gemcitabine alone
 9 only had a 17% probability of being the preferred option for any of the conventionally used
 10 willingness to pay thresholds suggesting strongly that multimodal therapy was likely to be
 11 cost effective.

12 FOLFIRINOX was the preferred option when added in the secondary analysis, being the
 13 preferred treatment in both the deterministic results and in over 50% of the iterations of the
 14 probabilistic sensitivity analysis. However, despite its prevalent usage for treatment of LAPC
 15 across England no direct, randomised comparative evidence was identified for this
 16 intervention solely in this patient group. The comparability of FOLFIRINOX to other
 17 interventions considered in the NMA and economic model is not strong. Whilst FOLFIRINOX
 18 was robust to the PSA, as the OS and PFS for FOLFIRINOX was reduced closer to those of
 19 other interventions in the NMA the strength of this conclusion was largely reduced.
 20 Comparative randomised evidence comparing FOLFIRINOX with other interventions in the
 21 NMA, would increase the comparability of this intervention and the strength of any
 22 conclusions drawn.

23 The plateauing of the lines in the CEACs suggest that most of the uncertainty around the
 24 model revolves around the clinical inputs. Additional randomised clinical trials which would
 25 strengthen and increase the power of the NMA would likely reduce this uncertainty and
 26 increase the strength of any recommendations made from the model.

27 The cost effectiveness evidence in TA25 compared 5-FU chemotherapy with gemcitabine
 28 chemotherapy. The two economic evaluations for this topic were largely based around 1

1 RCT (Burriss et al. 1997) comparing gemcitabine monotherapy to 5-FU monotherapy in
 2 patients with either locally advanced or metastatic pancreatic cancer. The models submitted
 3 estimated a cost per QALY for gemcitabine compared to 5-FU of between £7,200 and
 4 £18,700.

5 It is difficult to draw comparisons with the NMA and economic model above given that 5-FU
 6 monotherapy was not used as a comparison in any of the identified evidence. Burriss et al
 7 (1997) on which TA25 was based was not included as it was conducted before 2000 and had
 8 a mixed population of LAPC and metastatic cancer. Where evidence of 5-FU has been
 9 included in the NMA it is alongside radiotherapy, an intervention markedly different to 5-FU
 10 monotherapy. All regimens including 5-FU in the base case analysis are cost increasing and
 11 health decreasing compared to gemcitabine. This is mirrored by the PSA where again the 5-
 12 FU based regimens are rarely cost effective.

13 The costs of gemcitabine are also now likely to be much reduced compared to those
 14 considered in TA25 given that the treatment is now 'off patent' for this condition. The costs of
 15 gemcitabine and 5-FU are now likely to be very similar and that the total costs and costs per
 16 QALYs for gemcitabine are likely to be much lower than those reported in TA25 in 2001 even
 17 without taking account of inflation.

18 Despite the TA25 models not being strictly comparable to the bespoke economic model
 19 above the most pertinent difference is that gemcitabine monotherapy is now very unlikely to
 20 be the preferred option with the PSA estimating an almost 0% probability. This however is
 21 compared to regimens that were not considered by TA25. However, interventions that have a
 22 component of gemcitabine, in particular chemoradiotherapy with gemcitabine perform
 23 favourably in the bespoke economic model.

13.5.4 References

25 Burriss HA, Moore MJ, Andersen J et al. (1997) Improvements in survival and clinical benefit
 26 with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a
 27 randomized trial. *Journal of Clinical Oncology* 15(6): 2403-13

28 Cantore M, Fiorentini G, Luppi G et al. (2004) Gemcitabine versus FLEC regimen given intra-
 29 arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase
 30 III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. *Journal of*
 31 *Chemotherapy* 16(6): 589-94

32 Chung HW, Bang SM, Park SW et al. (2004) A prospective randomized study of gemcitabine
 33 with doxifluridine versus paclitaxel with doxifluridine in concurrent chemoradiotherapy for
 34 locally advanced pancreatic cancer. *International Journal of Radiation*Oncology*Biolog*
 35 Physics* 60(5): 1494-501

36 Department of Health (2016) NHS reference costs 2015 to 2016. Reference costs 2015-
 37 2016. UK Government

38 Department of Health (2016) eMit national database. UK Government

39 Dias S, Welton NJ, Sutton AJ et al. (2016) NICE DSU technical support document 2:Gnereal
 40 Meta-analysis [Available at: [http://www.bristol.ac.uk/media-library/sites/social-community-
 41 medicine/documents/mpes/TSD2%20General%20meta%20analysis%20Sep2016.pdf](http://www.bristol.ac.uk/media-library/sites/social-community-medicine/documents/mpes/TSD2%20General%20meta%20analysis%20Sep2016.pdf)
 42 (accessed 27 April 2017)]

43 Hamada T, Nakai Y, Isayama H et al. (2016) Progression-free survival as a surrogate for
 44 overall survival in first-line chemotherapy for advanced pancreatic cancer. *European Journal*
 45 *of Cancer* 65: 11-20

46 Hammel P, Huguet F, van Laethem JL et al. (2016) Effect of Chemoradiotherapy vs
 47 Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled

- 1 After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical
2 Trial. *JAMA* 315(17): 1844-53
- 3 Heinemann V, Ebert MP, Laubender RP et al. (2013) Phase II randomised proof-of-concept
4 study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine
5 compared with gemcitabine alone in patients with non-resectable, locally advanced
6 pancreatic cancer. *British Journal of Cancer* 108(4): 766-70
- 7 Herman JM, Wild AT, Wang H et al. (2013) Randomized phase III multi-institutional study of
8 TNFerade biologic with fluorouracil and radiotherapy for locally advanced pancreatic cancer:
9 final results. *Journal of Clinical Oncology* 31(7): 886-94
- 10 Hoyle MW and Henley W (2011) Improved curve fits to summary survival data: application to
11 economic evaluation of health technologies. *BMC Medical Research Methodology* 11(1): 139
- 12 Joint Formulary Committee (2017) *British National Formulary*. 73rd ed. London, UK: BMJ
13 Group and Pharmaceutical Press
- 14 Khan K, Cunningham D, Peckitt C et al. (2016) miR-21 expression and clinical outcome in
15 locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux,
16 radiotherapy and UFT (PERU) trial. *Oncotarget* 7(11): 12672-81
- 17 Li CP, Chao Y, Chi KH et al. (2003) Concurrent chemoradiotherapy treatment of locally
18 advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled
19 study. *International Journal of Radiation*Oncology*Biology* Physics* 57(1): 98-104
- 20 Loehrer PJ Sr, Feng Y, Cardenes H et al. (2011) Gemcitabine alone versus gemcitabine plus
21 radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative
22 Oncology Group trial. *Journal of Clinical Oncology* 29(31): 4105-12
- 23 Morris S, Gurusamy KS, Sheringham J et al. (2015) Cost-effectiveness of preoperative biliary
24 drainage for obstructive jaundice in pancreatic and periampullary cancer. *Journal of Surgical*
25 *Research* 193(1): 202-9
- 26 Mukherjee S, Hurt CN, Bridgewater J et al. (2013) Gemcitabine-based or capecitabine-based
27 chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre,
28 randomised, phase 2 trial. *Lancet Oncology* 14(4): 317-26
- 29 Murphy JD, Chang DT, Abelson J et al. (2012) Cost-effectiveness of modern radiotherapy
30 techniques in locally advanced pancreatic cancer. *Cancer* 118(4): 1119-29
- 31 NICE (2014) *Developing NICE guidelines: the manual*. London, UK: National Institute of
32 Health and Care Excellence
- 33 NICE (2001) *Pancreatic cancer - gemcitabine*. TA25. London, UK: National Institute of Health
34 and Care Excellence [Available at <http://guidance.nice.org.uk/TA25> (accessed 27 April
35 2017)]
- 36 Parmar MK, Torri V, Stewart L. (1998) Extracting summary statistics to perform meta-
37 analyses of the published literature for survival endpoints. *Statistics In Medicine* 17(24):
38 2815-34
- 39 Rich TA, Winter K, Safran H et al. (2012) Weekly paclitaxel, gemcitabine, and external
40 irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally
41 advanced pancreatic cancer. *Onco Targets and Therapy* 5: 161-70
- 42 Sacco JJ, Botten J, Macbeth F et al. (2010) The average body surface area of adult cancer
43 patients in the UK: a multicentre retrospective study. *PloS One* 5(1): e8933
- 44 Shinchi H, Takao S, Noma H et al. (2002) Length and quality of survival after external-beam
45 radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable

- 1 pancreatic cancer. International Journal of Radiation Oncology* Biology* Physics 53(1): 146-
2 50
- 3 Suker M, Beumer BR, Sadot E et al. (2016) FOLFIRINOX for locally advanced pancreatic
4 cancer: a systematic review and patient-level meta-analysis. The Lancet Oncology 17(6):
5 801-10
- 6 Wilkowski R, Boeck S, Ostermaier S et al. (2009) Chemoradiotherapy with concurrent
7 gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin
8 vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced
9 pancreatic cancer - a multi-centre randomised phase II study. British Journal of Cancer
10 101(11): 1853-9
- 11 Woods B, Sideris E, Palmer S et al. (2017) NICE DSU Technical Support Document 19:
12 Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. Report
13 by the Decision Support Unit [Available at: <http://www.nicedsu.org.uk> (accessed 27 April
14 2017)]